EP2740730A1 - Dibenzooxepin derivative - Google Patents
Dibenzooxepin derivative Download PDFInfo
- Publication number
- EP2740730A1 EP2740730A1 EP12820117.5A EP12820117A EP2740730A1 EP 2740730 A1 EP2740730 A1 EP 2740730A1 EP 12820117 A EP12820117 A EP 12820117A EP 2740730 A1 EP2740730 A1 EP 2740730A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- substituent
- compound
- optionally
- methyl
- oxepin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims abstract description 81
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 38
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 21
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract description 16
- 229940080774 Peroxisome proliferator-activated receptor gamma agonist Drugs 0.000 claims abstract description 7
- 238000011321 prophylaxis Methods 0.000 claims abstract description 5
- 150000001875 compounds Chemical class 0.000 claims description 545
- 125000001424 substituent group Chemical group 0.000 claims description 143
- -1 cyano, formyl Chemical group 0.000 claims description 99
- 125000000217 alkyl group Chemical group 0.000 claims description 52
- 229910052736 halogen Inorganic materials 0.000 claims description 40
- 150000002367 halogens Chemical class 0.000 claims description 40
- 201000010099 disease Diseases 0.000 claims description 39
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 39
- 238000000034 method Methods 0.000 claims description 39
- 108010016731 PPAR gamma Proteins 0.000 claims description 38
- 102000000536 PPAR gamma Human genes 0.000 claims description 34
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 34
- 125000003545 alkoxy group Chemical group 0.000 claims description 26
- 229910052757 nitrogen Inorganic materials 0.000 claims description 25
- 125000000623 heterocyclic group Chemical group 0.000 claims description 23
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 21
- 238000004519 manufacturing process Methods 0.000 claims description 19
- 125000005115 alkyl carbamoyl group Chemical group 0.000 claims description 18
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 17
- 125000001589 carboacyl group Chemical group 0.000 claims description 17
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 16
- 206010020772 Hypertension Diseases 0.000 claims description 15
- 208000031773 Insulin resistance syndrome Diseases 0.000 claims description 15
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 15
- 208000008589 Obesity Diseases 0.000 claims description 15
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 15
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims description 15
- 235000020824 obesity Nutrition 0.000 claims description 15
- 201000009104 prediabetes syndrome Diseases 0.000 claims description 15
- 208000002705 Glucose Intolerance Diseases 0.000 claims description 14
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 14
- 239000004480 active ingredient Substances 0.000 claims description 14
- 208000004611 Abdominal Obesity Diseases 0.000 claims description 13
- 125000001931 aliphatic group Chemical group 0.000 claims description 13
- 208000006575 hypertriglyceridemia Diseases 0.000 claims description 13
- 125000004414 alkyl thio group Chemical group 0.000 claims description 12
- 125000003118 aryl group Chemical group 0.000 claims description 10
- 125000003282 alkyl amino group Chemical group 0.000 claims description 9
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 9
- 229910052731 fluorine Inorganic materials 0.000 claims description 9
- 125000004423 acyloxy group Chemical group 0.000 claims description 8
- 125000003342 alkenyl group Chemical group 0.000 claims description 8
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 8
- 125000000304 alkynyl group Chemical group 0.000 claims description 8
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims description 8
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 8
- 230000000069 prophylactic effect Effects 0.000 claims description 8
- 230000001225 therapeutic effect Effects 0.000 claims description 8
- 238000011282 treatment Methods 0.000 claims description 6
- 230000003213 activating effect Effects 0.000 claims description 5
- 125000004104 aryloxy group Chemical group 0.000 claims description 5
- 125000004043 oxo group Chemical group O=* 0.000 claims description 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- CJBPIZBHRWDBGQ-COSFPPCYSA-N rfa-1 Chemical compound C1([C@H]2N[C@H](CC3(N=C4C=5C6=C7O[C@](C6=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@@H](C)[C@@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC(=C4N3)C(=O)C=5C(O)=C7C)C)OC)C2)C=2C=CC=CC=2)=CC=CC=C1 CJBPIZBHRWDBGQ-COSFPPCYSA-N 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 5
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 claims 3
- 230000000694 effects Effects 0.000 abstract description 15
- APMCUORPNXHBQK-UHFFFAOYSA-N benzo[c][1]benzoxepine Chemical class O1C=C2C=CC=CC2=CC2=CC=CC=C12 APMCUORPNXHBQK-UHFFFAOYSA-N 0.000 abstract description 8
- 239000003814 drug Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 766
- 238000005160 1H NMR spectroscopy Methods 0.000 description 431
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 431
- 239000000203 mixture Substances 0.000 description 333
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 236
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 140
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 129
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 123
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 117
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 114
- 239000002904 solvent Substances 0.000 description 113
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 105
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 101
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 90
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 78
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 75
- 239000000243 solution Substances 0.000 description 70
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 64
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 63
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 62
- 238000010898 silica gel chromatography Methods 0.000 description 59
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 57
- 239000012044 organic layer Substances 0.000 description 57
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 51
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 48
- AJZHGXBPXQSWBD-WOJGMQOQSA-N (2e)-2-[8-(bromomethyl)-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1OC2=CC(F)=CC=C2C(=C(C#N)/C)\C2=CC=C(CBr)C=C21 AJZHGXBPXQSWBD-WOJGMQOQSA-N 0.000 description 43
- 239000002585 base Substances 0.000 description 40
- 238000009835 boiling Methods 0.000 description 38
- 229920006395 saturated elastomer Polymers 0.000 description 36
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 33
- 238000006243 chemical reaction Methods 0.000 description 33
- MBVKIIKBEZZPES-WOJGMQOQSA-N (2e)-2-(3-fluoro-8-formyl-6h-benzo[c][1]benzoxepin-11-ylidene)propanenitrile Chemical compound C1OC2=CC(F)=CC=C2C(=C(C#N)/C)\C2=CC=C(C=O)C=C21 MBVKIIKBEZZPES-WOJGMQOQSA-N 0.000 description 32
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 31
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 31
- 235000017557 sodium bicarbonate Nutrition 0.000 description 31
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 27
- 238000010438 heat treatment Methods 0.000 description 27
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 26
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 25
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 25
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 24
- 239000013078 crystal Substances 0.000 description 23
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 22
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 22
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 22
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 22
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 22
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 21
- 239000011541 reaction mixture Substances 0.000 description 21
- 235000011121 sodium hydroxide Nutrition 0.000 description 21
- NCKSUADAPSBLNI-UHFFFAOYSA-N 2-(8-ethynyl-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene)propanenitrile Chemical compound C1OC2=CC(F)=CC=C2C(=C(C#N)C)C2=CC=C(C#C)C=C21 NCKSUADAPSBLNI-UHFFFAOYSA-N 0.000 description 20
- 238000001816 cooling Methods 0.000 description 20
- 239000000706 filtrate Substances 0.000 description 20
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 20
- 238000000967 suction filtration Methods 0.000 description 19
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 16
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 16
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 16
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 15
- WADSJYLPJPTMLN-UHFFFAOYSA-N 3-(cycloundecen-1-yl)-1,2-diazacycloundec-2-ene Chemical compound C1CCCCCCCCC=C1C1=NNCCCCCCCC1 WADSJYLPJPTMLN-UHFFFAOYSA-N 0.000 description 14
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 14
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical class [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 14
- 125000004429 atom Chemical group 0.000 description 13
- 229910000027 potassium carbonate Inorganic materials 0.000 description 13
- 235000011181 potassium carbonates Nutrition 0.000 description 13
- 229910052938 sodium sulfate Inorganic materials 0.000 description 13
- 235000011152 sodium sulphate Nutrition 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 12
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 12
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 12
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 12
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 12
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 12
- 239000012046 mixed solvent Substances 0.000 description 12
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 12
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 12
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 11
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 11
- 125000004432 carbon atom Chemical group C* 0.000 description 11
- 238000010992 reflux Methods 0.000 description 11
- 239000012312 sodium hydride Substances 0.000 description 11
- 229910000104 sodium hydride Inorganic materials 0.000 description 11
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 10
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 10
- 239000000556 agonist Substances 0.000 description 10
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 10
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 10
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 10
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 9
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 9
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 229910052805 deuterium Inorganic materials 0.000 description 9
- 238000001914 filtration Methods 0.000 description 9
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 9
- 125000004430 oxygen atom Chemical group O* 0.000 description 9
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 9
- 229910052717 sulfur Inorganic materials 0.000 description 9
- 125000004434 sulfur atom Chemical group 0.000 description 9
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 8
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 8
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 8
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 8
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 8
- 235000019270 ammonium chloride Nutrition 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 8
- 239000003054 catalyst Substances 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 239000000543 intermediate Substances 0.000 description 8
- GVOISEJVFFIGQE-YCZSINBZSA-N n-[(1r,2s,5r)-5-[methyl(propan-2-yl)amino]-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](N(C)C(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 GVOISEJVFFIGQE-YCZSINBZSA-N 0.000 description 8
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 8
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 8
- 239000002253 acid Substances 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 229960004592 isopropanol Drugs 0.000 description 7
- KUJCBBGNFSSDID-WGOQTCKBSA-N (2e)-2-[8-[(8-bromo-2-cyclopropylimidazo[1,2-a]pyridin-3-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3C(=C(C#N)/C)\C2=CC=C1CC(N1C=CC=C(Br)C1=N1)=C1C1CC1 KUJCBBGNFSSDID-WGOQTCKBSA-N 0.000 description 6
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 6
- RZJPBQGRCNJYBU-UHFFFAOYSA-N 3-chloropyridin-2-amine Chemical compound NC1=NC=CC=C1Cl RZJPBQGRCNJYBU-UHFFFAOYSA-N 0.000 description 6
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 6
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- 201000004624 Dermatitis Diseases 0.000 description 6
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 6
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 6
- 201000004681 Psoriasis Diseases 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- 235000011114 ammonium hydroxide Nutrition 0.000 description 6
- 239000003638 chemical reducing agent Substances 0.000 description 6
- NKLCNNUWBJBICK-UHFFFAOYSA-N dessāmartin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 6
- UZVGSSNIUNSOFA-UHFFFAOYSA-N dibenzofuran-1-carboxylic acid Chemical compound O1C2=CC=CC=C2C2=C1C=CC=C2C(=O)O UZVGSSNIUNSOFA-UHFFFAOYSA-N 0.000 description 6
- 239000007789 gas Substances 0.000 description 6
- 208000027866 inflammatory disease Diseases 0.000 description 6
- 230000002757 inflammatory effect Effects 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- IUYHWZFSGMZEOG-UHFFFAOYSA-M magnesium;propane;chloride Chemical compound [Mg+2].[Cl-].C[CH-]C IUYHWZFSGMZEOG-UHFFFAOYSA-M 0.000 description 6
- ATYBXHSAIOKLMG-UHFFFAOYSA-N oxepin Chemical compound O1C=CC=CC=C1 ATYBXHSAIOKLMG-UHFFFAOYSA-N 0.000 description 6
- 229910052763 palladium Inorganic materials 0.000 description 6
- 239000000825 pharmaceutical preparation Substances 0.000 description 6
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 6
- ZZHLCJLJYCMULY-ZZEZOPTASA-N (2e)-2-[8-(bromomethyl)-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]-2-cyclopropylacetonitrile Chemical compound C=1C(F)=CC=C2C=1OCC1=CC(CBr)=CC=C1\C2=C(/C#N)C1CC1 ZZHLCJLJYCMULY-ZZEZOPTASA-N 0.000 description 5
- BZRLLADHGGRETG-ZZEZOPTASA-N (2e)-2-cyclopropyl-2-(3-fluoro-8-formyl-6h-benzo[c][1]benzoxepin-11-ylidene)acetonitrile Chemical compound C=1C(F)=CC=C2C=1OCC1=CC(C=O)=CC=C1\C2=C(/C#N)C1CC1 BZRLLADHGGRETG-ZZEZOPTASA-N 0.000 description 5
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 5
- FBLJZPQLNMVEMR-UHFFFAOYSA-N 2-propyl-1h-benzimidazole Chemical compound C1=CC=C2NC(CCC)=NC2=C1 FBLJZPQLNMVEMR-UHFFFAOYSA-N 0.000 description 5
- HNAYRVKSWGSQTP-UHFFFAOYSA-N 3-methoxypyridin-2-amine Chemical compound COC1=CC=CN=C1N HNAYRVKSWGSQTP-UHFFFAOYSA-N 0.000 description 5
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 5
- 208000024827 Alzheimer disease Diseases 0.000 description 5
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 5
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 5
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 5
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Natural products P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 5
- 210000001789 adipocyte Anatomy 0.000 description 5
- 125000003435 aroyl group Chemical group 0.000 description 5
- 229910052801 chlorine Inorganic materials 0.000 description 5
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 5
- 238000004891 communication Methods 0.000 description 5
- JMYVMOUINOAAPA-UHFFFAOYSA-N cyclopropanecarbaldehyde Chemical compound O=CC1CC1 JMYVMOUINOAAPA-UHFFFAOYSA-N 0.000 description 5
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 5
- 229910052740 iodine Inorganic materials 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 210000001853 liver microsome Anatomy 0.000 description 5
- 238000004020 luminiscence type Methods 0.000 description 5
- 239000002184 metal Chemical class 0.000 description 5
- 229910052751 metal Inorganic materials 0.000 description 5
- 201000006417 multiple sclerosis Diseases 0.000 description 5
- 230000000626 neurodegenerative effect Effects 0.000 description 5
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 5
- 229960005095 pioglitazone Drugs 0.000 description 5
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 5
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
- XTSVPYPLIQQXMU-WPWMEQJKSA-N (2e)-2-[3-fluoro-8-[[2-(methoxymethyl)-4-methylsulfanylbenzimidazol-1-yl]methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3\C(=C(/C)C#N)C2=CC=C1CN1C2=CC=CC(SC)=C2N=C1COC XTSVPYPLIQQXMU-WPWMEQJKSA-N 0.000 description 4
- FUXRJBTZGGZZFX-MFKUBSTISA-N (2e)-2-[3-fluoro-8-[[4-hydroxy-2-(hydroxymethyl)benzimidazol-1-yl]methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3C(=C(C#N)/C)\C2=CC=C1CN1C2=CC=CC(O)=C2N=C1CO FUXRJBTZGGZZFX-MFKUBSTISA-N 0.000 description 4
- ZVEZJCIGALMSDM-WPWMEQJKSA-N (2e)-2-[3-fluoro-8-[[4-methoxy-2-(methoxymethyl)benzimidazol-1-yl]methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3\C(=C(/C)C#N)C2=CC=C1CN1C2=CC=CC(OC)=C2N=C1COC ZVEZJCIGALMSDM-WPWMEQJKSA-N 0.000 description 4
- SQBOXJMQSZWKCR-WPWMEQJKSA-N (2e)-2-[8-[(2-cyclopropyl-8-methoxyimidazo[1,2-a]pyridin-3-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound N1=C2C(OC)=CC=CN2C(CC=2C=C3C(C(/C4=CC=C(F)C=C4OC3)=C(/C)C#N)=CC=2)=C1C1CC1 SQBOXJMQSZWKCR-WPWMEQJKSA-N 0.000 description 4
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 description 4
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 4
- WCCCDMWRBVVYCQ-UHFFFAOYSA-N 2-bromo-1-cyclopropylethanone Chemical compound BrCC(=O)C1CC1 WCCCDMWRBVVYCQ-UHFFFAOYSA-N 0.000 description 4
- URJOUYRTHKWERB-UHFFFAOYSA-N 3-(difluoromethoxy)pyridin-2-amine Chemical compound NC1=NC=CC=C1OC(F)F URJOUYRTHKWERB-UHFFFAOYSA-N 0.000 description 4
- RQMWVVBHJMUJNZ-UHFFFAOYSA-N 4-chloropyridin-2-amine Chemical compound NC1=CC(Cl)=CC=N1 RQMWVVBHJMUJNZ-UHFFFAOYSA-N 0.000 description 4
- VJHMQWFNOFVZBV-UHFFFAOYSA-N 4-methoxy-2-(methoxymethyl)-1h-benzimidazole Chemical compound C1=CC=C2NC(COC)=NC2=C1OC VJHMQWFNOFVZBV-UHFFFAOYSA-N 0.000 description 4
- 206010003210 Arteriosclerosis Diseases 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 125000005915 C6-C14 aryl group Chemical group 0.000 description 4
- 125000005914 C6-C14 aryloxy group Chemical group 0.000 description 4
- 208000020446 Cardiac disease Diseases 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- 206010008190 Cerebrovascular accident Diseases 0.000 description 4
- 206010009900 Colitis ulcerative Diseases 0.000 description 4
- 208000011231 Crohn disease Diseases 0.000 description 4
- 206010012438 Dermatitis atopic Diseases 0.000 description 4
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 4
- 208000004145 Endometritis Diseases 0.000 description 4
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical class C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 4
- LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Chemical compound IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 4
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 4
- 208000018737 Parkinson disease Diseases 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical class C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 4
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 206010041303 Solar dermatitis Diseases 0.000 description 4
- 208000006011 Stroke Diseases 0.000 description 4
- 201000006704 Ulcerative Colitis Diseases 0.000 description 4
- 208000011775 arteriosclerosis disease Diseases 0.000 description 4
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 4
- 201000008937 atopic dermatitis Diseases 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 4
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 4
- 229910000024 caesium carbonate Inorganic materials 0.000 description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 description 4
- 230000002490 cerebral effect Effects 0.000 description 4
- 125000001309 chloro group Chemical group Cl* 0.000 description 4
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 4
- 125000000000 cycloalkoxy group Chemical group 0.000 description 4
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 4
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 208000019622 heart disease Diseases 0.000 description 4
- 125000002632 imidazolidinyl group Chemical group 0.000 description 4
- 125000002883 imidazolyl group Chemical group 0.000 description 4
- 208000017169 kidney disease Diseases 0.000 description 4
- AMXOYNBUYSYVKV-UHFFFAOYSA-M lithium bromide Chemical compound [Li+].[Br-] AMXOYNBUYSYVKV-UHFFFAOYSA-M 0.000 description 4
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 4
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 4
- 125000000160 oxazolidinyl group Chemical group 0.000 description 4
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 4
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 4
- SIOXPEMLGUPBBT-UHFFFAOYSA-M picolinate Chemical compound [O-]C(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-M 0.000 description 4
- 125000004193 piperazinyl group Chemical group 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 4
- 229910000105 potassium hydride Inorganic materials 0.000 description 4
- 235000011118 potassium hydroxide Nutrition 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 4
- 125000002755 pyrazolinyl group Chemical group 0.000 description 4
- 125000003226 pyrazolyl group Chemical group 0.000 description 4
- LEHBURLTIWGHEM-UHFFFAOYSA-N pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 description 4
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 description 4
- 208000008742 seborrheic dermatitis Diseases 0.000 description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 description 4
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- PYOKUURKVVELLB-UHFFFAOYSA-N trimethyl orthoformate Chemical compound COC(OC)OC PYOKUURKVVELLB-UHFFFAOYSA-N 0.000 description 4
- 229910052727 yttrium Inorganic materials 0.000 description 4
- AWUCXNGLCPJBTD-WPWMEQJKSA-N (2e)-2-[3-fluoro-8-[[2-(methoxymethyl)-4-methylsulfonylbenzimidazol-1-yl]methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3\C(=C(/C)C#N)C2=CC=C1CN1C2=CC=CC(S(C)(=O)=O)=C2N=C1COC AWUCXNGLCPJBTD-WPWMEQJKSA-N 0.000 description 3
- CEROSOPZDMXYRP-WPWMEQJKSA-N (2e)-2-[3-fluoro-8-[[4-(hydroxymethyl)-2-(methoxymethyl)benzimidazol-1-yl]methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3\C(=C(/C)C#N)C2=CC=C1CN1C2=CC=CC(CO)=C2N=C1COC CEROSOPZDMXYRP-WPWMEQJKSA-N 0.000 description 3
- YAQCORZABWFDMC-OGLMXYFKSA-N (2e)-2-[3-fluoro-8-[[7-fluoro-2-(oxolan-3-yl)imidazo[1,2-a]pyridin-3-yl]methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3C(=C(C#N)/C)\C2=CC=C1CC(N1C=CC(F)=CC1=N1)=C1C1CCOC1 YAQCORZABWFDMC-OGLMXYFKSA-N 0.000 description 3
- PMUFGPRHUDXFCP-CVKSISIWSA-N (2e)-2-[8-[(7-bromo-2-methylimidazo[1,2-a]pyridin-3-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3C(=C(C#N)/C)\C2=CC=C1CC1=C(C)N=C2N1C=CC(Br)=C2 PMUFGPRHUDXFCP-CVKSISIWSA-N 0.000 description 3
- NNTPEAXKKUPBHQ-UHFFFAOYSA-N 1-bromo-3-methylbutan-2-one Chemical compound CC(C)C(=O)CBr NNTPEAXKKUPBHQ-UHFFFAOYSA-N 0.000 description 3
- MCXRFRMWZBEFGY-UHFFFAOYSA-N 2-(3,3-difluorocyclobutyl)-1h-benzimidazole Chemical compound C1C(F)(F)CC1C1=NC2=CC=CC=C2N1 MCXRFRMWZBEFGY-UHFFFAOYSA-N 0.000 description 3
- LBCREEUWXFNSAC-UHFFFAOYSA-N 2-(chloromethyl)imidazo[1,2-a]pyridine Chemical compound C1=CC=CC2=NC(CCl)=CN21 LBCREEUWXFNSAC-UHFFFAOYSA-N 0.000 description 3
- PJXCBKYCXYPXRJ-UHFFFAOYSA-N 2-chloro-3-iodoimidazo[1,2-a]pyridine Chemical compound C1=CC=CN2C(I)=C(Cl)N=C21 PJXCBKYCXYPXRJ-UHFFFAOYSA-N 0.000 description 3
- LTUVNURYIZAIQS-UHFFFAOYSA-N 2-cyclopropyl-2-(8-ethynyl-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene)acetonitrile Chemical compound C=1C(F)=CC=C2C=1OCC1=CC(C#C)=CC=C1C2=C(C#N)C1CC1 LTUVNURYIZAIQS-UHFFFAOYSA-N 0.000 description 3
- JJKWHOSQTYYFAE-UHFFFAOYSA-N 2-methoxyacetyl chloride Chemical compound COCC(Cl)=O JJKWHOSQTYYFAE-UHFFFAOYSA-N 0.000 description 3
- XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 3
- HNAYRVKSWGSQTP-FIBGUPNXSA-N 3-(trideuteriomethoxy)pyridin-2-amine Chemical compound [2H]C([2H])([2H])OC1=CC=CN=C1N HNAYRVKSWGSQTP-FIBGUPNXSA-N 0.000 description 3
- AKMWBVLXCGSOSV-PCLIKHOPSA-N 3-[(1e)-1-[3-fluoro-8-[(2-propylimidazo[4,5-b]pyridin-3-yl)methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound CCCC1=NC2=CC=CN=C2N1CC(C=1)=CC=C2C=1COC1=CC(F)=CC=C1\C2=C(/C)C1=NOC(=O)N1 AKMWBVLXCGSOSV-PCLIKHOPSA-N 0.000 description 3
- XQEOZJWZOBQCDS-PCLIKHOPSA-N 3-[(1e)-1-[3-fluoro-8-[(7-methoxy-2-propan-2-ylimidazo[1,2-a]pyrimidin-3-yl)methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound CC(C)C=1N=C2N=C(OC)C=CN2C=1CC(C=1)=CC=C2C=1COC1=CC(F)=CC=C1\C2=C(/C)C1=NOC(=O)N1 XQEOZJWZOBQCDS-PCLIKHOPSA-N 0.000 description 3
- ISYZLBHQEVZFSI-YZSQISJMSA-N 3-[(1e)-1-[3-fluoro-8-[(8-methoxy-2-propan-2-ylimidazo[1,2-a]pyridin-3-yl)methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound CC(C)C=1N=C2C(OC)=CC=CN2C=1CC(C=1)=CC=C2C=1COC1=CC(F)=CC=C1\C2=C(/C)C1=NOC(=O)N1 ISYZLBHQEVZFSI-YZSQISJMSA-N 0.000 description 3
- VLNIFGQGTJFRDJ-WGOQTCKBSA-N 3-[(1e)-1-[3-fluoro-8-[[2-(methoxymethyl)-4-methylsulfonylbenzimidazol-1-yl]methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound COCC1=NC2=C(S(C)(=O)=O)C=CC=C2N1CC(C=1)=CC=C2C=1COC1=CC(F)=CC=C1\C2=C(/C)C1=NOC(=O)N1 VLNIFGQGTJFRDJ-WGOQTCKBSA-N 0.000 description 3
- AOBNEXUVVAGTJO-ZVHZXABRSA-N 3-[(1e)-1-[3-fluoro-8-[[2-methoxy-7-(trifluoromethyl)imidazo[1,2-a]pyridin-3-yl]methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound COC=1N=C2C=C(C(F)(F)F)C=CN2C=1CC(C=1)=CC=C2C=1COC1=CC(F)=CC=C1\C2=C(/C)C1=NOC(=O)N1 AOBNEXUVVAGTJO-ZVHZXABRSA-N 0.000 description 3
- OISANYUIYWBDAW-WPWMEQJKSA-N 3-[(1e)-1-[3-fluoro-8-[[4-(2-hydroxypropan-2-yl)-2-(methoxymethyl)benzimidazol-1-yl]methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound COCC1=NC2=C(C(C)(C)O)C=CC=C2N1CC(C=1)=CC=C2C=1COC1=CC(F)=CC=C1\C2=C(/C)C1=NOC(=O)N1 OISANYUIYWBDAW-WPWMEQJKSA-N 0.000 description 3
- SKZQZBKMPZSOQH-CVKSISIWSA-N 3-[(1e)-1-[8-[(2-cyclopropyl-6-fluoroimidazo[1,2-a]pyridin-3-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound C/12=CC=C(CC=3N4C=C(F)C=CC4=NC=3C3CC3)C=C2COC2=CC(F)=CC=C2C\1=C(/C)C1=NOC(=O)N1 SKZQZBKMPZSOQH-CVKSISIWSA-N 0.000 description 3
- YXWZACQWYMHYOI-YZSQISJMSA-N 3-[(1e)-1-[8-[(2-cyclopropyl-8-methylimidazo[1,2-a]pyridin-3-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound C/12=CC=C(CC=3N4C=CC=C(C)C4=NC=3C3CC3)C=C2COC2=CC(F)=CC=C2C\1=C(/C)C1=NOC(=O)N1 YXWZACQWYMHYOI-YZSQISJMSA-N 0.000 description 3
- SWHUURKTJADRBF-MFKUBSTISA-N 3-[(1e)-1-[8-[(2-cyclopropylimidazo[1,2-b]pyridazin-3-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound C/12=CC=C(CC=3N4N=CC=CC4=NC=3C3CC3)C=C2COC2=CC(F)=CC=C2C\1=C(/C)C1=NOC(=O)N1 SWHUURKTJADRBF-MFKUBSTISA-N 0.000 description 3
- IFGOCAWEEAVDIP-MTDXEUNCSA-N 3-[(1e)-1-[8-[(2-ethyl-4-phenylimidazol-1-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound CCC1=NC(C=2C=CC=CC=2)=CN1CC(C=1)=CC=C2C=1COC1=CC(F)=CC=C1\C2=C(/C)C1=NOC(=O)N1 IFGOCAWEEAVDIP-MTDXEUNCSA-N 0.000 description 3
- POTCVXCAZIFVLP-WGOQTCKBSA-N 3-[(1e)-1-[8-[(2-ethylbenzimidazol-1-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound CCC1=NC2=CC=CC=C2N1CC(C=1)=CC=C2C=1COC1=CC(F)=CC=C1\C2=C(/C)C1=NOC(=O)N1 POTCVXCAZIFVLP-WGOQTCKBSA-N 0.000 description 3
- OYAXCQNSVJFIOP-MFKUBSTISA-N 3-[(1e)-1-[8-[(4-chloro-2-cyclopropylbenzimidazol-1-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound C/12=CC=C(CN3C4=CC=CC(Cl)=C4N=C3C3CC3)C=C2COC2=CC(F)=CC=C2C\1=C(/C)C1=NOC(=O)N1 OYAXCQNSVJFIOP-MFKUBSTISA-N 0.000 description 3
- KRIVHCKOIYXTAP-OEAKJJBVSA-N 3-[(1e)-1-[8-[(7-chloro-2-cyclopropylimidazo[4,5-b]pyridin-3-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound C/12=CC=C(CN3C4=NC=CC(Cl)=C4N=C3C3CC3)C=C2COC2=CC(F)=CC=C2C\1=C(/C)C1=NOC(=O)N1 KRIVHCKOIYXTAP-OEAKJJBVSA-N 0.000 description 3
- USUSDBPMMWFHAC-WGOQTCKBSA-N 3-[(1e)-1-[8-[(8-chloro-2-cyclobutylimidazo[1,2-a]pyridin-3-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound C/12=CC=C(CC=3N4C=CC=C(Cl)C4=NC=3C3CCC3)C=C2COC2=CC(F)=CC=C2C\1=C(/C)C1=NOC(=O)N1 USUSDBPMMWFHAC-WGOQTCKBSA-N 0.000 description 3
- RKHUZGOIUQBFAF-ZVHZXABRSA-N 3-[(1e)-1-[8-[[2-cyclopropyl-7-(trifluoromethyl)imidazo[1,2-a]pyrimidin-3-yl]methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound C/12=CC=C(CC=3N4C=CC(=NC4=NC=3C3CC3)C(F)(F)F)C=C2COC2=CC(F)=CC=C2C\1=C(/C)C1=NOC(=O)N1 RKHUZGOIUQBFAF-ZVHZXABRSA-N 0.000 description 3
- GOWYNWBJMDNOIQ-PCLIKHOPSA-N 3-[(1e)-1-[8-[[2-cyclopropyl-8-(dimethylamino)imidazo[1,2-a]pyrazin-3-yl]methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound C1CC1C=1N=C2C(N(C)C)=NC=CN2C=1CC(C=1)=CC=C2C=1COC1=CC(F)=CC=C1\C2=C(/C)C1=NOC(=O)N1 GOWYNWBJMDNOIQ-PCLIKHOPSA-N 0.000 description 3
- ZYXVKWNPVNLCQQ-ILIWNJCXSA-N 3-[(1e)-1-[8-[[2-cyclopropyl-8-(trideuteriomethoxy)imidazo[1,2-a]pyridin-3-yl]methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound C1CC1C=1N=C2C(OC([2H])([2H])[2H])=CC=CN2C=1CC(C=1)=CC=C2C=1COC1=CC(F)=CC=C1\C2=C(/C)C1=NC(=O)ON1 ZYXVKWNPVNLCQQ-ILIWNJCXSA-N 0.000 description 3
- IOYJDYRYYJBISS-MFKUBSTISA-N 3-[(1e)-1-[8-[[4-(dimethylamino)-6-(methoxymethyl)-2-methylpyrimidin-5-yl]methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound COCC1=NC(C)=NC(N(C)C)=C1CC(C=C1COC=2C\3=CC=C(F)C=2)=CC=C1C/3=C(/C)C1=NOC(=O)N1 IOYJDYRYYJBISS-MFKUBSTISA-N 0.000 description 3
- CBMITQSJYIAYPC-MFKUBSTISA-N 3-[(1e)-1-[8-[[4-chloro-2-(methoxymethyl)benzimidazol-1-yl]methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound COCC1=NC2=C(Cl)C=CC=C2N1CC(C=1)=CC=C2C=1COC1=CC(F)=CC=C1\C2=C(/C)C1=NOC(=O)N1 CBMITQSJYIAYPC-MFKUBSTISA-N 0.000 description 3
- ZIUZEZVWWPZBBQ-MFKUBSTISA-N 3-[(1e)-1-[8-[[8-chloro-2-(methoxymethyl)imidazo[1,2-a]pyridin-3-yl]methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound COCC=1N=C2C(Cl)=CC=CN2C=1CC(C=1)=CC=C2C=1COC1=CC(F)=CC=C1\C2=C(/C)C1=NOC(=O)N1 ZIUZEZVWWPZBBQ-MFKUBSTISA-N 0.000 description 3
- ZIUZEZVWWPZBBQ-BKTUNJTESA-N 3-[(1e)-1-[8-[[8-chloro-2-(trideuteriomethoxymethyl)imidazo[1,2-a]pyridin-3-yl]methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound [2H]C([2H])([2H])OCC=1N=C2C(Cl)=CC=CN2C=1CC(C=1)=CC=C2C=1COC1=CC(F)=CC=C1\C2=C(/C)C1=NC(=O)ON1 ZIUZEZVWWPZBBQ-BKTUNJTESA-N 0.000 description 3
- RFEDZSBDCBMQMU-FYJGNVAPSA-N 3-[(e)-[8-[(8-chloro-2-cyclopropylimidazo[1,2-a]pyridin-3-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]methyl]-2h-1,2,4-oxadiazol-5-one Chemical compound C=1C(F)=CC=C(C(/C2=CC=3)=C/C=4NC(=O)ON=4)C=1OCC2=CC=3CC(N1C=CC=C(Cl)C1=N1)=C1C1CC1 RFEDZSBDCBMQMU-FYJGNVAPSA-N 0.000 description 3
- YWINDTKPDCDISX-BYYHNAKLSA-N 3-[(e)-cyclopropyl-[8-[(2-cyclopropylbenzimidazol-1-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]methyl]-2h-1,2,4-oxadiazol-5-one Chemical compound C=1C(F)=CC=C(C(/C2=CC=3)=C(\C4CC4)C=4NC(=O)ON=4)C=1OCC2=CC=3CN(C1=CC=CC=C1N=1)C=1C1CC1 YWINDTKPDCDISX-BYYHNAKLSA-N 0.000 description 3
- IZBMNYGOMPDASN-VHXPQNKSSA-N 3-[(z)-[8-[(8-chloro-2-cyclopropylimidazo[1,2-a]pyridin-3-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]-fluoromethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound C/12=CC=C(CC=3N4C=CC=C(Cl)C4=NC=3C3CC3)C=C2COC2=CC(F)=CC=C2C\1=C(/F)C1=NOC(=O)N1 IZBMNYGOMPDASN-VHXPQNKSSA-N 0.000 description 3
- TTYAYECYWJQUTI-UHFFFAOYSA-N 3-iodo-2-(methoxymethyl)imidazo[1,2-a]pyridine Chemical compound C1=CC=CN2C(I)=C(COC)N=C21 TTYAYECYWJQUTI-UHFFFAOYSA-N 0.000 description 3
- TTYAYECYWJQUTI-FIBGUPNXSA-N 3-iodo-2-(trideuteriomethoxymethyl)imidazo[1,2-a]pyridine Chemical compound C1=CC=CN2C(I)=C(COC([2H])([2H])[2H])N=C21 TTYAYECYWJQUTI-FIBGUPNXSA-N 0.000 description 3
- KJWYWWFKEUJIAC-UHFFFAOYSA-N 4-(6-fluoro-2-nitropyridin-3-yl)butan-1-amine Chemical compound C1=CC(=NC(=C1CCCCN)[N+](=O)[O-])F KJWYWWFKEUJIAC-UHFFFAOYSA-N 0.000 description 3
- WCCFLOQQACDOAX-UHFFFAOYSA-N 4-fluoropyridin-2-amine Chemical compound NC1=CC(F)=CC=N1 WCCFLOQQACDOAX-UHFFFAOYSA-N 0.000 description 3
- XNITVICVSAUJEW-UHFFFAOYSA-N 7-chloro-3-iodo-2-(methoxymethyl)imidazo[1,2-a]pyridine Chemical compound C1=C(Cl)C=CN2C(I)=C(COC)N=C21 XNITVICVSAUJEW-UHFFFAOYSA-N 0.000 description 3
- QXRQACDTEHQLGU-UHFFFAOYSA-N 7-chloro-3-iodo-2-methylimidazo[1,2-a]pyridine Chemical compound C1=C(Cl)C=CN2C(I)=C(C)N=C21 QXRQACDTEHQLGU-UHFFFAOYSA-N 0.000 description 3
- BLKCOEUZAFDPMQ-UHFFFAOYSA-N 8-chloro-2-(chloromethyl)imidazo[1,2-a]pyridine Chemical compound C1=CC=C(Cl)C2=NC(CCl)=CN21 BLKCOEUZAFDPMQ-UHFFFAOYSA-N 0.000 description 3
- XDEUOMIEZKNLMF-UHFFFAOYSA-N 8-chloro-3-iodo-2-(methoxymethyl)imidazo[1,2-a]pyridine Chemical compound ClC1=CC=CN2C(I)=C(COC)N=C21 XDEUOMIEZKNLMF-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 102100039556 Galectin-4 Human genes 0.000 description 3
- 101000608765 Homo sapiens Galectin-4 Proteins 0.000 description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 239000012448 Lithium borohydride Substances 0.000 description 3
- 108060001084 Luciferase Proteins 0.000 description 3
- 239000005089 Luciferase Substances 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 3
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 125000005333 aroyloxy group Chemical group 0.000 description 3
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 3
- 125000002619 bicyclic group Chemical group 0.000 description 3
- 229910052796 boron Inorganic materials 0.000 description 3
- YHASWHZGWUONAO-UHFFFAOYSA-N butanoyl butanoate Chemical compound CCCC(=O)OC(=O)CCC YHASWHZGWUONAO-UHFFFAOYSA-N 0.000 description 3
- RBHJBMIOOPYDBQ-UHFFFAOYSA-N carbon dioxide;propan-2-one Chemical compound O=C=O.CC(C)=O RBHJBMIOOPYDBQ-UHFFFAOYSA-N 0.000 description 3
- BULLHNJGPPOUOX-UHFFFAOYSA-N chloroacetone Chemical compound CC(=O)CCl BULLHNJGPPOUOX-UHFFFAOYSA-N 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- CCERQOYLJJULMD-UHFFFAOYSA-M magnesium;carbanide;chloride Chemical compound [CH3-].[Mg+2].[Cl-] CCERQOYLJJULMD-UHFFFAOYSA-M 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- IZDROVVXIHRYMH-UHFFFAOYSA-N methanesulfonic anhydride Chemical compound CS(=O)(=O)OS(C)(=O)=O IZDROVVXIHRYMH-UHFFFAOYSA-N 0.000 description 3
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 3
- IJEBKHCMUDQAPX-UHFFFAOYSA-N methyl 2-(methoxymethyl)-1h-benzimidazole-4-carboxylate Chemical compound C1=CC=C2NC(COC)=NC2=C1C(=O)OC IJEBKHCMUDQAPX-UHFFFAOYSA-N 0.000 description 3
- GLFMAFIHYMNSRK-UHFFFAOYSA-N methyl 2-propyl-1h-benzimidazole-4-carboxylate Chemical compound C1=CC=C2NC(CCC)=NC2=C1C(=O)OC GLFMAFIHYMNSRK-UHFFFAOYSA-N 0.000 description 3
- 102000006255 nuclear receptors Human genes 0.000 description 3
- 108020004017 nuclear receptors Proteins 0.000 description 3
- 229910000160 potassium phosphate Inorganic materials 0.000 description 3
- 235000011009 potassium phosphates Nutrition 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 125000000168 pyrrolyl group Chemical group 0.000 description 3
- 235000009518 sodium iodide Nutrition 0.000 description 3
- 235000019345 sodium thiosulphate Nutrition 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- VOPXFMHNPAKBMQ-ZNLRHDTNSA-N tert-butyl N-[[1-[[(11E)-11-(2-cyanoethylidene)-3-fluoro-6H-benzo[c][1]benzoxepin-8-yl]methyl]benzimidazol-2-yl]methyl]-N-methylcarbamate Chemical compound C1=C2COC3=CC(F)=CC=C3\C(=C\CC#N)C2=CC=C1CN1C2=CC=CC=C2N=C1CN(C)C(=O)OC(C)(C)C VOPXFMHNPAKBMQ-ZNLRHDTNSA-N 0.000 description 3
- 239000008096 xylene Substances 0.000 description 3
- RBWMYPKAPIYTJQ-VMBFOHBNSA-N (1R,2S,5S)-6,6-dimethyl-N-[(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]-3-[2-[4-(trifluoromethoxy)phenoxy]acetyl]-3-azabicyclo[3.1.0]hexane-2-carboxamide Chemical compound CC1([C@@H]2[C@H]1[C@H](N(C2)C(=O)COC3=CC=C(C=C3)OC(F)(F)F)C(=O)N[C@@H](C[C@@H]4CCNC4=O)C=O)C RBWMYPKAPIYTJQ-VMBFOHBNSA-N 0.000 description 2
- HBENZIXOGRCSQN-VQWWACLZSA-N (1S,2S,6R,14R,15R,16R)-5-(cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylpentan-2-yl]-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol Chemical compound N1([C@@H]2CC=3C4=C(C(=CC=3)O)O[C@H]3[C@@]5(OC)CC[C@@]2([C@@]43CC1)C[C@@H]5[C@](C)(O)C(C)(C)CC)CC1CC1 HBENZIXOGRCSQN-VQWWACLZSA-N 0.000 description 2
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 2
- FANCTJAFZSYTIS-IQUVVAJASA-N (1r,3s,5z)-5-[(2e)-2-[(1r,3as,7ar)-7a-methyl-1-[(2r)-4-(phenylsulfonimidoyl)butan-2-yl]-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol Chemical compound C([C@@H](C)[C@@H]1[C@]2(CCCC(/[C@@H]2CC1)=C\C=C\1C([C@@H](O)C[C@H](O)C/1)=C)C)CS(=N)(=O)C1=CC=CC=C1 FANCTJAFZSYTIS-IQUVVAJASA-N 0.000 description 2
- XGEKGCZJDVVOJA-UHFFFAOYSA-N (2-nitrophenyl) trifluoromethanesulfonate Chemical compound [O-][N+](=O)C1=CC=CC=C1OS(=O)(=O)C(F)(F)F XGEKGCZJDVVOJA-UHFFFAOYSA-N 0.000 description 2
- KSFKAHQARADUOF-UHFFFAOYSA-N (2-propyl-1h-benzimidazol-4-yl)methanol Chemical compound C1=CC=C2NC(CCC)=NC2=C1CO KSFKAHQARADUOF-UHFFFAOYSA-N 0.000 description 2
- SHAHPWSYJFYMRX-GDLCADMTSA-N (2S)-2-(4-{[(1R,2S)-2-hydroxycyclopentyl]methyl}phenyl)propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C[C@@H]1[C@@H](O)CCC1 SHAHPWSYJFYMRX-GDLCADMTSA-N 0.000 description 2
- QMGHHBHPDDAGGO-IIWOMYBWSA-N (2S,4R)-1-[(2S)-2-[[2-[3-[4-[3-[4-[[5-bromo-4-[3-[cyclobutanecarbonyl(methyl)amino]propylamino]pyrimidin-2-yl]amino]phenoxy]propoxy]butoxy]propoxy]acetyl]amino]-3,3-dimethylbutanoyl]-4-hydroxy-N-[[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide Chemical compound CN(CCCNC1=NC(NC2=CC=C(OCCCOCCCCOCCCOCC(=O)N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)NCC3=CC=C(C=C3)C3=C(C)N=CS3)C(C)(C)C)C=C2)=NC=C1Br)C(=O)C1CCC1 QMGHHBHPDDAGGO-IIWOMYBWSA-N 0.000 description 2
- QSZQOJNNNXNKIW-FRKPEAEDSA-N (2e)-2-(8-ethynyl-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene)acetonitrile Chemical compound O1CC2=CC(C#C)=CC=C2\C(=C/C#N)C2=CC=C(F)C=C12 QSZQOJNNNXNKIW-FRKPEAEDSA-N 0.000 description 2
- GCYGFPBUAOOWLN-WPWMEQJKSA-N (2e)-2-[1,3-difluoro-8-[(2-propylbenzimidazol-1-yl)methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC(F)=C3\C(=C(/C)C#N)C2=CC=C1CN1C2=CC=CC=C2N=C1CCC GCYGFPBUAOOWLN-WPWMEQJKSA-N 0.000 description 2
- UAGVAICVYSJXNC-OGLMXYFKSA-N (2e)-2-[2,3-difluoro-8-[(2-propylbenzimidazol-1-yl)methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=C(F)C=C3\C(=C(/C)C#N)C2=CC=C1CN1C2=CC=CC=C2N=C1CCC UAGVAICVYSJXNC-OGLMXYFKSA-N 0.000 description 2
- ICSGNGFRJCQJFB-YZSQISJMSA-N (2e)-2-[3,4-difluoro-8-[(2-propylbenzimidazol-1-yl)methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=C(F)C(F)=CC=C3\C(=C(/C)C#N)C2=CC=C1CN1C2=CC=CC=C2N=C1CCC ICSGNGFRJCQJFB-YZSQISJMSA-N 0.000 description 2
- ZPVHMJFFDZSEBU-WOJGMQOQSA-N (2e)-2-[3-fluoro-8-(hydroxymethyl)-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1OC2=CC(F)=CC=C2C(=C(C#N)/C)\C2=CC=C(CO)C=C21 ZPVHMJFFDZSEBU-WOJGMQOQSA-N 0.000 description 2
- NSKUFGIJZFOVFC-JVWAILMASA-N (2e)-2-[3-fluoro-8-[(2-methyl-1h-indol-3-yl)methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3C(=C(C#N)/C)\C2=CC=C1CC1=C(C)NC2=CC=CC=C12 NSKUFGIJZFOVFC-JVWAILMASA-N 0.000 description 2
- UFJHCYVJFLCTKG-MFKUBSTISA-N (2e)-2-[3-fluoro-8-[(2-methyl-4-oxo-6-propyl-1h-pyrimidin-5-yl)methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound N1=C(C)NC(=O)C(CC=2C=C3C(C(/C4=CC=C(F)C=C4OC3)=C(/C)C#N)=CC=2)=C1CCC UFJHCYVJFLCTKG-MFKUBSTISA-N 0.000 description 2
- BSQKYNAWBDEMGK-ZTKZIYFRSA-N (2e)-2-[3-fluoro-8-[(2-piperidin-1-ylbenzimidazol-1-yl)methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3C(=C(C#N)/C)\C2=CC=C1CN(C1=CC=CC=C1N=1)C=1N1CCCCC1 BSQKYNAWBDEMGK-ZTKZIYFRSA-N 0.000 description 2
- ORERWYJTRFPOFX-OVVQPSECSA-N (2e)-2-[3-fluoro-8-[(2-propan-2-ylbenzimidazol-1-yl)methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3\C(=C(/C)C#N)C2=CC=C1CN1C2=CC=CC=C2N=C1C(C)C ORERWYJTRFPOFX-OVVQPSECSA-N 0.000 description 2
- XBMCBEMUDANTPM-OVVQPSECSA-N (2e)-2-[3-fluoro-8-[(2-propan-2-ylimidazo[1,2-a]pyridin-3-yl)methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3\C(=C(/C)C#N)C2=CC=C1CC1=C(C(C)C)N=C2N1C=CC=C2 XBMCBEMUDANTPM-OVVQPSECSA-N 0.000 description 2
- HECKPBYJAYJABX-RDRPBHBLSA-N (2e)-2-[3-fluoro-8-[(2-propyl-1h-indol-3-yl)methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3\C(=C(/C)C#N)C2=CC=C1CC1=C(CCC)NC2=CC=CC=C21 HECKPBYJAYJABX-RDRPBHBLSA-N 0.000 description 2
- ONYDVJFACMUMBU-YZSQISJMSA-N (2e)-2-[3-fluoro-8-[(2-propyl-2,3-dihydroimidazo[4,5-b]pyridin-1-yl)methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3\C(=C(/C)C#N)C2=CC=C1CN1C2=CC=CN=C2NC1CCC ONYDVJFACMUMBU-YZSQISJMSA-N 0.000 description 2
- VGQDSGMENXFLFF-MTDXEUNCSA-N (2e)-2-[3-fluoro-8-[(2-propylbenzimidazol-1-yl)methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3\C(=C(/C)C#N)C2=CC=C1CN1C2=CC=CC=C2N=C1CCC VGQDSGMENXFLFF-MTDXEUNCSA-N 0.000 description 2
- CQROTHYQLPRSKD-MTDXEUNCSA-N (2e)-2-[3-fluoro-8-[(2-propylimidazo[1,2-a]pyridin-3-yl)methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3\C(=C(/C)C#N)C2=CC=C1CC1=C(CCC)N=C2N1C=CC=C2 CQROTHYQLPRSKD-MTDXEUNCSA-N 0.000 description 2
- GTCBQKYRTMSHGU-LFVJCYFKSA-N (2e)-2-[3-fluoro-8-[(2-propylimidazo[4,5-b]pyrazin-3-yl)methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3\C(=C(/C)C#N)C2=CC=C1CN1C2=NC=CN=C2N=C1CCC GTCBQKYRTMSHGU-LFVJCYFKSA-N 0.000 description 2
- XOLBGDYWZJBXJU-WPWMEQJKSA-N (2e)-2-[3-fluoro-8-[(2-propylimidazo[4,5-c]pyridin-1-yl)methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3\C(=C(/C)C#N)C2=CC=C1CN1C2=CC=NC=C2N=C1CCC XOLBGDYWZJBXJU-WPWMEQJKSA-N 0.000 description 2
- SIMVBSNQFVSPPB-VUTHCHCSSA-N (2e)-2-[3-fluoro-8-[(2-pyridin-2-ylbenzimidazol-1-yl)methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3C(=C(C#N)/C)\C2=CC=C1CN(C1=CC=CC=C1N=1)C=1C1=CC=CC=N1 SIMVBSNQFVSPPB-VUTHCHCSSA-N 0.000 description 2
- HNIDSUQJGLHIJN-TURZUDJPSA-N (2e)-2-[3-fluoro-8-[(2-pyrrolidin-1-ylbenzimidazol-1-yl)methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3C(=C(C#N)/C)\C2=CC=C1CN(C1=CC=CC=C1N=1)C=1N1CCCC1 HNIDSUQJGLHIJN-TURZUDJPSA-N 0.000 description 2
- LHMQQGZIFHEMBD-MTDXEUNCSA-N (2e)-2-[3-fluoro-8-[(4-methoxy-2-propylbenzimidazol-1-yl)methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3\C(=C(/C)C#N)C2=CC=C1CN1C2=CC=CC(OC)=C2N=C1CCC LHMQQGZIFHEMBD-MTDXEUNCSA-N 0.000 description 2
- LUQMDFFSWAHAHU-WGOQTCKBSA-N (2e)-2-[3-fluoro-8-[(5-fluoro-2-propylimidazo[4,5-b]pyridin-1-yl)methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3\C(=C(/C)C#N)C2=CC=C1CN1C2=CC=C(F)N=C2N=C1CCC LUQMDFFSWAHAHU-WGOQTCKBSA-N 0.000 description 2
- SPEJNPWRJFEKAQ-WGOQTCKBSA-N (2e)-2-[3-fluoro-8-[(5-fluoro-2-propylimidazo[4,5-b]pyridin-3-yl)methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3\C(=C(/C)C#N)C2=CC=C1CN1C2=NC(F)=CC=C2N=C1CCC SPEJNPWRJFEKAQ-WGOQTCKBSA-N 0.000 description 2
- XWOSOVDPAURTKN-YZSQISJMSA-N (2e)-2-[3-fluoro-8-[(7-methoxy-2-propan-2-ylimidazo[1,2-a]pyrimidin-3-yl)methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3\C(=C(/C)C#N)C2=CC=C1CC1=C(C(C)C)N=C2N1C=CC(OC)=N2 XWOSOVDPAURTKN-YZSQISJMSA-N 0.000 description 2
- UGMVWUPVALQMNT-OVVQPSECSA-N (2e)-2-[3-fluoro-8-[(8-methoxy-2-propan-2-ylimidazo[1,2-a]pyridin-3-yl)methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3\C(=C(/C)C#N)C2=CC=C1CC1=C(C(C)C)N=C2C(OC)=CC=CN21 UGMVWUPVALQMNT-OVVQPSECSA-N 0.000 description 2
- OXNRBHKRPRTQFH-WPWMEQJKSA-N (2e)-2-[3-fluoro-8-[(8-methyl-2-propylimidazo[1,2-a]pyrazin-3-yl)methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3\C(=C(/C)C#N)C2=CC=C1CC1=C(CCC)N=C2N1C=CN=C2C OXNRBHKRPRTQFH-WPWMEQJKSA-N 0.000 description 2
- KGWUVELCQCXGOO-OVVQPSECSA-N (2e)-2-[3-fluoro-8-[[2-(1-methylcyclopropyl)benzimidazol-1-yl]methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3C(=C(C#N)/C)\C2=CC=C1CN(C1=CC=CC=C1N=1)C=1C1(C)CC1 KGWUVELCQCXGOO-OVVQPSECSA-N 0.000 description 2
- JFJYFVOFBIBMPM-MTDXEUNCSA-N (2e)-2-[3-fluoro-8-[[2-(furan-2-yl)benzimidazol-1-yl]methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3C(=C(C#N)/C)\C2=CC=C1CN(C1=CC=CC=C1N=1)C=1C1=CC=CO1 JFJYFVOFBIBMPM-MTDXEUNCSA-N 0.000 description 2
- STDVCSIFSSZWDS-ILIWNJCXSA-N (2e)-2-[3-fluoro-8-[[2-(hydroxymethyl)-4-(trideuteriomethoxy)benzimidazol-1-yl]methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3\C(=C(/C)C#N)C2=CC=C1CN1C(C=CC=C2OC([2H])([2H])[2H])=C2N=C1CO STDVCSIFSSZWDS-ILIWNJCXSA-N 0.000 description 2
- ZVEZJCIGALMSDM-GAYJSTNSSA-N (2e)-2-[3-fluoro-8-[[2-(methoxymethyl)-4-(trideuteriomethoxy)benzimidazol-1-yl]methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3\C(=C(/C)C#N)C2=CC=C1CN1C(C=CC=C2OC([2H])([2H])[2H])=C2N=C1COC ZVEZJCIGALMSDM-GAYJSTNSSA-N 0.000 description 2
- FBIVWEMIUMVXAV-TURZUDJPSA-N (2e)-2-[3-fluoro-8-[[2-(methoxymethyl)benzimidazol-1-yl]methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]butanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3C(=C(C#N)/CC)\C2=CC=C1CN1C2=CC=CC=C2N=C1COC FBIVWEMIUMVXAV-TURZUDJPSA-N 0.000 description 2
- WMBSRYMADZNGNK-WPWMEQJKSA-N (2e)-2-[3-fluoro-8-[[2-(methoxymethyl)benzimidazol-1-yl]methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3\C(=C(/C)C#N)C2=CC=C1CN1C2=CC=CC=C2N=C1COC WMBSRYMADZNGNK-WPWMEQJKSA-N 0.000 description 2
- YAUDCMARIRRWIE-WPWMEQJKSA-N (2e)-2-[3-fluoro-8-[[2-(methoxymethyl)imidazo[1,2-a]pyridin-3-yl]methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3\C(=C(/C)C#N)C2=CC=C1CC1=C(COC)N=C2N1C=CC=C2 YAUDCMARIRRWIE-WPWMEQJKSA-N 0.000 description 2
- WUGHXKWFCKBNDD-MFKUBSTISA-N (2e)-2-[3-fluoro-8-[[2-(methoxymethyl)thieno[3,4-d]imidazol-3-yl]methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3\C(=C(/C)C#N)C2=CC=C1CN1C2=CSC=C2N=C1COC WUGHXKWFCKBNDD-MFKUBSTISA-N 0.000 description 2
- UJEFXWISVXTJPV-WPWMEQJKSA-N (2e)-2-[3-fluoro-8-[[2-(methylaminomethyl)benzimidazol-1-yl]methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3\C(=C(/C)C#N)C2=CC=C1CN1C2=CC=CC=C2N=C1CNC UJEFXWISVXTJPV-WPWMEQJKSA-N 0.000 description 2
- FMTYMIZRZUYBRT-MFKUBSTISA-N (2e)-2-[3-fluoro-8-[[2-methoxy-7-(trifluoromethyl)imidazo[1,2-a]pyridin-3-yl]methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3\C(=C(/C)C#N)C2=CC=C1CC1=C(OC)N=C2N1C=CC(C(F)(F)F)=C2 FMTYMIZRZUYBRT-MFKUBSTISA-N 0.000 description 2
- VTNPQVSCSCTEAE-AJBULDERSA-N (2e)-2-[3-fluoro-8-[[2-methyl-7-(2-trimethylsilylethynyl)imidazo[1,2-a]pyridin-3-yl]methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3C(=C(C#N)/C)\C2=CC=C1CC1=C(C)N=C2N1C=CC(C#C[Si](C)(C)C)=C2 VTNPQVSCSCTEAE-AJBULDERSA-N 0.000 description 2
- GZHSPVLUFUODRB-CVKSISIWSA-N (2e)-2-[3-fluoro-8-[[2-methyl-7-(trifluoromethyl)imidazo[1,2-a]pyridin-3-yl]methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3C(=C(C#N)/C)\C2=CC=C1CC1=C(C)N=C2N1C=CC(C(F)(F)F)=C2 GZHSPVLUFUODRB-CVKSISIWSA-N 0.000 description 2
- HEXLFKVVPAONGO-MFKUBSTISA-N (2e)-2-[3-fluoro-8-[[2-methyl-8-(trifluoromethyl)imidazo[1,2-a]pyridin-3-yl]methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3C(=C(C#N)/C)\C2=CC=C1CC1=C(C)N=C2N1C=CC=C2C(F)(F)F HEXLFKVVPAONGO-MFKUBSTISA-N 0.000 description 2
- UGMVWUPVALQMNT-SZEFNLLYSA-N (2e)-2-[3-fluoro-8-[[2-propan-2-yl-8-(trideuteriomethoxy)imidazo[1,2-a]pyridin-3-yl]methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3\C(=C(/C)C#N)C2=CC=C1CC1=C(C(C)C)N=C2C(OC([2H])([2H])[2H])=CC=CN21 UGMVWUPVALQMNT-SZEFNLLYSA-N 0.000 description 2
- WEXJMZYNBMQMCO-MTDXEUNCSA-N (2e)-2-[3-fluoro-8-[[4-(2-hydroxypropan-2-yl)-2-(methoxymethyl)benzimidazol-1-yl]methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3\C(=C(/C)C#N)C2=CC=C1CN1C2=CC=CC(C(C)(C)O)=C2N=C1COC WEXJMZYNBMQMCO-MTDXEUNCSA-N 0.000 description 2
- IDDUQAACICWUFO-MTDXEUNCSA-N (2e)-2-[3-fluoro-8-[[4-(hydroxymethyl)-2-propylbenzimidazol-1-yl]methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3\C(=C(/C)C#N)C2=CC=C1CN1C2=CC=CC(CO)=C2N=C1CCC IDDUQAACICWUFO-MTDXEUNCSA-N 0.000 description 2
- KJHYSGKIHAPBAA-ZVHZXABRSA-N (2e)-2-[3-fluoro-8-[[6-(methoxymethyl)-2-methyl-4-oxo-1h-pyrimidin-5-yl]methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound N1=C(C)NC(=O)C(CC=2C=C3C(C(/C4=CC=C(F)C=C4OC3)=C(/C)C#N)=CC=2)=C1COC KJHYSGKIHAPBAA-ZVHZXABRSA-N 0.000 description 2
- AFWDLXKGYZVFTM-WPWMEQJKSA-N (2e)-2-[3-fluoro-8-[[8-methoxy-2-(methoxymethyl)imidazo[1,2-a]pyridin-3-yl]methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3\C(=C(/C)C#N)C2=CC=C1CC1=C(COC)N=C2N1C=CC=C2OC AFWDLXKGYZVFTM-WPWMEQJKSA-N 0.000 description 2
- HUQYRGUJVDNWBR-KOEQRZSOSA-N (2e)-2-[3-fluoro-8-[hydroxy-(2-propan-2-ylimidazo[1,2-a]pyridin-3-yl)methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3\C(=C(/C)C#N)C2=CC=C1C(O)C1=C(C(C)C)N=C2N1C=CC=C2 HUQYRGUJVDNWBR-KOEQRZSOSA-N 0.000 description 2
- NMXXSZSFCNSBOM-YZSQISJMSA-N (2e)-2-[3-fluoro-8-[hydroxy-(2-propylimidazo[1,2-a]pyridin-3-yl)methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3\C(=C(/C)C#N)C2=CC=C1C(O)C1=C(CCC)N=C2N1C=CC=C2 NMXXSZSFCNSBOM-YZSQISJMSA-N 0.000 description 2
- UJQSPQBSRALDNE-LFVJCYFKSA-N (2e)-2-[3-fluoro-8-[hydroxy-(7-methoxy-2-propan-2-ylimidazo[1,2-a]pyrimidin-3-yl)methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3\C(=C(/C)C#N)C2=CC=C1C(O)C1=C(C(C)C)N=C2N1C=CC(OC)=N2 UJQSPQBSRALDNE-LFVJCYFKSA-N 0.000 description 2
- CSASRJHKGJHFIY-KOEQRZSOSA-N (2e)-2-[3-fluoro-8-[hydroxy-(8-methoxy-2-propan-2-ylimidazo[1,2-a]pyridin-3-yl)methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3\C(=C(/C)C#N)C2=CC=C1C(O)C1=C(C(C)C)N=C2C(OC)=CC=CN21 CSASRJHKGJHFIY-KOEQRZSOSA-N 0.000 description 2
- LAYZBLAPNDHOAD-PCLIKHOPSA-N (2e)-2-[3-fluoro-8-[hydroxy-(8-methyl-2-propylimidazo[1,2-a]pyrazin-3-yl)methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3\C(=C(/C)C#N)C2=CC=C1C(O)C1=C(CCC)N=C2N1C=CN=C2C LAYZBLAPNDHOAD-PCLIKHOPSA-N 0.000 description 2
- CCFLUSPKBXDBCF-BUVRLJJBSA-N (2e)-2-[3-fluoro-8-[hydroxy-[2-(methoxymethyl)-8-(trifluoromethyl)imidazo[1,2-a]pyridin-3-yl]methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3\C(=C(/C)C#N)C2=CC=C1C(O)C1=C(COC)N=C2N1C=CC=C2C(F)(F)F CCFLUSPKBXDBCF-BUVRLJJBSA-N 0.000 description 2
- SNAFWORAGGRCMJ-PCLIKHOPSA-N (2e)-2-[3-fluoro-8-[hydroxy-[2-(methoxymethyl)imidazo[1,2-a]pyridin-3-yl]methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3\C(=C(/C)C#N)C2=CC=C1C(O)C1=C(COC)N=C2N1C=CC=C2 SNAFWORAGGRCMJ-PCLIKHOPSA-N 0.000 description 2
- SNAFWORAGGRCMJ-JBCQSPKQSA-N (2e)-2-[3-fluoro-8-[hydroxy-[2-(trideuteriomethoxymethyl)imidazo[1,2-a]pyridin-3-yl]methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3\C(=C(/C)C#N)C2=CC=C1C(O)C1=C(COC([2H])([2H])[2H])N=C2N1C=CC=C2 SNAFWORAGGRCMJ-JBCQSPKQSA-N 0.000 description 2
- MEELFMDOHCSRRC-OEAKJJBVSA-N (2e)-2-[3-fluoro-8-[hydroxy-[2-methoxy-7-(trifluoromethyl)imidazo[1,2-a]pyridin-3-yl]methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3\C(=C(/C)C#N)C2=CC=C1C(O)C1=C(OC)N=C2N1C=CC(C(F)(F)F)=C2 MEELFMDOHCSRRC-OEAKJJBVSA-N 0.000 description 2
- COKYKRZWXAMEMU-ZVHZXABRSA-N (2e)-2-[3-fluoro-8-[hydroxy-[2-methyl-7-(trifluoromethyl)imidazo[1,2-a]pyridin-3-yl]methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1OC2=CC(F)=CC=C2C(=C(C#N)/C)\C2=CC=C(C(O)C=3N4C=CC(=CC4=NC=3C)C(F)(F)F)C=C21 COKYKRZWXAMEMU-ZVHZXABRSA-N 0.000 description 2
- CSASRJHKGJHFIY-IZQXHPOISA-N (2e)-2-[3-fluoro-8-[hydroxy-[2-propan-2-yl-8-(trideuteriomethoxy)imidazo[1,2-a]pyridin-3-yl]methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3\C(=C(/C)C#N)C2=CC=C1C(O)C1=C(C(C)C)N=C2C(OC([2H])([2H])[2H])=CC=CN21 CSASRJHKGJHFIY-IZQXHPOISA-N 0.000 description 2
- LUQUHWFYHJUEHE-PCLIKHOPSA-N (2e)-2-[3-fluoro-8-[hydroxy-[8-methoxy-2-(methoxymethyl)imidazo[1,2-a]pyridin-3-yl]methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3\C(=C(/C)C#N)C2=CC=C1C(O)C1=C(COC)N=C2N1C=CC=C2OC LUQUHWFYHJUEHE-PCLIKHOPSA-N 0.000 description 2
- ZVNBWKONRDWYLP-HYARGMPZSA-N (2e)-2-[8-[(2-chloroimidazo[1,2-a]pyridin-3-yl)-hydroxymethyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1OC2=CC(F)=CC=C2C(=C(C#N)/C)\C2=CC=C(C(O)C=3N4C=CC=CC4=NC=3Cl)C=C21 ZVNBWKONRDWYLP-HYARGMPZSA-N 0.000 description 2
- VJAJZJVBZLBHOV-BUVRLJJBSA-N (2e)-2-[8-[(2-chloroimidazo[1,2-a]pyridin-3-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3C(=C(C#N)/C)\C2=CC=C1CC1=C(Cl)N=C2N1C=CC=C2 VJAJZJVBZLBHOV-BUVRLJJBSA-N 0.000 description 2
- ZEWNJOAWGLUUIS-WGOQTCKBSA-N (2e)-2-[8-[(2-cyclobutyl-5-fluoroimidazo[4,5-b]pyridin-1-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3C(=C(C#N)/C)\C2=CC=C1CN(C1=CC=C(F)N=C1N=1)C=1C1CCC1 ZEWNJOAWGLUUIS-WGOQTCKBSA-N 0.000 description 2
- XYESAKIRNCCVGY-MTDXEUNCSA-N (2e)-2-[8-[(2-cyclobutylbenzimidazol-1-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3C(=C(C#N)/C)\C2=CC=C1CN(C1=CC=CC=C1N=1)C=1C1CCC1 XYESAKIRNCCVGY-MTDXEUNCSA-N 0.000 description 2
- KVXDITWHGUZYNF-MTDXEUNCSA-N (2e)-2-[8-[(2-cyclobutylimidazo[1,2-a]pyridin-3-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3C(=C(C#N)/C)\C2=CC=C1CC(N1C=CC=CC1=N1)=C1C1CCC1 KVXDITWHGUZYNF-MTDXEUNCSA-N 0.000 description 2
- CCTVTXWXDTWXPI-VUTHCHCSSA-N (2e)-2-[8-[(2-cyclopentylbenzimidazol-1-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3C(=C(C#N)/C)\C2=CC=C1CN(C1=CC=CC=C1N=1)C=1C1CCCC1 CCTVTXWXDTWXPI-VUTHCHCSSA-N 0.000 description 2
- SGUJLCFTBQZHQC-VUTHCHCSSA-N (2e)-2-[8-[(2-cyclopentylimidazo[1,2-a]pyridin-3-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3C(=C(C#N)/C)\C2=CC=C1CC(N1C=CC=CC1=N1)=C1C1CCCC1 SGUJLCFTBQZHQC-VUTHCHCSSA-N 0.000 description 2
- PQVKTHJJOPFPSH-JVWAILMASA-N (2e)-2-[8-[(2-cyclopropyl-6-fluoroimidazo[1,2-a]pyridin-3-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3C(=C(C#N)/C)\C2=CC=C1CC(N1C=C(F)C=CC1=N1)=C1C1CC1 PQVKTHJJOPFPSH-JVWAILMASA-N 0.000 description 2
- DZQJCQUWOPFREX-JVWAILMASA-N (2e)-2-[8-[(2-cyclopropyl-7-fluoroimidazo[1,2-a]pyridin-3-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3C(=C(C#N)/C)\C2=CC=C1CC(N1C=CC(F)=CC1=N1)=C1C1CC1 DZQJCQUWOPFREX-JVWAILMASA-N 0.000 description 2
- DWOLCFIQLUAOTK-OGLMXYFKSA-N (2e)-2-[8-[(2-cyclopropyl-7-methoxyimidazo[1,2-a]pyridin-3-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound N1=C2C=C(OC)C=CN2C(CC=2C=C3C(C(/C4=CC=C(F)C=C4OC3)=C(/C)C#N)=CC=2)=C1C1CC1 DWOLCFIQLUAOTK-OGLMXYFKSA-N 0.000 description 2
- XMYKDIMJZPJDEF-MTDXEUNCSA-N (2e)-2-[8-[(2-cyclopropyl-8-ethoxyimidazo[1,2-a]pyridin-3-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound N1=C2C(OCC)=CC=CN2C(CC=2C=C3C(C(/C4=CC=C(F)C=C4OC3)=C(/C)C#N)=CC=2)=C1C1CC1 XMYKDIMJZPJDEF-MTDXEUNCSA-N 0.000 description 2
- HRBCBVSMSVJROK-WGOQTCKBSA-N (2e)-2-[8-[(2-cyclopropyl-8-fluoroimidazo[1,2-a]pyridin-3-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3C(=C(C#N)/C)\C2=CC=C1CC(N1C=CC=C(F)C1=N1)=C1C1CC1 HRBCBVSMSVJROK-WGOQTCKBSA-N 0.000 description 2
- OGCQIUZEYLHBJF-HZHRSRAPSA-N (2e)-2-[8-[(2-cyclopropyl-8-methoxyimidazo[1,2-a]pyrazin-3-yl)-hydroxymethyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound N1=C2C(OC)=NC=CN2C(C(O)C=2C=C3C(C(/C4=CC=C(F)C=C4OC3)=C(/C)C#N)=CC=2)=C1C1CC1 OGCQIUZEYLHBJF-HZHRSRAPSA-N 0.000 description 2
- GCQWXSUWPHRGTE-PCLIKHOPSA-N (2e)-2-[8-[(2-cyclopropyl-8-methoxyimidazo[1,2-a]pyrazin-3-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound N1=C2C(OC)=NC=CN2C(CC=2C=C3C(C(/C4=CC=C(F)C=C4OC3)=C(/C)C#N)=CC=2)=C1C1CC1 GCQWXSUWPHRGTE-PCLIKHOPSA-N 0.000 description 2
- FESIYKKSGBMYIY-LSHDLFTRSA-N (2e)-2-[8-[(2-cyclopropyl-8-methoxyimidazo[1,2-a]pyridin-3-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]acetonitrile Chemical compound N1=C2C(OC)=CC=CN2C(CC=2C=C3C(C(/C4=CC=C(F)C=C4OC3)=C\C#N)=CC=2)=C1C1CC1 FESIYKKSGBMYIY-LSHDLFTRSA-N 0.000 description 2
- YPDOQWREDOVNTL-BUVRLJJBSA-N (2e)-2-[8-[(2-cyclopropyl-8-methylimidazo[1,2-a]pyrazin-3-yl)-hydroxymethyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3C(=C(C#N)/C)\C2=CC=C1C(O)C(N1C=CN=C(C)C1=N1)=C1C1CC1 YPDOQWREDOVNTL-BUVRLJJBSA-N 0.000 description 2
- LQVGDCAQTYXNBV-WGOQTCKBSA-N (2e)-2-[8-[(2-cyclopropyl-8-methylimidazo[1,2-a]pyrazin-3-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3C(=C(C#N)/C)\C2=CC=C1CC(N1C=CN=C(C)C1=N1)=C1C1CC1 LQVGDCAQTYXNBV-WGOQTCKBSA-N 0.000 description 2
- KEKDBJPVVIKJCN-OVVQPSECSA-N (2e)-2-[8-[(2-cyclopropyl-8-methylimidazo[1,2-a]pyridin-3-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3C(=C(C#N)/C)\C2=CC=C1CC(N1C=CC=C(C)C1=N1)=C1C1CC1 KEKDBJPVVIKJCN-OVVQPSECSA-N 0.000 description 2
- SNTHCLZEKHFPNW-BUVRLJJBSA-N (2e)-2-[8-[(2-cyclopropyl-8-oxo-7h-imidazo[1,2-a]pyrazin-3-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3C(=C(C#N)/C)\C2=CC=C1CC(N1C=CN=C(O)C1=N1)=C1C1CC1 SNTHCLZEKHFPNW-BUVRLJJBSA-N 0.000 description 2
- PSRDIGUPIQDLNC-WPWMEQJKSA-N (2e)-2-[8-[(2-cyclopropylbenzimidazol-1-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3C(=C(C#N)/C)\C2=CC=C1CN(C1=CC=CC=C1N=1)C=1C1CC1 PSRDIGUPIQDLNC-WPWMEQJKSA-N 0.000 description 2
- NYFLSKDJRKXGLV-WGOQTCKBSA-N (2e)-2-[8-[(2-cyclopropylimidazo[1,2-a]pyrazin-3-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3C(=C(C#N)/C)\C2=CC=C1CC(N1C=CN=CC1=N1)=C1C1CC1 NYFLSKDJRKXGLV-WGOQTCKBSA-N 0.000 description 2
- FDOPLMFFMJITSZ-WPWMEQJKSA-N (2e)-2-[8-[(2-cyclopropylimidazo[1,2-a]pyridin-3-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3C(=C(C#N)/C)\C2=CC=C1CC(N1C=CC=CC1=N1)=C1C1CC1 FDOPLMFFMJITSZ-WPWMEQJKSA-N 0.000 description 2
- DJCZOZNMBRXVOD-HZHRSRAPSA-N (2e)-2-[8-[(2-cyclopropylimidazo[1,2-a]pyrimidin-3-yl)-hydroxymethyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3C(=C(C#N)/C)\C2=CC=C1C(O)C(N1C=CC=NC1=N1)=C1C1CC1 DJCZOZNMBRXVOD-HZHRSRAPSA-N 0.000 description 2
- QCPMXFUHVDMBJC-PCLIKHOPSA-N (2e)-2-[8-[(2-cyclopropylimidazo[1,2-a]pyrimidin-3-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3C(=C(C#N)/C)\C2=CC=C1CC(N1C=CC=NC1=N1)=C1C1CC1 QCPMXFUHVDMBJC-PCLIKHOPSA-N 0.000 description 2
- BNCBAYNECSLZKR-BUVRLJJBSA-N (2e)-2-[8-[(2-cyclopropylimidazo[1,2-b]pyridazin-3-yl)-hydroxymethyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3C(=C(C#N)/C)\C2=CC=C1C(O)C(N1N=CC=CC1=N1)=C1C1CC1 BNCBAYNECSLZKR-BUVRLJJBSA-N 0.000 description 2
- NZFSLUFZNNXQOW-WGOQTCKBSA-N (2e)-2-[8-[(2-cyclopropylimidazo[1,2-b]pyridazin-3-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3C(=C(C#N)/C)\C2=CC=C1CC(N1N=CC=CC1=N1)=C1C1CC1 NZFSLUFZNNXQOW-WGOQTCKBSA-N 0.000 description 2
- HDUXQIDTMHJMRL-MFKUBSTISA-N (2e)-2-[8-[(2-cyclopropylthieno[3,4-d]imidazol-3-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3C(=C(C#N)/C)\C2=CC=C1CN(C1=CSC=C1N=1)C=1C1CC1 HDUXQIDTMHJMRL-MFKUBSTISA-N 0.000 description 2
- SQIXUWCUBICWQW-VUTHCHCSSA-N (2e)-2-[8-[(2-ethyl-4-phenylimidazol-1-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C=1N(CC=2C=C3C(C(/C4=CC=C(F)C=C4OC3)=C(/C)C#N)=CC=2)C(CC)=NC=1C1=CC=CC=C1 SQIXUWCUBICWQW-VUTHCHCSSA-N 0.000 description 2
- PBHGEBXXLKRBTF-KGENOOAVSA-N (2e)-2-[8-[(4,5-dichloro-2-propan-2-ylimidazol-1-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound CC(C)C1=NC(Cl)=C(Cl)N1CC1=CC=C2C(=C(/C)C#N)/C3=CC=C(F)C=C3OCC2=C1 PBHGEBXXLKRBTF-KGENOOAVSA-N 0.000 description 2
- VIAXWPZQWUZYJZ-PCLIKHOPSA-N (2e)-2-[8-[(4-chloro-2-cyclobutylimidazo[4,5-c]pyridin-1-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3C(=C(C#N)/C)\C2=CC=C1CN(C1=CC=NC(Cl)=C1N=1)C=1C1CCC1 VIAXWPZQWUZYJZ-PCLIKHOPSA-N 0.000 description 2
- CDNIDFPIOPSKPE-COOPMVRXSA-N (2e)-2-[8-[(4-chloro-2-cyclopropylbenzimidazol-1-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]-2-cyclopropylacetonitrile Chemical compound C=1C(F)=CC=C(C(/C2=CC=3)=C(/C#N)C4CC4)C=1OCC2=CC=3CN(C1=CC=CC(Cl)=C1N=1)C=1C1CC1 CDNIDFPIOPSKPE-COOPMVRXSA-N 0.000 description 2
- HRRCNZKPJZNOCA-WGOQTCKBSA-N (2e)-2-[8-[(4-chloro-2-cyclopropylbenzimidazol-1-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3C(=C(C#N)/C)\C2=CC=C1CN(C1=CC=CC(Cl)=C1N=1)C=1C1CC1 HRRCNZKPJZNOCA-WGOQTCKBSA-N 0.000 description 2
- UHJGWSYRNZEBEU-MFKUBSTISA-N (2e)-2-[8-[(4-chloro-2-methyl-6-propylpyrimidin-5-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound CCCC1=NC(C)=NC(Cl)=C1CC1=CC=C2C(=C(/C)C#N)/C3=CC=C(F)C=C3OCC2=C1 UHJGWSYRNZEBEU-MFKUBSTISA-N 0.000 description 2
- OYZWUOMFAALLMN-JVWAILMASA-N (2e)-2-[8-[(6-chloro-2-cyclopropylimidazo[1,2-a]pyridin-3-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3C(=C(C#N)/C)\C2=CC=C1CC(N1C=C(Cl)C=CC1=N1)=C1C1CC1 OYZWUOMFAALLMN-JVWAILMASA-N 0.000 description 2
- LZOLUALNDSJNFJ-MFKUBSTISA-N (2e)-2-[8-[(7-bromo-2-cyclopropylimidazo[1,2-a]pyridin-3-yl)-hydroxymethyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3C(=C(C#N)/C)\C2=CC=C1C(O)C(N1C=CC(Br)=CC1=N1)=C1C1CC1 LZOLUALNDSJNFJ-MFKUBSTISA-N 0.000 description 2
- GKBREKYFHMRAMA-JVWAILMASA-N (2e)-2-[8-[(7-bromo-2-cyclopropylimidazo[1,2-a]pyridin-3-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3C(=C(C#N)/C)\C2=CC=C1CC(N1C=CC(Br)=CC1=N1)=C1C1CC1 GKBREKYFHMRAMA-JVWAILMASA-N 0.000 description 2
- GINSYDPFHQVHIT-ZVHZXABRSA-N (2e)-2-[8-[(7-bromo-2-methylimidazo[1,2-a]pyridin-3-yl)-hydroxymethyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1OC2=CC(F)=CC=C2C(=C(C#N)/C)\C2=CC=C(C(O)C=3N4C=CC(Br)=CC4=NC=3C)C=C21 GINSYDPFHQVHIT-ZVHZXABRSA-N 0.000 description 2
- LJEHSSSEBVLGRZ-PCLIKHOPSA-N (2e)-2-[8-[(7-chloro-2-cyclobutylimidazo[4,5-b]pyridin-3-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3C(=C(C#N)/C)\C2=CC=C1CN(C1=NC=CC(Cl)=C1N=1)C=1C1CCC1 LJEHSSSEBVLGRZ-PCLIKHOPSA-N 0.000 description 2
- NMFOUTPYTFADAS-JVWAILMASA-N (2e)-2-[8-[(7-chloro-2-cyclopropylimidazo[1,2-a]pyridin-3-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3C(=C(C#N)/C)\C2=CC=C1CC(N1C=CC(Cl)=CC1=N1)=C1C1CC1 NMFOUTPYTFADAS-JVWAILMASA-N 0.000 description 2
- FRCQZWFLGOVXJV-BUVRLJJBSA-N (2e)-2-[8-[(7-chloro-2-cyclopropylimidazo[4,5-b]pyridin-3-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3C(=C(C#N)/C)\C2=CC=C1CN(C1=NC=CC(Cl)=C1N=1)C=1C1CC1 FRCQZWFLGOVXJV-BUVRLJJBSA-N 0.000 description 2
- OLFXYKLFWCPUSQ-MFKUBSTISA-N (2e)-2-[8-[(7-chloro-2-ethylimidazo[1,2-a]pyridin-3-yl)-hydroxymethyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3\C(=C(/C)C#N)C2=CC=C1C(O)C1=C(CC)N=C2N1C=CC(Cl)=C2 OLFXYKLFWCPUSQ-MFKUBSTISA-N 0.000 description 2
- DKCNCNCHSGCDOJ-JVWAILMASA-N (2e)-2-[8-[(7-chloro-2-ethylimidazo[1,2-a]pyridin-3-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3\C(=C(/C)C#N)C2=CC=C1CC1=C(CC)N=C2N1C=CC(Cl)=C2 DKCNCNCHSGCDOJ-JVWAILMASA-N 0.000 description 2
- YUNGBQASLWDYAR-RWEWTDSWSA-N (2e)-2-[8-[(7-chloro-2-methylimidazo[1,2-a]pyridin-3-yl)-hydroxymethyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]-2-cyclopropylacetonitrile Chemical compound CC=1N=C2C=C(Cl)C=CN2C=1C(O)C(C=1)=CC=C2C=1COC1=CC(F)=CC=C1\C2=C(\C#N)C1CC1 YUNGBQASLWDYAR-RWEWTDSWSA-N 0.000 description 2
- GDINJNGMPZLTDD-ZVHZXABRSA-N (2e)-2-[8-[(7-chloro-2-methylimidazo[1,2-a]pyridin-3-yl)-hydroxymethyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1OC2=CC(F)=CC=C2C(=C(C#N)/C)\C2=CC=C(C(O)C=3N4C=CC(Cl)=CC4=NC=3C)C=C21 GDINJNGMPZLTDD-ZVHZXABRSA-N 0.000 description 2
- PBTLYYOBWVCGLP-COOPMVRXSA-N (2e)-2-[8-[(7-chloro-2-methylimidazo[1,2-a]pyridin-3-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]-2-cyclopropylacetonitrile Chemical compound CC=1N=C2C=C(Cl)C=CN2C=1CC(C=1)=CC=C2C=1COC1=CC(F)=CC=C1\C2=C(\C#N)C1CC1 PBTLYYOBWVCGLP-COOPMVRXSA-N 0.000 description 2
- QHDGUCQFONRJFS-CVKSISIWSA-N (2e)-2-[8-[(7-chloro-2-methylimidazo[1,2-a]pyridin-3-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3C(=C(C#N)/C)\C2=CC=C1CC1=C(C)N=C2N1C=CC(Cl)=C2 QHDGUCQFONRJFS-CVKSISIWSA-N 0.000 description 2
- OHOXSUYESJBIFS-STBIYBPSSA-N (2e)-2-[8-[(7-cyclopropyl-2-methylimidazo[1,2-a]pyridin-3-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3C(=C(C#N)/C)\C2=CC=C1CC(N1C=C2)=C(C)N=C1C=C2C1CC1 OHOXSUYESJBIFS-STBIYBPSSA-N 0.000 description 2
- HEOWKLRDRQIVNI-OGLMXYFKSA-N (2e)-2-[8-[(7-ethynyl-2-methylimidazo[1,2-a]pyridin-3-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3C(=C(C#N)/C)\C2=CC=C1CC1=C(C)N=C2N1C=CC(C#C)=C2 HEOWKLRDRQIVNI-OGLMXYFKSA-N 0.000 description 2
- SWTDDFZQEWKDLD-BUVRLJJBSA-N (2e)-2-[8-[(8-bromo-2-cyclopropylimidazo[1,2-a]pyridin-3-yl)-hydroxymethyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3C(=C(C#N)/C)\C2=CC=C1C(O)C(N1C=CC=C(Br)C1=N1)=C1C1CC1 SWTDDFZQEWKDLD-BUVRLJJBSA-N 0.000 description 2
- NVRCWGDLVURIEE-WPWMEQJKSA-N (2e)-2-[8-[(8-chloro-2-cyclobutylimidazo[1,2-a]pyridin-3-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3C(=C(C#N)/C)\C2=CC=C1CC(N1C=CC=C(Cl)C1=N1)=C1C1CCC1 NVRCWGDLVURIEE-WPWMEQJKSA-N 0.000 description 2
- YLPAFRWROXMWBB-BUVRLJJBSA-N (2e)-2-[8-[(8-chloro-2-cyclopropylimidazo[1,2-a]pyrazin-3-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3C(=C(C#N)/C)\C2=CC=C1CC(N1C=CN=C(Cl)C1=N1)=C1C1CC1 YLPAFRWROXMWBB-BUVRLJJBSA-N 0.000 description 2
- JAOVWUOKFGSBIY-BUVRLJJBSA-N (2e)-2-[8-[(8-chloro-2-cyclopropylimidazo[1,2-a]pyridin-3-yl)-hydroxymethyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3C(=C(C#N)/C)\C2=CC=C1C(O)C(N1C=CC=C(Cl)C1=N1)=C1C1CC1 JAOVWUOKFGSBIY-BUVRLJJBSA-N 0.000 description 2
- JFPCHKRSPXEZCO-ZVBGSRNCSA-N (2e)-2-[8-[(8-chloro-2-cyclopropylimidazo[1,2-a]pyridin-3-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]acetonitrile Chemical compound C=1C(F)=CC=C(C(/C2=CC=3)=C/C#N)C=1OCC2=CC=3CC(N1C=CC=C(Cl)C1=N1)=C1C1CC1 JFPCHKRSPXEZCO-ZVBGSRNCSA-N 0.000 description 2
- ODDBTKZFTSWWOE-WGOQTCKBSA-N (2e)-2-[8-[(8-chloro-2-cyclopropylimidazo[1,2-a]pyridin-3-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3C(=C(C#N)/C)\C2=CC=C1CC(N1C=CC=C(Cl)C1=N1)=C1C1CC1 ODDBTKZFTSWWOE-WGOQTCKBSA-N 0.000 description 2
- ABVVEOVOLQCIPI-OEAKJJBVSA-N (2e)-2-[8-[(8-chloro-2-methylimidazo[1,2-a]pyridin-3-yl)-hydroxymethyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1OC2=CC(F)=CC=C2C(=C(C#N)/C)\C2=CC=C(C(O)C=3N4C=CC=C(Cl)C4=NC=3C)C=C21 ABVVEOVOLQCIPI-OEAKJJBVSA-N 0.000 description 2
- MWSBUJBCJUADHJ-MFKUBSTISA-N (2e)-2-[8-[(8-chloro-2-methylimidazo[1,2-a]pyridin-3-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3C(=C(C#N)/C)\C2=CC=C1CC1=C(C)N=C2N1C=CC=C2Cl MWSBUJBCJUADHJ-MFKUBSTISA-N 0.000 description 2
- VOELOOUQWGKJIQ-YZSQISJMSA-N (2e)-2-[8-[(8-chloro-2-propan-2-ylimidazo[1,2-a]pyridin-3-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3\C(=C(/C)C#N)C2=CC=C1CC1=C(C(C)C)N=C2N1C=CC=C2Cl VOELOOUQWGKJIQ-YZSQISJMSA-N 0.000 description 2
- FIWIPTKQBCKHTM-MTDXEUNCSA-N (2e)-2-[8-[[2,4-bis(methoxymethyl)benzimidazol-1-yl]methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3\C(=C(/C)C#N)C2=CC=C1CN1C2=CC=CC(COC)=C2N=C1COC FIWIPTKQBCKHTM-MTDXEUNCSA-N 0.000 description 2
- RPXLIATXVGCLIT-WPWMEQJKSA-N (2e)-2-[8-[[2-(3,3-difluorocyclobutyl)benzimidazol-1-yl]methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3C(=C(C#N)/C)\C2=CC=C1CN(C1=CC=CC=C1N=1)C=1C1CC(F)(F)C1 RPXLIATXVGCLIT-WPWMEQJKSA-N 0.000 description 2
- KBGOUOMKLIPFKE-OVVQPSECSA-N (2e)-2-[8-[[2-(azetidin-1-yl)benzimidazol-1-yl]methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3C(=C(C#N)/C)\C2=CC=C1CN(C1=CC=CC=C1N=1)C=1N1CCC1 KBGOUOMKLIPFKE-OVVQPSECSA-N 0.000 description 2
- NPEGZMGGXKLJTP-RDRPBHBLSA-N (2e)-2-[8-[[2-(cyclopropylmethyl)benzimidazol-1-yl]methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3C(=C(C#N)/C)\C2=CC=C1CN(C1=CC=CC=C1N=1)C=1CC1CC1 NPEGZMGGXKLJTP-RDRPBHBLSA-N 0.000 description 2
- DKQRUNMNFFVCOF-MTDXEUNCSA-N (2e)-2-[8-[[2-[(dimethylamino)methyl]benzimidazol-1-yl]methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3\C(=C(/C)C#N)C2=CC=C1CN1C2=CC=CC=C2N=C1CN(C)C DKQRUNMNFFVCOF-MTDXEUNCSA-N 0.000 description 2
- VESSPDIGVVKINB-TWKHWXDSSA-N (2e)-2-[8-[[2-[[tert-butyl(dimethyl)silyl]oxymethyl]-4-hydroxybenzimidazol-1-yl]methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3C(=C(C#N)/C)\C2=CC=C1CN1C2=CC=CC(O)=C2N=C1CO[Si](C)(C)C(C)(C)C VESSPDIGVVKINB-TWKHWXDSSA-N 0.000 description 2
- XGWLHTUWFARIMR-LPYMAVHISA-N (2e)-2-[8-[[2-chloro-7-(trifluoromethyl)imidazo[1,2-a]pyridin-3-yl]-hydroxymethyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1OC2=CC(F)=CC=C2C(=C(C#N)/C)\C2=CC=C(C(O)C=3N4C=CC(=CC4=NC=3Cl)C(F)(F)F)C=C21 XGWLHTUWFARIMR-LPYMAVHISA-N 0.000 description 2
- FXTLJXLWUHVOLZ-MFKUBSTISA-N (2e)-2-[8-[[2-cyclopropyl-7-(trifluoromethyl)imidazo[1,2-a]pyrimidin-3-yl]methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3C(=C(C#N)/C)\C2=CC=C1CC(N1C=CC(=NC1=N1)C(F)(F)F)=C1C1CC1 FXTLJXLWUHVOLZ-MFKUBSTISA-N 0.000 description 2
- ROELRCVCOQXGRM-MTDXEUNCSA-N (2e)-2-[8-[[2-cyclopropyl-8-(2-hydroxypropan-2-yl)imidazo[1,2-a]pyridin-3-yl]methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3C(=C(C#N)/C)\C2=CC=C1CC(N1C=CC=C(C1=N1)C(C)(C)O)=C1C1CC1 ROELRCVCOQXGRM-MTDXEUNCSA-N 0.000 description 2
- GMHUFNJVBGZLHC-WGOQTCKBSA-N (2e)-2-[8-[[2-cyclopropyl-8-(difluoromethoxy)imidazo[1,2-a]pyridin-3-yl]methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3C(=C(C#N)/C)\C2=CC=C1CC(N1C=CC=C(OC(F)F)C1=N1)=C1C1CC1 GMHUFNJVBGZLHC-WGOQTCKBSA-N 0.000 description 2
- HNNBPEPCBSPWQV-YZSQISJMSA-N (2e)-2-[8-[[2-cyclopropyl-8-(dimethylamino)imidazo[1,2-a]pyrazin-3-yl]methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound N1=C2C(N(C)C)=NC=CN2C(CC=2C=C3C(C(/C4=CC=C(F)C=C4OC3)=C(/C)C#N)=CC=2)=C1C1CC1 HNNBPEPCBSPWQV-YZSQISJMSA-N 0.000 description 2
- RAHJUCMKAIMEEA-MTDXEUNCSA-N (2e)-2-[8-[[2-cyclopropyl-8-(dimethylamino)imidazo[1,2-a]pyridin-3-yl]methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound N1=C2C(N(C)C)=CC=CN2C(CC=2C=C3C(C(/C4=CC=C(F)C=C4OC3)=C(/C)C#N)=CC=2)=C1C1CC1 RAHJUCMKAIMEEA-MTDXEUNCSA-N 0.000 description 2
- BMTZDIMJOFFSMG-BUVRLJJBSA-N (2e)-2-[8-[[2-cyclopropyl-8-(trifluoromethyl)imidazo[1,2-a]pyridin-3-yl]-hydroxymethyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3C(=C(C#N)/C)\C2=CC=C1C(O)C(N1C=CC=C(C1=N1)C(F)(F)F)=C1C1CC1 BMTZDIMJOFFSMG-BUVRLJJBSA-N 0.000 description 2
- RYMNKKQMARSOAB-WGOQTCKBSA-N (2e)-2-[8-[[2-cyclopropyl-8-(trifluoromethyl)imidazo[1,2-a]pyridin-3-yl]methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3C(=C(C#N)/C)\C2=CC=C1CC(N1C=CC=C(C1=N1)C(F)(F)F)=C1C1CC1 RYMNKKQMARSOAB-WGOQTCKBSA-N 0.000 description 2
- QLYARCPAYJVKLU-MTDXEUNCSA-N (2e)-2-[8-[[4-(azetidin-1-yl)-2-methyl-6-propylpyrimidin-5-yl]methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C=1C=C(C(/C2=CC=C(F)C=C2OC2)=C(/C)C#N)C2=CC=1CC=1C(CCC)=NC(C)=NC=1N1CCC1 QLYARCPAYJVKLU-MTDXEUNCSA-N 0.000 description 2
- QYECPYWGHYBQSP-MFKUBSTISA-N (2e)-2-[8-[[4-(difluoromethoxy)-2-(hydroxymethyl)benzimidazol-1-yl]methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3C(=C(C#N)/C)\C2=CC=C1CN1C2=CC=CC(OC(F)F)=C2N=C1CO QYECPYWGHYBQSP-MFKUBSTISA-N 0.000 description 2
- VPIFQTITBNZHLK-WGOQTCKBSA-N (2e)-2-[8-[[4-(difluoromethoxy)-2-(methoxymethyl)benzimidazol-1-yl]methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3\C(=C(/C)C#N)C2=CC=C1CN1C2=CC=CC(OC(F)F)=C2N=C1COC VPIFQTITBNZHLK-WGOQTCKBSA-N 0.000 description 2
- AWJBHDBJNSKSFS-WGOQTCKBSA-N (2e)-2-[8-[[4-(dimethylamino)-6-(methoxymethyl)-2-methylpyrimidin-5-yl]methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound COCC1=NC(C)=NC(N(C)C)=C1CC1=CC=C2C(=C(/C)C#N)/C3=CC=C(F)C=C3OCC2=C1 AWJBHDBJNSKSFS-WGOQTCKBSA-N 0.000 description 2
- XDIUSIBYCHJMDR-WGOQTCKBSA-N (2e)-2-[8-[[4-chloro-2-(methoxymethyl)benzimidazol-1-yl]methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3\C(=C(/C)C#N)C2=CC=C1CN1C2=CC=CC(Cl)=C2N=C1COC XDIUSIBYCHJMDR-WGOQTCKBSA-N 0.000 description 2
- QETMSOCCGQTIHI-ZVHZXABRSA-N (2e)-2-[8-[[4-chloro-6-(methoxymethyl)-2-methylpyrimidin-5-yl]methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound COCC1=NC(C)=NC(Cl)=C1CC1=CC=C2C(=C(/C)C#N)/C3=CC=C(F)C=C3OCC2=C1 QETMSOCCGQTIHI-ZVHZXABRSA-N 0.000 description 2
- QWPSIOVSYAQIDN-WPWMEQJKSA-N (2e)-2-[8-[[4-ethoxy-2-(hydroxymethyl)benzimidazol-1-yl]methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3\C(=C(/C)C#N)C2=CC=C1CN1C(C=CC=C2OCC)=C2N=C1CO QWPSIOVSYAQIDN-WPWMEQJKSA-N 0.000 description 2
- NEGYWFOFWHJXHU-MTDXEUNCSA-N (2e)-2-[8-[[4-ethoxy-2-(methoxymethyl)benzimidazol-1-yl]methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3\C(=C(/C)C#N)C2=CC=C1CN1C(C=CC=C2OCC)=C2N=C1COC NEGYWFOFWHJXHU-MTDXEUNCSA-N 0.000 description 2
- JRPRXKFQZJTKGY-VYIQYICTSA-N (2e)-2-[8-[[7-chloro-2-(methoxymethyl)imidazo[1,2-a]pyridin-3-yl]-hydroxymethyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]-2-cyclopropylacetonitrile Chemical compound COCC=1N=C2C=C(Cl)C=CN2C=1C(O)C(C=1)=CC=C2C=1COC1=CC(F)=CC=C1\C2=C(\C#N)C1CC1 JRPRXKFQZJTKGY-VYIQYICTSA-N 0.000 description 2
- ICIKKARBBRPZDH-MFKUBSTISA-N (2e)-2-[8-[[7-chloro-2-(methoxymethyl)imidazo[1,2-a]pyridin-3-yl]-hydroxymethyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3\C(=C(/C)C#N)C2=CC=C1C(O)C1=C(COC)N=C2N1C=CC(Cl)=C2 ICIKKARBBRPZDH-MFKUBSTISA-N 0.000 description 2
- GDZRPQSVTYHLQZ-OLFWJLLRSA-N (2e)-2-[8-[[7-chloro-2-(methoxymethyl)imidazo[1,2-a]pyridin-3-yl]methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]-2-cyclopropylacetonitrile Chemical compound COCC=1N=C2C=C(Cl)C=CN2C=1CC(C=1)=CC=C2C=1COC1=CC(F)=CC=C1\C2=C(\C#N)C1CC1 GDZRPQSVTYHLQZ-OLFWJLLRSA-N 0.000 description 2
- RRNZGUZCMUTJCY-JVWAILMASA-N (2e)-2-[8-[[7-chloro-2-(methoxymethyl)imidazo[1,2-a]pyridin-3-yl]methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3\C(=C(/C)C#N)C2=CC=C1CC1=C(COC)N=C2N1C=CC(Cl)=C2 RRNZGUZCMUTJCY-JVWAILMASA-N 0.000 description 2
- PJVLOMFZJABUDR-WGOQTCKBSA-N (2e)-2-[8-[[8-(difluoromethoxy)-2-(methoxymethyl)imidazo[1,2-a]pyridin-3-yl]methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3\C(=C(/C)C#N)C2=CC=C1CC1=C(COC)N=C2N1C=CC=C2OC(F)F PJVLOMFZJABUDR-WGOQTCKBSA-N 0.000 description 2
- ZKFWSGJAVRRXOE-LFVJCYFKSA-N (2e)-2-[8-[[8-(difluoromethoxy)-2-propan-2-ylimidazo[1,2-a]pyridin-3-yl]-hydroxymethyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3\C(=C(/C)C#N)C2=CC=C1C(O)C1=C(C(C)C)N=C2N1C=CC=C2OC(F)F ZKFWSGJAVRRXOE-LFVJCYFKSA-N 0.000 description 2
- TYQVXTWFCNGLME-YZSQISJMSA-N (2e)-2-[8-[[8-(difluoromethoxy)-2-propan-2-ylimidazo[1,2-a]pyridin-3-yl]methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3\C(=C(/C)C#N)C2=CC=C1CC1=C(C(C)C)N=C2N1C=CC=C2OC(F)F TYQVXTWFCNGLME-YZSQISJMSA-N 0.000 description 2
- ZKJDAIKKPWGDJC-ROMGYVFFSA-N (2e)-2-[8-[[8-chloro-2-(methoxymethyl)imidazo[1,2-a]pyridin-3-yl]-hydroxymethyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]-2-cyclopropylacetonitrile Chemical compound COCC=1N=C2C(Cl)=CC=CN2C=1C(O)C(C=1)=CC=C2C=1COC1=CC(F)=CC=C1\C2=C(\C#N)C1CC1 ZKJDAIKKPWGDJC-ROMGYVFFSA-N 0.000 description 2
- WZQXQMBTFVECCQ-BUVRLJJBSA-N (2e)-2-[8-[[8-chloro-2-(methoxymethyl)imidazo[1,2-a]pyridin-3-yl]-hydroxymethyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3\C(=C(/C)C#N)C2=CC=C1C(O)C1=C(COC)N=C2N1C=CC=C2Cl WZQXQMBTFVECCQ-BUVRLJJBSA-N 0.000 description 2
- XANKJRODEWHHQV-NFFVHWSESA-N (2e)-2-[8-[[8-chloro-2-(methoxymethyl)imidazo[1,2-a]pyridin-3-yl]methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]-2-cyclopropylacetonitrile Chemical compound COCC=1N=C2C(Cl)=CC=CN2C=1CC(C=1)=CC=C2C=1COC1=CC(F)=CC=C1\C2=C(\C#N)C1CC1 XANKJRODEWHHQV-NFFVHWSESA-N 0.000 description 2
- RUFXGODXKDXTBT-WGOQTCKBSA-N (2e)-2-[8-[[8-chloro-2-(methoxymethyl)imidazo[1,2-a]pyridin-3-yl]methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3\C(=C(/C)C#N)C2=CC=C1CC1=C(COC)N=C2N1C=CC=C2Cl RUFXGODXKDXTBT-WGOQTCKBSA-N 0.000 description 2
- WZQXQMBTFVECCQ-FGJJXYMWSA-N (2e)-2-[8-[[8-chloro-2-(trideuteriomethoxymethyl)imidazo[1,2-a]pyridin-3-yl]-hydroxymethyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3\C(=C(/C)C#N)C2=CC=C1C(O)C1=C(COC([2H])([2H])[2H])N=C2N1C=CC=C2Cl WZQXQMBTFVECCQ-FGJJXYMWSA-N 0.000 description 2
- RUFXGODXKDXTBT-ILIWNJCXSA-N (2e)-2-[8-[[8-chloro-2-(trideuteriomethoxymethyl)imidazo[1,2-a]pyridin-3-yl]methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3\C(=C(/C)C#N)C2=CC=C1CC1=C(COC([2H])([2H])[2H])N=C2N1C=CC=C2Cl RUFXGODXKDXTBT-ILIWNJCXSA-N 0.000 description 2
- HQCSXQIKLSEAFF-JVCXMKTPSA-N (2e)-2-cyclopropyl-2-[3-fluoro-8-[(2-propylbenzimidazol-1-yl)methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]acetonitrile Chemical compound CCCC1=NC2=CC=CC=C2N1CC(C=1)=CC=C2C=1COC1=CC(F)=CC=C1\C2=C(\C#N)C1CC1 HQCSXQIKLSEAFF-JVCXMKTPSA-N 0.000 description 2
- AKEVMEYNZYSELM-OLFWJLLRSA-N (2e)-2-cyclopropyl-2-[3-fluoro-8-[[2-(methoxymethyl)imidazo[1,2-a]pyridin-3-yl]methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]acetonitrile Chemical compound COCC=1N=C2C=CC=CN2C=1CC(C=1)=CC=C2C=1COC1=CC(F)=CC=C1\C2=C(\C#N)C1CC1 AKEVMEYNZYSELM-OLFWJLLRSA-N 0.000 description 2
- YFBLLEVNRKKNSH-JVCXMKTPSA-N (2e)-2-cyclopropyl-2-[3-fluoro-8-[[4-(2-hydroxypropan-2-yl)-2-(methoxymethyl)benzimidazol-1-yl]methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]acetonitrile Chemical compound COCC1=NC2=C(C(C)(C)O)C=CC=C2N1CC(C=1)=CC=C2C=1COC1=CC(F)=CC=C1\C2=C(\C#N)C1CC1 YFBLLEVNRKKNSH-JVCXMKTPSA-N 0.000 description 2
- OBEHKSNCISBGRA-VYIQYICTSA-N (2e)-2-cyclopropyl-2-[3-fluoro-8-[hydroxy-[2-(methoxymethyl)imidazo[1,2-a]pyridin-3-yl]methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]acetonitrile Chemical compound COCC=1N=C2C=CC=CN2C=1C(O)C(C=1)=CC=C2C=1COC1=CC(F)=CC=C1\C2=C(\C#N)C1CC1 OBEHKSNCISBGRA-VYIQYICTSA-N 0.000 description 2
- GMLKMZIDQCIBLC-GNVQSUKOSA-N (2e)-2-cyclopropyl-2-[8-[(2-cyclopropylbenzimidazol-1-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]acetonitrile Chemical compound C=1C(F)=CC=C(C(/C2=CC=3)=C(/C#N)C4CC4)C=1OCC2=CC=3CN(C1=CC=CC=C1N=1)C=1C1CC1 GMLKMZIDQCIBLC-GNVQSUKOSA-N 0.000 description 2
- PJBAJXOYFXRPSO-GNVQSUKOSA-N (2e)-2-cyclopropyl-2-[8-[[2-(3,3-difluorocyclobutyl)benzimidazol-1-yl]methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]acetonitrile Chemical compound C=1C(F)=CC=C(C(/C2=CC=3)=C(/C#N)C4CC4)C=1OCC2=CC=3CN(C1=CC=CC=C1N=1)C=1C1CC(F)(F)C1 PJBAJXOYFXRPSO-GNVQSUKOSA-N 0.000 description 2
- DIXMBHMNEHPFCX-MCMMXHMISA-N (2r)-2-[5-[6-amino-5-[(1r)-1-[5-fluoro-2-(triazol-2-yl)phenyl]ethoxy]pyridin-3-yl]-4-methyl-1,3-thiazol-2-yl]propane-1,2-diol Chemical compound O([C@H](C)C=1C(=CC=C(F)C=1)N1N=CC=N1)C(C(=NC=1)N)=CC=1C=1SC([C@](C)(O)CO)=NC=1C DIXMBHMNEHPFCX-MCMMXHMISA-N 0.000 description 2
- HPJGEESDHAUUQR-SKGSPYGFSA-N (2s)-2-[[(2s)-5-(diaminomethylideneamino)-2-[[(2s)-1-[(2s)-5-(diaminomethylideneamino)-2-[[(2s)-2-[[(2s)-3-naphthalen-2-yl-2-(3-pyridin-3-ylpropanoylamino)propanoyl]amino]-3-phenylpropanoyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]amino]buta Chemical compound NC(=O)C[C@@H](C(N)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=C2C=CC=CC2=CC=1)NC(=O)CCC=1C=NC=CC=1)CC1=CC=CC=C1 HPJGEESDHAUUQR-SKGSPYGFSA-N 0.000 description 2
- LJIOTBMDLVHTBO-CUYJMHBOSA-N (2s)-2-amino-n-[(1r,2r)-1-cyano-2-[4-[4-(4-methylpiperazin-1-yl)sulfonylphenyl]phenyl]cyclopropyl]butanamide Chemical compound CC[C@H](N)C(=O)N[C@]1(C#N)C[C@@H]1C1=CC=C(C=2C=CC(=CC=2)S(=O)(=O)N2CCN(C)CC2)C=C1 LJIOTBMDLVHTBO-CUYJMHBOSA-N 0.000 description 2
- KORCWPOBTZTAFI-YVTYUBGGSA-N (2s,3r,4r,5s,6r)-2-[7-chloro-6-[(4-cyclopropylphenyl)methyl]-2,3-dihydro-1-benzofuran-4-yl]-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=CC(CC=2C=CC(=CC=2)C2CC2)=C(Cl)C2=C1CCO2 KORCWPOBTZTAFI-YVTYUBGGSA-N 0.000 description 2
- KRIWIRSMQRQYJG-DLBZAZTESA-N (2s,3s)-3-[[7-(benzylamino)-3-propan-2-ylpyrazolo[1,5-a]pyrimidin-5-yl]amino]butane-1,2,4-triol Chemical compound C=1C(N[C@@H](CO)[C@H](O)CO)=NC2=C(C(C)C)C=NN2C=1NCC1=CC=CC=C1 KRIWIRSMQRQYJG-DLBZAZTESA-N 0.000 description 2
- YIHHGJFGBIHIJI-LVWGJNHUSA-N (2z)-2-[8-[(8-chloro-2-cyclopropylimidazo[1,2-a]pyridin-3-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]-2-fluoroacetonitrile Chemical compound C1=C2COC3=CC(F)=CC=C3C(=C(C#N)/F)\C2=CC=C1CC(N1C=CC=C(Cl)C1=N1)=C1C1CC1 YIHHGJFGBIHIJI-LVWGJNHUSA-N 0.000 description 2
- PHDIJLFSKNMCMI-ITGJKDDRSA-N (3R,4S,5R,6R)-6-(hydroxymethyl)-4-(8-quinolin-6-yloxyoctoxy)oxane-2,3,5-triol Chemical compound OC[C@@H]1[C@H]([C@@H]([C@H](C(O1)O)O)OCCCCCCCCOC=1C=C2C=CC=NC2=CC=1)O PHDIJLFSKNMCMI-ITGJKDDRSA-N 0.000 description 2
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 2
- NUJWKQSEJDYCDB-GNRVTEMESA-N (3s)-1-[(1s,2r,4r)-4-[methyl(propan-2-yl)amino]-2-propylcyclohexyl]-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-2-one Chemical compound CCC[C@@H]1C[C@H](N(C)C(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 NUJWKQSEJDYCDB-GNRVTEMESA-N 0.000 description 2
- WHQUHTXULUACFD-KRWDZBQOSA-N (3s)-4-[[2-(4-fluoro-3-methylphenyl)-4-methyl-6-propan-2-ylphenyl]methoxy-hydroxyphosphoryl]-3-hydroxybutanoic acid Chemical compound CC(C)C1=CC(C)=CC(C=2C=C(C)C(F)=CC=2)=C1COP(O)(=O)C[C@@H](O)CC(O)=O WHQUHTXULUACFD-KRWDZBQOSA-N 0.000 description 2
- DMQYDVBIPXAAJA-VHXPQNKSSA-N (3z)-5-[(1-ethylpiperidin-4-yl)amino]-3-[(3-fluorophenyl)-(5-methyl-1h-imidazol-2-yl)methylidene]-1h-indol-2-one Chemical compound C1CN(CC)CCC1NC1=CC=C(NC(=O)\C2=C(/C=3NC=C(C)N=3)C=3C=C(F)C=CC=3)C2=C1 DMQYDVBIPXAAJA-VHXPQNKSSA-N 0.000 description 2
- VUDZSIYXZUYWSC-DBRKOABJSA-N (4r)-1-[(2r,4r,5r)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-hydroxy-1,3-diazinan-2-one Chemical compound FC1(F)[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N[C@H](O)CC1 VUDZSIYXZUYWSC-DBRKOABJSA-N 0.000 description 2
- VPMIAOSOTOODMY-KJAPKAAFSA-N (4r)-6-[(e)-2-[6-tert-butyl-4-(4-fluorophenyl)-2-propan-2-ylpyridin-3-yl]ethenyl]-4-hydroxyoxan-2-one Chemical compound C([C@H](O)C1)C(=O)OC1/C=C/C=1C(C(C)C)=NC(C(C)(C)C)=CC=1C1=CC=C(F)C=C1 VPMIAOSOTOODMY-KJAPKAAFSA-N 0.000 description 2
- PNHBRYIAJCYNDA-VQCQRNETSA-N (4r)-6-[2-[2-ethyl-4-(4-fluorophenyl)-6-phenylpyridin-3-yl]ethyl]-4-hydroxyoxan-2-one Chemical compound C([C@H](O)C1)C(=O)OC1CCC=1C(CC)=NC(C=2C=CC=CC=2)=CC=1C1=CC=C(F)C=C1 PNHBRYIAJCYNDA-VQCQRNETSA-N 0.000 description 2
- QVBVQHTXLPNXEY-ZMFCMNQTSA-N (4r)-6-[2-[4-(4-fluorophenyl)-6-phenyl-2-propan-2-ylpyridin-3-yl]ethyl]-4-hydroxyoxan-2-one Chemical compound C([C@H](O)C1)C(=O)OC1CCC=1C(C(C)C)=NC(C=2C=CC=CC=2)=CC=1C1=CC=C(F)C=C1 QVBVQHTXLPNXEY-ZMFCMNQTSA-N 0.000 description 2
- AXQACEQYCPKDMV-RZAWKFBISA-N (4r,4as,7ar,12bs)-3-(cyclopropylmethyl)-4a,7,9-trihydroxy-n-[2-(3-phenyl-1,2,4-oxadiazol-5-yl)propan-2-yl]-1,2,4,5,7a,13-hexahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-6-carboxamide Chemical compound N1([C@@H]2CC=3C4=C(C(=CC=3)O)O[C@H]3C(O)=C(C[C@]2(O)[C@]34CC1)C(=O)NC(C)(C)C=1ON=C(N=1)C=1C=CC=CC=1)CC1CC1 AXQACEQYCPKDMV-RZAWKFBISA-N 0.000 description 2
- FRJJJAKBRKABFA-TYFAACHXSA-N (4r,6s)-6-[(e)-2-[6-chloro-4-(4-fluorophenyl)-2-propan-2-ylquinolin-3-yl]ethenyl]-4-hydroxyoxan-2-one Chemical compound C(\[C@H]1OC(=O)C[C@H](O)C1)=C/C=1C(C(C)C)=NC2=CC=C(Cl)C=C2C=1C1=CC=C(F)C=C1 FRJJJAKBRKABFA-TYFAACHXSA-N 0.000 description 2
- VIMMECPCYZXUCI-MIMFYIINSA-N (4s,6r)-6-[(1e)-4,4-bis(4-fluorophenyl)-3-(1-methyltetrazol-5-yl)buta-1,3-dienyl]-4-hydroxyoxan-2-one Chemical compound CN1N=NN=C1C(\C=C\[C@@H]1OC(=O)C[C@@H](O)C1)=C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 VIMMECPCYZXUCI-MIMFYIINSA-N 0.000 description 2
- QOLHWXNSCZGWHK-BWBORTOCSA-N (6r,7r)-1-[(4s,5r)-4-acetyloxy-5-methyl-3-methylidene-6-phenylhexyl]-4,7-dihydroxy-6-(11-phenoxyundecylcarbamoyloxy)-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid Chemical compound C([C@@H](C)[C@H](OC(C)=O)C(=C)CCC12[C@@H]([C@@H](OC(=O)NCCCCCCCCCCCOC=3C=CC=CC=3)C(O1)(C(O)=O)C(O)(C(O2)C(O)=O)C(O)=O)O)C1=CC=CC=C1 QOLHWXNSCZGWHK-BWBORTOCSA-N 0.000 description 2
- ZRYMMWAJAFUANM-INIZCTEOSA-N (7s)-3-fluoro-4-[3-(8-fluoro-1-methyl-2,4-dioxoquinazolin-3-yl)-2-methylphenyl]-7-(2-hydroxypropan-2-yl)-6,7,8,9-tetrahydro-5h-carbazole-1-carboxamide Chemical compound C1[C@@H](C(C)(C)O)CCC2=C1NC1=C2C(C2=C(C(=CC=C2)N2C(C3=CC=CC(F)=C3N(C)C2=O)=O)C)=C(F)C=C1C(N)=O ZRYMMWAJAFUANM-INIZCTEOSA-N 0.000 description 2
- LVHOHZHTZXRVRJ-CMDGGOBGSA-N (e)-3-(3-methoxyphenyl)-n-(3,4,5-trimethoxyphenyl)prop-2-enamide Chemical compound COC1=CC=CC(\C=C\C(=O)NC=2C=C(OC)C(OC)=C(OC)C=2)=C1 LVHOHZHTZXRVRJ-CMDGGOBGSA-N 0.000 description 2
- QRDAPCMJAOQZSU-KQQUZDAGSA-N (e)-3-[4-[(e)-3-(3-fluorophenyl)-3-oxoprop-1-enyl]-1-methylpyrrol-2-yl]-n-hydroxyprop-2-enamide Chemical compound C1=C(\C=C\C(=O)NO)N(C)C=C1\C=C\C(=O)C1=CC=CC(F)=C1 QRDAPCMJAOQZSU-KQQUZDAGSA-N 0.000 description 2
- APJSHECCIRQQDV-ZRDIBKRKSA-N (e)-3-[4-hydroxy-3-(5,5,8,8-tetramethyl-3-pentoxy-6,7-dihydronaphthalen-2-yl)phenyl]prop-2-enoic acid Chemical compound CCCCCOC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C1=CC(\C=C\C(O)=O)=CC=C1O APJSHECCIRQQDV-ZRDIBKRKSA-N 0.000 description 2
- IGVKWAAPMVVTFX-BUHFOSPRSA-N (e)-octadec-5-en-7,9-diynoic acid Chemical compound CCCCCCCCC#CC#C\C=C\CCCC(O)=O IGVKWAAPMVVTFX-BUHFOSPRSA-N 0.000 description 2
- JNPGUXGVLNJQSQ-BGGMYYEUSA-M (e,3r,5s)-7-[4-(4-fluorophenyl)-1,2-di(propan-2-yl)pyrrol-3-yl]-3,5-dihydroxyhept-6-enoate Chemical compound CC(C)N1C(C(C)C)=C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)C(C=2C=CC(F)=CC=2)=C1 JNPGUXGVLNJQSQ-BGGMYYEUSA-M 0.000 description 2
- VAVHMEQFYYBAPR-ITWZMISCSA-N (e,3r,5s)-7-[4-(4-fluorophenyl)-1-phenyl-2-propan-2-ylpyrrol-3-yl]-3,5-dihydroxyhept-6-enoic acid Chemical compound CC(C)C1=C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)C(C=2C=CC(F)=CC=2)=CN1C1=CC=CC=C1 VAVHMEQFYYBAPR-ITWZMISCSA-N 0.000 description 2
- DPRJPRMZJGWLHY-HNGSOEQISA-N (e,3r,5s)-7-[5-(4-fluorophenyl)-3-propan-2-yl-1-pyrazin-2-ylpyrazol-4-yl]-3,5-dihydroxyhept-6-enoic acid Chemical compound OC(=O)C[C@H](O)C[C@H](O)/C=C/C=1C(C(C)C)=NN(C=2N=CC=NC=2)C=1C1=CC=C(F)C=C1 DPRJPRMZJGWLHY-HNGSOEQISA-N 0.000 description 2
- NDQXKKFRNOPRDW-UHFFFAOYSA-N 1,1,1-triethoxyethane Chemical compound CCOC(C)(OCC)OCC NDQXKKFRNOPRDW-UHFFFAOYSA-N 0.000 description 2
- HDPNBNXLBDFELL-UHFFFAOYSA-N 1,1,1-trimethoxyethane Chemical compound COC(C)(OC)OC HDPNBNXLBDFELL-UHFFFAOYSA-N 0.000 description 2
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 2
- LVEYOSJUKRVCCF-UHFFFAOYSA-N 1,3-bis(diphenylphosphino)propane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCCP(C=1C=CC=CC=1)C1=CC=CC=C1 LVEYOSJUKRVCCF-UHFFFAOYSA-N 0.000 description 2
- SUNMBRGCANLOEG-UHFFFAOYSA-N 1,3-dichloroacetone Chemical compound ClCC(=O)CCl SUNMBRGCANLOEG-UHFFFAOYSA-N 0.000 description 2
- OLWVAUVJFNOSRQ-UHFFFAOYSA-N 1-(2-nitrophenyl)pentan-2-one Chemical compound CCCC(=O)CC1=CC=CC=C1[N+]([O-])=O OLWVAUVJFNOSRQ-UHFFFAOYSA-N 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- FJZNNKJZHQFMCK-LRDDRELGSA-N 1-[(3S,4R)-4-(2,6-difluoro-4-methoxyphenyl)-2-oxopyrrolidin-3-yl]-3-phenylurea Chemical compound C1(=CC(=CC(=C1[C@H]1[C@@H](C(=O)NC1)NC(=O)NC1=CC=CC=C1)F)OC)F FJZNNKJZHQFMCK-LRDDRELGSA-N 0.000 description 2
- MOQCFMZWVKQBAP-UHFFFAOYSA-N 1-[3,5-bis(trifluoromethyl)benzoyl]-n-(4-chlorophenyl)piperidine-3-carboxamide Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C(=O)N2CC(CCC2)C(=O)NC=2C=CC(Cl)=CC=2)=C1 MOQCFMZWVKQBAP-UHFFFAOYSA-N 0.000 description 2
- RZFJBSIAXYEPBX-UHFFFAOYSA-N 1-[4-[4-[2-[4-chloro-3-(diethylsulfamoyl)anilino]pyrimidin-4-yl]pyridin-2-yl]phenyl]-3-methylurea Chemical compound C1=C(Cl)C(S(=O)(=O)N(CC)CC)=CC(NC=2N=C(C=CN=2)C=2C=C(N=CC=2)C=2C=CC(NC(=O)NC)=CC=2)=C1 RZFJBSIAXYEPBX-UHFFFAOYSA-N 0.000 description 2
- SURWSNJWDXZHBU-WPWMEQJKSA-N 1-[[(11e)-11-(1-cyanoethylidene)-3-fluoro-6h-benzo[c][1]benzoxepin-8-yl]methyl]-2-propylbenzimidazole-4-carboxamide Chemical compound C1=C2COC3=CC(F)=CC=C3\C(=C(/C)C#N)C2=CC=C1CN1C2=CC=CC(C(N)=O)=C2N=C1CCC SURWSNJWDXZHBU-WPWMEQJKSA-N 0.000 description 2
- PLFSEHGRLOPZFQ-WPWMEQJKSA-N 1-[[(11e)-11-(1-cyanoethylidene)-3-fluoro-6h-benzo[c][1]benzoxepin-8-yl]methyl]-2-propylbenzimidazole-4-carboxylic acid Chemical compound C1=C2COC3=CC(F)=CC=C3\C(=C(/C)C#N)C2=CC=C1CN1C2=CC=CC(C(O)=O)=C2N=C1CCC PLFSEHGRLOPZFQ-WPWMEQJKSA-N 0.000 description 2
- YKYWUHHZZRBGMG-JWTNVVGKSA-N 1-methyl-2-[[(1r,5s)-6-[[5-(trifluoromethyl)pyridin-2-yl]methoxymethyl]-3-azabicyclo[3.1.0]hexan-3-yl]methyl]benzimidazole Chemical compound C1([C@@H]2CN(C[C@@H]21)CC=1N(C2=CC=CC=C2N=1)C)COCC1=CC=C(C(F)(F)F)C=N1 YKYWUHHZZRBGMG-JWTNVVGKSA-N 0.000 description 2
- HQHYDYGGPVIZCZ-UHFFFAOYSA-N 1-nitro-2-pent-1-ynylbenzene Chemical compound CCCC#CC1=CC=CC=C1[N+]([O-])=O HQHYDYGGPVIZCZ-UHFFFAOYSA-N 0.000 description 2
- 125000006017 1-propenyl group Chemical group 0.000 description 2
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 2
- YLSSVFGTKZXLPA-UHFFFAOYSA-N 2-(1-benzyl-2-ethyl-3-oxamoylbenzo[g]indol-4-yl)oxyacetic acid Chemical compound CCC1=C(C(=O)C(N)=O)C2=C(OCC(O)=O)C=C3C=CC=CC3=C2N1CC1=CC=CC=C1 YLSSVFGTKZXLPA-UHFFFAOYSA-N 0.000 description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 2
- JENUMEXEVAAAJX-SNVBAGLBSA-N 2-(3,5-dimethyl-1,2,4-triazol-1-yl)-1-[(2r)-2-methyl-4-[2-(trifluoromethyl)-4-[2-(trifluoromethyl)pyrimidin-5-yl]-1,3-thiazol-5-yl]piperazin-1-yl]ethanone Chemical compound C([C@H]1C)N(C2=C(N=C(S2)C(F)(F)F)C=2C=NC(=NC=2)C(F)(F)F)CCN1C(=O)CN1N=C(C)N=C1C JENUMEXEVAAAJX-SNVBAGLBSA-N 0.000 description 2
- LDHCACQIPNQGQT-UHFFFAOYSA-N 2-(azetidin-1-yl)-1h-benzimidazole Chemical compound C1CCN1C1=NC2=CC=CC=C2N1 LDHCACQIPNQGQT-UHFFFAOYSA-N 0.000 description 2
- MEYPQXCVKIIOQI-UHFFFAOYSA-N 2-(chloromethyl)-8-(difluoromethoxy)imidazo[1,2-a]pyridine Chemical compound FC(F)OC1=CC=CN2C=C(CCl)N=C12 MEYPQXCVKIIOQI-UHFFFAOYSA-N 0.000 description 2
- DAGVTMLBIIBFHD-UHFFFAOYSA-N 2-(chloromethyl)-8-(trifluoromethyl)imidazo[1,2-a]pyridine Chemical compound FC(F)(F)C1=CC=CN2C=C(CCl)N=C12 DAGVTMLBIIBFHD-UHFFFAOYSA-N 0.000 description 2
- CFNABGLHIVYERN-UHFFFAOYSA-N 2-(chloromethyl)-8-methoxyimidazo[1,2-a]pyridine Chemical compound COC1=CC=CN2C=C(CCl)N=C12 CFNABGLHIVYERN-UHFFFAOYSA-N 0.000 description 2
- PHBCKTTUXIONFQ-UHFFFAOYSA-N 2-(methoxymethyl)-1h-benzimidazole Chemical compound C1=CC=C2NC(COC)=NC2=C1 PHBCKTTUXIONFQ-UHFFFAOYSA-N 0.000 description 2
- SFAANQMRASILRF-UHFFFAOYSA-N 2-(methoxymethyl)-1h-thieno[3,4-d]imidazole Chemical compound S1C=C2NC(COC)=NC2=C1 SFAANQMRASILRF-UHFFFAOYSA-N 0.000 description 2
- IDDGYQNTUMBPDH-UHFFFAOYSA-N 2-(methoxymethyl)-8-(trifluoromethyl)imidazo[1,2-a]pyridine Chemical compound C1=CC=C(C(F)(F)F)C2=NC(COC)=CN21 IDDGYQNTUMBPDH-UHFFFAOYSA-N 0.000 description 2
- BBFMYWHMIVZUNS-UHFFFAOYSA-N 2-(methoxymethyl)imidazo[1,2-a]pyridine Chemical compound C1=CC=CC2=NC(COC)=CN21 BBFMYWHMIVZUNS-UHFFFAOYSA-N 0.000 description 2
- BBFMYWHMIVZUNS-FIBGUPNXSA-N 2-(trideuteriomethoxymethyl)imidazo[1,2-a]pyridine Chemical compound C1=CC=CC2=NC(COC([2H])([2H])[2H])=CN21 BBFMYWHMIVZUNS-FIBGUPNXSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- IOOWNWLVCOUUEX-WPRPVWTQSA-N 2-[(3r,6s)-2-hydroxy-3-[(2-thiophen-2-ylacetyl)amino]oxaborinan-6-yl]acetic acid Chemical compound OB1O[C@H](CC(O)=O)CC[C@@H]1NC(=O)CC1=CC=CS1 IOOWNWLVCOUUEX-WPRPVWTQSA-N 0.000 description 2
- PPSMYAUEJRADFE-HXUWFJFHSA-N 2-[(5r)-4-[2-[3-(6-methylpyridin-3-yl)oxyphenyl]acetyl]-8-(trifluoromethyl)-1,2,3,5-tetrahydropyrido[2,3-e][1,4]diazepin-5-yl]acetic acid Chemical compound C1=NC(C)=CC=C1OC1=CC=CC(CC(=O)N2[C@@H](C3=CC=C(N=C3NCC2)C(F)(F)F)CC(O)=O)=C1 PPSMYAUEJRADFE-HXUWFJFHSA-N 0.000 description 2
- VPOJDVAEMGUXIT-UHFFFAOYSA-N 2-[2-(methoxymethyl)-1h-benzimidazol-4-yl]propan-2-ol Chemical compound C1=CC=C2NC(COC)=NC2=C1C(C)(C)O VPOJDVAEMGUXIT-UHFFFAOYSA-N 0.000 description 2
- AKBHYCHPWZPGAH-UHFFFAOYSA-N 2-[3-[(3-chloro-4-methylphenyl)methoxy]azetidine-1-carbonyl]-7-oxa-5-azaspiro[3.4]octan-6-one Chemical compound CC1=C(Cl)C=C(COC2CN(C2)C(=O)C2CC3(C2)COC(=O)N3)C=C1 AKBHYCHPWZPGAH-UHFFFAOYSA-N 0.000 description 2
- YLPAFRWROXMWBB-UHFFFAOYSA-N 2-[8-[(8-chloro-2-cyclopropylimidazo[1,2-a]pyrazin-3-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3C(=C(C#N)C)C2=CC=C1CC(N1C=CN=C(Cl)C1=N1)=C1C1CC1 YLPAFRWROXMWBB-UHFFFAOYSA-N 0.000 description 2
- CODBZFJPKJDNDT-UHFFFAOYSA-N 2-[[5-[3-(dimethylamino)propyl]-2-methylpyridin-3-yl]amino]-9-(trifluoromethyl)-5,7-dihydropyrimido[5,4-d][1]benzazepine-6-thione Chemical compound CN(C)CCCC1=CN=C(C)C(NC=2N=C3C4=CC=C(C=C4NC(=S)CC3=CN=2)C(F)(F)F)=C1 CODBZFJPKJDNDT-UHFFFAOYSA-N 0.000 description 2
- QLVGHFBUSGYCCG-UHFFFAOYSA-N 2-amino-n-(1-cyano-2-phenylethyl)acetamide Chemical compound NCC(=O)NC(C#N)CC1=CC=CC=C1 QLVGHFBUSGYCCG-UHFFFAOYSA-N 0.000 description 2
- AYPSHJCKSDNETA-UHFFFAOYSA-N 2-chloro-1h-benzimidazole Chemical compound C1=CC=C2NC(Cl)=NC2=C1 AYPSHJCKSDNETA-UHFFFAOYSA-N 0.000 description 2
- USYCVFDOTUIELS-UHFFFAOYSA-N 2-chloro-3-iodo-7-(trifluoromethyl)imidazo[1,2-a]pyridine Chemical compound C1=C(C(F)(F)F)C=CN2C(I)=C(Cl)N=C21 USYCVFDOTUIELS-UHFFFAOYSA-N 0.000 description 2
- WVPGUNFEMDBITD-UHFFFAOYSA-N 2-cyclobutyl-3h-imidazo[4,5-c]pyridine Chemical compound C1CCC1C1=NC2=CN=CC=C2N1 WVPGUNFEMDBITD-UHFFFAOYSA-N 0.000 description 2
- ACQZKAMBZDAMRZ-UHFFFAOYSA-N 2-cyclopropyl-1h-benzimidazole Chemical compound C1CC1C1=NC2=CC=CC=C2N1 ACQZKAMBZDAMRZ-UHFFFAOYSA-N 0.000 description 2
- FVEJDZAUEZPOFP-UHFFFAOYSA-N 2-cyclopropyl-1h-thieno[3,4-d]imidazole Chemical compound C1CC1C1=NC2=CSC=C2N1 FVEJDZAUEZPOFP-UHFFFAOYSA-N 0.000 description 2
- VZELHIUVXWAMGG-CVKSISIWSA-N 2-cyclopropyl-3-[[(11e)-3-fluoro-11-[1-(5-oxo-2h-1,2,4-oxadiazol-3-yl)ethylidene]-6h-benzo[c][1]benzoxepin-8-yl]methyl]imidazo[1,2-a]pyridine-7-carboxamide Chemical compound C/12=CC=C(CC=3N4C=CC(=CC4=NC=3C3CC3)C(N)=O)C=C2COC2=CC(F)=CC=C2C\1=C(/C)C1=NOC(=O)N1 VZELHIUVXWAMGG-CVKSISIWSA-N 0.000 description 2
- KPWUHXJJKLYLEW-UHFFFAOYSA-N 2-cyclopropyl-3-iodo-8-(trifluoromethyl)imidazo[1,2-a]pyridine Chemical compound N1=C2C(C(F)(F)F)=CC=CN2C(I)=C1C1CC1 KPWUHXJJKLYLEW-UHFFFAOYSA-N 0.000 description 2
- ATNJTTFEUFPWQU-UHFFFAOYSA-N 2-cyclopropyl-3-iodo-8-methoxyimidazo[1,2-a]pyrazine Chemical compound N1=C2C(OC)=NC=CN2C(I)=C1C1CC1 ATNJTTFEUFPWQU-UHFFFAOYSA-N 0.000 description 2
- BQTOKODOIVRYQS-UHFFFAOYSA-N 2-cyclopropyl-3-iodo-8-methylimidazo[1,2-a]pyrazine Chemical compound N1=C2C(C)=NC=CN2C(I)=C1C1CC1 BQTOKODOIVRYQS-UHFFFAOYSA-N 0.000 description 2
- YYVQMTMQIZXGBO-UHFFFAOYSA-N 2-cyclopropyl-3-iodoimidazo[1,2-a]pyrimidine Chemical compound N1=C2N=CC=CN2C(I)=C1C1CC1 YYVQMTMQIZXGBO-UHFFFAOYSA-N 0.000 description 2
- IINXBUTXZQZUFH-UHFFFAOYSA-N 2-cyclopropyl-3-iodoimidazo[1,2-b]pyridazine Chemical compound N1=C2C=CC=NN2C(I)=C1C1CC1 IINXBUTXZQZUFH-UHFFFAOYSA-N 0.000 description 2
- MOBSPUKJWHXCEN-UHFFFAOYSA-N 2-cyclopropyl-8-(trifluoromethyl)imidazo[1,2-a]pyridine Chemical compound N1=C2C(C(F)(F)F)=CC=CN2C=C1C1CC1 MOBSPUKJWHXCEN-UHFFFAOYSA-N 0.000 description 2
- IHAZOERTAFTLCP-UHFFFAOYSA-N 2-cyclopropyl-8-methoxyimidazo[1,2-a]pyrazine Chemical compound N1=C2C(OC)=NC=CN2C=C1C1CC1 IHAZOERTAFTLCP-UHFFFAOYSA-N 0.000 description 2
- IWSXWXMYYJGHMC-UHFFFAOYSA-N 2-cyclopropyl-8-methylimidazo[1,2-a]pyrazine Chemical compound N1=C2C(C)=NC=CN2C=C1C1CC1 IWSXWXMYYJGHMC-UHFFFAOYSA-N 0.000 description 2
- LYQSKAJZDSVMPO-UHFFFAOYSA-N 2-cyclopropylimidazo[1,2-a]pyrimidine Chemical compound C1CC1C1=CN(C=CC=N2)C2=N1 LYQSKAJZDSVMPO-UHFFFAOYSA-N 0.000 description 2
- BTHAWDQJAOYKCF-UHFFFAOYSA-N 2-cyclopropylimidazo[1,2-b]pyridazine Chemical compound C1CC1C1=CN(N=CC=C2)C2=N1 BTHAWDQJAOYKCF-UHFFFAOYSA-N 0.000 description 2
- HOZYYLDGTURKTB-UHFFFAOYSA-N 2-methoxy-n-(2-methoxy-6-nitrophenyl)acetamide Chemical compound COCC(=O)NC1=C(OC)C=CC=C1[N+]([O-])=O HOZYYLDGTURKTB-UHFFFAOYSA-N 0.000 description 2
- ZXCUZMIEAZHMIC-UHFFFAOYSA-N 2-methoxy-n-(3-methylsulfanyl-2-nitrophenyl)acetamide Chemical compound COCC(=O)NC1=CC=CC(SC)=C1[N+]([O-])=O ZXCUZMIEAZHMIC-UHFFFAOYSA-N 0.000 description 2
- BHNHHSOHWZKFOX-UHFFFAOYSA-N 2-methyl-1H-indole Chemical compound C1=CC=C2NC(C)=CC2=C1 BHNHHSOHWZKFOX-UHFFFAOYSA-N 0.000 description 2
- NWLBNJPJVFBSCL-UHFFFAOYSA-N 2-methyl-7-(trifluoromethyl)imidazo[1,2-a]pyridine Chemical compound C1=CC(C(F)(F)F)=CC2=NC(C)=CN21 NWLBNJPJVFBSCL-UHFFFAOYSA-N 0.000 description 2
- LSXHCFSGOBFNDX-FIBGUPNXSA-N 2-nitro-3-(trideuteriomethoxy)pyridine Chemical compound [2H]C([2H])([2H])OC1=CC=CN=C1[N+]([O-])=O LSXHCFSGOBFNDX-FIBGUPNXSA-N 0.000 description 2
- DPJCXCZTLWNFOH-UHFFFAOYSA-N 2-nitroaniline Chemical compound NC1=CC=CC=C1[N+]([O-])=O DPJCXCZTLWNFOH-UHFFFAOYSA-N 0.000 description 2
- RTKNAELQDOLQCB-HPRDVNIFSA-N 2-propan-2-yl-8-(trideuteriomethoxy)imidazo[1,2-a]pyridine Chemical compound [2H]C([2H])([2H])OC1=CC=CN2C=C(C(C)C)N=C12 RTKNAELQDOLQCB-HPRDVNIFSA-N 0.000 description 2
- CTVRFJSJXPCPFX-UHFFFAOYSA-N 2-propan-2-ylimidazo[1,2-a]pyridine Chemical compound C1=CC=CC2=NC(C(C)C)=CN21 CTVRFJSJXPCPFX-UHFFFAOYSA-N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- PWGYPFFWCUUEIP-UHFFFAOYSA-N 2-propyl-1h-imidazo[4,5-b]pyrazine Chemical compound C1=CN=C2NC(CCC)=NC2=N1 PWGYPFFWCUUEIP-UHFFFAOYSA-N 0.000 description 2
- HJENUMMIFDMCEN-UHFFFAOYSA-N 2-propyl-1h-indole Chemical compound C1=CC=C2NC(CCC)=CC2=C1 HJENUMMIFDMCEN-UHFFFAOYSA-N 0.000 description 2
- RDAGNFLSUIXMDB-UHFFFAOYSA-N 2-propylimidazo[1,2-a]pyridine Chemical compound C1=CC=CC2=NC(CCC)=CN21 RDAGNFLSUIXMDB-UHFFFAOYSA-N 0.000 description 2
- KHOKREOCKCIIQD-UHFFFAOYSA-N 3,3-difluoro-n-(2-nitrophenyl)cyclobutane-1-carboxamide Chemical compound [O-][N+](=O)C1=CC=CC=C1NC(=O)C1CC(F)(F)C1 KHOKREOCKCIIQD-UHFFFAOYSA-N 0.000 description 2
- QIAOBDSINGSZRL-UHFFFAOYSA-N 3-(difluoromethoxy)-2-nitropyridine Chemical compound [O-][N+](=O)C1=NC=CC=C1OC(F)F QIAOBDSINGSZRL-UHFFFAOYSA-N 0.000 description 2
- YWOWJQMFMXHLQD-UHFFFAOYSA-N 3-(trifluoromethyl)pyridin-2-amine Chemical compound NC1=NC=CC=C1C(F)(F)F YWOWJQMFMXHLQD-UHFFFAOYSA-N 0.000 description 2
- WFOVEDJTASPCIR-UHFFFAOYSA-N 3-[(4-methyl-5-pyridin-4-yl-1,2,4-triazol-3-yl)methylamino]-n-[[2-(trifluoromethyl)phenyl]methyl]benzamide Chemical compound N=1N=C(C=2C=CN=CC=2)N(C)C=1CNC(C=1)=CC=CC=1C(=O)NCC1=CC=CC=C1C(F)(F)F WFOVEDJTASPCIR-UHFFFAOYSA-N 0.000 description 2
- FAEPRYCWEKKNIC-BYYHNAKLSA-N 3-[(e)-cyclopropyl-[3-fluoro-8-[(2-propan-2-ylimidazo[1,2-a]pyridin-3-yl)methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]methyl]-2h-1,2,4-oxadiazol-5-one Chemical compound CC(C)C=1N=C2C=CC=CN2C=1CC(C=1)=CC=C2C=1COC1=CC(F)=CC=C1\C2=C(C=1NC(=O)ON=1)/C1CC1 FAEPRYCWEKKNIC-BYYHNAKLSA-N 0.000 description 2
- WNFAQVLTRONMFD-UHFFFAOYSA-N 3-[4-carbamoyl-1-[5-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-1,3-thiazol-2-yl]piperidin-4-yl]benzoic acid Chemical compound C1CC(C(=O)N)(C=2C=C(C=CC=2)C(O)=O)CCN1C1=NC=C(C(O)(C(F)(F)F)C(F)(F)F)S1 WNFAQVLTRONMFD-UHFFFAOYSA-N 0.000 description 2
- MESHCVLFTQAHQU-JVWAILMASA-N 3-[[(11e)-11-(1-cyanoethylidene)-3-fluoro-6h-benzo[c][1]benzoxepin-8-yl]methyl]-2-cyclopropylimidazo[1,2-a]pyridine-7-carboxylic acid Chemical compound C1=C2COC3=CC(F)=CC=C3C(=C(C#N)/C)\C2=CC=C1CC(N1C=CC(=CC1=N1)C(O)=O)=C1C1CC1 MESHCVLFTQAHQU-JVWAILMASA-N 0.000 description 2
- QWWYKHUCZSLKHH-WGOQTCKBSA-N 3-[[(11e)-11-(1-cyanoethylidene)-3-fluoro-6h-benzo[c][1]benzoxepin-8-yl]methyl]-2-cyclopropylimidazo[1,2-a]pyridine-8-carboxamide Chemical compound C1=C2COC3=CC(F)=CC=C3C(=C(C#N)/C)\C2=CC=C1CC(N1C=CC=C(C1=N1)C(N)=O)=C1C1CC1 QWWYKHUCZSLKHH-WGOQTCKBSA-N 0.000 description 2
- VBZOMIDBYZYAGE-WGOQTCKBSA-N 3-[[(11e)-11-(1-cyanoethylidene)-3-fluoro-6h-benzo[c][1]benzoxepin-8-yl]methyl]-2-cyclopropylimidazo[1,2-a]pyridine-8-carboxylic acid Chemical compound C1=C2COC3=CC(F)=CC=C3C(=C(C#N)/C)\C2=CC=C1CC(N1C=CC=C(C1=N1)C(O)=O)=C1C1CC1 VBZOMIDBYZYAGE-WGOQTCKBSA-N 0.000 description 2
- RBCARPJOEUEZLS-UHFFFAOYSA-N 3-bromopyridin-2-amine Chemical compound NC1=NC=CC=C1Br RBCARPJOEUEZLS-UHFFFAOYSA-N 0.000 description 2
- YADOEPHJIBKBCN-UHFFFAOYSA-N 3-chloro-2-nitroaniline Chemical compound NC1=CC=CC(Cl)=C1[N+]([O-])=O YADOEPHJIBKBCN-UHFFFAOYSA-N 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- QBPDSKPWYWIHGA-UHFFFAOYSA-N 3-hydroxy-2-nitropyridine Chemical compound OC1=CC=CN=C1[N+]([O-])=O QBPDSKPWYWIHGA-UHFFFAOYSA-N 0.000 description 2
- JDHJDEYTJHCPLO-UHFFFAOYSA-N 3-iodo-2-(methoxymethyl)-8-(trifluoromethyl)imidazo[1,2-a]pyridine Chemical compound FC(F)(F)C1=CC=CN2C(I)=C(COC)N=C21 JDHJDEYTJHCPLO-UHFFFAOYSA-N 0.000 description 2
- DNMRHCFTKCCCOA-UHFFFAOYSA-N 3-iodo-2-methyl-7-(trifluoromethyl)imidazo[1,2-a]pyridine Chemical compound C1=C(C(F)(F)F)C=CN2C(I)=C(C)N=C21 DNMRHCFTKCCCOA-UHFFFAOYSA-N 0.000 description 2
- OAGXWLQZWNXXGH-HPRDVNIFSA-N 3-iodo-2-propan-2-yl-8-(trideuteriomethoxy)imidazo[1,2-a]pyridine Chemical compound [2H]C([2H])([2H])OC1=CC=CN2C(I)=C(C(C)C)N=C12 OAGXWLQZWNXXGH-HPRDVNIFSA-N 0.000 description 2
- PTZRCVRKVSTNMH-UHFFFAOYSA-N 3-iodo-2-propan-2-ylimidazo[1,2-a]pyridine Chemical compound C1=CC=CN2C(I)=C(C(C)C)N=C21 PTZRCVRKVSTNMH-UHFFFAOYSA-N 0.000 description 2
- IQDANAOOIITVQT-UHFFFAOYSA-N 3-iodo-2-propylimidazo[1,2-a]pyridine Chemical compound C1=CC=CN2C(I)=C(CCC)N=C21 IQDANAOOIITVQT-UHFFFAOYSA-N 0.000 description 2
- YNQIXFRMQCXHHX-UHFFFAOYSA-N 3-iodo-7-methoxy-2-propan-2-ylimidazo[1,2-a]pyrimidine Chemical compound N1=C(OC)C=CN2C(I)=C(C(C)C)N=C21 YNQIXFRMQCXHHX-UHFFFAOYSA-N 0.000 description 2
- NFQUORZVCFUEJG-UHFFFAOYSA-N 3-iodo-8-methoxy-2-(methoxymethyl)imidazo[1,2-a]pyridine Chemical compound COC1=CC=CN2C(I)=C(COC)N=C21 NFQUORZVCFUEJG-UHFFFAOYSA-N 0.000 description 2
- OAGXWLQZWNXXGH-UHFFFAOYSA-N 3-iodo-8-methoxy-2-propan-2-ylimidazo[1,2-a]pyridine Chemical compound COC1=CC=CN2C(I)=C(C(C)C)N=C12 OAGXWLQZWNXXGH-UHFFFAOYSA-N 0.000 description 2
- JUWDLYJJGAYLEJ-UHFFFAOYSA-N 3-iodo-8-methyl-2-propylimidazo[1,2-a]pyrazine Chemical compound CC1=NC=CN2C(I)=C(CCC)N=C21 JUWDLYJJGAYLEJ-UHFFFAOYSA-N 0.000 description 2
- VQPHZDDLWFHRHR-UHFFFAOYSA-N 3-methylpyrazin-2-amine Chemical compound CC1=NC=CN=C1N VQPHZDDLWFHRHR-UHFFFAOYSA-N 0.000 description 2
- SGHVTQWWVZBGFN-UHFFFAOYSA-N 3-methylsulfanyl-2-nitroaniline Chemical compound CSC1=CC=CC(N)=C1[N+]([O-])=O SGHVTQWWVZBGFN-UHFFFAOYSA-N 0.000 description 2
- BLTWATTXUZKZPB-UHFFFAOYSA-N 4,5-dichloro-2-propan-2-yl-1h-imidazole Chemical compound CC(C)C1=NC(Cl)=C(Cl)N1 BLTWATTXUZKZPB-UHFFFAOYSA-N 0.000 description 2
- RWGBXAQMUBGGKQ-UHFFFAOYSA-N 4-(trifluoromethyl)pyridin-2-amine Chemical compound NC1=CC(C(F)(F)F)=CC=N1 RWGBXAQMUBGGKQ-UHFFFAOYSA-N 0.000 description 2
- TXEBWPPWSVMYOA-UHFFFAOYSA-N 4-[3-[(1-amino-2-chloroethyl)amino]propyl]-1-[[3-(2-chlorophenyl)phenyl]methyl]-5-hydroxyimidazolidin-2-one Chemical compound NC(CCl)NCCCC1NC(=O)N(Cc2cccc(c2)-c2ccccc2Cl)C1O TXEBWPPWSVMYOA-UHFFFAOYSA-N 0.000 description 2
- WCDLCPLAAKUJNY-UHFFFAOYSA-N 4-[4-[3-(1h-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-6-yl]phenyl]morpholine Chemical compound C1COCCN1C1=CC=C(C2=CN3N=CC(=C3N=C2)C2=CNN=C2)C=C1 WCDLCPLAAKUJNY-UHFFFAOYSA-N 0.000 description 2
- XBBHHYRHYRNTLW-UHFFFAOYSA-N 4-bromo-2-[(3-fluorophenoxy)methyl]benzoic acid Chemical compound OC(=O)C1=CC=C(Br)C=C1COC1=CC=CC(F)=C1 XBBHHYRHYRNTLW-UHFFFAOYSA-N 0.000 description 2
- BAQKUNMKVAPWGU-UHFFFAOYSA-N 4-bromopyridin-2-amine Chemical compound NC1=CC(Br)=CC=N1 BAQKUNMKVAPWGU-UHFFFAOYSA-N 0.000 description 2
- LZPHIRVHIJRDCR-UHFFFAOYSA-N 4-chloro-2-(methoxymethyl)-1h-benzimidazole Chemical compound C1=CC(Cl)=C2NC(COC)=NC2=C1 LZPHIRVHIJRDCR-UHFFFAOYSA-N 0.000 description 2
- IVGFFDIZRFYFNO-UHFFFAOYSA-N 4-chloro-2-cyclobutyl-1h-imidazo[4,5-c]pyridine Chemical compound N=1C=2C(Cl)=NC=CC=2NC=1C1CCC1 IVGFFDIZRFYFNO-UHFFFAOYSA-N 0.000 description 2
- BPNWPVSOJSABLV-UHFFFAOYSA-N 4-chloro-2-cyclopropyl-1h-benzimidazole Chemical compound N1C=2C(Cl)=CC=CC=2N=C1C1CC1 BPNWPVSOJSABLV-UHFFFAOYSA-N 0.000 description 2
- YNXLSFXQTQKQEF-UHFFFAOYSA-N 4-methoxypyrimidin-2-amine Chemical compound COC1=CC=NC(N)=N1 YNXLSFXQTQKQEF-UHFFFAOYSA-N 0.000 description 2
- YUXWMCKGSHXUGW-UHFFFAOYSA-N 4-methyl-6-[2-[5-[3-(methylamino)propyl]pyridin-3-yl]ethyl]pyridin-2-amine Chemical compound CC1=CC(=NC(=C1)CCC=1C=NC=C(C=1)CCCNC)N YUXWMCKGSHXUGW-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- ZAJBYTSUTBCMRM-UHFFFAOYSA-N 5-(2-methylpyrazol-3-yl)-1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carboxylic acid Chemical compound CN1N=CC=C1C1CC(C(C(O)=O)=NN2)=C2C1 ZAJBYTSUTBCMRM-UHFFFAOYSA-N 0.000 description 2
- KUZSBKJSGSKPJH-VXGBXAGGSA-N 5-[(9R)-6-[(3R)-3-methylmorpholin-4-yl]-11-oxa-1,3,5-triazatricyclo[7.4.0.02,7]trideca-2,4,6-trien-4-yl]pyrazin-2-amine Chemical compound C[C@@H]1COCCN1c1nc(nc2N3CCOC[C@H]3Cc12)-c1cnc(N)cn1 KUZSBKJSGSKPJH-VXGBXAGGSA-N 0.000 description 2
- SRSGVKWWVXWSJT-ATVHPVEESA-N 5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-n-(2-pyrrolidin-1-ylethyl)-1h-pyrrole-3-carboxamide Chemical compound CC=1NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C(C)C=1C(=O)NCCN1CCCC1 SRSGVKWWVXWSJT-ATVHPVEESA-N 0.000 description 2
- HIHOEGPXVVKJPP-JTQLQIEISA-N 5-fluoro-2-[[(1s)-1-(5-fluoropyridin-2-yl)ethyl]amino]-6-[(5-methyl-1h-pyrazol-3-yl)amino]pyridine-3-carbonitrile Chemical compound N([C@@H](C)C=1N=CC(F)=CC=1)C(C(=CC=1F)C#N)=NC=1NC=1C=C(C)NN=1 HIHOEGPXVVKJPP-JTQLQIEISA-N 0.000 description 2
- LSOKLMDQVZDBEX-UHFFFAOYSA-N 5-fluoro-2-propyl-1h-imidazo[4,5-b]pyridine Chemical compound C1=C(F)N=C2NC(CCC)=NC2=C1 LSOKLMDQVZDBEX-UHFFFAOYSA-N 0.000 description 2
- RRELDGDKULRRDM-UHFFFAOYSA-N 6-[2-chloro-4-nitro-5-(oxan-4-yloxy)anilino]-3,4-dihydro-1H-quinolin-2-one Chemical compound [O-][N+](=O)c1cc(Cl)c(Nc2ccc3NC(=O)CCc3c2)cc1OC1CCOCC1 RRELDGDKULRRDM-UHFFFAOYSA-N 0.000 description 2
- YTHMOBMZVVFNBE-UHFFFAOYSA-N 6-fluoropyridin-3-amine Chemical compound NC1=CC=C(F)N=C1 YTHMOBMZVVFNBE-UHFFFAOYSA-N 0.000 description 2
- XDGHIVNTSHRFGK-UHFFFAOYSA-N 7-bromo-2-cyclopropyl-3-iodoimidazo[1,2-a]pyridine Chemical compound N1=C2C=C(Br)C=CN2C(I)=C1C1CC1 XDGHIVNTSHRFGK-UHFFFAOYSA-N 0.000 description 2
- WMEJSLGULVMORW-UHFFFAOYSA-N 7-bromo-2-cyclopropylimidazo[1,2-a]pyridine Chemical compound N1=C2C=C(Br)C=CN2C=C1C1CC1 WMEJSLGULVMORW-UHFFFAOYSA-N 0.000 description 2
- WUWNXFKNYAWAAZ-UHFFFAOYSA-N 7-bromo-2-methylimidazo[1,2-a]pyridine Chemical compound C1=CC(Br)=CC2=NC(C)=CN21 WUWNXFKNYAWAAZ-UHFFFAOYSA-N 0.000 description 2
- ARQMGSVGVMSSIV-UHFFFAOYSA-N 7-bromo-3-iodo-2-methylimidazo[1,2-a]pyridine Chemical compound C1=C(Br)C=CN2C(I)=C(C)N=C21 ARQMGSVGVMSSIV-UHFFFAOYSA-N 0.000 description 2
- UCEJKAASHOWNTE-UHFFFAOYSA-N 7-chloro-2-(chloromethyl)imidazo[1,2-a]pyridine Chemical compound C1=CC(Cl)=CC2=NC(CCl)=CN21 UCEJKAASHOWNTE-UHFFFAOYSA-N 0.000 description 2
- XQICGBNNEYMJOW-UHFFFAOYSA-N 7-chloro-2-(methoxymethyl)imidazo[1,2-a]pyridine Chemical compound C1=CC(Cl)=CC2=NC(COC)=CN21 XQICGBNNEYMJOW-UHFFFAOYSA-N 0.000 description 2
- ONXXQANFAUBLDF-UHFFFAOYSA-N 7-chloro-2-ethyl-3-iodoimidazo[1,2-a]pyridine Chemical compound C1=C(Cl)C=CN2C(I)=C(CC)N=C21 ONXXQANFAUBLDF-UHFFFAOYSA-N 0.000 description 2
- QMJACFWOPIQBRW-UHFFFAOYSA-N 7-chloro-2-ethylimidazo[1,2-a]pyridine Chemical compound C1=CC(Cl)=CC2=NC(CC)=CN21 QMJACFWOPIQBRW-UHFFFAOYSA-N 0.000 description 2
- BAJGSKUHHVZENM-UHFFFAOYSA-N 7-chloro-2-methylimidazo[1,2-a]pyridine Chemical compound C1=CC(Cl)=CC2=NC(C)=CN21 BAJGSKUHHVZENM-UHFFFAOYSA-N 0.000 description 2
- PAZHKDXJULVFLZ-UHFFFAOYSA-N 7-fluoro-2-(oxolan-3-yl)imidazo[1,2-a]pyridine Chemical compound N1=C2C=C(F)C=CN2C=C1C1CCOC1 PAZHKDXJULVFLZ-UHFFFAOYSA-N 0.000 description 2
- YZXKSQUHLXBLCT-YDZHTSKRSA-N 7-fluoro-3-[[(11e)-3-fluoro-11-[1-(5-oxo-2h-1,2,4-oxadiazol-3-yl)ethylidene]-6h-benzo[c][1]benzoxepin-8-yl]methyl]imidazo[1,2-a]pyridine-2-carboxamide Chemical compound C/12=CC=C(CC=3N4C=CC(F)=CC4=NC=3C(N)=O)C=C2COC2=CC(F)=CC=C2C\1=C(/C)C1=NC(=O)ON1 YZXKSQUHLXBLCT-YDZHTSKRSA-N 0.000 description 2
- FRWPLYFNWKAOOY-UHFFFAOYSA-N 7-fluoro-3-iodo-2-(oxolan-3-yl)imidazo[1,2-a]pyridine Chemical compound N1=C2C=C(F)C=CN2C(I)=C1C1CCOC1 FRWPLYFNWKAOOY-UHFFFAOYSA-N 0.000 description 2
- RXIXMXHCFNQXEL-UHFFFAOYSA-N 7-methoxy-2-propan-2-ylimidazo[1,2-a]pyrimidine Chemical compound N1=C(OC)C=CN2C=C(C(C)C)N=C21 RXIXMXHCFNQXEL-UHFFFAOYSA-N 0.000 description 2
- IESBYFIAOSXWFT-UHFFFAOYSA-N 8-(difluoromethoxy)-2-(methoxymethyl)imidazo[1,2-a]pyridine Chemical compound C1=CC=C(OC(F)F)C2=NC(COC)=CN21 IESBYFIAOSXWFT-UHFFFAOYSA-N 0.000 description 2
- PTVVAJOSRJJOGR-UHFFFAOYSA-N 8-(difluoromethoxy)-2-propan-2-ylimidazo[1,2-a]pyridine Chemical compound C1=CC=C(OC(F)F)C2=NC(C(C)C)=CN21 PTVVAJOSRJJOGR-UHFFFAOYSA-N 0.000 description 2
- BGDHVCLEDQWRRG-UHFFFAOYSA-N 8-(difluoromethoxy)-3-iodo-2-(methoxymethyl)imidazo[1,2-a]pyridine Chemical compound FC(F)OC1=CC=CN2C(I)=C(COC)N=C21 BGDHVCLEDQWRRG-UHFFFAOYSA-N 0.000 description 2
- YSZSFLYLVBTODR-UHFFFAOYSA-N 8-(difluoromethoxy)-3-iodo-2-propan-2-ylimidazo[1,2-a]pyridine Chemical compound FC(F)OC1=CC=CN2C(I)=C(C(C)C)N=C21 YSZSFLYLVBTODR-UHFFFAOYSA-N 0.000 description 2
- PPPNCMBDUYAIMA-UHFFFAOYSA-N 8-bromo-2-cyclopropyl-3-iodoimidazo[1,2-a]pyridine Chemical compound N1=C2C(Br)=CC=CN2C(I)=C1C1CC1 PPPNCMBDUYAIMA-UHFFFAOYSA-N 0.000 description 2
- MKOGCUKUUFHBIR-UHFFFAOYSA-N 8-bromo-2-cyclopropylimidazo[1,2-a]pyridine Chemical compound N1=C2C(Br)=CC=CN2C=C1C1CC1 MKOGCUKUUFHBIR-UHFFFAOYSA-N 0.000 description 2
- OPRRNZGMQPBGEG-UHFFFAOYSA-N 8-chloro-2-(methoxymethyl)imidazo[1,2-a]pyridine Chemical compound C1=CC=C(Cl)C2=NC(COC)=CN21 OPRRNZGMQPBGEG-UHFFFAOYSA-N 0.000 description 2
- POKJCMVJYCYKGL-UHFFFAOYSA-N 8-chloro-2-cyclopropyl-3-iodoimidazo[1,2-a]pyridine Chemical compound N1=C2C(Cl)=CC=CN2C(I)=C1C1CC1 POKJCMVJYCYKGL-UHFFFAOYSA-N 0.000 description 2
- HOKARCUJWOXELD-UHFFFAOYSA-N 8-chloro-2-cyclopropylimidazo[1,2-a]pyridine Chemical compound N1=C2C(Cl)=CC=CN2C=C1C1CC1 HOKARCUJWOXELD-UHFFFAOYSA-N 0.000 description 2
- DLIKCSGMQBOHGQ-UHFFFAOYSA-N 8-chloro-2-methylimidazo[1,2-a]pyridine Chemical compound C1=CC=C(Cl)C2=NC(C)=CN21 DLIKCSGMQBOHGQ-UHFFFAOYSA-N 0.000 description 2
- IESLSDQYFSPLPD-UHFFFAOYSA-N 8-chloro-3-iodo-2-methylimidazo[1,2-a]pyridine Chemical compound ClC1=CC=CN2C(I)=C(C)N=C21 IESLSDQYFSPLPD-UHFFFAOYSA-N 0.000 description 2
- OMLIMAYXBQHLTG-UHFFFAOYSA-N 8-chloro-3-iodo-2-propan-2-ylimidazo[1,2-a]pyridine Chemical compound ClC1=CC=CN2C(I)=C(C(C)C)N=C21 OMLIMAYXBQHLTG-UHFFFAOYSA-N 0.000 description 2
- YRIQZXHHHBPSAU-UHFFFAOYSA-N 8-methoxy-2-(methoxymethyl)imidazo[1,2-a]pyridine Chemical compound C1=CC=C(OC)C2=NC(COC)=CN21 YRIQZXHHHBPSAU-UHFFFAOYSA-N 0.000 description 2
- RTKNAELQDOLQCB-UHFFFAOYSA-N 8-methoxy-2-propan-2-ylimidazo[1,2-a]pyridine Chemical compound COC1=CC=CN2C=C(C(C)C)N=C12 RTKNAELQDOLQCB-UHFFFAOYSA-N 0.000 description 2
- AERYWGANAVWBJX-UHFFFAOYSA-N 8-methyl-2-propylimidazo[1,2-a]pyrazine Chemical compound C1=CN=C(C)C2=NC(CCC)=CN21 AERYWGANAVWBJX-UHFFFAOYSA-N 0.000 description 2
- FJNCXZZQNBKEJT-UHFFFAOYSA-N 8beta-hydroxymarrubiin Natural products O1C(=O)C2(C)CCCC3(C)C2C1CC(C)(O)C3(O)CCC=1C=COC=1 FJNCXZZQNBKEJT-UHFFFAOYSA-N 0.000 description 2
- MITGKKFYIJJQGL-UHFFFAOYSA-N 9-(4-chlorobenzoyl)-6-methylsulfonyl-2,3-dihydro-1H-carbazol-4-one Chemical compound ClC1=CC=C(C(=O)N2C3=CC=C(C=C3C=3C(CCCC2=3)=O)S(=O)(=O)C)C=C1 MITGKKFYIJJQGL-UHFFFAOYSA-N 0.000 description 2
- VCUKKMIXURRDKL-UHFFFAOYSA-N 9-(dimethylamino)-3-(4-ethylphenyl)pyrido[1,2]thieno[3,4-d]pyrimidin-4-one Chemical compound C1=CC(CC)=CC=C1N1C(=O)C(SC=2C3=C(N(C)C)C=CN=2)=C3N=C1 VCUKKMIXURRDKL-UHFFFAOYSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 2
- 239000007848 Bronsted acid Substances 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- REDUQXCPUSNJOL-UHFFFAOYSA-N C(C1=CC=CC=C1)NC(CN(C(C1=CC=C(C=C1)C(C)C)=O)CC1=CC=C(C=C1)C(NO)=O)=O Chemical compound C(C1=CC=CC=C1)NC(CN(C(C1=CC=C(C=C1)C(C)C)=O)CC1=CC=C(C=C1)C(NO)=O)=O REDUQXCPUSNJOL-UHFFFAOYSA-N 0.000 description 2
- KAUXVLPBUXHPPO-YZSQISJMSA-N C/C(\C#N)=C1\C(C=CC(F)=C2)=C2OCC2=C\1C=CC(CNCCCCC(C([N+]([O-])=O)=N1)=CC=C1F)=C2 Chemical compound C/C(\C#N)=C1\C(C=CC(F)=C2)=C2OCC2=C\1C=CC(CNCCCCC(C([N+]([O-])=O)=N1)=CC=C1F)=C2 KAUXVLPBUXHPPO-YZSQISJMSA-N 0.000 description 2
- NZSQBRZWARZNQH-ZWOACCQCSA-N C1(CC1)NC(=O)O[C@H]1C(C2CC[C@]3([C@@]4(CC[C@@]5(C(C4CCC3[C@]2(CC1)C)[C@@H](CC5)[C@H](C)O)C(=O)O)C)C)(C)C Chemical compound C1(CC1)NC(=O)O[C@H]1C(C2CC[C@]3([C@@]4(CC[C@@]5(C(C4CCC3[C@]2(CC1)C)[C@@H](CC5)[C@H](C)O)C(=O)O)C)C)(C)C NZSQBRZWARZNQH-ZWOACCQCSA-N 0.000 description 2
- QUMCIHKVKQYNPA-RUZDIDTESA-N C1(CCCCC1)CN1[C@@H](C=2N(C=3C=NC(=NC1=3)NC1=C(C=C(C(=O)NC3CCN(CC3)C)C=C1)OC)C(=NN=2)C)CC Chemical compound C1(CCCCC1)CN1[C@@H](C=2N(C=3C=NC(=NC1=3)NC1=C(C=C(C(=O)NC3CCN(CC3)C)C=C1)OC)C(=NN=2)C)CC QUMCIHKVKQYNPA-RUZDIDTESA-N 0.000 description 2
- YMTGWGPHKRFJHD-LQKURTRISA-N C1=C2COC3=CC(F)=CC=C3C(=C(C#N)/C)\C2=CC=C1CC(N1C(O)=CC(F)=CC1=N1)=C1C1CCOC1 Chemical compound C1=C2COC3=CC(F)=CC=C3C(=C(C#N)/C)\C2=CC=C1CC(N1C(O)=CC(F)=CC1=N1)=C1C1CCOC1 YMTGWGPHKRFJHD-LQKURTRISA-N 0.000 description 2
- QCMHGCDOZLWPOT-FMNCTDSISA-N COC1=C(CC[C@@H]2CCC3=C(C2)C=CC(=C3)[C@H]2CC[C@](N)(CO)C2)C=CC=C1 Chemical compound COC1=C(CC[C@@H]2CCC3=C(C2)C=CC(=C3)[C@H]2CC[C@](N)(CO)C2)C=CC=C1 QCMHGCDOZLWPOT-FMNCTDSISA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 2
- CYSWUSAYJNCAKA-FYJFLYSWSA-N ClC1=C(C=CC=2N=C(SC=21)OCC)OC1=CC=C(C=N1)/C=C/[C@H](C)NC(C)=O Chemical compound ClC1=C(C=CC=2N=C(SC=21)OCC)OC1=CC=C(C=N1)/C=C/[C@H](C)NC(C)=O CYSWUSAYJNCAKA-FYJFLYSWSA-N 0.000 description 2
- QBXVXKRWOVBUDB-GRKNLSHJSA-N ClC=1C(=CC(=C(CN2[C@H](C[C@H](C2)O)C(=O)O)C1)OCC1=CC(=CC=C1)C#N)OCC1=C(C(=CC=C1)C1=CC2=C(OCCO2)C=C1)C Chemical compound ClC=1C(=CC(=C(CN2[C@H](C[C@H](C2)O)C(=O)O)C1)OCC1=CC(=CC=C1)C#N)OCC1=C(C(=CC=C1)C1=CC2=C(OCCO2)C=C1)C QBXVXKRWOVBUDB-GRKNLSHJSA-N 0.000 description 2
- 229940126279 Compound 14f Drugs 0.000 description 2
- 229940126559 Compound 4e Drugs 0.000 description 2
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 2
- 230000004568 DNA-binding Effects 0.000 description 2
- 239000006144 Dulbeccoās modiļ¬ed Eagle's medium Substances 0.000 description 2
- KGPGFQWBCSZGEL-ZDUSSCGKSA-N GSK690693 Chemical compound C=12N(CC)C(C=3C(=NON=3)N)=NC2=C(C#CC(C)(C)O)N=CC=1OC[C@H]1CCCNC1 KGPGFQWBCSZGEL-ZDUSSCGKSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical class NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- 239000002841 Lewis acid Substances 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 2
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- HPKJGHVHQWJOOT-ZJOUEHCJSA-N N-[(2S)-3-cyclohexyl-1-oxo-1-({(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}amino)propan-2-yl]-1H-indole-2-carboxamide Chemical compound C1C(CCCC1)C[C@H](NC(=O)C=1NC2=CC=CC=C2C=1)C(=O)N[C@@H](C[C@H]1C(=O)NCC1)C=O HPKJGHVHQWJOOT-ZJOUEHCJSA-N 0.000 description 2
- CZAFIFBJBFDMTP-UHFFFAOYSA-N N-[(4-bromophenyl)methyl]-2-[4-(2-phenylethylsulfamoyl)phenoxy]acetamide Chemical compound Brc1ccc(CNC(=O)COc2ccc(cc2)S(=O)(=O)NCCc2ccccc2)cc1 CZAFIFBJBFDMTP-UHFFFAOYSA-N 0.000 description 2
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 229940125907 SJ995973 Drugs 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- KSQVGVMZECCPAT-AEFFLSMTSA-N [(1R)-4-phenyl-1-[[(2R)-2-(pyrazine-2-carbonylamino)pentanoyl]amino]butyl]boronic acid Chemical compound B([C@H](CCCC1=CC=CC=C1)NC(=O)[C@@H](CCC)NC(=O)C2=NC=CN=C2)(O)O KSQVGVMZECCPAT-AEFFLSMTSA-N 0.000 description 2
- NELWQUQCCZMRPB-UBPLGANQSA-N [(2r,3r,4r,5r)-4-acetyloxy-5-(4-amino-5-ethenyl-2-oxopyrimidin-1-yl)-2-methyloxolan-3-yl] acetate Chemical compound CC(=O)O[C@@H]1[C@H](OC(C)=O)[C@@H](C)O[C@H]1N1C(=O)N=C(N)C(C=C)=C1 NELWQUQCCZMRPB-UBPLGANQSA-N 0.000 description 2
- ONSQLDCEJIIUJS-XVFCMESISA-N [(2r,3s,4r,5r)-5-(2-amino-4-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate Chemical compound NC1=NC(=O)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(O)=O)O1 ONSQLDCEJIIUJS-XVFCMESISA-N 0.000 description 2
- KEHUSUNAGOZRMA-UHFFFAOYSA-N [2-(methoxymethyl)-1h-benzimidazol-4-yl]methanol Chemical compound C1=CC=C2NC(COC)=NC2=C1CO KEHUSUNAGOZRMA-UHFFFAOYSA-N 0.000 description 2
- YLEIFZAVNWDOBM-ZTNXSLBXSA-N ac1l9hc7 Chemical compound C([C@H]12)C[C@@H](C([C@@H](O)CC3)(C)C)[C@@]43C[C@@]14CC[C@@]1(C)[C@@]2(C)C[C@@H]2O[C@]3(O)[C@H](O)C(C)(C)O[C@@H]3[C@@H](C)[C@H]12 YLEIFZAVNWDOBM-ZTNXSLBXSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 150000001343 alkyl silanes Chemical class 0.000 description 2
- SRVFFFJZQVENJC-IHRRRGAJSA-N aloxistatin Chemical compound CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C SRVFFFJZQVENJC-IHRRRGAJSA-N 0.000 description 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 2
- OYTKINVCDFNREN-UHFFFAOYSA-N amifampridine Chemical compound NC1=CC=NC=C1N OYTKINVCDFNREN-UHFFFAOYSA-N 0.000 description 2
- 229960004012 amifampridine Drugs 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 230000006229 amino acid addition Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 125000005098 aryl alkoxy carbonyl group Chemical group 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 125000002393 azetidinyl group Chemical group 0.000 description 2
- 125000004069 aziridinyl group Chemical group 0.000 description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 2
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 2
- KSCRVOKQPYZBHZ-IXPOFIJOSA-N benzyl n-[(2s)-1-[[(2s)-1-[[(2s)-1-(1,3-benzothiazol-2-yl)-1-oxo-3-[(3s)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamate Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C[C@H]1C(NCC1)=O)C(=O)C=1SC2=CC=CC=C2N=1)C(C)C)C(=O)OCC1=CC=CC=C1 KSCRVOKQPYZBHZ-IXPOFIJOSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 2
- VQFAIAKCILWQPZ-UHFFFAOYSA-N bromoacetone Chemical compound CC(=O)CBr VQFAIAKCILWQPZ-UHFFFAOYSA-N 0.000 description 2
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 2
- OSVHLUXLWQLPIY-KBAYOESNSA-N butyl 2-[(6aR,9R,10aR)-1-hydroxy-9-(hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a-hexahydrobenzo[c]chromen-3-yl]-2-methylpropanoate Chemical compound C(CCC)OC(C(C)(C)C1=CC(=C2[C@H]3[C@H](C(OC2=C1)(C)C)CC[C@H](C3)CO)O)=O OSVHLUXLWQLPIY-KBAYOESNSA-N 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- AEULIVPVIDOLIN-UHFFFAOYSA-N cep-11981 Chemical compound C1=C2C3=C4CNC(=O)C4=C4C5=CN(C)N=C5CCC4=C3N(CC(C)C)C2=CC=C1NC1=NC=CC=N1 AEULIVPVIDOLIN-UHFFFAOYSA-N 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- DCFKHNIGBAHNSS-UHFFFAOYSA-N chloro(triethyl)silane Chemical compound CC[Si](Cl)(CC)CC DCFKHNIGBAHNSS-UHFFFAOYSA-N 0.000 description 2
- 229940127206 compound 14d Drugs 0.000 description 2
- 229940126086 compound 21 Drugs 0.000 description 2
- 229940125796 compound 3d Drugs 0.000 description 2
- 229940126540 compound 41 Drugs 0.000 description 2
- 229940125872 compound 4d Drugs 0.000 description 2
- 229940126115 compound 4f Drugs 0.000 description 2
- 229940125880 compound 4j Drugs 0.000 description 2
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 2
- SBTSVTLGWRLWOD-UHFFFAOYSA-L copper(ii) triflate Chemical compound [Cu+2].[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F SBTSVTLGWRLWOD-UHFFFAOYSA-L 0.000 description 2
- TXWOGHSRPAYOML-UHFFFAOYSA-N cyclobutanecarboxylic acid Chemical compound OC(=O)C1CCC1 TXWOGHSRPAYOML-UHFFFAOYSA-N 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 150000001975 deuterium Chemical group 0.000 description 2
- RAFNCPHFRHZCPS-UHFFFAOYSA-N di(imidazol-1-yl)methanethione Chemical compound C1=CN=CN1C(=S)N1C=CN=C1 RAFNCPHFRHZCPS-UHFFFAOYSA-N 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 125000004459 dihydrobenzooxazolyl group Chemical group O1C(NC2=C1C=CC=C2)* 0.000 description 2
- 125000001070 dihydroindolyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 2
- 125000004611 dihydroisoindolyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- LIKFHECYJZWXFJ-UHFFFAOYSA-N dimethyldichlorosilane Chemical compound C[Si](C)(Cl)Cl LIKFHECYJZWXFJ-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- AVAACINZEOAHHE-VFZPANTDSA-N doripenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](CNS(N)(=O)=O)C1 AVAACINZEOAHHE-VFZPANTDSA-N 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- VTPUZXVVFKOJIC-PCLIKHOPSA-N ethyl 2-[[(11e)-11-(1-cyanoethylidene)-3-fluoro-6h-benzo[c][1]benzoxepin-8-yl]methyl]-3-oxohexanoate Chemical compound C1OC2=CC(F)=CC=C2\C(=C(/C)C#N)C2=CC=C(CC(C(=O)CCC)C(=O)OCC)C=C12 VTPUZXVVFKOJIC-PCLIKHOPSA-N 0.000 description 2
- FCLKQCMWPFJSDD-UHFFFAOYSA-N ethyl 7-fluoro-3-iodoimidazo[1,2-a]pyridine-2-carboxylate Chemical compound C1=C(F)C=CN2C(I)=C(C(=O)OCC)N=C21 FCLKQCMWPFJSDD-UHFFFAOYSA-N 0.000 description 2
- JSAPJXGLIRVDFJ-UHFFFAOYSA-N ethyl 7-fluoroimidazo[1,2-a]pyridine-2-carboxylate Chemical compound C1=CC(F)=CC2=NC(C(=O)OCC)=CN21 JSAPJXGLIRVDFJ-UHFFFAOYSA-N 0.000 description 2
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- DBUMITZHDMTTNX-UHFFFAOYSA-N gtpl6365 Chemical compound C1=CC(OC)=CC=C1N1C(=O)C(SC=2C3=C(NC4CC4)N=CN=2)=C3N=C1 DBUMITZHDMTTNX-UHFFFAOYSA-N 0.000 description 2
- 230000002140 halogenating effect Effects 0.000 description 2
- 125000006038 hexenyl group Chemical group 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000005980 hexynyl group Chemical group 0.000 description 2
- 230000001969 hypertrophic effect Effects 0.000 description 2
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229910052741 iridium Inorganic materials 0.000 description 2
- GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 125000001786 isothiazolyl group Chemical group 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 150000007517 lewis acids Chemical class 0.000 description 2
- JFOZKMSJYSPYLN-QHCPKHFHSA-N lifitegrast Chemical compound CS(=O)(=O)C1=CC=CC(C[C@H](NC(=O)C=2C(=C3CCN(CC3=CC=2Cl)C(=O)C=2C=C3OC=CC3=CC=2)Cl)C(O)=O)=C1 JFOZKMSJYSPYLN-QHCPKHFHSA-N 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 2
- DBTNVRCCIDISMV-UHFFFAOYSA-L lithium;magnesium;propane;dichloride Chemical compound [Li+].[Mg+2].[Cl-].[Cl-].C[CH-]C DBTNVRCCIDISMV-UHFFFAOYSA-L 0.000 description 2
- RENRQMCACQEWFC-UGKGYDQZSA-N lnp023 Chemical compound C1([C@H]2N(CC=3C=4C=CNC=4C(C)=CC=3OC)CC[C@@H](C2)OCC)=CC=C(C(O)=O)C=C1 RENRQMCACQEWFC-UGKGYDQZSA-N 0.000 description 2
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 2
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 2
- MUTCAPXLKRYEPR-ITWZMISCSA-N methyl (e,3r,5s)-7-[4-bromo-2,3-bis(4-fluorophenyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyhept-6-enoate Chemical compound COC(=O)C[C@H](O)C[C@H](O)\C=C\N1C(C(C)C)=C(Br)C(C=2C=CC(F)=CC=2)=C1C1=CC=C(F)C=C1 MUTCAPXLKRYEPR-ITWZMISCSA-N 0.000 description 2
- DZVCZPQORNKZCP-LIMNOBDPSA-N methyl 1-[[(11e)-11-(2-cyanoethylidene)-3-fluoro-6h-benzo[c][1]benzoxepin-8-yl]methyl]-2-propylbenzimidazole-4-carboxylate Chemical compound C1=C2COC3=CC(F)=CC=C3\C(=C\CC#N)C2=CC=C1CN1C2=CC=CC(C(=O)OC)=C2N=C1CCC DZVCZPQORNKZCP-LIMNOBDPSA-N 0.000 description 2
- UWEWTBNSCVDMHC-UHFFFAOYSA-N methyl 2-[(2-methoxyacetyl)amino]-3-nitrobenzoate Chemical compound COCC(=O)NC1=C(C(=O)OC)C=CC=C1[N+]([O-])=O UWEWTBNSCVDMHC-UHFFFAOYSA-N 0.000 description 2
- ROGDOCLTUJYXDB-OEAKJJBVSA-N methyl 2-[[(11e)-11-(1-cyanoethylidene)-3-fluoro-6h-benzo[c][1]benzoxepin-8-yl]methyl]-4-methoxy-3-oxobutanoate Chemical compound C1OC2=CC(F)=CC=C2\C(=C(/C)C#N)C2=CC=C(CC(C(=O)COC)C(=O)OC)C=C12 ROGDOCLTUJYXDB-OEAKJJBVSA-N 0.000 description 2
- VAMXMNNIEUEQDV-UHFFFAOYSA-N methyl anthranilate Chemical compound COC(=O)C1=CC=CC=C1N VAMXMNNIEUEQDV-UHFFFAOYSA-N 0.000 description 2
- KQNYTTDHCMFOME-UHFFFAOYSA-N methyl n-[[3-[(4-tert-butylpiperazin-1-yl)methyl]-8-fluoro-2-phenylquinoline-4-carbonyl]amino]-n-phenylcarbamate Chemical compound C=1C=CC=CC=1N(C(=O)OC)NC(=O)C(C1=CC=CC(F)=C1N=C1C=2C=CC=CC=2)=C1CN1CCN(C(C)(C)C)CC1 KQNYTTDHCMFOME-UHFFFAOYSA-N 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- NMTCCVZABWWGSB-UHFFFAOYSA-N n,n-dimethyl-1h-benzimidazol-2-amine Chemical compound C1=CC=C2NC(N(C)C)=NC2=C1 NMTCCVZABWWGSB-UHFFFAOYSA-N 0.000 description 2
- WNOHFJIMKSDPHP-UHFFFAOYSA-N n-(2-chlorophenyl)-7-(1h-1,2,4-triazol-5-yl)benzo[c][2,6]naphthyridin-5-amine Chemical compound ClC1=CC=CC=C1NC1=NC2=C(C=3NC=NN=3)C=CC=C2C2=CN=CC=C12 WNOHFJIMKSDPHP-UHFFFAOYSA-N 0.000 description 2
- OZLUGGUKYCREHO-UHFFFAOYSA-N n-(3-chloro-2-nitrophenyl)-2-methoxyacetamide Chemical compound COCC(=O)NC1=CC=CC(Cl)=C1[N+]([O-])=O OZLUGGUKYCREHO-UHFFFAOYSA-N 0.000 description 2
- GVNOTQBVXRPURE-UHFFFAOYSA-N n-(6-fluoro-2-nitropyridin-3-yl)cyclobutanecarboxamide Chemical compound [O-][N+](=O)C1=NC(F)=CC=C1NC(=O)C1CCC1 GVNOTQBVXRPURE-UHFFFAOYSA-N 0.000 description 2
- RQBGSNXMOGUSPZ-UHFFFAOYSA-N n-(6-fluoropyridin-3-yl)cyclobutanecarboxamide Chemical compound C1=NC(F)=CC=C1NC(=O)C1CCC1 RQBGSNXMOGUSPZ-UHFFFAOYSA-N 0.000 description 2
- QAPTWHXHEYAIKG-RCOXNQKVSA-N n-[(1r,2s,5r)-5-(tert-butylamino)-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](NC(C)(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 QAPTWHXHEYAIKG-RCOXNQKVSA-N 0.000 description 2
- MUJNAWXXOJRNGK-UHFFFAOYSA-N n-[3-(6-methyl-1,2,3,4-tetrahydrocarbazol-9-yl)propyl]cyclohexanamine Chemical compound C1=2CCCCC=2C2=CC(C)=CC=C2N1CCCNC1CCCCC1 MUJNAWXXOJRNGK-UHFFFAOYSA-N 0.000 description 2
- XZMHJYWMCRQSSI-UHFFFAOYSA-N n-[5-[2-(3-acetylanilino)-1,3-thiazol-4-yl]-4-methyl-1,3-thiazol-2-yl]benzamide Chemical compound CC(=O)C1=CC=CC(NC=2SC=C(N=2)C2=C(N=C(NC(=O)C=3C=CC=CC=3)S2)C)=C1 XZMHJYWMCRQSSI-UHFFFAOYSA-N 0.000 description 2
- MSRMDTJYESOJDR-WGOQTCKBSA-N n-[[(11e)-11-(1-cyanoethylidene)-3-fluoro-6h-benzo[c][1]benzoxepin-8-yl]methyl]-n-(6-fluoro-2-nitropyridin-3-yl)cyclobutanecarboxamide Chemical compound C1=C2COC3=CC(F)=CC=C3C(=C(C#N)/C)\C2=CC=C1CN(C=1C(=NC(F)=CC=1)[N+]([O-])=O)C(=O)C1CCC1 MSRMDTJYESOJDR-WGOQTCKBSA-N 0.000 description 2
- YRCHYHRCBXNYNU-UHFFFAOYSA-N n-[[3-fluoro-4-[2-[5-[(2-methoxyethylamino)methyl]pyridin-2-yl]thieno[3,2-b]pyridin-7-yl]oxyphenyl]carbamothioyl]-2-(4-fluorophenyl)acetamide Chemical compound N1=CC(CNCCOC)=CC=C1C1=CC2=NC=CC(OC=3C(=CC(NC(=S)NC(=O)CC=4C=CC(F)=CC=4)=CC=3)F)=C2S1 YRCHYHRCBXNYNU-UHFFFAOYSA-N 0.000 description 2
- GSJRUEBQWPLHSN-UHFFFAOYSA-N n-methylmethanamine;oxolane Chemical compound CNC.C1CCOC1 GSJRUEBQWPLHSN-UHFFFAOYSA-N 0.000 description 2
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000002560 nitrile group Chemical group 0.000 description 2
- 230000000269 nucleophilic effect Effects 0.000 description 2
- PFGVNLZDWRZPJW-OPAMFIHVSA-N otamixaban Chemical compound C([C@@H](C(=O)OC)[C@@H](C)NC(=O)C=1C=CC(=CC=1)C=1C=C[N+]([O-])=CC=1)C1=CC=CC(C(N)=N)=C1 PFGVNLZDWRZPJW-OPAMFIHVSA-N 0.000 description 2
- 125000001715 oxadiazolyl group Chemical group 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- 125000005981 pentynyl group Chemical group 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 2
- RPDAUEIUDPHABB-UHFFFAOYSA-N potassium ethoxide Chemical compound [K+].CC[O-] RPDAUEIUDPHABB-UHFFFAOYSA-N 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- WYVAMUWZEOHJOQ-UHFFFAOYSA-N propionic anhydride Chemical compound CCC(=O)OC(=O)CC WYVAMUWZEOHJOQ-UHFFFAOYSA-N 0.000 description 2
- UHGTWUCDRPJLRT-VUTHCHCSSA-N propyl 3-[[(11E)-11-(1-cyanoethylidene)-3-fluoro-6H-benzo[c][1]benzoxepin-8-yl]methyl]-2-cyclopropylimidazo[1,2-a]pyridine-8-carboxylate Chemical compound N1=C2C(C(=O)OCCC)=CC=CN2C(CC=2C=C3C(C(/C4=CC=C(F)C=C4OC3)=C(/C)C#N)=CC=2)=C1C1CC1 UHGTWUCDRPJLRT-VUTHCHCSSA-N 0.000 description 2
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- MVILWLLYYQVYNH-UHFFFAOYSA-N pyridine-2-carboxamide Chemical compound NC(=O)C1=CC=CC=N1.NC(=O)C1=CC=CC=N1 MVILWLLYYQVYNH-UHFFFAOYSA-N 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 description 2
- 229960004586 rosiglitazone Drugs 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 2
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 2
- MRTAVLDNYYEJHK-UHFFFAOYSA-M sodium;2-chloro-2,2-difluoroacetate Chemical compound [Na+].[O-]C(=O)C(F)(F)Cl MRTAVLDNYYEJHK-UHFFFAOYSA-M 0.000 description 2
- SUBJHSREKVAVAR-UHFFFAOYSA-N sodium;methanol;methanolate Chemical compound [Na+].OC.[O-]C SUBJHSREKVAVAR-UHFFFAOYSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 235000011150 stannous chloride Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- WGRQANOPCQRCME-PMACEKPBSA-N teneligliptin Chemical compound O=C([C@H]1NC[C@H](C1)N1CCN(CC1)C1=CC(=NN1C=1C=CC=CC=1)C)N1CCSC1 WGRQANOPCQRCME-PMACEKPBSA-N 0.000 description 2
- QKSQWQOAUQFORH-VAWYXSNFSA-N tert-butyl (ne)-n-[(2-methylpropan-2-yl)oxycarbonylimino]carbamate Chemical compound CC(C)(C)OC(=O)\N=N\C(=O)OC(C)(C)C QKSQWQOAUQFORH-VAWYXSNFSA-N 0.000 description 2
- FWQHRZXEQNUCSY-UHFFFAOYSA-N tert-butyl N-[2-(ethoxycarbonylamino)-5-[(4-fluorophenyl)methyl-prop-2-ynylamino]phenyl]carbamate Chemical compound CCOC(=O)NC1=C(C=C(C=C1)N(CC#C)CC2=CC=C(C=C2)F)NC(=O)OC(C)(C)C FWQHRZXEQNUCSY-UHFFFAOYSA-N 0.000 description 2
- FRACPXUHUTXLCX-BELIEFIBSA-N tert-butyl N-{1-[(1S)-1-{[(1R,2S)-1-(benzylcarbamoyl)-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]carbamoyl}-2-cyclopropylethyl]-2-oxopyridin-3-yl}carbamate Chemical compound CC(C)(C)OC(=O)NC1=CC=CN(C1=O)[C@@H](CC2CC2)C(=O)N[C@@H](C[C@@H]3CCNC3=O)[C@H](C(=O)NCC4=CC=CC=C4)O FRACPXUHUTXLCX-BELIEFIBSA-N 0.000 description 2
- OJSANQPEUWHPMB-TWKHWXDSSA-N tert-butyl n-[2-[n-[[(11e)-11-(1-cyanoethylidene)-3-fluoro-6h-benzo[c][1]benzoxepin-8-yl]methyl]-2-nitroanilino]-2-oxoethyl]-n-methylcarbamate Chemical compound C=1C=C(C(/C2=CC=C(F)C=C2OC2)=C(/C)C#N)C2=CC=1CN(C(=O)CN(C)C(=O)OC(C)(C)C)C1=CC=CC=C1[N+]([O-])=O OJSANQPEUWHPMB-TWKHWXDSSA-N 0.000 description 2
- FXOIYBFRFJRFCE-VUTHCHCSSA-N tert-butyl n-[[1-[[(11e)-3-fluoro-11-[1-(5-oxo-2h-1,2,4-oxadiazol-3-yl)ethylidene]-6h-benzo[c][1]benzoxepin-8-yl]methyl]benzimidazol-2-yl]methyl]-n-methylcarbamate Chemical compound CC(C)(C)OC(=O)N(C)CC1=NC2=CC=CC=C2N1CC(C=1)=CC=C2C=1COC1=CC(F)=CC=C1\C2=C(/C)C1=NOC(=O)N1 FXOIYBFRFJRFCE-VUTHCHCSSA-N 0.000 description 2
- QTEBCWYVWSIZOA-UHFFFAOYSA-N tert-butyl n-methyl-n-[2-(2-nitroanilino)-2-oxoethyl]carbamate Chemical compound CC(C)(C)OC(=O)N(C)CC(=O)NC1=CC=CC=C1[N+]([O-])=O QTEBCWYVWSIZOA-UHFFFAOYSA-N 0.000 description 2
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- 125000001113 thiadiazolyl group Chemical group 0.000 description 2
- 150000001467 thiazolidinediones Chemical class 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- RAMOMCXNLLLICQ-UHFFFAOYSA-N thiophene-3,4-diamine;dihydrochloride Chemical compound Cl.Cl.NC1=CSC=C1N RAMOMCXNLLLICQ-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 125000004306 triazinyl group Chemical group 0.000 description 2
- 125000001425 triazolyl group Chemical group 0.000 description 2
- TUQOTMZNTHZOKS-UHFFFAOYSA-N tributylphosphine Chemical compound CCCCP(CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-N 0.000 description 2
- GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 description 2
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- 239000005051 trimethylchlorosilane Substances 0.000 description 2
- CWMFRHBXRUITQE-UHFFFAOYSA-N trimethylsilylacetylene Chemical group C[Si](C)(C)C#C CWMFRHBXRUITQE-UHFFFAOYSA-N 0.000 description 2
- JQSHBVHOMNKWFT-DTORHVGOSA-N varenicline Chemical compound C12=CC3=NC=CN=C3C=C2[C@H]2C[C@@H]1CNC2 JQSHBVHOMNKWFT-DTORHVGOSA-N 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- BFDBKMOZYNOTPK-UHFFFAOYSA-N vonoprazan Chemical compound C=1C=CN=CC=1S(=O)(=O)N1C=C(CNC)C=C1C1=CC=CC=C1F BFDBKMOZYNOTPK-UHFFFAOYSA-N 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical compound C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 description 1
- YAUDCMARIRRWIE-CVYWFUOZSA-N (2e)-2-[3-fluoro-8-[[2-(trideuteriomethoxymethyl)imidazo[1,2-a]pyridin-3-yl]methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3\C(=C(/C)C#N)C2=CC=C1CC1=C(COC([2H])([2H])[2H])N=C2N1C=CC=C2 YAUDCMARIRRWIE-CVYWFUOZSA-N 0.000 description 1
- ZCQKNIVGPDZSHH-BUVRLJJBSA-N (2e)-2-[3-fluoro-8-[[2-(trifluoromethyl)benzimidazol-1-yl]methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3C(=C(C#N)/C)\C2=CC=C1CN1C2=CC=CC=C2N=C1C(F)(F)F ZCQKNIVGPDZSHH-BUVRLJJBSA-N 0.000 description 1
- PUKYIKFDUIYYLV-YZSQISJMSA-N (2e)-2-[3-fluoro-8-[[4-methoxy-7-(methoxymethyl)benzimidazol-1-yl]methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3\C(=C(/C)C#N)C2=CC=C1CN1C=NC2=C1C(COC)=CC=C2OC PUKYIKFDUIYYLV-YZSQISJMSA-N 0.000 description 1
- NTFRDSNAOYHMII-WPWMEQJKSA-N (2e)-2-[3-fluoro-8-[[7-methoxy-2-(methoxymethyl)benzimidazol-1-yl]methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3\C(=C(/C)C#N)C2=CC=C1CN1C2=C(OC)C=CC=C2N=C1COC NTFRDSNAOYHMII-WPWMEQJKSA-N 0.000 description 1
- JHGNVQJFVJEETP-LICLKQGHSA-N (2e)-2-[8-(bromomethyl)-1,3-difluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1OC2=CC(F)=CC(F)=C2C(=C(C#N)/C)\C2=CC=C(CBr)C=C21 JHGNVQJFVJEETP-LICLKQGHSA-N 0.000 description 1
- PREPLZLCDDOHJF-VCHYOVAHSA-N (2e)-2-[8-(bromomethyl)-2,3-difluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1OC2=CC(F)=C(F)C=C2C(=C(C#N)/C)\C2=CC=C(CBr)C=C21 PREPLZLCDDOHJF-VCHYOVAHSA-N 0.000 description 1
- RTRKOFDXDLVQBQ-MHWRWJLKSA-N (2e)-2-[8-(bromomethyl)-3,4-difluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1OC2=C(F)C(F)=CC=C2C(=C(C#N)/C)\C2=CC=C(CBr)C=C21 RTRKOFDXDLVQBQ-MHWRWJLKSA-N 0.000 description 1
- LRGCOOYHIPYELC-CPNJWEJPSA-N (2e)-2-[8-(bromomethyl)-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]butanenitrile Chemical compound C1OC2=CC(F)=CC=C2C(=C(C#N)/CC)\C2=CC=C(CBr)C=C21 LRGCOOYHIPYELC-CPNJWEJPSA-N 0.000 description 1
- HYZGGAGTOSVOKR-WPWMEQJKSA-N (2e)-2-[8-[(2-ethylbenzimidazol-1-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3\C(=C(/C)C#N)C2=CC=C1CN1C2=CC=CC=C2N=C1CC HYZGGAGTOSVOKR-WPWMEQJKSA-N 0.000 description 1
- LYDUYGVYWASQEQ-LFVJCYFKSA-N (2e)-2-[8-[(8-chloro-2-propan-2-ylimidazo[1,2-a]pyridin-3-yl)-hydroxymethyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3\C(=C(/C)C#N)C2=CC=C1C(O)C1=C(C(C)C)N=C2N1C=CC=C2Cl LYDUYGVYWASQEQ-LFVJCYFKSA-N 0.000 description 1
- PWXFFVGZEYGBOT-YZSQISJMSA-N (2e)-2-[8-[[2-(dimethylamino)benzimidazol-1-yl]methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3\C(=C(/C)C#N)C2=CC=C1CN1C2=CC=CC=C2N=C1N(C)C PWXFFVGZEYGBOT-YZSQISJMSA-N 0.000 description 1
- SQBOXJMQSZWKCR-CVYWFUOZSA-N (2e)-2-[8-[[2-cyclopropyl-8-(trideuteriomethoxy)imidazo[1,2-a]pyridin-3-yl]methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound N1=C2C(OC([2H])([2H])[2H])=CC=CN2C(CC=2C=C3C(C(/C4=CC=C(F)C=C4OC3)=C(/C)C#N)=CC=2)=C1C1CC1 SQBOXJMQSZWKCR-CVYWFUOZSA-N 0.000 description 1
- JYZPUNCGSKLWOO-BUVRLJJBSA-N (2e)-2-[8-[[8-(difluoromethoxy)-2-(methoxymethyl)imidazo[1,2-a]pyridin-3-yl]-hydroxymethyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]propanenitrile Chemical compound C1=C2COC3=CC(F)=CC=C3\C(=C(/C)C#N)C2=CC=C1C(O)C1=C(COC)N=C2N1C=CC=C2OC(F)F JYZPUNCGSKLWOO-BUVRLJJBSA-N 0.000 description 1
- UTFLYMJTOGYPBZ-GNVQSUKOSA-N (2e)-2-cyclopropyl-2-[3-fluoro-8-[(2-propan-2-ylimidazo[1,2-a]pyridin-3-yl)methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]acetonitrile Chemical compound CC(C)C=1N=C2C=CC=CN2C=1CC(C=1)=CC=C2C=1COC1=CC(F)=CC=C1\C2=C(\C#N)C1CC1 UTFLYMJTOGYPBZ-GNVQSUKOSA-N 0.000 description 1
- MDOHXVXRJFYMNO-GNVQSUKOSA-N (2e)-2-cyclopropyl-2-[8-[(2-cyclopropylimidazo[1,2-a]pyridin-3-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]acetonitrile Chemical compound C=1C(F)=CC=C(C(/C2=CC=3)=C(/C#N)C4CC4)C=1OCC2=CC=3CC(N1C=CC=CC1=N1)=C1C1CC1 MDOHXVXRJFYMNO-GNVQSUKOSA-N 0.000 description 1
- YGKIYJCGKOEWTP-GNVQSUKOSA-N (2e)-2-cyclopropyl-2-[8-[(2-cyclopropylimidazo[1,2-a]pyridin-3-yl)methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]acetonitrile Chemical compound C\12=CC=C(CC=3N4C=CC=CC4=NC=3C3CC3)C=C2COC2=CC=CC=C2C/1=C(/C#N)C1CC1 YGKIYJCGKOEWTP-GNVQSUKOSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- ABDDQTDRAHXHOC-QMMMGPOBSA-N 1-[(7s)-5,7-dihydro-4h-thieno[2,3-c]pyran-7-yl]-n-methylmethanamine Chemical compound CNC[C@@H]1OCCC2=C1SC=C2 ABDDQTDRAHXHOC-QMMMGPOBSA-N 0.000 description 1
- RGNJTPPLXGEOEW-WGOQTCKBSA-N 1-[[(11e)-3-fluoro-11-[1-(5-oxo-2h-1,2,4-oxadiazol-3-yl)ethylidene]-6h-benzo[c][1]benzoxepin-8-yl]methyl]-2-propylbenzimidazole-4-carboxamide Chemical compound CCCC1=NC2=C(C(N)=O)C=CC=C2N1CC(C=1)=CC=C2C=1COC1=CC(F)=CC=C1\C2=C(/C)C1=NC(=O)ON1 RGNJTPPLXGEOEW-WGOQTCKBSA-N 0.000 description 1
- CCXQVBSQUQCEEO-UHFFFAOYSA-N 1-bromobutan-2-one Chemical compound CCC(=O)CBr CCXQVBSQUQCEEO-UHFFFAOYSA-N 0.000 description 1
- XNHTZBFSFZSWOO-UHFFFAOYSA-N 1-bromopentan-2-one Chemical compound CCCC(=O)CBr XNHTZBFSFZSWOO-UHFFFAOYSA-N 0.000 description 1
- IBXNCJKFFQIKKY-UHFFFAOYSA-N 1-pentyne Chemical compound CCCC#C IBXNCJKFFQIKKY-UHFFFAOYSA-N 0.000 description 1
- ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 description 1
- XALYOHSTMDJDAO-UHFFFAOYSA-N 2-(1-methylcyclopropyl)-1h-benzimidazole Chemical compound N=1C2=CC=CC=C2NC=1C1(C)CC1 XALYOHSTMDJDAO-UHFFFAOYSA-N 0.000 description 1
- HEPRJDRTCYIEHE-UHFFFAOYSA-N 2-(8-ethynyl-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene)-2-fluoroacetonitrile Chemical compound C1OC2=CC(F)=CC=C2C(=C(C#N)F)C2=CC=C(C#C)C=C21 HEPRJDRTCYIEHE-UHFFFAOYSA-N 0.000 description 1
- CGMDFQJABKJUGX-UHFFFAOYSA-N 2-(cyclopropylmethyl)-1h-benzimidazole Chemical compound N=1C2=CC=CC=C2NC=1CC1CC1 CGMDFQJABKJUGX-UHFFFAOYSA-N 0.000 description 1
- OZMLUMPWPFZWTP-UHFFFAOYSA-N 2-(tributyl-$l^{5}-phosphanylidene)acetonitrile Chemical compound CCCCP(CCCC)(CCCC)=CC#N OZMLUMPWPFZWTP-UHFFFAOYSA-N 0.000 description 1
- MXFMPTXDHSDMTI-UHFFFAOYSA-N 2-(trifluoromethyl)-1h-benzimidazole Chemical compound C1=CC=C2NC(C(F)(F)F)=NC2=C1 MXFMPTXDHSDMTI-UHFFFAOYSA-N 0.000 description 1
- KJFJIEHJCVSAKJ-UHFFFAOYSA-N 2-(trimethyl-$l^{5}-phosphanylidene)acetonitrile Chemical compound CP(C)(C)=CC#N KJFJIEHJCVSAKJ-UHFFFAOYSA-N 0.000 description 1
- YRXIMPFOTQVOHG-UHFFFAOYSA-N 2-[methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]acetic acid Chemical compound OC(=O)CN(C)C(=O)OC(C)(C)C YRXIMPFOTQVOHG-UHFFFAOYSA-N 0.000 description 1
- AFYWQQAFNRKSGS-UHFFFAOYSA-N 2-bromo-1-(oxolan-3-yl)ethanone Chemical compound BrCC(=O)C1CCOC1 AFYWQQAFNRKSGS-UHFFFAOYSA-N 0.000 description 1
- ANLLPTFGRAIIOZ-UHFFFAOYSA-N 2-cyclobutyl-1h-benzimidazole Chemical compound C1CCC1C1=NC2=CC=CC=C2N1 ANLLPTFGRAIIOZ-UHFFFAOYSA-N 0.000 description 1
- JIHVGOLTABHOBF-UHFFFAOYSA-N 2-cyclopentyl-1h-benzimidazole Chemical compound C1CCCC1C1=NC2=CC=CC=C2N1 JIHVGOLTABHOBF-UHFFFAOYSA-N 0.000 description 1
- RUKQNLVBBKDIJW-JVWAILMASA-N 2-cyclopropyl-3-[[(11e)-3-fluoro-11-[1-(5-oxo-2h-1,2,4-oxadiazol-3-yl)ethylidene]-6h-benzo[c][1]benzoxepin-8-yl]methyl]imidazo[1,2-a]pyridine-7-carbonitrile Chemical compound C/12=CC=C(CC=3N4C=CC(=CC4=NC=3C3CC3)C#N)C=C2COC2=CC(F)=CC=C2C\1=C(/C)C1=NOC(=O)N1 RUKQNLVBBKDIJW-JVWAILMASA-N 0.000 description 1
- DTCCGIPJYNSHQD-MFKUBSTISA-N 2-cyclopropyl-3-[[(11e)-3-fluoro-11-[1-(5-oxo-2h-1,2,4-oxadiazol-3-yl)ethylidene]-6h-benzo[c][1]benzoxepin-8-yl]methyl]imidazo[1,2-a]pyridine-8-carboxamide Chemical compound C/12=CC=C(CC=3N4C=CC=C(C4=NC=3C3CC3)C(N)=O)C=C2COC2=CC(F)=CC=C2C\1=C(/C)C1=NOC(=O)N1 DTCCGIPJYNSHQD-MFKUBSTISA-N 0.000 description 1
- FAUQRRGKJKMEIW-UHFFFAOYSA-N 2-cyclopropylacetonitrile Chemical compound N#CCC1CC1 FAUQRRGKJKMEIW-UHFFFAOYSA-N 0.000 description 1
- QHCCOYAKYCWDOJ-UHFFFAOYSA-N 2-ethyl-1h-benzimidazole Chemical compound C1=CC=C2NC(CC)=NC2=C1 QHCCOYAKYCWDOJ-UHFFFAOYSA-N 0.000 description 1
- JCQOGMHNCICGIX-UHFFFAOYSA-N 2-ethyl-5-phenyl-1h-imidazole Chemical compound N1C(CC)=NC=C1C1=CC=CC=C1 JCQOGMHNCICGIX-UHFFFAOYSA-N 0.000 description 1
- NDKWDGCTUOOAPF-UHFFFAOYSA-N 2-methoxy-6-nitroaniline Chemical compound COC1=CC=CC([N+]([O-])=O)=C1N NDKWDGCTUOOAPF-UHFFFAOYSA-N 0.000 description 1
- IQUPABOKLQSFBK-UHFFFAOYSA-N 2-nitrophenol Chemical compound OC1=CC=CC=C1[N+]([O-])=O IQUPABOKLQSFBK-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- JUYQSMXGDBGGSX-UHFFFAOYSA-N 2-piperidin-1-yl-1h-benzimidazole Chemical compound C1CCCCN1C1=NC2=CC=CC=C2N1 JUYQSMXGDBGGSX-UHFFFAOYSA-N 0.000 description 1
- RITUGMAIQCZEOG-UHFFFAOYSA-N 2-propan-2-yl-1h-benzimidazole Chemical compound C1=CC=C2NC(C(C)C)=NC2=C1 RITUGMAIQCZEOG-UHFFFAOYSA-N 0.000 description 1
- FUOZJYASZOSONT-UHFFFAOYSA-N 2-propan-2-yl-1h-imidazole Chemical compound CC(C)C1=NC=CN1 FUOZJYASZOSONT-UHFFFAOYSA-N 0.000 description 1
- QDDCHASDSHHKLY-UHFFFAOYSA-N 2-propyl-1h-imidazo[4,5-b]pyridine Chemical compound C1=CC=C2NC(CCC)=NC2=N1 QDDCHASDSHHKLY-UHFFFAOYSA-N 0.000 description 1
- KYYMSVYUONLYNF-UHFFFAOYSA-N 2-propyl-3h-imidazo[4,5-c]pyridine Chemical compound N1=CC=C2NC(CCC)=NC2=C1 KYYMSVYUONLYNF-UHFFFAOYSA-N 0.000 description 1
- YNFBMDWHEHETJW-UHFFFAOYSA-N 2-pyridin-2-yl-1h-benzimidazole Chemical compound N1=CC=CC=C1C1=NC2=CC=CC=C2N1 YNFBMDWHEHETJW-UHFFFAOYSA-N 0.000 description 1
- RXWCRIKVVODMRG-UHFFFAOYSA-N 2-pyrrolidin-1-yl-1h-benzimidazole Chemical compound C1CCCN1C1=NC2=CC=CC=C2N1 RXWCRIKVVODMRG-UHFFFAOYSA-N 0.000 description 1
- PLRCVBKYFLWAAT-UHFFFAOYSA-N 3,3-difluorocyclobutane-1-carboxylic acid Chemical compound OC(=O)C1CC(F)(F)C1 PLRCVBKYFLWAAT-UHFFFAOYSA-N 0.000 description 1
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- RBCZLNWYEDEEIB-WGOQTCKBSA-N 3-[(1e)-1-[1,3-difluoro-8-[(2-propylbenzimidazol-1-yl)methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound CCCC1=NC2=CC=CC=C2N1CC(C=1)=CC=C2C=1COC1=CC(F)=CC(F)=C1\C2=C(/C)C1=NOC(=O)N1 RBCZLNWYEDEEIB-WGOQTCKBSA-N 0.000 description 1
- AKQRXPDFNKRLSJ-JVWAILMASA-N 3-[(1e)-1-[2,3-difluoro-8-[(2-propylbenzimidazol-1-yl)methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound CCCC1=NC2=CC=CC=C2N1CC(C=1)=CC=C2C=1COC1=CC(F)=C(F)C=C1\C2=C(/C)C1=NOC(=O)N1 AKQRXPDFNKRLSJ-JVWAILMASA-N 0.000 description 1
- LTUAZVOQWGZIRY-PCLIKHOPSA-N 3-[(1e)-1-[3,4-difluoro-8-[(2-propylbenzimidazol-1-yl)methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound CCCC1=NC2=CC=CC=C2N1CC(C=1)=CC=C2C=1COC1=C(F)C(F)=CC=C1\C2=C(/C)C1=NOC(=O)N1 LTUAZVOQWGZIRY-PCLIKHOPSA-N 0.000 description 1
- ADFQIDXAXALYRW-CVKSISIWSA-N 3-[(1e)-1-[3-fluoro-8-[(2-methyl-1h-indol-3-yl)methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound C/12=CC=C(CC=3C4=CC=CC=C4NC=3C)C=C2COC2=CC(F)=CC=C2C\1=C(/C)C1=NOC(=O)N1 ADFQIDXAXALYRW-CVKSISIWSA-N 0.000 description 1
- QBCWEIUORKIKJY-TURZUDJPSA-N 3-[(1e)-1-[3-fluoro-8-[(2-piperidin-1-ylbenzimidazol-1-yl)methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound C/12=CC=C(CN3C4=CC=CC=C4N=C3N3CCCCC3)C=C2COC2=CC(F)=CC=C2C\1=C(/C)C1=NOC(=O)N1 QBCWEIUORKIKJY-TURZUDJPSA-N 0.000 description 1
- BWXXACZCXMMONZ-YZSQISJMSA-N 3-[(1e)-1-[3-fluoro-8-[(2-propan-2-ylbenzimidazol-1-yl)methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound CC(C)C1=NC2=CC=CC=C2N1CC(C=1)=CC=C2C=1COC1=CC(F)=CC=C1\C2=C(/C)C1=NOC(=O)N1 BWXXACZCXMMONZ-YZSQISJMSA-N 0.000 description 1
- PMAFYGMNSMLGFP-YZSQISJMSA-N 3-[(1e)-1-[3-fluoro-8-[(2-propan-2-ylimidazo[1,2-a]pyridin-3-yl)methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound CC(C)C=1N=C2C=CC=CN2C=1CC(C=1)=CC=C2C=1COC1=CC(F)=CC=C1\C2=C(/C)C1=NOC(=O)N1 PMAFYGMNSMLGFP-YZSQISJMSA-N 0.000 description 1
- IUYLQPJPGPSEQN-OGLMXYFKSA-N 3-[(1e)-1-[3-fluoro-8-[(2-propyl-1h-indol-3-yl)methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound CCCC=1NC2=CC=CC=C2C=1CC(C=1)=CC=C2C=1COC1=CC(F)=CC=C1\C2=C(/C)C1=NOC(=O)N1 IUYLQPJPGPSEQN-OGLMXYFKSA-N 0.000 description 1
- PBUIWUMZZZXLAE-WPWMEQJKSA-N 3-[(1e)-1-[3-fluoro-8-[(2-propylbenzimidazol-1-yl)methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound CCCC1=NC2=CC=CC=C2N1CC(C=1)=CC=C2C=1COC1=CC(F)=CC=C1\C2=C(/C)C1=NOC(=O)N1 PBUIWUMZZZXLAE-WPWMEQJKSA-N 0.000 description 1
- UREQGMMFXZEGMF-WPWMEQJKSA-N 3-[(1e)-1-[3-fluoro-8-[(2-propylimidazo[1,2-a]pyridin-3-yl)methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound CCCC=1N=C2C=CC=CN2C=1CC(C=1)=CC=C2C=1COC1=CC(F)=CC=C1\C2=C(/C)C1=NOC(=O)N1 UREQGMMFXZEGMF-WPWMEQJKSA-N 0.000 description 1
- IHPGLYSWGJOYSD-HZHRSRAPSA-N 3-[(1e)-1-[3-fluoro-8-[(2-propylimidazo[4,5-b]pyrazin-3-yl)methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound CCCC1=NC2=NC=CN=C2N1CC(C=1)=CC=C2C=1COC1=CC(F)=CC=C1\C2=C(/C)C1=NOC(=O)N1 IHPGLYSWGJOYSD-HZHRSRAPSA-N 0.000 description 1
- HVHMQEZGGKWDMS-WGOQTCKBSA-N 3-[(1e)-1-[3-fluoro-8-[(2-propylimidazo[4,5-c]pyridin-1-yl)methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound CCCC1=NC2=CN=CC=C2N1CC(C=1)=CC=C2C=1COC1=CC(F)=CC=C1\C2=C(/C)C1=NOC(=O)N1 HVHMQEZGGKWDMS-WGOQTCKBSA-N 0.000 description 1
- RKJAKKDYFSBZGT-MTDXEUNCSA-N 3-[(1e)-1-[3-fluoro-8-[(2-pyridin-2-ylbenzimidazol-1-yl)methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound C/12=CC=C(CN3C4=CC=CC=C4N=C3C=3N=CC=CC=3)C=C2COC2=CC(F)=CC=C2C\1=C(/C)C1=NOC(=O)N1 RKJAKKDYFSBZGT-MTDXEUNCSA-N 0.000 description 1
- YZTIZFGOAKOXET-OVVQPSECSA-N 3-[(1e)-1-[3-fluoro-8-[(2-pyrrolidin-1-ylbenzimidazol-1-yl)methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound C/12=CC=C(CN3C4=CC=CC=C4N=C3N3CCCC3)C=C2COC2=CC(F)=CC=C2C\1=C(/C)C1=NOC(=O)N1 YZTIZFGOAKOXET-OVVQPSECSA-N 0.000 description 1
- BRLFTHHHDUBGHK-WPWMEQJKSA-N 3-[(1e)-1-[3-fluoro-8-[(4-methoxy-2-propylbenzimidazol-1-yl)methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound CCCC1=NC2=C(OC)C=CC=C2N1CC(C=1)=CC=C2C=1COC1=CC(F)=CC=C1\C2=C(/C)C1=NOC(=O)N1 BRLFTHHHDUBGHK-WPWMEQJKSA-N 0.000 description 1
- LLTDQPNZAOBSFF-MFKUBSTISA-N 3-[(1e)-1-[3-fluoro-8-[(5-fluoro-2-propylimidazo[4,5-b]pyridin-1-yl)methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound CCCC1=NC2=NC(F)=CC=C2N1CC(C=1)=CC=C2C=1COC1=CC(F)=CC=C1\C2=C(/C)C1=NOC(=O)N1 LLTDQPNZAOBSFF-MFKUBSTISA-N 0.000 description 1
- AVKISKWVOUJXNP-MFKUBSTISA-N 3-[(1e)-1-[3-fluoro-8-[(5-fluoro-2-propylimidazo[4,5-b]pyridin-3-yl)methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound CCCC1=NC2=CC=C(F)N=C2N1CC(C=1)=CC=C2C=1COC1=CC(F)=CC=C1\C2=C(/C)C1=NOC(=O)N1 AVKISKWVOUJXNP-MFKUBSTISA-N 0.000 description 1
- PMRQIHBKDDTGBO-WPWMEQJKSA-N 3-[(1e)-1-[3-fluoro-8-[(8-methoxy-2-propylimidazo[1,2-a]pyridin-3-yl)methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound CCCC=1N=C2C(OC)=CC=CN2C=1CC(C=1)=CC=C2C=1COC1=CC(F)=CC=C1\C2=C(/C)C1=NOC(=O)N1 PMRQIHBKDDTGBO-WPWMEQJKSA-N 0.000 description 1
- AUTDDWUMVGMQEE-WGOQTCKBSA-N 3-[(1e)-1-[3-fluoro-8-[(8-methyl-2-propylimidazo[1,2-a]pyrazin-3-yl)methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound CCCC=1N=C2C(C)=NC=CN2C=1CC(C=1)=CC=C2C=1COC1=CC(F)=CC=C1\C2=C(/C)C1=NOC(=O)N1 AUTDDWUMVGMQEE-WGOQTCKBSA-N 0.000 description 1
- FPZRIAPCQDJXMM-YZSQISJMSA-N 3-[(1e)-1-[3-fluoro-8-[[2-(1-methylcyclopropyl)benzimidazol-1-yl]methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound C/12=CC=C(CN3C4=CC=CC=C4N=C3C3(C)CC3)C=C2COC2=CC(F)=CC=C2C\1=C(/C)C1=NOC(=O)N1 FPZRIAPCQDJXMM-YZSQISJMSA-N 0.000 description 1
- AHJFXTHQFIPKCJ-WPWMEQJKSA-N 3-[(1e)-1-[3-fluoro-8-[[2-(furan-2-yl)benzimidazol-1-yl]methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound C/12=CC=C(CN3C4=CC=CC=C4N=C3C=3OC=CC=3)C=C2COC2=CC(F)=CC=C2C\1=C(/C)C1=NOC(=O)N1 AHJFXTHQFIPKCJ-WPWMEQJKSA-N 0.000 description 1
- BGHQNCCITABFTN-XVPJKIDTSA-N 3-[(1e)-1-[3-fluoro-8-[[2-(methoxymethyl)-4-(trideuteriomethoxy)benzimidazol-1-yl]methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound COCC1=NC=2C(OC([2H])([2H])[2H])=CC=CC=2N1CC(C=1)=CC=C2C=1COC1=CC(F)=CC=C1\C2=C(/C)C1=NC(=O)ON1 BGHQNCCITABFTN-XVPJKIDTSA-N 0.000 description 1
- HLARBCWEYNKZJT-WGOQTCKBSA-N 3-[(1e)-1-[3-fluoro-8-[[2-(methoxymethyl)-4-methylsulfanylbenzimidazol-1-yl]methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound COCC1=NC2=C(SC)C=CC=C2N1CC(C=1)=CC=C2C=1COC1=CC(F)=CC=C1\C2=C(/C)C1=NOC(=O)N1 HLARBCWEYNKZJT-WGOQTCKBSA-N 0.000 description 1
- XATBJLZINBAUKL-WGOQTCKBSA-N 3-[(1e)-1-[3-fluoro-8-[[2-(methoxymethyl)benzimidazol-1-yl]methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound COCC1=NC2=CC=CC=C2N1CC(C=1)=CC=C2C=1COC1=CC(F)=CC=C1\C2=C(/C)C1=NOC(=O)N1 XATBJLZINBAUKL-WGOQTCKBSA-N 0.000 description 1
- ALWADRDJKFYTLL-NHFJDJAPSA-N 3-[(1e)-1-[3-fluoro-8-[[2-(methoxymethyl)benzimidazol-1-yl]methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]propyl]-2h-1,2,4-oxadiazol-5-one Chemical compound C/12=CC=C(CN3C4=CC=CC=C4N=C3COC)C=C2COC2=CC(F)=CC=C2C\1=C(/CC)C1=NOC(=O)N1 ALWADRDJKFYTLL-NHFJDJAPSA-N 0.000 description 1
- SAVDAKHTZFWCKO-WGOQTCKBSA-N 3-[(1e)-1-[3-fluoro-8-[[2-(methoxymethyl)imidazo[1,2-a]pyridin-3-yl]methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound COCC=1N=C2C=CC=CN2C=1CC(C=1)=CC=C2C=1COC1=CC(F)=CC=C1\C2=C(/C)C1=NOC(=O)N1 SAVDAKHTZFWCKO-WGOQTCKBSA-N 0.000 description 1
- PEDZABOSQREGLI-ZVHZXABRSA-N 3-[(1e)-1-[3-fluoro-8-[[2-(methoxymethyl)thieno[3,4-d]imidazol-3-yl]methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound COCC1=NC2=CSC=C2N1CC(C=1)=CC=C2C=1COC1=CC(F)=CC=C1\C2=C(/C)C1=NOC(=O)N1 PEDZABOSQREGLI-ZVHZXABRSA-N 0.000 description 1
- DAUCUQXSMVPSTI-SAVLHYOGSA-N 3-[(1e)-1-[3-fluoro-8-[[2-(methylaminomethyl)benzimidazol-1-yl]methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one;hydrochloride Chemical compound Cl.CNCC1=NC2=CC=CC=C2N1CC(C=1)=CC=C2C=1COC1=CC(F)=CC=C1\C2=C(/C)C1=NOC(=O)N1 DAUCUQXSMVPSTI-SAVLHYOGSA-N 0.000 description 1
- SAVDAKHTZFWCKO-ILIWNJCXSA-N 3-[(1e)-1-[3-fluoro-8-[[2-(trideuteriomethoxymethyl)imidazo[1,2-a]pyridin-3-yl]methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound [2H]C([2H])([2H])OCC=1N=C2C=CC=CN2C=1CC(C=1)=CC=C2C=1COC1=CC(F)=CC=C1\C2=C(/C)C1=NC(=O)ON1 SAVDAKHTZFWCKO-ILIWNJCXSA-N 0.000 description 1
- TUEMKKGIZLSNNP-AFUMVMLFSA-N 3-[(1e)-1-[3-fluoro-8-[[2-methyl-7-(trifluoromethyl)imidazo[1,2-a]pyridin-3-yl]methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound C/12=CC=C(CC=3N4C=CC(=CC4=NC=3C)C(F)(F)F)C=C2COC2=CC(F)=CC=C2C\1=C(/C)C1=NOC(=O)N1 TUEMKKGIZLSNNP-AFUMVMLFSA-N 0.000 description 1
- YOLRJKVMHDKLMJ-ZVHZXABRSA-N 3-[(1e)-1-[3-fluoro-8-[[2-methyl-8-(trifluoromethyl)imidazo[1,2-a]pyridin-3-yl]methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound C/12=CC=C(CC=3N4C=CC=C(C4=NC=3C)C(F)(F)F)C=C2COC2=CC(F)=CC=C2C\1=C(/C)C1=NOC(=O)N1 YOLRJKVMHDKLMJ-ZVHZXABRSA-N 0.000 description 1
- ISYZLBHQEVZFSI-HYYXXEKWSA-N 3-[(1e)-1-[3-fluoro-8-[[2-propan-2-yl-8-(trideuteriomethoxy)imidazo[1,2-a]pyridin-3-yl]methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound CC(C)C=1N=C2C(OC([2H])([2H])[2H])=CC=CN2C=1CC(C=1)=CC=C2C=1COC1=CC(F)=CC=C1\C2=C(/C)C1=NC(=O)ON1 ISYZLBHQEVZFSI-HYYXXEKWSA-N 0.000 description 1
- IIZHPSPZGVFMQE-WGOQTCKBSA-N 3-[(1e)-1-[3-fluoro-8-[[4-(hydroxymethyl)-2-(methoxymethyl)benzimidazol-1-yl]methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound COCC1=NC2=C(CO)C=CC=C2N1CC(C=1)=CC=C2C=1COC1=CC(F)=CC=C1\C2=C(/C)C1=NC(=O)ON1 IIZHPSPZGVFMQE-WGOQTCKBSA-N 0.000 description 1
- VTSJWWFLFWCHSO-WPWMEQJKSA-N 3-[(1e)-1-[3-fluoro-8-[[4-(hydroxymethyl)-2-propylbenzimidazol-1-yl]methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound CCCC1=NC2=C(CO)C=CC=C2N1CC(C=1)=CC=C2C=1COC1=CC(F)=CC=C1\C2=C(/C)C1=NOC(=O)N1 VTSJWWFLFWCHSO-WPWMEQJKSA-N 0.000 description 1
- BGHQNCCITABFTN-WGOQTCKBSA-N 3-[(1e)-1-[3-fluoro-8-[[4-methoxy-2-(methoxymethyl)benzimidazol-1-yl]methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound COCC1=NC2=C(OC)C=CC=C2N1CC(C=1)=CC=C2C=1COC1=CC(F)=CC=C1\C2=C(/C)C1=NOC(=O)N1 BGHQNCCITABFTN-WGOQTCKBSA-N 0.000 description 1
- UFBMRKWWXHJWHZ-OEAKJJBVSA-N 3-[(1e)-1-[8-[(2-chloroimidazo[1,2-a]pyridin-3-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound C/12=CC=C(CC=3N4C=CC=CC4=NC=3Cl)C=C2COC2=CC(F)=CC=C2C\1=C(/C)C1=NOC(=O)N1 UFBMRKWWXHJWHZ-OEAKJJBVSA-N 0.000 description 1
- HANLCBHGEOTPLO-MFKUBSTISA-N 3-[(1e)-1-[8-[(2-cyclobutyl-5-fluoroimidazo[4,5-b]pyridin-1-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound C/12=CC=C(CN3C4=CC=C(F)N=C4N=C3C3CCC3)C=C2COC2=CC(F)=CC=C2C\1=C(/C)C1=NOC(=O)N1 HANLCBHGEOTPLO-MFKUBSTISA-N 0.000 description 1
- COQCDQPSQPKTBJ-WPWMEQJKSA-N 3-[(1e)-1-[8-[(2-cyclobutylimidazo[1,2-a]pyridin-3-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound C/12=CC=C(CC=3N4C=CC=CC4=NC=3C3CCC3)C=C2COC2=CC(F)=CC=C2C\1=C(/C)C1=NOC(=O)N1 COQCDQPSQPKTBJ-WPWMEQJKSA-N 0.000 description 1
- YXWKBACBVBXAQO-MTDXEUNCSA-N 3-[(1e)-1-[8-[(2-cyclopentylbenzimidazol-1-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound C/12=CC=C(CN3C4=CC=CC=C4N=C3C3CCCC3)C=C2COC2=CC(F)=CC=C2C\1=C(/C)C1=NOC(=O)N1 YXWKBACBVBXAQO-MTDXEUNCSA-N 0.000 description 1
- YYRCXXSHGCQZRZ-MTDXEUNCSA-N 3-[(1e)-1-[8-[(2-cyclopentylimidazo[1,2-a]pyridin-3-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound C/12=CC=C(CC=3N4C=CC=CC4=NC=3C3CCCC3)C=C2COC2=CC(F)=CC=C2C\1=C(/C)C1=NOC(=O)N1 YYRCXXSHGCQZRZ-MTDXEUNCSA-N 0.000 description 1
- QYYKQKYNIQLGNT-CVKSISIWSA-N 3-[(1e)-1-[8-[(2-cyclopropyl-7-fluoroimidazo[1,2-a]pyridin-3-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound C/12=CC=C(CC=3N4C=CC(F)=CC4=NC=3C3CC3)C=C2COC2=CC(F)=CC=C2C\1=C(/C)C1=NOC(=O)N1 QYYKQKYNIQLGNT-CVKSISIWSA-N 0.000 description 1
- BUFBDWACLNGXRL-JVWAILMASA-N 3-[(1e)-1-[8-[(2-cyclopropyl-7-methoxyimidazo[1,2-a]pyridin-3-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound C1CC1C=1N=C2C=C(OC)C=CN2C=1CC(C=1)=CC=C2C=1COC1=CC(F)=CC=C1\C2=C(/C)C1=NOC(=O)N1 BUFBDWACLNGXRL-JVWAILMASA-N 0.000 description 1
- DDLQOSPQQUAWEG-WPWMEQJKSA-N 3-[(1e)-1-[8-[(2-cyclopropyl-8-ethoxyimidazo[1,2-a]pyridin-3-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound C1CC1C=1N=C2C(OCC)=CC=CN2C=1CC(C=1)=CC=C2C=1COC1=CC(F)=CC=C1\C2=C(/C)C1=NOC(=O)N1 DDLQOSPQQUAWEG-WPWMEQJKSA-N 0.000 description 1
- AZTGNMJHVRUAEW-MFKUBSTISA-N 3-[(1e)-1-[8-[(2-cyclopropyl-8-fluoroimidazo[1,2-a]pyridin-3-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound C/12=CC=C(CC=3N4C=CC=C(F)C4=NC=3C3CC3)C=C2COC2=CC(F)=CC=C2C\1=C(/C)C1=NOC(=O)N1 AZTGNMJHVRUAEW-MFKUBSTISA-N 0.000 description 1
- SXMKTRCIAXOWFX-BUVRLJJBSA-N 3-[(1e)-1-[8-[(2-cyclopropyl-8-methoxyimidazo[1,2-a]pyrazin-3-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound C1CC1C=1N=C2C(OC)=NC=CN2C=1CC(C=1)=CC=C2C=1COC1=CC(F)=CC=C1\C2=C(/C)C1=NOC(=O)N1 SXMKTRCIAXOWFX-BUVRLJJBSA-N 0.000 description 1
- ZYXVKWNPVNLCQQ-WGOQTCKBSA-N 3-[(1e)-1-[8-[(2-cyclopropyl-8-methoxyimidazo[1,2-a]pyridin-3-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound C1CC1C=1N=C2C(OC)=CC=CN2C=1CC(C=1)=CC=C2C=1COC1=CC(F)=CC=C1\C2=C(/C)C1=NOC(=O)N1 ZYXVKWNPVNLCQQ-WGOQTCKBSA-N 0.000 description 1
- FROJGEDNSTXFBV-MFKUBSTISA-N 3-[(1e)-1-[8-[(2-cyclopropyl-8-methylimidazo[1,2-a]pyrazin-3-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound C/12=CC=C(CC=3N4C=CN=C(C)C4=NC=3C3CC3)C=C2COC2=CC(F)=CC=C2C\1=C(/C)C1=NOC(=O)N1 FROJGEDNSTXFBV-MFKUBSTISA-N 0.000 description 1
- JLDRCCYVCZPOOK-WGOQTCKBSA-N 3-[(1e)-1-[8-[(2-cyclopropylbenzimidazol-1-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound C/12=CC=C(CN3C4=CC=CC=C4N=C3C3CC3)C=C2COC2=CC(F)=CC=C2C\1=C(/C)C1=NOC(=O)N1 JLDRCCYVCZPOOK-WGOQTCKBSA-N 0.000 description 1
- VHUWCJWOVYFIEA-MFKUBSTISA-N 3-[(1e)-1-[8-[(2-cyclopropylimidazo[1,2-a]pyrazin-3-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound C/12=CC=C(CC=3N4C=CN=CC4=NC=3C3CC3)C=C2COC2=CC(F)=CC=C2C\1=C(/C)C1=NOC(=O)N1 VHUWCJWOVYFIEA-MFKUBSTISA-N 0.000 description 1
- LFRNEGDVYOWLIP-WGOQTCKBSA-N 3-[(1e)-1-[8-[(2-cyclopropylimidazo[1,2-a]pyridin-3-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound C/12=CC=C(CC=3N4C=CC=CC4=NC=3C3CC3)C=C2COC2=CC(F)=CC=C2C\1=C(/C)C1=NOC(=O)N1 LFRNEGDVYOWLIP-WGOQTCKBSA-N 0.000 description 1
- OSPLBKUARBZRPL-BUVRLJJBSA-N 3-[(1e)-1-[8-[(2-cyclopropylimidazo[1,2-a]pyrimidin-3-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound C/12=CC=C(CC=3N4C=CC=NC4=NC=3C3CC3)C=C2COC2=CC(F)=CC=C2C\1=C(/C)C1=NOC(=O)N1 OSPLBKUARBZRPL-BUVRLJJBSA-N 0.000 description 1
- ZEOQBVHXTQSRRD-ZVHZXABRSA-N 3-[(1e)-1-[8-[(2-cyclopropylthieno[3,4-d]imidazol-3-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound C/12=CC=C(CN3C4=CSC=C4N=C3C3CC3)C=C2COC2=CC(F)=CC=C2C\1=C(/C)C1=NOC(=O)N1 ZEOQBVHXTQSRRD-ZVHZXABRSA-N 0.000 description 1
- CQRGBVMRONTGGO-DEDYPNTBSA-N 3-[(1e)-1-[8-[(4,5-dichloro-2-propan-2-ylimidazol-1-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound CC(C)C1=NC(Cl)=C(Cl)N1CC(C=C1COC=2C\3=CC=C(F)C=2)=CC=C1C/3=C(/C)C1=NOC(=O)N1 CQRGBVMRONTGGO-DEDYPNTBSA-N 0.000 description 1
- BATWCZSYSQUUTQ-BUVRLJJBSA-N 3-[(1e)-1-[8-[(4-chloro-2-cyclobutylimidazo[4,5-c]pyridin-1-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound C/12=CC=C(CN3C4=CC=NC(Cl)=C4N=C3C3CCC3)C=C2COC2=CC(F)=CC=C2C\1=C(/C)C1=NOC(=O)N1 BATWCZSYSQUUTQ-BUVRLJJBSA-N 0.000 description 1
- ZOKBCLWPLALHLZ-CVKSISIWSA-N 3-[(1e)-1-[8-[(6-chloro-2-cyclopropylimidazo[1,2-a]pyridin-3-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound C/12=CC=C(CC=3N4C=C(Cl)C=CC4=NC=3C3CC3)C=C2COC2=CC(F)=CC=C2C\1=C(/C)C1=NOC(=O)N1 ZOKBCLWPLALHLZ-CVKSISIWSA-N 0.000 description 1
- LDSXTGTXJLWTOZ-BUVRLJJBSA-N 3-[(1e)-1-[8-[(7-chloro-2-cyclobutylimidazo[4,5-b]pyridin-3-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound C/12=CC=C(CN3C4=NC=CC(Cl)=C4N=C3C3CCC3)C=C2COC2=CC(F)=CC=C2C\1=C(/C)C1=NOC(=O)N1 LDSXTGTXJLWTOZ-BUVRLJJBSA-N 0.000 description 1
- WCVHNSAVEPWGCQ-CVKSISIWSA-N 3-[(1e)-1-[8-[(7-chloro-2-cyclopropylimidazo[1,2-a]pyridin-3-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound C/12=CC=C(CC=3N4C=CC(Cl)=CC4=NC=3C3CC3)C=C2COC2=CC(F)=CC=C2C\1=C(/C)C1=NOC(=O)N1 WCVHNSAVEPWGCQ-CVKSISIWSA-N 0.000 description 1
- NKGCXSINYRWOLP-CVKSISIWSA-N 3-[(1e)-1-[8-[(7-chloro-2-ethylimidazo[1,2-a]pyridin-3-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound CCC=1N=C2C=C(Cl)C=CN2C=1CC(C=1)=CC=C2C=1COC1=CC(F)=CC=C1\C2=C(/C)C1=NOC(=O)N1 NKGCXSINYRWOLP-CVKSISIWSA-N 0.000 description 1
- UOBJQUKXZVGLIY-LQKURTRISA-N 3-[(1e)-1-[8-[(7-cyclopropyl-2-methylimidazo[1,2-a]pyridin-3-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound C/12=CC=C(CC=3N4C=CC(=CC4=NC=3C)C3CC3)C=C2COC2=CC(F)=CC=C2C\1=C(/C)C1=NOC(=O)N1 UOBJQUKXZVGLIY-LQKURTRISA-N 0.000 description 1
- ZHHRZGXFHNEBGV-MFKUBSTISA-N 3-[(1e)-1-[8-[(8-bromo-2-cyclopropylimidazo[1,2-a]pyridin-3-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound C/12=CC=C(CC=3N4C=CC=C(Br)C4=NC=3C3CC3)C=C2COC2=CC(F)=CC=C2C\1=C(/C)C1=NOC(=O)N1 ZHHRZGXFHNEBGV-MFKUBSTISA-N 0.000 description 1
- YMJQPWIALYBIJM-MFKUBSTISA-N 3-[(1e)-1-[8-[(8-chloro-2-cyclopropylimidazo[1,2-a]pyridin-3-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound C/12=CC=C(CC=3N4C=CC=C(Cl)C4=NC=3C3CC3)C=C2COC2=CC(F)=CC=C2C\1=C(/C)C1=NOC(=O)N1 YMJQPWIALYBIJM-MFKUBSTISA-N 0.000 description 1
- VWFSJWBBYVDJJY-ZVHZXABRSA-N 3-[(1e)-1-[8-[(8-chloro-2-methylimidazo[1,2-a]pyridin-3-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound C/12=CC=C(CC=3N4C=CC=C(Cl)C4=NC=3C)C=C2COC2=CC(F)=CC=C2C\1=C(/C)C1=NOC(=O)N1 VWFSJWBBYVDJJY-ZVHZXABRSA-N 0.000 description 1
- QBRZTGHNVWYCSK-PCLIKHOPSA-N 3-[(1e)-1-[8-[(8-chloro-2-propan-2-ylimidazo[1,2-a]pyridin-3-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound CC(C)C=1N=C2C(Cl)=CC=CN2C=1CC(C=1)=CC=C2C=1COC1=CC(F)=CC=C1\C2=C(/C)C1=NOC(=O)N1 QBRZTGHNVWYCSK-PCLIKHOPSA-N 0.000 description 1
- ZZIWUYNDYSEAQL-WPWMEQJKSA-N 3-[(1e)-1-[8-[[2,4-bis(methoxymethyl)benzimidazol-1-yl]methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound COCC1=NC2=C(COC)C=CC=C2N1CC(C=1)=CC=C2C=1COC1=CC(F)=CC=C1\C2=C(/C)C1=NOC(=O)N1 ZZIWUYNDYSEAQL-WPWMEQJKSA-N 0.000 description 1
- FLQKWWNEFBLKHN-WGOQTCKBSA-N 3-[(1e)-1-[8-[[2-(3,3-difluorocyclobutyl)benzimidazol-1-yl]methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound C/12=CC=C(CN3C4=CC=CC=C4N=C3C3CC(F)(F)C3)C=C2COC2=CC(F)=CC=C2C\1=C(/C)C1=NOC(=O)N1 FLQKWWNEFBLKHN-WGOQTCKBSA-N 0.000 description 1
- BHABEWSKZFIMAG-OGLMXYFKSA-N 3-[(1e)-1-[8-[[2-(cyclopropylmethyl)benzimidazol-1-yl]methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound C/12=CC=C(CN3C4=CC=CC=C4N=C3CC3CC3)C=C2COC2=CC(F)=CC=C2C\1=C(/C)C1=NOC(=O)N1 BHABEWSKZFIMAG-OGLMXYFKSA-N 0.000 description 1
- NEMDAPURMGTIII-PCLIKHOPSA-N 3-[(1e)-1-[8-[[2-(dimethylamino)benzimidazol-1-yl]methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound CN(C)C1=NC2=CC=CC=C2N1CC(C=1)=CC=C2C=1COC1=CC(F)=CC=C1\C2=C(/C)C1=NOC(=O)N1 NEMDAPURMGTIII-PCLIKHOPSA-N 0.000 description 1
- UHIYSSRLHYNUQA-WPWMEQJKSA-N 3-[(1e)-1-[8-[[2-[(dimethylamino)methyl]benzimidazol-1-yl]methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound CN(C)CC1=NC2=CC=CC=C2N1CC(C=1)=CC=C2C=1COC1=CC(F)=CC=C1\C2=C(/C)C1=NOC(=O)N1 UHIYSSRLHYNUQA-WPWMEQJKSA-N 0.000 description 1
- DDVJUXMZIKLLAO-WPWMEQJKSA-N 3-[(1e)-1-[8-[[2-cyclopropyl-8-(2-hydroxypropan-2-yl)imidazo[1,2-a]pyridin-3-yl]methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound C/12=CC=C(CC=3N4C=CC=C(C4=NC=3C3CC3)C(C)(C)O)C=C2COC2=CC(F)=CC=C2C\1=C(/C)C1=NOC(=O)N1 DDVJUXMZIKLLAO-WPWMEQJKSA-N 0.000 description 1
- NBWWBNBXEMKPJU-MFKUBSTISA-N 3-[(1e)-1-[8-[[2-cyclopropyl-8-(difluoromethoxy)imidazo[1,2-a]pyridin-3-yl]methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound C/12=CC=C(CC=3N4C=CC=C(OC(F)F)C4=NC=3C3CC3)C=C2COC2=CC(F)=CC=C2C\1=C(/C)C1=NOC(=O)N1 NBWWBNBXEMKPJU-MFKUBSTISA-N 0.000 description 1
- CYUAERWNDIQVOJ-WPWMEQJKSA-N 3-[(1e)-1-[8-[[2-cyclopropyl-8-(dimethylamino)imidazo[1,2-a]pyridin-3-yl]methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound C1CC1C=1N=C2C(N(C)C)=CC=CN2C=1CC(C=1)=CC=C2C=1COC1=CC(F)=CC=C1\C2=C(/C)C1=NOC(=O)N1 CYUAERWNDIQVOJ-WPWMEQJKSA-N 0.000 description 1
- XVCIPAAAHNTHET-MFKUBSTISA-N 3-[(1e)-1-[8-[[2-cyclopropyl-8-(trifluoromethyl)imidazo[1,2-a]pyridin-3-yl]methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound C/12=CC=C(CC=3N4C=CC=C(C4=NC=3C3CC3)C(F)(F)F)C=C2COC2=CC(F)=CC=C2C\1=C(/C)C1=NOC(=O)N1 XVCIPAAAHNTHET-MFKUBSTISA-N 0.000 description 1
- BKTZHBKFSUDOSB-WPWMEQJKSA-N 3-[(1e)-1-[8-[[4-(azetidin-1-yl)-2-methyl-6-propylpyrimidin-5-yl]methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound C=1C=C(C(/C2=CC=C(F)C=C2OC2)=C(/C)C=3NC(=O)ON=3)C2=CC=1CC=1C(CCC)=NC(C)=NC=1N1CCC1 BKTZHBKFSUDOSB-WPWMEQJKSA-N 0.000 description 1
- ZDXBYJWDIIHBBO-MFKUBSTISA-N 3-[(1e)-1-[8-[[4-(difluoromethoxy)-2-(methoxymethyl)benzimidazol-1-yl]methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound COCC1=NC2=C(OC(F)F)C=CC=C2N1CC(C=1)=CC=C2C=1COC1=CC(F)=CC=C1\C2=C(/C)C1=NOC(=O)N1 ZDXBYJWDIIHBBO-MFKUBSTISA-N 0.000 description 1
- VPVAHWROYMHXEL-WPWMEQJKSA-N 3-[(1e)-1-[8-[[4-ethoxy-2-(methoxymethyl)benzimidazol-1-yl]methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound COCC1=NC=2C(OCC)=CC=CC=2N1CC(C=1)=CC=C2C=1COC1=CC(F)=CC=C1\C2=C(/C)C1=NOC(=O)N1 VPVAHWROYMHXEL-WPWMEQJKSA-N 0.000 description 1
- QZNUPRHBNYAKDD-CVKSISIWSA-N 3-[(1e)-1-[8-[[7-chloro-2-(methoxymethyl)imidazo[1,2-a]pyridin-3-yl]methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound COCC=1N=C2C=C(Cl)C=CN2C=1CC(C=1)=CC=C2C=1COC1=CC(F)=CC=C1\C2=C(/C)C1=NOC(=O)N1 QZNUPRHBNYAKDD-CVKSISIWSA-N 0.000 description 1
- FBNGURXTCGQADS-MFKUBSTISA-N 3-[(1e)-1-[8-[[8-(difluoromethoxy)-2-(methoxymethyl)imidazo[1,2-a]pyridin-3-yl]methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound COCC=1N=C2C(OC(F)F)=CC=CN2C=1CC(C=1)=CC=C2C=1COC1=CC(F)=CC=C1\C2=C(/C)C1=NOC(=O)N1 FBNGURXTCGQADS-MFKUBSTISA-N 0.000 description 1
- JBSOXRBSFVJFPQ-PCLIKHOPSA-N 3-[(1e)-1-[8-[[8-(difluoromethoxy)-2-propan-2-ylimidazo[1,2-a]pyridin-3-yl]methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]ethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound CC(C)C=1N=C2C(OC(F)F)=CC=CN2C=1CC(C=1)=CC=C2C=1COC1=CC(F)=CC=C1\C2=C(/C)C1=NOC(=O)N1 JBSOXRBSFVJFPQ-PCLIKHOPSA-N 0.000 description 1
- FYMOGUKDALAQSQ-HYARGMPZSA-N 3-[(e)-[8-[(2-cyclopropyl-8-methoxyimidazo[1,2-a]pyridin-3-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]methyl]-2h-1,2,4-oxadiazol-5-one Chemical compound C1CC1C=1N=C2C(OC)=CC=CN2C=1CC(C=1)=CC=C2C=1COC1=CC(F)=CC=C1\C2=C\C1=NOC(=O)N1 FYMOGUKDALAQSQ-HYARGMPZSA-N 0.000 description 1
- WMKDEKVUTSPTEK-CYYJNZCTSA-N 3-[(e)-[8-[(4-chloro-2-cyclopropylbenzimidazol-1-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]-cyclopropylmethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound C=1C(F)=CC=C(C(/C2=CC=3)=C(\C4CC4)C=4NC(=O)ON=4)C=1OCC2=CC=3CN(C1=CC=CC(Cl)=C1N=1)C=1C1CC1 WMKDEKVUTSPTEK-CYYJNZCTSA-N 0.000 description 1
- QRWJJNQHNISJJP-CYYJNZCTSA-N 3-[(e)-[8-[(7-chloro-2-methylimidazo[1,2-a]pyridin-3-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]-cyclopropylmethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound CC=1N=C2C=C(Cl)C=CN2C=1CC(C=1)=CC=C2C=1COC1=CC(F)=CC=C1\C2=C(C=1NC(=O)ON=1)/C1CC1 QRWJJNQHNISJJP-CYYJNZCTSA-N 0.000 description 1
- MNZHXQJFPGMNAQ-CYYJNZCTSA-N 3-[(e)-[8-[(8-chloro-2-cyclopropylimidazo[1,2-a]pyridin-3-yl)methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]-cyclopropylmethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound C=1C(F)=CC=C(C(/C2=CC=3)=C(\C4CC4)C=4NC(=O)ON=4)C=1OCC2=CC=3CC(N1C=CC=C(Cl)C1=N1)=C1C1CC1 MNZHXQJFPGMNAQ-CYYJNZCTSA-N 0.000 description 1
- FNGZSNXSZBQOLJ-BYYHNAKLSA-N 3-[(e)-[8-[[7-chloro-2-(methoxymethyl)imidazo[1,2-a]pyridin-3-yl]methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]-cyclopropylmethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound COCC=1N=C2C=C(Cl)C=CN2C=1CC(C=1)=CC=C2C=1COC1=CC(F)=CC=C1\C2=C(C=1NC(=O)ON=1)/C1CC1 FNGZSNXSZBQOLJ-BYYHNAKLSA-N 0.000 description 1
- QNNGUDGFWRJRSS-CYYJNZCTSA-N 3-[(e)-[8-[[8-chloro-2-(methoxymethyl)imidazo[1,2-a]pyridin-3-yl]methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]-cyclopropylmethyl]-2h-1,2,4-oxadiazol-5-one Chemical compound COCC=1N=C2C(Cl)=CC=CN2C=1CC(C=1)=CC=C2C=1COC1=CC(F)=CC=C1\C2=C(C=1NC(=O)ON=1)/C1CC1 QNNGUDGFWRJRSS-CYYJNZCTSA-N 0.000 description 1
- VMRBVPORNXHAFM-ZQHSETAFSA-N 3-[(e)-cyclopropyl-[3-fluoro-8-[(2-propylbenzimidazol-1-yl)methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]methyl]-2h-1,2,4-oxadiazol-5-one Chemical compound CCCC1=NC2=CC=CC=C2N1CC(C=1)=CC=C2C=1COC1=CC(F)=CC=C1\C2=C(C=1NC(=O)ON=1)/C1CC1 VMRBVPORNXHAFM-ZQHSETAFSA-N 0.000 description 1
- MPHPPTKWJOJUHS-BYYHNAKLSA-N 3-[(e)-cyclopropyl-[3-fluoro-8-[[2-(methoxymethyl)imidazo[1,2-a]pyridin-3-yl]methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]methyl]-2h-1,2,4-oxadiazol-5-one Chemical compound COCC=1N=C2C=CC=CN2C=1CC(C=1)=CC=C2C=1COC1=CC(F)=CC=C1\C2=C(C=1NC(=O)ON=1)/C1CC1 MPHPPTKWJOJUHS-BYYHNAKLSA-N 0.000 description 1
- URNMROAGXAIHMB-ZQHSETAFSA-N 3-[(e)-cyclopropyl-[3-fluoro-8-[[4-(2-hydroxypropan-2-yl)-2-(methoxymethyl)benzimidazol-1-yl]methyl]-6h-benzo[c][1]benzoxepin-11-ylidene]methyl]-2h-1,2,4-oxadiazol-5-one Chemical compound COCC1=NC2=C(C(C)(C)O)C=CC=C2N1CC(C=1)=CC=C2C=1COC1=CC(F)=CC=C1\C2=C(C=1NC(=O)ON=1)/C1CC1 URNMROAGXAIHMB-ZQHSETAFSA-N 0.000 description 1
- QNAZJZXYHMYYSC-BYYHNAKLSA-N 3-[(e)-cyclopropyl-[8-[[2-(3,3-difluorocyclobutyl)benzimidazol-1-yl]methyl]-3-fluoro-6h-benzo[c][1]benzoxepin-11-ylidene]methyl]-2h-1,2,4-oxadiazol-5-one Chemical compound C=1C(F)=CC=C(C(/C2=CC=3)=C(\C4CC4)C=4NC(=O)ON=4)C=1OCC2=CC=3CN(C1=CC=CC=C1N=1)C=1C1CC(F)(F)C1 QNAZJZXYHMYYSC-BYYHNAKLSA-N 0.000 description 1
- KGNMEGAMHWIHLZ-JVWAILMASA-N 3-[[(11e)-11-(1-cyanoethylidene)-3-fluoro-6h-benzo[c][1]benzoxepin-8-yl]methyl]-2-cyclopropylimidazo[1,2-a]pyridine-7-carboxamide Chemical compound C1=C2COC3=CC(F)=CC=C3C(=C(C#N)/C)\C2=CC=C1CC(N1C=CC(=CC1=N1)C(N)=O)=C1C1CC1 KGNMEGAMHWIHLZ-JVWAILMASA-N 0.000 description 1
- AEVSSZHXGJAPIE-UHFFFAOYSA-N 3-chloropyrazin-2-amine Chemical compound NC1=NC=CN=C1Cl AEVSSZHXGJAPIE-UHFFFAOYSA-N 0.000 description 1
- ASJVXZBTTFDZDW-UHFFFAOYSA-N 3-ethoxypyridin-2-amine Chemical compound CCOC1=CC=CN=C1N ASJVXZBTTFDZDW-UHFFFAOYSA-N 0.000 description 1
- SJTBRFHBXDZMPS-UHFFFAOYSA-N 3-fluorophenol Chemical compound OC1=CC=CC(F)=C1 SJTBRFHBXDZMPS-UHFFFAOYSA-N 0.000 description 1
- WWEINXQNCAWBPD-UHFFFAOYSA-N 3-fluoropyridin-2-amine Chemical compound NC1=NC=CC=C1F WWEINXQNCAWBPD-UHFFFAOYSA-N 0.000 description 1
- MTMGQKFGZHMTTK-UHFFFAOYSA-N 3-methoxypyrazin-2-amine Chemical compound COC1=NC=CN=C1N MTMGQKFGZHMTTK-UHFFFAOYSA-N 0.000 description 1
- RGDQRXPEZUNWHX-UHFFFAOYSA-N 3-methylpyridin-2-amine Chemical compound CC1=CC=CN=C1N RGDQRXPEZUNWHX-UHFFFAOYSA-N 0.000 description 1
- NKOTXYPTXKUCDL-UHFFFAOYSA-N 4-(trifluoromethyl)pyrimidin-2-amine Chemical compound NC1=NC=CC(C(F)(F)F)=N1 NKOTXYPTXKUCDL-UHFFFAOYSA-N 0.000 description 1
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
- DBGFGNCFYUNXLD-UHFFFAOYSA-N 4-chloropyrimidin-2-amine Chemical compound NC1=NC=CC(Cl)=N1 DBGFGNCFYUNXLD-UHFFFAOYSA-N 0.000 description 1
- ANFNQGJFSPDBMM-UHFFFAOYSA-N 4-methoxy-2-propyl-1h-benzimidazole Chemical compound C1=CC=C2NC(CCC)=NC2=C1OC ANFNQGJFSPDBMM-UHFFFAOYSA-N 0.000 description 1
- QPHBCOSULYSASF-UHFFFAOYSA-N 4-methoxypyridin-2-amine Chemical compound COC1=CC=NC(N)=C1 QPHBCOSULYSASF-UHFFFAOYSA-N 0.000 description 1
- IUSPXLCLQIZFHL-UHFFFAOYSA-N 5-bromo-3h-2-benzofuran-1-one Chemical compound BrC1=CC=C2C(=O)OCC2=C1 IUSPXLCLQIZFHL-UHFFFAOYSA-N 0.000 description 1
- MAXBVGJEFDMHNV-UHFFFAOYSA-N 5-chloropyridin-2-amine Chemical compound NC1=CC=C(Cl)C=N1 MAXBVGJEFDMHNV-UHFFFAOYSA-N 0.000 description 1
- YJTXQLYMECWULH-UHFFFAOYSA-N 5-fluoropyridin-2-amine Chemical compound NC1=CC=C(F)C=N1 YJTXQLYMECWULH-UHFFFAOYSA-N 0.000 description 1
- IORVGTOEXKOSCK-UHFFFAOYSA-N 7-chloro-2-cyclobutyl-1h-imidazo[4,5-b]pyridine Chemical compound N=1C=2C(Cl)=CC=NC=2NC=1C1CCC1 IORVGTOEXKOSCK-UHFFFAOYSA-N 0.000 description 1
- IXMYWOKUFVCWBE-UHFFFAOYSA-N 7-chloro-2-cyclopropyl-1h-imidazo[4,5-b]pyridine Chemical compound N=1C=2C(Cl)=CC=NC=2NC=1C1CC1 IXMYWOKUFVCWBE-UHFFFAOYSA-N 0.000 description 1
- KCGNSIRBERLIDC-AFUMVMLFSA-N 7-fluoro-3-[[(11e)-3-fluoro-11-[1-(5-oxo-2h-1,2,4-oxadiazol-3-yl)ethylidene]-6h-benzo[c][1]benzoxepin-8-yl]methyl]imidazo[1,2-a]pyridine-2-carbonitrile Chemical compound C/12=CC=C(CC=3N4C=CC(F)=CC4=NC=3C#N)C=C2COC2=CC(F)=CC=C2C\1=C(/C)C1=NOC(=O)N1 KCGNSIRBERLIDC-AFUMVMLFSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- AKGKESRPLLJKGJ-UHFFFAOYSA-N 8-chloro-2-propan-2-ylimidazo[1,2-a]pyridine Chemical compound C1=CC=C(Cl)C2=NC(C(C)C)=CN21 AKGKESRPLLJKGJ-UHFFFAOYSA-N 0.000 description 1
- XDEUOMIEZKNLMF-FIBGUPNXSA-N 8-chloro-3-iodo-2-(trideuteriomethoxymethyl)imidazo[1,2-a]pyridine Chemical compound ClC=1C=2N(C=CC=1)C(=C(N=2)COC([2H])([2H])[2H])I XDEUOMIEZKNLMF-FIBGUPNXSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical class [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 102000008873 Angiotensin II receptor Human genes 0.000 description 1
- 108050000824 Angiotensin II receptor Proteins 0.000 description 1
- 229920001342 BakeliteĀ® Polymers 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N Butyraldehyde Chemical compound CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Chemical class OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Chemical class 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000741790 Homo sapiens Peroxisome proliferator-activated receptor gamma Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical class OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical class OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical class OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 1
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
- PHSPJQZRQAJPPF-UHFFFAOYSA-N N-alpha-Methylhistamine Chemical compound CNCCC1=CN=CN1 PHSPJQZRQAJPPF-UHFFFAOYSA-N 0.000 description 1
- WCZKTUCDHDAAGU-UHFFFAOYSA-L N1=CC=CC=C1.[Cr](=O)(=O)(Cl)Cl Chemical compound N1=CC=CC=C1.[Cr](=O)(=O)(Cl)Cl WCZKTUCDHDAAGU-UHFFFAOYSA-L 0.000 description 1
- ACFIXJIJDZMPPO-NNYOXOHSSA-J NADPH(4-) Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP([O-])(=O)OP([O-])(=O)OC[C@@H]2[C@H]([C@@H](OP([O-])([O-])=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-J 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000023984 PPAR alpha Human genes 0.000 description 1
- 108010028924 PPAR alpha Proteins 0.000 description 1
- 108010015181 PPAR delta Proteins 0.000 description 1
- 102000012132 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 1
- 208000001280 Prediabetic State Diseases 0.000 description 1
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229910021627 Tin(IV) chloride Inorganic materials 0.000 description 1
- GCTFWCDSFPMHHS-UHFFFAOYSA-M Tributyltin chloride Chemical compound CCCC[Sn](Cl)(CCCC)CCCC GCTFWCDSFPMHHS-UHFFFAOYSA-M 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- WLLIXJBWWFGEHT-UHFFFAOYSA-N [tert-butyl(dimethyl)silyl] trifluoromethanesulfonate Chemical compound CC(C)(C)[Si](C)(C)OS(=O)(=O)C(F)(F)F WLLIXJBWWFGEHT-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229940124358 agent for type 2 diabetes Drugs 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- 125000005604 azodicarboxylate group Chemical group 0.000 description 1
- 125000003828 azulenyl group Chemical group 0.000 description 1
- 239000004637 bakelite Substances 0.000 description 1
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 1
- 229910001863 barium hydroxide Inorganic materials 0.000 description 1
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- ACFIXJIJDZMPPO-UHFFFAOYSA-N beta-NADPH Natural products C1=CCC(C(=O)N)=CN1C1C(O)C(O)C(COP(O)(=O)OP(O)(=O)OCC2C(C(OP(O)(O)=O)C(O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Chemical class OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- KWTSZCJMWHGPOS-UHFFFAOYSA-M chloro(trimethyl)stannane Chemical compound C[Sn](C)(C)Cl KWTSZCJMWHGPOS-UHFFFAOYSA-M 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- KRVSOGSZCMJSLX-UHFFFAOYSA-L chromic acid Substances O[Cr](O)(=O)=O KRVSOGSZCMJSLX-UHFFFAOYSA-L 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- JGDFBJMWFLXCLJ-UHFFFAOYSA-N copper chromite Chemical compound [Cu]=O.[Cu]=O.O=[Cr]O[Cr]=O JGDFBJMWFLXCLJ-UHFFFAOYSA-N 0.000 description 1
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 1
- JFWMYCVMQSLLOO-UHFFFAOYSA-N cyclobutanecarbonyl chloride Chemical compound ClC(=O)C1CCC1 JFWMYCVMQSLLOO-UHFFFAOYSA-N 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- SNRCKKQHDUIRIY-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloromethane;dichloropalladium;iron(2+) Chemical compound [Fe+2].ClCCl.Cl[Pd]Cl.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 SNRCKKQHDUIRIY-UHFFFAOYSA-L 0.000 description 1
- WLVKDFJTYKELLQ-UHFFFAOYSA-N cyclopropylboronic acid Chemical compound OB(O)C1CC1 WLVKDFJTYKELLQ-UHFFFAOYSA-N 0.000 description 1
- 125000003493 decenyl group Chemical group [H]C([*])=C([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005070 decynyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C#C* 0.000 description 1
- JGFBRKRYDCGYKD-UHFFFAOYSA-N dibutyl(oxo)tin Chemical compound CCCC[Sn](=O)CCCC JGFBRKRYDCGYKD-UHFFFAOYSA-N 0.000 description 1
- QVQGTNFYPJQJNM-UHFFFAOYSA-N dicyclohexylmethanamine Chemical compound C1CCCCC1C(N)C1CCCCC1 QVQGTNFYPJQJNM-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 125000000723 dihydrobenzofuranyl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- CNXMDTWQWLGCPE-UHFFFAOYSA-N ditert-butyl-(2-phenylphenyl)phosphane Chemical group CC(C)(C)P(C(C)(C)C)C1=CC=CC=C1C1=CC=CC=C1 CNXMDTWQWLGCPE-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- WCQOBLXWLRDEQA-UHFFFAOYSA-N ethanimidamide;hydrochloride Chemical compound Cl.CC(N)=N WCQOBLXWLRDEQA-UHFFFAOYSA-N 0.000 description 1
- XQVVLJSNTJWBMG-UHFFFAOYSA-N ethyl 2-methoxyethanimidate;hydrochloride Chemical compound Cl.CCOC(=N)COC XQVVLJSNTJWBMG-UHFFFAOYSA-N 0.000 description 1
- VICYTAYPKBLQFB-UHFFFAOYSA-N ethyl 3-bromo-2-oxopropanoate Chemical compound CCOC(=O)C(=O)CBr VICYTAYPKBLQFB-UHFFFAOYSA-N 0.000 description 1
- KQWWVLVLVYYYDT-UHFFFAOYSA-N ethyl 3-oxohexanoate Chemical compound CCCC(=O)CC(=O)OCC KQWWVLVLVYYYDT-UHFFFAOYSA-N 0.000 description 1
- SGEMMELRMUVIHJ-UHFFFAOYSA-N ethyl cyclopropanecarboximidate;hydrochloride Chemical compound Cl.CCOC(=N)C1CC1 SGEMMELRMUVIHJ-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- UYJUZNLFJAWNEZ-UHFFFAOYSA-N fuberidazole Chemical compound C1=COC(C=2NC3=CC=CC=C3N=2)=C1 UYJUZNLFJAWNEZ-UHFFFAOYSA-N 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- AWJWCTOOIBYHON-UHFFFAOYSA-N furo[3,4-b]pyrazine-5,7-dione Chemical compound C1=CN=C2C(=O)OC(=O)C2=N1 AWJWCTOOIBYHON-UHFFFAOYSA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000004220 glutamic acid Chemical class 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 125000002140 imidazol-4-yl group Chemical group [H]N1C([H])=NC([*])=C1[H] 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 1
- 229910052808 lithium carbonate Inorganic materials 0.000 description 1
- 229910000032 lithium hydrogen carbonate Inorganic materials 0.000 description 1
- WGOPGODQLGJZGL-UHFFFAOYSA-N lithium;butane Chemical compound [Li+].CC[CH-]C WGOPGODQLGJZGL-UHFFFAOYSA-N 0.000 description 1
- HQRPHMAXFVUBJX-UHFFFAOYSA-M lithium;hydrogen carbonate Chemical compound [Li+].OC([O-])=O HQRPHMAXFVUBJX-UHFFFAOYSA-M 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- IWCVDCOJSPWGRW-UHFFFAOYSA-M magnesium;benzene;chloride Chemical compound [Mg+2].[Cl-].C1=CC=[C-]C=C1 IWCVDCOJSPWGRW-UHFFFAOYSA-M 0.000 description 1
- YCCXQARVHOPWFJ-UHFFFAOYSA-M magnesium;ethane;chloride Chemical compound [Mg+2].[Cl-].[CH2-]C YCCXQARVHOPWFJ-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- OYEVFSJZQTUDDN-UHFFFAOYSA-N methanol;n-methylmethanamine Chemical compound OC.CNC OYEVFSJZQTUDDN-UHFFFAOYSA-N 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- ZQSAWKDSWWJRGP-UHFFFAOYSA-N methyl 2-[(2-methoxyacetyl)amino]benzoate Chemical compound COCC(=O)NC1=CC=CC=C1C(=O)OC ZQSAWKDSWWJRGP-UHFFFAOYSA-N 0.000 description 1
- QGBPKJFJAVDUNC-UHFFFAOYSA-N methyl 4-methoxy-3-oxobutanoate Chemical compound COCC(=O)CC(=O)OC QGBPKJFJAVDUNC-UHFFFAOYSA-N 0.000 description 1
- XMJHPCRAQCTCFT-UHFFFAOYSA-N methyl chloroformate Chemical compound COC(Cl)=O XMJHPCRAQCTCFT-UHFFFAOYSA-N 0.000 description 1
- DVSDBMFJEQPWNO-UHFFFAOYSA-N methyllithium Chemical compound C[Li] DVSDBMFJEQPWNO-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004998 naphthylethyl group Chemical group C1(=CC=CC2=CC=CC=C12)CC* 0.000 description 1
- 125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 125000005187 nonenyl group Chemical group C(=CCCCCCCC)* 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005071 nonynyl group Chemical group C(#CCCCCCCC)* 0.000 description 1
- 125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005069 octynyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C#C* 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- YWWARDMVSMPOLR-UHFFFAOYSA-M oxolane;tetrabutylazanium;fluoride Chemical compound [F-].C1CCOC1.CCCC[N+](CCCC)(CCCC)CCCC YWWARDMVSMPOLR-UHFFFAOYSA-M 0.000 description 1
- GNWXVOQHLPBSSR-UHFFFAOYSA-N oxolane;toluene Chemical compound C1CCOC1.CC1=CC=CC=C1 GNWXVOQHLPBSSR-UHFFFAOYSA-N 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- AHWALFGBDFAJAI-UHFFFAOYSA-N phenyl carbonochloridate Chemical compound ClC(=O)OC1=CC=CC=C1 AHWALFGBDFAJAI-UHFFFAOYSA-N 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Chemical class OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 235000008729 phenylalanine Nutrition 0.000 description 1
- NHKJPPKXDNZFBJ-UHFFFAOYSA-N phenyllithium Chemical compound [Li]C1=CC=CC=C1 NHKJPPKXDNZFBJ-UHFFFAOYSA-N 0.000 description 1
- 125000004346 phenylpentyl group Chemical group C1(=CC=CC=C1)CCCCC* 0.000 description 1
- 125000004344 phenylpropyl group Chemical group 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920000137 polyphosphoric acid Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 229940086066 potassium hydrogencarbonate Drugs 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- 210000000229 preadipocyte Anatomy 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- QQKDTTWZXHEGAQ-UHFFFAOYSA-N propyl carbonochloridate Chemical compound CCCOC(Cl)=O QQKDTTWZXHEGAQ-UHFFFAOYSA-N 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- XFTQRUTUGRCSGO-UHFFFAOYSA-N pyrazin-2-amine Chemical compound NC1=CN=CC=N1 XFTQRUTUGRCSGO-UHFFFAOYSA-N 0.000 description 1
- CAFSXVAFGILCCI-UHFFFAOYSA-N pyrazine-2,3-diamine Chemical compound NC1=NC=CN=C1N CAFSXVAFGILCCI-UHFFFAOYSA-N 0.000 description 1
- LETVJWLLIMJADE-UHFFFAOYSA-N pyridazin-3-amine Chemical compound NC1=CC=CN=N1 LETVJWLLIMJADE-UHFFFAOYSA-N 0.000 description 1
- LJXQPZWIHJMPQQ-UHFFFAOYSA-N pyrimidin-2-amine Chemical compound NC1=NC=CC=N1 LJXQPZWIHJMPQQ-UHFFFAOYSA-N 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 229910052703 rhodium Inorganic materials 0.000 description 1
- 239000010948 rhodium Substances 0.000 description 1
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 1
- 229910052707 ruthenium Inorganic materials 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- RMBAVIFYHOYIFM-UHFFFAOYSA-M sodium methanethiolate Chemical compound [Na+].[S-]C RMBAVIFYHOYIFM-UHFFFAOYSA-M 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000001119 stannous chloride Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- UDYFLDICVHJSOY-UHFFFAOYSA-N sulfur trioxide pyridine complex Chemical compound O=S(=O)=O.C1=CC=NC=C1 UDYFLDICVHJSOY-UHFFFAOYSA-N 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical class C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- AXZWODMDQAVCJE-UHFFFAOYSA-L tin(II) chloride (anhydrous) Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 1
- HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- ZGYICYBLPGRURT-UHFFFAOYSA-N tri(propan-2-yl)silicon Chemical compound CC(C)[Si](C(C)C)C(C)C ZGYICYBLPGRURT-UHFFFAOYSA-N 0.000 description 1
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 1
- WLPUWLXVBWGYMZ-UHFFFAOYSA-N tricyclohexylphosphine Chemical compound C1CCCCC1P(C1CCCCC1)C1CCCCC1 WLPUWLXVBWGYMZ-UHFFFAOYSA-N 0.000 description 1
- OKKJLVBELUTLKV-FIBGUPNXSA-N trideuteriomethanol Chemical compound [2H]C([2H])([2H])O OKKJLVBELUTLKV-FIBGUPNXSA-N 0.000 description 1
- ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 1
- GRGCWBWNLSTIEN-UHFFFAOYSA-N trifluoromethanesulfonyl chloride Chemical compound FC(F)(F)S(Cl)(=O)=O GRGCWBWNLSTIEN-UHFFFAOYSA-N 0.000 description 1
- PQDJYEQOELDLCP-UHFFFAOYSA-N trimethylsilane Chemical compound C[SiH](C)C PQDJYEQOELDLCP-UHFFFAOYSA-N 0.000 description 1
- ZHOVAWFVVBWEGQ-UHFFFAOYSA-N tripropylsilane Chemical compound CCC[SiH](CCC)CCC ZHOVAWFVVBWEGQ-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00Ā -Ā C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00Ā -Ā C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Definitions
- the present invention relates to a dibenzoxepin derivative having a peroxisome proliferator-activated receptor (PPAR) ā agonist activity, which is useful as an agent for treating and/or preventing, for example, type 2 diabetes, impaired glucose tolerance, insulin resistance syndrome, hypertension, hyperlipidemia, metabolic syndrome, visceral obesity, obesity, hypertriglyceridemia, inflammatory skin diseases, inflammatory diseases, inflammatory neuropsychiatric diseases, neurodegenerative neuropsychiatric diseases and the like.
- PPAR peroxisome proliferator-activated receptor
- Peroxisome proliferator-activated receptor is a member of the nuclear receptor superfamily of ligand activated transcription factor. Three subtypes of PPAR, i.e., PPAR ā , PPAR ā , and PPAR ā , have been cloned from mouse and human. PPAR is known as an important nuclear hormone receptor for the metabolism of carbohydrate and lipid, immunoregulation, and inflammatory reaction.
- PPAR ā specifically is said to play an important role in adipocyte differentiation.
- Hypertrophic adipocytes secrete large amounts of cytokines, namely TNF- ā and free fatty acid which induce insulin resistance.
- thiazolidinedione derivatives such as pioglitazone, rosiglitazone and the like improve insulin resistance by activating PPAR ā to decrease hypertrophic adipocytes by apoptosis, and promoting differentiation of preadipocytes into small adipocytes having normal function (non-patent documents 1 and 2).
- Pioglitazone and rosiglitazone, which are PPAR ā agonists have already been clinically used as therapeutic drugs for diabetes (patent documents 1 and 2).
- PPAR ā agonists are also useful as agents for treating and/or preventing diseases besides diabetes, such as metabolic syndrome, obesity, impaired glucose tolerance and other insulin resistance syndrome, which are prediabetic conditions, hypertension, atherosclerosis, hyperlipidemia, inflammatory diseases such as psoriasis and the like, inflammatory bowel disease, and the like.
- diseases besides diabetes such as metabolic syndrome, obesity, impaired glucose tolerance and other insulin resistance syndrome, which are prediabetic conditions, hypertension, atherosclerosis, hyperlipidemia, inflammatory diseases such as psoriasis and the like, inflammatory bowel disease, and the like.
- a tricyclic compound represented by the following formula (A) and a derivative thereof are known as PPAR agonists/antagonists/regulators (patent document 3).
- a compound represented by the following formula (C), which is a tricyclic compound, and a derivative thereof are known as PPAR ā agonists (see patent document 5).
- An object of the present invention is to provide a novel dibenzoxepin derivative or a pharmaceutically acceptable salt thereof having a peroxisome proliferator-activated receptor ā (PPAR ā ) agonist activity , or the like.
- the dibenzoxepin derivative provided by the present invention or a pharmaceutically acceptable salt thereof is useful as a therapeutic and/or prophylactic agent for type 2 diabetes, impaired glucose tolerance, insulin resistance syndrome, hypertension, hyperlipidemia, metabolic syndrome, visceral obesity, obesity, hypertriglyceridemia, inflammatory skin diseases (e.g., psoriasis, atopic dermatitis, seborrheic dermatitis, solar dermatitis etc.), inflammatory diseases (e.g., rheumatoid arthritis, ulcerative colitis, Crohn's disease, endometritis etc.), inflammatory neuropsychiatric diseases (e.g., multiple sclerosis etc.), neurodegenerative neuropsychiatric diseases (e.g., Alzheimer's disease,
- Another object of the present invention is to provide a PPAR ā agonist containing a dibenzoxepin derivative as an active ingredient.
- the present invention relates to the following (1) - (30).
- a dibenzoxepin derivative having a PPAR ā function regulatory activity which is useful as a therapeutic and/or prophylactic agent for, for example, type 2 diabetes, impaired glucose tolerance, insulin resistance syndrome, hypertension, hyperlipidemia, metabolic syndrome, visceral obesity, obesity, hypertriglyceridemia, inflammatory skin diseases (e.g., psoriasis, atopic dermatitis, seborrheic dermatitis, solar dermatitis etc.), inflammatory diseases (e.g., rheumatoid arthritis, ulcerative colitis, Crohn's disease, endometritis etc.), inflammatory neuropsychiatric diseases (e.g., multiple sclerosis etc.), neurodegenerative neuropsychiatric diseases (e.g., Alzheimer's disease, Parkinson's disease etc.), cardiovascular diseases such as arteriosclerosis, cardiac disease, cerebral apoplexy, renal diseases, or the like, or a pharmaceutically acceptable salt thereof and the like are provided.
- inflammatory skin diseases e.
- the dibenzoxepin derivative or a pharmaceutically acceptable salt thereof disclosed in the present invention is superior in the metabolic stability in human, and has preferable properties as an active ingredient of the pharmaceutical product used for the above-mentioned diseases.
- the present invention provides a PPAR ā function modulator containing a dibenzoxepin derivative as an active ingredient.
- compound (I) a compound represented by the general formula (I) is referred to as compound (I).
- compound (I) a compound represented by the general formula (I).
- examples of lower alkyl, and the lower alkyl moiety of lower alkoxy, lower alkylsulfanyl, lower alkylsulfonyl, lower alkanoyloxy, lower alkanoyl, lower alkoxycarbonyl, lower alkylcarbamoyl, di-lower alkylcarbamoyl, lower alkylamino, and di-lower alkylamino include straight chain or branched alkyl having 1 - 10 carbon atoms.
- More specific examples thereof include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, hexyl, heptyl, octyl, nonyl, decyl and the like.
- Preferable examples thereof include straight chain or branched alkyl having 1 - 6 carbon atoms, which is more specifically methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, hexyl and the like.
- Two lower alkyl moieties of di-lower alkylcarbamoyl and di-lower alkylamino may be the same or different.
- Examples of the lower alkenyl include straight chain or branched alkenyl having 2 - 10 carbon atoms, and more specific examples thereof include vinyl, allyl, 1-propenyl, butenyl, pentenyl, hexenyl, heptenyl, octenyl, nonenyl, decenyl and the like.
- Preferable examples thereof include straight chain or branched alkenyl having 2 - 6 carbon atoms, and more specific examples thereof include vinyl, allyl, 1-propenyl, butenyl, pentenyl, hexenyl and the like.
- Examples of the lower alkynyl include straight chain or branched alkynyl having 2 - 10 carbon atoms, and more specific examples thereof include ethynyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl, octynyl, nonynyl, decynyl and the like.
- Preferable examples thereof include straight chain or branched alkynyl having 2 - 6 carbon atoms, and more specific examples thereof include ethynyl, propynyl, butynyl, pentynyl, hexynyl and the like.
- cycloalkyl examples include cycloalkyl having 3 to 8 carbon atoms, and more specific examples thereof include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl and the like. Preferable examples thereof include cycloalkyl having 3 - 6 carbon atoms, and more specific examples thereof include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like.
- aralkyl and the aralkyl moiety of aralkyloxy include aralkyl having 7 to 16 carbon atoms, and more specific examples thereof include benzyl, phenethyl, phenylpropyl, phenylbutyl, phenylpentyl, phenylhexyl, phenylheptyl, phenyloctyl, phenylnonyl, phenyldecyl, naphthylmethyl, naphthylethyl, naphthylpropyl, naphthylbutyl, naphthylpentyl, naphthylhexyl, anthrylmethyl, anthrylethyl and the like.
- aryl and the aryl moiety of aryloxy include aryl having 6 - 14 carbon atoms, and more specific examples thereof include phenyl, naphthyl, azulenyl, anthryl and the like.
- Examples of the aliphatic heterocyclic group and the aliphatic heterocyclic group moiety of aliphatic heterocyclylcarbonyl include a 5-membered or 6-membered monocyclic aliphatic heterocyclic group comprising at least one atom selected from a nitrogen atom, an oxygen atom and a sulfur atom, a bicyclic or tricyclic condensed aliphatic heterocyclic group with 3- to 8-membered rings fused together containing at least one atom selected from a nitrogen atom, an oxygen atom and a sulfur atom, and the like, and more specific examples thereof include aziridinyl, azetidinyl, pyrrolidinyl, piperidino, piperidinyl, azepanyl, 1,2,5,6-tetrahydropyridyl, imidazolidinyl, pyrazolidinyl, piperazinyl, homopiperazinyl, pyrazolinyl, oxiranyl, t
- Preferable examples thereof include a 5-membered or 6-membered monocyclic aliphatic heterocyclic group containing at least one atom selected from a nitrogen atom, an oxygen atom and a sulfur atom, and the like, and more specific examples thereof include pyrrolidinyl, piperidino, piperidinyl, 1,2,5,6-tetrahydropyridyl, imidazolidinyl, pyrazolidinyl, piperazinyl, pyrazolinyl, tetrahydrofuranyl, tetrahydro-2H-pyranyl, 5,6-dihydro-2H-pyranyl, oxazolidinyl, morpholino, morpholinyl, thioxazolidinyl, thiomorpholinyl, 2H-oxazolyl, 2H-thioxazolyl and the like.
- aromatic heterocyclic group examples include a 5-membered or 6-membered monocyclic aromatic heterocyclic group containing at least one atom selected from a nitrogen atom, an oxygen atom and a sulfur atom, a bicyclic or tricyclic condensed aromatic heterocyclic group with 3- to 8-membered rings fused together, containing at least one atom selected from a nitrogen atom, an oxygen atom and a sulfur atom, and the like, and more specific examples thereof include furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, benzofuranyl, benzothiophenyl, benzox
- Preferable examples thereof include a 5-membered or 6-membered monocyclic aromatic heterocyclic group having at least one atom selected from a nitrogen atom, an oxygen atom and a sulfur atom and the like, and more specific examples thereof include furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl and the like.
- Examples of the nitrogen-containing heterocyclic group formed together with the adjacent nitrogen atom thereto include a 5-membered or 6-membered monocyclic heterocyclic group with 3- to 8-membered rings fused together, containing at least one nitrogen atom (said monocyclic heterocyclic group may contain other nitrogen atom(s), oxygen atom(s) or sulfur atom(s)), a bicyclic or tricyclic fused heterocyclic group containing at least one nitrogen atom (said fused heterocyclic group may contain other nitrogen atom(s), oxygen atom(s) or sulfur atom(s)), and the like, and more specific examples thereof include aziridinyl, azetidinyl, pyrrolidinyl, piperidino, azepanyl, pyrrolyl, imidazolidinyl, imidazolyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, piperazinyl, homopiperazinyl, oxazolidin
- Preferable examples thereof include a 5-membered or 6-membered monocyclic heterocyclic group containing at least one nitrogen atom (said monocyclic heterocyclic group may contain other nitrogen atom(s), oxygen atom(s) or sulfur atom(s)) and the like, and more specific examples thereof include pyrrolidinyl, piperidino, pyrrolyl, imidazolidinyl, imidazolyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, piperazinyl, oxazolidinyl, 2H-oxazolyl, thioxazolidinyl, 2H-thioxazolyl, morpholino, thiomorpholinyl and the like.
- Halogen means each atom of fluorine, chlorine, bromine or iodine.
- the substituents of the lower alkyl optionally having substituent(s), the lower alkylsulfonyl optionally having substituent(s), the lower alkenyl optionally having substituent(s), the lower alkynyl optionally having substituent(s), the lower alkoxy optionally having substituent(s), the lower alkylsulfanyl optionally having substituent(s), the lower alkanoyloxy optionally having substituent(s), the lower alkanoyl optionally having substituent(s), the lower alkoxycarbonyl optionally having substituent(s), the lower alkylcarbamoyl optionally having substituent(s), and the di-lower alkylcarbamoyl optionally having substituent(s) are the same or different and examples thereof include 1 to 3 substituents selected from the group consisting of halogen, hydroxy, sulfanyl, nitro, cyano, carboxy, carbamoyl, C 3-8 cycloalkyl, an aliphatic hetero
- the substituents of the aryl optionally having substituent(s), the aryloxy optionally having substituent(s), the aralkyl optionally having substituent(s), the aralkyloxy optionally having substituent(s) and the aromatic heterocyclic group optionally having substituent(s) are the same or different and examples thereof include 1 to 3 substituents selected from the group consisting of halogen, hydroxy, sulfanyl, nitro, cyano, carbamoyl, C 1-10 alkyl, trifluoromethyl, C 3-8 cycloalkyl, C 6-14 aryl, aliphatic heterocyclic group, aromatic heterocyclic group, C 1-10 alkoxy, C 3-8 cycloalkoxy, C 6-14 aryloxy, C 7-16 aralkyloxy, C 2-11 alkanoyloxy, C 7-15 aroyloxy, C 1-10 alkylsulfanyl, -NR X R Y (wherein R X and R Y are the
- the substituents of the cycloalkyl optionally having substituent(s), the aliphatic heterocyclic group optionally having substituent(s), the aliphatic heterocyclylcarbonyl optionally having substituent(s) and the nitrogen-containing heterocyclic group formed together with the adjacent nitrogen atom optionally having substituent(s) are the same or different and examples thereof include 1 to 3 substituents selected from the group consisting of oxo, halogen, hydroxy, sulfanyl, nitro, cyano, carbamoyl, C 1-10 alkyl, trifluoromethyl, C 3-8 cycloalkyl, C 6-14 aryl, aliphatic heterocyclic group, aromatic heterocyclic group, C 1-10 alkoxy, C 3-8 cycloalkoxy, C 6-14 aryloxy, C 7-16 aralkyloxy, C 2-11 alkanoyloxy, C 7-15 aryloxy, C 1-10 alkylsulfanyl, -NR X R Y
- Examples of the C 1-10 alkyl and the C 1-10 alkyl moiety of the C 1-10 alkoxy, the C 2-11 alkanoyloxy, the C 1-10 alkylsulfanyl, the C 2-11 alkanoyl, the C 1-10 alkoxycarbonyl, the C 1-10 alkylcarbamoyl and the di-C 1-10 alkylcarbamoyl include the groups recited as examples of the aforementioned lower alkyl.
- Two C 1-10 alkyl of the di-C 1-10 alkylcarbamoyl may be the same or different.
- Examples of the C 3-8 cycloalkyl and the cycloalkyl moiety of the C 3-8 cycloalkoxy include the groups recited as examples of the aforementioned cycloalkyl.
- Examples of the C 6-14 aryl and the aryl moiety of the C 6-14 aryloxy, the C 7-15 aroyl, the C 7-15 aroyloxy and the C 6-14 aryloxycarbonyl include the groups recited as examples of the aforementioned aryl.
- C 7-16 aralkyl and the C 7-16 aralkyl moiety of the C 7-16 aralkyloxy and the C 7-16 aralkyloxycarbonyl include the groups recited as examples of the aforementioned aralkyl.
- Examples of the aliphatic heterocyclic group, the aromatic heterocyclic group and the halogen include the groups recited as examples of the aforementioned aliphatic heterocyclic group, the aforementioned aromatic heterocyclic group and the aforementioned halogen, respectively.
- the pharmaceutically acceptable salt of compound (I) comprises, for example, pharmaceutically acceptable acid addition salts, metal salts, ammonium salts, organic amine addition salts, amino acid addition salts and the like.
- pharmaceutically acceptable acid addition salt of compound (I) include inorganic acid salts such as hydrochloride, hydrobromide, nitrate, sulfate, phosphate and the like, organic acid salts such as acetate, oxalate, maleate, fumarate, citrate, benzoate, methanesulfonate etc., and the like.
- Examples of the pharmaceutically acceptable metal salts include alkali metal salts such as sodium salt, potassium salt and the like, alkaline earth metal salts such as magnesium salt, calcium salt and the like, aluminum salt, zinc salt and the like.
- Examples of the pharmaceutically acceptable ammonium salt include salts of ammonium, tetramethylammonium and the like.
- Examples of the pharmaceutically acceptable organic amine addition salt include addition salts of morpholine, piperidine and the like.
- Examples of the pharmaceutically acceptable amino acid addition salt include addition salts of lysine, glycine, phenylalanine, aspartic acid, glutamic acid and the like.
- the desired compound when the defined groups change under the conditions of the production methods or are inappropriate for performing the production methods, the desired compound can be produced by performing the methods for the introduction and removal of the protecting groups conventionally performed in the synthetic organic chemistry (e.g., methods described in Protective Groups in Organic Synthesis, third edition, T.W. Greene, John Wiley & Sons Inc., 1999 etc.) or the like. If necessary, the order of the reaction steps such as substituent introduction or the like can also be changed.
- a compound represented by the following formula (VII), which is a synthetic intermediate for compound (I), can be produced by the following steps.
- Compound (III) can be obtained by reacting compound (IIa) with 1 equivalent - 5 equivalents of compound (IIb) in the presence of 1 equivalent - large excess of a base in a solvent at a temperature between -20Ā°C and the boiling point of the solvent to be used for 5 min - 120 hr.
- Examples of the base include sodium hydride, potassium hydride, butyllithium, lithium diisopropylamide (LDA), lithium bistrimethylsilylamide, sodium bistrimethylsilylamide, sodium methoxide, potassium ethoxide, potassium tert-butoxide, potassium carbonate, sodium hydroxide, 1,8-diazabicyclo[5.4.0]-7-undecene (DBU), triethylamine, diisopropylethylamine and the like.
- LDA lithium diisopropylamide
- DBU 1,8-diazabicyclo[5.4.0]-7-undecene
- solvent examples include dimethylformamide (DMF), dimethylacetamide (DMA), N-methylpyrrolidone (NMP), dimethyl sulfoxide (DMSO), tetrahydrofuran (THF), acetonitrile and the like, and these can be used alone or in a mixture.
- DMF dimethylformamide
- DMA dimethylacetamide
- NMP N-methylpyrrolidone
- DMSO dimethyl sulfoxide
- THF tetrahydrofuran
- compound (IIa) can be obtained by the method described in Journal of Medicinal Chemistry, 1996, vol. 39, p. 246 , EP2072507 or the like, and compound (IIb) is commercially available or can be obtained by a known method (e.g., J. Chem. Soc. Perkin Trans.1, 1992, p. 313 , Synthesis, 1987, p. 411 ) or a method analogous thereto.
- Compound (IV) can be produced by reacting compound (III) in a solvent, in the presence of carbon monoxide, 0.1 - 10 equivalents of a base and 0.001 - 0.5 equivalents of a palladium catalyst at a temperature between -20Ā°C and the boiling point of the solvent to be used for 5 min - 72 hr.
- Examples of the base include potassium carbonate, cesium carbonate, potassium phosphate, potassium hydroxide, sodium hydroxide, potassium tert-butoxide, triethylamine, diisopropylethylamine, N-methylmorpholine, pyridine, DBU and the like.
- Examples of the palladium catalyst include palladium acetate, tris(dibenzylideneacetone)dipalladium (Pd 2 (dba) 3 ), tetrakis(triphenylphosphine)palladium, 1,1'-bis(diphenylphosphino)ferrocene dichloropalladium. dichloromethane 1:1 adduct and the like.
- Examples of the solvent include methanol, ethanol, propanol, butanol and the like.
- chloroform 1,2-dichloroethane, ethyl acetate, acetonitrile, THF, 1,2-dimethoxyethane (DME), 1,4-dioxane, DMF, DMA, NMP and the like can be used alone or in a mixture.
- Compound (V) can be obtained by reacting compound (IV) in the presence of 1 equivalent - large excess of a reducing agent in a solvent at a temperature between -20Ā°C and the boiling point of the solvent to be used for 5 min - 120 hr.
- Examples of the reducing agent include sodium borohydride, lithium borohydride, lithium aluminum hydride, diisobutylaluminum hydride and the like.
- Examples of the solvent include THF, diethyl ether, dioxane, dichloromethane, hexane, toluene and the like, and these can be used alone or in a mixture.
- Compound (VI) can be obtained by reacting compound (V) in the presence of 1 equivalent - large excess of a halogenating agent or sulfonylating agent in a solvent or without solvent at a temperature between -20Ā°C and the boiling point of the solvent to be used for 5 min - 72 hr.
- halogenating agent examples include thionyl chloride; phosphorus tribromide; boron tribromide; a combination of triphenylphosphine, 2,6-lutidine and carbon tetrachloride; a combination of triphenylphosphine, 2,6-lutidine and carbon tetrabromide; a combination of methanesulfonyl chloride and lithium chloride; a combination of methanesulfonic anhydride and lithium chloride; a combination of methanesulfonyl chloride and lithium bromide; a combination of methanesulfonic anhydride and lithium bromide, and the like.
- Examples of the sulfonylating agent include trifluoromethanesulfonyl chloride, methanesulfonyl chloride, methanesulfonic anhydride, benzenesulfonyl chloride, p-toluenesulfonyl chloride and the like.
- Examples of the solvent include THF, DMF, DMA, dichloromethane, dichloroethane, acetonitrile and the like, and these can be used alone or in a mixture.
- Compound (VII) can be obtained by reacting compound (VI) with 1 equivalent - 5 equivalents of compound (VIa) in the presence of, if necessary, 1 equivalent - large excess of a base in a solvent at a temperature between -20Ā°C and the boiling point of the solvent to be used for 5 min - 120 hr.
- Examples of the base include sodium carbonate, potassium carbonate, lithium carbonate, cesium carbonate, sodium hydrogen carbonate, potassium hydrogen carbonate, lithium hydrogen carbonate, sodium hydroxide, potassium hydroxide, lithium hydroxide, sodium methoxide, potassium ethoxide, potassium tert-butoxide, sodium hydride, potassium hydride, LDA, lithium bistrimethylsilylamide, sodium bistrimethylsilylamide, triethylamine, diisopropylethylamine, tributylamine, dicyclohexylmethylamine and the like.
- Examples of the solvent include DMF, DMA, NMP, DMSO, THF, acetonitrile, isopropyl alcohol and the like, and these can be used alone or in a mixture.
- Compound (VIa) is commercially available or can be obtained by a known method (e.g., US Patent No. 5332744 , EP-B-400835 , JP-A-5-783228 or the like) or a method analogous thereto.
- Compound (VII) can be produced by reacting compound (V) with preferably 1 - 10 equivalents of compound (VIa) in a solvent in the presence of preferably 1 - 10 equivalents of a phosphine compound and preferably 1 - 10 equivalents of an azo compound at a temperature between -78Ā°C and the boiling point of the solvent to be used for 5 min - 72 hr.
- Examples of the phosphine compound include triphenylphosphine, tributylphosphine and the like.
- Examples of the azo compound include diethyl azodicarboxylate (DEAD), di-tert-butyl azadicarboxylate (DBAD), diisopropyl azadicarboxylate, N,N, N', N'-tetramethylazadicarboxamide, 1,1'-(azadicarbonyl)dipiperazine, N,N,N',N'-tetraisopropylazadicarboxamide and the like.
- DEAD diethyl azodicarboxylate
- DBAD di-tert-butyl azadicarboxylate
- diisopropyl azadicarboxylate N,N, N', N'-tetramethylazadicarboxamide
- 1,1'-(azadicarbonyl)dipiperazine N,N,N',N'-te
- the combination of the phosphine compound and the azo compound to be used include a combination of triphenylphosphine and DEAD or DBAD.
- the solvent include dichloromethane, chloroform, 1,2-dichloroethane, toluene, ethyl acetate, acetonitrile, diethyl ether, THF, DME, 1,4-dioxane, DMF, DMA, NMP and the like, and these can be used alone or in a mixture.
- a compound represented by the following formula (X), which is a synthetic intermediate for compound (I), can be produced by the following steps.
- Compound (VIII) can be produced by treating compound (V) in a solvent, with preferably 1 - 10 equivalents of an oxidant at a temperature between -20Ā°C and the boiling point of the solvent to be used for 5 min - 72 hr.
- oxidant examples include manganese dioxide, chromic acid, pyridinium chlorochromate (PCC), pyridinium dichlorochromate (PDC), potassium permanganate, sulfur trioxide-pyridine, oxone (registered trade mark), DMSO/oxalyl chloride, Dess-Martin periodinane (DMPI) and the like.
- solvent examples include dichloromethane, chloroform, 1,2-dichloroethane, toluene, ethyl acetate, acetonitrile, diethyl ether, THF, DME, dioxane, DMF, DMA, NMP, DMSO, pyridine, hydrochloric acid, acetic acid, propionic acid, acetic anhydride, sulfuric acid, water and the like, and these can be used alone or in a mixture.
- Compound (IX) can be produced by reacting compounds (VIII) and (VIIa) in the presence of preferably 1 - 10 equivalents of an organic metal reagent in a solvent at a temperature between -78Ā°C and the boiling point of the solvent to be used for 5 min - 72 hr.
- organic metal reagent examples include methyllithium, butyllithium, sec-butyllithium, phenyllithium, methylmagnesium chloride, ethylmagnesium chloride, isopropylmagnesium chloride, phenylmagnesium chloride, isopropylmagnesium chloride lithium chloride complex and the like.
- solvent examples include toluene, diethyl ether, THF, DME, 1,4-dioxane, hexane and the like, and these can be used alone or in a mixture.
- Compound (X) can be produced by reacting compound (IX) with 1 equivalent - a large excess of alkylchlorosilane and 1 equivalent - a large excess of sodium iodide in a solvent at a temperature between -20Ā°C and the boiling point of the solvent to be used for 5 min - 72 hr, or by reacting compound (IX) in 1 equivalent - a large excess of alkylsilane and 1 equivalent - a large excess of trifluoroacetic acid at a temperature between - 20Ā°C and the boiling point of the solvent to be used for 5 min - 72 hr.
- alkylchlorosilane examples include trimethylchlorosilane, triethylchlorosilane, dimethyldichlorosilane and the like.
- the solvent examples include dichloromethane, hexane, acetonitrile and the like, and these can be used alone or in a mixture.
- alkylsilane examples include trimethylsilane, triethylsilane, tripropylsilane, and triisopropylsilane.
- compound (X) can be produced by reacting compound (VIII) with preferably 1 - 10 equivalents of A 3 -H (wherein A 3 is as defined above), in a solvent, in the presence of preferably 1 - 10 equivalents of a reducing agent and preferably 1 - 10 equivalents of Br ā nsted acid, at a temperature between -78Ā°C and the boiling point of the solvent to be used for 5 min - 72 hr.
- the reducing agent include sodium borohydride, lithium borohydride, triethylsilane and the like.
- Examples of the Br ā nsted acid include hydrochloric acid, sulfuric acid, trifluoroacetic acid, acetic acid, methanesulfonic acid and the like.
- Examples of the solvent include toluene, THF, DME, 1,4-dioxane, DMF and the like, and these can be used alone or in a mixture.
- compound (VIIa) is commercially available or can be obtained by a known method (e.g., Bioorganic and Chemistry Letter, 2008, vol. 18, p688 ) or a method analogous thereto.
- a compound represented by the following formula (XII), which is a synthetic intermediate for compound (I), can be produced by the following steps.
- Compound (XI) can be produced by reacting compound (III), for example, in a solvent such as toluene, dioxane, THF, DMF, DMA and the like, in the presence of 0.001 - 0.5 equivalents of copper (I) iodide, 1 - 10 equivalents of trimethylsilylacetylene, preferably 0.1 - 10 equivalents of a base and preferably 0.001 - 0.5 equivalent of a palladium catalyst at a temperature between -20Ā°C and the boiling point of the solvent to be used for 5 min - 72 hr, and successively reacting, for example, in a solvent such as methanol, ethanol, isopropyl alcohol, THF, DMF, DMA and the like, for example, in the presence of 1 - a large excess of a base or tetrabutylammonium fluoride at a temperature between -20Ā°C and the boiling point of the solvent to be used for 5 min - 72 hr.
- Examples of the base include potassium carbonate, potassium phosphate, potassium hydroxide, sodium hydroxide, potassium tert-butoxide, triethylamine, diisopropylethylamine, pyridine, DBU and the like.
- Examples of the palladium catalyst include palladium acetate, tris(dibenzylideneacetone)dipalladium, tetrakis(triphenylphosphine)palladium, 1,1'-bis(diphenylphosphino)ferrocene dichloropalladium ā dichloromethane 1:1 adduct, bis(triphenylphosphine)dichloropalladium and the like.
- Compound (XII) can be produced by reacting compound (XI) in the presence of compound (XIa), and R 4 -CHO (wherein R 4 is as defined above), preferably in the presence of 0.001 - 0.5 equivalents of copper trifluoromethanesulfonate and preferably 0.001 - 0.5 equivalents of copper chloride in a solvent at a temperature between -20Ā°C and the boiling point of the solvent to be used for 5 min - 72 hr.
- R 4 -CHO examples include formaldehyde, propanecarboxyaldehyde, cyclopropanecarboxyaldehyde, isopropylcarboxyaldehyde, cyclobutanecarboxyaldehyde, cyclopentanecarboxyaldehyde and the like.
- the solvent include THF, 1,4-dioxane, dichloroethane, chloroform, toluene, DMF, DMA and the like, and these can be used alone or in a mixture.
- Compound (XIII) can be produced by reacting compound (VI) with compound (VIb) in a solvent in the presence of preferably 1 - a large excess of a base, at a temperature between -20Ā°C and the boiling point of the solvent to be used for 5 min - 72 hr.
- Examples of the base include sodium hydride, potassium hydride, sodium methoxide, potassium tert-butoxide, potassium carbonate, sodium carbonate, sodium hydroxide, LDA and the like.
- Examples of the solvent include DMF, DMA, THF, DME, 1,4-dioxane, NMP and the like, and these can be used alone or in a mixture.
- compound (VIb) is commercially available or can be obtained by a known method (e.g., Synthesis, 2008, vol. 19, p3065 and the like) or a method analogous thereto.
- Compound (XIV) can be produced by reacting compound (XIII) in a solvent in the presence of preferably 1 - a large excess of a reducing agent at a temperature between -20Ā°C and the boiling point of the solvent to be used for 5 min - 72 hr.
- a reducing agent include iron, stannic chloride, zinc and the like.
- the solvent include acetic acid, ethanol, DME, 1,4-dioxane, DMF, NMP and the like, and these can be used alone or in a mixture.
- Compound (XV) can be produced by reacting compound (VI) with compound (VIc) in a solvent in the presence of preferably 1 - a large excess of a base, at a temperature between -20Ā°C and the boiling point of the solvent to be used for 5 min - 72 hr.
- a base include sodium hydride, potassium hydride, sodium methoxide, potassium tert-butoxide, potassium carbonate, sodium carbonate, sodium hydroxide, LDA and the like.
- the solvent include DMF, DMA, THF, DME, 1,4-dioxane, NMP and the like, and these can be used alone or in a mixture.
- Examples of the base include sodium hydride, sodium methoxide, sodium ethoxide, potassium carbonate, sodium carbonate, sodium hydroxide, LDA and the like.
- Examples of the solvent include DMF, ethanol, methanol, THF, DME, 1,4-dioxane and the like, and these can be used alone or in a mixture
- Compound (XVII) can be produced by reacting compound (XVI) in the presence of phosphorus oxychloride, by adding a solvent such as acetonitrile, chloroform, 1,2-dichloroethane and the like if necessary, at a temperature between room temperature and the boiling point of the solvent to be used for 5 min - 72 hr, and successively reacting, for example, in a solvent such as methanol, ethanol, isopropyl alcohol, THF, DMF, DMA and the like in the presence of, for example, 1 equivalent - a large excess of R k H (wherein R k is as defined above) or an anionic nucleophilic species thereof, at a temperature between room temperature and the boiling point of the solvent to be used for 5 min - 72 hr.
- a solvent such as acetonitrile, chloroform, 1,2-dichloroethane and the like if necessary
- R k H (wherein R k is as defined above) or an anionic nucleophilic species thereof include sodium methoxide, sodium ethoxide, dimethylamine, azetidine, morpholine, piperidine, piperazine and the like.
- Compound (Ia) can be obtained by reacting compound (XVIII) with 1 equivalent - 10 equivalents of sodium azide in a solvent in the presence of 1 equivalent - large excess of a weak acid for 5 min - 120 hr at a temperature between -20Ā°C and the boiling point of the solvent to be used.
- Examples of the weak acid include ammonium chloride, triethylamine hydrochloride and the like.
- the solvent include DMF, DMA, NMP, DMSO and the like, and these can be used alone or in a mixture.
- Compound (XVIII) can be synthesized by a known method (e.g., WO2010/016549 and the like) or a method analogous thereto.
- compound (Ia) can also be obtained by reacting compound (XVIII) with 1 equivalent - 10 equivalents of sodium azide in a solvent in the presence of 0.01 - 10 equivalents of an additive at a temperature between-10Ā°C and the boiling point of the solvent to be used for 1 hr-120 hr.
- Examples of the additive include tributyltin chloride, trimethyltin chloride, dibutyltin oxide and the like.
- Examples of the solvent include toluene, xylene and the like, and these can be used alone or in a mixture.
- Compound (XIX) can be obtained by reacting compound (XVIII) with 1 equivalent - large excess of hydroxylamine in a solvent at a temperature between -20Ā°C and the boiling point of the solvent to be used for 5 min - 120 hr.
- hydroxylamine for example, an inorganic acid salt such as hydroxylamine hydrochloride or the like can be used.
- a base such as sodium methoxide, sodium hydrogen carbonate or the like is preferably copresent.
- the solvent include methanol, ethanol, DMF, DMA, DMSO and the like, and these can be used alone or in a mixture.
- Compound (Ib) can be obtained by reacting compound (XIX) with 1 equivalent - a large excess of chlorocarbonate ester in the presence of 1 equivalent - a large excess of a base, for example, in a solvent such as THF, DMF, DMA, toluene, xylene, dichloromethane and the like, at a temperature between -20Ā°C and the boiling point of the solvent to be used for 5 min - 72 hr, and successively reacting, for example, in a solvent such as THF, DMF, DMA, toluene, xylene and the like or a mixed solvent such as toluene-THF and the like, in the presence of, if necessary, a catalytic amount - 10 equivalents of a base, at a temperature between -20Ā°C and the boiling point of the solvent to be used for 5 min - 72 hr.
- the above-mentioned steps can also be performed sequentially by adding chlorocarbonate ester and
- Examples of the base used for the reaction with chlorocarbonate ester include potassium tert-butoxide, potassium carbonate, DBU, triethylamine and the like.
- Examples of the chlorocarbonate ester include methyl chlorocarbonate, ethyl chlorocarbonate, propyl chlorocarbonate, phenyl chlorocarbonate and the like.
- Examples of the base used for intermediate carbonate ester include triethylamine, pyridine, 4-dimethylaminopyridine, diazabicycloundecene and the like.
- Compound (Ib) can be obtained by reacting compound (XIX) with 1 equivalent - a large excess of N,N'-carbonyldiimidazole (CDI) in the presence of 1 equivalent - a large excess of a base, at a temperature between -20Ā°C and the boiling point of the solvent to be used for 5 min - 72 hr.
- CDI N,N'-carbonyldiimidazole
- Examples of the base include potassium tert-butoxide, potassium carbonate, DBU, triethylamine and the like.
- Examples of the solvent include THF, DMF, DMA, 1,4-dioxane and the like, and these can be used alone or in a mixture.
- Compound (Ic) can be obtained by reacting compound (XIX) with 1 equivalent - a large excess of (R B-4 CO) 2 O (wherein R B-4 is lower alkyl optionally having substituent(s) or cycloalkyl optionally having substituent(s)), in the presence of 1 equivalent - a large excess of a base if necessary, in a solvent at a temperature between -20Ā°C and the boiling point of the solvent to be used for 5 min - 72 hr.
- Examples of (R B4 CO) 2 O include acetic anhydride, propionic anhydride, trifluoroacetic anhydride and the like.
- Examples of the base include triethylamine, pyridine, 4-dimethylaminopyridine, diazabicycloundecene and the like.
- Examples of the solvent include THF, 1,4-dioxane, dichloromethane, chloroform, acetonitrile, acetone, DMF, DMA, DMSO and the like, and these can be used alone or in a mixture.
- R B C(OR L ) 3 As another method, it can be obtained by reacting compound (XIX) with 1 equivalent - a large excess of R B C(OR L ) 3 (wherein R B is as defined above, and R L is lower alkyl), in a solvent or without solvent, at a temperature between -20Ā°C and the boiling point of the solvent to be used for 5 min - 72 hr.
- R B C(OR L ) 3 examples include trimethyl orthoformate, triethyl orthoformate, trimethyl orthoacetate, triethyl orthoacetate and the like.
- solvent examples include THF, 1,4-dioxane, dichloromethane, chloroform, acetonitrile, acetone, DMF, DMA, DMSO and the like, and these can be used alone or in a mixture.
- Compound (Id) can be obtained by reacting compound (XIX) with 1 equivalent - a large excess of N,N'-thiocarbonyldiimidazole in the presence of 1 equivalent - a large excess of a Lewis acid in a solvent at a temperature between -20Ā°C and the boiling point of the solvent to be used for 5 min - 72 hr.
- a Lewis acid include boron trifluoride diethyl ether complex, stannous chloride, zinc chloride, silica gel and the like.
- the solvent include THF, 1,4-dioxane, dichloromethane, chloroform, methanol, ethanol and the like, and these can be used alone or in a mixture.
- Compound (Ie) can be obtained by reacting compound (XIX) with 1 equivalent - a large excess of N,N'-thiocarbonyldiimidazole, in the presence of 1 equivalent - a large excess of a base in a solvent at a temperature between - 20Ā°C and the boiling point of the solvent to be used for 5 min - 72 hr.
- Examples of the base include triethylamine, pyridine, 4 -dimethylaminopyridine, diazabicycloundecene and the like.
- Examples of the solvent include THF, 1,4-dioxane, dichloromethane, chloroform, acetonitrile, acetone and the like, and these can be used alone or in a mixture.
- the nitrile group of compound (VII), (X), (XII), (XIV), (XVII) can also be converted in the same manner as in the cyano of group of compound (XVIII).
- Compound (XX) can be obtained, for example, by hydrolyzing the cyano group by reacting compound (XVIII) in the presence of a base such as lithium hydroxide, sodium hydroxide, potassium hydroxide, barium hydroxide and the like, in a suitable water-containing solvent such as a water-containing solvent of methanol, ethanol, ethylene glycol, dioxane, glyme and the like, at a temperature between room temperature and the boiling point of the solvent to be used for 1 hr - 120 hr, or in an aqueous solution of sulfuric acid, hydrochloric acid, acetic acid or the like or a mixture of acids thereof at a temperature between room temperature and the boiling point of the solvent to be used for 1 hr - 120 hr.
- a base such as lithium hydroxide, sodium hydroxide, potassium hydroxide, barium hydroxide and the like
- a suitable water-containing solvent such as a water-containing solvent of methanol, ethanol,
- Compound (XXI) can be obtained by reacting compound (XX) in the presence of 1 equivalent - 50 equivalents of a condensing agent, 1 equivalent - large excess of hydrazine and, if necessary, a base in a solvent at a temperature between - 20Ā°C and the boiling point of the solvent to be used for 5 min - 72 hr.
- a condensing agent include N,N'-carbonyldiimidazole, dicyclohexylcarbodiimide, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride and the like.
- Examples of the base include triethylamine, pyridine, 4-dimethylaminopyridine, diazabicycloundecene and the like.
- Examples of the solvent include THF, 1,4-dioxane, dichloromethane, chloroform, acetonitrile, acetone and the like, and these can be used alone or in a mixture.
- Compound (If) can be obtained by reacting compound (XXI) with 1 equivalent - 50 equivalents of N,N'-carbonyldiimidazole in the presence of, if necessary, a base in a solvent at a temperature between -20Ā°C and the boiling point of the solvent to be used for 5 min - 72 hr.
- a base include triethylamine, pyridine, 4-dimethylaminopyridine, diazabicycloundecene and the like.
- the solvent include THF, 1,4-dioxane, dichloromethane, chloroform, acetonitrile, acetone and the like, and these can be used alone or in a mixture.
- Compound (Ih) can be obtained by reacting compound (XXI) with 1 equivalent - a large excess of (R B-4 CO) 2 O (wherein R B-4 is as defined above) in the presence of 1 equivalent - a large excess of a base if necessary in a solvent at a temperature between -20Ā°C and the boiling point of the solvent to be used for 5 min - 72 hr.
- R B-4 CO) 2 O examples include acetic anhydride, propionic anhydride, trifluoroacetic anhydride and the like.
- the base include triethylamine, pyridine, 4-dimethylaminopyridine, DBU and the like.
- the solvent examples include THF, 1,4-dioxane, dichloromethane, chloroform, acetonitrile, acetone, DMF, DMA, DMSO and the like, and these can be used alone or in a mixture.
- it can be obtained by reacting compound (XXI) with 1 equivalent - a large excess of R B C(OR L ) 3 (wherein R B and R L are each as defined above), in a solvent or without solvent, at a temperature between -20Ā°C and the boiling point of the solvent to be used for 5 min - 72 hr.
- R B C(OR L ) 3 examples include trimethyl orthoformate, triethyl orthoformate, trimethyl orthoacetate, triethyl orthoacetate and the like.
- the solvent examples include THF, 1,4-dioxane, dichloromethane, chloroform, acetonitrile, acetone, DMF, DMA, DMSO and the like, and these can be used alone or in a mixture.
- Compound (Ig) can be obtained by treating compound (XX) with 1 - 50 equivalents of a condensing agent, and reacting the compound with 1 - 50 equivalents of compound (XXa) in the presence of 1 - 30 equivalents of a base, in a solvent at a temperature between -20Ā°C and the boiling point of the solvent to be used for 5 min - 72 hr.
- Examples of the condensing agent include CDI, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDCI) or hydrochloride thereof, dicyclohexylcarbodiimide (DCC) and the like.
- Examples of the solvent include dichloromethane, acetonitrile, toluene, ethyl acetate, THF, 1,4-dioxane, DMF, NMP and the like, and these can be used alone or in a mixture.
- Examples of the base include diazabicycloundecene, triethylamine, 4-dimethylaminopyridine, N,N-dimethylaniline, pyridine, N-methylmorpholine and the like.
- Compound (XXa) can be obtained as a commercially available product.
- the nitrile group of compound (VII), (X), (XII), (XIV), (XVII) can also be converted in the same manner as in the cyano of group of compound (XVIII).
- a compound wherein X is the following formula (b1) - (b6) (wherein R B is as defined above), and R B is a hydrogen atom is the compound (Ia), (Ib), (Ie), (Id) or (If) synthesized in Production method 5 or 6, and a compound wherein R B is lower alkyl optionally having substituent(s) or cycloalkyl optionally having substituent(s) can be obtained by treating the compound (Ia), (Ib), (Ie), (Id) or (If) synthesized in Production method 5 or 6 with R B-1 U (wherein U is a leaving group such as a chlorine atom, a bromine atom, an iodine atom, trifluoromethanesulfonyloxy, methanesulfonyloxy, benzenesulfonyloxy, p-toluenesulfonyloxy and the like, and R B-1 is lower alkyl optionally having substituent
- Examples of the base include sodium hydride, sodium methoxide, potassium tert-butoxide, potassium carbonate, sodium hydroxide, diazabicycloundecene (DBU), triethylamine, diisopropylethylamine and the like.
- Examples of the solvent include DMF, DMA, THF, DME, 1,4-dioxane, NMP and the like, and these can be used alone or in a mixture.
- Examples of the condensing agent include diethyl azodicarboxylate, diisopropyl azodicarboxylate, di(tert-butyl) azodicarboxylate, (cyanomethylene)trimethylphosphorane, (cyanomethylene)tributylphosphorane and the like.
- Examples of the phosphine compound include triphenylphosphine, tributylphosphine, polymer supported triphenylphosphine and the like.
- Examples of the solvent include THF, DMF, dichloromethane, acetonitrile and the like, and these can be used alone or in a mixture.
- the functional groups contained in X, Y, A, R A and the like in compound (I) can also be converted by a known method (e.g., the method described in Comprehensive Organic Transformations 2nd edition, R. C. Larock, Vch Verlagsgesellschaft Mbh, 1999 and the like) or a method analogous thereto.
- intermediates and the desired compounds in the above-mentioned production methods can be isolated and purified by applying separation and purification methods usually used in the synthetic organic chemistry such as filtration, extraction, washing, drying, concentration, recrystallization, various chromatographies and the like.
- separation and purification methods usually used in the synthetic organic chemistry such as filtration, extraction, washing, drying, concentration, recrystallization, various chromatographies and the like.
- intermediates can also be subjected to a next reaction without particular purification.
- Some of compounds (I) contain a stereoisomer such as a geometric isomer, an optical isomer or the like, a tautomer and the like.
- the present invention comprises all possible isomers and mixtures thereof including these.
- each atom may be partly or entirely substituted by the corresponding isotope atom, and the present invention also encompasses a compound substituted by such isotope atom(s).
- a hydrogen atom of compound (I) may be partly or entirely a hydrogen atom with atomic weight 2 (deuterium atom).
- Compound (I) wherein each atom is partly or entirely substituted by the corresponding isotope atom can be produced using a commercially available building block and by a method similar to each of the above-mentioned production methods.
- Compound (I) wherein each atom is partly or entirely substituted by a deuterium atom can also be synthesized by, for example, 1) a method including deuterating carboxylic acid and the like by using deuterium peroxide under basic conditions (see US Patent No. 3849458 ), 2) a method including deuterating alcohol, carboxylic acid and the like by using an iridium complex as a catalyst and deuterated water as a deuterium source [see Journal of American Chemical Society (J. Am. Chem. Soc.), Vol.
- compound (I) obtained in the form of a salt can be directly purified.
- compound (I) may be dissolved or suspended in a suitable solvent, and an acid or a base is added thereto to form a salt, which may be isolated and purified.
- compound (I) and pharmaceutically acceptable salts thereof may exist in the form of adducts with water or various solvents, these adducts are also comprised in the present invention.
- Test Example 1 PPAR ā activation action based on transactivation assay of PPAR ā by transient gene transfer
- the agonist activity of the test compound to PPAR ā was determined by a transactivation assay method using a chimeric nuclear receptor of a DNA binding region of a yeast transcription factor GAL4 and a PPAR ā ligand binding region. Specifically, the PPAR ā agonist activity of the test compound was evaluated by the following method based on the method of Lehmann et al. (J Biol Chem., 1995, vol. 270, page 12953 ).
- HEK293EBNA cells cultured in Dulbecco's Modified Eagle medium (Invitrogen) containing 10 v/v% fetal bovine serum (Invitrogen) were used.
- 30 mL of the above-mentioned cells density: 1 ā 10 5 cells/mL were inoculated in a 10 cm 2 culture dish (Iwaki Glass), and cultured overnight.
- a plasmid expressing a GAL4-PPAR ā chimeric nuclear receptor fusing 174-475 amino acids, which are human PPAR ā ligand binding domain, and 1-147 amino acids, which are GAL4 DNA binding domain, and a reporter plasmid expressing a GAL4 responsive luciferase were transiently introduced into the cells at a proportion of 4:1. After 5 hr from transfection, the cells were detached from the culture dish, and the detached cells (density: 2 ā 10 4 cells/mL) were inoculated by 100 ā L in each well of a 96 well white plate (SUMITOMO BAKELITE), and cultured overnight.
- the medium was removed, the test compound diluted in various concentrations with serum-free Dulbecco's Modified Eagle medium was added by 100 ā L, and the mixture was reacted under a 5% carbon dioxide gas stream (5% CO 2 ) at 37Ā°C for 24 hr.
- 5% CO 2 5% carbon dioxide
- 10 ā mol/L of pioglitazone (100 ā L) was added, and the mixture was reacted under a 5% carbon dioxide gas stream (5% CO 2 ) at 37Ā°C for 24 hr.
- As a substrate of luciferase 100 ā L of Steady-Glo (Promega) was added to each well and the mixture was thoroughly stirred. Immediately thereafter, the chemical luminescence due to luciferase was measured using TopCount NTX (Packard).
- the agonist activity (activity rate (%)) of the test compound to PPAR ā was calculated according to the following formula, as a relative activity when the agonist activity on addition of pioglitazone (10 ā mol/L) was 100%.
- activity rate % luminescence intensity with addition of test compound - luminescence intensity without addition of test compound luminescence intensity with addition of pioglitazone 10 ā mol / L - luminescence intensity without addition of test compound ā 100
- compound (I) or a pharmaceutically acceptable salt thereof provided in the present invention are shown to be useful as agents for treating and/or preventing diseases related to PPAR ā , such as type 2 diabetes, impaired glucose tolerance, insulin resistance syndrome, hypertension, hyperlipidemia, metabolic syndrome, visceral obesity, obesity, hypertriglyceridemia, inflammatory skin diseases (e.g., psoriasis, atopic dermatitis, seborrheic dermatitis, solar dermatitis etc.), inflammatory diseases (e.g., rheumatoid arthritis, ulcerative colitis, Crohn's disease, endometritis etc.), inflammatory neuropsychiatric diseases (e.g., multiple sclerosis etc.), neurodegenerative neuropsychiatric diseases (e.g., Alzheimer's disease, Parkinson's disease etc.), cardiovascular diseases such as arteriosclerosis, cardiac disease, cerebral apoplexy, renal diseases, or the like.
- diseases related to PPAR ā such as type 2 diabetes, impaired glucose tolerance,
- Human liver microsome (pool of 50 donors) was purchased from XenoTech. A reaction mixture containing phosphate buffer (100 mmol/L, pH 7.4), ethylenediamine tetraacetic acid (0.1 mmol/L), magnesium chloride (6 mmol/L), human liver microsome (0.2 mg/mL protein) and test compound (1 ā mol/L) was prepared. The reaction mixture was preincubated at 37Ā°C for 5 min, ā -NADPH (1 mmol/L) was added and the mixture was incubated at 37Ā°C for 30 min. The protein was removed with acetonitrile from the sample after the reaction and the sample was measured by LC-MS/MS. The ratio of the organic solvent in the reaction mixture was set to about 0.5%, and the reaction was performed in 2 samples.
- the elimination rate constant (k e ) was calculated from the linear regression of the logarithm plot of the residual ratio of the test compound and at 30 min after the reaction, and the liver inherent clearance (CL int ) was calculated by the following formula.
- hCL int L / h / kg k e a ā b ā c ā 1 1000
- compound (I) and a pharmaceutically acceptable salt thereof provided in the present invention have high metabolic stability in human. That is, it was revealed that compound (I) or a pharmaceutically acceptable salt thereof have preferable properties as a pharmaceutical product to be used for the treatment and/or prophylaxis of diseases related to PPAR ā , such as type 2 diabetes, impaired glucose tolerance, insulin resistance syndrome, hypertension, hyperlipidemia, metabolic syndrome, visceral obesity, obesity, hypertriglyceridemia, inflammatory skin diseases (e.g., psoriasis, atopic dermatitis, seborrheic dermatitis, solar dermatitis etc.), inflammatory diseases (e.g., rheumatoid arthritis, ulcerative colitis, Crohn's disease, endometritis etc.), inflammatory neuropsychiatric diseases (e.g., multiple sclerosis etc.), neurodegenerative neuropsychiatric diseases (e.g., Alzheimer's disease, Parkinson's
- diseases related to PPAR ā such as type
- compound (I) or pharmaceutically acceptable salts thereof can be administered alone as they are, generally, they are desirably provided as various pharmaceutical preparations. In addition, such pharmaceutical preparations are used for animals and humans.
- the pharmaceutical preparation relating to the present invention can contain, as an active ingredient, compound (I) or a pharmaceutically acceptable salt thereof alone or as a mixture with an active ingredient for any other treatment.
- the pharmaceutical preparation can be produced by mixing the active ingredient with one or more kinds of pharmaceutically acceptable carriers (e.g., diluent, solvent, excipient and the like) according to any method well known in the technical field of pharmaceutics.
- pharmaceutically acceptable carriers e.g., diluent, solvent, excipient and the like
- a route most effective for the treatment is desirably employed, which may be an oral or parenteral route such as intravenous route and the like.
- the dosage form may be, for example, tablet, injection and the like.
- a form suitable for oral administration such as tablet and the like, can be produced by using an excipient such as lactose and the like, a disintegrant such as starch and the like, a lubricant such as magnesium stearate and the like, a binder such as hydroxypropylcellulose and the like.
- an excipient such as lactose and the like, a disintegrant such as starch and the like, a lubricant such as magnesium stearate and the like, a binder such as hydroxypropylcellulose and the like.
- a form suitable for parenteral administration, such as injection and the like, can be produced by using a diluent such as a salt solution, a glucose solution, a mixture of salt solution and a glucose solution, or the like, or a solvent, or the like.
- a diluent such as a salt solution, a glucose solution, a mixture of salt solution and a glucose solution, or the like, or a solvent, or the like.
- the dose and administration frequency of compound (I) or a pharmaceutically acceptable salt thereof varies depending on the mode of administration, age and body weight of patients, nature and severity of the symptom to be treated or the like, it is generally within the range of 0.01 to 1000 mg, preferably 0.05 to 100 mg, for oral administration to an adult, which is administered at once or in several portions a day.
- parenteral administration such as intravenous administration or the like
- 0.001 to 1000 mg, preferably 0.01 to 100 mg is administered to an adult at once or in several portions a day.
- these doses and administration frequencies vary depending on the aforementioned various conditions.
- the proton nuclear magnetic resonance spectrum ( 1 H NMR) used in the Examples and Reference Examples were measured at 270 MHz, 300 MHz or 400 MHz, and exchanging protons may not be clearly observed depending on the compound and measurement conditions.
- the indication of the multiplicity of the signals is conventional, where br means an apparently broad signal.
- a tablet having the following formulation is prepared by a conventional method.
- Compound 1a 40 g
- lactose (286.8 g) and potato starch (60 g) are mixed, and a 10% aqueous solution (120 g) of hydroxypropylcellulose is added.
- the obtained mixture is kneaded, granulated, dried, and sieved by conventional methods to give granules for tableting.
- magnesium stearate 1.2 g
- the mixture is tableted by a tableting machine with a punch (diameter 8 mm) (manufactured by Kikusui, RT-15) to give tablets (containing active ingredient 20 mg per tablet).
- Formulation compound 1a 20 mg lactose 143.4 mg potato starch 30 mg hydroxypropylcellulose 6 mg magnesium stearate 0.6 mg 200 mg
- An injection having the following formulation is prepared by a conventional method.
- Compound 1a (1 g) is added to distilled water for injection and the mixture is mixed. Further, hydrochloric acid and aqueous sodium hydroxide solution are added to adjust the pH to 7, and distilled water for injection is added to make the total amount 1000 mL.
- the obtained mixture is aseptically filled in a glass vial by 2 mL to give an injection (containing active ingredient 2 mg per vial).
- the obtained residue was dissolved in phosphorus oxychloride (2.5 mL), diisopropylethylamine (0.42 mL) was added, and the mixture was stirred with heating at 50Ā°C for 3 hr.
- the mixture was diluted with ethyl acetate, added dropwise to saturated aqueous sodium hydrogen carbonate solution under ice-cooling, and the mixture was extracted 3 times with ethyl acetate.
- the combined organic layers were dried over anhydrous magnesium sulfate, and concentrated under reduced pressure.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Description
- The present invention relates to a dibenzoxepin derivative having a peroxisome proliferator-activated receptor (PPAR) Ī³ agonist activity, which is useful as an agent for treating and/or preventing, for example, type 2 diabetes, impaired glucose tolerance, insulin resistance syndrome, hypertension, hyperlipidemia, metabolic syndrome, visceral obesity, obesity, hypertriglyceridemia, inflammatory skin diseases, inflammatory diseases, inflammatory neuropsychiatric diseases, neurodegenerative neuropsychiatric diseases and the like.
- Peroxisome proliferator-activated receptor (PPAR) is a member of the nuclear receptor superfamily of ligand activated transcription factor. Three subtypes of PPAR, i.e., PPAR Ī±, PPAR Ī³, and PPAR Ī“, have been cloned from mouse and human. PPAR is known as an important nuclear hormone receptor for the metabolism of carbohydrate and lipid, immunoregulation, and inflammatory reaction. It has been reported that compounds that activate PPAR are useful for the treatment and prophylaxis of various clinical diseases such as metabolic syndrome, obesity, prediabetes, type 2 diabetes and the other insulin resistance syndrome, hypertension, atherosclerosis, lipemia, inflammatory skin diseases such as psoriasis, inflammatory bowel disease, and inflammatory neurodegenerative diseases such as multiple sclerosis, Alzheimer's disease etc., and the like. PPAR Ī³ specifically is said to play an important role in adipocyte differentiation. Hypertrophic adipocytes secrete large amounts of cytokines, namely TNF-Ī± and free fatty acid which induce insulin resistance. On the other hand, it has been reported that thiazolidinedione derivatives such as pioglitazone, rosiglitazone and the like improve insulin resistance by activating PPAR Ī³ to decrease hypertrophic adipocytes by apoptosis, and promoting differentiation of preadipocytes into small adipocytes having normal function (non-patent documents 1 and 2). Pioglitazone and rosiglitazone, which are PPAR Ī³ agonists, have already been clinically used as therapeutic drugs for diabetes (patent documents 1 and 2).
- PPAR Ī³ agonists are also useful as agents for treating and/or preventing diseases besides diabetes, such as metabolic syndrome, obesity, impaired glucose tolerance and other insulin resistance syndrome, which are prediabetic conditions, hypertension, atherosclerosis, hyperlipidemia, inflammatory diseases such as psoriasis and the like, inflammatory bowel disease, and the like.
- It has been reported that selective partial agonists for PPAR Ī³ do not accompany side effects such as body weight increase, adipocyte accumulation and the like, as compared to the existing full agonists (thiazolidinedione derivative or the like) (non-patent document 3).
-
-
-
-
- patent document 1:
JP-A-61-267580 - patent document 2:
JP-A-1-131169 - patent document 3:
WO2005/105736 - patent document 4:
JP-A-6-228065 - patent document 5:
WO2010/016549 -
- non-patent document 1: J. Biol. Chem., 1995, vol. 270, p. 12953
- non-patent document 2: J. Med. Chem., 1996, vol. 39, p. 665
- non-patent document 3: Molecular Endocrinology, 2003, vol. 17, No. 4, p. 662
- An object of the present invention is to provide a novel dibenzoxepin derivative or a pharmaceutically acceptable salt thereof having a peroxisome proliferator-activated receptor Ī³ (PPARĪ³) agonist activity , or the like. The dibenzoxepin derivative provided by the present invention or a pharmaceutically acceptable salt thereof is useful as a therapeutic and/or prophylactic agent for type 2 diabetes, impaired glucose tolerance, insulin resistance syndrome, hypertension, hyperlipidemia, metabolic syndrome, visceral obesity, obesity, hypertriglyceridemia, inflammatory skin diseases (e.g., psoriasis, atopic dermatitis, seborrheic dermatitis, solar dermatitis etc.), inflammatory diseases (e.g., rheumatoid arthritis, ulcerative colitis, Crohn's disease, endometritis etc.), inflammatory neuropsychiatric diseases (e.g., multiple sclerosis etc.), neurodegenerative neuropsychiatric diseases (e.g., Alzheimer's disease, Parkinson's disease etc.), cardiovascular diseases such as arteriosclerosis, cardiac disease, cerebral apoplexy, renal diseases, or the like.
- Another object of the present invention is to provide a PPAR Ī³ agonist containing a dibenzoxepin derivative as an active ingredient.
- The present invention relates to the following (1) - (30).
- (1) A tricyclic compound represented by the general formula (I)
- [wherein Y is a hydrogen atom, lower alkyl, optionally having substituent(s), lower alkoxy optionally having substituent(s), cycloalkyl optionally having substituent(s) or halogen,
- RA is a hydrogen atom, halogen, hydroxy, lower alkoxy, or lower alkyl,
- X is the formula (b1) - (b16)
- (wherein RB-2 is lower alkyl optionally having substituent(s) or cycloalkyl optionally having substituent (s), RB is a hydrogen atom, lower alkyl optionally having substituent(s) or cycloalkyl optionally having substituent(s), and the broken line shows absent or a single bond),
- A is the formula (a1) - (a29)
- (wherein R1, R2 and R3 are the same or different and each is a hydrogen atom, cyano, lower alkyl optionally having substituent(s), cycloalkyl optionally having substituent(s), halogen, lower alkoxy optionally having substituent(s), -NRFRG (wherein RF and RG are the same or different and each is a hydrogen atom, lower alkyl optionally having substituent(s), lower alkanoyl optionally having substituent(s), lower alkoxycarbonyl optionally having substituent(s) or aralkyl optionally having substituent(s), or RF and RG form, together with the adjacent nitrogen atom, a nitrogen-containing heterocyclic group optionally having substituent(s)), lower alkylsulfanyl optionally having substituent(s), lower alkenyl optionally having substituent(s), lower alkanoyl optionally having substituent(s), lower alkoxycarbonyl optionally having substituent(s), carbamoyl, lower alkylcarbamoyl optionally having substituent(s), di-lower alkylcarbamoyl optionally having substituent(s), aliphatic heterocyclylcarbonyl optionally having substituent(s), aryloxy optionally having substituent(s), aryl optionally having substituent(s), aromatic heterocyclic group optionally having substituent(s), aliphatic heterocyclic group optionally having substituent(s), aralkyl optionally having substituent(s) or aralkyloxy optionally having substituent(s), RC, RD and RE are the same or different and each is a hydrogen atom, halogen, nitro, cyano, formyl, oxo, hydroxy, lower alkoxy optionally having substituent(s), -NRFaRGa (wherein RFa and RGa are as defined for the aforementioned RF and RG, respectively), lower alkanoyloxy optionally having substituent(s), lower alkyl optionally having substituent(s), lower alkenyl optionally having substituent(s), lower alkynyl optionally having substituent(s), lower alkanoyl optionally having substituent(s), lower alkoxycarbonyl optionally having substituent(s), lower alkylsulfonyl optionally having substituent(s), lower alkylsulfanyl optionally having substituent(s), cycloalkyl optionally having substituent(s) or -CONRHRI (wherein RH and RI are the same or different and each is a hydrogen atom, lower alkyl optionally having substituent(s), lower alkanoyl optionally having substituent(s), lower alkoxycarbonyl optionally having substituent(s) or aralkyl optionally having substituent(s), or RH and RI form, together with the adjacent nitrogen atom, a nitrogen-containing heterocyclic group optionally having substituent(s)), RJ is a hydrogen atom, lower alkyl optionally having substituent(s), lower alkanoyl optionally having substituent(s), lower alkoxycarbonyl optionally having substituent(s), aryl optionally having substituent(s), lower alkylsulfonyl optionally having substituent(s), aralkyl optionally having substituent(s) or cycloalkyl optionally having substituent(s), and RK is a hydrogen atom, halogen, hydroxy, lower alkoxy, lower alkyl or -NRFbRGb (wherein REb and RGb are as defined for the aforementioned RF and RG, respectively)], or a pharmaceutically acceptable salt thereof.
- (2) The tricyclic compound according to (1), wherein Y is halogen, lower alkyl or cycloalkyl, or a pharmaceutically acceptable salt thereof.
- (3) The tricyclic compound according to (1), wherein Y is lower alkyl, or a pharmaceutically acceptable salt thereof.
- (4) The tricyclic compound according to (1), wherein Y is cycloalkyl, or a pharmaceutically acceptable salt thereof.
- (5) The tricyclic compound according to any of (1), (2), (3) or (4), wherein X is the formula (b1-1), (b3-1), (b4-1) or (b5-1)
- (6) The tricyclic compound according to any of (1), (2), (3) or (4), wherein X is the formula (b3-1)
- (7) The tricyclic compound according to any of (1), (2), (3), (4), (5) or (6), wherein A is the formula (a15), (a16), (a17), (a18), (a19), (a21), (a22), (a23), (a24), (a25), (a26), (a28) or (a29)
- (8) The tricyclic compound according to any of (1), (2), (3), (4), (5) or (6), wherein A is the formula (a18)
- (9) The tricyclic compound according to any of (1), (2), (3), (4), (5) or (6), wherein A is the formula (a24)
or a pharmaceutically acceptable salt thereof. - (10) The tricyclic compound according to any of (1), (2), (3), (4), (5) or (6), wherein A is the formula (a26)
or a pharmaceutically acceptable salt thereof. - (11) The tricyclic compound according to any of (1), (2), (3), (4), (5). (6), (7), (8), (9) or (10), wherein R1 is cyano; halogen; lower alkoxy; lower alkyl optionally substituted by 1 to 3 substituents of halogen, lower alkylamino, di-lower alkylamino, cycloalkyl or lower alkoxy; cycloalkyl optionally substituted by 1 to 3 substituents of halogen or lower alkyl; an aromatic heterocyclic group; an aliphatic heterocyclic group; or di-lower alkylamino, or a pharmaceutically acceptable salt thereof.
- (12) The tricyclic compound according to any of (1), (2), (3), (4), (5), (6), (7), (8), (9) or (10), wherein R1 is lower alkyl optionally substituted by 1 to 3 substituents of halogen or lower alkoxy, or a pharmaceutically acceptable salt thereof.
- (13) The tricyclic compound according to any of (1), (2), (3), (4), (5), (6), (7), (8), (9) or (10), wherein R1 is cycloalkyl, or a pharmaceutically acceptable salt thereof.
- (14) The tricyclic compound according to any of (1), (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12) or (13), wherein RC and RD are the same or different and each is a hydrogen atom; cyano; lower alkyl optionally substituted by 1 to 3 substituents of halogen, hydroxy or lower alkoxy; lower alkoxy optionally substituted by 1 to 3 halogens; lower alkylsulfanyl; lower alkylsulfonyl; cycloalkyl; lower alkynyl; -CONRH-1RI-1 (wherein RH-1 and RI-1 are the same or different and each is a hydrogen atom or lower alkyl, or RH-1 and RI-1 form, together with the adjacent nitrogen atom, a nitrogen-containing heterocyclic group); -NRFa-1RGa-1 (wherein RFa-1 and RGa-1 are the same or different and each is a hydrogen atom or lower alkyl); or halogen, or a pharmaceutically acceptable salt thereof.
- (15) The tricyclic compound according to any of (1), (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12) or (13), wherein RC and RD are the same or different and each is lower alkyl optionally substituted by 1 to 3 substituents of halogen, hydroxy or lower alkoxy; lower alkoxy optionally substituted by 1 to 3 halogens; or halogen, or a pharmaceutically acceptable salt thereof.
- (16) The tricyclic compound according to (14) or (15), wherein RC is a hydrogen atom, or a pharmaceutically acceptable salt thereof.
- (17) The tricyclic compound according to any of (1), (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13), (14), (15) or (16), wherein RA is a hydrogen atom or halogen, or a pharmaceutically acceptable salt thereof.
- (18) A pharmaceutical composition comprising the tricyclic compound or the pharmaceutically acceptable salt thereof according to any of (1) to (17), as an active ingredient.
- (19) A PPAR Ī³ agonist comprising the tricyclic compound or the pharmaceutically acceptable salt thereof according to any of (1) to (17) as an active ingredient.
- (20) A therapeutic and/or prophylactic agent for a disease associated with PPAR Ī³, which comprises the tricyclic compound or the pharmaceutically acceptable salt thereof according to any of (1) to (17), as an active ingredient.
- (21) The agent according to (20), wherein the disease associated with PPAR Ī³ is a disease selected from the group consisting of type 2 diabetes, impaired glucose tolerance, insulin resistance syndrome, hypertension, hyperlipidemia, metabolic syndrome, visceral obesity, obesity and hypertriglyceridemia.
- (22) A method of activating PPAR Ī³, comprising administering the tricyclic compound or the pharmaceutically acceptable salt thereof according to any of (1) to (17).
- (23) A therapeutic and/or prophylactic method of a disease associated with PPAR Ī³, comprising administering the tricyclic compound or the pharmaceutically acceptable salt thereof according to any of (1) to (17).
- (24) The method of (23), wherein the disease associated with PPAR Ī³ is a disease selected from the group consisting of type 2 diabetes, impaired glucose tolerance, insulin resistance syndrome, hypertension, hyperlipidemia, metabolic syndrome, visceral obesity, obesity and hypertriglyceridemia.
- (25) Use of the tricyclic compound or the pharmaceutically acceptable salt thereof according to any of (1) to (17), for the manufacture of a PPAR Ī³ agonist.
- (26) Use of the tricyclic compound or the pharmaceutically acceptable salt thereof according to any of (1) to (17), for the manufacture of a therapeutic and/or prophylactic agent for a disease associated with PPAR Ī³.
- (27) The use according to (26), wherein the disease associated with PPAR Ī³ is a disease selected from the group consisting of type 2 diabetes, impaired glucose tolerance, insulin resistance syndrome, hypertension, hyperlipidemia, metabolic syndrome, visceral obesity, obesity and hypertriglyceridemia.
- (28) The tricyclic compound according to any of (1) to (17) or a pharmaceutically acceptable salt thereof, for use in activating PPARĪ³.
- (29) The tricyclic compound according to any of (1) to (17) or a pharmaceutically acceptable salt thereof, for use in the treatment and/or prophylaxis of a disease associated with PPARĪ³.
- (30) The tricyclic compound according to (29) or a pharmaceutically acceptable salt thereof, wherein the disease associated with PPARĪ³ is a disease selected from the group consisting of type 2 diabetes, impaired glucose tolerance, insulin resistance syndrome, hypertension, hyperlipidemia, metabolic syndrome, visceral obesity, obesity, and hypertriglyceridemia.
- According to the present invention, a dibenzoxepin derivative having a PPAR Ī³ function regulatory activity, which is useful as a therapeutic and/or prophylactic agent for, for example, type 2 diabetes, impaired glucose tolerance, insulin resistance syndrome, hypertension, hyperlipidemia, metabolic syndrome, visceral obesity, obesity, hypertriglyceridemia, inflammatory skin diseases (e.g., psoriasis, atopic dermatitis, seborrheic dermatitis, solar dermatitis etc.), inflammatory diseases (e.g., rheumatoid arthritis, ulcerative colitis, Crohn's disease, endometritis etc.), inflammatory neuropsychiatric diseases (e.g., multiple sclerosis etc.), neurodegenerative neuropsychiatric diseases (e.g., Alzheimer's disease, Parkinson's disease etc.), cardiovascular diseases such as arteriosclerosis, cardiac disease, cerebral apoplexy, renal diseases, or the like, or a pharmaceutically acceptable salt thereof and the like are provided.
- The dibenzoxepin derivative or a pharmaceutically acceptable salt thereof disclosed in the present invention is superior in the metabolic stability in human, and has preferable properties as an active ingredient of the pharmaceutical product used for the above-mentioned diseases.
- In addition, the present invention provides a PPARĪ³ function modulator containing a dibenzoxepin derivative as an active ingredient.
- Hereinafter a compound represented by the general formula (I) is referred to as compound (I). The same applies to the compounds of other formula numbers.
- In the definition of each group of the general formula (I),
examples of lower alkyl, and the lower alkyl moiety of lower alkoxy, lower alkylsulfanyl, lower alkylsulfonyl, lower alkanoyloxy, lower alkanoyl, lower alkoxycarbonyl, lower alkylcarbamoyl, di-lower alkylcarbamoyl, lower alkylamino, and di-lower alkylamino include straight chain or branched alkyl having 1 - 10 carbon atoms. More specific examples thereof include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, hexyl, heptyl, octyl, nonyl, decyl and the like. Preferable examples thereof include straight chain or branched alkyl having 1 - 6 carbon atoms, which is more specifically methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, hexyl and the like. Two lower alkyl moieties of di-lower alkylcarbamoyl and di-lower alkylamino may be the same or different. - Examples of the lower alkenyl include straight chain or branched alkenyl having 2 - 10 carbon atoms, and more specific examples thereof include vinyl, allyl, 1-propenyl, butenyl, pentenyl, hexenyl, heptenyl, octenyl, nonenyl, decenyl and the like. Preferable examples thereof include straight chain or branched alkenyl having 2 - 6 carbon atoms, and more specific examples thereof include vinyl, allyl, 1-propenyl, butenyl, pentenyl, hexenyl and the like.
- Examples of the lower alkynyl include straight chain or branched alkynyl having 2 - 10 carbon atoms, and more specific examples thereof include ethynyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl, octynyl, nonynyl, decynyl and the like. Preferable examples thereof include straight chain or branched alkynyl having 2 - 6 carbon atoms, and more specific examples thereof include ethynyl, propynyl, butynyl, pentynyl, hexynyl and the like.
- Examples of cycloalkyl include cycloalkyl having 3 to 8 carbon atoms, and more specific examples thereof include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl and the like. Preferable examples thereof include cycloalkyl having 3 - 6 carbon atoms, and more specific examples thereof include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like.
- Examples of aralkyl and the aralkyl moiety of aralkyloxy include aralkyl having 7 to 16 carbon atoms, and more specific examples thereof include benzyl, phenethyl, phenylpropyl, phenylbutyl, phenylpentyl, phenylhexyl, phenylheptyl, phenyloctyl, phenylnonyl, phenyldecyl, naphthylmethyl, naphthylethyl, naphthylpropyl, naphthylbutyl, naphthylpentyl, naphthylhexyl, anthrylmethyl, anthrylethyl and the like.
- Examples of aryl and the aryl moiety of aryloxy include aryl having 6 - 14 carbon atoms, and more specific examples thereof include phenyl, naphthyl, azulenyl, anthryl and the like.
- Examples of the aliphatic heterocyclic group and the aliphatic heterocyclic group moiety of aliphatic heterocyclylcarbonyl include a 5-membered or 6-membered monocyclic aliphatic heterocyclic group comprising at least one atom selected from a nitrogen atom, an oxygen atom and a sulfur atom, a bicyclic or tricyclic condensed aliphatic heterocyclic group with 3- to 8-membered rings fused together containing at least one atom selected from a nitrogen atom, an oxygen atom and a sulfur atom, and the like, and more specific examples thereof include aziridinyl, azetidinyl, pyrrolidinyl, piperidino, piperidinyl, azepanyl, 1,2,5,6-tetrahydropyridyl, imidazolidinyl, pyrazolidinyl, piperazinyl, homopiperazinyl, pyrazolinyl, oxiranyl, tetrahydrofuranyl, tetrahydro-2H-pyranyl, 5,6-dihydro-2H-pyranyl, oxazolidinyl, morpholino, morpholinyl, thioxazolidinyl, thiomorpholinyl, 2H-oxazolyl, 2H-thioxazolyl, dihydroindolyl, dihydroisoindolyl, dihydrobenzofuranyl, benzimidazolidinyl, dihydrobenzooxazolyl, dihydrobenzothioxazolyl, benzodioxolinyl, tetrahydroquinolyl, tetrahydroisoquinolyl, dihydro-2H-chromanyl, dihydro-1H-chromanyl, dihydro-2H-thiochromanyl, dihydro-1H-thiochromanyl, tetrahydroquinoxalinyl, tetrahydroquinazolinyl, dihydrobenzodioxanyl and the like. Preferable examples thereof include a 5-membered or 6-membered monocyclic aliphatic heterocyclic group containing at least one atom selected from a nitrogen atom, an oxygen atom and a sulfur atom, and the like, and more specific examples thereof include pyrrolidinyl, piperidino, piperidinyl, 1,2,5,6-tetrahydropyridyl, imidazolidinyl, pyrazolidinyl, piperazinyl, pyrazolinyl, tetrahydrofuranyl, tetrahydro-2H-pyranyl, 5,6-dihydro-2H-pyranyl, oxazolidinyl, morpholino, morpholinyl, thioxazolidinyl, thiomorpholinyl, 2H-oxazolyl, 2H-thioxazolyl and the like.
- Examples of the aromatic heterocyclic group include a 5-membered or 6-membered monocyclic aromatic heterocyclic group containing at least one atom selected from a nitrogen atom, an oxygen atom and a sulfur atom, a bicyclic or tricyclic condensed aromatic heterocyclic group with 3- to 8-membered rings fused together, containing at least one atom selected from a nitrogen atom, an oxygen atom and a sulfur atom, and the like, and more specific examples thereof include furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, benzofuranyl, benzothiophenyl, benzoxazolyl, benzothiazolyl, isoindolyl, indolyl, indazolyl, benzimidazolyl, benzotriazolyl, oxazolopyrimidinyl, thiazolopyrimidinyl, pyrrolopyridinyl, pyrrolopyrimidinyl, imidazopyridinyl, purinyl, quinolinyl, isoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, naphthyridinyl and the like. Preferable examples thereof include a 5-membered or 6-membered monocyclic aromatic heterocyclic group having at least one atom selected from a nitrogen atom, an oxygen atom and a sulfur atom and the like, and more specific examples thereof include furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl and the like.
- Examples of the nitrogen-containing heterocyclic group formed together with the adjacent nitrogen atom thereto include a 5-membered or 6-membered monocyclic heterocyclic group with 3- to 8-membered rings fused together, containing at least one nitrogen atom (said monocyclic heterocyclic group may contain other nitrogen atom(s), oxygen atom(s) or sulfur atom(s)), a bicyclic or tricyclic fused heterocyclic group containing at least one nitrogen atom (said fused heterocyclic group may contain other nitrogen atom(s), oxygen atom(s) or sulfur atom(s)), and the like, and more specific examples thereof include aziridinyl, azetidinyl, pyrrolidinyl, piperidino, azepanyl, pyrrolyl, imidazolidinyl, imidazolyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, piperazinyl, homopiperazinyl, oxazolidinyl, 2H-oxazolyl, thioxazolidinyl, 2H-thioxazolyl, morpholino, thiomorpholinyl, dihydroindolyl, dihydroisoindolyl, indolyl, isoindolyl, tetrahydroquinolyl, tetrahydroisoquinolyl, dihydrobenzooxazolyl, dihydrobenzothioxazolyl, benzimidazolidinyl, benzimidazolyl, dihydroindazolyl, indazolyl, benzotriazolyl, pyrrolopyridinyl, pyrrolopyrimidinyl, imidazopyridinyl, purinyl and the like. Preferable examples thereof include a 5-membered or 6-membered monocyclic heterocyclic group containing at least one nitrogen atom (said monocyclic heterocyclic group may contain other nitrogen atom(s), oxygen atom(s) or sulfur atom(s)) and the like, and more specific examples thereof include pyrrolidinyl, piperidino, pyrrolyl, imidazolidinyl, imidazolyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, piperazinyl, oxazolidinyl, 2H-oxazolyl, thioxazolidinyl, 2H-thioxazolyl, morpholino, thiomorpholinyl and the like.
- Halogen means each atom of fluorine, chlorine, bromine or iodine.
- The substituents of the lower alkyl optionally having substituent(s), the lower alkylsulfonyl optionally having substituent(s), the lower alkenyl optionally having substituent(s), the lower alkynyl optionally having substituent(s), the lower alkoxy optionally having substituent(s), the lower alkylsulfanyl optionally having substituent(s), the lower alkanoyloxy optionally having substituent(s), the lower alkanoyl optionally having substituent(s), the lower alkoxycarbonyl optionally having substituent(s), the lower alkylcarbamoyl optionally having substituent(s), and the di-lower alkylcarbamoyl optionally having substituent(s) are the same or different and examples thereof include 1 to 3 substituents selected from the group consisting of halogen, hydroxy, sulfanyl, nitro, cyano, carboxy, carbamoyl, C3-8 cycloalkyl, an aliphatic heterocyclic group, an aromatic heterocyclic group, C1-10 alkoxy, C3-8 cycloalkoxy, C6-14 aryloxy, C7-16 aralkyloxy, C2-11 alkanoyloxy, C7-15 aroyloxy, C1-10 alkylsulfanyl, -NRXRY (wherein RX and RY are the same or different and each represents a hydrogen atom, C1-10 alkyl, C3-8 cycloalkyl, C6-14 aryl, an aromatic heterocyclic group, C7-16 aralkyl, C2-11 alkanoyl, C7-15 aroyl, C1-10 alkoxycarbonyl or C7-16 aralkyloxycarbonyl), C2-11 alkanoyl, C7-15 aroyl, C1-10 alkoxycarbonyl, C6-14 aryloxycarbonyl, C1-10 alkylcarbamoyl, di-C1-10 alkylcarbamoyl and the like.
- The substituents of the aryl optionally having substituent(s), the aryloxy optionally having substituent(s), the aralkyl optionally having substituent(s), the aralkyloxy optionally having substituent(s) and the aromatic heterocyclic group optionally having substituent(s) are the same or different and examples thereof include 1 to 3 substituents selected from the group consisting of halogen, hydroxy, sulfanyl, nitro, cyano, carbamoyl, C1-10 alkyl, trifluoromethyl, C3-8 cycloalkyl, C6-14 aryl, aliphatic heterocyclic group, aromatic heterocyclic group, C1-10 alkoxy, C3-8 cycloalkoxy, C6-14 aryloxy, C7-16 aralkyloxy, C2-11 alkanoyloxy, C7-15 aroyloxy, C1-10 alkylsulfanyl, -NRXRY (wherein RX and RY are the same or different and each as defined above), C2-11 alkanoyl, C7-15 aroyl, C1-10 alkoxycarbonyl, C6-14 aryloxycarbonyl, C1-10 alkylcarbamoyl, di-C1-10 alkylcarbamoyl and the like.
- The substituents of the cycloalkyl optionally having substituent(s), the aliphatic heterocyclic group optionally having substituent(s), the aliphatic heterocyclylcarbonyl optionally having substituent(s) and the nitrogen-containing heterocyclic group formed together with the adjacent nitrogen atom optionally having substituent(s) are the same or different and examples thereof include 1 to 3 substituents selected from the group consisting of oxo, halogen, hydroxy, sulfanyl, nitro, cyano, carbamoyl, C1-10 alkyl, trifluoromethyl, C3-8 cycloalkyl, C6-14 aryl, aliphatic heterocyclic group, aromatic heterocyclic group, C1-10 alkoxy, C3-8 cycloalkoxy, C6-14 aryloxy, C7-16 aralkyloxy, C2-11 alkanoyloxy, C7-15 aryloxy, C1-10 alkylsulfanyl, -NRXRY (wherein RX and RY are the same or different and each is as defined above), C2-11 alkanoyl, C7-15 aroyl, C1-10 alkoxycarbonyl, C6-14 aryloxycarbonyl, C1-10 alkylcarbamoyl, di-C1-10 alkylcarbamoyl and the like.
- Examples of the C1-10 alkyl and the C1-10 alkyl moiety of the C1-10 alkoxy, the C2-11 alkanoyloxy, the C1-10 alkylsulfanyl, the C2-11 alkanoyl, the C1-10 alkoxycarbonyl, the C1-10 alkylcarbamoyl and the di-C1-10 alkylcarbamoyl include the groups recited as examples of the aforementioned lower alkyl. Two C1-10 alkyl of the di-C1-10 alkylcarbamoyl may be the same or different.
- Examples of the C3-8 cycloalkyl and the cycloalkyl moiety of the C3-8 cycloalkoxy include the groups recited as examples of the aforementioned cycloalkyl.
- Examples of the C6-14 aryl and the aryl moiety of the C6-14 aryloxy, the C7-15 aroyl, the C7-15 aroyloxy and the C6-14 aryloxycarbonyl include the groups recited as examples of the aforementioned aryl.
- Examples of C7-16 aralkyl and the C7-16 aralkyl moiety of the C7-16 aralkyloxy and the C7-16 aralkyloxycarbonyl include the groups recited as examples of the aforementioned aralkyl.
- Examples of the aliphatic heterocyclic group, the aromatic heterocyclic group and the halogen include the groups recited as examples of the aforementioned aliphatic heterocyclic group, the aforementioned aromatic heterocyclic group and the aforementioned halogen, respectively.
- The pharmaceutically acceptable salt of compound (I) comprises, for example, pharmaceutically acceptable acid addition salts, metal salts, ammonium salts, organic amine addition salts, amino acid addition salts and the like. Examples of the pharmaceutically acceptable acid addition salt of compound (I) include inorganic acid salts such as hydrochloride, hydrobromide, nitrate, sulfate, phosphate and the like, organic acid salts such as acetate, oxalate, maleate, fumarate, citrate, benzoate, methanesulfonate etc., and the like. Examples of the pharmaceutically acceptable metal salts include alkali metal salts such as sodium salt, potassium salt and the like, alkaline earth metal salts such as magnesium salt, calcium salt and the like, aluminum salt, zinc salt and the like. Examples of the pharmaceutically acceptable ammonium salt include salts of ammonium, tetramethylammonium and the like. Examples of the pharmaceutically acceptable organic amine addition salt include addition salts of morpholine, piperidine and the like. Examples of the pharmaceutically acceptable amino acid addition salt include addition salts of lysine, glycine, phenylalanine, aspartic acid, glutamic acid and the like.
- The production methods of compound (I) are explained in the following.
- In the production methods shown below, when the defined groups change under the conditions of the production methods or are inappropriate for performing the production methods, the desired compound can be produced by performing the methods for the introduction and removal of the protecting groups conventionally performed in the synthetic organic chemistry (e.g., methods described in Protective Groups in Organic Synthesis, third edition, T.W. Greene, John Wiley & Sons Inc., 1999 etc.) or the like. If necessary, the order of the reaction steps such as substituent introduction or the like can also be changed.
-
- [wherein RA and Y axe each as defined above, E is a chlorine atom, a bromine atom, an iodine atom, trifluoromethanesulfonyloxy, methanesulfonyloxy, benzenesulfonyloxy, p-toluenesulfonyloxy or the like, G is a leaving group such as a chlorine atom, a bromine atom, an iodine atom, trifluoromethanesulfonyloxy, methanesulfonyloxy, benzenesulfonyloxy, p-toluenesulfonyloxy and the like, Raa and Rbb are each lower alkyl such as methyl, ethyl, propyl and the like, and
- A2 is (a1) - (a14), and (a16) - (a23)
- (wherein R1, R2, R3, RC, RD and RE are each as defined above)].
- Compound (III) can be obtained by reacting compound (IIa) with 1 equivalent - 5 equivalents of compound (IIb) in the presence of 1 equivalent - large excess of a base in a solvent at a temperature between -20Ā°C and the boiling point of the solvent to be used for 5 min - 120 hr.
- Examples of the base include sodium hydride, potassium hydride, butyllithium, lithium diisopropylamide (LDA), lithium bistrimethylsilylamide, sodium bistrimethylsilylamide, sodium methoxide, potassium ethoxide, potassium tert-butoxide, potassium carbonate, sodium hydroxide, 1,8-diazabicyclo[5.4.0]-7-undecene (DBU), triethylamine, diisopropylethylamine and the like. Examples of the solvent include dimethylformamide (DMF), dimethylacetamide (DMA), N-methylpyrrolidone (NMP), dimethyl sulfoxide (DMSO), tetrahydrofuran (THF), acetonitrile and the like, and these can be used alone or in a mixture.
- Here, compound (IIa) can be obtained by the method described in Journal of Medicinal Chemistry, 1996, vol. 39, p. 246,
EP2072507 or the like, and compound (IIb) is commercially available or can be obtained by a known method (e.g., J. Chem. Soc. Perkin Trans.1, 1992, p. 313, Synthesis, 1987, p. 411) or a method analogous thereto. - Compound (IV) can be produced by reacting compound (III) in a solvent, in the presence of carbon monoxide, 0.1 - 10 equivalents of a base and 0.001 - 0.5 equivalents of a palladium catalyst at a temperature between -20Ā°C and the boiling point of the solvent to be used for 5 min - 72 hr.
- Examples of the base include potassium carbonate, cesium carbonate, potassium phosphate, potassium hydroxide, sodium hydroxide, potassium tert-butoxide, triethylamine, diisopropylethylamine, N-methylmorpholine, pyridine, DBU and the like.
- Examples of the palladium catalyst include palladium acetate, tris(dibenzylideneacetone)dipalladium (Pd2(dba)3), tetrakis(triphenylphosphine)palladium, 1,1'-bis(diphenylphosphino)ferrocene dichloropalladium. dichloromethane 1:1 adduct and the like. Examples of the solvent include methanol, ethanol, propanol, butanol and the like. Furthermore, in addition to the above-mentioned solvent, chloroform, 1,2-dichloroethane, ethyl acetate, acetonitrile, THF, 1,2-dimethoxyethane (DME), 1,4-dioxane, DMF, DMA, NMP and the like can be used alone or in a mixture.
- Compound (V) can be obtained by reacting compound (IV) in the presence of 1 equivalent - large excess of a reducing agent in a solvent at a temperature between -20Ā°C and the boiling point of the solvent to be used for 5 min - 120 hr.
- Examples of the reducing agent include sodium borohydride, lithium borohydride, lithium aluminum hydride, diisobutylaluminum hydride and the like. Examples of the solvent include THF, diethyl ether, dioxane, dichloromethane, hexane, toluene and the like, and these can be used alone or in a mixture.
- Compound (VI) can be obtained by reacting compound (V) in the presence of 1 equivalent - large excess of a halogenating agent or sulfonylating agent in a solvent or without solvent at a temperature between -20Ā°C and the boiling point of the solvent to be used for 5 min - 72 hr. Examples of the halogenating agent include thionyl chloride; phosphorus tribromide; boron tribromide; a combination of triphenylphosphine, 2,6-lutidine and carbon tetrachloride; a combination of triphenylphosphine, 2,6-lutidine and carbon tetrabromide; a combination of methanesulfonyl chloride and lithium chloride; a combination of methanesulfonic anhydride and lithium chloride; a combination of methanesulfonyl chloride and lithium bromide; a combination of methanesulfonic anhydride and lithium bromide, and the like. Examples of the sulfonylating agent include trifluoromethanesulfonyl chloride, methanesulfonyl chloride, methanesulfonic anhydride, benzenesulfonyl chloride, p-toluenesulfonyl chloride and the like. Examples of the solvent include THF, DMF, DMA, dichloromethane, dichloroethane, acetonitrile and the like, and these can be used alone or in a mixture.
- Compound (VII) can be obtained by reacting compound (VI) with 1 equivalent - 5 equivalents of compound (VIa) in the presence of, if necessary, 1 equivalent - large excess of a base in a solvent at a temperature between -20Ā°C and the boiling point of the solvent to be used for 5 min - 120 hr.
- Examples of the base include sodium carbonate, potassium carbonate, lithium carbonate, cesium carbonate, sodium hydrogen carbonate, potassium hydrogen carbonate, lithium hydrogen carbonate, sodium hydroxide, potassium hydroxide, lithium hydroxide, sodium methoxide, potassium ethoxide, potassium tert-butoxide, sodium hydride, potassium hydride, LDA, lithium bistrimethylsilylamide, sodium bistrimethylsilylamide, triethylamine, diisopropylethylamine, tributylamine, dicyclohexylmethylamine and the like. Examples of the solvent include DMF, DMA, NMP, DMSO, THF, acetonitrile, isopropyl alcohol and the like, and these can be used alone or in a mixture.
- Compound (VIa) is commercially available or can be obtained by a known method (e.g.,
US Patent No. 5332744 ,EP-B-400835 JP-A-5-783228 - Compound (VII) can be produced by reacting compound (V) with preferably 1 - 10 equivalents of compound (VIa) in a solvent in the presence of preferably 1 - 10 equivalents of a phosphine compound and preferably 1 - 10 equivalents of an azo compound at a temperature between -78Ā°C and the boiling point of the solvent to be used for 5 min - 72 hr.
- Examples of the phosphine compound include triphenylphosphine, tributylphosphine and the like. Examples of the azo compound include diethyl azodicarboxylate (DEAD), di-tert-butyl azadicarboxylate (DBAD), diisopropyl azadicarboxylate, N,N, N', N'-tetramethylazadicarboxamide, 1,1'-(azadicarbonyl)dipiperazine, N,N,N',N'-tetraisopropylazadicarboxamide and the like. Preferable examples of the combination of the phosphine compound and the azo compound to be used include a combination of triphenylphosphine and DEAD or DBAD. Examples of the solvent include dichloromethane, chloroform, 1,2-dichloroethane, toluene, ethyl acetate, acetonitrile, diethyl ether, THF, DME, 1,4-dioxane, DMF, DMA, NMP and the like, and these can be used alone or in a mixture.
-
- [wherein RA and Y are each as defined above, Z is a chlorine atom, a bromine atom, or an iodine atom, and
- A3 is (a24) - (a29)
- Compound (VIII) can be produced by treating compound (V) in a solvent, with preferably 1 - 10 equivalents of an oxidant at a temperature between -20Ā°C and the boiling point of the solvent to be used for 5 min - 72 hr.
- Examples of the oxidant include manganese dioxide, chromic acid, pyridinium chlorochromate (PCC), pyridinium dichlorochromate (PDC), potassium permanganate, sulfur trioxide-pyridine, oxone (registered trade mark), DMSO/oxalyl chloride, Dess-Martin periodinane (DMPI) and the like. Examples of the solvent include dichloromethane, chloroform, 1,2-dichloroethane, toluene, ethyl acetate, acetonitrile, diethyl ether, THF, DME, dioxane, DMF, DMA, NMP, DMSO, pyridine, hydrochloric acid, acetic acid, propionic acid, acetic anhydride, sulfuric acid, water and the like, and these can be used alone or in a mixture.
- Compound (IX) can be produced by reacting compounds (VIII) and (VIIa) in the presence of preferably 1 - 10 equivalents of an organic metal reagent in a solvent at a temperature between -78Ā°C and the boiling point of the solvent to be used for 5 min - 72 hr.
- Examples of the organic metal reagent include methyllithium, butyllithium, sec-butyllithium, phenyllithium, methylmagnesium chloride, ethylmagnesium chloride, isopropylmagnesium chloride, phenylmagnesium chloride, isopropylmagnesium chloride lithium chloride complex and the like. Examples of the solvent include toluene, diethyl ether, THF, DME, 1,4-dioxane, hexane and the like, and these can be used alone or in a mixture.
- Compound (X) can be produced by reacting compound (IX) with 1 equivalent - a large excess of alkylchlorosilane and 1 equivalent - a large excess of sodium iodide in a solvent at a temperature between -20Ā°C and the boiling point of the solvent to be used for 5 min - 72 hr, or by reacting compound (IX) in 1 equivalent - a large excess of alkylsilane and 1 equivalent - a large excess of trifluoroacetic acid at a temperature between - 20Ā°C and the boiling point of the solvent to be used for 5 min - 72 hr.
- Examples of the alkylchlorosilane include trimethylchlorosilane, triethylchlorosilane, dimethyldichlorosilane and the like. Examples of the solvent include dichloromethane, hexane, acetonitrile and the like, and these can be used alone or in a mixture. Examples of the alkylsilane include trimethylsilane, triethylsilane, tripropylsilane, and triisopropylsilane.
- As another method besides the above-mentioned steps 7 and 8, compound (X) can be produced by reacting compound (VIII) with preferably 1 - 10 equivalents of A3-H (wherein A3 is as defined above), in a solvent, in the presence of preferably 1 - 10 equivalents of a reducing agent and preferably 1 - 10 equivalents of BrĆønsted acid, at a temperature between -78Ā°C and the boiling point of the solvent to be used for 5 min - 72 hr. Examples of the reducing agent include sodium borohydride, lithium borohydride, triethylsilane and the like. Examples of the BrĆønsted acid include hydrochloric acid, sulfuric acid, trifluoroacetic acid, acetic acid, methanesulfonic acid and the like. Examples of the solvent include toluene, THF, DME, 1,4-dioxane, DMF and the like, and these can be used alone or in a mixture.
- Here, compound (VIIa) is commercially available or can be obtained by a known method (e.g., Bioorganic and Chemistry Letter, 2008, vol. 18, p688) or a method analogous thereto.
-
- [wherein E, RA and Y are each as defined above,
- J is (d1) - (d5)
- (wherein RC, RD are each as defined above), and
- A4 is (a24-1) - (a28-1)
- (wherein R4 is a hydrogen atom, lower alkyl or cycloalkyl, and
- RC and RD are each as defined above)].
- Compound (XI) can be produced by reacting compound (III), for example, in a solvent such as toluene, dioxane, THF, DMF, DMA and the like, in the presence of 0.001 - 0.5 equivalents of copper (I) iodide, 1 - 10 equivalents of trimethylsilylacetylene, preferably 0.1 - 10 equivalents of a base and preferably 0.001 - 0.5 equivalent of a palladium catalyst at a temperature between -20Ā°C and the boiling point of the solvent to be used for 5 min - 72 hr, and successively reacting, for example, in a solvent such as methanol, ethanol, isopropyl alcohol, THF, DMF, DMA and the like, for example, in the presence of 1 - a large excess of a base or tetrabutylammonium fluoride at a temperature between -20Ā°C and the boiling point of the solvent to be used for 5 min - 72 hr. The above-mentioned steps can also be performed sequentially by adding a base to the reaction mixture continuously without isolating the resultant product.
- Examples of the base include potassium carbonate, potassium phosphate, potassium hydroxide, sodium hydroxide, potassium tert-butoxide, triethylamine, diisopropylethylamine, pyridine, DBU and the like. Examples of the palladium catalyst include palladium acetate, tris(dibenzylideneacetone)dipalladium, tetrakis(triphenylphosphine)palladium, 1,1'-bis(diphenylphosphino)ferrocene dichloropalladiumĀ· dichloromethane 1:1 adduct, bis(triphenylphosphine)dichloropalladium and the like.
- Compound (XII) can be produced by reacting compound (XI) in the presence of compound (XIa), and R4-CHO (wherein R4 is as defined above), preferably in the presence of 0.001 - 0.5 equivalents of copper trifluoromethanesulfonate and preferably 0.001 - 0.5 equivalents of copper chloride in a solvent at a temperature between -20Ā°C and the boiling point of the solvent to be used for 5 min - 72 hr.
- Examples of R4-CHO (wherein R4 is as defined above) include formaldehyde, propanecarboxyaldehyde, cyclopropanecarboxyaldehyde, isopropylcarboxyaldehyde, cyclobutanecarboxyaldehyde, cyclopentanecarboxyaldehyde and the like. Examples of the solvent include THF, 1,4-dioxane, dichloroethane, chloroform, toluene, DMF, DMA and the like, and these can be used alone or in a mixture.
- Compounds represented by the following formulas (XIV), (XVII), which are synthetic intermediates for compound (I), can be produced by the following steps.
- Compound (XIII) can be produced by reacting compound (VI) with compound (VIb) in a solvent in the presence of preferably 1 - a large excess of a base, at a temperature between -20Ā°C and the boiling point of the solvent to be used for 5 min - 72 hr.
- Examples of the base include sodium hydride, potassium hydride, sodium methoxide, potassium tert-butoxide, potassium carbonate, sodium carbonate, sodium hydroxide, LDA and the like. Examples of the solvent include DMF, DMA, THF, DME, 1,4-dioxane, NMP and the like, and these can be used alone or in a mixture. Here, compound (VIb) is commercially available or can be obtained by a known method (e.g., Synthesis, 2008, vol. 19, p3065 and the like) or a method analogous thereto.
- Compound (XIV) can be produced by reacting compound (XIII) in a solvent in the presence of preferably 1 - a large excess of a reducing agent at a temperature between -20Ā°C and the boiling point of the solvent to be used for 5 min - 72 hr. Examples of the reducing agent include iron, stannic chloride, zinc and the like. Examples of the solvent include acetic acid, ethanol, DME, 1,4-dioxane, DMF, NMP and the like, and these can be used alone or in a mixture.
- Compound (XV) can be produced by reacting compound (VI) with compound (VIc) in a solvent in the presence of preferably 1 - a large excess of a base, at a temperature between -20Ā°C and the boiling point of the solvent to be used for 5 min - 72 hr. Examples of the base include sodium hydride, potassium hydride, sodium methoxide, potassium tert-butoxide, potassium carbonate, sodium carbonate, sodium hydroxide, LDA and the like. Examples of the solvent include DMF, DMA, THF, DME, 1,4-dioxane, NMP and the like, and these can be used alone or in a mixture.
- Compound (XVI) can be produced by reacting compound (XV) in a solvent in the presence of an inorganic acid salt of R2-C(=NH)NH2 (wherein R2 is as defined above) and 1 - a large excess of a base, at a temperature between -20Ā°C and the boiling point of the solvent to be used for 5 min - 72 hr.
- Examples of the base include sodium hydride, sodium methoxide, sodium ethoxide, potassium carbonate, sodium carbonate, sodium hydroxide, LDA and the like. Examples of the solvent include DMF, ethanol, methanol, THF, DME, 1,4-dioxane and the like, and these can be used alone or in a mixture
- Compound (XVII) can be produced by reacting compound (XVI) in the presence of phosphorus oxychloride, by adding a solvent such as acetonitrile, chloroform, 1,2-dichloroethane and the like if necessary, at a temperature between room temperature and the boiling point of the solvent to be used for 5 min - 72 hr, and successively reacting, for example, in a solvent such as methanol, ethanol, isopropyl alcohol, THF, DMF, DMA and the like in the presence of, for example, 1 equivalent - a large excess of RkH (wherein Rk is as defined above) or an anionic nucleophilic species thereof, at a temperature between room temperature and the boiling point of the solvent to be used for 5 min - 72 hr. Examples of RkH (wherein Rk is as defined above) or an anionic nucleophilic species thereof include sodium methoxide, sodium ethoxide, dimethylamine, azetidine, morpholine, piperidine, piperazine and the like.
-
- Compound (Ia) can be obtained by reacting compound (XVIII) with 1 equivalent - 10 equivalents of sodium azide in a solvent in the presence of 1 equivalent - large excess of a weak acid for 5 min - 120 hr at a temperature between -20Ā°C and the boiling point of the solvent to be used.
- Examples of the weak acid include ammonium chloride, triethylamine hydrochloride and the like. Examples of the solvent include DMF, DMA, NMP, DMSO and the like, and these can be used alone or in a mixture.
- Compound (XVIII) can be synthesized by a known method (e.g.,
WO2010/016549 and the like) or a method analogous thereto. - In addition, as another method, compound (Ia) can also be obtained by reacting compound (XVIII) with 1 equivalent - 10 equivalents of sodium azide in a solvent in the presence of 0.01 - 10 equivalents of an additive at a temperature between-10Ā°C and the boiling point of the solvent to be used for 1 hr-120 hr.
- Examples of the additive include tributyltin chloride, trimethyltin chloride, dibutyltin oxide and the like. Examples of the solvent include toluene, xylene and the like, and these can be used alone or in a mixture.
- Compound (XIX) can be obtained by reacting compound (XVIII) with 1 equivalent - large excess of hydroxylamine in a solvent at a temperature between -20Ā°C and the boiling point of the solvent to be used for 5 min - 120 hr.
- As hydroxylamine, for example, an inorganic acid salt such as hydroxylamine hydrochloride or the like can be used. In this case, approximately an equivalent of a base such as sodium methoxide, sodium hydrogen carbonate or the like is preferably copresent. Examples of the solvent include methanol, ethanol, DMF, DMA, DMSO and the like, and these can be used alone or in a mixture.
- Compound (Ib) can be obtained by reacting compound (XIX) with 1 equivalent - a large excess of chlorocarbonate ester in the presence of 1 equivalent - a large excess of a base, for example, in a solvent such as THF, DMF, DMA, toluene, xylene, dichloromethane and the like, at a temperature between -20Ā°C and the boiling point of the solvent to be used for 5 min - 72 hr, and successively reacting, for example, in a solvent such as THF, DMF, DMA, toluene, xylene and the like or a mixed solvent such as toluene-THF and the like, in the presence of, if necessary, a catalytic amount - 10 equivalents of a base, at a temperature between -20Ā°C and the boiling point of the solvent to be used for 5 min - 72 hr. The above-mentioned steps can also be performed sequentially by adding chlorocarbonate ester and a base to the reaction mixture continuously without isolating the resultant product.
- Examples of the base used for the reaction with chlorocarbonate ester include potassium tert-butoxide, potassium carbonate, DBU, triethylamine and the like. Examples of the chlorocarbonate ester include methyl chlorocarbonate, ethyl chlorocarbonate, propyl chlorocarbonate, phenyl chlorocarbonate and the like. Examples of the base used for intermediate carbonate ester include triethylamine, pyridine, 4-dimethylaminopyridine, diazabicycloundecene and the like.
- Compound (Ib) can be obtained by reacting compound (XIX) with 1 equivalent - a large excess of N,N'-carbonyldiimidazole (CDI) in the presence of 1 equivalent - a large excess of a base, at a temperature between -20Ā°C and the boiling point of the solvent to be used for 5 min - 72 hr.
- Examples of the base include potassium tert-butoxide, potassium carbonate, DBU, triethylamine and the like. Examples of the solvent include THF, DMF, DMA, 1,4-dioxane and the like, and these can be used alone or in a mixture.
- Compound (Ic) can be obtained by reacting compound (XIX) with 1 equivalent - a large excess of (RB-4CO)2O (wherein RB-4 is lower alkyl optionally having substituent(s) or cycloalkyl optionally having substituent(s)), in the presence of 1 equivalent - a large excess of a base if necessary, in a solvent at a temperature between -20Ā°C and the boiling point of the solvent to be used for 5 min - 72 hr. Examples of (RB4CO)2O (wherein RB-4 is as defined above) include acetic anhydride, propionic anhydride, trifluoroacetic anhydride and the like. Examples of the base include triethylamine, pyridine, 4-dimethylaminopyridine, diazabicycloundecene and the like. Examples of the solvent include THF, 1,4-dioxane, dichloromethane, chloroform, acetonitrile, acetone, DMF, DMA, DMSO and the like, and these can be used alone or in a mixture. As another method, it can be obtained by reacting compound (XIX) with 1 equivalent - a large excess of RBC(ORL)3 (wherein RB is as defined above, and RL is lower alkyl), in a solvent or without solvent, at a temperature between -20Ā°C and the boiling point of the solvent to be used for 5 min - 72 hr. Examples of the above-mentioned RBC(ORL)3 (wherein RB and RL are each as defined above) include trimethyl orthoformate, triethyl orthoformate, trimethyl orthoacetate, triethyl orthoacetate and the like. Examples of the solvent include THF, 1,4-dioxane, dichloromethane, chloroform, acetonitrile, acetone, DMF, DMA, DMSO and the like, and these can be used alone or in a mixture.
- Compound (Id) can be obtained by reacting compound (XIX) with 1 equivalent - a large excess of N,N'-thiocarbonyldiimidazole in the presence of 1 equivalent - a large excess of a Lewis acid in a solvent at a temperature between -20Ā°C and the boiling point of the solvent to be used for 5 min - 72 hr. Examples of the Lewis acid include boron trifluoride diethyl ether complex, stannous chloride, zinc chloride, silica gel and the like. Examples of the solvent include THF, 1,4-dioxane, dichloromethane, chloroform, methanol, ethanol and the like, and these can be used alone or in a mixture.
- Compound (Ie) can be obtained by reacting compound (XIX) with 1 equivalent - a large excess of N,N'-thiocarbonyldiimidazole, in the presence of 1 equivalent - a large excess of a base in a solvent at a temperature between - 20Ā°C and the boiling point of the solvent to be used for 5 min - 72 hr.
- Examples of the base include triethylamine, pyridine, 4 -dimethylaminopyridine, diazabicycloundecene and the like. Examples of the solvent include THF, 1,4-dioxane, dichloromethane, chloroform, acetonitrile, acetone and the like, and these can be used alone or in a mixture.
- Using a method similar to that in steps 16 - 21, the nitrile group of compound (VII), (X), (XII), (XIV), (XVII) can also be converted in the same manner as in the cyano of group of compound (XVIII).
-
- Compound (XX) can be obtained, for example, by hydrolyzing the cyano group by reacting compound (XVIII) in the presence of a base such as lithium hydroxide, sodium hydroxide, potassium hydroxide, barium hydroxide and the like, in a suitable water-containing solvent such as a water-containing solvent of methanol, ethanol, ethylene glycol, dioxane, glyme and the like, at a temperature between room temperature and the boiling point of the solvent to be used for 1 hr - 120 hr, or in an aqueous solution of sulfuric acid, hydrochloric acid, acetic acid or the like or a mixture of acids thereof at a temperature between room temperature and the boiling point of the solvent to be used for 1 hr - 120 hr. Alternatively, it can also be obtained by once obtaining the corresponding amide compound as an intermediate and then performing the above-mentioned reaction.
- Compound (XXI) can be obtained by reacting compound (XX) in the presence of 1 equivalent - 50 equivalents of a condensing agent, 1 equivalent - large excess of hydrazine and, if necessary, a base in a solvent at a temperature between - 20Ā°C and the boiling point of the solvent to be used for 5 min - 72 hr. Examples of the condensing agent include N,N'-carbonyldiimidazole, dicyclohexylcarbodiimide, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride and the like. Examples of the base include triethylamine, pyridine, 4-dimethylaminopyridine, diazabicycloundecene and the like. Examples of the solvent include THF, 1,4-dioxane, dichloromethane, chloroform, acetonitrile, acetone and the like, and these can be used alone or in a mixture.
- Compound (If) can be obtained by reacting compound (XXI) with 1 equivalent - 50 equivalents of N,N'-carbonyldiimidazole in the presence of, if necessary, a base in a solvent at a temperature between -20Ā°C and the boiling point of the solvent to be used for 5 min - 72 hr. Examples of the base include triethylamine, pyridine, 4-dimethylaminopyridine, diazabicycloundecene and the like. Examples of the solvent include THF, 1,4-dioxane, dichloromethane, chloroform, acetonitrile, acetone and the like, and these can be used alone or in a mixture.
- Compound (Ih) can be obtained by reacting compound (XXI) with 1 equivalent - a large excess of (RB-4CO)2O (wherein RB-4 is as defined above) in the presence of 1 equivalent - a large excess of a base if necessary in a solvent at a temperature between -20Ā°C and the boiling point of the solvent to be used for 5 min - 72 hr. Examples of the above-mentioned (RB-4CO)2O (wherein RB-4 is as defined above) include acetic anhydride, propionic anhydride, trifluoroacetic anhydride and the like. Examples of the base include triethylamine, pyridine, 4-dimethylaminopyridine, DBU and the like. Examples of the solvent include THF, 1,4-dioxane, dichloromethane, chloroform, acetonitrile, acetone, DMF, DMA, DMSO and the like, and these can be used alone or in a mixture. As another method, it can be obtained by reacting compound (XXI) with 1 equivalent - a large excess of RBC(ORL)3 (wherein RB and RL are each as defined above), in a solvent or without solvent, at a temperature between -20Ā°C and the boiling point of the solvent to be used for 5 min - 72 hr. Examples of the aforementioned RBC(ORL)3 (wherein RB and RL are each as defined above) include trimethyl orthoformate, triethyl orthoformate, trimethyl orthoacetate, triethyl orthoacetate and the like. Examples of the solvent include THF, 1,4-dioxane, dichloromethane, chloroform, acetonitrile, acetone, DMF, DMA, DMSO and the like, and these can be used alone or in a mixture.
- Compound (Ig) can be obtained by treating compound (XX) with 1 - 50 equivalents of a condensing agent, and reacting the compound with 1 - 50 equivalents of compound (XXa) in the presence of 1 - 30 equivalents of a base, in a solvent at a temperature between -20Ā°C and the boiling point of the solvent to be used for 5 min - 72 hr.
- Examples of the condensing agent include CDI, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDCI) or hydrochloride thereof, dicyclohexylcarbodiimide (DCC) and the like. Examples of the solvent include dichloromethane, acetonitrile, toluene, ethyl acetate, THF, 1,4-dioxane, DMF, NMP and the like, and these can be used alone or in a mixture. Examples of the base include diazabicycloundecene, triethylamine, 4-dimethylaminopyridine, N,N-dimethylaniline, pyridine, N-methylmorpholine and the like. Compound (XXa) can be obtained as a commercially available product.
- Using a method similar to that in steps 22 - 26, the nitrile group of compound (VII), (X), (XII), (XIV), (XVII) can also be converted in the same manner as in the cyano of group of compound (XVIII).
- Of compounds (I), a compound wherein X is the following formula (b1) - (b6)
- As another method, it can be obtained by reacting (Ia), (Ib), (Ie), (Id) or (If) with 1 equivalent - 5 equivalents of RB-1OH (wherein RB-1 is as defined above) in the presence of 1 equivalent - large excess of a condensing agent and, if necessary, 1 equivalent - large excess of a phosphine compound in a solvent at a temperature between -20Ā°C and the boiling point of the solvent to be used for 5 min - 72 hr.
- Examples of the condensing agent include diethyl azodicarboxylate, diisopropyl azodicarboxylate, di(tert-butyl) azodicarboxylate, (cyanomethylene)trimethylphosphorane, (cyanomethylene)tributylphosphorane and the like. Examples of the phosphine compound include triphenylphosphine, tributylphosphine, polymer supported triphenylphosphine and the like. Examples of the solvent include THF, DMF, dichloromethane, acetonitrile and the like, and these can be used alone or in a mixture.
- The functional groups contained in X, Y, A, RA and the like in compound (I) can also be converted by a known method (e.g., the method described in Comprehensive Organic Transformations 2nd edition, R. C. Larock, Vch Verlagsgesellschaft Mbh, 1999 and the like) or a method analogous thereto.
- The intermediates and the desired compounds in the above-mentioned production methods can be isolated and purified by applying separation and purification methods usually used in the synthetic organic chemistry such as filtration, extraction, washing, drying, concentration, recrystallization, various chromatographies and the like. In addition, intermediates can also be subjected to a next reaction without particular purification.
- Some of compounds (I) contain a stereoisomer such as a geometric isomer, an optical isomer or the like, a tautomer and the like. The present invention comprises all possible isomers and mixtures thereof including these.
- In compound (I), each atom may be partly or entirely substituted by the corresponding isotope atom, and the present invention also encompasses a compound substituted by such isotope atom(s). For example, a hydrogen atom of compound (I) may be partly or entirely a hydrogen atom with atomic weight 2 (deuterium atom).
- Compound (I) wherein each atom is partly or entirely substituted by the corresponding isotope atom can be produced using a commercially available building block and by a method similar to each of the above-mentioned production methods. Compound (I) wherein each atom is partly or entirely substituted by a deuterium atom can also be synthesized by, for example, 1) a method including deuterating carboxylic acid and the like by using deuterium peroxide under basic conditions (see
US Patent No. 3849458 ), 2) a method including deuterating alcohol, carboxylic acid and the like by using an iridium complex as a catalyst and deuterated water as a deuterium source [see Journal of American Chemical Society (J. Am. Chem. Soc.), Vol. 124, No. 10, 2092 (2002)], 3) a method including deuterating fatty acid by using palladium carbon as a catalyst and deuterium gas alone as a deuterium source [see LIPIDS, Vol. 9, No. 11, 913 (1974)], 4) a method including deuterating acrylic acid, methyl acrylate, methacrylic acid, methyl methacrylate and the like by using a metal such as platinum, palladium, rhodium, ruthenium, iridium and the like as a catalyst and deuterated water or deuterated water and deuterium gas as a deuterium source (seeJP-B-5-19536 JP-A-61-277648 JP-A-61-275241 JP-A-63-198638 - When a salt of compound (I) is to be obtained, compound (I) obtained in the form of a salt can be directly purified. When it is obtained in a free form, compound (I) may be dissolved or suspended in a suitable solvent, and an acid or a base is added thereto to form a salt, which may be isolated and purified.
- While compound (I) and pharmaceutically acceptable salts thereof may exist in the form of adducts with water or various solvents, these adducts are also comprised in the present invention.
- Specific examples of compound (I) obtained by the present invention are shown in Table 1 to Table 14. However, the compound of the present invention is not limited to them. In the Tables, Me is methyl.
-
-
-
-
-
-
-
-
-
-
-
-
-
-
- Next, the pharmacological action of the representative compound (I) is specifically explained by Test Examples.
- The agonist activity of the test compound to PPAR Ī³ was determined by a transactivation assay method using a chimeric nuclear receptor of a DNA binding region of a yeast transcription factor GAL4 and a PPAR Ī³ ligand binding region. Specifically, the PPAR Ī³ agonist activity of the test compound was evaluated by the following method based on the method of Lehmann et al. (J Biol Chem., 1995, vol. 270, page 12953).
- HEK293EBNA cells cultured in Dulbecco's Modified Eagle medium (Invitrogen) containing 10 v/v% fetal bovine serum (Invitrogen) were used. 30 mL of the above-mentioned cells (density: 1Ć105 cells/mL) were inoculated in a 10 cm2 culture dish (Iwaki Glass), and cultured overnight. Using SuperFect Transfection Reagent (QIAGEN), a plasmid expressing a GAL4-PPAR Ī³ chimeric nuclear receptor fusing 174-475 amino acids, which are human PPAR Ī³ ligand binding domain, and 1-147 amino acids, which are GAL4 DNA binding domain, and a reporter plasmid expressing a GAL4 responsive luciferase were transiently introduced into the cells at a proportion of 4:1. After 5 hr from transfection, the cells were detached from the culture dish, and the detached cells (density: 2Ć104 cells/mL) were inoculated by 100 ĀµL in each well of a 96 well white plate (SUMITOMO BAKELITE), and cultured overnight. The medium was removed, the test compound diluted in various concentrations with serum-free Dulbecco's Modified Eagle medium was added by 100 ĀµL, and the mixture was reacted under a 5% carbon dioxide gas stream (5% CO2) at 37Ā°C for 24 hr. On the other hand, as a positive control, 10 Āµmol/L of pioglitazone (100 ĀµL) was added, and the mixture was reacted under a 5% carbon dioxide gas stream (5% CO2) at 37Ā°C for 24 hr. As a substrate of luciferase, 100 ĀµL of Steady-Glo (Promega) was added to each well and the mixture was thoroughly stirred. Immediately thereafter, the chemical luminescence due to luciferase was measured using TopCount NTX (Packard).
-
- The activity rate at which the test compound shows the maximum activity is referred as efficacy and the concentration showing 50% activity rate of the efficacy was calculated as EC50 value. The results are shown in Table 15.
- [Table 15]
Table 15 compound No. EC50 value (nmol/L) compound No. EC50 value (nmol/L) 1a 7.4 8c 33.3 1b 11.7 8f 31.7 1d 9.0 8n 54.5 1j 7.2 9h 11.9 2a 45.6 9i 13.9 2b 59.5 10a 6.4 3b 22.8 10c 12.7 3i 8.5 10e 5.3 4a 33.5 11b 13.9 4g 54.9 11h 19.0 41 38.0 12a 18.8 6a 11.5 12c 78.2 7a 27.7 13c 39.9 8a 4.2 13d 36.7 8b 27.7 13g 209 14a 15.9 14d 7.4 14g 130 14h 304 14i 239 14j 83 - From the above-mentioned results, compound (I) or a pharmaceutically acceptable salt thereof provided in the present invention are shown to be useful as agents for treating and/or preventing diseases related to PPAR Ī³, such as type 2 diabetes, impaired glucose tolerance, insulin resistance syndrome, hypertension, hyperlipidemia, metabolic syndrome, visceral obesity, obesity, hypertriglyceridemia, inflammatory skin diseases (e.g., psoriasis, atopic dermatitis, seborrheic dermatitis, solar dermatitis etc.), inflammatory diseases (e.g., rheumatoid arthritis, ulcerative colitis, Crohn's disease, endometritis etc.), inflammatory neuropsychiatric diseases (e.g., multiple sclerosis etc.), neurodegenerative neuropsychiatric diseases (e.g., Alzheimer's disease, Parkinson's disease etc.), cardiovascular diseases such as arteriosclerosis, cardiac disease, cerebral apoplexy, renal diseases, or the like.
- Human liver microsome (pool of 50 donors) was purchased from XenoTech. A reaction mixture containing phosphate buffer (100 mmol/L, pH 7.4), ethylenediamine tetraacetic acid (0.1 mmol/L), magnesium chloride (6 mmol/L), human liver microsome (0.2 mg/mL protein) and test compound (1 Āµmol/L) was prepared. The reaction mixture was preincubated at 37Ā°C for 5 min, Ī²-NADPH (1 mmol/L) was added and the mixture was incubated at 37Ā°C for 30 min. The protein was removed with acetonitrile from the sample after the reaction and the sample was measured by LC-MS/MS. The ratio of the organic solvent in the reaction mixture was set to about 0.5%, and the reaction was performed in 2 samples.
-
- ke: elimination rate constant (1/h)
- a: concentration (mg/mL) of liver microsome in the reaction mixture
- b: liver microsome amount per liver unit weight (32.3 mg/g liver)
- c: liver weight per unit body weight (25.7 g liver/kg body weight)
- Each test compound was tested in two samples, and the average thereof was calculated. The results are shown in Table 16.
- [Table 16]
Table 16 compound No. hCLint (L/h/kg) compound No. hCLint (L/h/kg) 1a 3.2 8c 3.0 1b 1.9 8f 1.0 1d 1.4 8n 1.1 1j 1.7 9h 1.5 2a 0.44 9i 4.3 2b 1.6 10a 6.1 3b 0.57 10c 3.9 3i 1.3 10e 2.4 4a 1.9 11b 2.1 4g 4.7 11h 5.4 41 2.2 12a 4.7 6a 2.0 12c 3.9 7a 2.9 13c 5.3 8a 2.2 13d 1.6 8b 2.4 13g 3.9 14a 1.8 14d 3.7 14g 1.7 14h 2.2 14i 7.6 14j 0.68 - From the above-mentioned results, it was revealed that compound (I) and a pharmaceutically acceptable salt thereof provided in the present invention have high metabolic stability in human. That is, it was revealed that compound (I) or a pharmaceutically acceptable salt thereof have preferable properties as a pharmaceutical product to be used for the treatment and/or prophylaxis of diseases related to PPAR Ī³, such as type 2 diabetes, impaired glucose tolerance, insulin resistance syndrome, hypertension, hyperlipidemia, metabolic syndrome, visceral obesity, obesity, hypertriglyceridemia, inflammatory skin diseases (e.g., psoriasis, atopic dermatitis, seborrheic dermatitis, solar dermatitis etc.), inflammatory diseases (e.g., rheumatoid arthritis, ulcerative colitis, Crohn's disease, endometritis etc.), inflammatory neuropsychiatric diseases (e.g., multiple sclerosis etc.), neurodegenerative neuropsychiatric diseases (e.g., Alzheimer's disease, Parkinson's disease etc.), cardiovascular diseases such as arteriosclerosis, cardiac disease, cerebral apoplexy, renal diseases, or the like.
- While compound (I) or pharmaceutically acceptable salts thereof can be administered alone as they are, generally, they are desirably provided as various pharmaceutical preparations. In addition, such pharmaceutical preparations are used for animals and humans.
- The pharmaceutical preparation relating to the present invention can contain, as an active ingredient, compound (I) or a pharmaceutically acceptable salt thereof alone or as a mixture with an active ingredient for any other treatment. Moreover, the pharmaceutical preparation can be produced by mixing the active ingredient with one or more kinds of pharmaceutically acceptable carriers (e.g., diluent, solvent, excipient and the like) according to any method well known in the technical field of pharmaceutics.
- As the administration route, a route most effective for the treatment is desirably employed, which may be an oral or parenteral route such as intravenous route and the like.
- The dosage form may be, for example, tablet, injection and the like.
- A form suitable for oral administration, such as tablet and the like, can be produced by using an excipient such as lactose and the like, a disintegrant such as starch and the like, a lubricant such as magnesium stearate and the like, a binder such as hydroxypropylcellulose and the like.
- A form suitable for parenteral administration, such as injection and the like, can be produced by using a diluent such as a salt solution, a glucose solution, a mixture of salt solution and a glucose solution, or the like, or a solvent, or the like.
- While the dose and administration frequency of compound (I) or a pharmaceutically acceptable salt thereof varies depending on the mode of administration, age and body weight of patients, nature and severity of the symptom to be treated or the like, it is generally within the range of 0.01 to 1000 mg, preferably 0.05 to 100 mg, for oral administration to an adult, which is administered at once or in several portions a day. In the case of parenteral administration such as intravenous administration or the like, 0.001 to 1000 mg, preferably 0.01 to 100 mg, is administered to an adult at once or in several portions a day. However, these doses and administration frequencies vary depending on the aforementioned various conditions.
- The present invention is explained in more detail in the following by Examples and Reference Examples, which are not to be construed as limitative.
- The proton nuclear magnetic resonance spectrum (1H NMR) used in the Examples and Reference Examples were measured at 270 MHz, 300 MHz or 400 MHz, and exchanging protons may not be clearly observed depending on the compound and measurement conditions. The indication of the multiplicity of the signals is conventional, where br means an apparently broad signal.
- (E)-2-{3-fluoro-8-[(2-propyl-1H-benzo[d]imidazol-1-yl)methyl]dibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (640 mg, 1.47 mmol) obtained in Reference Example 1A was dissolved in ethanol (7 mL), hydroxylamine (50% aqueous solution, 4.83 mL, 73.3 mmol) was added, and the mixture was heated under reflux for 16 hr. Water was added to the mixture, and the mixture was extracted 3 times with chloroform. The combined organic layers were dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained residue was dissolved in dichloromethane (7 mL), triethylamine (0.41 mL, 2.93 mmol) and ethyl chlorocarbonate (0.28 mL, 2.93 mmol) were added at 0Ā°C, and the mixture was stirred at room temperature for 1 hr. Saturated aqueous sodium hydrogen carbonate solution was added to the mixture, and the mixture was extracted 3 times with chloroform. The combined organic layers were dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained residue was dissolved in toluene (3 mL)-THF (3 mL) mixed solvent, potassium tert-butoxide (328 mg, 2.93 mmol) was added, and the mixture was stirred at room temperature for 20 min. To the mixture was added 5% aqueous citric acid solution, and the mixture was extracted 3 times with chloroform. The combined organic layers were dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform/methanol = 95/5 v/v) to give the title compound (compound 1a) (700 mg, 95%).
ESIMS m/z: 497 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 0.98 (t, J = 7.4 Hz, 3H), 1.74-1.94 (m, 2H), 2.28 (s, 3H), 2.79 (t, J = 7.4 Hz, 2H), 4.65 (d, J = 12.0 Hz, 1H), 5.34 (s, 2H), 5.45 (d, J = 12.0 Hz, 1H), 6.48-6.56 (m, 1H), 6.60-6.70 (m, 1H), 6.95-7.30 (m, 7H), 7.67-7.74 (m, 1H). - Using (E)-2-(3-fluoro-8-{[2-(methoxymethyl)-1H-benzo[d]imidazol-1-yl]methyl}dibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (540 mg, 1.23 mmol) obtained in Reference Example 1B, and in the same manner as in Example 1, the title compound (compound 1b) (267 mg, 44%) was obtained.
ESIMS m/z: 499 (M + H)+; 1H NMR (300 MHz, CDCl3,Ī“): 2.28 (s, 3H), 3.35 (s, 3H), 4.70 (s, 2H), 4.74 (d, J= 12.5 Hz, 1H), 5.45-5.59 (m, 3H), 6.53 (dd, J = 10.3, 2.6 Hz, 1H), 6.61-6.72 (m, 1H), 7.07 (dd, J = 8.8, 6.6 Hz, 1H), 7.13-7.20 (m, 3H), 7.20-7.34 (m, 3H), 7.77-7.83 (m, 1H). - Using (E)-2-{3-fluoro-8-[(2-isopropyl-1H-benzo[d]imidazol-1-yl)methyl]dibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (240 mg, 0.55 mmol) obtained in Reference Example 1C, and in the same manner as in Example 1, the title compound (compound 1c) (156 mg, 57%) was obtained.
ESIMS m/z: 497 (M + H)+; 1H NMR (300 MHz, CDCl3,Ī“) 1.34-1.46 (m, 6H), 2.28 (s, 3H), 3.05-3.19 (m, 1H), 4.75 (d, J = 12.9 Hz, 1H), 5.36-5.45 (m, 2H), 5.51 (d, J = 12.9 Hz, 1H), 6.54 (dd, J = 10.2, 2.6 Hz, 1H), 6.61-6.71 (m, 1H), 7.02-7.30 (m, 7H), 7.77-7.83 (m, 1H). - Using (E)-2-{8-[(2-cyclopropyl-1H-benzo[d]imidazol-1-yl)methyl]-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (180 mg, 0.413 mmol) obtained in Reference Example 1D, and in the same manner as in Example 1, the title compound (compound 1d) (114 mg, 56%) was obtained.
ESIMS m/z: 495 (M + H)+; 1H NMR (270 MHz, CDCl3,Ī“): 1.00-1.12 (m, 2H), 1.17-1.35 (m, 2H), 1.78-1.93 (m, 1H), 2.29 (s, 3H), 4.73 (d, J = 12.8 Hz, 1H), 5.40-5.60 (m, 3H), 6.46-6.59 (m, 1H), 6.59-6.75 (m, 1H), 6.99-7.34 (m, 7H), 7.57-7.78 (m, 1H). - Using (E)-2-{8-[(2-cyclobutyl-1H-benzo[d]imidazol-1-yl)methyl]-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (170 mg, 0.379 mmol) obtained in Reference Example 1E, and in the same manner as in Example 1, the title compound (compound 1e) (108 mg, 56%) was obtained.
ESIMS m/z: 509 (M + H)+; 1H NMR (270 MHz, CDCl3,Ī“): 1.92-2.17 (m, 2H), 2.23-2.41 (m, 5H), 2.46-2.66 (m, 2H), 3.55-3.73 (m, 1H), 4.69 (d, J = 12.8 Hz, 1H), 5.28 (s, 2H), 5.48 (d, J = 12.8 Hz, 1H), 6.48-6.59 (m, 1H), 6.59-6.74 (m, 1H), 6.93-7.32 (m, 7H), 7.72-7.83 (m, 1H). - Using (E)-2-{8-[(2-cyclopentyl-1H-benzo[d]imidazol-1-yl)methyl]-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (148 mg, 0.32 mmol) obtained in Reference Example 1F, and in the same manner as in Example 1, the title compound (compound 1f) (53 mg, 32%) was obtained.
ESIMS m/z: 523 (M + H)+; 1H NMR (270 MHz, CDCl3,Ī“): 1.58-1.78 (m, 2H), 1.78-2.14 (m, 6H), 2.27 (s, 3H), 3.09-3.27 (m, 1H), 4.74 (d, J = 12.8 Hz, 1H), 5.36-5.46 (m, 2H), 5.51 (d, J = 12.8 Hz, 1H), 6.48-6.59 (m, 1H), 6.59-6.74 (m, 1H), 6.95-7.32 (m, 7H), 7.68-7.85 (m, 1H). - Using (E)-2-(8-{[2-(cyclopropylmethyl)-1H-benzo[d]imidazol-1-yl]methyl}-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (172 mg, 0.383 mmol) obtained in Reference Example 1G, and in the same manner as in Example 1, the title compound (compound 1g) (99 mg, 49%) was obtained.
ESIMS m/z: 509 (M + H)+; 1H NMR (270 MHz, CDCl3,Ī“): 0.20-0.30 (m, 2H), 0.49-0.50 (m, 2H), 1.11-1.21 (m, 1H), 2.28 (s, 3H), 2.78 (d, J = 6.8 Hz, 2H), 4.68 (d, J = 12.7 Hz, 1H), 5.39 (s, 2H), 5.47 (d, J = 12.7 Hz, 1H), 6.52 (dd, J = 2.4, 10.2 Hz, 1H), 6.60-6.70 (m, 1H), 7.00 (s, 1H), 7.02-7.30 (m, 6H), 7.75 (d, J= 7.8 Hz, 1H). - Using (E)-2-{8-[(2-ethyl-1H-benzo[d]imidazol-1-yl)methyl]-3-fluorodibenzo[b,e]axepin-11(6H)-ylidene}propanenitrile (168 mg, 0.397 mmol) obtained in Reference Example 1H, and in the same manner as in Example 1, the title compound (compound 1h) (85 mg, 42%) was obtained.
ESIMS m/z: 483 (M + H)+; 1H NMR (270 MHz, CDCl3,Ī“): 1.25 (t, J = 7.4 Hz, 3H), 2.15 (s, 3H), 2.81 (q, J = 7.4 Hz, 2H), 4.93 (d, J = 12.7 Hz, 1H), 5.47 (s, 2H), 5.48 (d, J = 12.7 Hz, 1H), 6.65 (dd, J = 2.9, 10.7 Hz, 1H), 6.79 (dt, J= 2. 6, 8.5 Hz, 1H), 7.70-7.29 (m, 6H), 7.40-7.49 (m, 1H), 7.53-7.61 (m, 1H). - Using (E)-2-(3-fluoro-8-{[2-(trifluoromethyl)-1H-benzo[d]imidazol-1-yl]methyl}dibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (138 mg, 0.298 mmol) obtained in Reference Example 1I, and in the same manner as in Example 1, the title compound (compound 2I) (100 mg, 64%) was obtained.
ESIMS m/z: 523 (M + H)+; 1H NMR (270 MHz, DMSO-d6,Ī“): 2.17 (s, 3H), 4.92 (d, J = 12.6 Hz, 1H), 5.48 (d, J = 12.6 Hz, 1H), 5.73 (s, 2H), 6.57-6.72 (m, 1H), 6.73-6.87 (m, 1H), 7.05-7.10 (m, 2H), 7.18-7.31 (m, 2H), 7.33-7.51 (m, 2H), 7.59-7.69 (m, 1H), 7.79-7.93 (m, 1H), 12.11 (br s, 1H). - Using (E)-2-(8-{[2-(3,3-difluorocyclobutyl)-1H-benzo[d]imidazol-1-yl]methyl}-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (125 mg, 0.26 mmol) obtained in Reference Example 1J, and in the same manner as in Example 1, the title compound (compound 1j) (70 mg, 50%) was obtained.
ESIMS m/z: 545 (M + H)+; 1H NMR (300 MHz, DMSO-d6,Ī“): 2.16 (s, 3H), 2.79-3.10 (m, 4H), 3.65-3.82 (m, 1H), 4.93 (d, J = 12.5 Hz, 1H), 5.44-5.54 (m, 3H), 6.65 (dd, J = 10.6, 2.6 Hz, 1H), 6.75-6.84 (m, 1H), 7.03-7.12 (m, 2H), 7.17-7.28 (m, 4H), 7.44-7.52 (m, 1H), 7.64-7.70 (m, 1H), 12.15 (br s, 1H). - Using (E)-2-(3-fluoro-8-{[2-(1-methylcyclopropyl)-1H-benzo[d]imidazol-1-yl]methyl}dibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (58 mg, 0.129 mmol) obtained in Reference Example 1L, and in the same manner as in Example 1, the title compound (compound 11) (37 mg, 56%) was obtained.
ESIMS m/z: 509 (M + H)+; 1H NMR (270 MHz, CDCl3,Ī“): 0.74-0.92 (m, 2H), 1.01-1.16 (m, 2H), 1.37 (s, 3H), 2.28 (s, 3H), 4.66 (d, J = 12.8 Hz, 1H), 5.36-5.64 (m, 3H), 6.47-6.58 (m, 1H), 6.58-6.69 (m, 1H), 6.94-7.23 (m, 7H), 7.55-7.68 (m, 1H). - Using (E)-2-(3-fluoro-8-{[2-(furan-2-yl)-1H-benzo[d]imidazol-1-yl]methyl}dibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (145 mg, 0.31 mmol) obtained in Reference Example 1M, and in the same manner as in Example 1, the title compound (compound 1m) (59 mg, 36%) was obtained.
ESIMS m/z: 521 (M + H)+; 1H NMR (270 MHz, DMSO-d6, Ī“): 2.14 (s, 3H), 4.88 (d, J = 12.8 Hz, 1H), 5.46 (d, J = 12.8 Hz, 1H), 5.78 (s, 2H), 6.69-6.70 (m, 1H), 6.75-6.81 (m, 1H), 7.03-7.11 (m, 3H), 7.20-7.28 (m, 5H), 7.51-7.54 (m, 1H), 7.67-7.70 (m, 1H), 7.90-7.91 (m, 1H). - Using (E)-2-(3-fluoro-8-{[2-(pyridin-2-yl)-1H-benzo[d]imidazol-1-yl]methyl}dibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (120 mg, 0.28 mmol) obtained in Reference Example 1N, and in the same manner as in Example 1, the title compound (compound 1n) (26 mg, 19%) was obtained.
ESIMS m/z: 532 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 2.26 (s, 3H), 4.71 (d, J = 12.8 Hz, 1H), 5.48 (d, J = 12.8 Hz, 1H), 6.11-6.25 (m, 2H), 6.48-6.67 (m, 2H), 7.02-7.36 (m, 8H), 7.82-7.90 (m, 2H), 8.45-8.48 (m, 1H), 8.60-8.62 (m, 1H). - (E)-2-(3-fluoro-8-{[4-(methoxy-d3)-2-(methoxymethyl)-1H-benzo[d]imidazol-1-yl]methyl}dibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (25 mg, 0.053 mmol) obtained in Reference Example 2A was dissolved in ethanol (1 mL), hydroxylamine (50% aqueous solution, 0.16 mL, 2.65 mmol) was added, and the mixture was stirred with heating under reflux for 16 hr. Water was added to the mixture, and the mixture was extracted 3 times with chloroform. The combined organic layers were dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained residue (24 mg) was dissolved in 1,4-dioxane (1 mL), 1,8-diazabicyclo[5,4,0]undec-7-ene (11 ĀµL, 0.071 mmol) and 1,1'-carbonyldiimidazole (15 mg, 0.095 mmol) were added, and the mixture was stirred with heating under reflux for 2 hr. To the mixture was added 1 mol/L hydrochloric acid, and the mixture was extracted 3 times with chloroform-methanol (10/1) mixed solvent. The combined organic layers were dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified by reversed-phase liquid chromatography (water/acetonitrile = 70/30-10/90) to give the title compound (compound 2a) (14 mg, 50%).
ESIMS m/z: 532 (M + H)+; 1H NMR (300 MHz, CDCl3,Ī“): 2.28 (s, 3H), 3. 32 (s, 3H), 4.66-4.75 (m, 3H), 5.42-5.58 (m, 3H), 6.53 (dd, J = 10.3, 2.6 Hz, 1H), 6.60-6.74 (m, 2H), 6.83 (d, J= 7.7 Hz, 1H), 7.02-7.13 (m, 2H), 7.13-7.24 (m, 3H). - Using (E)-1-{[11-(1-cyanoethylidene)-3-fluoro-6,11-dihydrodibenzo[b,e]oxepin-8-yl]methyl}-2-propyl-1H-benzo[d]imidazole-4-carboxamide (97 mg, 0.20 mmol) obtained in Reference Example 2B, and in the same manner as in Example 1, the title compound (compound 2b) (7.8 mg, 7%) was obtained.
ESIMS m/z: 540 (M + H)+; 1H NMR (300 MHz, DMSO-d6,Ī“): 0.93 (t, J = 7.5 Hz, 3H), 1.65-1.82 (m, 2H), 2.16 (s, 3H), 2.86 (t, J = 7.5 Hz, 2H), 4.94 (d, J= 12.5 Hz, 1H), 5.48 (d, J = 12.5 Hz, 1H), 5.57 (s, 2H), 6.65 (dd, J= 10.8, 2.7 Hz, 1H), 6.79 (td, J = 8.3, 2.7 Hz, 1H), 7.04-7.13 (m, 2H), 7.20-7.32 (m, 3H), 7.68 (d, J = 7.3 Hz, 1H), 7.71 (br s, 1H), 7.83 (d, J= 7.3 Hz, 1H), 9.27 (br d, J = 3.3 Hz, 1H). - Using (E)-2-{3-fluoro-8-[(4-methoxy-2-propyl-1H-benzo[d]imidazol-1-yl)methyl]dibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (445 mg, 0.95 mmol) obtained in Reference Example 2C, and in the same manner as in Example 1, the title compound (compound 2c) (281 mg, 56%) was obtained.
ESIMS m/z: 527 (M + H)+; 1H NMR (300 MHz, CDCl3,Ī“): 0.97 (t, J = 7.3 Hz, 3H), 1.77-1.93 (m, 2H), 2.28 (s, 3H), 2.77 (t, J = 7.3 Hz, 2H), 4.00 (s, 3H), 4.69 (d, J= 12.5 Hz, 1H), 5.35 (s, 2H), 5.49 (d, J = 12.5 Hz, 1H), 6.53 (dd, J= 10.3, 2.6 Hz, 1H), 6.61-6.72 (m, 2H), 6.76 (d, J = 8.1 Hz, 1H), 6.98 (br s, 1H), 7.03-7.20 (m, 4H). - Using (E)-2-(3-fluoro-8-{[4-methoxy-2-(methoxymethyl)-1H-benzo[d]imidazol-1-yl]methyl}dibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (70 mg, 0.15 mmol) obtained in Reference Example 2D, and in the same manner as in Example 1, the title compound (compound 2d) (45 mg, 55%) was obtained.
ESIMS m/z: 529 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 2.25 (s, 3H), 3.34 (s, 3H), 4.02 (s, 3H), 4.62-4.71 (m, 3H), 5.43-5.55 (m, 3H), 6.50-6.56 (m, 1H), 6.62-6.66 (m, 1H), 6.70-6.72 (m, 1H), 7.05-7.10 (m, 2H), 7.15-7.24 (m, 4H). - Using (E)-2-(3-fluoro-B-{[7-methoxy-2-(methoxymethyl)-1H-benzo[d]imidazol-1-yl]methyl}dibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (67 mg, 0.14 mmol) obtained in Reference Example 2E, and in the same manner as in Example 1, the title compound (compound 2e) (28 mg, 36%) was obtained.
ESIMS m/z: 529 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 2.28 (s, 3H), 3.32 (s, 3H), 3.81 (s, 3H), 4.63 (s, 2H), 4.74 (d, J = 12.8 Hz, 1H), 5.51 (d, J = 12.8 Hz, 1H), 5.77 (s, 2H), 6.51-6.55 (m, 1H), 6.62-6.74 (m, 2H), 7.04-7.23 (m, 5H), 7.37-7.40 (m, 1H). - Using (E)-2-(8-{[4-ethoxy-2-(methoxymethyl)-1H-benzo[d]imidazol-1-yl]methyl}-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (81 mg, 0.17 mmol) obtained in Reference Example 2F, and in the same manner as in Example 1, the title compound (compound 2f) (39 mg, 43%) was obtained.
ESIMS m/z: 543 (M + H)+; 1H NMR (300 MHz, CDCl3,Ī“): 1.54 (t, J = 7.0 Hz, 3H), 2.27 (s, 3H), 3.32 (s, 3H), 4.28 (q, J = 7.0 Hz, 2H), 4.65-4.75 (m, 3H), 5.41-5.56 (m, 3H), 6.52 (dd, J = 10.3, 2.6 Hz, 1H), 6.60-6.68 (m, 1H), 6.70 (d, J = 8.1 Hz, 1H), 6.81 (d, J = 8.1 Hz, 1H), 7.01-7.11 (m, 2H), 7.11-7.22 (m, 3H). - Using (E)-2-(8-{[4-(difluoromethoxy)-2-(methoxymethyl)-1H-benzo[d]imidazol-1-yl]methyl}-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (35 mg, 0.065 mmol) obtained in Reference Example 2G, and in the same manner as in Example 1, the title compound (compound 2g) (25 mg, 68%) was obtained.
ESIMS m/z: 565 (M + H)+; 1H NMR (300 MHz, CDCl3,Ī“): 2.28 (s, 3H), 3.35 (s, 3H), 4.69 (s, 2H), 4.76 (d, J= 12.5 Hz, 1H), 5.46-5.58 (m, 3H), 6.54 (dd, J = 10.3, 2.6 Hz, 1H), 6.60-6.75 (m, 1H), 7.02-7.30 (m, 7H), 7.29 (t, J = 76.6 Hz, 1H). - Using (E)-2-(3-fluoro-8-{[4-(hydroxymethyl)-2-propyl-1H-benzo[d]imidazol-1-yl]methyl}dibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (105 mg, 0.23 mmol) obtained in Reference Example 2H, and in the same manner as in Example 1, the title compound (compound 2h) (16 mg, 14%) was obtained.
ESIMS m/z: 527 (M + H)+; 1H NMR (300 MHz, CDCl3,Ī“): 1.00 (t, J = 7.3 Hz, 3H), 1.58-2.01 (m, 3H), 2.28 (s, 3H), 2.79 (t, J = 7.3 Hz, 2H), 4.75 (d, J = 12.8 Hz, 1H), 5.13 (s, 2H), 5.37 (s, 2H), 5.51 (d, J = 12.8 Hz, 1H), 6.53 (dd, J= 10.1, 2.4 Hz, 1H), 6.61-6.72 (m, 1H), 7.00-7.22 (m, 7H). - Using (E)-2-(3-fluoro-8-{[4-(hydroxymethyl)-2-(methoxymethyl)-1H-benzo[d]imidazol-1-yl]methyl}dibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (215 mg, 0.46 mmol) obtained in Reference Example 2I, and in the same manner as in Example 1, the title compound (compound 2i) (38 mg, 16%) was obtained.
ESIMS m/z: 529 (M + H)+; 1H NMR (400 MHz, CDCl3,Ī“): 2.28 (s, 3H), 3.35 (s, 3H), 4.68 (s, 2H), 4.75 (d, J= 12.7 Hz, 1H), 5.13 (s, 2H), 5.44-5.58 (m, 3H), 6.53 (dd, J = 9.8, 2.9 Hz, 1H), 6.62-6.70 (m, 1H), 7.03-7.11 (m, 1H), 7.11-7.29 (m, 6H). - Using (E)-2-(8-{[4-chloro-2-(methoxymethyl)-1H-benzo[d]imidazol-1-yl]methyl}-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (100 mg, 0.21 mmol) obtained in Reference Example 2J, and in the same manner as in Example 1, the title compound (compound 2j) (47 mg, 42%) was obtained.
ESIMS m/z: 533 (M + H)+; 1H NMR (300 MHz, CDCl3,Ī“): 2.16 (s, 3H), 3.25 (s, 3H), 4.70 (s, 2H), 4.92 (d, J= 12.5 Hz, 1H), 5.48 (d, J = 12.5 Hz, 1H), 5.55 (s, 2H), 6.65 (dd, J= 10.6, 2.6 Hz, 1H), 6.79 (dt, J = 8.2, 2.7 Hz, 1H), 7.05 (d, J = 7.7 Hz, 1H), 7.11-7.17 (m, 1H), 7.20 (d, J = 8.1 Hz, 1H), 7.23-7.33 (m, 3H), 7.41 (d, J = 8.1 Hz, 1H). - Using (E)-2-(3-fluoro-8-{[4-(2-hydroxypropan-2-yl)-2-(methoxymethyl)-1H-benzo[d]imidazol-1-yl]methyl}dibenzo[b,e]oxepin-11(6H)-ylidene) propanenitrile (170 mg, 0.35 mmol) obtained in Reference Example 2K, and in the same manner as in Example 1, the title compound (compound 2k) (100 mg, 50%) was obtained.
ESIMS m/z: 557 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 1.70 (s, 6H), 2.27 (s, 3H), 3.37 (s, 3H), 4.73-4.98 (m, 3H), 5.59-5.68 (m, 3H), 6.50-6.69 (m, 2H), 7.04-7.18 (m, 4H), 7.35-7.52 (m, 3H). - Using (E)-2-(8-{[2,4-bis(methoxymethyl)-1H-benzo[d]imidazol-1-yl]methyl}-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (153 mg, 0.32 mmol) obtained in Reference Example 2L, and in the same manner as in Example 1, the title compound (compound 21) (122 mg, 70%) was obtained.
ESIMS m/z: 543 (M + H)+; 1H NMR (270 MHz, CDCl3,Ī“): 2.27 (s, 3H), 3.35 (s, 3H), 3.51 (s, 3H), 4.70 (s, 2H), 4.73 (d, J = 12.8 Hz, 1H), 4.96 (s, 2H), 5.50 (s, 2H), 5.51 (d, J= 12.8 Hz, 1H), 6.50-6.71 (m, 2H), 7.10-7.38 (m, 7H). - Using (E)-2-(3-fluoro-8-{[2-(methoxymethyl)-4-(methylthio)-1H-benzo[d]imidazol-1-yl]methyl}dibenzo[b,e]oxepin-11(6H)-ylidene)propionitrile (100 mg, 0.21 mmol) obtained in reference Example 2M, and in the same manner as in Example 1, the title compound (compound 2m) (14 mg, 12%) was obtained.
ESIMS m/z: 545 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 2.24 (s, 3H), 2.61 (s, 3H), 3.34 (s, 3H), 4.69 (s, 3H), 4.72 (d, J = 12.8 Hz, 1H), 5.47 (d, J = 4.8 Hz, 1H), 5.52 (d, J = 12.8 Hz, 1H), 6.49-6.70 (m, 3H), 6.97-7.15 (m, 5H), 7.24 (t, J = 7.9 Hz, 1H). - Using (E)-2-(3-fluoro-8-{[2-(methoxymethyl)-4-(methylsulfonyl)-1H-benzo[d]imidazol-1-yl]methyl}dibenzo[b,e]oxepin-11(6H)-ylidene)propionitrile (79 mg, 0.15 mmol) obtained in Reference Example 2N, and in the same manner as in Example 1, the title compound (compound 2n) (9.5 mg, 11%) was obtained.
ESIMS m/z: 577 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 2.29 (s, 3H), 3.37 (s, 3H), 3.43 (s, 3H), 4.65-4.75 (m, 3H), 5.46-5.59 (m, 3H), 6.49-6.53 (m, 1H), 6.62-6.69 (m, 1H), 7.08-7.16 (m, 4H), 7.33-7.39 (m, 1H) 7.51-7.54 (m, 1H), 7.86-7.89 (m, 1H). - Using (E)-2-{8-[(4-chloro-2-cyclopropyl-1H-benzo[d]imidazol-1-yl)methyl]-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (105 mg, 0.22 mmol) obtained in Reference Example 2P, and in the same manner as in Example 1, the title compound (compound 2o) (43 mg, 36%) was obtained.
ESIMS m/z: 529 (M + H)+; 1H NMR (300 MHz, CDCl3,Ī“): 1.01-1.10 (m, 2H), 1.23-1.32 (m, 2H), 1.80-1.91 (m, 1H), 2.28 (s, 3H), 4.75 (d, J = 12.8 Hz, 1H), 5.42 (s, 2H), 5.51 (d, J= 12.8 Hz, 1H), 6.54 (dd, J = 10.3, 2.6 Hz, 1H), 6.61-6.70 (m, 1H), 7.04-7.12 (m, 4H), 7.13-7.19 (m, 2H), 7.22-7.26 (m, 1H). - Using (E)-2-{3-fluoro-8-[(2-propyl-1H-imidazo[4,5-c]pyridin-1-yl)methyl]dibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (50 mg, 0.114 mmol) obtained in Reference Example 3A, and in the same manner as in Example 1, the title compound (compound 3a) (15 mg, 26%) was obtained.
ESIMS m/z: 498 (M + H)+; 1H NMR (270 MHz, CDCl3,Ī“): 1.01 (t, J = 7.4 Hz, 3H), 1.76-2.03 (m, 2H), 2.30 (s, 3H), 2.81 (t, J = 7.4 Hz, 2H), 4.47 (d, J = 12.6 Hz, 1H), 5.28-5.48 (m, 3H), 6.48-6.55 (m, 1H), 6.62-6.71 (m, 1H), 6.73-6.76 (m, 1H), 7.00-7.29 (m, 4H), 8.13 (d, J = 5.8 Hz, 1H), 8.86 (s, 1H). - Using (E)-2-{8-[(4-chloro-2-cyclobutyl-1H-imidazo[4,5-c]pyridin-1-yl)methyl]-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (87 mg, 0.179 mmol) obtained in Reference Example 3B, and in the same manner as in Example 1, the title compound (compound 3b) (54 mg, 55%) was obtained.
ESIMS m/z: 544 (M + H)+; 1H NMR (270 MHz, DMSO-d6,Ī“): 1.74-2.21 (m, 7H), 2.22-2.44 (m, 2H), 3.67-3.89 (m, 1H), 4.93 (d, J = 12.8 Hz, 1H), 5.39-5.55 (m, 3H), 6.58-6.73 (m, 1H), 6.73-6.88 (m, 1H), 7.02-7.12 (m, 1H), 7.11-7.30 (m, 2H), 7.58 (d, J = 5.6 Hz, 1H), 8.07 (d, J = 5.6 Hz, 1H), 8.31 (s, 1H). - Using (E)-2-{8-[(7-chloro-2-cyclopropyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (107 mg, 0.228 mmol) obtained in Reference Example 3C, and in the same manner as in Example 1, the title compound (compound 3c) (65 mg, 54%) was obtained.
ESIMS m/z: 530 (M + H)+; 1H NMR (270 MHz, CDCl3,Ī“): 1.05-1.17 (m, 2H), 1.24-1.33 (m, 2H), 1.85-1.97 (m, 1H), 2.28 (s, 3H), 4.78 (d, J = 12.8 Hz, 1H), 5.45-5.68 (m, 3H), 6.47-6.58 (m, 1H), 6.58-6.71 (m, 1H), 6.98-7.29 (m, 5H), 8.14 (d, J = 5.4 Hz, 1H). - Using (E)-2-{8-[(7-chloro-2-cyclobutyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (100 mg, 0.206 mmol) obtained in Reference Example 3D, and in the same manner as in Example 1, the title compound (compound 3d) (28 mg, 25%) was obtained.
ESIMS m/z: 544 (M + H)+; 1H NMR (270 MHz, CDCl3,Ī“): 1.19-1.42 (m, 2H), 1.91-2.19 (m, 2H), 2.30 (s, 3H), 2.47-2.73 (m, 2H), 3.55-3.77 (m, 1H), 4.77 (d, J = 12.8 Hz, 1H), 5.27-5.60 (m, 3H), 6.46-6.59 (m, 1H), 6.59-6.75 (m, 1H), 6.97-7.22 (m, 4H), 7.23-7.30 (m, 1H), 8.11-8.26 (m, 1H). - Using (E)-2-{3-fluoro-8-[(2-propyl-3H-imidazo[4,5-b]pyridin-1-yl)methyl]dibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (44 mg, 0.10 mmol) obtained in Reference Example 3E, and in the same manner as in Example 1, the title compound (compound 3e) (26 mg, 52%) was obtained.
ESIMS m/z: 498 (M + H)+; 1H NMR (270 MHz, CDCl3,Ī“): 0.98 (t, J = 7.2 Hz, 3H), 1.75-1.95 (m, 2H), 2.26 (s, 3H), 2.77 (t, J = 7.2 Hz, 2H), 4.72 (d, J = 12.8 Hz, 1H), 5.39-5.55 (m, 3H), 6.45-6.57 (m, 1H), 6.58-6.70 (m, 1H), 7.00-7.25 (m, 5H), 7.96-8.04 (m, 1H), 8.23-8.32 (m, 1H). - Using (E)-2-{3-fluoro-8-[(5-fluoro-2-propyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]dibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (46 mg, 0.101 mmol) obtained in Reference Example 3G, and in the same manner as in Example 1, the title compound (compound 3g) (14 mg, 27%) was obtained.
ESIMS m/z: 516 (M + H)+; 1H NMR (270 MHz, CDCl3,Ī“): 0.93-1.09 (m, 3H), 1.69-1.91 (m, 2H), 2.30 (s, 3H), 2.69-2.78 (m, 2H), 4.80 (d, J = 12.8 Hz, 1H), 5.40 (s, 2H), 5.54 (d, J= 12.8 Hz, 1H), 6.42-6.58 (m, 1H), 6.58-6.72 (m, 1H), 6.75-6.93 (m, 1H), 7.01-7.23 (m, 4H), 7.97-8.10 (m, 1H). - Using (E)-2-{3-fluoro-8-[(5-fluoro-2-propyl-1H-imidazo[4,5-b]pyridin-1-yl)methyl]dibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (56 mg, 0.123 mmol) obtained in Reference Example 3H, and in the same manner as in Example 1, the title compound (compound 3h) (4 mg, 6%) was obtained.
ESIMS m/z: 516 (M + H)+; 1H NMR (270 MHz, CDCl3,Ī“): 0.84-1.12 (m, 3H), 1.67-1.95 (m, 2H), 2.37 (s, 3H), 2.79-3.01 (m, 2H), 4.63-4.81 (m, 1H), 5.37 (s, 2H), 5.53-5.72 (m, 1H), 6.43-6.84 (m, 3H), 6.84-6.99 (m, 1H), 6.98-7.12 (m, 1H), 7.12-7.37 (m, 2H), 7.40-7.62 (m, 1H). - Using (E)-2-{8-[(2-cyclobutyl-5-fluoro-1H-imidazo[4,5-b]pyridin-1-yl)methyl]-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (100 mg, 0.213 mmol) obtained in Reference Example 3I, and in the same manner as in Example 1, the title compound (compound 3i) (66 mg, 31%) was obtained.
ESIMS m/z: 528 (M + H)+; 1H NMR (270 MHz, CDCl3,Ī“): 1.95-2.12 (m, 2H), 2.21-2.41 (m, 5H), 2.52-2.71 (m, 2H), 3.56-3.69 (m, 1H), 4.74 (d, J = 12.8 Hz, 1H), 5.28 (s, 2H), 5.52 (d, J = 12.8 Hz, 1H), 6.50-6.61 (m, 1H), 6.60-6.71 (m, 1H), 6.71-6.79 (m, 1H), 6.98 (s, 1H), 7.03-7.14 (m, 2H), 7.16-7.30 (m, 1H), 7.39-7.52 (m, 1H). - Using (E)-2-{3-fluoro-8-[(2-propyl-1H-imidazo[4,5-b]pyrazin-1-yl)methyl]dibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (219 mg, 0.50 mmol) obtained in Reference Example 3J, and in the same manner as in Example 1, the title compound (compound 3j) (93 mg, 37%) was obtained.
ESIMS m/z: 499 (M + H)+; 1H NMR (300 MHz, CDCl3,Ī“): 0.99 (t, J = 7.3 Hz, 3H), 1.80-1.95 (m, 2H), 2.29 (s, 3H), 2.85 (t, J = 7.5 Hz, 2H), 4.77 (d, J = 12.8 Hz, 1H), 5.41-5.54 (m, 2H), 5.56 (d, J = 12.8 Hz, 1H), 6.53 (dd, J = 9.9, 2.6 Hz, 1H), 6.60-6.69 (m, 1H), 7.10 (dd, J = 8.6, 6.4 Hz, 1H), 7.14-7.21 (m, 3H), 8.26 (d, J = 2.9 Hz, 1H), 8.47 (d, J = 2.9 Hz, 1H). - Using (E)-2-[8-({2-[(dimethylamino)methyl]-1H-benzo[d]imidazol-1-yl}methyl)-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene]propanenitrile (57 mg, 0.13 mmol) obtained in Reference Example 4A, and in the same manner as in Example 1, the title compound (compound 4a) (10 mg, 15%) was obtained.
ESIMS m/z: 512 (M + H)+; 1H NMR (300 MHz, CDCl3, Ī“): 2.32 (s, 3H), 2.93 (s, 6H), 4.22 (d, J = 14.7 Hz, 1H), 4.67 (d, J = 14.7 Hz, 1H), 4.81 (d, J = 12.8 Hz, 1H), 5.54 (s, 2H), 5.61 (d, J = 12.8 Hz, 1H), 6.49-6.60 (m, 2H), 6.60-6.68 (m, 1H), 7.01 (d, J = 7.7 Hz, 1H), 7.11 (dd, J = 8.8, 6.6 Hz, 1H), 7.26-7.28 (m, 1H), 7.35-7.41 (m, 3H), 7.80-7.87 (m, 1H). - (E)-tert-butyl [1-({3-fluoro-11-[1-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)ethylidene]-6,11-dihydrodibenzo[b,e]oxepin-8-yl}methyl)-1H-benzo[d]imidazol-2-yl]methyl(methyl)carbamate (45 mg, 0.075 mmol) obtained in Reference Example 4B was dissolved in dichloromethane (1 mL), trifluoroacetic acid (0.17 mL, 2.26 mmol) was added, and the mixture was stirred at room temperature for 3 hr. To the mixture was added saturated aqueous sodium hydrogen carbonate, and the mixture was extracted 3 times with chloroform-methanol (10/1) mixed solvent. The combined organic layers were dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform/methanol = 10/1 v/v). To the obtained compound was added hydrogen chloride (4 mol/L 1,4-dioxane solution, 0.38 mL), and the mixture was stirred at room temperature for 30 min and concentrated under reduced pressure. To the residue was added ethyl acetate (1 mL), and the mixture was stirred at room temperature for 30 min. The precipitated crystals were collected by suction filtration to give the title compound (compound 4b) (17 mg, 43%).
ESIMS m/z: 498 (M + H)+; 1H NMR (300 MHz, DMSO-d6, Ī“): 2.17 (s, 3H), 2.73 (s, 3H), 4.58 (br s, 2H), 4.94 (d, J = 12.5 Hz, 1H), 5.46-5.58 (m, 3H), 6.65 (dd, J= 10.8, 2.4 Hz, 1H), 6.75-6.85 (m, 1H), 7.09 (d, J = 7.7 Hz, 1H), 7.14-7.38 (m, 5H), 7.47-7.54 (m, 1H), 7.66-7.74 (m, 1H), 9.44 (br s, 1H), 12.32 (br s, 1H). - Using (E)-2-(8-{[2-(azetidin-1-yl)-1H-benzo[d]imidazol-1-yl]methyl}-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (56 mg, 0.12 mmol) obtained in Reference Example 4C, and in the same manner as in Example 1, the title compound (compound 4c) (16 mg, 25%) was obtained.
ESIMS m/z: 510 (M + H)+; 1H NMR (300 MHz, CDCl3, Ī“): 2.27 (s, 3H), 2.31-2.44 (m, 2H), 4.28-4.44 (m, 4H), 4.76 (d, J = 12.8 Hz, 1H), 5.09-5.25 (m, 2H), 5.67 (d, J = 12.8 Hz, 1H), 6.50 (dd, J = 10.3, 2.6 Hz, 1H), 6.61-6.70 (m, 1H), 6.85-6.92 (m, 1H), 7.02-7.31 (m, 6H), 7.51 (d, J = 7.3 Hz, 1H). - Using (E)-2-(3-fluoro-8-{[2-(pyrrolidin-1-yl)-1H-benzo[d]imidazol-1-yl]methyl}dibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (140 mg, 0.30 mmol) obtained in Reference Example 4D, and in the same manner as in Example 1, the title compound (compound 4d) (37 mg, 23%) was obtained.
ESIMS m/z: 524 (M + H)+; 1H NMR (300 MHz, CDCl3, Ī“): 1.85-1.98 (m, 4H), 2.27 (s, 3H), 3.47-3.58 (m, 4H), 4.71 (d, J = 12.5 Hz, 1H), 5.29 (s, 2H), 5.51 (d, J = 12.5 Hz, 1H), 6.53 (dd, J = 10.3, 2.6 Hz, 1H), 6.60-6.70 (m, 1H), 6.90-7.21 (m, 7H), 7.48 (d, J = 7.7 Hz, 1H). - Using (E)-2-(3-fluoro-8-{[2-(piperidin-1-yl)-1H-benzo[d]imidazol-1-yl]methyl}dibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (123 mg, 0.26 mmol) obtained in Reference Example 4E, and in the same manner as in Example 1, the title compound (compound 4e) (48 mg, 35%) was obtained.
ESIMS m/z: 538 (M + H)+; 1H NMR (300 MHz, CDCl3, Ī“) : 1.54-1.74 (m, 6H), 2.28 (s, 3H), 3.14-3.22 (m, 4H), 4.78 (d, J = 12.5 Hz, 1H), 5.22 (s, 2H), 5.53 (d, J = 12.5 Hz, 1H), 6.55 (dd, J = 10.3, 2.6 Hz, 1H), 6.62-6.71 (m, 1H), 6.95 (d, J = 8.1 Hz, 1H), 7.04-7.13 (m, 2H), 7.14-7.26 (m, 4H), 7.62 (d, J = 7.3 Hz, 1H). - Using (E)-2-(8-{(dimethylamino)-1H-benzo[d]imidazol-1-yl]methyl}-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (100 mg, 0.23 mmol) obtained in Reference Example 4F, and in the same manner as in Example 1, the title compound (compound 4f) (56 mg, 50%) was obtained.
ESIMS m/z: 498 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 2.28 (s, 3H), 3.04 (s, 6H), 4.77 (d, J = 12. 6 Hz, 1H), 5.18-5.36 (m, 2H), 5. 66 (d, J = 12. 6 Hz, 1H), 6.54 (dd, J= 10.4, 2.5 Hz, 1H), 6.62-6.71 (m, 1H), 6.88-6.95 (m, 1H), 7.04-7.31 (m, 6H), 7.58 (d, J = 7.9 Hz, 1H). - Using (E)-2-cyclopropyl-2-{3-fluoro-8-[(2-propyl-1H-benzo[d]imidazol-1-yl)methyl]dibenzo[b,e]oxepin-11(6H)-ylidene)acetonitrile (132 mg, 0.29 mmol) obtained in Reference Example 4G, and in the same manner as in Example 1, the title compound (compound 4g) (88 mg, 59%) was obtained.
ESIMS m/z: 523 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 0.53-1.00 (m, 7H), 1.59-1.69 (m, 2H), 2.05-2.14 (m, 1H), 2.91-3.02 (m, 2H), 4.64 (d, J= 12.5 Hz, 1H), 5.39 (s, 2H), 5.69 (d, J = 12.5 Hz, 1H), 6.48-6.52 (m, 1H), 6.62-6.68 (m, 1H), 6.89-6.93 (m, 1H), 7.07-7.08 (m, 1H), 7.23-7.40 (m, 4H), 7.48-7.53 (m, 1H), 7.83-7.86 (m, 1H). - Using (E)-2-cyclopropyl-2-{8-[(2-cyclopropyl-1H-benzo[d]imidazol-1-yl)methyl]-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)acetonitrile (133 mg, 0.29 mmol) obtained in Reference Example 4H, and in the same manner as in Example 1, the title compound (compound 4h) (98 mg, 65%) was obtained.
ESIMS m/z: 521 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 0.47-1.04 (m, 8H), 1.74-1.81 (m, 1H), 2.00-2.07 (m, 1H), 4.39 (d, J = 12.8 Hz, 1H), 5.32-5.47 (m, 3H), 6.45-6.49 (m, 1H), 6.60-6.66 (m, 1H), 6.87 (br s, 1H), 7.08-7.21 (m, 5H), 7.38-7.43 (m, 1H), 7.59-7.62 (m, 1H). - Using (E)-2-cyclopropyl-2-(8-{[2-(3,3-difluorocyclobutyl)-1H-benzo[d]imidazol-1-yl]methyl}-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)acetonitrile (152 mg, 0.297 mmol) obtained in Reference Example 4I, and in the same manner as in Example 1, the title compound (compound 4i) (66 mg, 39%) was obtained.
ESIMS m/z: 571 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“) : 0.42-1.02 (m, 4H), 1.96-2.05 (m, 1H), 2.75-2.83 (m, 2H), 2.97-3.11 (m, 2H), 3.35-3.40 (m, 1H), 4.67 (d, J = 12.8 Hz, 1H), 5.27 (s, 2H), 5.48 (d, J = 12.8 Hz, 1H), 6.52-6.56 (m, 1H), 6.63-6.70 (m, 1H), 6.91-6.97 (m, 2H), 7.12-7.14 (m, 1H), 7.20-7.32 (m, 3H), 7.40-7.45 (m, 1H), 7.76-7.79 (m, 1H). - Using (E)-2-cyclopropyl-2-(3-fluoro-8-{[4-(2-hydroxypropan-2-yl)-2-(methoxymethyl)-1H-benzo[d]imidazol-1-yl]methyl}dibenzo[b,e]oxepin-11(6H)-ylidene)acetonitrile (139 mg, 0.265 mmol) obtained in Reference Example 4J, and in the same manner as in Example 1, the title compound (compound 4j) (62 mg, 40%) was obtained.
ESIMS m/z: 583 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“) : 0.41-0.97 (m, 4H), 1.69 (s, 6H), 2.00-2.06 (m, 1H), 3.34 (s, 3H), 4.62-4.70 (m, 2H), 4.84 (d, J = 13.8 Hz, 1H), 5.48-5.65 (m, 3H), 6.49-6.54 (m, 1H), 6.62-6.64 (m, 1H), 7.03-7.08 (m, 2H), 7.16-7.19 (m, 1H), 7.32-7.50 (m, 4H). - Using (E)-2-{8-[(4-chloro-2-cyclopropyl-1H-benzo[d]imidazol-1-yl)methyl]-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene}-2-cyclopropylacetonitrile (115 mg, 0.232 mmol) obtained in Reference Example 4K, and in the same manner as in Example 1, the title compound (compound 4k) (52 mg, 40%) was obtained.
ESIMS m/z: 555 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“) : 0.40-1.05 (m, 8H), 1.76-1.87 (m, 1H), 1.94-2.04 (m, 1H), 4.65 (d, J = 12.2 Hz, 1H), 5.42-5.48 (m, 3H), 6.51-6.56 (m, 1H), 6.62-6.68 (m, 1H), 6.91-6.92 (m, 1H), 7.07-7.21 (m, 5H), 7.40-7.46 (m, 1H). - Using (E)-2-(3-fluoro-8-{[2-(methoxymethyl)-1H-benzo[d]imidazol-1-yl]methyl}dibenzo[b,e]oxepin-11(6H)-ylidene)butanenitrile (171 mg, 0.377 mmol) obtained in Reference Example 4L, and in the same manner as in Example 1, the title compound (compound 41) (100 mg, 51%) was obtained.
ESIMS m/z: 513 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 1.07-1.21 (m, 3H), 2.57-2.86 (m, 2H), 3.34 (s, 3H), 4.55-4.74 (m, 3H), 5.35-5.58 (m, 3H), 6.47-6.56 (m, 1H), 6.58-6.75 (m, 1H), 6.95-7.15 (m, 4H), 7.17-7.32 (m, 3H), 7.67-7.85 (m, 1H). - Using (E)-2-{1,3-difluoro-8-[(2-propyl-1H-benzo[d]imidazol-1-yl)methyl]dibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (183 mg, 0.40 mmol) obtained in Reference Example 5A, and in the same manner as in Example 1, the title compound (compound 5a) (93 mg, 45%) was obtained.
ESIMS m/z: 515 (M + H)+; 1H NMR (300 MHz, CDCl3, Ī“): 1.00 (t, J = 7.5 Hz, 3H), 1.79-1.94 (m, 2H), 2.17 (d, J = 3.3 Hz, 3H), 2.80 (t, J = 7.5 Hz, 2H), 4.72 (d, J= 12.8 Hz, 1H), 5.37 (s, 2H), 5.55 (d, J = 12.8 Hz, 1H), 6.33-6.39 (m, 1H), 6.41-6.50 (m, 1H), 7.01 (br s, 1H), 7.09-7.29 (m, 5H), 7.72-7.77 (m, 1H). - Using (E)-2-{2,3-difluoro-8-[(2-propyl-1H-benzo[d]imidazol-1-yl)methyl]dibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (132 mg, 0.29 mmol) obtained in Reference Example 6A, and in the same manner as in Example 1, the title compound (compound 6a) (36 mg, 24%) was obtained.
ESIMS m/z: 515 (M + H)+; 1H NMR (270 MHz, CD3OD, Ī“) : 0.89 (t, J = 7.2 Hz, 3H), 1.59-1.76 (m, 2H), 2.13 (s, 3H), 2.90-3.01 (m, 2H), 4.64-4.79 (m, 1H), 5.45 (d, J = 12.8 Hz, 1H), 5.52-5.62 (m, 2H), 6.57-6.67 (m, 1H), 7.01-7.11 (m, 3H), 7.12-7.18 (m, 1H), 7.29-7.41 (m, 2H), 7.43-7.51 (m, 1H), 7.58-7.67 (m, 1H). - Using (E)-2-{3,4-difluoro-8-[(2-propyl-1H-benzo[d]imidazol-1-yl)methyl]dibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (40 mg, 0.088 mmol) obtained in Reference Example 7A, and in the same manner as in Example 1, the title compound (compound 7a) (24 mg, 53%) was obtained.
ESIMS m/z: 515 (M + H)+; 1H NMR (300 MHz, CDCl3, Ī“): 0.90 (t, J = 7.3 Hz, 3H), 1.68-1.85 (m, 2H), 2.28 (s, 3H), 2.94 (t, J = 7.3 Hz, 2H), 4.86 (d, J = 12.8 Hz, 1H), 5.43 (s, 2H), 5.63 (d, J = 12.8 Hz, 1H), 6.69-6.80 (m, 1H), 6.84-6.93 (m, 1H), 6.94-7.02 (m, 1H), 7.10-7.18 (m, 2H), 7.26-7.42 (m, 3H), 7.80 (d, J= 8.1 Hz, 1H). - Using (E)-2-{8-[(8-chloro-2-cyclopropylimidazo[1,2-a]pyridin-3-yl)methyl]-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (170 mg, 0.362 mmol) obtained in Reference Example 8A, and in the same manner as in Example 1, the title compound (compound 8a) (70 mg, 37%) was obtained.
ESIMS m/z: 529 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 0.86-1.16 (m, 4H), 1.92-2.10 (m, 1H), 2.27 (s, 3H), 4.27-4.42 (m, 2H), 4.68 (d, J = 12.6 Hz, 1H), 5.48 (d, J = 12.6 Hz, 1H), 6.43-6.57 (m, 1H), 6.57-6.68 (m, 2H), 7.02-7.20 (m, 5H), 7.50-7.58 (m, 1H). - Using (E)-2-{8-[(2-cyclopropylimidazo[1,2-a]pyridin-3-yl)methyl]-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (201 mg, 0.462 mmol) obtained in Reference Example 8B, and in the same manner as in Example 1, the title compound (compound 8b) (62 mg, 27%) was obtained.
ESIMS m/z: 495 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“) : 0.93-1.07 (m, 2H), 1.07-1.21 (m, 2H), 1.95-2.09 (m, 1H), 2.29 (s, 3H), 4.29-4.47 (m, 2H), 4.74 (d, J = 12.8 Hz, 1H), 5.50 (d, J = 12.8 Hz, 1H), 6.47-6.58 (m, 1H), 6.59-6.75 (m, 2H), 7.01-7.25 (m, 5H), 7.44-7.54 (m, 1H), 7.54-7.63 (m, 1H). - Using (E)-2-{3-fluoro-8-[(2-isopropylimidazo[1,2-a]pyridin-3-yl)methyl]dibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (52 mg, 0.119 mmol) obtained in Reference Example 8C, and in the same manner as in Example 1, the title compound (compound 8c) (25 mg, 42%) was obtained.
ESIMS m/z: 497 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“) : 1.31-1.45 (m, 6H), 2.27 (s, 3H), 3.10-3.30 (m, 1H), 4.19-4.33 (m, 2H), 4.66 (d, J = 12.8 Hz, 1H), 5.50 (d, J = 12.8 Hz, 1H), 6.46-6.58 (m, 1H), 6.58-6.66 (m, 1H), 6.66-6.77 (m, 1H), 7.01-7.16 (m, 5H), 7.47-7.55 (m, 1H), 7.56-7.64 (m, 1H). - Using (E)-2-{8-[(2-cyclobutylimidazo[1,2-a]pyridin-3-yl)methyl]-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (125 mg, 0.278 mmol) obtained in Reference Example 8D, and in the same manner as in Example 1, the title compound (compound 8d) (30 mg, 21%) was obtained.
ESIMS m/z: 509 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 1.89-2.15 (m, 2H), 2.19-2.42 (m, 5H), 2.43-2.70 (m, 2H), 3.65-3.83 (m, 1H), 4.15-4.32 (m, 2H), 4.63 (d, J= 12.8 Hz, 1H), 5.46 (d, J = 12.8 Hz, 1H), 6.45-6.57 (m, 1H), 6.56-6.75 (m, 2H), 6.93-7.21 (m, 5H), 7.46-7.57 (m, 1H), 7.57-7.66 (m, 1H). - Using (E)-2-{8-[(2-cyclopentylimidazo[1,2-a]pyridin-3-yl)methyl]-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (92 mg, 0.198 mmol) obtained in Reference Example 8E, and in the same manner as in Example 1, the title compound (compound 8e) (30 mg, 29%) was obtained.
ESIMS m/z: 523 (M + H)+; 1H NMR (270 MHz, CDCl3,Ī“): 1.18-2.12 (m, 8H), 2.29 (s, 3H), 3.13-3.39 (m, 1H), 4.26-4.40 (m, 2H), 4.75 (d, J = 12.8 Hz, 1H), 5.51 (d, J = 12.8 Hz, 1H), 6.49-6.58 (m, 1H), 6.60-6.78 (m, 2H), 6.98-7.29 (m, 5H), 7.53-7.68 (m, 2H). - Using (E)-2-(3-fluoro8-{[2-(methoxymethyl)imidazo[1,2-a]pyridin-3-yl]methyl}dibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (84 mg, 0.19 mmol) obtained in Reference Example 8F, and in the same manner as in Example 1, the title compound (compound 8f) (40 mg, 42%) was obtained.
ESIMS m/z: 499 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 2.29 (s, 3H), 3.48 (s, 3H), 4.41 (s, 2H), 4.76-4.80 (m, 3H), 5.63 (d, J = 12.1 Hz, 1H), 6.42-6.46 (m, 1H), 6.62-6.68 (m, 1H), 7.04-7.22 (m, 5H), 7.61-7.66 (m, 1H), 7.85-7.87 (m, 1H), 8.11-8.14 (m, 1H). - Using (E)-2-[3-fluoro-8-({2-[(methoxy-d3)-methyl]imidazo[1,2-a]pyridin-3-yl}methyl)dibenzo[b,e]oxepin-11(6H)-ylidene]propanenitrile (110 mg, 0.25 mmol) obtained in Reference Example 8G, and in the same manner as in Example 1, the title compound (compound 8g) (38 mg, 30%) was obtained.
ESIMS m/z: 502 (M + H)+; 1H NMR (270 MHz, DMSO-d6,Ī“): 2.15 (s, 3H), 4.32-4.44 (m, 2H), 4.58 (s, 2H), 4.87 (d, J = 12.7 Hz, 1H), 5.48 (d, J = 12.7 Hz, 1H), 6.65 (d, J = 10.7 Hz, 1H), 6.70-6.90 (m, 2H), 7.00 (d, J = 7.8 Hz, 1H), 7.14-7.30 (m, 3H), 7.30 (s, 1H), 7.51 (d, J = 8.8 Hz, 1H), 8.10 (d, J= 6.8 Hz, 1H), 12.11 (br s, 1H). - Using (E)-2-{8-[(8-chloro-2-isopropylimidazo[1,2-a]pyridin-3-yl)methyl]-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (263 mg, 0.56 mmol) obtained in Reference Example 8H, and in the same manner as in Example 1, the title compound (compound 8h) (159 mg, 54%) was obtained.
ESIMS m/z: 531 (M + H)+; 1H NMR (300 MHz, DMSO-d6, Ī“): 1.19-1.29 (m, 6H), 2.15 (s, 3H), 3.12-3.26 (m, 1H), 4.35 (s, 2H), 4.90 (d, J = 12.5 Hz, 1H), 5.47 (d, J= 12.5 Hz, 1H), 6.65 (dd, J = 10.6, 2.6 Hz, 1H), 6.72-6.83 (m, 2H), 7.01 (d, J = 7.7 Hz, 1H), 7.05-7.12 (m, 1H), 7.18-7.27 (m, 2H), 7.34 (dd, J= 7.3, 0.7 Hz, 1H), 8.08 (d, J = 5.9 Hz, 1H), 12.09 (br s, 1H). - Using (E)-2-{3-fluoro-8-[(2-propylimidazo[1,2-a]pyridin-3-yl)methyl]dibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (148 mg, 0.338 mmol) obtained in Reference Example 8I, and in the same manner as in Example 1, the title compound (compound 8i) (29 mg, 17%) was obtained.
ESIMS m/z: 497 (M + H)+; 1H NMR (270 MHz, CDCl3, CD3OD, Ī“): 0.98 (t, J = 7.2 Hz, 3H), 1.77-1.89 (m, 2H), 2.25 (s, 3H), 2.78 (t, J = 7.2 Hz, 2H), 4.24 (d, J = 17.6 Hz, 1H), 4.31 (d, J = 17.6 Hz, 1H), 4.72 (d, J = 12.7 Hz, 1H), 5.51 (d, J= 12.7 Hz, 1H), 6.53 (d, J = 9.8 Hz, 1H), 6.60-6.79 (m, 2H), 7.00-7.19 (m, 5H), 7.75-7.64 (m, 2H). - Using (E)-2-{8-[(8-chloro-2-cyclobutylimidazo[1,2-a]pyridin-3-yl)methyl]-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (84 mg, 0.174 mmol) obtained in Reference Example 8J, and in the same manner as in Example 1, the title compound (compound 8j) (18 mg, 19%) was obtained.
ESIMS m/z: 543 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“) : 1.84-2.14 (m, 2H), 2.21-2.42 (m, 5H), 2.56-2.74 (m, 2H), 3.70-3.92 (m, 1H), 4.23-4.42 (m, 2H), 4.73 (d, J= 12.8 Hz, 1H), 5.50 (d, J = 12.8 Hz, 1H), 6.44-6.57 (m, 1H), 6.58-6.77 (m, 2H), 7.01-7.18 (m, 4H), 7.18-7.31 (m, 1H), 7.52-7.60 (m, 1H). - Using (E)-2-(3-fluoro-8-{[8-chloro-2-(methoxymethyl)imidazo[1,2-a]pyridin-3-yl]methyl}dibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (100 mg, 0.211 mmol) obtained in Reference Example 8K, and in the same manner as in Example 14, the title compound (compound 8k) (48 mg, 42%) was obtained.
ESIMS m/z: 531 (M - H)-; 1H NMR (270 MHz, DMSO-d6, Ī“): 2.15 (s, 3H), 3.29 (s, 3H), 4.38 (d, J = 17.0 Hz, 1H), 4.44 (d, J = 17.0 Hz, 1H), 4.61 (s, 2H), 4.48 (d, J = 12.8 Hz, 1H), 4.88 (d, J = 12.8 Hz, 1H), 6.65 (dd, J = 2.9, 10.7 Hz, 1H), 6.71-6.89 (m, 2H), 7.00 (d, J = 7.8 Hz, 1H), 7.12-7.32 (m, 2H), 7.29 (s, 1H), 7.41 (d, J = 7.8 Hz, 1H), 8.13 (d, J= 6.8 Hz, 1H), 12.10 (s, 1H). - Using (E)-2-{8-[(8-chloro-2-cyclopropylimidazo[1,2-a]pyridin-3-yl)methyl]-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene}acetonitrile (225 mg, 0.494 mmol) obtained in Reference Example 8L, and in the same manner as in Example 1, the title compound (compound 81) (52 mg, 32%) was obtained.
ESIMS m/z: 515 (M + H)+; 1H NMR (300 MHz, CDCl3, Ī“): 1.02-1.08 (m, 2H), 1.19-1.24 (m, 2H), 2.02-2.10 (m, 1H), 4.44 (s, 2H), 4.82 (br s, 1H), 5.44 (br s, 1H), 6.52-6.57 (m, 2H), 6.63-6.75 (m, 2H), 7.18-7.38 (m, 5H), 7.57 (d, J = 5.9 Hz, 1H). - Using (E)-2-{8-[(2-cyclopropyl-8-methoxyimidazo[1,2-a]pyridin-3-yl)methyl]-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene}acetonitrile (93 mg, 0.206 mmol) obtained in Reference Example 8M, and in the same manner as in Example 1, the title compound (compound 8m) (17 mg, 16%) was obtained.
ESIMS m/z: 511 (M + H)+; 1H NMR (300 MHz, CDCl3,Ī“): 0.97-1.04 (m, 2H), 1.20-1.27 (m, 2H), 1.98-2.08 (m, 1H), 3.99 (s, 3H), 4.41 (s, 2H), 4.79 (br s, 1H), 5.42 (br s, 1H), 6.44 (d, J = 7.3 Hz, 1H), 6.51-6.57 (m, 2H), 6.61-6.74 (m, 2H), 7.16-7.37 (m, 5H). - Using (Z)-2-{8-[(8-chloro-2-cyclopropylimidazo[1,2-a]pyridin-3-yl)methyl]-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene}-2-fluoroacetonitrile (46 mg, 0.097 mmol) obtained in Reference Example 8N, and in the same manner as in Example 1, the title compound (compound 8n) (11 mg, 21%) was obtained.
ESIMS m/z: 533 (M + H)+; 1H NMR (270 MHz, CDCl3,Ī“) : 1.01-1.16 (m, 2H), 1.18-1.29 (m, 2H), 2.00-2.12 (m, 1H), 4.39 (s, 2H), 4.77 (d, J = 12.8 Hz, 1H), 5.56 (d, J = 12.8 Hz, 1H), 6.44-6.57 (m, 1H), 6.58-6.71 (m, 1H), 6.90-7.01 (m, 1H), 7.01-7.14 (m, 1H), 7.20-7.30 (m, 2H), 7.36-7.49 (m, 2H), 7.62-7.77 (m, 1H). - Using (E)-2-{8-[(2-cyclopropyl-8-methoxyimidazo[1,2-a]pyridin-3-yl)methyl]-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (100 mg, 0.215 mmol) obtained in Reference Example 9A, and in the same manner as in Example 1, the title compound (compound 9a) (65 mg, 55%) was obtained.
ESIMS m/z: 525 (M + H)+; 1H NMR (270 MHz, CDCl3,Ī“) : 0.09-1.03 (m, 2H), 1.09-1.25 (m, 2H), 1.93-2.07 (m, 1H), 2.27 (s, 3H), 3.95 (s, 3H), 4.32 (d, J = 17.4 Hz, 1H), 4.40 (d, J = 17.4 Hz, 1H), 4.73 (d, J = 12.6 Hz, 1H), 5.49 (d, J = 12.6 Hz, 1H), 6.40 (d, J = 7.2 Hz, 1H), 6.45-6.73 (m, 3H), 7.01-7.30 (m, 5H). - Using (E)-2-{8-[(2-cyclopropyl-8-ethoxyimidazo[1,2-a]pyridin-3-yl)methyl]-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (160 mg, 0.334 mmol) obtained in Reference Example 9B, and in the same manner as in Example 1, the title compound (compound 9b) (60 mg, 33%) was obtained.
ESIMS m/z: 539 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“) : 0.90-1.00 (m, 2H), 1.09-1.19 (m, 2H), 1.48 (t, J = 6.8 Hz, 3H), 1.94-2.06 (m, 1H), 2.26 (s, 3H), 4.19 (q, J = 6.8 Hz, 2H), 4.32 (d, J = 17.0 Hz, 1H), 4.38 (d, J = 17.0 Hz, 1H), 4.69 (d, J = 22.7 Hz, 1H), 5.47 (d, J = 12.7 Hz, 1H), 6.39 (d, J = 7.8 Hz, 1H), 6.51 (d, J = 7.8 Hz, 1H), 6.57-6.70 (m, 2H), 7.01-7.28 (m, 5H). - Using (E)-2-(8-{[2-cyclopropyl-8-{difluoromethoxy)imidazo[1,2-a]pyridin-3-yl]methyl}-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (205 mg, 0.409 mmol) obtained in Reference Example 9C, and in the same manner as in Example 1, the title compound (compound 9c) (52 mg, 23%) was obtained.
ESIMS m/z: 561 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 0.95-1.08 (m, 2H), 1.08-1.19 (m, 2H), 1.94-2.08 (m, 1H), 2.31 (s, 3H), 4.27-4.49 (m, 2H), 4.79 (d, J = 12.8 Hz, 1H), 5.52 (d, J = 12.8 Hz, 1H), 6.50-6.59 (m, 1H), 6.63-6.74 (m, 2H), 6.84-6.99 (m, 1H), 7.05-7.23 (m, 4H), 7.35-7.61 (m, 2H). - Using (E)-2-{3-fluoro-8-[(2-isopropyl-8-methoxyimidazo[1,2-a]pyridin-3-yl)methyl]dibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (148 mg, 0.32 mmol) obtained in Reference Example 9D, and in the same manner as in Example 1, the title compound (compound 9d) (68 mg, 41%) was obtained.
ESIMS m/z: 527 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 1.36-1.50 (m, 6H), 2.27 (s, 3H), 3.12-3.28 (m, 1H), 3.97 (s, 3H), 4.23-4.37 (m, 2H), 4.72 (d, J = 12.7 Hz, 1H), 5.50 (d, J= 12.7 Hz, 1H), 6.41 (d, J = 7.8 Hz, 1H), 6.48-6.57 (m, 1H), 6.59-6.71 (m, 2H), 7.02-7.19 (m, 4H), 7.22 (d, J = 6,8 Hz, 1H). - Using (E)-2-(3-fluoro-8-{[8-methoxy-2-(methoxymethyl)imidazo[1,2-a]pyridin-3-yl]methyl}dibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (75 mg, 0.16 mmol) obtained in Reference Example 9E, and in the same manner as in Example 14, the title compound (compound 9e) (35 mg, 42%) was obtained.
ESIMS m/z: 529 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 2.28 (s, 3H), 3.39 (s, 3H), 3.96 (s, 3H), 4.37 (s, 2H), 4.66 (d, J = 12.7 Hz, 1H), 4.67 (s, 2H), 5.51 (d, J = 12.7 Hz, 1H), 6.45-6.68 (m, 2H), 6.64 (t, J = 7.3 Hz, 1H), 6.77 (t, J = 6.8 Hz, 1H), 7.04-7.21 (m, 4H), 7.35 (d, J = 6.8 Hz, 1H). - Using (E)-2-(3-fluoro-8-{[2-isopropyl-8-(methoxy-d3)-imidazo[1,2-a]pyridin-3-yl]methyl}dibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (123 mg, 0.26 mmol) obtained in Reference Example 9F, and in the same manner as in Example 1, the title compound (compound 9f) (57 mg, 41%) was obtained.
ESIMS m/z: 530 (M + H)+; 1H NMR (300 MHz, CDCl3, Ī“) : 1.37-1.48 (m, 6H), 2.28 (s, 3H), 3.15-3.29 (m, 1H), 4.21-4.39 (m, 2H), 4.73 (d, J = 12.5 Hz, 1H), 5.53 (d, J = 12.5 Hz, 1H), 6.43-6.57 (m, 2H), 6.60-6.75 (m, 2H), 7.03-7.18 (m, 4H), 7.21-7.27 (m, 1H). - Using (E)-2-(8-{[8-(difluoromethoxy)-2-isopropylimidazo[1,2-a]pyridin-3-yl]methyl}-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (149 mg, 0.30 mmol) obtained in Reference Example 9G, and in the same manner as in Example 1, the title compound (compound 9g) (65 mg, 39%) was obtained.
ESIMS m/z: 563 (M + H)+; 1H NMR (300 MHz, CDCl3, Ī“) : 1.34-1.44 (m, 6H), 2.28 (s, 3H) ; 3.14-3.27 (m, 1H), 4.25-4.39 (m, 2H), 4.77 (d, J = 12.5 Hz, 1H), 5.52 (d, J = 12.5 Hz, 1H), 6.54 (dd, J = 10.3, 2.6 Hz, 1H), 6.61-6.70 (m, 2H), 6.85-6.93 (m, 1H), 7.07 (dd, J = 8.6, 6.4 Hz, 1H), 7.10-7.18 (m, 3H), 7.44 (dd, J= 7.0, 0.7 Hz, 1H), 7.51 (t, J = 74.4 Hz, 1H). - Using (E)-2-(8-{[2-cyclopropyl-8-(methoxy-d3-)imidazo[1,2-a]pyridin-3-yl]methyl}-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (147 mg, 0.31 mmol) obtained in Reference Example 9H, and in the same manner as in Example 1, the title compound (compound 9h) (51 mg, 31%) was obtained.
ESIMS m/z: 528 (M + H)+; 1H NMR (300 MHz, CDCl3, Ī“) : 0.91-1.01 (m, 2H), 1.12-1.22 (m, 2H), 1.93-2.07 (m, 1H), 2.28 (s, 3H), 4.28-4.44 (m, 2H), 4.73 (d, J = 12.5 Hz, 1H), 5.49 (d, J= 12.5 Hz, 1H), 6.39 (d, J = 7.7 Hz, 1H), 6.53 (dd, J = 10.3, 2.6 Hz, 1H), 6.57-6.69 (m, 2H), 7.06 (dd, J = 8.8, 6.6 Hz, 1H), 7.11-7.17 (m, 2H), 7.19-7.26 (m, 2H). - Using (E)-2-{8-[(2-cyclopropyl-8-fluoroimidazo[1,2-a]pyridin-3-yl)methyl]-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (155 mg, 0.342 mmol) obtained in Reference Example 9I, and in the same manner as in Example 1, the title compound (compound 9i) (32 mg, 17%) was obtained.
ESIMS m/z: 513 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 0.95-1.09 (m, 2H), 1.09-1.22 (m, 2H), 1.99-2.10 (m, 1H), 2.28 (s, 3H), 4.35 (d, J = 17.6 Hz, 1H), 4.42 (d, J = 17.6 Hz, 1H), 4.75 (d, J = 12.7 Hz, 1H), 5.51 (d, J= 12.7 Hz, 1H), 6.53 (dd, J = 2.9, 9.8 Hz, 1H), 6.54-6.70 (m, 2H), 6.77-6.84 (m, 1H), 7.05-7.27 (m, 4H), 7.41 (d, J = 6.8 Hz, 1H). - Using (E)-2-(8-{[8-(difluoromethoxy)-2-(methoxymethyl)imidazo[1,2-a]pyridin-3-yl]methyl}-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (48 mg, 0.089 mmol) obtained in Reference Example 9J, and in the same manner as in Example 14, the title compound (compound 9j) (19 mg, 36%) was obtained.
ESIMS m/z: 565 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 2.28 (s, 3H), 3.44 (s, 3H), 4.36 (d, J = 12.9 Hz, 1H), 4.45 (d, J = 12.9 Hz, 1H), 4.71 (s, 2H), 4.75 (d, J = 12.6 Hz, 1H), 5.52 (d, J = 12.6 Hz, 1H), 6.53 (dd, J = 2.6, 10.2 Hz, 1H), 6.66 (d t, J = 2.6, 8.3 Hz, 1H), 6.78 (t, J = 7.1 Hz, 1H), 6.95-7.28 (m, 5H), 7.21 (t, J = 72.4 Hz, 1H), 7.56 (d, J = 5.9 Hz, 1H). - Using (E)-2-{3-fluoro-8-[(8-methoxy-2-cyclopropylimidazo[1,2-a]pyridin-3-yl)methyl]dibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (74 mg, 0.158 mmol) obtained in Reference Example 9K, and in the same manner as in Example 1, the title compound (compound 9k) (2.5 mg, 3%) was obtained.
ESIMS m/z: 527 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“) : 0.90 (t, J = 7.3 Hz, 3H), 1.70-1.90 (m, 2H), 2.23 (s, 3H), 2.77-2.95 (m, 2H), 3.96 (s, 3H), 4.26 (s, 2H), 4.74 (d, J = 12.8 Hz, 1H), 5.65 (d, J = 12.8 Hz, 1H), 6.48 (dd, J = 10.3, 2.6 Hz, 1H), 6.60-6.73 (m, 1H), 6.78-6.93 (m, 2H), 6.94-7.21 (m, 4H), 7.41 (d, J = 6.6 Hz, 1H). - Using (E)-2-(8-{[8-chloro-2-(methoxy-d3-methyl)imidazo[1,2-a]pyridin-3-yl]methyl}-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (135 mg, 0.28 mmol) obtained in Reference Example 9L, and in the same manner as in Example 1, the title compound (compound 91) (78 mg, 51%) was obtained.
ESIMS m/z: 536 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“) : 2.29 (s, 3H), 4.42 (s, 2H), 4.65 (d, J = 12.7 Hz, 1H), 4.70 (s, 2H), 5.48 (d, J = 12.7 Hz, 1H), 6.50-6.55 (m, 1H), 6.64-6.76 (m, 2H), 7.05-7.15 (m, 2H), 7.16 (d, J = 7.8 Hz, 1H), 7.23-7.29 (m, 2H), 7.60 (d, J = 6.8 Hz, 1H). - Using (E)-2-{8-[(7-chloro-2-cyclopropylimidazo[1,2-a]pyridin-3-yl)methyl]-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (83 mg, 0.177 mmol) obtained in Reference Example 10A, and in the same manner as in Example 1, the title compound (compound 10a) (42 mg, 44%) was obtained.
ESIMS m/z: 529 (M + H)+; 1H NMR (270 MHz, DMSO-d6, Ī“): 0.82-0.99 - (m, 4H), 2.09-2.20 (m, 1H), 2.15 (s, 3H), 4.38 (d, J = 17.1 Hz, 1H), 4.44 (d, J = 17.1 Hz, 1H), 4.90 (d, J = 12.7 Hz, 1H), 5.49 (d, J = 12.7 Hz, 1H), 6.65 (dd, J = 10.8, 2.0 Hz, 1H), 6.74-6.84 (m, 1H), 6.84 (dd, J = 7.8, 2.0 Hz, 1H), 7. 02 (d, J = 7.8, 1H), 7.16 (d, J = 7.8, 1H), 7.19-7.20 (m, 1H), 7.26 (s, 1H), 7.57 (d, J = 2.0, 1H), 8.09 (d, J = 7.8, 1H).
- Using (E)-2-{8-[(6-chloro-2-cyclopropylimidazo[1,2-a]pyridin-3-yl)methyl]-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (88 mg, 0.187 mmol) obtained in Reference Example 10B, and in the same manner as in Example 1, the title compound (compound 10b) (37 mg, 36%) was obtained.
ESIMS m/z: 529 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 0.95-1.20 (m, 4H), 1.94-2.07 (m, 1H), 2.28 (s, 3H), 4.34 (s, 2H), 4.80 (d, J = 12.7 Hz, 1H), 5.54 (d, J = 12.7 Hz, 1H), 6.50-6.73 (m, 2H), 7.00-7.30 (m, 5H), 7.45 (d, J = 9.8 Hz, 1H), 7.67 (s, 1H). - Using (E)-2-{8-[(2-cyclopropyl-7-fluoroimidazo[1,2-a]pyridin-3-yl)methyl]-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (21 mg, 0.046 mmol) obtained in Reference Example 10C, and in the same manner as in Example 1, the title compound (compound 10c) (1.6 mg, 7%) was obtained.
ESIMS m/z: 513 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 0.91-1.18 (m, 4H), 1.89-2.08 (m, 1H), 2.29 (s, 3H), 4.26-4.50 (m, 2H), 4.78 (d, J = 12.8 Hz, 1H), 5.53 (d, J = 12.8 Hz, 1H), 6.39-6.77 (m, 3H), 7.00-7.30 (m, 5H), 7.44-7.59 (m, 1H). - Using (E)-2-{8-[(2-cyclopropyl-6-fluoroimidazo[1,2-a]pyridin-3-yl)methyl]-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (110 mg, 0.24 mmol) obtained in Reference Example 10D, and in the same manner as in Example 14, the title compound (compound 10d) (48 mg, 39%) was obtained.
ESIMS m/z: 513 (M + H)+; 1H NMR (300 MHz, CDCl3,Ī“) : 0.96-1.16 (m, 4H), 1.94-2.07 (m, 1H), 2.28 (s, 3H), 4.35 (s, 2H), 4.80 (d, J = 12.5 Hz, 1H), 5.54 (d, J = 12.5 Hz, 1H), 6.54 (dd, J = 10.3, 2.6 Hz, 1H), 6.61-6.70 (m, 1H), 6.97-7.11 (m, 2H), 7.11-7.26 (m, 3H), 7.48 (dd, J = 10.1, 4.9 Hz, 1H), 7.52-7.58 (m, 1H). - Using (E)-2-(8-{[7-chloro-2-(methoxymethyl)imidazo[1,2-a]pyridin-3-yl]methyl}-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (72mg, 0.15 mmol) obtained in Reference Example 10E, and in the same manner as in Example 14, the title compound (compound 10e) (16 mg, 19%) was obtained.
ESIMS m/z: 533 (M + H)+; 1H NMR (270 MHz, DMSO-d6, Ī“): 2.15 (s, 3H), 3.27 (s, 3H), 4.39 (s, 2H), 4.56 (s, 2H), 4.87 (d, J = 12.5 Hz, 1H), 5.48 (d, J = 12.5 Hz, 1H), 6.65 (dd, J = 2.6, 10.8 Hz, 1H), 6.79 (d t, J = 2.7, 8.3 Hz, 1H), 6.81-6.96 (m, 1H), 7.18 (d, J = 7.9 Hz, 1H), 7.22 (d, J= 6.9 Hz, 1H), 7.25 (d, J = 6.9 Hz, 1H), 7.27 (s, 1H), 7.70 (s, 1H), 8.16 (d, J = 7.6 Hz, 1H), 12.08 (br s, 1H). - Using (E)-2-{8-[(2-cyclopropyl-7-methoxyimidazo[1,2-a]pyridin-3-yl)methyl]-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (127 mg, 0.27 mmol) obtained in Reference Example 10G, and in the same manner as in Example 1, the title compound (compound 10g) (7.2 mg, 5%) was obtained.
ESIMS m/z: 525 (M + H)+; 1H NMR (300 MHz, CDCl3,Ī“): 0.92-1.02 (m, 2H), 1.04-1.12 (m, 2H), 1.89-2.01 (m, 1H), 2.28 (s, 3H), 3.78 (s, 3H), 4.23-4.39 (m, 2H), 4.74 (d, J = 12.5 Hz, 1H), 5.52 (d, J = 12.5 Hz, 1H), 6.43 (dd, J = 7.3, 2.6 Hz, 1H), 6.53 (dd, J = 10.3, 2.6 Hz, 1H), 6.60-6.68 (m, 2H), 6.85 (d, J = 2.2 Hz, 1H), 7.02-7.22 (m, 4H), 7.40 (d, J = 7.3 Hz, 1H). - Using (E)-2-(3-fluoro-8-{[2-methyl-8-(trifluoromethyl)imidazo[1,2-a]pyridin-3-yl]methyl}dibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (74 mg, 0.16 mmol) obtained in Reference Example 10H, and in the same manner as in Example 14, the title compound (compound 10h) (9.5 mg, 11%) was obtained.
ESIMS m/z: 537 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 2.21 (s, 3H), 2.34 (s, 3H), 4.19-4.40 (m, 3H), 5.42 (d, J = 12.5 Hz, 1H), 6.48 (dd, J = 2.6, 10.3 Hz, 1H), 6.63-6.74 (m, 2H), 6.85 (t, J = 7.0 Hz, 1H), 7.11-7.21 (m, 1H), 7.23-7.32 (m, 2H), 7.56 (d, J = 7.3 Hz, 1H), 7.55 (d, J = 7.0 Hz, 1H). - Using (E)-2-{8-[(8-bromo-2-cyclopropylimidazo[1,2-a]pyridin-3-yl)methyl]-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (72 mg, 0.14 mmol) obtained in Reference Example 10I, and in the same manner as in Example 1, the title compound (compound 10i) (30 mg, 38%) was obtained.
ESIMS m/z: 573 (M + H)+; 1H NMR (270 MHz, CDCl3,Ī“): 0.90-1.29 (m, 4H), 1.89-2.08 (m, 1H), 2.22 (s, 3H), 4.21-4.36 (m, 2H), 4.68 (d, J = 12.7 Hz, 1H), 5.54 (d, J = 12.7 Hz, 1H), 6.45 (dd, J = 10.2, 2.4 Hz, 1H), 6.49-6.60 (m, 1H), 6.66-6.75 (m, 1H), 6.95-7.20 (m, 4H), 7. 42 (d, J = 7.8 Hz, 1H), 7.60 (d, J = 6.8 Hz, 1H). - Using (E)-2-(8-{[7-chloro-2-methylimidazo[1,2-a]pyridin-3-yl]methyl}-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (360 mg, 0.811 mmol) obtained in Reference Example 10J, and in the same manner as in Example 14, the title compound (compound 10j) (84 mg, 20%) was obtained.
ESIMS m/z: 503 (M + H)+; 1H NMR (270 MHz, DMSO-d6, Ī“): 2.15 (s, 3H), 2.37 (s, 3H), 4.28 (d, J = 17.1 Hz, 1H), 4.34 (d, J = 17.1 Hz, 1H), 4.92 (d, J = 11.7 Hz, 1H), 5.47 (d, J = 11. 7 Hz, 1H), 6.65 (d, J = 10.7 Hz, 1H), 6.81-6.90 (m, 2H), 7.00 (d, J = 7.8 Hz, 1H), 7.01-7.29 (m, 3H), 7.59 (s, 1H), 8.11 (d, J= 6.8 Hz, 1H), 12.10 (br s, 1H). - Using (E)-2-{8-[(2-cyclopropyl-8-methylimidazo[1,2-a]pyridin-3-yl)methyl]-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (180 mg, 0.40 mmol) obtained in Reference Example 10K, and in the same manner as in Example 1, the title compound (compound 10k) (85 mg, 42%) was obtained.
ESIMS m/z: 509 (M + H)+; 1H NMR (270 MHz, CDCl3,Ī“): 0.94-1.24 (m, 4H), 1.95-2.10 (m, 1H), 2.27 (s, 3H), 2.53 (s, 3H), 4.29-4.44 (m, 2H), 4.72 (d, J = 12.7 Hz, 1H), 5.47 (d, J= 12.7 Hz, 1H), 6.53 (dd, J = 10.2, 2.4 Hz, 1H), 6.55-6.69 (m, 2H), 6.88 (d, J = 6.8 Hz, 1H), 7.00-7.18 (m, 3H), 7.21 (d, J = 7.8 Hz, 1H), 7.46 (d, J = 6.8 Hz, 1H). - Using (E)-2-{8-[(7-chloro-2-ethylimidazo[1,2-a]pyridin-3-yl)methyl]-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (200 mg, 0.437 mmol) obtained in Reference Example 10L, and in the same manner as in Example 1, the title compound (compound 101) (112 mg, 50%) was obtained.
ESIMS m/z: 517 (M + H)+; 1H NMR (270 MHz, DMSO-d6,Ī“): 1.21 (t, J = 7.5 Hz, 3H), 2.15 (s, 3H), 2.72 (q, J = 7.5 Hz, 2H), 4.32 (s, 2H), 4.91 (d, J = 12.5 Hz, 1H), 5.48 (d, J = 12.5 Hz, 1H), 6.65 (dd, J = 2.7, 10.7 Hz, 1H), 6.79 (dt, J= 2.6, 8.4 Hz, 1H), 6.85 (dd, J = 2.2, 7.3 Hz, 1H), 7.01 (d, J = 7.7 Hz, 1H), 7.12 (d, J = 7.7 Hz, 1H), 7.17-7.29 (m, 2H), 7.63 (d, J= 1.8 Hz, 1H), 8.11 (d, J = 7.3 Hz, 1H), 12.11 (br s, 1H). - Using (E)-2-{8-[(8-chloro-2-methylimidazo[1,2-a]pyridin-3-yl)methyl]-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (329 mg, 0.741 mmol) obtained in Reference Example 11A, and in the same manner as in Example 1, the title compound (compound 11a) (18 mg, 5%) was obtained.
ESIMS m/z: 503 (M + H)+; 1H NMR (270 MHz, CDCl3,Ī“): 2. 16 (s, 3H), 2.34 (s, 3H), 3.96-4.43 (m, 3H), 5.37 (d, J = 12.8 Hz, 1H), 6.39-6.56 (m, 2H), 6.58-6.82 (m, 2H), 7.12-7.40 (m, 4H), 7.47-7.60 (m, 1H). - Using (E)-2-(3-fluoro-8-{[2-methyl-7-(trifluoromethyl)imidazo[1,2-a]pyridin-3-yl]methyl}dibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (450 mg, 0.943 mmol) obtained in Reference Example 11B, and in the same manner as in Example 14, the title compound (compound 11b) (350 mg, 70%) was obtained.
ESIMS m/z: 537 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 2.27 (s, 3H), 2.62 (s, 3H), 4.27-4.40 (m, 2H), 4.74-4.78 (m, 1H), 5.48-5.55 (m, 1H), 6.62-6.68 (m, 1H), 7.03-7.16 (m, 5H), 7.27-7.35(m, 2H), 7.73-7.74 (m, 1H). - Using (E)-2-(8-{[2-cyclopropyl-8-(2-hydroxypropan-2-yl)imidazo[1,2-a]pyridin-3-yl]methyl}-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (240 mg, 0.49 mmol) obtained in Reference Example 11C, and in the same manner as in Example 1, the title compound (compound 11c) (68 mg, 25%) was obtained.
ESIMS m/z: 553 (M + H)+; 1H NMR (300 MHz, CDCl3,Ī“): 0.92-1.03 (m, 2H), 1.06-1.15 (m, 2H), 1.67 (s, 3H), 1.67 (s, 3H), 1.93-2.04 (m, 1H), 2.28 (s, 3H), 4.29-4.45 (m, 2H), 4.79 (d, J= 12.8 Hz, 1H), 5.52 (d, J = 12.8 Hz, 1H), 6.54 (dd, J = 9.9, 2.6 Hz, 1H), 6.61-6.71 (m, 2H), 6.92-6.98 (m, 1H), 7.02-7.10 (m, 1H), 7.12-7.26 (m, 3H), 7.48 (d, J = 6.6 Hz, 1H). - Using (E)-2-(8-{[2-cyclopropyl-8-(trifluoromethyl)imidazo[1,2-a]pyridin-3-yl]methyl}-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (290 mg, 0.58 mmol) obtained in Reference Example 11D, and in the same manner as in Example 1, the title compound (compound 11d) (149 mg, 46%) was obtained.
ESIMS m/z: 563 (M + H)+; 1H NMR (270 MHz, DMSO-d6,Ī“): 0.90-0.95 (m, 4H), 2.15 (s, 3H), 2.11-2.24 (m, 1H), 4.35-4.54 (m, 2H), 4.92 (d, J = 12.7 Hz, 1H), 5.49 (d, J= 12.7 Hz, 1H), 6.65 (dd, J = 10.7, 2.0 Hz, 1H), 6.74-6.82 (m, 1H), 6.91 (t, J = 6.8 Hz, 1H), 7.03 (d, J = 7.8 Hz, 1H), 7.14-7.30 (m, 2H), 7.30 (s, 1H), 7.58 (d, J = 7.8 Hz, 1H), 8.53 (d, J = 6.8 Hz, 1H), 12.10 (br s, 1H). - Using (E)-2-{8-[(2-cyclopropylimidazo[1,2-b]pyridazin-3-yl)methyl]-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (40 mg, 0.092 mmol) obtained in Reference Example 11E, and in the same manner as in Example 14, the title compound (compound 11e) (2.2 mg, 4.4%) was obtained.
ESIMS m/z: 496 (M + H)+; 1H NMR (300 MHz, CDCl3, Ī“): 1.01-1.17 (m, 4H), 2.05-2.11 (m, 1H), 2.27 (s, 3H), 4.48 (s, 2H), 4.79 (d, J = 12.5 Hz, 1H), 5.53 (d, J = 12.5 Hz, 1H), 6.52 (dd, J = 10.3, 2.6 Hz, 1H). 6.60-6.67 (m, 1H), 6.91-7.14 (m, 3H), 7.30-7.35 (m, 2H), 7.80 (dd, J = 9.0, 1.6 Hz, 1H), 8.21-8.24 (m, 1H). - Using (E)-2-{3-fluoro-8-[(2-isopropyl-7-methoxyimidazo[1,2-a]pyrimidin-3-yl)methyl]dibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (110 mg, 0.235 mmol) obtained in Reference Example 11F, and in the same manner as in Example 1, the title compound (compound 11f) (6.8 mg, 5%) was obtained.
ESIMS m/z: 528 (M + H)+; 1H NMR (270 MHz, CDCl3,Ī“): 1.30-1.46 (m, 6H), 2.17 (s, 3H), 3.02-3.20 (m, 1H), 4.01 (s, 3H), 4.09-4.27 (m, 2H), 4.72 (d, J = 12.8 Hz, 1H), 5.54 (d, J = 12.8 Hz, 1H), 6.14-6.29 (m, 1H), 6.46-6.57 (m, 1H), 6.57-6.67 (m, 1H), 6.94-7.20 (m, 3H), 7.21-7.30 (m, 1H), 7.58-7.70 (m, 1H). - Using (E)-2-{8-[(2-cyclopropylimidazo[1,2-a]pyrazin-3-yl)methyl]-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (28 mg, 0.177 mmol) obtained in Reference Example 11G, and in the same manner as in Example 14, the title compound (compound 11g) (8.9 mg, 28%) was obtained.
ESIMS m/z: 496 (M + H)+; 1H NMR (270 MHz, DMSO-d6, Ī“): 0.82-1.09 (m, 4H), 2.00-2.30 (m, 1H), 2.16 (s, 3H), 4.47 (s, 2H), 4.91 (d,J = 12.5 Hz, 1H), 5.49 (d, J = 12.5 Hz, 1H), 6.65 (dd, J = 10.4, 2.4 Hz, 1H), 6.73-6.85 (m, 1H), 6.77 (d, J = 8.2 Hz, 1H), 7.14-7.36 (m, 3H), 7.77 (d, J = 4.6 Hz, 1H), 8.22 (d, J = 4.6 Hz, 1H), 8.86 (s, 1H), 12.11 (br s, 1H). - Using (E)-2-(8-{[2-cyclopropyl-7-(trifluoromethyl)imidazo[1,2-a]pyrimidin-3-yl]methyl}-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (91 mg, 0.180 mmol) obtained in Reference Example 11H, and in the same manner as in Example 1, the title compound (compound 11h) (1.0 mg, 1%) was obtained.
ESIMS m/z: 564 (M + H)+; 1H NMR (270 MHz, CDCl3,Ī“): 0.80-0.95 (m, 2H), 1.02-1.19 (m, 2H), 1.90-2.10 (m, 1H), 2.29 (s, 3H), 4.28-4.60 (m, 2H), 4.71-4.85 (m, 1H), 5.46-5.62 (m, 1H), 6.47-6.59 (m, 1H), 6.59-6.73 (m, 1H), 6.99-7.35 (m, 5H), 7.97-8.07 (m, 1H). - Using (E)-2-{8-[(2-cyclopropyl-8-methoxyimidazo[1,2-a]pyrazin-3-yl)methyl]-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (31 mg, 0.67 mmol) obtained in Reference Example 11I, and in the same manner as in Example 1, the title compound (compound 11i) (9.0 mg, 26%) was obtained.
ESIMS m/z: 526 (M + H)+; 1H NMR (270 MHz, CDCl3,Ī“): 1.10-1.48 (m, 4H), 1.95-2.12 (m, 1H), 2.32 (s, 3H), 4.12 (s, 3H), 4.25-4.48 (m, 2H), 4.76 (d, J = 12.8 Hz, 1H), 5.51 (d, J = 12.8 Hz, 1H), 6.46-6.77 (m, 2H), 6.98-7.41 (m, 6H). - Using (E)-2-{8-[(2-cyclopropylimidazo[1,2-a]pyrimidin-3-yl)methyl]-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (118 mg, 0.362 mmol) obtained in Reference Example 11J, and in the same manner as in Example 1, the title compound (compound 11j) (2.2 mg, 1.5%) was obtained.
ESIMS m/z: 496 (M + H)+; 1H NMR (270 MHz, CDCl3,Ī“): 0.74-0.93 (m, 2H), 1.00-1.19 (m, 2H), 1.99-2.15 (m, 1H), 2.29 (s, 3H), 4.39 (s, 2H), 4.73 (d, J = 12.7 Hz, 1H), 5.55 (d, J = 12.7 Hz, 1H), 6.51 (d, J = 10.7 Hz, 1H), 6.59-6.72 (m, 1H), 6.89-7.30 (m, 1H), 7.06-7.28 (m, 4H), 7.96 (dd, J = 6.8, Hz, 1H), 8.37-8.48 (m, 1H). - Using (E)-2-({8-[(8-chloro-2-cyclopropylimidazo[1,2-a]pyridin-3-yl)methyl]-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene}-2-cyclopropylacetonitrile (260 mg, 0.524 mmol) obtained in Reference Example 12A, and in the same manner as in Example 14, the title compound (compound 12a) (34 mg, 12%) was obtained.
ESIMS m/z: 555 (M + H)+; 1H NMR (270 MHz, CD3OH, Ī“): 0.27-0.95 (m, 8H), 1.92-2.07 (m, 2H), 4.32-4.43 (m, 2H), 4.69-4.72 (m, 1H), 5.44-5.47 (m, 1H), 6.42-6.46 (m, 1H), 6.58-6.63 (m, 1H), 6.99-7.01(m, 2H),7.06-7.10 (m, 2H), 7.38-7.42 (m, 2H), 7.80-7.86 (m, 1H), - Using (E)-2-cyclopropyl-2-(3-fluoro-{8-[{2-isopropylimidazo[1,2-a]pyridin-3-yl)methyl]dibenzo[b,e]oxepin-11(6H)-ylidene}acetonitrile (260 mg, 0.524 mmol) obtained in Reference Example 12B, and in the same manner as in Example 1, the title compound (compound 12b) (20 mg, 10%) was obtained.
ESIMS m/z: 523 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 0.46-0.99 (m, 4H), 1.24-1.30 (m, 6H), 1.98-2.09 (m, 1H), 3.20-3.32 (m, 1H), 4.18-4.31 (m, 2H), 4.57-4.61 (m, 1H), 5.57-5.61 (m, 1H), 6.61-6.67 (m, 1H), 6.79-6.91 (m, 1H), 7.03-7.08 (m, 2H), 7.17-7.22 (m, 2H), 7.39-7.50 (m, 2H), 7.61-7.68 (m, 1H), 7.80-7.83 (m, 1H). - Using (E)-2-cyclopropyl-2-{8-[(2-cyclopropylimidazo[1,2-a]pyridin-3-yl)methyl]dibenzo[b,e]oxepin-11(6H)-ylidene}acetonitrile (152 mg, 0.329 mmol) obtained in Reference Example 12C, and in the same manner as in Example 1, the title compound (compound 12c) (25 mg, 15%) was obtained.
ESIMS m/z: 521 (M + H)+; 1H NMR (270 MHz, CDCl3, 5): 0.45-1.14 (m, 8H), 1.94-2.08 (m, 1H), 3.61-3.67 (m, 1H), 4.20-4.30 (m, 2H), 4.52-4.56 (m, 1H), 5.48-5.52 (m, 1H), 6.39-6.43 (m, 1H), 6.61-6.66 (m, 3H), 6.92-7.03 (m, 3H), 7.17-7.19 (m, 1H), 7.43-7.48 (m, 1H), 7.61-7.66 (m, 1H). - Using (E)-2-cyclopropyl-2-{3-fluoro-8-[(2-(methoxymethyl)imidazo[1,2-a]pyridin-3-yl)methyl]dibenzo[b,e]oxepin-11(6H)-ylidene}acetonitrile (150 mg, 0.322 mmol) obtained in Reference Example 12D, and in the same manner as in Example 14, the title compound (compound 12d) (61 mg, 36%) was obtained.
ESIMS m/z: 525 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 0.52-1.18 (m, 4H), 2.03-2.15 (m, 1H), 3.34 (s, 3H), 4.28 (d, J = 12.7 Hz, 1H), 4.31 (s, 2H), 4.58 (s, 2H), 5.23 (d, J = 12.7 Hz, 1H), 6.44 (d, J = 10.7 Hz, 1H), 6.62 (t, J= 8.3 Hz, 1H), 6.76 (t, J = 6.8 Hz, 1H), 6.86 (s, 1H), 7.06-7.20 (m, 3H), 7.42 (t, J = 7.8 Hz, 1H), 7.49 (d, J = 9.8 Hz, 1H), 7.65 (d, J= 6.8 Hz, 1H). - Using (E)-2-{8-[(8-chloro-2-(methoxymethyl)imidazo[1,2-a]pyridin-3-yl)methyl]-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene}-2-cyclopropylacetonitrile (82 mg, 0.17 mmol) obtained in Reference Example 12E, and in the same manner as in Example 14, the title compound (compound 12e) (17 mg, 19%) was obtained.
ESIMS m/z: 559 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 0.45-1.02 (m, 4H), 1.96-2.05 (m, 1H), 3.43 (s, 3H), 4.37 (s, 2H), 4.46-4.51 (m, 1H), 4.67 (s, 2H), 5.49-5.53 (m, 1H), 6.30-6.35 (m, 1H), 6.58-6.67 (m, 1H), 7.01-7.06 (m, 2H), 7.12-7.22 (m, 2H), 7.42-7.52 (m, 2H), 7.75-7.77 (m, 1H). - Using (E)-2-{8-[(7-chloro-2-methylimidazo[1,2-a]pyridin-3-yl)methyl]-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene}-2-cyclopropylacetonitrile (120 mg, 0.26 mmol) obtained in Reference Example 12F, and in the same manner as in Example 14, the title compound (compound 12f) (19 mg, 14%) was obtained.
ESIMS m/z: 529 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 0.46-1.05 (m, 4H), 2.00-2.10 (m, 1H), 2.40 (s, 3H), 4.20 (s, 2H), 4.44 (d, J = 12.2 Hz, 1H), 5.45 (d, J= 12.2 Hz, 1H), 6.39 (dd, J = 2.4, 7.8 Hz, 1H), 6.59-6.68 (m, 1H), 6.93 (s, 1H), 6.59-6.68 (m, 1H), 6.95-7.08 (m, 2H), 7.19 (d, J = 7.8 Hz, 1H), 7.40-7.50 (m, 1H), 7.63-7.78 (m, 1H). - Using (E)-2-(8-{[7-chloro-2-(methoxymethyl)imidazo[1,2-a]pyridin-3-yl]methyl}-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)-2-cyclopropylacetonitrile (80 mg, 0.16 mmol) obtained in Reference Example 12G, and in the same manner as in Example 14, the title compound (compound 12g) (19 mg, 21%) was obtained.
ESIMS m/z: 559 (M + H)+; 1H NMR (270 MHz, DMSO-d6, Ī“): 0.34-0.87(m, 4H), 1.96-2.03 (m, 1H), 3.36 (s, 3H), 4.37-4.43 (m, 2H), 4.55 (s, 2H), 4.85-4.88 (m, 1H), 5.48-5.51 (m, 1H), 6.65-6.67 (m, 1H), 6.79-6.90 (m, 1H), 6.98-7.08 (m, 1H), 7.18-7.25 (m, 3H), 7.43-7.47 (m, 1H), 7.60-7.68 (m, 1H), 8.10-8.26 (m, 1H). - Using (E)- 2-cyclopropyl-2-(3-fluoro-8-{[2-(methoxy-d3methyl)imidazo[1,2-a]pyridin-3-yl]methyl}dibenzo[b,e]oxepin-11(6H)-ylidene)acetonitrile (92 mg, 0.20 mmol) obtained in Reference Example 12H, and in the same manner as in Example 14, the title compound (compound 12h) (17 mg, 16%) was obtained.
ESIMS m/z: 528 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 0.44-1.00 (m, 4H), 1.99-2.07 (m, 1H), 4.36 (s, 2H), 4.65-4.86 (m, 3H), 5. 69 (d, J = 12.5 Hz, 1H), 6.26-6.31 (m, 1H), 6.57-6.64 (m, 1H), 7.00-7.02 (m, 1H), 7.18-7.21 (m, 3H), 7.42-7.47 (m, 1H), 7.54-7.61 (m, 1H), 7.84-8.00 (m, 2H). - Using (E)-2-{3-fluoro-8-[(2-methyl-1H-indol-3-yl)methyl]dibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (100 mg, 0.245 mmol) obtained in Reference Example 13A, and in the same manner as in Example 14, the title compound (compound 13a) (65 mg, 57%) was obtained.
ESIMS m/z: 468 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 2.27 (s, 3H), 2.39 (s, 3H), 4.10 (s, 2H), 4.77 (d, J = 12.7 Hz, 1H), 5.51 (d, J = 12.7 Hz, 1H), 6.52 (dd, J = 10.2, 2.4 Hz, 1H), 6.64 (td, J = 8.1, 2.4 Hz, 1H), 7.00-7.14 (m, 4H), 7.26-7.36 (m, 4H), 7.86 (br s, 1H). - Using (E)-2-{3-fluoro-8-[(2-propyl-1H-indol-3-yl)methyl]dibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (120 mg, 0.275 mmol) obtained in Reference Example 13B, and in the same manner as in Example 14, the title compound (compound 13b) (48 mg, 35%) was obtained.
ESIMS m/z: 496 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 0.93 (t, J = 7.5 Hz, 3H), 1.61-1.70 (m, 2H), 2.26 (s, 3H), 2.69-2.73 (m, 2H), 4.10 (s, 2H), 4.77 (d, J= 12.7 Hz, 1H), 5.51 (d, J = 12.7 Hz, 1H), 6.50-6.53 (m, 1H), 6.61-6.65 (m, 1H), 7.02-7.07 (m, 3H), 7.10-7.13 (m, 1H), 7.23-7.32 (m, 4H), 7.89 (br s, 1H). - Using (E)-2-{8-[(4,5-dichloro-2-isopropyl-1H-imidazol-1-yl)methyl]-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (150 mg, 0.329 mmol) obtained in Reference Example 13C, and in the same manner as in Example 1, the title compound (compound 13c) (100 mg, 59%) was obtained.
ESIMS m/z: 515 (M + H)+; 1H NMR (270 MHz, CDCl3,Ī“): 1.03-1.35 (m, 6H), 2.30 (s, 3H), 2.73-2.98 (m, 1H), 4.77-4.94 (m, 1H), 5.05-5.26 (m, 2H), 5.50-5.67 (m, 1H), 6.48-6.77 (m, 2H), 7.02-7.38 (m, 4H). - Using (E)-2-(3-fluoro-8-{[2-(methoxymethyl)-1H-thieno[3,4-d]imidazol-1-yl]methyl}dibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (165 mg, 0.37 mmol) obtained in Reference Example 13D, and in the same manner as in Example 1, the title compound (compound 13d) (47 mg, 25%) was obtained.
ESIMS m/z: 505 (M + H)+; 1H NMR (270 MHz, DMSO-d6,Ī“): 2.17 (s, 3H), 3.27 (s, 3H), 4.57 (s, 2H), 4.96 (d, J = 12.8 Hz, 1H), 5.17 (s, 2H), 5.52 (d, J = 12.8 Hz, 1H), 6.60 (s, 1H), 6.61-6.72 (m, 1H), 6.72-6.90 (m, 1H), 7.08 (d, J= 7.9 Hz, 1H), 7.15-7.35 (m, 3H), 7.42 (s, 1H), 12.14 (br s, 1H). - Using (E)-2-{8-[(2-cyclopropyl-1H-thieno[3,4-d]imidazol-1-yl)methyl]-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (160 mg, 0.36 mmol) obtained in Reference Example 13E, and in the same manner as in Example 1, the title compound (compound 13e) (65 mg, 36%) was obtained.
ESIMS m/z: 501 (M + H)+; 1H NMR (270 MHz, DMSO-d6,Ī“): 0.90-1.19 (m, 4H), 2.04-2.20 (m, 1H), 2.17 (s, 3H), 4.96 (d, J = 12.5 Hz, 1H), 5.34 (s, 2H), 5.52 (d, J= 12.5 Hz, 1H), 6.58-6.72 (m, 2H), 6.74-6.86 (m, 1H), 6.95 (d, J = 2.6 Hz, 1H), 7.09 (d, J = 7.9 Hz, 1H), 7.19-7.29 (m, 2H), 7.39-7.44 (m, 1H), 12.16 (br s, 1H). - Using (E)-2-{8-[(2-ethyl-4-phenyl-1H-imidazol-1-yl)methyl]-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (114 mg, 0.254 mmol) obtained in Reference Example 13F, and in the same manner as in Example 1, the title compound (compound 13f) (54 mg, 42%) was obtained.
ESIMS m/z: 509 (M + H)+; 1H NMR (270 MHz, CDCl3,Ī“): 1.28 (t, J = 7.4 Hz, 3H), 2.24 (s, 3H), 2.66 (q, J = 7.4 Hz, 2H), 4.75 (d, J = 12.8 Hz, 1H), 5.11 (s, 2H), 5.49 (d, J = 12.8 Hz, 1H), 6.49-6.59 (m, 1H), 6.59-6.70 (m, 1H), 6.93-7.28 (m, 6H), 7.29-7.41 (m, 2H), 7.67-7.83 (m, 2H). - Using (E)-2-(8-{[4-(azetidin-1-yl)-2-methyl-6-propylpyrimidin-5-yl]methyl}-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (143 mg, 0.305 mmol) obtained in Reference Example 13G, and in the same manner as in Example 1, the title compound (compound 13g) (36 mg, 12%) was obtained.
ESIMS m/z: 528 (M + H)+; 1H NMR (270 MHz, CDCl3,Ī“): 0.85 (t, J = 7.6 Hz, 3H), 1.56 (q, J = 7.6 Hz, 2H), 2.19-2.55 (m, 4H), 2.28 (s, 3H), 2.50 (s, 3H), 3.92 (s, 2H), 4.04-4.20 (m, 4H), 4.77 (d, J = 12.7 Hz, 1H), 5.57 (d, J= 12.7 Hz, 1H), 6.50-6.58 (m, 1H), 6.60-6.70 (m, 1H), 7.03 (d, J = 7.8 Hz, 1H), 7.04 (s, 1H), 7.10-7.21 (m, 2H). - Using (E)-2-(8-{[4-(dimethylamino)-6-(methoxymethyl)-2-methylpyrimidin-5-yl]methyl}-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (93 mg, 0.202 mmol) obtained in Reference Example 13H, and in the same manner as in Example 1, the title compound (compound 13h) (23 mg, 22%) was obtained.
ESIMS m/z: 518 (M + H)+; 1H NMR (270 MHz, CDCl3,Ī“): 2.28 (s, 3H), 2.57 (s, 3H), 2.93 (s, 6H), 3.30 (s, 3H), 4.14 (s, 2H), 4.21 (d, J = 11.7 Hz, 1H), 4.25 (d, J = 11.7 Hz, 1H), 4.78 (d, J = 12.7 Hz, 1H), 5.55 (d, J = 12.7 Hz, 1H), 6.50-6.70 (m, 2H), 7.05-7.15 (m, 4H). - Using (E)-2-{8-[(2-cyclopropyl-8-methylimidazo[1,2-a]pyrazin-3-yl)methyl]-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (90 mg, 0.20 mmol) obtained in Reference Example 14A, and in the same manner as in Example 1, the title compound (compound 14a) (23 mg, 22%) was obtained.
ESIMS m/z: 510 (M + H)+; 1H NMR (300 MHz, CDCl3,Ī“): 0.99-1.08 (m, 2H), 1.09-1.18 (m, 2H), 1.97-2.08 (m, 1H), 2.28 (s, 3H), 2.82 (s, 3H), 4.30-4.46 (m, 2H), 4.76 (d, J = 12.5 Hz, 1H), 5.51 (d, J = 12.5 Hz, 1H), 6.53 (dd, J = 10.3, 2.6 Hz, 1H), 6.61-6.69 (m, 1H), 7.07 (dd, J = 8.8, 6.6 Hz, 1H), 7.12-7.23 (m, 3H), 7.44 (d, J= 4.4 Hz, 1H), 7.62 (d, J = 4.4 Hz, 1H). -
- [step 1] Using (E)-3-{[11(6H)-(1-cyanoethylidene)-3-fluorodihydrodibenzo[b,e]oxepin-8-yl]methyl}-2-cyclopropylimidazo[1,2-a]pyridine-7-carboxamide (1.6 g, 3.3 mmol) obtained in Reference Example 14B, and in the same manner as in Example 14, (E)-2-cyclopropyl-3-({3-fluoro-11(6H)-[1-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)ethylidene]dibenzo[b,e]oxepin-8-yl}methyl)imidazo[1,2-a]pyridine-7-carboxamide (0.21 g, 12%) was obtained.
ESIMS m/z: 538 (M + H)+; 1H NMR (400 MHz, DMSO-d6,Ī“): 0.89-0.98 (m, 4H), 2.12-2.20 (m, 1H), 2.15 (s, 3H), 4.37-4.50 (m, 2H), 4.89 (d, J = 12.7 Hz, 1H), 5.48 (d, J= 12.7 Hz, 1H), 6.65 (dd, J = 10.7, 2.0 Hz, 1H), 6.75-6.82 (m, 1H), 7.02 (d, J = 7.8 Hz, 1H), 7.14-7.30 (m, 4H), 7.46 (br s, 1H), 7.93-8.04 (m, 2H), 8.15 (d, J = 6.8 Hz, 1H). - [step 2] (E)-2-cyclopropyl-3-({3-fluoro-11(6H)-[1-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)ethylidene]dibenzo[b,e]oxepin-8-yl}methyl)imidazo[1,2-a]pyridine-7-carboxamide (83 mg, 0.15 mmol) obtained in step 1 was suspended in THF (0.77 mL), and triethylamine (0.11 mL, 0.77 mmol) was added. Under icecooling, trifluoroacetic anhydride (0.11 mL, 0.77 mmol) was added, and the mixture was stirred at room temperature for 4 hr. Saturated aqueous sodium hydrogen carbonate solution was added to the mixture, and the mixture was extracted 3 times with chloroform-methanol mixed solvent. The combined organic layers were dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform/methanol = 100/0 v/v - 90/10 v/v) to give the title compound (compound 14b) (41 mg, 51%).
ESIMS m/z: 520 (M + H)+; 1H NMR (300 MHz, DMSO-d6,Ī“): 0.91-1.02 (m, 4H), 2.15 (s, 3H), 2.16-2.26 (m, 1H), 4.40-4.56 (m, 2H), 4.90 (d, J = 12.8 Hz, 1H), 5.48 (d, J = 12.8 Hz, 1H), 6.65 (dd, J = 10.6, 2.6 Hz, 1H), 6.74-6.83 (m, 1H), 7.02 (d, J = 7.7 Hz, 1H), 7.09 (dd, J = 7.1, 1.6 Hz, 1H), 7.14-7.26 (m, 2H), 7.26-7.30 (m, 1H), 8.13-8.16 (m, 1H), 8.29 (d, J = 6.6 Hz, 1H). - Using (E)-3-{[11(6H)-(1-cyanoethylidene)-3-fluorodibenzo[b,e]oxepin-8-yl]methyl}-2-cyclopropylimidazo[1,2-a]pyridine-8-carboxamide (0.62 g, 1.3 mmol) obtained in Reference Example 14C, and in the same manner as in Example 14, the title compound (compound 14c) (0.25 g, 36%) was obtained.
ESIMS m/z: 538 (M + H)+; 1H NMR (400 MHz, DMSO-d6,Ī“): 0.92-1.03 (m, 4H), 2.15 (s, 3H), 2.16-2.26 (m, 1H), 4.40-4.52 (m, 2H), 4.90 (d, J = 12.7 Hz, 1H), 5.48 (d, J = 12.7 Hz, 1H), 6.64 (dd, J = 10.7, 2.9 Hz, 1H), 6.74-6.81 (m, 1H), 6.93-6.99 (m, 1H), 7.02 (d, J = 7.8 Hz, 1H), 7.16-7.25 (m, 2H), 7.29 (br s, 1H), 7.85-7.93 (m, 2H), 8.30 (d, J = 7.8 Hz, 1H), 9.45 (d, J = 2.9 Hz, 1H). - Using (E)-2-{3-fluoro-8-[(8-methyl-2-propylimidazo[1,2-a]pyrazin-3-yl)methyl]dibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (0.32 g, 0.71 mmol) obtained in Reference Example 14D, and in the same manner as in Example 1, the title compound (compound 14d) (0.14 g, 39%) was obtained.
ESIMS m/z: 512 (M + H)+; 1H NMR (300 MHz, DMSO-d6,Ī“): 0.87 (d, J = 7.3 Hz, 3H), 1.57-1.71 (m, 2H), 2.15 (s, 3H), 2.69 (s, 3H), 2.72 (t, J = 7.3 Hz, 2H), 4.28-4.41 (m, 2H), 4.90 (d, J = 12.5 Hz, 1H), 5.47 (d, J = 12.5 Hz, 1H), 6.65 (dd, J = 10.6, 2.6 Hz, 1H), 6.74-6.83 (m, 1H), 7.01 (d, J= 7.7 Hz, 1H), 7.07-7.14 (m, 1H), 7.18-7.27 (m, 2H), 7.63 (d, J = 4.8 Hz, 1H), 8.06 (d, J = 4.8 Hz, 1H), 12.10 (br s, 1H). - Using (E)-2-(8-{[2-cyclopropyl-8-(dimethylamino)imidazo[1,2-a]pyrazin-3-yl]methyl}-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (177 mg, 0.369 mmol) obtained in Reference Example 14E, and in the same manner as in Example 14, the title compound (compound 14e) (25 mg, 13%) was obtained.
ESIMS m/z: 539 (M + H)+; 1H NMR (300 MHz, DMSO-d6,Ī“): 0.83-0.94 (m, 4H), 2.06-2.15 (m, 1H), 2.15 (s, 3H), 3.40 (s, 6H), 4.30-4.35 (m, 2H), 4.90 (d, J = 12.8 Hz, 1H), 5.49 (d, J = 12.8 Hz, 1H), 6.65 (dd, J = 10.6, 2.6 Hz, 1H), 6.74-6.83 (m, 1H), 7.02 (d, J = 7.7 Hz, 1H), 7.11-7.29 (m, 4H), 7.42 (d, J= 4.4 Hz, 1H), 12.11 (br s, 1H). - Using (E)-2-(8-{[2-cyclopropyl-8-(dimethylamino)imidazo[1,2-a]pyridin-3-yl]methyl}-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (94 mg, 0.20 mmol) obtained in Reference Example 14F, and in the same manner as in Example 14, the title compound (compound 14f) (29 mg, 28%) was obtained.
ESIMS m/z: 538 (M + H)+; 1H NMR (300 MHz, CDCl3,Ī“): 0.90-1.00 (m, 2H), 1.10-1.19 (m, 2H), 1.94-2.05 (m, 1H), 2.27 (s, 3H), 3.15 (s, 6H), 4.27-4.43 (m, 2H), 4.76 (d, J = 12.6 Hz, 1H), 5.51 (d, J = 12.6 Hz, 1H), 6.25 (d, J = 7.5 Hz, 1H), 6.49-6.69 (m, 3H), 7.06 (dd, J = 8.6, 6.6 Hz, 1H), 7.11-7.25 (m, 4H). - Using (E)-2-{8-[(7-cyclopropyl-2-methylimidazo[1,2-a]pyridin-3-yl)methyl]-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (280 mg, 0.62 mmol) obtained in Reference Example 14G, and in the same manner as in Example 1, the title compound (compound 14g) (80 mg, 25%) was obtained.
ESIMS m/z: 509 (M + H)+; 1H NMR (270 MHz, DMSO-d6,Ī“): 0.67-0.78 (m, 2H), 0.86-1.04 (m, 2H), 1.87-2.00 (m, 1H), 2.16 (s, 3H), 2.34 (s, 3H), 4.15-4.34 (m, 2H), 4.89 (d, J = 12.4 Hz, 1H), 5.47 (d, J = 12.4 Hz, 1H), 6.39-6.53 (m, 1H), 6.58-6.70 (m, 1H), 6.71-6.85 (m, 1H), 6.89-7.06 (m, 1H), 7.06-7.28 (m, 4H), 7.80-7.95 (m, 1H). - Using (E)-2-{8-[(7-ethynyl-2-methylimidazo[1,2-a]pyridin-3-yl)methyl]-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (152 mg, 0.35 mmol) obtained in Reference Example 14H, and in the same manner as in Example 1, the title compound (compound 14h) (8 mg, 5%) was obtained.
ESIMS m/z: 493 (M + H)+; 1H NMR (270 MHz, DMSO-d6,Ī“): 2.15 (s, 3H), 2.40 (s, 3H), 4.29-4.42 (m, 2H), 4.49 (s, 1H), 4.92 (d, J = 12.4 Hz, 1H), 5.47 (d, J = 12.4 Hz, 1H), 6.61-6.72 (m, 1H), 6.74-6.84 (m, 1H), 6.90-7.06 (m, 1H), 7.07-7.30 (m, 2H), 7.66-7.80 (m, 1H), 8.14-8.26 (m, 1H), 8.54-8.65 (m, 1H). -
- [step 1] Using (E)-3-({11(6H)-[1-(cyanoethylidene)]-3-fluorodibenzo[b,e]oxepin}methyl)-7-fluoroimidazo[1,2-a]pyridine-2-carboxamide (330 mg, 0.73 mmol) obtained in Reference Example 141, and in the same manner as in Example 1, (E)-7-fluoro-3-({3-fluoro-11-[1-(5-oxo-1,2,4-oxadiazol-3-yl)ethylidene]dibenzo[b,e]oxepin-8-yl}methyl)imidazo[1,2-a]pyridine-2-carboxamide (98 mg, 26%) was obtained.
ESIMS m/z: 516 (M + H)+; 1H NMR (270 MHz, DMSO-d6,Ī“): 2.16 (s, 3H), 4.67-4.84 (m, 2H), 4.89 (d, J= 12.4 Hz, 1H), 5.46 (d, J = 12.4 Hz, 1H), 6.58-6.68 (m, 1H), 6.75-6.83 (m, 1H), 6.94-7.03 (m, 2H), 7.18-7.26 (m, 2H), 7.31-7.37 (m, 1H), 7.39-7.54 (m, 2H), 7.71-7.79 (m, 1H), 8.28-8.36 (m, 1H). - [step 2] (E)-7-fluoro-3-({3-fluoro-11-[1-(5-oxo-1,2,4-oxadiazol-3-yl)ethylidene]dibenzo[b,e]oxepin-8-yl}methyl)imidazo[1,2-a]pyridine-2-carboxamide (113 mg, 0.22 mmol) obtained in step 1 was dissolved in THF (2 mL), triethylamine (67 mg, 0.66 mmol) and trifluoroacetic anhydride (138 mg, 0.66 mmol) were added and the mixture was stirred at room temperature for 2 hr. Furthermore, triethylamine (89 mg, 0.88 mmol) and trifluoroacetic anhydride (184 mg, 0.88 mmol) were added, and the mixture was stirred at room temperature for 8 hr. Water was added to the reaction mixture, and the mixture was extracted 3 times with chloroform. The combined organic layers were dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (chloroform/methanol = 9/1 v/v) to give the title compound (compound 14i) (15 mg, 14%).
ESIMS m/z: 498 (M + H)+; 1H NMR (270 MHz, DMSO-d6,Ī“): 2.16 (s, 3H), 4.40-4.60 (m, 2H), 4.93 (d, J= 12.4 Hz, 1H), 5.49 (d, J = 12.4 Hz, 1H), 6.58-6.71 (m, 1H), 6.71-6.89 (m, 1H), 6.99-7.37 (m, 5H), 7.49-7.66 (m, 1H), 8.30-8.47 (m, 1H), 12.11 (br s, 1H). - Using (E)-2-(8-{[7-fluoro-2-(tetrahydrofuran-3-yl)imidazo[1,2-a]pyridin-3-yl]methyl}-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (104 mg, 0.215 mmol) obtained in Reference Example 14J, and in the same manner as in Example 1, the title compound (compound 14j) (25 mg, 21%) was obtained.
ESIMS m/z: 543 (M + H)+; 1H NMR (270 MHz, CDCl3,Ī“): 2.24-2.49 (m, 5H), 3.52-3.71 (m, 1H), 3.87-4.05 (m, 2H), 4.05-4.23 (m, 2H), 4.23-4.42 (m, 2H), 4.76 (d, J = 12.4 Hz, 1H), 5.55 (d, J = 12.4 Hz, 1H), 6.50-6.72 (m, 3H), 7.04-7.20 (m, 4H), 7.20-7.35 (m, 1H), 7.50-7.64 (m, 1H). - Using (E)-2-{8-[(2-chloroimidazo[1,2-a]pyridin-3-yl)methyl]-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (106 mg, 0.247 mmol) obtained in Reference Example 14K, and in the same manner as in Example 1, the title compound (compound 14k) (5.5 mg, 4.3%) was obtained.
ESIMS m/z: 489 (M + H)+; 1H NMR (270 MHz, CDCl3,Ī“): 1.99 (s, 3H), 4.35 (s, 2H), 4.92 (d, J = 12.7 Hz, 1H), 5.47 (d, J = 12.7 Hz, 1H), 6.63-6.82 (m, 2H), 6.92-7.03 (m, 3H), 7.17-7.25 (m, 2H), 7.28-7.33 (m, 2H), 7.54-7.56 (m, 1H). - Using (E)-2-(3-fluoro-8{[2-methoxy-7-(trifluoromethyl)imidazo[1,2-a]pyridin-3-yl]methyl}-dibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (220 mg, 0.446 mmol) obtained in Reference Example 14L, and in the same manner as in Example 1, the title compound (compound 141) (26 mg, 11%) was obtained.
ESIMS m/z: 553 (M + H)+; 1H NMR (270 MHz, CDCl3,Ī“): 2.28 (s, 3H), 4.14 (s, 3H), 4.19-4.34 (m, 2H), 4.81 (d, J = 12.7 Hz, 1H), 5.53 (d, J = 12.7 Hz, 1H), 6.52-6.56 (m, 1H), 6.62-6.72 (m, 1H), 6.96-6.99 (m, 1H), 7.04-7.09 (m, 1H), 7.13-7.16 (m, 1H), 7.21-7.23 (m, 2H), 7.70-7.73 (m, 1H), 7.80-7.81 (m, 1H). - A tablet having the following formulation is prepared by a conventional method. Compound 1a (40 g), lactose (286.8 g) and potato starch (60 g) are mixed, and a 10% aqueous solution (120 g) of hydroxypropylcellulose is added. The obtained mixture is kneaded, granulated, dried, and sieved by conventional methods to give granules for tableting. Thereto is added magnesium stearate (1.2 g), and the mixture is tableted by a tableting machine with a punch (diameter 8 mm) (manufactured by Kikusui, RT-15) to give tablets (containing active ingredient 20 mg per tablet). Formulation
compound 1a 20 mg lactose 143.4 mg potato starch 30 mg hydroxypropylcellulose 6 mg magnesium stearate 0.6 mg 200 mg - An injection having the following formulation is prepared by a conventional method. Compound 1a (1 g) is added to distilled water for injection and the mixture is mixed. Further, hydrochloric acid and aqueous sodium hydroxide solution are added to adjust the pH to 7, and distilled water for injection is added to make the total amount 1000 mL. The obtained mixture is aseptically filled in a glass vial by 2 mL to give an injection (containing active ingredient 2 mg per vial).
-
compound 1a 2 mg hydrochloric acid q.s. aqueous sodium hydroxide solution q.s. distilled water for injection q.s. 2.00 mL - 2-Propyl-1H-benzo[d]imidazole (Synthetic Communication, 2002, vol. 32, p3703, 246 mg, 1.54 mmol) and (E)-2-[8-(bromomethyl)-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene]propanenitrile (550 mg, 1.54 mmol) obtained in Reference Example 1 were dissolved in DMF (7 mL), potassium carbonate (1.06 g, 7.68 mmol) was added and the mixture was stirred overnight. To the mixture was added water (20 mL), and the precipitated crystals were collected by suction filtration to give the title compound (640 mg, 94%).
ESIMS m/z: 438 (M + H)+; 1H NMR (300 MHz, CDCl3,Ī“): 1.02 (t, J = 7.4 Hz, 3H), 1.77-1.97 (m, 2H), 2.23 (s, 3H), 2.80 (t, J = 7.4 Hz, 2H), 4.73 (d, J = 12.6 Hz, 1H), 5.32-5.48 (m, 3H), 6.51-6.58 (m, 1H), 6.59-6.69 (m, 1H), 6.94-7.07 (m, 3H), 7.11-7.29 (m, 3H), 7.43 (d, J = 7.8 Hz, 1H), 7.78 (d, J = 7.5 Hz, 1H) - Using 2-methoxymethyl-1H-benzo[d]imidazole (Journal of Organometallic Chemistry, 2008, vol. 26, p3889; 244 mg, 1.51 mmol) and (E)-2-[8-(bromomethyl)-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene]propanenitrile (550 mg, 1.54 mmol) obtained in Reference Example 1, and in the same manner as in Reference Example 1A, the title compound (576 mg, 87%) was obtained.
ESIMS m/z: 440 (M + H)+; 1H NMR (300 MHz, CDCl3,Ī“): 2.23 (s, 3H), 3.36 (s, 3H), 4.66-4.77 (m, 3H), 5.40 (d, J = 12.5 Hz, 1H), 5.44-5.58 (m, 2H), 6.55 (dd, J = 10.3, 2.6 Hz, 1H), 6.60-6.68 (m, 1H), 6.98-7.08 (m, 2H), 7.15-7.22 (m, 1H), 7.23-7.33 (m, 3H), 7.42 (d, J = 7.7 Hz, 1H), 7.77-7.84 (m, 1H). - Using 2-isopropyl-1H-benzo[d]imidazole (Angewandte Chemie, International Edition, 2010, vol. 9, p1656; 89 mg, 0.56 mmol) and (E)-2-[8-(bromomethyl)-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene]propanenitrile (200 mg, 0.56 mmol) obtained in Reference Example 1, and in the same manner as in Reference Example 1A, the title compound (240 mg, 98%) was obtained.
ESIMS m/z: 438 (M + H)+; 1H NMR (270 MHz, CDCl3,Ī“): 1.33-1.46 (m, 6H), 2.23 (s, 3H), 3.04-3.20 (m, 1H), 4.72 (d, J = 12.8 Hz, 1H), 5.31-5.46 (m, 3H), 6.55 (dd, J = 10.2, 2.3 Hz, 1H), 6.60-6.69 (m, 1H), 6.94-6.98 (m, 1H), 7.02 (dd, J = 8.7, 6.4 Hz, 1H), 7.09-7.16 (m, 1H), 7.16-7.21 (m, 2H), 7.22-7.30 (m, 1H), 7.43 (d, J= 7.9 Hz, 1H), 7.77-7.84 (m, 1H). - Using 2-cyclopropyl-1H-benzo[d]imidazole (Europeane Journal of Organic Chemistry, 2000, p1229, 69 mg, 0.434 mmol) and (E)-2-[8-(bromomethyl)-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene]propanenitrile (160 mg, 0.447 mmol) obtained in Reference Example 1, and in the same manner as in Reference Example 1A, the title compound (182 mg, 95%) was obtained.
ESIMS m/z: 436 (M + H)+; 1H NMR (270 MHz, CDCl3,Ī“): 0.96-1.15 (m, 2H), 1.15-1.32 (m, 2H), 1.81-1.99 (m, 1H), 2.23 (s, 3H), 4.73 (d, J = 12.8 Hz, 1H), 5.32-5.57 (m, 3H), 6.52-6.60 (m, 1H), 6.59-6.69 (m, 1H), 6.98-7.07 (m, 2H), 7.16-7.29 (m, 4H), 7.41-7.48 (m, 1H), 7.66-7.75 (m, 1H). - Using 2-cyclobutyl-1H-benzo[d]imidazole (72 mg, 0.419 mmol) and (E)-2-[8-(bromomethyl)-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene]propanenitrile (150 mg, 0.419 mmol) obtained in Reference Example 1, and in the same manner as in Reference Example 1A, the title compound (170 mg, 90%) was obtained.
ESIMS m/z: 450 (M + H)+; 1H NMR (270 MHz, CDCl3,Ī“): 1.88-2.12 (m, 2H), 2.23 (s, 3H), 2.25-2.41 (m, 2H), 2.48-2.72 (m, 2H), 3.54-3.73 (m, 1H), 4.72 (d, J = 12.8 Hz, 1H), 5.28 (s, 2H), 5.39 (d, J = 12.8 Hz, 1H), 6.49-6.73 (m, 2H), 6.89-7.31 (m, 6H), 7.36-7.49 (m, 1H), 7.77-7.88 (m, 1H). - Using 2-cyclopentyl-1H-benzo[d]imidazole (62 mg, 0.335 mmol) and (E)-2-[8-(bromomethyl)-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene]propanenitrile (120 mg, 0.335 mmol) obtained in Reference Example 1, and in the same manner as in Reference Example 1A, the title compound (148 mg, 95%) was obtained.
ESIMS m/z: 464 (M + H)+; 1H NMR (270 MHz, CDCl3,Ī“): 1.53-1.76 (m, 2H), 1.78-2.16 (m, 6H), 2.23 (s, 3H), 3.03-3.27 (m, 1H), 4.72 (d, J = 12.8 Hz, 1H), 5.27-5.47 (m, 3H), 6.46-6.74 (m, 2H), 6.92-7.10 (m, 2H), 7.10-7.32 (m, 4H), 7.38-7.50 (m, 1H), 7.75-7.86 (m, 1H). - Using 2-cyclopropylmethyl-1H-benzo[d]imidazole (72 mg, 0.419 mmol) and (E)-2-[8-(bromomethyl)-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene]propanenitrile (150 mg, 0.419 mmol) obtained in Reference Example 1, and in the same manner as in Reference Example 1A, the title compound (175 mg, 93%) was obtained.
ESIMS m/z: 450 (M + H)+; 1H NMR (270 MHz, CDCl3,Ī“): 0.18-0.34 (m, 2H), 0.42-0.67 (m, 2H), 1.05-1.24 (m, 1H), 2.24 (s, 3H), 2.79 (d, J = 6.7 Hz, 2H), 4.72 (d, J = 12.6 Hz, 1H), 5.32-5.50 (m, 3H), 6.51-6.59 (m, 1H), 6.60-6.69 (m, 1H), 6.95-7.06 (m, 2H), 7.08-7.34 (m, 4H), 7.40-7.45 (m, 1H), 7.77-7.83 (m, 1H). - Using 2-ethyl-1H-benzo[d]imidazole (61 mg, 0.419 mmol) and (E)-2-[8-(bromomethyl)-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene]propanenitrile (150 mg, 0.419 mmol) obtained in Reference Example 1, and in the same manner as in Reference Example 1A, the title compound (170 mg, 96%) was obtained.
ESIMS m/z: 424 (M + H)+; 1H NMR (270 MHz, CDCl3,Ī“): 1.43 (t, J = 7.6 Hz, 3H), 2.24 (s, 3H), 2.84 (q, J = 7.6 Hz, 2H), 4.72 (d, J = 12.6 Hz, 1H), 5.29-5.44 (m, 3H), 6.50-6.59 (m, 1H), 6.59-6.68 (m, 1H), 6.90-7.07 (m, 2H), 7.11-7.30 (m, 4H), 7.37-7.46 (m, 1H), 7.73-7.85 (m, 1H). - Using 2-(trifluoromethyl)-1H-benzo[d]imidazole (62 mg, 0.335 mmol) and (E)-2-[8-(bromomethyl)-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene]propanenitrile (120 mg, 0.335 mmol) obtained in Reference Example 1, and in the same manner as in Reference Example 1A, the title compound (138 mg, 88%) was obtained.
ESIMS m/z: 464 (M + H)+; 1H NMR (270 MHz, CDCl3,Ī“): 2.23 (s, 3H), 4.75 (d, J = 12.6 Hz, 1H), 5.40 (d, J = 12.6 Hz, 1H), 5.55 (s, 2H), 6.51-6.59 (m, 1H), 6.59-6.70 (m, 1H), 7.00-7.07 (m, 2H), 7.16-7.31 (m, 2H), 7.33-7.49 (m, 3H), 7.86-7.98 (m, 1H). -
- [step 1] 3,3-Difluorocyclobutanecarboxylic acid (500 mg, 3.67 mmol) was dissolved in DMF (18 mL), 1,1'-carbonyldiimidazole (1.19 g, 7.35 mmol) was added, and the mixture was stirred at room temperature for 1 hr. To the mixture were added 2-nitroaniline (1.02 g, 7.35 mmol) and triethylamine (1.02 mL, 7.35 mmol), and the mixture was stirred at 80Ā°C for 13 hr. To the mixture were added 5% aqueous citric acid solution and ethanol (5 mL), and the mixture was stirred for 1 hr. The precipitated crystals were collected by suction filtration to give 3,3-difluoro-N-(2-nitrophenyl)cyclobutanecarboxamide (527 mg, 56%).
ESIMS m/z: 257 (M + H)+; 1H NMR (300 MHz, CDCl3,Ī“): 2.78-3.16 (m, 5H), 7.17-7.26 (m, 1H), 7.62-7.74 (m, 1H), 8.20-8.30 (m, 1H), 8.75-8.84 (m, 1H), 10.46 (br s, 1H). - [step 2] 3,3-Difluoro-N-(2-nitrophenyl)cyclobutanecarboxamide (400 mg, 1.56 mmol) obtained in step 1 was dissolved in ethanol (10 mL), methanol (40 mL), and ethyl acetate (40 mL), and 10% Pd-C (120 mg) was added. The reaction system was purged with hydrogen gas, and the mixture was stirred at room temperature for 3 hr. After completion of the reaction, the reaction mixture was filtered through celite, and the solution was concentrated under reduced pressure. To the obtained residue was added acetic acid (2.2 mL, 38.4 mmol), and the mixture was stirred at 80Ā°C for 1 hr. Under ice-cooling, saturated aqueous sodium hydrogen carbonate was added to the mixture, and the mixture was extracted 3 times with ethyl acetate. The combined organic layers were washed with water, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate = 100/0 v/v - 30/70 v/v) to give 2-(3,3-difluorocyclobutyl)-1H-benzo[d]imidazole (135 mg, 42%).
ESIMS m/z: 209 (M + H)+; 1H NMR (300 MHz, DMSO-d6,Ī“): 2.91-3.16 (m, 4H), 3.52-3.68 (m, 1H), 7.08-7.21 (m, 2H), 7.38-7.48 (m, 1H), 7.52-7.62 (m, 1H), 12.37 (br s, 1H). - [step 3] Using 2-(3,3-difluorocyclobutyl)-1H-benzo[d]imidazole (57 mg, 0.27 mmol) obtained in step 2 and (E)-2-[8-(bromomethyl)-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene]propanenitrile (100 mg, 0.28 mmol) obtained in Reference Example 1, and in the same manner as in Reference Example 1A, the title compound (127 mg, 96%) was obtained.
ESIMS m/z: 486 (M + H)+; 1H NMR (300 MHz, CDCl3,Ī“): 2.23 (s, 3H), 2.75-2.98 (m, 2H), 3.00-3.28 (m, 2H), 3.34-3.49 (m, 1H), 4.73 (d, J = 12.8 Hz, 1H), 5.33 (s, 2H), 5.40 (d, J= 12.8 Hz, 1H), 6.56 (dd, J = 9.9, 2.6 Hz, 1H), 6.60-6.70 (m, 1H), 6.92-6.97 (m, 1H), 7.03 (dd, J = 8.6, 6.4 Hz, 1H), 7.06-7.12 (m, 1H), 7.19-7.36 (m, 3H), 7.44 (d, J = 7.7 Hz, 1H), 7.78-7.85 (m, 1H). - Using 2-(1-methylcyclopropyl)-1H-benzo[d]imidazole (58 mg, 0.335 mmol) and (E)-2-[8-(bromomethyl)-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene]propanenitrile (120 mg, 0.335 mmol) obtained in Reference Example 1, and in the same manner as in Reference Example 1A, the title compound (60 mg, 40%) was obtained.
ESIMS m/z: 450 (M + H)+; 1H NMR (270 MHz, CDCl3,Ī“): 0.78-0.89 (m, 2H), 1.10-1.19 (m, 2H), 1.39 (s, 3H), 2.23 (s, 3H), 4.74 (d, J = 12.8 Hz, 1H), 5.39 (d, J = 12.8 Hz, 1H), 5.55-5.61 (m, 2H), 6.50-6.62 (m, 1H), 6.62-6.71 (m, 1H), 6.96-7.11 (m, 3H), 7.12-7.30 (m, 3H), 7.39-7.51 (m, 1H), 7.70-7.82 (m, 1H). - Using commercially available 2-(furan-2-yl)-1H-benzo[d]imidazole (62 mg, 0.34 mmol) and (E)-2-[8-(bromomethyl)-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene]propanenitrile (120 mg, 0.335 mmol) obtained in Reference Example 1, and in the same manner as in Reference Example 1A, the title compound (146 mg, 94%) was obtained.
ESIMS m/z: 462 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 2.23 (s, 3H), 4.72 (d, J = 12.8 Hz, 1H), 5.39 (d, J = 12.8 Hz, 1H), 5.67-5.79 (m, 2H), 6.52-6.67 (m, 3H), 6.99-7.07 (m, 2H), 7.11-7.13 (m, 1H), 7.25-7.34 (m, 4H), 7.43-7.45 (m, 1H), 7.56-7.57 (m, 1H), 7.82-7.85 (m, 1H). - Using commercially available 2-(pyridin-2-yl)-1H-benzo[d]imidazole (50 mg, 0.34 mmol) and (E)-2-[8-(bromomethyl)-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene]propanenitrile (120 mg, 0.335 mmol) obtained in Reference Example 1, and in the same manner as in Reference Example 1A, the title compound (123 mg, 86%) was obtained.
ESIMS m/z: 473 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 2.21 (s, 3H), 4.70 (d, J = 11.6 Hz, 1H), 5.37 (d, J = 12.8 Hz, 1H), 6.19-6.24 (m, 2H), 6.50-6.55 (m, 1H), 6.58-6.65 (m, 1H), 6.97-7.02 (m, 1H), 7.14-7.15 (m, 1H), 7.29-7.39 (m, 6H), 7.79-7.89 (m, 2H), 8.45-8.48 (m, 1H), 8.60-8.62 (m, 1H). -
- [step 1] 2-Methoxy-6-nitroaniline (4.0 g, 23.8 mmol) was dissolved in DMA (24 mL), pyridine (5.8 mL, 71.4 mmol) and 2-methoxyacetyl chloride (6.5 mL, 71.4 mmol) were added at 0Ā°C, and the mixture was stirred at room temperature for 1 hr. Under ice-cooling, methanol and aqueous ammonia solution were added to the mixture, and the mixture was stirred at room temperature for 30 min. Water was added, and the mixture was extracted 3 times with ethyl acetate. The combined organic layers were washed with water and saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate = 100/0 v/v - 30/70 v/v) to give 2-methoxy-N-(2-methoxy-6-nitrophenyl)acetamide (5.4 g, 95%).
ESIMS m/z: 241 (M + H)+; 1H NMR (400 MHz, CDCl3,Ī“): 3.54 (s, 3H), 3.94 (s, 3H), 4.06 (s, 2H), 7.14-7.19 (m, 1H), 7.30 (d, J = 7.8 Hz, 1H), 7.52 (d, J = 7.8 Hz, 1H), 8.54 (br s, 1H). - [step 2] 2-Methoxy-N-(2-methoxy-6-nitrophenyl)acetamide (5.4 g, 22.5 mmol) obtained in step 1 was dissolved in ethanol (45 mL), tin (II) chlorideĀ·2 hydrate (24.4 g, 108 mmol) was added, and the mixture was stirred with heating under reflux for 1 hr. After cooling to room temperature, 4 mol/L aqueous sodium hydroxide solution was added to the mixture. The mixture was filtered through celite, and the solution was extracted 3 times with ethyl acetate. The combined organic layers were dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained brown oil (3.7 g) was suspended in diisopropyl ether (30 mL) and isopropyl alcohol (3 mL), and stirred at room temperature for 1 hr. The suspension was suction filtered, and the obtained solid was dried under reduced pressure to give 4-methoxy-2-(methoxymethyl)-1H-benzo[d]imidazole (1.38 g, 32%).
ESIMS m/z: 193 (M + H)+; 1H NMR (300 MHz, CDCl3,Ī“): 3.49 (d, J = 5.9 Hz, 3H), 3.98 (d, J= 14.7 Hz, 3H), 4.76 (s, 2H), 6.70 (t, J = 8.6 Hz, 1H), 7.05 (d, J= 8.1 Hz, 0.5H), 7.17 (t, J = 8.1 Hz, 1H), 7.36 (d, J = 8.1 Hz, 0.5H), 9.60 (br s, 1H). - [step 3] Using 4-methoxy-2-(methoxymethyl)-1H-benzo[d]imidazole (1.3 g, 6.8 mmol) obtained in step 2 and (E)-2-[8-(bromomethyl)-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene]propanenitrile (2.5 g, 7.0 mmol) obtained in Reference Example 1, and in the same manner as in Reference Example 1A, (E)-2-(3-fluoro-8-{[4-methoxy-2-(methoxymethyl)-1H-benzo[d]imidazol-1-yl]methyl}dibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (1.7 g, 53%) was obtained.
ESIMS m/z: 470 (M + H)+; 1H NMR (270 MHz, CDCl3,Ī“): 2.23 (s, 3H), 3.33 (s, 3H), 4.04 (s, 3H), 4.65-4.78 (m, 3H), 5.39 (d, J = 12.5 Hz, 1H), 5.41-5.56 (m, 2H), 6.55 (dd, J= 10.2, 2.3 Hz, 1H), 6.59-6.68 (m, 1H), 6.71 (d, J = 7.9 Hz, 1H), 6.86 (d, J = 8.2 Hz, 1H), 6.97-7.06 (m, 2H), 7.13-7.23 (m, 2H), 7.41 (d, J= 7.9 Hz, 1H). - [step 4] (E)-2-(3-fluoro-8-{[4-methoxy-2-(methoxymethyl)-1H-benzo[d]imidazol-1-yl]methyl}dibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (1.0 g, 2.1 mmol) obtained in step 3 was dissolved in dichloromethane (11 mL), boron tribromide (21.0 mL, 21.0 mmol, 1.0 mol/L dichloromethane solution) was added at 0Ā°C, and the mixture was stirred at room temperature for 2 hr. To the mixture was added 2 mol/L aqueous sodium hydroxide solution, and the mixture was extracted 3 times with chloroform. The combined organic layers were dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform/methanol= 100/0 v/v - 90/10 v/v) to give (E)-2-(3-fluoro-8-{[4-hydroxy-2-(hydroxymethyl)-1H-benzo[d]imidazol-1-yl]methyl}dibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (0.7 g, 75%).
ESIMS m/z: 442 (M + H)+; 1H NMR (300 MHz, CDCl3,Ī“): 1.36-1.97 (m, 1H), 2.22 (s, 3H), 4.74 (d, J= 12.5 Hz, 1H), 4.85 (s, 2H), 5.32-5.45 (m, 3H), 6.54 (dd, J = 10.1, 2.4 Hz, 1H), 6.59-6.69 (m, 1H), 6.76-6.88 (m, 2H), 7.01 (dd, J = 8.6, 6.6 Hz, 1H), 7.05-7.10 (m, 1H), 7.12-7.23 (m, 2H), 7.42 (d, J = 8.1 Hz, 1H). - [step 5] (E)-2-(3-fluoro-8-{[4-hydroxy-2-(hydroxymethyl)-1H-benzo[d]imidazol-1-yl]methyl]dibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (52 mg, 0.12 mmol) obtained in step 4 was dissolved in THF (1 mL), deuterated methanol (0.10 mL, 2.36 mmol), triphenylphosphine (118 mg, 0.35 mmol, polymer support), (E)-di-tert-butyl diazene-1,2-dicarboxylate (54 mg, 0.24 mmol) were added, and the mixture was stirred at room temperature for 1 hr. To the mixture were further added triphenylphosphine (118 mg, 0.35 mmol, polymer support), and (E)-di-tert-butyl diazene-1,2-dicarboxylate (54 mg, 0.24 mmol), and the mixture was stirred at room temperature for 16 hr. The mixture was filtered through celite, and the solution was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate = 70/30 v/v - 0/100 v/v) to give (E)-2-(3-fluoro-8-{[2-(hydroxymethyl)-4-(methoxy-d3)-1H-benzo[d]imidazol-1-yl]methyl}dibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (29 mg, 54%).
ESIMS m/z: 459 (M + H)+; 1H NMR (400 MHz, CDCl3,Ī“): 2.23 (s, 3H), 4.71 (d, J = 12.7 Hz, 1H), 4.85 (s, 2H), 5.38 (d, J = 12.7 Hz, 1H), 5.38-5.50 (m, 2H), 6.54 (dd, J= 10.2, 2.4 Hz, 1H), 6.59-6.67 (m, 1H), 6.70 (d, J = 7.8 Hz, 1H), 6.84 (d, J = 7.8 Hz, 1H), 6.97-7.05 (m, 2H), 7.12-7.21 (m, 2H), 7.41 (d, J= 7.8 Hz, 1H). - [step 6] (E)-2-(3-fluoro-8-{[2-(hydroxymethyl)-4-(methoxy-d3)-1H-benzo[d]imidazol-1-yl]methyl}dibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (29 mg, 0.063 mmol) obtained in step 5 was dissolved in THF (1 mL), sodium hydride (3.3 mg, 0.082 mmol) and iodomethane (5.1 ĀµL, 0.082 mmol) were added, and the mixture was stirred at room temperature for 5 hr. Water was added to the mixture, and the mixture was extracted 3 times with a mixed solvent of chloroform and methanol. The combined organic layers were dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform/methanol = 99/1 v/v - 90/10 v/v) to give the title compound (25 mg, 84%).
ESIMS m/z: 473 (M + H)+; 1H NMR (300 MHz, CDCl3,Ī“): 2.23 (s, 3H), 3.32 (s, 3H), 4.67-4.76 (m, 3H), 5.39 (d, J = 12.5 Hz, 1H), 5.41-5.57 (m, 2H), 6.55 (dd, J = 9.9, 2.6 Hz, 1H), 6.60-6.68 (m, 1H), 6.68-6.73 (m, 1H), 6.83-6.87 (m, 1H), 6.98-7.05 (m, 2H), 7.13-7.22 (m, 2H), 7.41 (d, J = 7.7 Hz, 1H). -
- [step 1] To methyl 2-aminobenzoate (3.0 g, 19.8 mmol) was added butyric anhydride (9.7 mL, 59.4 mmol), and the mixture was stirred at room temperature for 3 hr. Under ice-cooling, to the mixture was added dropwise fuming nitric acid (3.2 mL) and the mixture was stirred at 0Ā°C for 15 min. Water was added to the mixture, and the mixture was neutralized by dropwise addition of 4 mol/L aqueous sodium hydroxide solution, and extracted 3 times with ethyl acetate. The combined organic layers were dried over anhydrous magnesium sulfate and purified by silica gel column chromatography (hexane/ethyl acetate = 100/0 v/v - 60/40 v/v) to give methyl 2-butylamido-3-nitrobenzoate (3.0 g, 57%).
ESIMS m/z: 267 (M + H)+; 1H NMR (270 MHz, CDCl3,Ī“): 1.01 (t, J = 7.3 Hz, 3H), 1.67-1.86 (m, 2H), 2.43 (t, J = 7.3 Hz, 2H), 3.97 (s, 3H), 7.24-7.36 (m, 1H), 8.09 (dd, J = 8.1, 1.5 Hz, 1H), 8.21 (dd, J = 8.1, 1.5 Hz, 1H), 10.39 (br s, 1H). - [step 2] Methyl 2-butylamido-3-nitrobenzoate (3.0 g, 11.3 mmol) obtained in step 1 was dissolved in methanol (42 mL), and 10% Pd-C (750 mg) was added. The reaction system was purged with hydrogen gas, and the mixture was stirred at room temperature for 5 hr. After completion of the reaction, and the mixture was filtered through celite, and the solution was concentrated under reduced pressure. To the obtained residue was added acetic acid (16 mL), and the mixture was stirred at 80Ā°C for 1 hr. Under ice-cooling, saturated aqueous sodium hydrogen carbonate was added to the mixture, and the mixture was extracted 3 times with ethyl acetate. The combined organic layers were washed with water, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate = 90/10 v/v - 40/60 v/v) to give methyl 2-propyl-1H-benzo[d]imidazole-4-carboxylate (1.8 g, 73%).
ESIMS m/z: 219 (M + H)+; 1H NMR (300 MHz, CDCl3,Ī“): 1.06 (t, J = 7.3 Hz, 3H), 1.85-2.00 (m, 2H), 2.93 (t, J = 7.3 Hz, 2H), 3.99 (s, 3H), 7.23-7.31 (m, 1H), 7.85 (dd, J = 7.9, 0.9 Hz, 1H), 7.88-7.94 (m, 1H), 10.17 (br s, 1H). - [step 3] Using methyl 2-propyl-1H-benzo[d]imidazole-4-carboxylate (64 mg, 0.29 mmol) obtained in step 2 and (E)-2-[8-(bromomethyl)-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene]propanenitrile (110 mg, 0.31 mmol) obtained in Reference Example 1, and in the same manner as in Reference Example 1A, (E)-methyl 1-{[11-(cyanoethylidene)-3-fluoro-6,11-dihydrodibenzo[b,e]oxepin-8-yl]methyl}-2-propyl-1H-benzo[d]imidazole-4-carboxylate (120 mg, 83%) was obtained.
ESIMS m/z: 496 (M + H)+; 1H NMR (300 MHz, CDCl3,Ī“): 1.03 (t, J = 7.3 Hz, 3H), 1.81-1.97 (m, 2H), 2.23 (s, 3H), 2.80-2.95 (m, 2H), 4.05 (s, 3H), 4.69 (d, J = 12.5 Hz, 1H), 5.31-5.48 (m, 3H), 6.55 (dd, J = 10.3, 2.6 Hz, 1H), 6.60-6.69 (m, 1H), 6.83-6.91 (m, 1H), 7.02 (dd, J = 8.8, 6.2 Hz, 1H), 7.09-7.16 (m, 1H), 7.19-7.26 (m, 1H), 7.34 (dd, J = 8.1, 1.5 Hz, 1H), 7.43 (d, J = 8.1 Hz, 1H), 7.94 (dd, J = 7.5, 1.5 Hz, 1H). - [step 4] (E)-methyl1-{[11-(cyanoethylidene)-3-fluoro-6,11-dihydrodibenzo[b,e]oxepin-8-yl]methyl}-2-propyl-1H-benzo[d]imidazole-4-carboxylate (115 mg, 0.23 mmol) obtained in step 3 was dissolved in THF (0.3 mL) and ethanol (1.7 mL), 4 mol/L aqueous sodium hydroxide solution (1.2 mL) was added, and the mixture was stirred at 50Ā°C for 30 min. After cooling to room temperature, the mixture was concentrated under reduced pressure. To the obtained residue were added 1 mol/L hydrochloric acid and water, and the precipitated crystals were collected by suction filtration to give (E)-1-{[11-(1-cyanoethylidene)-3-fluoro-6,11-dihydrodibenzo[b,e]oxepin-8-yl]methyl}-2-propyl-1H-benzo[d]imidazole-4-carboxylic acid (99 mg, 88%).
ESIMS m/z: 482 (M + H)+; 1H NMR (300 MHz, DMSO-d6,Ī“): 0.94 (t, J = 7.3 Hz, 3H), 1.60-1.78 (m, 2H), 2.16 (s, 3H), 3.00-3.17 (m, 2H), 4.96 (d, J = 12.8 Hz, 1H), 5.46 (d, J= 12.8 Hz, 1H), 5.71-5.85 (m, 2H), 6.70 (dd, J = 10.6, 2.6 Hz, 1H), 6.78-6.87 (m, 1H), 7.22-7.35 (m, 2H), 7.35-7.56 (m, 3H), 7.84-8.03 (m, 2H). - [step 5] (E)-1-{[11-(1-cyanoethylidene)-3-fluoro-6,11-dihydrodibenzo[b,e]oxepin-8-yl]methyl}-2-propyl-1H-benzo[d]imidazole-4-carboxylic acid (97 mg, 0.20 mmol) obtained in step 4 was dissolved in THF (1.0 mL), 1,1'-carbonyldiimidazole (130 mg, 0.80 mmol) was added, and the mixture was stirred at 50Ā°C for 4 hr. After cooling to room temperature, 25% aqueous ammonia solution (55 ĀµL, 0.80 mmol) was added, and the mixture was stirred at room temperature for 17 hr. To the mixture were added 1 mol/L hydrochloric acid and water, and the mixture was extracted 3 times with chloroform. The combined organic layers were washed with saturated aqueous sodium hydrogen carbonate, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform/methanol = 100/0 v/v - 93/7 v/v) to give the title compound (97 mg, 100%).
ESIMS m/z: 481 (M + H)+; 1H NMR (270 MHz, DMSO-d6,Ī“): 0.95 (t, J = 7.4 Hz, 3H), 1.71-1.87 (m, 2H), 2.15 (s, 3H), 2.91 (t, J = 7.4 Hz, 2H), 4.97 (d, J = 12.5 Hz, 1H), 5.45 (d, J = 12.5 Hz, 1H), 5.59-5.68 (m, 2H), 6.69 (dd, J = 10.5, 2.6 Hz, 1H), 6.76-6.87 (m, 1H), 7.14-7.36 (m, 4H), 7.42 (d, J = 7.6 Hz, 1H), 7.65-7.76 (m, 2H), 7.84 (d, J = 7.2 Hz, 1H), 9.23-9.33 (m, 1H). - Using 4-methoxy-2-propyl-1H-benzo[d]imidazole (Journal of Pharmacy and Pharmacology; 1956, vol.8, p661, 338 mg, 1.78 mmol) and (E)-2-[8-(bromomethyl)-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene]propanenitrile (700 mg, 1.95 mmol) obtained in Reference Example 1, and in the same manner as in Reference Example 1A, the title compound (448 mg, 54%) was obtained.
ESIMS m/z: 468 (M + H)+; 1H NMR (270 MHz, CDCl3,Ī“): 0.98 (t, J = 7.4 Hz, 3H), 1.79-1.94 (m, 2H), 2.23 (s, 3H), 2.74-2.83 (m, 2H), 4.03 (s, 3H), 4.70 (d, J = 12.6 Hz, 1H), 5.29-5.44 (m, 3H), 6.55 (dd, J = 10.2, 2.6 Hz, 1H), 6.60-6.71 (m, 2H), 6.76-6.81 (m, 1H), 6.90-6.94 (m, 1H), 7.02 (dd, J = 8.8, 6.4 Hz, 1H), 7.07-7.16 (m, 2H), 7.42 (d, J = 7.6 Hz, 1H). - Using 4-methoxy-2-(methoxymethyl)-1H-benzo[d]imidazole (64 mg, 0.34 mmol) obtained in Reference Example 2A, step 2 and (E)-2-[8-(bromomethyl)-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene]propanenitrile (120 mg, 0.335 mmol) obtained in Reference Example 1, and in the same manner as in Reference Example 1A, the title compound (70 mg, 45%) and (E)-2-(3-fluoro-8-{[4-methoxy-7-(methoxymethyl)-1H-benzo[d]imidazol-1-yl]methyl}dibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile were obtained.
ESIMS m/z: 470 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 2.23 (s, 3H), 3.32 (s, 3H), 4.04 (s, 3H), 4.70-4.74 (m, 3H),5.36-5.49 (m, 3H), 6.52-6.72 (m, 2H), 6.84-6.87 (m, 1H), 6.99-7.02 (m, 2H), 7.15-7.21 (m, 3H), 7.39-7.42 (m, 1H). - Using 4-methoxy-2-(methoxymethyl)-1H-benzo[d]imidazole (64 mg, 0.34 mmol) obtained in Reference Example 2A, step 2 and (E)-2-[8-(bromomethyl)-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene]propanenitrile (120 mg, 0.335 mmol) obtained in Reference Example 1, and in the same manner as in Reference Example 2D, the title compound (67 mg, 43%) was obtained.
ESIMS m/z: 470 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 2.24 (s, 3H), 3.32 (s, 3H), 3.80 (s, 3H), 4.61 (s, 2H), 4.73 (d, J = 12.8 Hz, 1H), 5.39 (d, J = 12.8 Hz, 1H), 5.78 (s, 2H), 6.52-6.57 (m, 1H), 6.60-6.67 (m, 1H), 6.70-6.73 (m, 1H), 6.99-7.05 (m, 2H), 7.15-7.21 (m, 2H), 7.38-7.41 (m, 2H). -
- [step 1] Using (E)-2-(3-fluoro-8-{[4-hydroxy-2-(hydroxymethyl)-1H-benzo[d]imidazol-1-yl]methyl}dibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (201 mg, 0.46 mmol) obtained in Reference Example 2A, step 4, and ethanol (0.27 mL, 4.55 mmol) instead of deuterated methanol, and in the same manner as in Reference Example 2A, step 5, (E)-2-(8-{[4-ethoxy-2-(hydroxymethyl)-1H-benzo[d]imidazol-1-yl]methyl}-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (107 mg, 50%) was obtained.
ESIMS m/z: 470 (M + H)+; 1H NMR (270 MHz, CDCl3,Ī“): 1.50-1.60 (m, 3H), 2.23 (s, 3H), 4.29 (q, J= 7.0 Hz, 2H), 4.71 (d, J = 12.8 Hz, 1H), 4.86 (s, 2H), 5.38 (d, J= 12.8 Hz, 1H), 5.41-5.49 (m, 2H), 6.55 (dd, J = 10.2, 2.6 Hz, 1H), 6.60-6.68 (m, 1H), 6.71 (d, J = 7.6 Hz, 1H), 6.80-6.86 (m, 1H), 6.96-7.06 (m, 2H), 7.16-7.21 (m, 2H), 7.41 (d, J = 7.6 Hz, 1H). - [step 2] Using (E)-2-(8-{[4-ethoxy-2-(hydroxymethyl)-1H-benzo[d]imidazol-1-yl]methyl}-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (105 mg, 0.22 mmol) obtained in step 1, and in the same manner as in Reference Example 2A, step 6, the title compound (86 mg, 80%) was obtained.
ESIMS m/z: 484 (M + H)+; 1H NMR (400 MHz, CDCl3,Ī“): 1.52-1.59 (m, 3H), 2.23 (s, 3H), 3.33 (s, 3H), 4.30 (q, J = 6.8 Hz, 2H), 4.66-4.75 (m, 3H), 5.38 (d, J = 12.7 Hz, 1H), 5.43-5.56 (m, 2H), 6.55 (dd, J = 10.7, 2.9 Hz, 1H), 6.60-6.67 (m, 1H), 6.70 (d, J = 8.8 Hz, 1H), 6.83 (d, J = 8.8 Hz, 1H), 6.99-7.04 (m, 2H), 7.13-7.19 (m, 2H), 7.41 (d, J = 8.8 Hz, 1H). -
- [step 1] (E)-2-(3-fluoro-8-{[4-hydroxy-2-(hydroxymethyl)-1H-benzo[d]imidazol-1-yl]methyl}dibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (245 mg, 0.56 mmol) obtained in Reference Example 2A, step 4 was dissolved in dichloromethane (2.8 mL), 2,6-lutidine (0.22 mL, 1.89 mmol) and tertbutyldimethylsilyl trifluoromethanesulfonate (0.38 mL, 1.67 mmol) were added under ice-cooling, and the mixture was stirred at room temperature for 1 hr. To the mixture was added saturated aqueous sodium hydrogen carbonate, and the mixture was extracted 3 times with chloroform. The combined organic layers were washed with 1 mol/L hydrochloric acid and saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The obtained residue was dissolved in methanol (2.8 mL), potassium carbonate (384 mg, 2.77 mmol) was added, and the mixture was stirred at room temperature for 13 hr. Water was added to the mixture, and the mixture was extracted 3 times with chloroform. The combined organic layers were dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform/methanol = 100/0 v/v - 85/15 v/v) to give (E)-2-[8-({2-[(tert-butyldimethylsiloxy)methyl]-4-hydroxy-1H-benzo[d]imidazol-1-yl}methyl)-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene]propanenitrile (203 mg, 66%).
ESIMS m/z: 556 (M + H)+; 1H NMR (300 MHz, CDCl3,Ī“): 0.01 (br s, 6H), 0.76-0.81 (m, 9H), 2.23 (s, 3H), 4.72 (d, J = 12.5 Hz, 1H), 4.97 (s, 2H), 5.38 (d, J = 12.5 Hz, 1H), 5.45-5.61 (m, 2H), 6.54 (dd, J = 10.3, 2.6 Hz, 1H), 6.59-6.68 (m, 1H), 6.71-6.78 (m, 1H), 6.78-6.85 (m, 1H), 6.96-7.06 (m, 2H), 7.14 (t, J = 7.9 Hz, 1H), 7.18-7.25 (m, 1H), 7.42 (d, J = 7.7 Hz, 1H). - [step 2] (E)-2-[8-({2-[(tert-butyldimethylsiloxy)methyl]-4-hydroxy-1H-benzo[d]imidazol-1-yl}methyl)-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene]propanenitrile (200 mg, 0.36 mmol) obtained in step 1 was dissolved in DMF (5.5 mL), cesium carbonate (352 mg, 1.08 mmol) and sodium 2-chloro-2,2-difluoroacetate (165 mg, 1.08 mmol) were added, and the mixture was stirred at 60Ā°C for 1 hr. To the mixture was added saturated aqueous ammonium chloride solution, and the mixture was extracted 3 times with ethyl acetate. The combined organic layers were washed with water, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate = 100/0 v/v - 20/80 v/v) to give (E)-2-(8-{[4-(difluoromethoxy)-2-(hydroxymethyl)-1H-benzo[d]imidazol-1-yl]methyl}-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (55 mg, 31%).
ESIMS m/z: 492 (M + H)+; 1H NMR (400 MHz, CDCl3,Ī“): 2.23 (s, 3H), 4.74 (d, J = 12.7 Hz, 1H), 4.88 (s, 2H), 5.39 (d, J = 12.7 Hz, 1H), 5.43-5.54 (m, 2H), 6.55 (dd, J= 10.2, 2.4 Hz, 1H), 6.61-6.67 (m, 1H), 6.97-7.09 (m, 4H), 7.15-7.21 (m, 2H), 7.29-7.62 (m, 2H). - [step 3] Using (E)-2-(8-{[4-(difluoromethoxy)-2-(hydroxymethyl)-1H-benzo[d]imidazol-1-yl]methyl}-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (55 mg, 0.11 mmol) obtained in step 2, and in the same manner as in Reference Example 2A, step 6, the title compound (35 mg, 62%) was obtained.
ESIMS m/z: 506 (M + H)+; 1H NMR (300 MHz, CDCl3,Ī“): 2.23 (s, 3H), 3.37 (s, 3H), 4.70 (s, 2H), 4.75 (d, J = 12.8 Hz, 1H), 5.40 (d, J = 12.8 Hz, 1H), 5.43-5.58 (m, 2H), 6.55 (dd, J = 10.3, 2.6 Hz, 1H), 6.61-6.69 (m, 1H), 6.98-7.12 (m, 4H), 7.16-7.22 (m, 2H), 7.33-7.61 (m, 2H). -
- [step 1] Methyl 2-propyl-1H-benzo[d]imidazole-4-carboxylate (350 mg, 1.6 mmol) obtained in Reference Example 2B, step 2 was dissolved in THF (16 mL), lithium aluminum hydride (303 mg, 8.0 mmol) was added, and the mixture was stirred at 80Ā°C for 3 hr. After completion of the reaction, saturated sodium sulfate aqueous solution (10 mL) was added to the mixture under ice-cooling. The mixture was stirred at room temperature for 1 hr, filtered through celite, and the solution was concentrated under reduced pressure to quantitatively give (2-propyl-1H-benzo[d]imidazol-4-yl)methanol (304 mg).
ESIMS m/z: 191 (M + H)+; 1H NMR (300 MHz, CDCl3,Ī“): 1.03 (t, J = 7.3 Hz, 3H), 1.81-1.95 (m, 2H), 2.87 (t, J = 7.3 Hz, 2H), 5.07 (s, 2H), 6.99-7.09 (m, 1H), 7.16 (t, J = 7.7 Hz, 1H), 7.49 (d, J = 7.7 Hz, 1H). - [step 2] Using (2-propyl-1H-benzo[d]imidazol-4-yl)methanol (47 mg, 0.25 mmol) obtained in step 1 and (E)-2-[8-(bromomethyl)-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene]propanenitrile (92 mg, 0.26 mmol) obtained in Reference Example 1, and in the same manner as in Reference Example 1A, the title compound (106 mg, 92%) was obtained.
ESIMS m/z: 468 (M + H)+; 1H NMR (270 MHz, CDCl3,Ī“): 1.01 (t, J = 7.4 Hz, 3H), 1.77-1.93 (m, 2H), 2.23 (s, 3H), 2.74-2.84 (m, 2H), 4.18-4.35 (m, 1H), 4.73 (d, J = 12.5 Hz, 1H), 5.15 (s, 2H), 5.32-5.46 (m, 3H), 6.55 (dd, J = 10.2, 2.6 Hz, 1H), 6.60-6.69 (m, 1H), 6.94-6.98 (m, 1H), 7.02 (dd, J = 8.7, 6.4 Hz, 1H), 7.07-7.18 (m, 4H), 7.43 (d, J = 7.9 Hz, 1H). -
- [step 1] Methyl 2-(2-methoxyacetamido)benzoate (
US5091403 ; 3.0 g, 13.4 mmol) was suspended in butyric anhydride (12.7 mL, 134.0 mmol), fuming nitric acid (2.3 mL, 51.1 mmol) was added dropwise under ice-cooling, and the mixture was stirred at 0Ā°C for 40 min. Water was added to the mixture, 4 mol/L aqueous sodium hydroxide solution was added dropwise to neutralize the mixture, and the mixture was extracted 3 times with ethyl acetate. The combined organic layers were dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate = 100/0 v/v - 60/40 v/v) to give methyl 2-(2-methoxyacetamido)-3-nitrobenzoate (1.9 g, 51%).
ESIMS m/z: 269 (M + H)+; 1H NMR (300 MHz, CDCl3,Ī“); 3.58 (s, 3H), 3.97 (s, 3H), 4.06 (s, 2H), 7.35 (t, J = 8.1 Hz, 1H), 8.12 (dd, J = 8.1, 1.5 Hz, 1H), 8.22 (dd, J= 8.1, 1.5 Hz, 1H), 10.98 (br s, 1H). - [step 2] methyl 2-(2-methoxyacetamido)-3-nitrobenzoate (1.9 g, 6.9 mmol) obtained in step 1 was dissolved in a mixed solvent of ethanol (14 mL) and acetic acid (14 mL), reduced iron (2.3 g, 41.4 mmol) was added, and the mixture was stirred at 120Ā°C for 3 hr. After completion of the reaction, the mixture was filtered through celite. Saturated aqueous sodium hydrogen carbonate was added to the solution, and the mixture was extracted 3 times with ethyl acetate. The combined organic layers were dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate = 100/0 v/v - 20/80 v/v) to give methyl 2-(methoxymethyl)-1H-benzo[d]imidazole-4-carboxylate (1.1 g, 71%).
ESIMS m/z: 221 (M + H)+; 1H NMR (300 MHz, CDCl3,Ī“): 3.52 (s, 3H), 4.01 (s, 3H), 4.79 (s, 2H), 7.31 (t, J = 8.9 Hz, 1H), 7.88-7.97 (m, 2H), 10.48 (br s, 1H). - [step 3] Using methyl 2-(methoxymethyl)-1H-benzo[d]imidazole-4-carboxylate (370 mg, 1.7 mmol) obtained in step 2, and in the same manner as in Reference Example 2H, step 1, [2-(methoxymethyl)-1H-benzo[d]imidazol-4-yl]methanol (203 mg, 63%) was obtained.
ESIMS m/z: 193 (M + H)+; 1H NMR (300 MHz, CDCl3,Ī“): 3.45 (s, 3H), 4.66 (s, 2H), 5.06 (s, 2H), 7.07-7.14 (m, 1H), 7.20 (t, J = 7.7 Hz, 1H), 7.43-7.58 (m, 1H). - [step 4] Using [2-(methoxymethyl)-1H-benzo[d]imidazol-4-yl]methanol (203 mg, 1.06 mmol) obtained in step 3 and (E)-2-[8-(bromomethyl)-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene]propanenitrile (386 mg, 1.08 mmol) obtained in Reference Example 1, and in the same manner as in Reference Example 1A, the title compound (451 mg, 91%) was obtained.
ESIMS m/z: 470 (M + H)+; 1H NMR (300 MHz, CDCl3,Ī“): 2.23 (s, 3H), 3.37 (s, 3H), 3.70-3.77 (m, 1H), 4.69 (s, 2H), 4.74 (d, J = 12.5 Hz, 1H), 5.15 (d, J = 6.2 Hz, 2H), 5.40 (d, J = 12.5 Hz, 1H), 5.44-5.58 (m, 2H), 6.55 (dd, J = 10.3, 2.6 Hz, 1H), 6.60-6.69 (m, 1H), 6.98-7.09 (m, 2H), 7.14-7.25 (m, 4H), 7.43 (d, J= 7.7 Hz, 1H). -
- [step 1] 3-Chloro-2-nitroaniline (2.0 g, 11.6 mmol) was dissolved in dichloromethane, triethylamine (2.6 mL, 18.5 mmol) and 2-methoxyacetyl chloride (1.4 mL, 15.1 mmol) were added, and the mixture was stirred at 70Ā°C for 18 hr. To the mixture was added 1 mol/L hydrochloric acid, and the mixture was extracted 3 times with chloroform. The combined organic layers were washed with saturated aqueous sodium hydrogen carbonate and saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate = 90/10 v/v - 50/50 v/v) to give N-(3-chloro-2-nitrophenyl)-2-methoxyacetamide (1.7 g, 62%).
ESIMS m/z: 245 (M + H)+; 1H NMR (300 MHz, CDCl3, Ī“): 3.51 (s, 3H), 4.03 (s, 2H), 7.29 (dd, J= 8.2, 1.5 Hz, 1H), 7.45 (t, J = 8.2 Hz, 1H), 8.31 (dd, J = 8.2, 1.5 Hz, 1H), 9.19 (br s, 1H). - [step 2] Using N-(3-chloro-2-nitrophenyl)-2-methoxyacetamide (900 mg, 3.68 mmol) obtained in step 1, and in the same manner as in Reference Example 2A, step 2, 4-chloro-2-(methoxymethyl)-1H-benzo[d]imidazole (710 mg, 98%) was obtained.
ESIMS m/z: 197 (M + H)+; 1H NMR (300 MHz, CDCl3, Ī“): 3.53 (s, 3H), 4.81 (s, 2H), 7.21 (d, J = 7.9 Hz, 1H), 7.25-7.30 (m, 1H), 7.50 (dd, J = 7.9, 0.9 Hz, 1H). - [step 3] Using 4-chloro-2-(methoxymethyl)-1H-benzo[d]imidazole (50 mg, 0.25 mmol) obtained in step 2 and (E)-2-[8-(bromomethyl)-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene]propanenitrile (96 mg, 0.27 mmol) obtained in Reference Example 1, and in the same manner as in Reference Example 1A, the title compound (107 mg, 89%) was obtained.
ESIMS m/z: 474 (M + H)+; 1H NMR (300 MHz, CDCl3, Ī“): 2.23 (s, 3H), 3.37 (s, 3H), 4.68-4.79 (m, 3H), 5.40 (d, J = 12.8 Hz, 1H), 5.45-5.59 (m, 2H), 6.55 (dd, J = 10.3, 2.6 Hz, 1H), 6.61-6.69 (m, 1H), 6.98-7.06 (m, 2H), 7.11-7.22 (m, 3H), 7.31 (dd, J = 7.1, 1.6 Hz, 1H), 7.43 (d, J = 8.1 Hz, 1H). -
- [step 1] Methyl 2-(methoxymethyl)-1H-benzo[d]imidazole-4-carboxylate (200 mg, 0.91 mmol) obtained in Reference Example 2I, step 2 was dissolved in THF (0.14 mL), 3 mol/L methylmagnesium chloride THF solution (3.0 mL, 9.1 mmol) was added at 0Ā°C, and the mixture was stirred at room temperature for 1 hr. The reaction was discontinued with saturated aqueous sodium chloride solution, and the mixture was extracted with ethyl acetate, and the extract was dried over sodium sulfate and filtered. The filtrate was concentrated under reduced pressure, and the residue was crystallized from isopropyl ether to give 2-[2-(methoxymethyl)-1H-benzo[d]imidazol-4-yl]propan-2-ol (195 mg, 97%).
ESIMS m/z: 221 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 1.72 (s, 6H), 3.51 (s, 3H), 4.75 (s, 2H), 7.06-7.09 (m, 1H), 7.17-7.23 (m, 1H), 7.26-7.27 (m, 1H). - [step 2] Using 2-[2-(methoxymethyl)-1H-benzo[d]imidazol-4-yl]propan-2-ol (74 mg, 0.34 mmol) obtained in step 1 and (E)-2-[8-(bromomethyl)-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene]propanenitrile (120 mg, 0.335 mmol) obtained in Reference Example 1, and in the same manner as in Reference Example 1A, the title compound (166 mg, 99%) was obtained.
ESIMS m/z: 498 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 1.70 (s, 6H), 2.22 (s, 3H), 3.38 (s, 3H), 4.69 (s, 2H), 4.74-4.77 (m, 1H), 5.35-5.45 (m, 3H), 6.54-6.67 (m, 2H), 7.01-7.22 (m, 6H), 7.42-7.44 (m, 1H). - Using (E)-2-(3-fluoro-8-{[4-(hydroxymethyl)-2-(methoxymethyl)-1H-benzo[d]imidazol-1-yl]methyl}dibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (150 mg, 0.32 mmol) obtained in Reference Example 2I, and in the same manner as in Reference Example 2A, step 6, the title compound (153 mg, 99%) was obtained.
ESIMS m/z: 484 (M + H)+; 1H NMR (400 MHz, CDCl3, Ī“): 2.23 (s, 3H), 3.36 (s, 3H), 3.53 (s, 3H), 4.68-4.77 (m, 3H), 4.99 (s, 2H), 5.39 (d, J = 12.7 Hz, 1H), 5.45-5.57 (m, 2H), 6.55 (dd, J = 9.8, 2.9 Hz, 1H), 6.62-6.67 (m, 1H), 6.98-7.08 (m, 2H), 7.15-7.22 (m, 2H), 7.22-7.30 (m, 1H), 7.34 (d, J = 6.8 Hz, 1H), 7.42 (d, J= 7.8 Hz, 1H). -
- [step 1] Commercially available 3-chloro-2-nitroaniline (3.0 g, 17 mmol) was dissolved in DMF (87 mL), sodium thiomethoxide (1.54 g, 21 mmol) was added, and the mixture was stirred at room temperature for 3 hr. The reaction was discontinued with water, and the mixture was extracted with ethyl acetate, and the extract was dried over sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The residue was crystallized from isopropyl ether to give 3-(methylthio)-2-nitroaniline (2.5 g, 78%).
ESIMS m/z: 185 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“) : 2.42 (s, 3H), 5.92 (br s, 2H), 6.55 (d, J = 8.2 Hz, 2H), 7.21 (t, J = 8.2 Hz, 1H). - [step 2] 3-(Methylthio)-2-nitroaniline (1.0 g, 5.4 mmol) obtained in step 1 was dissolved in DMA (5.4 mL), pyridine (0.44 mL, 5.4 mmol) and 2-methoxyacetyl chloride (1.49 mL, 16 mmol) were added, and the mixture was stirred at room temperature for 2 hr. To the reaction solution were added methanol and aqueous ammonia, and the mixture was stirred at room temperature for 30 min. Water was added, and the crystals were collected by filtration, and dried to give 2-methoxy-N-[3-(methylthio)-2-nitrophenyl]acetamide (1.26 g, 91%).
ESIMS m/z: 257 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 2.42 (s, 3H), 3.37 (s, 3H), 4.31 (s, 2H), 7.01-7.06 (m, 1H), 7.22-7.38 (m, 1H), 8.17-8.36 (m, 1H). - [step 3] 2-Methoxy-N-[3-(methylthio)-2-nitrophenyl]acetamide (215 mg, 0.84 mmol) obtained in step 2 was dissolved in THF (4.2 mL), and sodium hydride (60 mg, 2.5 mmol), and (E)-2-[8-(bromomethyl)-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene]propanenitrile (300 mg, 0.84 mmol) obtained in Reference Example 1 were added at 0Ā°C, and the mixture was stirred for 5 hr. The reaction was discontinued with water, and the mixture was extracted with ethyl acetate, and the extract was dried over sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. To the obtained residue were added ethanol (4.5 mL), reduced iron (0.12 g, 2.1 mmol), and acetic acid (4.5 mL), and the mixture was stirred at 130Ā°C for 1 hr and half. Furthermore, reduced iron (0.12 g, 2.1 mmol) was added, and the mixture was stirred at 130Ā°C for 1 hr, and filtered through celite. To the obtained filtrate was added saturated aqueous sodium hydrogen carbonate solution, and the mixture was extracted with ethyl acetate, and the extract was dried over sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform/methanol = 95/5 v/v) to give (E)-2-(3-fluoro-8-{[2-(methoxymethyl)-4-(methylthio)-1H-benzo[d]imidazol-1-yl]methyl}dibenzo[b,e]oxepin-11(6H)-ylidene)propionitrile (320 mg, 78%).
ESIMS m/z: 486 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 2.23 (s, 3H), 2.63 (s, 3H), 3.35 (s, 3H), 4.73-4.75 (m, 2H), 5.32-5.44 (m, 2H), 5.50-5.51 (m, 2H), 6.54-6.57 (m, 1H), 6.60-6.72 (m, 2H), 6.97-7.11 (m, 5H), 7.40-7.43 (m, 1H). - (E)-2-(3-fluoro-8-{[2-(methoxymethyl)-4-(methylthio)-1H-benzo[d]imidazol-1-yl]methyl}dibenzo[b,e]oxepin-11(6H)-ylidene)propionitrile (120 mg, 0.25 mmol) obtained in Reference Example 2M was dissolved in methylene chloride (1.2 mL), m-chloroperbenzoic acid (227 mg, 0.989 mmol) was added at 0Ā°C, and the mixture was stirred at room temperature for 4 hr. The reaction was discontinued with aqueous sodium thiosulfate solution, the mixture was extracted with chloroform, and the extract was dried over sodium sulfate and filtered. The filtrate was concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (chloroform/methanol = 10/1 v/v) to give (E)-2-(3-fluoro-8-{[2-(methoxymethyl)-4-(methylsulfonyl)-1H-benzo[d]imidazol-1-yl]methyl}dibenzo[b,e]oxepin-11(6H)-ylidene)propionitrile (79 mg, 62 %).
ESIMS m/z: 518 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“) :2.27 (s, 3H), 3.38 (s, 3H), 3.45 (s, 3H), 4.62-4.73 (m, 3H), 5.47-5.58 (m, 3H), 6.43-6.50 (m, 1H), 6.62-6.67 (m, 1H), 7.08-7.18 (m, 4H), 7.30-7.39 (m, 1H) 7.51-7.54 (m, 1H), 7.88-7.89 (m, 1H). - Using 4-chloro-2-cyclopropyl-1H-benzo[d]imidazole (
EP1988091 ; 64 mg, 0.34 mmol) and (E)-2-[8-(bromomethyl)-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene]propanenitrile (120 mg, 0.34 mmol) obtained in Reference Example 1, and in the same manner as in Reference Example 1A, the title compound (105 mg, 67%) was obtained.
ESIMS m/z: 470 (M + H)+; 1H NMR (300 MHz, CDCl3, Ī“): 1.01-1.11 (m, 2H), 1.23-1.35 (m, 2H), 1.81-1.94 (m, 1H), 2.24 (s, 3H), 4.74 (d, J = 12.8 Hz, 1H), 5.40 (d, J = 12.8 Hz, 1H), 5.42-5.55 (m, 2H), 6.56 (dd, J = 10.3, 2.6 Hz, 1H), 6.61-6.68 (m, 1H), 6.97-7.06 (m, 2H), 7.06-7.13 (m, 2H), 7.17-7.26 (m, 2H), 7.45 (d, J= 7.7 Hz, 1H). - Using 2-propyl-1H-imidazo[4,5-c]pyridine (135 mg, 0.838 mmol) and (E)-2-[8-(bromomethyl)-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene]propanenitrile (300 mg, 0.838 mmol) obtained in Reference Example 1, and in the same manner as in Reference Example 1A, the title compound (50 mg, 14%) was obtained.
ESIMS m/z: 439 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 1.03 (t, J = 7.4 Hz, 3H), 1.82-2.03 (m, 2H), 2.23 (s, 3H), 2.84 (t, J = 7.4 Hz, 2H), 4.75 (d, J = 12.8 Hz, 1H), 5.34-5.48 (m, 3H), 6.50-6.61 (m, 1H), 6.61-6.71 (m, 1H), 6.96-7.09 (m, 2H), 7.12-7.21 (m, 1H), 7.40-7.52 (m, 1H), 7.64-7.72 (m, 1H), 8.38-8.52 (m, 1H), 8.59-8.69 (m, 1H). -
- [step 1] 3,4-Diaminopyridine (2.0 g, 18.4 mmol) was mixed with polyphosphoric acid (20 g), cyclobutanecarboxylic acid (2.63 mL, 27.5 mmol) was added, and the mixture was stirred with heating at 110Ā°C for 3 hr. The mixture was added dropwise to 5% aqueous ammonia solution under ice-cooling, and the mixture was extracted 3 times with chloroform. The combined organic layers were dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. To the obtained residue was added ethyl acetate (7 mL), and the precipitated crystals were collected by suction filtration to give 2-cyclobutyl-1H-imidazo[4,5-c]pyridine (2.3 g, 73%).
ESIMS m/z: 174 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“) : 1.87-2.28 (m, 2H), 2.34-2.75 (m, 4H), 3.76-3.99 (m, 1H), 7.51 (d, J = 5.5 Hz, 1H), 8.38 (d, J = 5.5 Hz, 1H), 8.96 (s, 1H). - [step 2] 2-Cyclobutyl-1H-imidazo[4,5-c]pyridine (500 mg, 2.89 mmol) obtained in step 1 was dissolved in chloroform (10 mL), m-chloroperbenzoic acid (860 mg, 3.76 mmol) was added and the mixture was stirred at room temperature for 2 hr. To the mixture was added dichloromethane, and the mixture was washed twice with water. The combined aqueous layers were washed 3 times with ethyl acetate, and concentrated under reduced pressure to give a residue.
- The obtained residue was dissolved in phosphorus oxychloride (2.5 mL), diisopropylethylamine (0.42 mL) was added, and the mixture was stirred with heating at 50Ā°C for 3 hr. The mixture was diluted with ethyl acetate, added dropwise to saturated aqueous sodium hydrogen carbonate solution under ice-cooling, and the mixture was extracted 3 times with ethyl acetate. The combined organic layers were dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (chloroform/methanol = 9/1 v/v) to give 4-chloro-2-cyclobutyl-1H-imidazo[4,5-c]pyridine (120 mg, 20%). ESIMS m/z: 208 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“) : 1.84-2.19 (m, 2H), 2.31-2.74 (m, 4H), 3.83-4.06 (m, 1H), 7.45 (d, J = 5.5 Hz, 1H), 8.15 (d, J = 5.5 Hz, 1H).
- [step 3] Using 4-chloro-2-cyclobutyl-1H-imidazo[4,5-c]pyridine (41 mg, 0.196 mmol) obtained in step 2 and (E)-2-[8-(bromomethyl)-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene]propanenitrile (70 mg, 0.196 mmol) obtained in Reference Example 1, and in the same manner as in Reference Example 1A, the title compound (87 mg, 91%) was obtained.
ESIMS m/z: 485 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 1.92-2.16 (m, 2H), 2.18-2.44 (m, 5H), 2.50-2.77 (m, 2H), 3.53-3.76 (m, 1H), 4.73 (d, J = 12.6 Hz, 1H), 5.28 (s, 2H), 5.40 (d, J = 12.6 Hz, 1H), 6.53-6.70 (m, 2H), 6.88 (s, 1H), 6.97-7.16 (m, 3H), 7.43-7.48 (m, 1H), 8.10-8.15 (m, 1H). - Using 7-chloro-2-cyclopropyl-3H-imidazo[4,5-b]pyridine (
EP1988091 , 81 mg, 0.419 mmol) and (E)-2-[8-(bromomethyl)-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene]propanenitrile (150 mg, 0.419 mmol) obtained in Reference Example 1, and in the same manner as in Reference Example 1A, the title compound (107 mg, 54%) was obtained.
ESIMS m/z: 471 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 1.02-1.16 (m, 2H), 1.25-1.38 (m, 2H), 1.83-1.97 (m, 1H), 2.26 (s, 3H), 4.76 (d, J = 12.8 Hz, 1H), 5.41 (d, J = 12.8 Hz, 1H), 5.59-5.63 (m, 2H), 6.51-6.59 (m, 1H), 6.59-6.70 (m, 1H), 6.97-7.08 (m, 1H), 7.13-7.35 (m, 3H), 7.38-7.48 (m, 1H), 8.11-8.24 (m, 1H). - Using 7-chloro-2-cyclobutyl-3H-imidazo[4,5-b]pyridine (
WO2009/29592
ESIMS m/z: 485 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“) : 1.92-2.12 (m, 2H), 2.17-2.35 (m, 5H), 2.51-2.73 (m, 2H), 3.54-3.70 (m, 1H), 4.74 (d, J = 12.8 Hz, 1H), 5.35-5.47 (m, 3H), 6.50-6.60 (m, 1H), 6.60-6.70 (m, 1H), 6.93-7.07 (m, 2H), 7.14-7.21 (m, 1H), 7.23-7.29 (m, 1H), 7.40-7.49 (m, 1H), 8.12-8.24 (m, 1H). - (E)-2-[3-fluoro-8-(hydroxymethyl)dibenzo[b,e]oxepin-11(6H)-ylidene]propanenitrile (58 mg, 0.198 mmol) obtained in Reference Example 1, step 5 and 2-propyl-3H-imidazo[4,5-b]pyridine (Journal of Medicinal Chemistry, 1991, vol. 34, p2919, 35 mg, 0.217 mmol) were dissolved in THF, triphenylphosphine polymer supported (3.02 mmol/g, 131 mg, 0.395 mmol), di-tert-butyl diazadicarboxylate (91 mg, 0.395 mmol) were added and the mixture was stirred at room temperature for 4 hr. The mixture was filtered through celite, and the filtrate was concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane/ethyl acetate = 1/2 v/v) to give the title compound (44 mg, 51%).
ESIMS m/z: 439 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“) : 1.00 (t, J = 7.4 Hz, 3H), 1.74-1.96 (m, 2H), 2.23 (s, 3H), 2.78 (t, J = 7.4 Hz, 2H), 4.75 (d, J = 12.8 Hz, 1H), 5.40 (d, J = 12.8 Hz, 1H), 5.52 (s, 2H), 6.48-6.57 (m, 1H), 6.57-6.69 (m, 1H), 6.95-7.06 (m, 1H), 7.09-7.15 (m, 1H), 7.19-7.29 (m, 2H), 7.37-7.47 (m, 1H), 7.96-8.09 (m, 1H), 8.27-8.38 (m, 1H). -
- [step 1] 6-Fluoropyridin-3-amine (800 mg, 7.14 mmol) was suspended in butyric anhydride (3.5 mL, 21.4 mmol), fuming nitric acid (1.15 mL, 25.6 mmol) was added dropwise under ice-cooling, and the mixture was stirred at 0Ā°C for 4 hr. The mixture was allowed to warm to room temperature, and stirred for 4 hr. Water was added to the mixture, 4 mol/L aqueous sodium hydroxide solution was added dropwise to neutralize the mixture, and the mixture was extracted 3 times with ethyl acetate. The combined organic layers were dried over anhydrous magnesium sulfate and purified by silica gel column chromatography (hexane/ethyl acetate = 2/1 v/v) to give N-(6-fluoro-2-nitropyridin-3-yl)butylamide (800 mg, 49%).
ESIMS m/z: 228 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“) : 1.05 (t, J = 7.3 Hz, 3H), 1.71-1.90 (m, 2H), 2.51 (t, J = 7.3 Hz, 2H), 7.35 (dd, J = 8.8, 3.8 Hz, 1H), 9.46 (dd, J = 8.8, 6.0 Hz, 1H), 10.13 (br s, 1H). - [step 2] N-(6-fluoro-2-nitropyridin-3-yl)butylamide (170 mg, 0.748 mmol) obtained in step 1 was dissolved in a mixed solvent of ethanol (1 mL)-ethyl acetate (1 mL), reduced iron (125 mg, 2.245 mmol) was added and the mixture was stirred at 100Ā°C overnight. The mixture was filtered through celite, and the filtrate was concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane/ethyl acetate = 1/2 v/v) to give a residue (106 mg).
The obtained residue (106 mg) was dissolved in acetic acid (2 mL), and the mixture was stirred with heating under reflux overnight. The mixture was concentrated under reduced pressure, and the obtained residue was purified by silica gel column chromatography (hexane/ethyl acetate = 1/1 v/v) to give 5-fluoro-2-propyl-3H-imidazo[4,5-b]pyridine (47 mg, 36%). ESIMS m/z: 180 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 1.03 (t, J = 7.4 Hz, 3H), 1.68-1.90 (m, 2H), 2.38 (t, J = 7.4 Hz, 2H), 6.27 (dd, J = 7.7, 2.6 Hz, 1H), 6.94 (s, 1H), 7.44 (t, J = 7.7 Hz, 1H). - [step 3] Using 5-fluoro-2-propyl-3H-imidazo[4,5-b]pyridine (47 mg, 0.262 mmol) obtained in step 2 and (E)-2-[3-fluoro-8-(hydroxymethyl)dibenzo[b,e]oxepin-11(6H)-ylidene]propanenitrile (70 mg, 0.238 mmol) obtained in Reference Example 1, step 5, and in the same manner as in Reference Example 3E, the title compound (46 mg, 42%) was obtained.
ESIMS m/z: 457 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“) : 0.99 (t, J = 7.6 Hz, 3H), 1.80-1.91 (m, 2H), 2.23 (s, 3H), 2.76 (t, J = 7.6 Hz, 2H), 4.77 (d, J = 12.8 Hz, 1H), 5.35-5.51 (m, 3H), 6.50-6.59 (m, 1H), 6.59-6.70 (m, 1H), 6.80-6.91 (m, 1H), 6.96-7.08 (m, 1H), 7.09-7.17 (m, 1H), 7.17-7.27 (m, 1H), 7.41-7.54 (m, 1H), 7.98-8.12 (m, 1H). -
- [step 1] Using N-(6-fluoro-2-nitropyridin-3-yl)butylamide (274 mg, 1.21 mmol) obtained in Reference Example 3G, step 1 and (E)-2-[8-(bromomethyl)-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene]propanenitrile (360 mg, 1.01 mmol) obtained in Reference Example 1, and in the same manner as in Reference Example 1A, (E)-N-{[11-(1-cyanoethylidene)-3-fluoro-6,11-dihydrodibenzo[b,e]oxepin-8-yl]methyl}-N-(6-fluoro-2-nitropyridin-3-yl)butylamide (390 mg, 78%) was obtained.
ESIMS m/z: 505 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 0.78-0.95 (m, 3H), 1.59-1.73 (m, 2H), 1.95-2.08 (m, 2H), 2.24 (s, 3H), 3.84-4.02 (m, 1H), 4.71-4.91 (m, 1H), 5.29-5.51 (m, 1H), 5.69-5.85 (m, 1H), 6.54-6.63 (m, 1H), 6.63-6.72 (m, 1H), 7.00-7.16 (m, 4H), 7.24-7.35 (m, 1H), 7.38-7.51 (m, 1H). - [step 2] (E)-N-{[11-(1-cyanoethylidene)-3-fluoro-6,11-dihydrodibenzo[b,e]oxepin-8-yl]methyl}-N-(6-fluoro-2-nitropyridin-3-yl)butylamide (70 mg, 0.139 mmol) obtained in step 1 was dissolved in ethanol (2.5 mL), reduced iron (23 mg, 0.417 mmol) and acetic acid (0.5 mL) were added and the mixture was stirred with heating under reflux overnight. The mixture was filtered through celite, and the filtrate was concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane/ethyl acetate=1/2 v/v) to give the title compound (12 mg, 19%).
ESIMS m/z: 457 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 1.01 (t, J = 7.6 Hz, 3H), 1.79-2.00 (m, 2H), 2.25 (s, 3H), 2.85 (t, J = 7.6 Hz, 2H), 4.71-4.79 (m, 1H), 5.35-5.48 (m, 3H), 6.53-6.62 (m, 1H), 6.60-6.71 (m, 1H), 6.71-6.83 (m, 1H), 6.92-6.98 (m, 1H), 6.98-7.09 (m, 1H), 7.09-7.17 (m, 1H), 7.38-7.56 (m, 2H). -
- [step 1] 6-Fluoropyridin-3-amine (600 mg, 5.35 mmol) was dissolved in dichloromethane (20 mL), triethylamine (1.49 mL, 10.7 mmol) and cyclobutanecarbonyl chloride (0.67 mL, 5.89 mmol) were added, and the mixture was stirred at room temperature overnight. Water was added to the mixture, and the mixture was extracted 3 times with ethyl acetate. The combined organic layers were dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. To the obtained residue was added diisopropyl ether and the precipitated crystals were collected by suction filtration to give N-(6-fluoropyridin-3-yl)cyclobutanecarboxamide (899 mg, 86%).
ESIMS m/z: 195 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 1.85-2.10 (m, 2H), 2.10-2.49 (m, 4H), 3.08-3.30 (m, 1H), 6.77-7.01 (m, 1H), 7.56 (br s, 1H), 8.17-8.35 (m, 2H). - [step 2] N-(6-fluoropyridin-3-yl)cyclobutanecarboxamide (800 mg, 4.12 mmol) obtained in step 1 was dissolved in acetic anhydride (4 mL), fuming nitric acid (0.7 mL, 15.7 mmol) was added under ice-cooling, and the mixture was stirred at room temperature for 3 hr. Under ice-cooling, 5 mol/L aqueous sodium hydroxide solution was added dropwise to the mixture, and the mixture was extracted 3 times with ethyl acetate. The combined organic layers were dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane/ethyl acetate = 1/1 v/v) to give N-(6-fluoro-2-nitropyridin-3-yl)cyclobutanecarboxamide (348 mg, 35%).
ESIMS m/z: 240 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 1.80-2.17 (m, 2H), 2.17-2.54 (m, 4H), 3.22-3.44 (m, 1H), 7.30-7.43 (m, 1H), 9.34-9.58 (m, 1H), 9.92-10.21 (m, 1H). - [step 3] Using N-(6-fluoro-2-nitropyridin-3-yl)cyclobutanecarboxamide (200 mg, 0.836 mmol) obtained in step 2 and (E)-2-[8-(bromomethyl)-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene]propanenitrile (250 mg, 0.697 mmol) obtained in Reference Example 1, and in the same manner as in Reference Example 1A, (E)-N-{[11-(1-cyanoethylidene)-3-fluoro-6,11-dihydrodibenzo[b,e]oxepin-8-yl]methyl}-N-(6-fluoro-2-nitropyridin-3-yl)cyclobutanecarboxamide (180 mg, 50%) was obtained.
ESIMS m/z: 517 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 1.64-1.90 (m, 4H), 2.18-2.52 (m, 5H), 2.67-2.84 (m, 1H), 3.89-4.05 (m, 1H), 4.70-4.97 (m, 1H), 5.34-5.51 (m, 1H), 5.69-5.89 (m, 1H), 6.52-6.75 (m, 2H), 6.93-7.16 (m, 3H), 7.17-7.52 (m, 3H). - [step 4] Using (E)-N-{[11-(1-cyanoethylidene)-3-fluoro-6,11-dihydrodibenzo[b,e]oxepin-8-yl]methyl}-N-(6-fluoro-2-nitropyridin-3-yl)cyclobutanecarboxamide (180 mg, 0.349 mmol) obtained in step 3, and in the same manner as in Reference Example 3H, step 2, the title compound (100 mg, 61%) was obtained.
ESIMS m/z: 469 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 1.97-2.16 (m, 2H), 2.24 (s, 3H), 2.29-2.46 (m, 2H), 2.54-2.78 (m, 2H), 3.55-3.76 (m, 1H), 4.72 (d, J = 12.8 Hz, 1H), 5.27-5.30 (m, 2H), 5.41 (d, J = 12.8 Hz, 1H), 6.50-6.61 (m, 1H), 6.61-6.71 (m, 1H), 6.71-6.81 (m, 1H), 6.87-6.94 (m, 1H), 6.99-7.08 (m, 1H), 7.08-7.16 (m, 1H), 7.39-7.55 (m, 2H). -
- [step 1] Using pyrazine-2,3-diamine (1.0 g, 9.1 mmol) instead of 3,4-diaminopyridine, and butyric acid (1.2 mL, 13.6 mmol) instead of cyclobutanecarboxylic acid, and in the same manner as in Reference Example 3B, step 1, 2-propyl-1H-imidazo[4,5-b]pyrazine (0.9 g, 60%) was obtained.
ESIMS m/z: 163 (M + H)+; 1H NMR (300 MHz, CDCl3, Ī“): 0.96 (t, J = 7.3 Hz, 3H), 1.75-1.91 (m, 2H), 2.88 (t, J = 7.3 Hz, 2H), 8.31 (s, 2H), 13.21 (br s, 1H). - [step 2] Using 2-propyl-1H-imidazo[4,5-b]pyrazine (68 mg, 0.42 mmol) obtained in step 1 and (E)-2-[8-(bromomethyl)-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene]propanenitrile (153 mg, 0.43 mmol) obtained in Reference Example 1, and in the same manner as in Reference Example 1A, the title compound (136 mg, 74%) was obtained.
ESIMS m/z: 440 (M + H)+; 1H NMR (300 MHz, CDCl3, Ī“): 1.01 (t, J = 7.3 Hz, 3H), 1.84-1.98 (m, 2H), 2.23 (s, 3H), 2.79-2.89 (m, 2H), 4.76 (d, J = 12.8 Hz, 1H), 5.41 (d, J = 12.8 Hz, 1H), 5.43-5.56 (m, 2H), 6.56 (dd, J = 10.3, 2.6 Hz, 1H), 6.60-6.69 (m, 1H), 7.02 (dd, J = 8.8, 6.6 Hz, 1H), 7.10-7.14 (m, 1H), 7.21-7.26 (m, 1H), 7.45 (d, J = 8.1 Hz, 1H), 8.27 (d, J = 2.6 Hz, 1H), 8.51 (d, J= 2.6 Hz, 1H). -
- [step 1] 2-Nitroaniline (0.7 g, 5.1 mmol) was dissolved in dichloromethane (25 mL), 2-[tert-butoxycarbonyl(methyl)amino]acetic acid (2.9 g, 15.2 mmol), N,N'-dicyclohexylcarbodiimide (3.1 g, 15.2 mmol) and N,N-dimethylaminopyridine (0.6 g, 5.1 mmol) were added, and the mixture was stirred at room temperature for 24 hr. The mixture was filtered to remove white solids, saturated aqueous sodium hydrogen carbonate was added to the obtained solution, and the mixture was extracted 3 times with chloroform. The combined organic layers were dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate = 100/0 v/v - 60/40 v/v) to give tert-butyl methyl[2-(2-nitrophenylamino)-2-oxoethyl]carbamate (1.1 g, 69%).
ESIMS m/z: 310 (M + H)+; 1H NMR (300 MHz, CDCl3, Ī“): 1.37-1.65 (m, 9H), 3.05 (s, 3H), 4.01-4.17 (m, 2H), 7.21 (t, J = 7.3 Hz, 1H), 7.67 (t, J = 7.3 Hz, 1H), 8.24 (d, J= 8.4, 1.5 Hz, 1H), 8.78-8.90 (m, 1H), 10.94 (br s, 1H). - [step 2] tert-Butyl methyl[2-(2-nitrophenylamino)-2-oxoethyl]carbamate (400 mg, 1.29 mmol) obtained in step 1 was dissolved in THF (7.6 mL), sodium hydride (62 mg, 1.55 mmol) and (E)-2-[8-(bromomethyl)-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene]propanenitrile (468 mg, 1.31 mmol) obtained in Reference Example 1 were added under ice-cooling, and the mixture was stirred at room temperature for 36 hr. To the mixture was added water (20 mL), and the mixture was extracted 3 times with chloroform. The combined organic layers were dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate = 100/0 v/v - 50/50 v/v) to give (E)-tert-butyl 2-({[11-(1-cyanoethylidene)-3-fluoro-6,11-dihydrodibenzo[b,e]oxepin-8-yl]methyl}(2-nitrophenyl)amino)-2-oxoethyl(methyl)carbamate (570 mg, 75%).
ESIMS m/z: 487 (M + H)+ (-Boc); 1H NMR (300 MHz, CDCl3, Ī“) : 1.34-1.50 (m, 9H), 2.24 (br s, 3H), 2.86-2.97 (m, 3H), 3.26-3.84 (m, 2H), 3.97-4.44 (m, 2H), 4.70-4.91 (m, 1H), 5.20-5.62 (m, 2H), 6.49-6.72 (m, 2H), 6.76-7.08 (m, 2H), 7.10-7.40 (m, 2H), 7.42-7.62 (m, 2H), 7.86-8.06 (m, 1H). - [step 3] Using (E)-tert-butyl 2-({[11-(1-cyanoethylidene)-3-fluoro-6,11-dihydrodibenzo[b,e]oxepin-8-yl]methyl}(2-nitrophenyl)amino)-2-oxoethyl(methyl)carbamate (570 mg, 0.97 mmol) obtained in step 2, and in the same manner as in Reference Example 2I, step 2, (E)-tert-butyl (1-{[11-(cyanoethylidene)-3-fluoro-6,11-dihydrodibenzo[b,e]oxepin-8-yl]methyl}-1H-benzo[d]imidazol-2-yl)methyl(methyl)carbamate (520 mg, 99%) was obtained.
ESIMS m/z: 539 (M + H)+; 1H NMR (300 MHz, CDCl3, Ī“): 1.15-1.27 (m, 9H), 2.22 (s, 3H), 2.84 (s, 3H), 4.61-4.93 (m, 3H), 5.39 (d, J = 12.8 Hz, 1H), 5.46-5.71 (m, 2H), 6.54 (dd, J= 10.3, 2.6 Hz, 1H), 6.58-6.68 (m, 1H), 6.90-6.96 (m, 1H), 6.97-7.11 (m, 2H), 7.14-7.33 (m, 3H), 7.34-7.44 (m, 1H), 7.76-7.83 (m, 1H). - [step 4] (E)-tert-butyl (1-{[11-(cyanoethylidene)-3-fluoro-6,11-dihydrodibenzo[b,e]oxepin-8-yl]methyl}-1H-benzo[d]imidazol-2-yl)methyl(methyl)carbamate (400 mg, 0.74 mmol) obtained in step 3 was dissolved in dichloromethane (3.7 mL), trifluoroacetic acid (1.72 mL, 22.3 mol) was added, and the mixture was stirred at room temperature for 3 hr. To the mixture was added saturated aqueous sodium hydrogen carbonate was added, and the mixture was extracted 3 times with chloroform. The combined organic layers were dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform/methanol = 100/0 v/v - 90/10 v/v) to give (E)-2-[3-fluoro-8-({2-[(methylamino)methyl]-1H-benzo[d]imidazol-1-yl}methyl)dibenzo[b,e]oxepin-11(6H)-ylidene]propanenitrile (311 mg, 96%).
ESIMS m/z: 439 (M + H)+; 1H NMR (300 MHz, CDCl3, Ī“): 2.23 (s, 3H), 2.47 (s, 3H), 3.97 (s, 2H), 4.73 (d, J= 12.8 Hz, 1H), 5.39 (d, J = 12.8 Hz, 1H), 5.47-5.62 (m, 2H), 6.54 (dd, J= 10.3, 2.6 Hz, 1H), 6.60-6.66 (m, 1H), 6.99-7.06 (m, 2H), 7.14-7.21 (m, 1H), 7.21-7.32 (m, 3H), 7.42 (d, J = 8.1 Hz, 1H), 7.76-7.82 (m, 1H). - [step 5] (E)-2-[3-fluoro-8-({2-[(methylamino)methyl]-1H-benzo[d]imidazol-1-yl}methyl)dibenzo[b,e]oxepin-11(6H)-ylidene]propanenitrile (215 mg, 0.49 mmol) obtained in step 4 was dissolved in acetonitrile (9.8 mL), formaldehyde (0.26 mL, 3.43 mmol) and sodium cyanoborohydride (62 mg, 0.98 mmol) were added, and the mixture was stirred at room temperature for 6 hr. To the mixture was added saturated aqueous sodium hydrogen carbonate, and the mixture was extracted 3 times with chloroform. The combined organic layers were dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate = 100/0 v/v - 0/100 v/v) to quantitatively give the title compound (222 mg).
ESIMS m/z: 453 (M + H)+; 1H NMR (300 MHz, CDCl3, Ī“): 2.23 (s, 3H), 2.26 (s, 6H), 3.60-3.73 (m, 2H), 4.72 (d, J = 12.8 Hz, 1H), 5.39 (d, J = 12.8 Hz, 1H), 5.54-5.70 (m, 2H), 6.55 (dd, J = 10.3, 2.6 Hz, 1H), 6.60-6.69 (m, 1H), 6.98-7.06 (m, 2H), 7.15-7.31 (m, 4H), 7.42 (d, J = 7.7 Hz, 1H), 7.76-7.81 (m, 1H). - Using (E)-tert-butyl (1-{[11-(cyanoethylidene)-3-fluoro-6,11-dihydrodibenzo[b,e]oxepin-8-yl]methyl}-1H-benzo[d]imidazol-2-yl)methyl(methyl)carbamate (80 mg, 0.15 mmol) obtained in Reference Example 4A, step 3, and in the same manner as in Example 1, the title compound (48 mg, 54%) was obtained.
ESIMS m/z: 598 (M + H)+; 1H NMR (300 MHz, CDCl3, Ī“) : 1.21-1.41 (m, 9H), 2.27 (s, 3H), 2.80-2.96 (m, 3H), 4.63-4.80 (m, 3H), 5.42-5.71 (m, 3H), 6.52 (dd, J = 10.3, 2.6 Hz, 1H), 6.60-6.70 (m, 1H), 6.93-7.01 (m, 1H), 7.02-7.16 (m, 3H), 7.22-7.38 (m, 3H), 7.78-7.87 (m, 1H). -
- [step 1] Commercially available 2-chloro-1H-benzo[d]imidazole (200 mg, 1.31 mmol) was dissolved in THF (1.9 mL), azetidine (0.27 mL, 3.93 mmol) and water (0.27 mL, 0.015 mmol) were added, and the mixture was stirred with heating in an Emrys Optimizer microwave synthesizer at 180Ā°C for 3 hr. Water was added to the mixture, and the mixture was extracted 3 times with chloroform. The combined organic layers were dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform/methanol = 100/0 v/v - 90/10 v/v) to give 2-(azetidin-1-yl)-1H-benzo[d]imidazole (40 mg, 18%).
ESIMS m/z: 174 (M + H)+; 1H NMR (300 MHz, DMSO-d6, Ī“): 2.28-2.43 (m, 2H), 3.98-4.07 (m, 4H), 6.81-6.99 (m, 2H), 7.08-7.24 (m, 2H), 11.28 (br s, 1H). - [step 2] Using 2-(azetidin-1-yl)-1H-benzo[d]imidazole (40 mg, 0.23 mmol) obtained in step 1 and (E)-2-[8-(bromomethyl)-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene]propanenitrile (84 mg, 0.24 mmol) obtained in Reference Example 1, and in the same manner as in Reference Example 1A, the title compound (61 mg, 59%) was obtained.
ESIMS m/z: 451 (M + H)+; 1H NMR (300 MHz, CDCl3, Ī“): 2.24 (s, 3H), 2.30-2.42 (m, 2H), 4.14 (t, J= 7.5 Hz, 4H), 4.75 (d, J = 12.5 Hz, 1H), 5.09-5.23 (m, 2H), 5.41 (d, J= 12.5 Hz, 1H), 6.56 (dd, J = 10.3, 2.6 Hz, 1H), 6.60-6.69 (m, 1H), 6.93-6.99 (m, 1H), 6.99-7.10 (m, 3H), 7.13-7.20 (m, 1H), 7.19-7.25 (m, 1H), 7.43 (d, J = 7.7 Hz, 1H), 7.56 (d, J = 7.7 Hz, 1H). - Using commercially available 2-(pyrrolidin-1-yl)-1H-benzo[d]imidazole (63 mg, 0.34 mmol) and (E)-2-[8-(bromomethyl)-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene]propanenitrile (120 mg, 0.34 mmol) obtained in Reference Example 1, and in the same manner as in Reference Example 1A, the title compound (141 mg, 91%) was obtained.
ESIMS m/z: 465 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“) : 1.86-1.97 (m, 4H), 2.24 (s, 3H), 3.46-3.60 (m, 4H), 4.76 (d, J = 12.8 Hz, 1H), 5.24-5.32 (m, 2H), 5.42 (d, J = 12.8 Hz, 1H), 6.57 (dd, J = 10.2, 2.6 Hz, 1H), 6.61-6.70 (m, 1H), 6.91-7.08 (m, 3H), 7.09-7.19 (m, 2H), 7.22-7.27 (m, 1H), 7.45 (d, J = 7.6 Hz, 1H), 7.54 (d, J = 7.6 Hz, 1H). - Using commercially available 2-(piperidin-1-yl)-1H-benzo[d]imidazole (67 mg, 0.34 mmol) and (E)-2-[8-(bromomethyl)-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene]propanenitrile (120 mg, 0.34 mmol) obtained in Reference Example 1, and in the same manner as in Reference Example 1A, the title compound (125 mg, 78%) was obtained.
ESIMS m/z: 479 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“) : 1.49-1.73 (m, 6H), 2.24 (s, 3H), 3.12-3.24 (m, 4H), 4.76 (d, J = 12.5 Hz, 1H), 5.12-5.29 (m, 2H), 5.42 (d, J = 12.5 Hz, 1H), 6.57 (dd, J = 10.2, 2.6 Hz, 1H), 6.61-6.69 (m, 1H), 6.94-7.11 (m, 3H), 7.12-7.22 (m, 2H), 7.23-7.30 (m, 1H), 7.45 (d, J = 7.9 Hz, 1H), 7.63 (d, J = 7.9 Hz, 1H). -
- [step 1] Commercially available 2-chloro-1H-benzo[d]imidazole (250 mg, 1.64 mmol) was dissolved in DMF (4.7 mL), dimethylamine (50% aqueous solution, 0.50 mL, 4.92 mmol) was added, and the mixture was stirred with heating at 200Ā°C for 30 min in an Emrys Optimizer microwave synthesizer. Water was added to the mixture, and the precipitated crystals were collected by suction filtration to give N,N-dimethyl-1H-benzo[d]imidazole-2-amine (234 mg, 89%).
ESIMS m/z: 162 (M + H)+; 1H NMR (270 MHz, DMSO-d6, Ī“): 3.03 (s, 6H), 6.79-6.97 (m, 2H), 7.07-7.20 (m, 2H), 11.17 (br s, 1H). - [step 2] Using N,N-dimethyl-1H-benzo[d]imidazole-2-amine (57 mg, 0.35 mmol) obtained in step 1 and (E)-2-[8-(bromomethyl)-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene]propanenitrile (129 mg, 0.36 mmol) obtained in Reference Example 1, and in the same manner as in Reference Example 1A, the title compound (103 mg, 66%) was obtained.
ESIMS m/z: 439 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 2.24 (s, 3H), 2.92 (s, 6H), 4.77 (d, J = 12.9 Hz, 1H), 5.20-5.30 (m, 2H), 5.43 (d, J = 12.9 Hz, 1H), 6.57 (dd, J= 10.2, 2.6 Hz, 1H), 6.61-6.70 (m, 1H), 6.94-7.11 (m, 3H), 7.14-7.23 (m, 2H), 7.24-7.30 (m, 1H), 7.46 (d, J = 7.9 Hz, 1H), 7.60-7.65 (m, 1H). - Using 2-propyl-1H-benzo[d]imidazole (Synthetic Communication, 2002, vol. 32, p3703, 55 mg, 0.33 mmol) and (E)-2-(8-bromomethyl-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)-2-cyclopropylacetonitrile (120 mg, 0.31 mmol) obtained in Reference Example 6, and in the same manner as in Reference Example 1A, the title compound (132 mg, 92%) was obtained.
ESIMS m/z: 464 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 0.84-1.09 (m, 7H), 1.84-2.00 (m, 3H), 2.80 (t, J = 7.7 Hz, 2H), 4.72 (d, J= 12.2 Hz, 1H), 5.36 (s, 2H), 5.45 (d, J = 12.2 Hz, 1H), 6.53-6.57 (m, 1H), 6.61-6.68 (m, 1H), 6.94-6.95 (m, 1H), 7.12-7.21 (m, 4H), 7.32-7.43 (m, 2H), 7.77-7.79 (m, 1H). - Using 2-cyclopropyl-1H-benzo[d]imidazole (Europeane Journal of Organic Chemistry, 2000, p1229, 58 mg, 0.33 mmol) and (E)-2-(8-bromomethyl-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)-2-cyclopropylacetonitrile (120 mg, 0.31 mmol) obtained in Reference Example 6, and in the same manner as in Reference Example 1A, the title compound (133 mg, 93%) was obtained.
ESIMS m/z: 462 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 0.86-1.26 (m, 8H), 1.84-2.02 (m, 2H), 4.74 (d, J = 12.5 Hz, 1H), 5.44-5.48 (m, 3H), 6.53-6.57 (m, 1H), 6.62-6.68 (m, 1H), 7.03-7.04 (m, 1H), 7.19-7.22 (m, 4H), 7.32-7.44 (m, 2H), 7.70-7.73 (m, 1H). - Using 2-(3,3-difluorocyclobutyl)-1H-benzo[d]imidazole (65 mg, 0.31 mmol) obtained in Reference Example 1J, step 2 and (E)-2-(8-bromomethyl-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)-2-cyclopropylacetonitrile (120 mg, 0.31 mmol) obtained in Reference Example 6, and in the same manner as in Reference Example 1A, the title compound (152 mg, 95%) was obtained.
ESIMS m/z: 512 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“) : 0.85-1.31 (m, 4H), 1.92-2.06 (m, 1H), 2.78-2.96 (m, 2H), 3.05-3.24 (m, 2H), 3.37-3.47 (m, 1H), 4.72 (d, J = 13.2 Hz, 1H), 5.32 (s, 2H), 5.45 (d, J = 13.2 Hz, 1H), 6.53-6.58 (m, 1H), 6.62-6.68 (m, 1H), 6.93-6.94 (m, 1H), 7.07-7.11 (m, 1H), 7.23-7.43 (m, 5H), 7.80-7.84 (m, 1H). - Using 2-[(2-(methoxymethyl)-1H-benzo[d]imidazol-4-yl]propan-2-ol (65 mg, 0.31 mmol) obtained in Reference Example 2K, step 1 and (E)-2-(8-bromomethyl-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)-2-cyclopropylacetonitrile (120 mg, 0.31 mmol) obtained in Reference Example 6, and in the same manner as in Reference Example 1A, the title compound (164 mg, 85%) was obtained.
ESIMS m/z: 524 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 0.85-1.09 (m, 4H), 1.74 (s, 6H), 1.92-2.00 (m, 1H), 3.36 (s, 3H), 4.68-4.78 (m, 3H), 5.43-5.49 (m, 3H), 6.33 (s, 1H), 6.53-6.68 (m, 2H), 7.08-7.24 (m, 4H), 7.32-7.42 (m, 2H). - Using 4-chloro-2-cyclopropyl-1H-benzo[d]imidazole (
EP1988091 , 60 mg, 0.31 mmol) and (E)-2-(8-bromomethyl-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)-2-cyclopropylacetonitrile (120 mg, 0.31 mmol) obtained in Reference Example 6, and in the same manner as in Reference Example 1A, the title compound (115 mg, 74%) was obtained.
ESIMS m/z: 496 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“) : 0.85-1.33 (m, 8H), 1.77-1.87 (m, 1H), 1.96-2.04 (m, 1H), 4.70 (d, J = 13.2 Hz, 1H), 5.42-5.48 (m, 3H), 6.52-6.56 (m, 1H), 6.62-6.68 (m, 1H), 6.90-6.92 (m, 1H), 7.07-7.18 (m, 5H), 7.40-7.45 (m, 1H). - Using 2-(methoxymethyl)-1H-benzo[d]imidazole (61 mg, 0.376 mmol) and (E)-2-[8-(bromomethyl)-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene]butanenitrile (140 mg, 0.376 mmol) obtained in Reference Example 8, and in the same manner as in Reference Example 1A, the title compound (171 mg, 100%) was obtained.
ESIMS m/z: 454 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 1.23-1.37 (m, 3H), 2.48-2.74 (m, 2H), 3.38 (s, 3H), 4.61-4.81 (m, 3H), 5.33-5.58 (m, 3H), 6.49-6.71 (m, 2H), 6.95-7.12 (m, 2H), 7.15-7.37 (m, 4H), 7.37-7.52 (m, 1H), 7.75-7.92 (m, 1H). - Using 2-propyl-1H-benzo[d]imidazole (Synthetic Communication, 2002, vol. 32, p3703; 67 mg, 0.42 mmol) and (E)-2-[8-(bromomethyl)-1,3-difluorodibenzo[b,e]oxepin-11(6H)-ylidene]propanenitrile (160 mg, 0.43 mmol) obtained in Reference Example 2, and in the same manner as in Reference Example 1A, the title compound (184 mg, 97%) was obtained.
ESIMS m/z: 456 (M + H)+; 1H NMR (300 MHz, CDCl3, Ī“) : 1.02 (t, J = 7.3 Hz, 3H), 1.81-1.96 (m, 2H), 2.09 (d, J = 4.0 Hz, 3H), 2.75-2.84 (m, 2H), 4.73 (d, J = 12.8 Hz, 1H), 5.32-5.40 (m, 2H), 5.46 (d, J = 12.8 Hz, 1H), 6.35-6.50 (m, 2H), 6.91-6.95 (m, 1H), 7.15-7.22 (m, 3H), 7.22-7.29 (m, 1H), 7.44 (d, J = 7.7 Hz, 1H), 7.75-7.81 (m, 1H). - Using 2-propyl-1H-benzo[d]imidazole (Synthetic Communication, 2002, vol. 32, p3703; 51 mg, 0.32 mmol) and (E)-2-[8-(bromomethyl)-2,3-difluorodibenzo[b,e]oxepin-11(6H)-ylidene]propanenitrile (120 mg, 0.32 mmol) obtained in Reference Example 3, and in the same manner as in Reference Example 1A, the title compound (132 mg, 91%) was obtained.
ESIMS m/z: 456 (M + H)+ - Using 2-propyl-1H-benzo[d]imidazole (Synthetic Communication, 2002, vol. 32, p3703; 17 mg, 0.10 mmol) and (E)-2-[8-(bromomethyl)-3,4-difluorodibenzo[b,e]oxepin-11(6H)-ylidene]propanenitrile (40 mg, 0.12 mmol) obtained in Reference Example 4, and in the same manner as in Reference Example 1A, the title compound (41 mg, 87%) was obtained.
ESIMS m/z: 456 (M + H)+; 1H NMR (300 MHz, CDCl3, Ī“) : 1.02 (t, J = 7.3 Hz, 3H), 1.82-1.96 (m, 2H), 2.23 (s, 3H), 2.76-2.85 (m, 2H), 4.90 (d, J = 12.8 Hz, 1H), 5.29-5.44 (m, 2H), 5.46 (d, J = 12.8 Hz, 1H), 6.69-6.82 (m, 2H), 7.01-7.04 (m, 1H), 7.11-7.16 (m, 1H), 7.17-7.22 (m, 2H), 7.23-7.29 (m, 1H), 7.42 (d, J = 8.1 Hz, 1H), 7.75-7.80 (m, 1H). -
- [step 1] 3-Chloropyridin-2-amine (15 g, 117 mmol) was dissolved in ethanol (117 mL), 2-bromo-1-cyclopropylethanone (22.8 g, 140 mmol) was added, and the mixture was stirred with heating under reflux for 3 hr. The mixture was concentrated under reduced pressure, ethyl acetate (60 mL) was added to the obtained residue, and the resulting precipitate was collected by suction filtration to give white crystals (27.2 g). The obtained crystals were dissolved in water (300 mL), saturated aqueous sodium hydrogen carbonate solution (100 mL) was added, and the precipitated crystals were collected by suction filtration to give 8-chloro-2-cyclopropylimidazo[1,2-a]pyridine (16 g, 71.4%).
ESIMS m/z: 193 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 0.84-0.93 (m, 2H), 0.93-1.06 (m, 2H), 2.01-2.17 (m, 1H), 6.64 (t, J = 7.2 Hz, 1H), 7.17 (dd, J = 7.2, 1.4 Hz, 1H), 7.33 (s, 1H), 7.94 (dd, J = 7.2, 1.4 Hz, 1H). - [step 2] 8-Chloro-2-cyclopropylimidazo[1,2-a]pyridine (2.23 g, 11.6 mmol) obtained in step 1 was dissolved in DMF (23 mL), N-iodosuccinimide (2.36 g, 12.7 mmol) was added, and the mixture was stirred at room temperature for 2 hr. To the mixture was added water (100 mL), and the precipitated crystals were collected by suction filtration to give 8-chloro-2-cyclopropyl-3-iodoimidazo[1,2-a]pyridine (3.46 g, 94%).
ESIMS m/z: 319 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 0.97-1.12 (m, 2H), 1.12-1.26 (m, 2H), 1.97-2.14 (m, 1H), 6.72-6.88 (m, 1H), 7.20-7.32 (m, 1H), 7.99-8.04 (m, 1H). - [step 3] 8-Chloro-2-cyclopropyl-3-iodoimidazo[1,2-a]pyridine (3.0 g, 9.42 mmol) obtained in step 2 was dissolved in THF (18 mL), cooled to -70Ā°C in a dry ice-acetone bath. A 2 mol/L isopropylmagnesium chloride THF solution (4.93 mL, 9.89 mmol) was added and the mixture was gradually warmed to -50Ā°C. The mixture was cooled again to -70Ā°C in a dry ice-acetone bath, a solution (5 mL) of (E)-2-(3-fluoro-8-formyldibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (1.38 g, 4.71 mmol) obtained in Reference Example 5 in THF was added, and the mixture was gradually warmed and stirred at -20Ā°C for 1 hr. To the mixture was added aqueous ammonium chloride solution, and the mixture was extracted 3 times with ethyl acetate. The combined organic layers were dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. To the obtained residue was added a mixed solution of hexane (10 mL)-ethyl acetate (10 mL), and the precipitated crystals were collected by suction filtration to give (E)-2-{8-[(8-chloro-2-cyclopropylimidazo[1,2-a]pyridin-3-yl)(hydroxy)methyl]-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (1.84 g, 80%.
ESIMS m/z: 486 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 0.77-1.07 (m, 4H), 2.06-2.24 (m, 4H), 4.92-5.09 (m, 1H), 5.42-5.61 (m, 1H), 6.37-6.54 (m, 2H), 6.61-6.89 (m, 3H), 7.20-7.72 (m, 4H), 8.16-8.26 (m, 1H). - [step 4] Sodium iodide (4.63 g, 30.9 mmol) was suspended in a mixed solution of dichloromethane (15 mL)-acetone (15 mL), dichlorodimethylsilane (1.84 mL, 15.4 mmol) was added under ice-cooling, and the mixture was stirred for 15 min. Under ice-cooling, a solution (15 mL) of (E)-2-{8-[(8-chloro-2-cyclopropylimidazo[1,2-a]pyridin-3-yl)(hydroxy)methyl]-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (1.5 g, 3.09 mmol) obtained in step 3 in dichloromethane was added, and the mixture was stirred at room temperature for 30 min. To the mixture were added 10% aqueous sodium thiosulfate solution (50 mL) and saturated aqueous sodium hydrogen carbonate solution (100 mL), and the mixture was extracted 3 times with ethyl acetate. The combined organic layers were dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. To the obtained residue was added isopropylalcohol (15 mL)-diisopropyl ether (15mL), and the precipitated crystals were collected by suction filtration to give the title compound (1.4 g, 97%).
ESIMS m/z: 470 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 0.92-1.09 (m, 2H), 1.09-1.28 (m, 2H), 1.93-2.10 (m, 1H), 2.23 (s, 3H), 4.24-4.52 (m, 2H), 4.75 (d, J = 12.6 Hz, 1H), 5.40 (d, J = 12.6 Hz, 1H), 6.45-6.73 (m, 3H), 6.95-7.31 (m, 4H), 7.40 (d, J = 7.8 Hz, 1H), 7.55 (d, J = 7.8 Hz, 1H). - 2-Aminopyridine (136 mg, 1.44 mmol) was dissolved in toluene (7 mL), 2-(8-ethynyl-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (500 mg, 1.73 mmol) obtained in Reference Example 9, copper trifluoromethanesulfonate (36 mg, 0.101 mmol), coprous chloride (10 mg, 0.101 mol) and cyclopropanecarboxyaldehyde (0.16 mL, 2.16 mmol) were added, and the mixture was stirred with heating under reflux for 6 hr. The mixture was filtered through celite, saturated aqueous sodium hydrogen carbonate solution was added to the filtrate and the mixture was extracted 3 times with ethyl acetate. The combined organic layers were dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane/ethyl acetate = 1/3 v/v) to give the title compound (205 mg, 32%).
ESIMS m/z: 436 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 0.92-1.08 (m, 2H), 1.08-1.18 (m, 2H), 1.91-2.09 (m, 1H), 2.23 (s, 3H), 4.24-4.51 (m, 2H), 4.76 (d, J = 12.8 Hz, 1H), 5.41 (d, J = 12.8 Hz, 1H), 6.50-6.70 (m, 3H), 6.94-7.15 (m, 3H), 7.21-7.30 (m, 1H), 7.35-7.46 (m, 1H), 7.49-7.58 (m, 1H), 7.58-7.66 (m, 1H). -
- [step 1] Using 2-aminopyridine (517 mg, 5.51 mmol) and 2-bromo-1-isopropylethanone (1.0 g, 6.06 mmol), and in the same manner as in Reference Example 8A, step 1, 2-isopropylimidazo[1,2-a]pyridine (868 mg, 98%) was obtained.
ESIMS m/z: 161 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 1.32-1.45 (m, 6H), 3.02-3.17 (m, 1H), 6.65-6.78 (m, 1H), 7.03-7.21 (m, 1H), 7.33 (s, 1H), 7.51-7.63 (m, 1H), 7.97-8.15 (m, 1H). - [step 2] Using 2-isopropylimidazo[1,2-a]pyridine (814 mg, 5.09 mmol) obtained in step 1, and in the same manner as in Reference Example 8A, step 2, 2-isopropyl-3-iodoimidazo[1,2-a]pyridine (1.05 g, 72%) was obtained.
ESIMS m/z: 287 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 1.38 (d, J = 7.0 Hz, 6H), 3.10-3.25 (m, 1H), 6.80-6.92 (m, 1H), 7.14-7.22 (m, 1H), 7.52-7.64 (m, 1H), 8.03-8.16 (m, 1H). - [step 3] Using 2-isopropyl-3-iodoimidazo[1,2-a]pyridine (366 mg, 1.28 mmol) obtained in step 2 and (E)-2-(3-fluoro-8-formyldibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (250 mg, 0.853 mmol) obtained in Reference Example 5, and in the same manner as in Reference Example 8A, step 3, (E)-2-{3-fluoro-8-[hydroxy(2-isopropylimidazo[1,2-a]pyridin-3-yl)methyl]dibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (175 mg, 45%) was obtained.
ESIMS m/z: 454 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 1.18-1.52 (m, 6H), 2.28 (s, 3H), 3.06-3.31 (m, 1H), 4.73-4.91 (m, 1H), 5.40-5.53 (m, 1H), 6.40-6.48 (m, 1H), 6.48-6.78 (m, 3H), 6.98-7.15 (m, 2H), 7.36-7.57 (m, 4H), 7.87-8.11 (m, 1H). - [step 4] Using (E)-2-{3-fluoro-8-[hydroxy(2-isopropylimidazo[1,2-a]pyridin-3-yl)methyl]dibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (173 mg, 0.382 mmol) obtained in step 3, and in the same manner as in Reference Example 8A, step 4, the title compound (108 mg, 31%) was obtained.
ESIMS m/z: 438 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 1.30-1.48 (m, 6H), 2.21 (s, 3H), 3.12-3.30 (m, 1H), 4.20-4.39 (m, 2H), 4.73 (d, J = 12.8 Hz, 1H), 5.40 (d, J = 12.8 Hz, 1H), 6.48-6.69 (m, 3H), 6.94-7.22 (m, 4H), 7.35-7.46 (m, 1H), 7.56-7.66 (m, 2H). - Using cyclobutanecarboxyaldehyde (0.127 mg, 1.51 mmol) and 2-(8-ethynyl-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (320 mg, 1.11 mmol) obtained in Reference Example 9, and in the same manner as in Reference Example 8B, the title compound (130 mg, 29%) was obtained.
ESIMS m/z: 450 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 1.92-2.14 (m, 2H), 2.23 (s, 3H), 2.27-2.42 (m, 2H), 2.52-2.71 (m, 2H), 3.64-3.85 (m, 1H), 4.17-4.34 (m, 2H), 4.73 (d, J = 12.8 Hz, 1H), 5.40 (d, J = 12.8 Hz, 1H), 6.51-6.72 (m, 3H), 6.97-7.05 (m, 2H), 7.08-7.22 (m, 2H), 7.35-7.45 (m, 1H), 7.57-7.68 (m, 2H). - Using cyclopentanecarboxyaldehyde (106 mg, 1.08 mmol) and 2-(8-ethynyl-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (250 mg, 0.864 mmol) obtained in Reference Example 9, and in the same manner as in Reference Example 8B, the title compound (94 mg, 28%) was obtained.
ESIMS m/z: 464 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 1.58-2.13 (m, 8H), 2.22 (s, 3H), 3.11-3.35 (m, 1H), 4.20-4.40 (m, 2H), 4.74 (d, J = 12.8 Hz, 1H), 5.41 (d, J = 12.8 Hz, 1H), 6.44-6.71 (m, 3H), 6.95-7.22 (m, 4H), 7.32-7.44 (m, 1H), 7.56-7.67 (m, 2H). -
- [step 1] To commercially available 2-aminopyridine (5.0 g, 53 mmol) were added dimethoxyethane (14 mL) and 1,3-dichloropropanone (7.4 g, 58 mmol), and the mixture was stirred at room temperature overnight. The obtained white crystals were collected by filtration, ethanol (140 mL) was added, and the mixture was stirred with heating under reflux for 1 hr. The reaction was discontinued with saturated aqueous sodium hydrogen carbonate, and the mixture was extracted with chloroform and the extract was dried over sodium sulfate. Filtration and concentration under reduced pressure gave 2-(chloromethyl)imidazo[1,2-a]pyridine (5.5 g, 62%).
ESIMS m/z: 167 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 4.78 (s, 2H), 6.78-6.82 (m, 1H), 7.17-7.21 (m, 1H), 7.57-7.62 (m, 2H), 8.07-8.09 (m, 1H). - [step 2] To 2-(chloromethyl)imidazo[1,2-a]pyridine (4.04 g, 24 mmol) obtained in step 1 were added methanol (121 mL) and sodium methoxide (3.93 g, 73 mmol), and the mixture was stirred at 50Ā°C for 6 hr. The reaction was discontinued with water, and the mixture was extracted with chloroform and the extract was dried over sodium sulfate. Filtration and concentration under reduced pressure gave 2-(methoxymethyl)imidazo[1,2-a]pyridine (3.45 g, 88%).
ESIMS m/z: 163 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 3.49 (s, 3H), 4.65 (s, 2H), 6.74-6.84 (m, 1H), 7.13-7.18 (m, 1H), 7.55-7.62 (m, 2H), 8.08-8.10 (m, 1H). - [step 3] To 2-(methoxymethyl)imidazo[1,2-a]pyridine (1.8 g, 11 mmol) obtained in step 2 were added DMF (22 mL) and N-iodosuccinimide (2.75 g, 12 mmol), and the mixture was stirred at room temperature for 3 hr. The reaction was discontinued with saturated aqueous sodium hydrogen carbonate solution, and the mixture was extracted with ethyl acetate and the extract was dried over sodium sulfate. Filtration, concentration under reduced pressure and purification by silica gel column chromatography (chloroform/methanol = 10/1 v/v) gave 3-iodo-2-(methoxymethyl)imidazo[1,2-a]pyridine (3.1 g, 99%).
ESIMS m/z: 289 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 3.47 (s, 3H), 4.65 (s, 2H), 6.92-6.95 (m, 1H), 7.23-7.28 (m, 1H), 7.58-7.60 (m, 1H), 8.12-8.14 (m, 1H). - [step 4] 3-Iodo-2-(methoxymethyl)imidazo[1,2-a]pyridine (500 mg, 1.74 mmol) obtained in step 3 was dissolved in THF (1 mL), and the mixture was cooled to -78Ā°C. Isopropylmagnesium chloride (0.87 mL, 1.7 mmol) was added, and the mixture was stirred at - 50Ā°C for 30 min. The mixture was cooled to -78Ā°C again. (E)-2-(3-fluoro-8-formyldibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (255 mg, 0.868 mmol) obtained in Reference Example 5 was dissolved in THF (2.4 mL), and the solution was added dropwise thereto. The mixture was allowed to warm to -20Ā°C, and stirred for 1 hr. The reaction was discontinued with saturated aqueous ammonium chloride, and the mixture was extracted with chloroform and the extract was dried over sodium sulfate. Filtration, concentration under reduced pressure and purification by silica gel column chromatography (chloroform/methanol = 10/1 v/v) gave (E)-2-(3-fluoro8-{hydroxy[2-(methoxymethyl)imidazo[1,2-a]pyridin-3-yl]methyl}dibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (395 mg, 92%).
ESIMS m/z: 456 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 2.24 (s, 3H), 3.43 (s, 3H), 4.54-4.73 (m, 2H), 4.81 (d, J = 13.7 Hz, 1H), 5.42-5.46 (m, 1H), 6.39-6.42 (m, 1H), 6.54-6.59 (m, 1H), 6.62-6.72 (m, 2H), 7.00-7.05 (m, 1H), 7.15-7.20 (m, 1H), 7.40-7.46 (m, 3H), 7.57-7.59 (m, 1H), 7.91-7.98 (m, 1H). - [step 5] To sodium iodide (197 mg, 1.32 mmol) were added trimethylchlorosilane (165 mL, 1.32 mmol) and acetonitrile (69 mL, 1.3 mmol), and the mixture was stirred at room temperature for 15 min. To the reaction mixture was added hexane (0.22 mL). Furthermore, (E)-2-(3-fluoro8-{hydroxy[2-(methoxymethyl)imidazo[1,2-a]pyridin-3-yl]methyl}dibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (100 mg, 0.22 mmol) obtained in step 4 was added, and the mixture was stirred for 1 hr. The reaction was discontinued with water, and the mixture was extracted with chloroform, the extract was washed with saturated sodium thiosulfate aqueous solution, dried over sodium sulfate and filtered. The filtrate was concentrated under reduced pressure and the obtained reaction residue was purified by silica gel column chromatography (chloroform/methanol= 10/1 v/v) to give the title compound (60 mg, 62%).
ESIMS m/z: 440 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 2.23 (s, 3H), 3.47 (s, 3H), 4.32-4.44 (m, 2H), 4.71-4.75 (m, 3H), 5.40 (d, J= 12.7 Hz, 1H), 6.53-6.57 (m, 1H), 6.61-6.65 (m, 1H), 6.70-6.74 (m, 1H), 7.00-7.04 (m, 1H), 7.12-7.31 (m, 3H), 7.38-7.40 (m, 1H), 7.60-7.63 (m, 1H), 7.68-7.70 (m, 1H). -
- [step 1] Under ice-cooling, sodium hydride (1.46 g, 36.6 mmol) was suspended in deuterated methanol (24 mL), and the mixture was stirred at room temperature for 30 min. To the mixture was added 2-(chloromethyl)imidazo[1,2-a]pyridine (1.22 g, 7.32 mmol) obtained in Reference Example 8F, step 1, and the mixture was stirred at room temperature for 24 hr. Water was added to the mixture, and the mixture was extracted 3 times with chloroform. The combined organic layers were dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate = 100/0 v/v - 0/100 v/v) to give 2-(methoxy-d3-methyl)imidazo[1,2-a]pyridine (1.10 g, 91%).
ESIMS m/z: 166 (M + H)+; 1H NMR (300 MHz, CDCl3, Ī“): 4.65 (s, 2H), 6.76 (d, J = 6.8 Hz, 1H), 7.10-7.20 (m, 1H), 7.51-7.60 (m, 2H), 8.08 (d, J = 6.8 Hz, 1H). - [step 2] Using 2-(methoxy-d3-methyl)imidazo[1,2-a]pyridine (1.1 g, 6.66 mmol) obtained in step 1, and in the same manner as in Reference Example 8A, step 2, 3-iodo-2-(methoxy-d3-methyl)imidazo[1,2-a]pyridine (1.5 g, 77%) was obtained.
ESIMS m/z: 292 (M + H)+; 1H NMR (300 MHz, CDCl3, Ī“): 4. 65 (s, 2H), 6.88-6.97 (m, 1H), 7.20-7.29 (m, 1H), 7.54-7.62 (m, 1H), 8.09-8.10 (m, 1H). - [step 3] Using 3-iodo-2-(methoxy-d3-methyl)imidazo[1,2-a]pyridine (500 mg, 1.72 mmol) obtained in step 2 and (E)-2-(3-fluoro-8-formyldibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (252 mg, 0.86 mmol) obtained in Reference Example 5, and in the same manner as in Reference Example 8A, step 3, (E)-2-(3-fluoro-8-{hydroxy[2-(methoxy-d3-methyl)imidazo[1,2-a]pyridin-3-yl]methyl}dibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (354 mg, 79%) was obtained.
ESIMS m/z: 459 (M + H)+; 1H NMR (300 MHz, CDCl3, Ī“): 2.23 (s, 3H), 4.41-4.67 (m, 3H), 4.80 (d, J = 12.5 Hz, 1H), 5.38-5.48 (m, 1H), 6.33-6.43 (m, 1H), 6.50-6.80 (m, 3H), 6.98-7.07 (m, 1H), 7.10-7.21 (m, 1H), 7.37-7.61 (m, 4H), 7.91-8.11 (m, 1H). - [step 4] Using (E)-2-(3-fluoro-8-{hydroxy[2-(methoxy-d3-methyl)imidazo[1,2-a]pyridin-3-yl]methyl}dibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (200 mg, 0.44 mmol) obtained in step 3, and in the same manner as in Reference Example 8A, step 4, the title compound (110 mg, 65%) was obtained.
ESIMS m/z: 443 (M + H)+; 1H NMR (300 MHz, CDCl3, Ī“): 2.23 (s, 3H), 4.29-4.46 (m, 2H), 4.70 (s, 2H), 4.74 (d, J = 12.5 Hz, 1H), 5.40 (d, J = 12.5 Hz, 1H), 6.55 (dd, J = 10.3, 2.6 Hz, 1H), 6.60-6.67 (m, 1H), 6.68-6.75 (m, 1H), 7.02 (dd, J = 8.8, 6.6 Hz, 1H), 7.09-7.26 (m, 3H), 7.39 (d, J = 7.7 Hz, 1H), 7.59-7.64 (m, 1H), 7.66-7.71 (m, 1H). -
- [step 1] Using 8-chloro-2-isopropylimidazo[1,2-a]pyridine (
WO2009086123 ; 1.02 g, 5.24 mmol), and in the same manner as in Reference Example 8A, step 2, 8-chloro-3-iodo-2-isopropylimidazo[1,2-a]pyridine (1.58 g, 94%) was obtained.
ESIMS m/z: 321 (M + H)+; 1H NMR (300 MHz, CDCl3, Ī“): 1.40 (d, J = 7.0 Hz, 6H), 3.14-3.30 (m, 1H), 6.77-6.86 (m, 1H), 7.24-7.31 (m, 1H), 8.02-8.09 (m, 1H). - [step 2] Using 8-chloro-3-iodo-2-isopropylimidazo[1,2-a]pyridine (393 mg, 1.23 mmol) obtained in step 1 and (E)-2-(3-fluoro-8-formyldibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (300 mg, 1.02 mmol) obtained in Reference Example 5, and in the same manner as in Reference Example 8A, step 3, (E)-2-{8-[(8-chloro2-isopropylimidazo[1,2-a]pyridin-3-yl)(hydroxy)methyl]-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (254 mg, 51%) was obtained.
ESIMS m/z: 488 (M + H)+; 1H NMR (300 MHz, CDCl3, Ī“): 1.38-1.51 (m, 6H), 2.24 (s, 3H), 3.19-3.34 (m, 1H), 4.75-4.86 (m, 1H), 5.39-5.49 (m, 1H), 6.36-6.43 (m, 1H), 6.47-6.69 (m, 3H), 7.00-7.08 (m, 1H), 7.15-7.23 (m, 1H), 7.29-7.47 (m, 4H), 7.87-8.95 (m, 1H). - [step 3] Using (E)-2-{8-[(8-chloro2-sopropylimidazo[1,2-a]pyridin-3-yl)(hydroxy)methyl]-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (150 mg, 0.31 mmol) obtained in step 2, and in the same manner as in Reference Example 8A, step 4, the title compound (131 mg, 90%) was obtained.
ESIMS m/z: 472 (M + H)+; 1H NMR (300 MHz, CDCl3, Ī“): 1.37-1.49 (m, 6H), 2.23 (s, 3H), 3.18-3.30 (m, 1H), 4.23-4.39 (m, 2H), 4.73 (d, J = 12.5 Hz, 1H), 5.40 (d, J = 12.5 Hz, 1H), 6.51-6.69 (m, 3H), 6.98-7.06 (m, 2H), 7.12-7.22 (m, 2H), 7.39 (d, J = 7.7 Hz, 1H), 7.51-7.57 (m, 1H). -
- [step 1] Using pyridin-2-amine (0.985 g, 10.2 mmol) and 1-bromopenta-2-one (2.00 g, 7.27 mmol), and in the same manner as in Reference Example 8A, step 1, 2-propylimidazo[1,2-a]pyridine (0.650 g, 56%) was obtained.
ESIMS m/z: 161 (M + H)+; 1H NMR (400 MHz, CDCl3, Ī“): 1.01 (t, J = 7.3Hz, 3H), 1.74-1.85 (m, 2H), 2.76 (t, J = 7.3 Hz, 2H), 6.71 (t, J = 6.8 Hz, 1H), 7.08-7.13 (m, 1H), 7.34 (s, 1H), 7.52 (d, J = 8.8, 1H), 8.04 (d, J = 6.8, 1H). - [step 2] Using 2-propylimidazo[1,2-a]pyridine (0.650 g, 4.06 mmol) obtained in step 1, and in the same manner as in Reference Example 8A, step 2, 3-iodo-2-propylimidazo[1,2-a]pyridine (1.07 g, 92%) was obtained.
ESIMS m/z: 287 (M + H)+; 1H NMR (400 MHz, CDCl3, Ī“): 1.00 (t, J = 7.3 Hz, 3H), 1.75-1.88 (m, 2H), 2.78 (t, J = 7.8 Hz, 2H), 6.81 (t, J = 6.8 Hz, 1H), 7.17-7.23 (m, 1H), 7.52 (d, J = 8.8, 1H), 8.08 (d, J = 6.8, 1H). - [step 3] Using 3-iodo-2-propylimidazo[1,2-a]pyridine (585 mg, mmol) obtained in step 2, and in the same manner as in Reference Example 8A, step 3, (E)-2-{3-fluoro-8-[hydroxy(2-propylimidazo[1,2-a]pyridin-3-yl)methyl]dibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (250mg, 54%) was obtained.
ESIMS m/z: 454 (M + H)+; 1H NMR (300 MHz, DMSO-d6, Ī“): 0.89 (t, J = 7.3 Hz, 3H), 1.61-1.75 (m, 2H), 2.16 (s, 3H), 2.64 (td, J = 7.3, 4.2 Hz, 2H), 5.00 (dd, J = 12.6, 6.0 Hz, 1H), 5.48 (dd, J = 12.6, 2.2 Hz, 1H), 6.25-6.36 (m, 2H), 6.64-6.86 (m, 3H), 7.11-7.18 (m, 1H), 7.24-7.31 (m, 1H), 7.33-7.64 (m, 4H), 8.15-8.22 (m, 1H). - [step 4] Using (E)-2-{3-fluoro-8-[hydroxy(2-propylimidazo[1,2-a]pyridin-3-yl)methyl]dibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (75 mg, 0.165 mmol) obtained in step 3, and in the same manner as in Reference Example 8A, step 4, the title compound (60 mg, 83%) was obtained.
ESIMS m/z: 438 (M + H)+; 1H NMR (400 MHz, CDCl3, Ī“): 1.04 (t, J = 7.3 Hz, 3H), 1.89-2.02 (m, 2H), 2.24 (s, 3H), 2.93 (t, J = 7.8 Hz, 2H), 4.31 (d, J = 17.6 Hz, 1H), 4.38 (d, J = 17.6 Hz, 1H), 4.77 (d, J = 12.6 Hz, 1H), 5.42 (d, J = 12.6 Hz, 1H), 6.52-6.70 (m, 2H), 7.00-7.10 (m, 3H), 7.19-7.22 (m, 1H), 7.42-7.47 (m, 1H), 7.52-7.57 (m, 1H), 7.82 (d, J = 5.9 Hz, 1H), 8.22 (d, J = 8.8 Hz, 1H). - Using cyclobutylcarboxyaldehyde (153 mg, 1.12 mmol), 3-chloropyridin-2-amine (171 mg, 1.33 mmol) and 2-(8-ethynyl-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (350 mg, 1.21 mmol) obtained in Reference Example 9, and in the same manner as in Reference Example 8B, the title compound (84 mg, 14%) was obtained.
ESIMS m/z: 484 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 1.87-2.13 (m, 2H), 2.13-2.45 (m, 5H), 2.48-2.77 (m, 2H), 3.65-3.89 (m, 1H), 4.14-4.39 (m, 2H), 4.63-4.81 (m, 1H), 5.31-5.48 (m, 1H), 6.49-6.70 (m, 3H), 6.93-7.09 (m, 2H), 7.11-7.23 (m, 1H), 7.35-7.58 (m, 2H), 7.93-8.06 (m, 1H). -
- [step 1] Using commercially available 3-chloro-2-aminopyridine (2.5 g, 19 mmol), and in the same manner as in Reference Example 8F, step 1, 8-chloro-2-(chloromethyl)imidazo[1,2-a]pyridine (3.25 g, 83%) was obtained.
ESIMS m/z: 201 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 4.78 (s, 2H), 6.78-6.82 (m, 1H), 7.17-7.21 (m, 1H), 7.57-7.62 (m, 1H), 8.07-8.09 (m, 1H). - [step 2] Using 8-chloro-2-(chloromethyl)imidazo[1,2-a]pyridine (1.79 g, 8.9 mmol) obtained in step 1, and in the same manner as in Reference Example 8F, step 2, 8-chloro-2-(methoxymethyl)imidazo[1,2-a]pyridine (1.6 g, 91%) was obtained.
ESIMS m/z: 197 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 3.50 (s, 3H), 4.71 (s, 2H), 6.71-6.78 (m, 1H), 7.24-7.29 (m, 1H), 7.64-7.72 (m, 1H), 8.03-8.05 (m, 1H). - [step 3] Using 8-chloro-2-(methoxymethyl)imidazo[1,2-a]pyridine (1.6 g, 8.2 mmol) obtained in step 2, and in the same manner as in Reference Example 8F, step 3, 8-chloro-3-iodo-2-(methoxymethyl)imidazo[1,2-a]pyridine (1.8 g, 69%) was obtained.
ESIMS m/z: 322 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 3.47 (s, 3H), 4.68 (s, 2H), 6.87-6.91 (m, 1H), 7.34-7.36 (m, 1H), 8.08-8.14 (m, 1H). - [step 4] Using 8-chloro-3-iodo-2-(methoxymethyl)imidazo[1,2-a]pyridine (500 mg, 1.55 mmol) obtained in step 3 and (E)-2-(3-fluoro-8-formyldibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (227 mg, 0.775 mmol) obtained in Reference Example 5, and in the same manner as in Reference Example 8F, step 4, (E)-2-(8-{[8-chloro-2-(methoxymethyl)imidazo[1,2-a]pyridin-3-yl](hydroxy)methyl}-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (205 mg, 54%) was obtained.
ESIMS m/z: 490 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 2.22 (s, 3H), 3.34 (s, 3H), 4.64-4.74 (m, 2H), 4.82 (d, J = 12.7 Hz, 1H), 5.42-5.47 (m, 1H), 6.41 (s, 1H), 6.53-6.59 (m, 1H), 6.63-6.67 (m, 2H), 7.03-7.08 (m, 1H), 7.26-7.32 (m, 2H), 7.41-7.52 (m, 3H). - [step 5] Using (E)-2-(8-{[8-chloro-2-(methoxymethyl)imidazo[1,2-a]pyridin-3-yl](hydroxy)methyl}-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (200 mg, 0.408 mmol) obtained in step 4, and in the same manner as in Reference Example 8F, step 5, the title compound (100 mg, 52%) was obtained.
ESIMS m/z: 474 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 2.23 (s, 3H), 3.47 (s, 3H), 4.33-4.46 (m, 2H), 4.76 (s, 3H), 5.39 (d, J = 12.7 Hz, 1H), 6.53-6.57 (m, 1H), 6.62-6.68 (m, 2H), 7.00-7.04 (m, 1H), 7.10-7.11 (m, 1H), 7.23-7.30 (m, 2H), 7.39-7.41 (m, 1H), 7.62-7.64 (m, 1H). - Using (E)-2-(8-ethynyl-3-fluoro-dibenzo[b,e]oxepin-11(6H)-ylidene)acetonitrile (270 mg, 0.981 mmol) obtained in Reference Example 11 and 3-chloropyridin-2-amine (126 mg, 0.981 mmol), and in the same manner as in Reference Example 8B, the title compound (225 mg, 50%) was obtained.
ESIMS m/z: 456 (M + H)+; 1H NMR (300 MHz, CDCl3, Ī“): 0.99-1.06 (m, 2H), 1.17-1.24 (m, 2H), 1.99-2.09 (m, 1H), 4.39 (s, 2H), 5.05 (s, 2H), 5.79 (s, 1H), 6.54-6.74 (m, 3H), 7.09-7.11 (m, 1H), 7.15-7.19 (m, 1H), 7.25-7.31 (m, 2H), 7.49-7.59 (m, 2H). - Using (E)-2-(8-ethynyl-3-fluoro-dibenzo[b,e]oxepin-11(6H)-ylidene)acetonitrile (270 mg, 0.981 mmol) obtained in Reference Example 11 and 3-methoxypyridin-2-amine (122 mg, 0.981 mmol), and in the same manner as in Reference Example 8B, the title compound (132 mg, 30%) was obtained.
ESIMS m/z: 452 (M + H)+; 1H NMR (300 MHz, CDCl3, Ī“): 1.14-1.22 (m, 2H), 1.32-1.44 (m, 2H), 1.98-2.07 (m, 1H), 4.09 (s, 3H), 4.43 (br s, 2H), 5.08 (s, 2H), 5.81 (s, 1H), 6.54-6.59 (m, 1H), 6.62-6.74 (m, 2H), 6.78-6.84 (m, 1H), 7.11 (br s, 1H), 7.21-7.32 (m, 3H), 7.53 (d, J = 8.1 Hz, 1H). - Using cyclopropanecarboxyaldehyde (93 mg, 1.33 mmol), 3-chloropyridin-2-amine (125 mg, 0.975 mmol) and 2-(8-ethynyl-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)-2-fluoroacetonitrile (260 mg, 0.887 mmol) obtained in Reference Example 12, and in the same manner as in Reference Example 8B, the title compound (44 mg, 11%) was obtained.
ESIMS m/z: 474 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 0.90-1.08 (m, 2H), 1.09-1.23 (m, 2H), 1.87-2.08 (m, 1H), 4.25-4.47 (m, 2H), 4.75-5.46 (m, 2H), 6.45-6.78 (m, 3H), 7.04-7.59 (m, 6H). - Using cyclopropanecarboxyaldehyde (330 mg, 4.71 mmol), 3-methoxypyridin-2-amine (390 mg, 3.14 mmol) and 2-(8-ethynyl-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (1.0 g, 3.46 mmol) obtained in Reference Example 9, and in the same manner as in Reference Example 8B, the title compound (240 mg, 16%) was obtained.
ESIMS m/z: 466 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 0.93-1.06 (m, 2H), 1.13-1.24 (m, 2H), 1.90-2.06 (m, 1H), 2.25 (s, 3H), 3.98 (s, 3H), 4.25-4.46 (m, 2H), 4.76 (d, J = 12.8 Hz, 1H), 5.40 (d, J = 12.8 Hz, 1H), 6.35-6.43 (m, 1H), 6.50-6.68 (m, 3H), 6.98-7.15 (m, 2H), 7.16-7.27 (m, 2H), 7.32-7.41 (m, 1H). - Using cyclopropanecarboxyaldehyde (0.2 mL, 2.66 mmol), 3-ethoxypyridin-2-amine (220 mg, 1.77 mmol) and 2-(8-ethynyl-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (564 mg, 1.95 mmol) obtained in Reference Example 9, and in the same manner as in Reference Example 8B, the title compound (120 mg, 9%) was obtained.
ESIMS m/z: 480 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 0.85-1.00 (m, 2H), 1.08-1.25 (m, 2H), 1.50-1.61 (m, 3H), 1.83-2.13 (m, 1H), 2.24 (s, 3H), 4.14-4.48 (m, 4H), 4.63-4.82 (m, 1H), 5.29-5.46 (m, 1H), 6.33-6.42 (m, 1H), 6.49-6.69 (m, 3H), 6.98-7.07 (m, 2H), 7.19-7.30 (m, 2H), 7.34-7.43 (m, 1H). -
- [step 1] 2-Nitropyridin-3-ol (600 mg, 4.28 mmol) was dissolved in DMF (50 mL), sodium 2-chloro-2,2-difluoroacetate (1.96 g, 12.9 mmol), and cesium carbonate (4.2 g, 12.9 mmol) were added, and the mixture was stirred with heating at 60Ā°C for 4 hr. To the mixture was added saturated aqueous ammonium chloride solution, and the mixture was extracted 3 times with ethyl acetate. The combined organic layers were dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained residue was purified by column chromatography (hexane/ethyl acetate = 1/3) to give 3-(difluoromethoxy)-2-nitropyridine (452 mg, 56%).
ESIMS m/z: 191 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 6. 65 (t, J = 71.5 Hz, 1H), 7.61-7.70 (m, 1H), 7.87-7.98 (m, 1H), 8.38-8.53 (m, 1H). - [step 2] 3-(Difluoromethoxy)-2-nitropyridine (450 mg, 2.37 mmol) obtained in step 1 was dissolved in ethanol (2 mL)-acetic acid (2 mL), reduced iron (397 mg, 7.10 mmol) was added, and the mixture was stirred at 100Ā°C overnight. Since the starting material did not disappear, reduced iron (397 mg, 7.10 mmol) was added, and the mixture was further stirred at 100Ā°C overnight. The mixture was filtered through celite, and the filtrate was concentrated under reduced pressure. To the obtained residue was added saturated aqueous sodium hydrogen carbonate solution, and the mixture was extracted 3 times with ethyl acetate. The combined organic layers were dried over anhydrous magnesium sulfate, and purified by silica gel column chromatography (chloroform/methanol = 9/1 v/v) to give 3-(difluoromethoxy)pyridin-2-amine (250 mg, 66%).
ESIMS m/z: 161 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 4.79 (br s, 2H), 6.14-6.80 (m, 2H), 7.19-7.35 (m, 1H), 7.85-7.98 (m, 1H). - [step 3] Using cyclopropanecarboxyaldehyde (0.216 mL, 2.12 mmol), 3-(difluoromethoxy)pyridin-2-amine (250 mg, 1.56 mmol) obtained in step 2 and 2-(8-ethynyl-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (410 mg, 1.42 mmol) obtained in Reference Example 9, and in the same manner as in Reference Example 8B, the title compound (440 mg, 29%) was obtained.
ESIMS m/z: 502 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 0.96-1.08 (m, 2H), 1.09-1.21 (m, 2H), 1.95-2.12 (m, 7.H), 2.22 (s, 3H), 4.24-4.49 (m, 2H), 4.76 (d, J = 12.8 Hz, 1H), 5.42 (d, J = 12.8 Hz, 1H), 6.48-6.72 (m, 3H), 6.81-6.90 (m, 1H), 6.97-7.08 (m, 1H), 7.08-7.14 (m, 1H), 7.19-7.88 (m, 4H). -
- [step 1] Commercially available 3-methoxypyridin-2-amine (1.0 g, 8.06 mmol) was dissolved in ethanol (8.1 mL), 1-bromo-3-methylbutan-2-one (Organic Syntheses, 1976, vol. 55, p24; 1.46 g, 8.86 mmol) was added, and the mixture was stirred at 110Ā°C for 13 hr. To the mixture was added saturated aqueous sodium hydrogen carbonate, and the mixture was extracted 3 times with chloroform. The combined organic layers were dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate = 100/0 v/v - 30/70 v/v) to give 2-isopropyl-8-methoxyimidazo[1,2-a]pyridine (746 mg, 49%).
ESIMS m/z: 191 (M + H)+; 1H NMR (300 MHz, CDCl3, Ī“): 1.37 (d, J = 7.0 Hz, 6H), 3.05-3.20 (m, 1H), 3.99 (s, 3H), 6.35-6.41 (m, 1H), 6.56-6.65 (m, 1H), 7.26-7.31 (m, 1H), 7.64-7.72 (m, 1H). - [step 2] Using 2-isopropyl-8-methoxyimidazo[1,2-a]pyridine (745 mg, 3.92 mmol) obtained in step 1, and in the same manner as in Reference Example 8A, step 2, 3-iodo-2-isopropyl-8-methoxyimidazo[1,2-a]pyridine (1.19 g, 96%) was obtained.
ESIMS m/z: 317 (M + H)+; 1H NMR (300 MHz, CDCl3, Ī“): 1.39 (d, J = 7.0 Hz, 6H), 3.10-3.27 (m, 1H), 4.01 (s, 3H), 6.47-6.53 (m, 1H), 6.75-6.82 (m, 1H), 7.73-7.78 (m, 1H). - [step 3] Using 3-iodo-2-isopropyl-8-methoxyimidazo[1,2-a]pyridine (600 mg, 1.90 mmol) obtained in step 2 and (E)-2-(3-fluoro-8-formyldibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (278 mg, 0.95 mmol) obtained in Reference Example 5, and in the same manner as in Reference Example 8A, step 3, (E)-2-{3-fluoro-8-[hydroxy(2-isopropyl-8-methoxyimidazo[1,2-a]pyridin-3-yl)methyl]dibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (159 mg, 35%) was obtained.
ESIMS m/z: 484 (M + H)+; 1H NMR (300 MHz, CDCl3, Ī“): 1.36-1.49 (m, 6H), 2.23 (s, 3H), 3.11-3.30 (m, 1H), 3.92-3.99 (m, 3H), 4.74-4.84 (m, 1H), 5.37-5.49 (m, 1H), 6.35-6.69 (m, 5H), 6.99-7.07 (m, 1H), 7.28-7.46 (m, 3H), 7.51-7.57 (m, 1H). - [step 4] Using (E)-2-{3-fluoro-8-[hydroxy(2-isopropyl-8-methoxyimidazo[1,2-a]pyridin-3-yl)methyl]dibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (152 mg, 0.31 mmol) obtained in step 3, and in the same manner as in Reference Example 8A, step 4, the title compound (112 mg, 76%) was obtained.
ESIMS m/z: 468 (M + H)+; 1H NMR (300 MHz, CDCl3, Ī“): 1.36-1.47 (m, 6H), 2.23 (s, 3H), 3.10-3.26 (m, 1H), 4.00 (s, 3H), 4.20-4.36 (m, 2H), 4.71 (d, J = 12.8 Hz, 1H), 5.39 (d, J = 12.8 Hz, 1H), 6.36-6.43 (m, 1H), 6.51-6.68 (m, 3H), 6.96-7.06 (m, 2H), 7.12-7.19 (m, 1H), 7.23-7.28 (m, 1H), 7.38 (d, J = 8.1 Hz, 1H). -
- [step 1] Using commercially available 3-methoxy-2-aminopyridine (1.0 g, 8.1 mmol), and in the same manner as in Reference Example 8F, step 1, 2-(chloromethyl)-8-methoxyimidazo[1,2-a]pyridine (1.5 g, 99%) was obtained.
ESIMS m/z: 197 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 4.01 (s, 3H), 4.76 (s, 2H), 6.46 (d, J = 7.8 Hz, 1H), 6.69-6.72 (m, 1H), 7.60 (s, 1H), 7.71-7.72 (m, 1H). - [step 2] Using 2-(chloromethyl)-8-methoxyimidazo[1,2-a]pyridine (1.58 g, 8.1 mmol) obtained in step 1, and in the same manner as in Reference Example 8F, step 2, 8-methoxy-2-(methoxymethyl)imidazo[1,2-a]pyridine (0.79 g, 51%) was obtained.
ESIMS m/z: 193 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 3.47 (s, 3H), 4.00 (s, 3H), 4.67 (s, 2H), 6.43 (d, J = 6.8 Hz, 1H), 6.65-6.69 (m, 1H), 7.54 (s, 1H), 7.71-7.73 (m, 1H). - [step 3] Using 8-methoxy-2-(methoxymethyl)imidazo[1,2-a]pyridine (0.786 g, 4.1 mmol) obtained in step 2, and in the same manner as in Reference Example 8F, step 3, 8-methoxy-3-iodo-2-(methoxymethyl)imidazo[1,2-a]pyridine (1.24 g, 95%) was obtained.
ESIMS m/z: 318 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 3.43 (s, 3H), 4.02 (s, 3H), 4.65 (s, 2H), 6.57 (d, J = 7.7 Hz, 1H), 6.83-6.88 (m, 1H), 7.77-7.80 (m, 1H). - [step 4] Using 8-methoxy-3-iodo-2-(methoxymethyl)imidazo[1,2-a]pyridine (500 mg, 1.57 mmol) obtained in step 3 and (E)-2-(3-fluoro-8-formyldibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (230 mg, 0.786 mmol) obtained in Reference Example 5, and in the same manner as in Reference Example 8F, step 4, (E)-2-(3-fluoro-8-{hydroxy[8-methoxy-2-(methoxymethyl)imidazo[1,2-a]pyridin-3-yl]methyl}dibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (250 mg, 66%) was obtained.
ESIMS m/z: 486 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 2.23 (s, 3H), 3.40 (s, 3H), 3.99 (s, 3H), 4.53-4.82 (m, 4H), 5.41-5.45 (m, 1H), 6.33-6.47 (m, 2H), 6.54-6.67 (m, 2H), 6.71 (s, 1H), 7.00-7.06 (m, 1H), 7.37-7.60 (m, 3H). - [step 5] Using (E)-2-(3-fluoro-8-{hydroxy[8-methoxy-2-(methoxymethyl)imidazo[1,2-a]pyridin-3-yl]methyl}dibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (180 mg, 0.37 mmol) obtained in step 4, and in the same manner as in Reference Example 8F, step 5, the title compound (77 mg, 44%) was obtained.
ESIMS m/z: 470 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 2.22 (s, 3H), 3.43 (s, 3H), 4.00 (s, 3H), 4.30-4.43 (m, 2H), 4.71-4.75 (m, 3H), 5.39 (d, J = 12.8 Hz, 1H),6.42-6.44 (m, 1H), 6.53-6.66 (m, 2H), 6.99-7.04 (m, 1H), 7.09-7.10 (m, 1H), 7.09-7.10 (m, 1H), 7.21-7.24 (m, 1H), 7.31-7.39 (m, 2H). -
- [step 1] Using commercially available 2-nitropyridin-3-ol (2.7 g, 19.3 mmol), and in the same manner as in Reference Example 2A, step 5, 3-(methoxy-d3)-2-nitropyridine (2.7 g, 88%) was obtained.
ESIMS m/z: 158 (M + H)+; 1H NMR (300 MHz, CDCl3, Ī“): 7.47-7.59 (m, 2H), 8.05-8.14 (m, 1H). - [step 2] 3-(Methoxy-d3)-2-nitropyridine (2.7 g, 16.9 mmol) obtained in step 1 was dissolved in ethanol (46 mL), 10% Pd-C (359 mg) was added, the reaction system was purged with hydrogen gas, and the mixture was stirred at room temperature for 3 hr. After completion of the reaction, the reaction mixture was filtered through celite, and the solution was concentrated under reduced pressure to quantitatively give 3-(methoxy-d3)-pyridin-2-amine (2.14 g).
ESIMS m/z: 128 (M + H)+; 1H NMR (300 MHz, CDCl3, Ī“): 4.29-4.84 (m, 2H), 6.62 (dd, J = 7.7, 5.1 Hz, 1H), 6.90 (dd, J = 7.7, 1.5 Hz, 1H), 7.66 (dd, J = 5.1, 1.5 Hz, 1H). - [step 3] Using 3-(methoxy-d3)-pyridin-2-amine (700 mg, 5.5 mmol) obtained in step 2, and in the same manner as in Reference Example 9D, step 1, 2-isopropyl-8-(methoxy-d3)-imidazo[1,2-a]pyridine (776 mg, 73%) was obtained.
ESIMS m/z: 194 (M + H)+; 1H NMR (300 MHz, CDCl3, Ī“): 1.37 (d, J = 7.0 Hz, 6H), 3.05-3.21 (m, 1H), 6.35-6.41 (m, 1H), 6.57-6.65 (m, 1H), 7.28-7.31 (m, 1H), 7.65-7.70 (m, 1H). - [step 4] Using 2-isopropyl-8-(methoxy-d3)-imidazo[1,2-a]pyridine (745 mg, 3.85 mmol) obtained in step 3, and in the same manner as in Reference Example 8A, step 2, 3-iodo-2-isopropyl-8-(methoxy-d3)-imidazo[1,2-a]pyridine (1.13 g, 92%) was obtained.
ESIMS m/z: 320 (M + H)+; 1H NMR (300 MHz, CDCl3, Ī“): 1.39 (d, J = 7.0 Hz, 6H), 3.11-3.24 (m, 1H), 6.48-6.53 (m, 1H), 6.75-6.82 (m, 1H), 7.73-7.78 (m, 1H). - [step 5] Using 3-iodo-2-isopropyl-8-(methoxy-d3)-imidazo[1,2-a]pyridine (653 mg, 2.05 mmol) obtained in step 4 and (E)-2-(3-fluoro-8-formyldibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (300 mg, 1.02 mmol) obtained in Reference Example 5, and in the same manner as in Reference Example 8A, step 3, (E)-2-(3-fluoro-8-{hydroxy[2-isopropyl-8-(methoxy-d3)-imidazo[1,2-a]pyridin-3-yl]methyl}dibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (228 mg, 46%) was obtained.
ESIMS m/z: 487 (M + H)+; 1H NMR (300 MHz, CDCl3, Ī“): 1.38-1.49 (m, 6H), 2.23 (s, 3H), 3.11-3.30 (m, 1H), 4.72-4.83 (m, 1H), 5.38-5.49 (m, 1H), 6.35-6.70 (m, 5H), 6.98-7.07 (m, 1H), 7.29-7.47 (m, 3H), 7.50-7.57 (m, 1H). - [step 6] Using (E)-2-(3-fluoro-8-{hydroxy[2-isopropyl-8-(methoxy-d3)-imidazo[1,2-a]pyridin-3-yl]methyl}dibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (220 mg, 0.45 mmol) obtained in step 5, and in the same manner as in Reference Example 8A, step 4, the title compound (129 mg, 61%) was obtained.
ESIMS m/z: 471 (M + H)+; 1H NMR (300 MHz, CDCl3, Ī“): 1.37-1.46 (m, 6H), 2.23 (s, 3H), 3.13-3.25 (m, 1H), 4.20-4.35 (m, 2H), 4.71 (d, J = 12.8 Hz, 1H), 5.39 (d, J = 12.8 Hz, 1H), 6.37-6.42 (m, 1H), 6.51-6.67 (m, 3H), 6.98-7.06 (m, 2H), 7.12-7.19 (m, 1H), 7.23-7.27 (m, 1H), 7.38 (d, J = 8.1 Hz, 1H). -
- [step 1] Using 3-(difluoromethoxy)pyridin-2-amine (700 mg, 4.37 mmol) obtained in Reference Example 9C, step 2, and in the same manner as in Reference Example 9D, step 1, 8-(difluoromethoxy)-2-isopropylimidazo[1,2-a]pyridine (766 mg, 77%) was obtained.
ESIMS m/z: 227 (M + H)+; 1H NMR (300 MHz, CDCl3, Ī“): 1.36 (d, J = 7.0 Hz, 6H), 3.04-3.20 (m, 1H), 6.60-6.70 (m, 1H), 6.86-6.91 (m, 1H), 7.36-7.39 (m, 1H), 7.39 (t, J = 74.6 Hz, 1H), 7.88-7.93 (m, 1H). - [step 2] Using 8-(difluoromethoxy)-2-isopropylimidazo[1,2-a]pyridine (745 mg, 3.29 mmol) obtained in step 1, and in the same manner as in Reference Example 8A, step 2, 8-(difluoromethoxy)-3-iodo-2-isopropylimidazo[1,2-a]pyridine (1.1 g, 95%) was obtained.
ESIMS m/z: 353 (M + H)+; 1H NMR (300 MHz, CDCl3, Ī“): 1.37 (d, J = 7.0 Hz, 6H), 3.10-3.26 (m, 1H), 6.78-6.86 (m, 1H), 6.97-7.04 (m, 1H), 7.47 (t, J = 74.6 Hz, 1H), 7.95-8.01 (m, 1H). - [step 3] Using 8-(difluoromethoxy)-3-iodo-2-isopropylimidazo[1,2-a]pyridine (600 mg, 1.71 mmol) obtained in step 2 and (E)-2-(3-fluoro-8-formyldibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (250 mg, 0.85 mmol) obtained in Reference Example 5, and in the same manner as in Reference Example 8A, step 3, (E)-2-(8-{[8-(difluoromethoxy)-2-isopropylimidazo[1,2-a]pyridin-3-yl](hydroxy)methyl}-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (426 mg, 96%) was obtained.
ESIMS m/z: 520 (M + H)+; 1H NMR (300 MHz, CDCl3, Ī“): 1.33-1.45 (m, 6H), 2.19-2.27 (m, 3H), 3.13-3.29 (m, 1H), 4.71-4.90 (m, 1H), 5.40-5.51 (m, 1H), 6.40-6.71 (m, 4H), 6.84-6.93 (m, 1H), 6.99-7.07 (m, 1H), 7.19-7.72 (m, 4H), 7.74-7.82 (m, 1H). - [step 4] Using (E)-2-(8-{[8-(difluoromethoxy)-2-isopropylimidazo[1,2-a]pyridin-3-yl](hydroxy)methyl}-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (200 mg, 0.39 mmol) obtained in step 3, and in the same manner as in Reference Example 8A, step 4, the title compound (151 mg, 78%) was obtained.
ESIMS m/z: 504 (M + H)+; 1H NMR (300 MHz, CDCl3, Ī“): 1.32-1.45 (m, 6H), 2.23 (s, 3H), 3.14-3.26 (m, 1H), 4.22-4.37 (m, 2H), 4.74 (d, J = 12.8 Hz, 1H), 5.41 (d, J = 12.8 Hz, 1H), 6.51-6.69 (m, 3H), 6.86-6.91 (m, 1H), 6.98-7.06 (m, 2H), 7.13-7.19 (m, 1H), 7.39 (d, J = 7.7 Hz, 1H), 7.44-7.49 (m, 1H), 7.56 (d, J = 74.6 Hz, 1H). - Using 2-(8-ethynyl-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (400 mg, 1.38 mmol, E/Z=1/1) obtained in Reference Example 9, 3-(methoxy-d3)-pyridin-2-amine (193 mg, 1.52 mmol) obtained in Reference Example 9F, step 2 and cyclopropanecarbaldehyde (0.16 mL, 2.07 mmol), and in the same manner as in Reference Example 8B, the title compound (220 mg, 34%) was obtained.
ESIMS m/z: 469 (M + H)+; 1H NMR (300 MHz, CDCl3, Ī“): 0.90-1.01 (m, 2H), 1.15-1.22 (m, 2H), 1.93-2.05 (m, 1H), 2.23 (s, 3H), 4.25-4.43 (m, 2H), 4.73 (d, J = 12.8 Hz, 1H), 5.40 (d, J = 12.8 Hz, 1H), 6.35-6.41 (m, 1H), 6.51-6.59 (m, 2H), 6.59-6.67 (m, 1H), 6.98-7.05 (m, 1H), 7.05-7.09 (m, 1H), 7.20-7.30 (m, 2H), 7.39 (d, J= 8.1 Hz, 1H). - Using cyclopropanecarboxyaldehyde (0.156 mL, 2.07 mmol), 3-fluoropyridin-2-amine (171 mg, 1.52 mmol) and 2-(8-ethynyl-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (400 mg, 1.38 mmol) obtained in Reference Example 9, and in the same manner as in Reference Example 8B, the title compound (179 mg, 29%) was obtained.
ESIMS m/z: 454 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 0.90-1.09 (m, 2H), 1.13-1.32 (m, 2H), 1.95-2.10 (m, 1H), 2.24 (s, 3H), 4.26-4.50 (m, 2H), 4.77 (d, J = 12.8 Hz, 1H), 5.41 (d, J = 12.8 Hz, 1H), 6.47-6.70 (m, 3H), 6.74-6.88 (m, 1H), 6.99-7.18 (m, 2H), 7.22-7.33 (m, 1H), 7.37-7.56 (m, 2H). -
- [step 1] Using 3-(difluoromethoxy)pyridin-2-amine (1.0 g, 6.3 mmol) obtained in Reference Example 9C, step 2, and in the same manner as in Reference Example 8F, step 1, 2-(chloromethyl)-8-(difluoromethoxy)imidazo[1,2-a]pyridine (1.5 g, 99%) was obtained.
ESIMS m/z: 233 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 4.78 (s, 2H), 6.24-7.05 (m, 4H), 7.92-7.97 (m, 1H). - [step 2] Using 2-(chloromethyl)-8-(difluoromethoxy)imidazo[1,2-a]pyridine (1.45 g, 6.25 mmol) obtained in step 1, and in the same manner as in Reference Example 8F, step 2, 8-(difluoromethoxy)-2-(methoxymethyl)imidazo[1,2-a]pyridine (1.33 g, 93%) was obtained.
ESIMS m/z: 229 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 3.49 (s, 3H), 4.66 (s, 2H), 6.24-7.06 (m, 4H), 7.92-7.97 (m, 1H). - [step 3] Using 8-(difluoromethoxy)-2-(methoxymethyl)imidazo[1,2-a]pyridine (1.33 g, 5.8 mmol) obtained in step 2, and in the same manner as in Reference Example 8F, step 3, 8-(difluoromethoxy)-3-iodo-2-(methoxymethyl)imidazo[1,2-a]pyridine (1.66 g, 80%) was obtained.
ESIMS m/z: 355 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 3.46 (s, 3H), 4.65 (s, 2H), 6.24-7.06 (m, 3H), 7.92-7.97 (m, 1H). - [step 4] Using 8-(difluoromethoxy)-3-iodo-2-(methoxymethyl)imidazo[1,2-a]pyridine (700 mg, 1.98 mmol) obtained in step 3 and (E)-2-(3-fluoro-8-formyldibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (290 mg, 0.988 mmol) obtained in Reference Example 5, and in the same manner as in Reference Example 8F, step 4, (E)-2-(8-{[8-(difluoromethoxy)-2-(methoxymethyl)imidazo[1,2-a]pyridin-3-yl](hydroxy)methyl1-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (400 mg, 78%) was obtained.
ESIMS m/z: 522 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 2.24 (s, 3H), 3.43 (s, 3H), 4.61-4.83 (m, 3H), 5.43-5.46 (m, 1H), 6.41-6.43 (m, 1H), 6.56-6.65 (m, 3H), 6.95-7.03 (m, 3H), 7.42-7.45 (m, 3H), 7.76-7.83 (m, 1H). - [step 5] Using (E)-2-(8-{[8-(difluoromethoxy)-2-(methoxymethyl)imidazo[1,2-a]pyridin-3-yl](hydroxy)methyl}-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (193 mg, 0.37 mmol) obtained in step 4, and in the same manner as in Reference Example 8F, step 5, the title compound (60 mg, 32%) was obtained.
ESIMS m/z: 506 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 2.23 (s, 3H), 3.47 (s, 3H), 4.33-4.44 (m, 2H), 4.72-4.77 (m, 1H), 5.39-5.42 (m, 1H), 6.54-6.57 (m, 1H), 6.62-6.69 (m, 2H), 6.93-7.04 (m, 3H), 7.12-7.14 (m, 1H), 7.23-7.25 (m, 1H), 7.30-7.33 (m, 1H), 7.39-7.41 (m, 1H), 7.51-7.57 (m, 1H). - Using 2-(8-ethynyl-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (200 mg, 0.691 mmol, E/Z = 1/1) obtained in Reference Example 9, 2-amino-3-methoxypyridine (112 mg, 0.899 mmol) and butylaldehyde (100 mg, 1.38 mmol), and in the same manner as in Reference Example 8B, the title compound (75 mg, 15%) was obtained.
ESIMS m/z: 468 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 0.98 (t, J = 7.3 Hz, 3H), 1.79-2.02 (m, 2H), 2.23 (s, 3H), 2.79 (t, J = 7.8 Hz, 2H), 4.01 (s, 3H), 4.23 (d, J= 17.6 Hz, 1H), 4.29 (d, J = 17.6 Hz, 1H), 4.72 (d, J = 12.7 Hz, 1H), 5.40 (d, J = 12.7 Hz, 1H), 6.42-6.46 (m, 1H), 6.53-6.67 (m, 3H),7.00-7.05 (m, 2H), 7.18 (d, J = 7.8 Hz, 1H), 7.24-7.28 (m, 1H), 7.39 (d, J = 7.8 Hz, 1H). -
- [step 1] Using 8-chloro-2-(chloromethyl)imidazo[1,2-a]pyridine obtained in Reference Example 8K, step 1, 8-chloro-3-iodo-2-(methoxy-d3-methyl)imidazo[1,2-a]pyridine (496 mg, 1.52 mmol) synthesized according to Reference Example 8G, step 1 and step 2 and (E)-2-(3-fluoro-8-formyldibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (223 mg, 0.76 mmol) obtained in Reference Example 5, and in the same manner as in Reference Example 8A, step 3, (E)-2-(8-{[8-chloro-2-(methoxy-d3-methyl)imidazo[1,2-a]pyridin-3-yl] (hydroxy)methyl}-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (334 mg, 89%) was obtained.
ESIMS m/z: 493 (M + H)+; 1H NMR (300 MHz, DMSO-d6, Ī“) : 2.16 (s, 3H), 4.59-4.64 (m, 2H), 4.93-5.04 (m, 1H), 5.43-5.52 (m, 1H), 6.40-6.54 (m, 2H), 6.76-6.91 (m, 3H), 7.23-7.31 (m, 1H), 7.37-7.45 (m, 2H), 7.50-7.58 (m, 1H), 8.23-8.28 (m, 1H), 8.49-8.55 (m, 1H). - [step 2] Using (E)-2-(8-{[8-chloro-2-(methoxy-d3-methyl)imidazo[1,2-a]pyridin-3-yl](hydroxy)methyl}-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (323 mg, 0.66 mmol) obtained in step 1, and in the same manner as in Reference Example 8A, step 4, the title compound (137 mg, 44%) was obtained.
ESIMS m/z: 477 (M + H)+; 1H NMR (300 MHz, CDCl3, Ī“) : 2.23 (s, 3H), 4.31-4.48 (m, 2H), 4.69-4.78 (m, 3H), 5.40 (d, J = 12.5 Hz, 1H), 6.55 (dd, J = 10.3, 2.6 Hz, 1H), 6.60-6.70 (m, 2H), 6.98-7.06 (m, 1H), 7.08-7.13 (m, 1H), 7.20-7.26 (m, 2H), 7.40 (d, J = 8.1 Hz, 1H), 7.60-7.66 (m, 1H). - Using 2-(8-ethynyl-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (350 mg, 1.21 mmol, E/Z = 1/1) obtained in Reference Example 9 and 2-amino-4-chloropyridine (156 mg, 1.21 mmol), and in the same manner as in Reference Example 8B, the title compound (73 mg, 13%) was obtained.
ESIMS m/z: 470 (M + H)+; 1H NMR (300 MHz, CDCl3, Ī“): 0.98-1.05 (m, 2H), 1.08-1.15 (m, 2H), 1.94-2.03 (m, 1H), 2.23 (s, 3H), 4.30 (d, J = 17.2 Hz, 1H), 4.38 (d, J = 17.2 Hz, 1H), 4.76 (d, J = 12.8 Hz, 1H), 5.41 (d, J = 12.8 Hz, 1H), 6.53-6.59 (m, 1H), 6.61-6.68 (m, 2H),6.99-7.06 (m, 1H), 7.08-7.10 (m, 1H), 7.20-7.24 (m, 1H), 7.41 (d, J = 7.7 Hz, 1H), 7.50-7.54 (m, 2H). - Using 2-(8-ethynyl-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (400 mg, 1.38 mmol) obtained in Reference Example 9 and 2-amino-5-chloropyridine (178 mg, 1.38 mmol), and in the same manner as in Reference Example 8B, the title compound (88 mg, 14%) was obtained.
ESIMS m/z: 470 (M + H)+; 1H NMR (300 MHz, CDCl3, Ī“): 0.99-1.04 (m, 2H), 1.09-1.15 (m, 2H), 1.95-2.02 (m, 1H), 2.24 (s, 3H), 4.30-4.35 (m, 2H), 4.78 (d, J = 12.7 Hz, 1H), 5. 43 (d, J = 12.7 Hz, 1H), 6.54-6.58 (m, 1H), 6.62-6.67 (m, 1H), 7.01-7.07 (m, 2H), 7.11 (br s, 1H), 7.23 (d, J = 7.8 Hz, 1H), 7.42 (d, J = 7.8 Hz, 1H), 7.46 (d, J = 9.8 Hz, 1H), 7.67 (d, J = 2.0 Hz, 1H). - Using cyclopropanecarboxyaldehyde (0.129 mL, 1.77 mmol), 4-fluoropyridin-2-amine (141 mg, 1.26 mmol) and 2-(8-ethynyl-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (330 mg, 1.14 mmol) obtained in Reference Example 9, and in the same manner as in Reference Example 8B, the title compound (25 mg, 5%) was obtained.
ESIMS m/z: 454 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“) : 0.90-1.18 (m, 4H), 1.92-2.07 (m, 1H), 2.23 (s, 3H), 4.21-4.44 (m, 2H), 4.75 (d, J = 12.8 Hz, 1H), 5.43 (d, J = 12.8 Hz, 1H), 6.43-6.74 (m, 3H), 6.99-7.31 (m, 4H), 7.33-7.62 (m, 2H). - Using 2-(8-ethynyl-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (400 mg, 1.38 mmol, E/Z = 1/1) obtained in Reference Example 9, commercially available 5-fluoropyridin-2-amine (155 mg, 1.38 mmol) and cyclopropanecarbaldehyde (0.16 mL, 2.07 mmol), and in the same manner as in Reference Example 8B, the title compound (151 mg, 24%) was obtained.
ESIMS m/z: 454 (M + H)+; 1H NMR (400 MHz, CDCl3, Ī“) : 0.95-1.14 (m, 4H), 1.96-2.07 (m, 1H), 2.24 (s, 3H), 4.27-4.39 (m, 2H), 4.78 (d, J = 12.7 Hz, 1H), 5.42 (d, J = 12.7 Hz, 1H), 6.56 (dd, J = 10.2, 2.4 Hz, 1H), 6.61-6.68 (m, 1H), 6.96-7.06 (m, 2H), 7.08-7.14 (m, 1H), 7.20-7.25 (m, 1H), 7.42 (d, J = 7.8 Hz, 1H), 7.45-7.51 (m, 1H), 7.52-7.57 (m, 1H). -
- [step 1] Using commercially available 4-chloro-2-aminopyridine (2.5 g, 19 mmol), and in the same manner as in Reference Example 8F, step 1, 7-chloro-2-(chloromethyl)imidazo[1,2-a]pyridine (3.9 g, 99%) was obtained.
ESIMS m/z: 201 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 4.74 (s, 2H), 6.78-6.81 (m, 1H), 7.57-7.60 (m, 2H), 7.99-8.02 (m, 1H). - [step 2] Using 7-chloro-2-(chloromethyl)imidazo[1,2-a]pyridine (3.9 g, 19 mmol) obtained in step 1, and in the same manner as in Reference Example 8F, step 2, 7-chloro-2-(methoxymethyl)imidazo[1,2-a]pyridine (3.8 g, 99%) was obtained.
ESIMS m/z: 197(M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 3.49 (s, 3H), 4.63 (s, 2H), 6.76-6.78 (m, 1H), 7.54-7.56 (m, 2H), 8.00-8.02 (m, 1H). - [step 3] Using 7-chloro-2-(methoxymethyl)imidazo[1,2-a]pyridine (3.8 g, 19 mmol) obtained in step 2, and in the same manner as in Reference Example 8F, step 3, 7-chloro-3-iodo-2-(methoxymethyl)imidazo[1,2-a]pyridine (5.1 g, 81%) was obtained.
ESIMS m/z: 323 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 3.46 (s, 3H), 4.61 (s, 2H), 6.90-6.92 (m, 1H), 7.55-7.58 (m, 1H), 8.04-8.06 (m, 1H). - [step 4] Using 7-chloro-3-iodo-2-(methoxymethyl)imidazo[1,2-a]pyridine (700 mg, 2.17 mmol) obtained in step 3 and (E)-2-(3-fluoro-8-formyldibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (318 mg, 1.09 mmol) obtained in Reference Example 5, and in the same manner as in Reference Example 8F, step 4, (E)-2-(8-{[7-chloro-2-(methoxymethyl)imidazo[1,2-a]pyridin-3-yl](hydroxy)methyl}-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (400 mg, 75%) was obtained.
ESIMS m/z: 490 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 2.24 (s, 3H), 3.44 (s, 3H), 4.55-4.70 (m, 2H), 4.78-4.82 (m, 1H), 5.42-5.46 (m, 1H), 6.39-6.42 (m, 1H), 6.54-6.59 (m, 1H), 6.62-6.68 (m, 2H), 7.01-7.05 (m, 1H), 7.35-7.46 (m, 3H), 7.53-7.55 (m, 1H), 7.85-7.89 (m, 1H). - [step 5] Using (E)-2-(8-{[7-chloro-2-(methoxymethyl)imidazo[1,2-a]pyridin-3-yl](hydroxy)methyl}-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (200 mg, 0.41 mmol) obtained in step 4, and in the same manner as in Reference Example 8F, step 5, the title compound (72 mg, 37%) was obtained.
ESIMS m/z: 474 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 2.23 (s, 3H), 3.47 (s, 3H), 4.35-4.37 (m, 1H), 4.63-4.76 (m, 4H), 5.38-5.42 (m, 1H), 6.53-6.71 (m, 3H), 7.00-7.10 (m, 2H), 7.20-7.24 (m, 2H), 7.39-7.42 (m, 1H), 7.58-7.60 (m, 1H). - Using 2-(8-ethynyl-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (400 mg, 1.38 mmol, E/Z=1/1) obtained in Reference Example 9, commercially available 4-methoxypyridin-2-amine (172 mg, 1.38 mmol) and cyclopropanecarbaldehyde (0.16 mL, 2.07 mmol), and in the same manner as in Reference Example 8B, the title compound (172 mg, 27%) was obtained.
ESIMS m/z: 466 (M + H)+; 1H NMR (300 MHz, CDCl3, Ī“): 0.93-1.17 (m, 4H), 1.89-2.03 (m, 1H), 2.23 (s, 3H), 3.81 (s, 3H), 4.22-4.41 (m, 2H), 4.76 (d, J = 12.8 Hz, 1H), 5.41 (d, J= 12.8 Hz, 1H), 6.38 (d, J = 7.3 Hz, 1H), 6.55 (dd, J = 10.3, 2.6 Hz, 1H), 6.59-6.68 (m, 1H), 6.81-6.91 (m, 1H), 7.02 (dd, J = 8.8, 6.6 Hz, 1H), 7.02-7.12 (m, 1H), 7.20-7.26 (m, 1H), 7.35-7.53 (m, 2H). -
- [step 1] Using commercially available 3-trifluoromethyl-2-aminopyridine (2.0 g, 12 mmol), and in the same manner as in Reference Example 8F, step 1, 2-(chloromethyl)-8-(trifluoromethyl)imidazo[1,2-a]pyridine (2.78 g, 96%) was obtained.
ESIMS m/z: 235 (M + H)+; 1H NMR (270 MHz, CDCl3, 5): 4.78 (s, 2H), 6.72-6.75 (m, 1H), 7.52-7.67 (m, 1H), 7.70-8.76 (m, 2H). - [step 2] Using 2-(chloromethyl)-8-(trifluoromethyl)imidazo[1,2-a]pyridine (2.78 g, 12 mmol) obtained in step 1, and in the same manner as in Reference Example 8F, step 2, 2-(methoxymethyl)-8-(trifluoromethyl)imidazo[1,2-a]pyridine (2.25 g, 82%) was obtained.
ESIMS m/z: 231 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“) : 3.57 (s, 3H), 4.73 (s, 2H), 6.71-6.87 (m, 1H), 7.51-7.53 (m, 1H), 7.68-7.72 (m, 1H), 8.25-8.26 (m, 1H). - [step 3] Using 2-(methoxymethyl)-8-(trifluoromethyl)imidazo[1,2-a]pyridine (2.25 g, 9.8 mmol) obtained in step 2, and in the same manner as in Reference Example 8F, step 3, 3-iodo-2-(methoxymethyl)-8-(trifluoromethyl)imidazo[1,2-a]pyridine (1.32 g, 38%) was obtained.
ESIMS m/z: 357 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 3.47 (s, 3H), 4.69 (s, 2H), 7.00 (t, J = 6.9 Hz, 1H), 7.62 (d, J= 6.9 Hz, 1H), 8.32 (d, J = 6.9 Hz, 1H). - [step 4] Using 3-iodo-2-(methoxymethyl)-8-(trifluoromethyl)imidazo[1,2-a]pyridine (700 mg, 1.97 mmol) obtained in step 3 and (E)-2-(3-fluoro-8-formyldibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (288 mg, 0.98 mmol) obtained in Reference Example 5, and in the same manner as in Reference Example 8F, step 4, (E)-2-(3-fluoro-8-{hydroxy[2-(methoxymethyl)-8-(trifluoromethyl)imidazo[1,2-a]pyridin-3-yl]methyl}dibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (420 mg, 82%) was obtained.
ESIMS m/z: 524 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 2.24 (s, 3H), 3.45 (s, 3H), 4.62-4.83 (m, 3H), 5.41-5.47 (m, 1H), 6.43-6.87 (m, 4H), 7.01-7.06 (m, 1H), 7.41-7.53 (m, 4H), 8.07-8.26 (m, 1H). - [step 5] Using (E)-2-(3-fluoro-8-{hydroxy[2-(methoxymethyl)-8-(trifluoromethyl)imidazo[1,2-a]pyridin-3-yl]methyl}dibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (400 mg, 0.76 mmol) obtained in step 4, and in the same manner as in Reference Example 8F, step 5, the title compound (74 mg, 20%) was obtained.
ESIMS m/z: 478 (M + H)+; 1H NMR to MHz, CDCl3, Ī“): 2.26 (s, 3H), 2.58 (s, 3H), 4.29-4.31 (m, 2H), 4.73-4.77 (m, 1H), 5.38-5.42 (m, 1H), 6.53-6.77 (m, 3H), 7.00-7.06 (m, 2H), 7.18-7.22 (m, 1H), 7.40-7.49 (m, 2H), 7.77-7.79 (m, 1H). - Using 2-(8-ethynyl-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (1.5 g, 5.18 mmol, E/Z-1/1) obtained in Reference Example 9, commercially available 3-bromopyridin-2-amine (0.9 g, 5.18 mmol) and cyclopropanecarbaldehyde (0.6 mL, 7.78 mmol), and in the same manner as in Reference Example 8B, the title compound (332 mg, 12%) was obtained.
ESIMS m/z: 514 (M + H)+; 1H NMR (400 MHz, CDCl3, Ī“): 0.97-1.05 (m, 2H), 1.13-1.22 (m, 2H), 1.98-2.08 (m, 1H), 2.23 (s, 3H), 4.28-4.44 (m, 2H), 4.75 (d, J = 12.7 Hz, 1H), 5.40 (d, J = 12.7 Hz, 1H), 6.52-6.58 (m, 2H), 6.60-6.67 (m, 1H), 6.99-7.09 (m, 2H), 7.20-7.25 (m, 1H), 7.35-7.43 (m, 2H), 7.57-7.62 (m, 1H). -
- [step 1] Using commercially available 4-chloro-2-aminopyridine (2.0 g, 16 mmol) and 1-chloro-2-propanone (1.37 mL, 17 mmol), and in the same manner as in Reference Example 8F, step 1, 7-chloro-2-methylimidazo[1,2-a]pyridine (2.59 g, 41%) was obtained.
ESIMS m/z: 167 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 2.51 (s, 3H), 6.92 (d, J = 6.8 Hz, 1H), 7.35 (s, 1H), 7.82 (s, 1H), 8.04 (d, J= 6.8 Hz, 1H). - [step 2] Using 7-chloro-2-methylimidazo[1,2-a]pyridine (1.06 g, 6.4 mmol) obtained in step 1, and in the same manner as in Reference Example 8F, step 3, 7-chloro-3-iodo-2-methylimidazo[1,2-a]pyridine (1.71 g, 92%) was obtained.
ESIMS m/z: 293 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 2.53 (s, 3H), 7.02 (d, J = 6.8 Hz, 1H), 7.77 (s, 1H), 8.04 (d, J= 6.8 Hz, 1H). - [step 3] Using 7-chloro-3-iodo-2-methylimidazo[1,2-a]pyridine (700 mg, 2.39 mmol) obtained in step 2 and (E)-2-(3-fluoro-8-formyldibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (351 mg, 1.20 mmol) obtained in Reference Example 5, and in the same manner as in Reference Example 8F, step 4, (E)-2-(8-{[7-chloro-2-methylimidazo[1,2-a]pyridin-3-yl](hydroxy)methyl}-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (471 mg, 86%) was obtained.
ESIMS m/z: 460 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 2.22 (s, 3H), 2.53 (s, 3H), 4.77-4.85 (m, 2H), 5.38-5.46 (m, 1H), 6.52-6.66 (m, 2H), 6.83-6.86 (m, 1H), 6.98-7.04 (m, 1H), 7.29-7.63 (m, 4H), 8.09-8.14 (m, 1H). - [step 4] Using (E)-2-(8-{[7-chloro-2-methylimidazo[1,2-a]pyridin-3-yl](hydroxy)methyl}-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (470 mg, 0.76 mmol) obtained in step 3, and in the same manner as in Reference Example 8F, step 5, the title compound (368 mg, 71%) was obtained.
ESIMS m/z: 444 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 2.23 (s, 3H), 2.70 (s, 3H), 4.22-4.36 (m, 2H), 4.74-4.77 (m, 1H), 5.38-5.41 (m, 1H), 6.54-6.57 (m, 1H), 6.63-6.66 (m, 1H), 6.97-7.04 (m, 2H), 7.12-7.18 (m, 2H), 7.45-7.50 (m, 1H), 7.74-7.75 (m, 1H), 8.31-8.32 (m, 1H). - Using 2-(8-ethynyl-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (400 mg, 1.38 mmol, E/Z=1/1) obtained in Reference Example 9, commercially available 3-methylpyridin-2-amine (150 mg, 1.38 mmol) and cyclopropanecarbaldehyde (0.16 mL, 2.07 mmol), and in the same manner as in Reference Example 8B, the title compound (189 mg, 30%) was obtained.
ESIMS m/z: 450 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 0.94-1.03 (m, 2H), 1.05-1.13 (m, 2H), 1.96-2.08 (m, 1H), 2.23 (s, 3H), 2.57 (s, 3H), 4.24-4.44 (m, 2H), 4.74 (d, J = 12.5 Hz, 1H), 5.40 (d, J = 12.5 Hz, 1H), 6.51-6.67 (m, 3H), 6.84-6.90 (m, 1H), 6.97-7.10 (m, 2H), 7.19-7.25 (m, 1H), 7.38 (d, J = 7.6 Hz, 1H), 7.45-7.51 (m, 1H). -
- [step 1] Using 4-chloropyridin-2-amine (2.0 g, 15.6 mmol) and 1-bromobutan-2-one (1.75 mL, 17.1 mmol), and in the same manner as in Reference Example 8A, step 1, 7-chloro-2-ethylimidazo[1,2-a]pyridine (1.08 g, 38%) was obtained.
ESIMS m/z: 182 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 1.34 (t, J = 7.6 Hz, 3H), 2.81 (q, J = 7.6 Hz, 2H), 6.66-6.77 (m, 1H), 7.32 (s, 1H), 7.46-7.60 (m, 1H), 7.90-8.01 (m, 1H). - [step 2] Using 7-chloro-2-ethylimidazo[1,2-a]pyridine (1.08 g, 5.94 mmol) obtained in step 1, and in the same manner as in Reference Example 8A, step 2, 7-chloro-2-ethyl-3-iodoimidazo[1,2-a]pyridine (1.58 g, 87%) was obtained.
ESIMS m/z: 308 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“) : 1.31 (t, J = 7.6 Hz, 3H), 2.78 (q, J= 7.6 Hz, 2H), 6.86 (d, J = 7.0 Hz, 1H), 7.53 (s, 1H), 7.99 (d, J= 7.0 Hz, 1H). - [step 3] Using 7-chloro-2-ethyl-3-iodoimidazo[1,2-a]pyridine (700 mg, 2.28 mmol) obtained in step 2 and (E)-2-(3-fluoro-8-formyldibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (335 mg, 1.14 mmol) obtained in Reference Example 5, and in the same manner as in Reference Example 8A, step 3, (E)-2-{3-fluoro-8-[(7-chloro-2-ethylimidazo[1,2-a]pyridin-3-yl)(hydroxy)methyl]dibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (480 mg, 89%) was obtained.
ESIMS m/z: 474 (M + H)+; 1H NMR (270 MHz, DMSO-d6, Ī“): 1.13-1.30 (m, 3H), 2.10-2.26 (m, 3H), 2.65-2.82 (m, 2H), 4.95-5.09 (m, 1H), 5.38-5.54 (m, 1H), 6.28-6.39 (m, 2H), 6.60-6.78 (m, 1H), 6.78-6.93 (m, 2H), 7.22-7.67 (m, 4H), 8.12-8.26 (m, 1H). - [step 4] Using (E)-2-{3-fluoro-8-[(7-chloro-2-ethylimidazo[1,2-a]pyridin-3-yl)(hydroxy)methyl]dibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (478 mg, 1.01 mmol) obtained in step 3, and in the same manner as in Reference Example 8A, step 4, the title compound (462 mg, 100%) was obtained.
ESIMS m/z: 458 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“) : 1.36 (t, J = 7.6 Hz, 3H), 2.24 (s, 3H), 2.82 (q, J = 7.6 Hz, 2H), 4.16-4.36 (m, 2H), 4.74 (d, J = 12.8 Hz, 1H), 5.40 (d, J = 12.8 Hz, 1H), 6.52-6.59 (m, 1H), 6.61-6.69 (m, 2H), 6.99-7.07 (m, 2H), 7.14-7.20 (m, 1H), 7.37-7.42 (m, 1H), 7.50-7.55 (m, 1H), 7.55-7.61 (m, 1 H). -
- [step 1] Using 3-chloropyridin-2-amine (1.0 g, 7.78 mmol) and 1-chloropropan-2-one (2.0 g, 21.6 mmol), and in the same manner as in Reference Example 8A, step 1, 8-chloro-2-methylimidazo[1,2-a]pyridine (700 mg, 54%) was obtained.
ESIMS m/z: 167 (M + H)+; 1H NMR (270 MHz, DMSO-d6, Ī“) : 2.50 (s, 3H), 7.40 (t, J = 7.4 Hz, 1H), 8.03 (d, J = 7.4 Hz, 1H), 8.18-8.22 (m, 1H), 8.85 (d, J = 7.4 Hz, 1H). - [step 2] Using 8-chloro-2-methylimidazo[1,2-a]pyridine (600 mg, 3.60 mmol) obtained in step 1, and in the same manner as in Reference Example 8A, step 2, 8-chloro-2-methyl-3-iodoimidazo[1,2-a]pyridine (1.01 g, 97%) was obtained.
ESIMS m/z: 293 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 2.54 (s, 3H), 6.83 (t, J = 6.9 Hz, 1H), 7.30 (dd, J = 6.9, 1.2 Hz, 1H), 8.01 (dd, J = 6.9, 1.2 Hz, 1H). - [step 3] Using 8-chloro-2-methyl-3-iodoimidazo[1,2-a]pyridine (598 mg, 2.05 mmol) obtained in step 2 and (E)-2-(3-fluoro-8-formyldibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (300 mg, 1.02 mmol) obtained in Reference Example 5, and in the same manner as in Reference Example 8A, step 3, (E)-2-{3-fluoro-8-[(8-chloro-2-methylimidazo[1,2-a]pyridin-3-yl)(hydroxy)methyl]dibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (430 mg, 91%) was obtained.
ESIMS m/z: 474 (M + H)+; 1H NMR (270 MHz, DMSO-d6, Ī“) : 2.16 (s, 3H), 2.39 (s, 3H), 4.89-5.10 (m, 1H), 5.40-5.53 (m, 1H), 6.26-6.43 (m, 2H), 6.58-6.92 (m, 3H), 7.20-7.65 (m, 4H), 8.10-8.28 (m, 1H). - [step 4] Using (E)-2-{3-fluoro-8-[(8-chloro-2-methylimidazo[1,2-a]pyridin-3-yl)(hydroxy)methyl]dibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (430 mg, 0.935 mmol) obtained in step 3, and in the same manner as in Reference Example 8A, step 4, the title compound (329 mg, 79%) was obtained.
ESIMS m/z: 444 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“) : 2.26 (s, 3H), 2.55 (s, 3H), 4.13-4.41 (m, 2H), 4.72 (d, J = 12.8 Hz, 1H), 5.39 (d, J = 12.8 Hz, 1H), 6.50-6.68 (m, 3H), 6.93-7.07 (m, 2H), 7.14-7.34 (m, 2H), 7.35-7.44 (m, 1H), 7.49-7.64 (m, 1H). -
- [step 1] Using commercially available 4-(trifluoromethyl)-2-aminopyridine (1.0 g, 6.2 mmol) and 1-chloro-2-propanone (0.54 mL, 6.8 mmol), and in the same manner as in Reference Example 8F, step 1, 2-methyl-7-(trifluoromethyl)imidazo[1,2-a]pyridine (1.0 g, 81%) was obtained.
ESIMS m/z: 201 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“) : 2.48 (s, 3H), 6.90-6.92 (m, 1H), 7.46 (s, 1H), 7.85 (s, 1H), 8.09-8.16 (m, 1H). - [step 2] Using 2-methyl-7-(trifluoromethyl)imidazo[1,2-a]pyridine (1.0 g, 5.0 mmol) obtained in step 1, and in the same manner as in Reference Example 8F, step 3, 3-iodo-2-methyl-7-(trifluoromethyl)imidazo[1,2-a]pyridine (0.75 g, 46%) was obtained.
ESIMS m/z: 327 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“) : 2.54 (s, 3H), 7.06 (dd, J = 6.8, 2.0 Hz, 1H), 7.80 (s, 1H), 8.16 (d, J= 6.8 Hz, 1H). - [step 3] Using 3-iodo-2-methyl-7-(trifluoromethyl)imidazo[1,2-a]pyridine (730 mg, 2.24 mmol) obtained in step 2 and (E)-2-(3-fluoro-8-formyldibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (328 mg, 1.12 mmol) obtained in Reference Example 5, and in the same manner as in Reference Example 8F, step 4, (E)-2-(3-fluoro-8-{hydroxy[2-methyl-7-(trifluoromethyl)imidazo[1,2-a]pyridin-3-yl]methyl}dibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (550 mg, 99%) was obtained.
ESIMS m/z: 494 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 2.22 (s, 3H), 2.43 (s, 3H), 4.80-4.84 (m, 1H), 5.43-5.47 (m, 1H), 6.39 (br s, 1H), 6.54-6.67 (m, 2H), 6.79-6.81 (m, 1H), 7.00-7.05 (m, 1H), 7.32-7.35 (m, 1H), 7.42-7.52 (m, 2H), 7.79-7.80 (m, 1H), 8.10-8.16 (m, 1H). - [step 4] Using (E)-2-(3-fluoro-8-{hydroxy[2-methyl-7-(trifluoromethyl)imidazo[1,2-a]pyridin-3-yl]methyl}dibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (550 mg, 1.12 mmol) obtained in step 3, and in the same manner as in Reference Example 8F, step 5, the title compound (464mg, 84%) was obtained.
ESIMS m/z: 478 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“) : 2.27 (s, 3H), 2.58 (s, 3H), 4.25-4.36 (m, 2H), 4.73-4.76 (m, 1H), 5.39-5.42 (m, 1H), 6.54-6.57 (m, 1H), 6.62-6.67 (m, 1H), 6.85-6.87 (m, 1H), 7.00-7.04 (m, 2H), 7.16-7.18 (m, 1H), 7.40-7.42 (m, 1H), 7.73-7.74 (m, 1H), 7.84-7.85 (m, 1H). -
- [step 1] (E)-2-{8-[(8-bromo-2-cyclopropylimidazo[1,2-a]pyridin-3-yl)methyl]-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (1.0 g, 1.94 mmol) obtained in Reference Example 10I was dissolved in a mixed solvent of DMF (5.3 mL) and n-propanol (5.3 mL), and 1,1'-bis(diphenylphosphino)ferrocene-palladium (II) dichloride-dichloromethane complex (318 mg, 0.39 mmol), 1,1'-bis(diphenylphosphino)ferrocene (431 mg, 0.78 mmol) and triethylamine (2.7 mL, 19.44 mmol) were added. After purging with nitrogen using a vacuum line, CO gas was filled and the mixture was stirred at 80Ā°C in the presence of CO gas for 5 hr. After completion of the reaction, the mixture was filtered through celite, saturated aqueous ammonium chloride solution was added to the solution, and the mixture was extracted 3 times with ethyl acetate. The combined organic layers were washed with water, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate = 100/0 v/v - 60/40 v/v) to give (E)-propyl 3-{[11-(1-cyanoethylidene)-3-fluoro-6,11-dihydrodibenzo[b,e]oxepin-8-yl]methyl}-2-cyclopropylimidazo[1,2-a]pyridine-8-carboxylate (847 mg, 84%).
ESIMS m/z: 522 (M + H)+; 1H NMR (300 MHz, CDCl3, Ī“) : 0.97-1.04 (m, 2H), 1.13 (t, J = 7.3 Hz, 3H), 1.18-1.29 (m, 2H), 1.79-1.93 (m, 2H), 1.99-2.09 (m, 1H), 2.23 (s, 3H), 4.29-4.48 (m, 4H), 4.72 (d, J = 12.5 Hz, 1H), 5.39 (d, J = 12.5 Hz, 1H), 6.55 (dd, J = 10.3, 2.6 Hz, 1H), 6.60-6.68 (m, 1H), 6.68-6.75 (m, 1H), 6.98-7.07 (m, 2H), 7.20-7.27 (m, 1H), 7.40 (d, J = 7.7 Hz, 1H), 7.75 (dd, J = 7.1, 1.3 Hz, 1H), 7.85 (dd, J = 7.1, 1.3 Hz, 1H). - [step 2] (E)-propyl 3-{[11-(1-cyanoethylidene)-3-fluoro-6,11-dihydrodibenzo[b,e]oxepin-8-yl]methyl}-2-cyclopropylimidazo[1,2-a]pyridine-8-carboxylate (350 mg, 0.55 mmol) obtained in step 1 was dissolved in THF (4.1 mL), methylmagnesium chloride (3 mol/L THF solution, 0.73 mL, 2.20 mmol) was added at -30Ā°C, and the mixture was stirred at -20Ā°C for 2 hr. To the mixture was added saturated aqueous ammonium chloride solution, and the mixture was extracted 3 times with ethyl acetate. The combined organic layers were dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate = 100/0 v/v - 70/30 v/v) to give the title compound (244 mg, 90%).
ESIMS m/z: 494 (M + H)+; 1H NMR (300 MHz, CDCl3, Ī“): 0.93-1.02 (m, 2H), 1.05-1.15 (m, 2H), 1.67 (s, 6H), 1.92-2.06 (m, 1H), 2.23 (s, 3H), 4.25-4.43 (m, 2H), 4.78 (d, J = 12.5 Hz, 1H), 5.41 (d, J = 12.5 Hz, 1H), 6.51-6.68 (m, 3H), 6.89-6.98 (m, 2H), 6.98-7.06 (m, 1H), 7.08-7.14 (m, 1H), 7.21-7.26 (m, 1H), 7.36-7.43 (m, 1H), 7.48-7.53 (m, 1H). -
- [step 1] Using 3-(trifluoromethyl)pyridin-2-amine (700 mg, 4.32 mmol), and in the same manner as in Reference Example 8A, step 1, 2-cyclopropyl-8-(trifluoromethyl)imidazo[1,2-a]pyridine (710 mg, 73%) was obtained.
ESIMS m/z: 227 (M + H)+; 1H NMR (300 MHz, CDCl3, Ī“): 0.83-0.95 (m, 2H), 0.95-1.07 (m, 2H), 2.05-2.19 (m, 1H), 6.76 (t, J = 6.8 Hz, 1H), 7.35 (s, 1H), 7.40-7.47 (m, 1H), 8.15 (d, J= 6.8 Hz, 1H). - [step 2] Using 2-cyclopropyl-8-(trifluoromethyl)imidazo[1,2-a]pyridine (710 mg, 3.14 mmol) obtained in step 1, and in the same manner as in Reference Example 8A, step 2, 2-cyclopropyl-3-iodo-8-(trifluoromethyl)imidazo[1,2-a]pyridine (1.06 g, 96%) was obtained.
ESIMS m/z: 353 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 0.88-1.27 (m, 4H), 1.95-2.15 (m, 1H), 6.88 (t, J = 6.9 Hz, 1H), 7.49 (d, J = 6.9 Hz, 1H), 8.20 (d, J= 6.9 Hz, 1H). - [step 3] Using 2-cyclopropyl-3-iodo-8-(trifluoromethyl)imidazo[1,2-a]pyridine (480 mg, 1.36 mmol) obtained in step 2 and (E)-2-(3-fluoro-8-formyldibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (200 mg, 0.68 mmol) obtained in Reference Example 5, and in the same manner as in Reference Example 8A, step 3, (E)-2-(8-{[2-cyclopropyl-8-(trifluoromethyl)imidazo[1,2-a]pyridin-3-yl](hydroxy)methyl}-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (356 mg) was obtained quantitatively.
ESIMS m/z: 520 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 0.79-1.09 (m, 4H), 1.65-1.82 (m, 1H), 2.23 (s, 3H), 4.77-4.88 (m, 1H), 5.38-5.50 (m, 1H), 6.41-6.49 (m, 1H), 6.50-6.70 (m, 3H), 6.98-7.07 (m, 1H), 7.36-7.50 (m, 4H), 8.08-8.15 (m, 1H). - [step 4] Using (E)-2-(8-{[2-cyclopropyl-8-(trifluoromethyl)imidazo[1,2-a]pyridin-3-yl](hydroxy)methyl}-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (345 mg, 0.66 mmol) obtained in step 3, and in the same manner as in Reference Example 8A, step 4, the title compound (305 mg, 91%) was obtained.
ESIMS m/z: 504 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 0.96-1.06 (m, 2H), 1.11-1.21 (m, 2H), 1.98-2.09 (m, 1H), 2.23 (s, 3H), 4.29-4.48 (m, 2H), 4.76 (d, J = 12.5 Hz, 1H), 5.41 (d, J = 12.5 Hz, 1H), 6.56 (dd, J = 10.2, 2.6 Hz, 1H), 6.60-6.73 (m, 2H), 6.99-7.06 (m, 1H), 7.06-7.11 (m, 1H), 7.21-7.26 (m, 1H), 7.37-7.44 (m, 2H), 7.70-7.76 (m, 1H). -
- [step 1] Using pyridazin-3-amine (300 mg, 3.15 mmol), and in the same manner as in Reference Example 8A, step 1, 2-cyclopropylimidazo[1,2-b]pyridazine (157 mg, 31%) was obtained.
ESIMS m/z: 160 (M + H)+; 1H NMR (400 MHz, CDCl3, Ī“): 0.95-1.05 (m, 4H), 2.05-2.12 (m, 1H), 6.95 (dd, J = 9.0, 4.0 Hz, 1H), 7.77 (s, 1H), 7.81 (d, J= 9.0 Hz, 1H), 8.21 (d, J = 4.0 Hz, 1H). - [step 2] Using 2-cyclopropylimidazo[1,2-b]pyridazine (120 mg, 0.754 mmol) obtained in step 1, and in the same manner as in Reference Example 8A, step 2, 2-cyclopropyl-3-iodoimidazo[1,2-b]pyridazine (164 mg, 76%) was obtained.
ESIMS m/z: 286 (M + H)+; 1H NMR (300 MHz, CDCl3, Ī“): 1.03-1.17 (m, 4H), 2.09-2.19 (m, 1H), 6.98-7.05 (m, 1H), 7.76 (d, J = 9.2, 2.0 Hz, 1H), 8.35-8.39 (m, 1H). - [step 3] Using 2-cyclopropyl-3-iodoimidazo[1,2-b]pyridazine (164 mg, 0.575 mmol) obtained in step 2, and in the same manner as in Reference Example 8A, step 3, (E)-2-{8-[(2-cyclopropylimidazo[1,2-b]pyridazin-3-yl)(hydroxy)methyl]-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (65 mg, 42%) was obtained.
ESIMS m/z: 453 (M + H)+; 1H NMR (400 MHz, CDCl3. Ī“): 0.94-1.13 (m, 4H), 1.87-2.02 (m, 1H), 2.24 (s, 3H), 4.25 (dd, J = 18.5, 8.8 Hz, 1H), 4.84 (d, J = 12.7, 1H), 5.46 (dd, J = 12.7, 2.9 Hz, 1H), 6.47-6.67 (m, 3H), 6.94-7.05 (m, 2H), 7.40-7.53 (m, 3H), 8.17-8.21(m, 1H). - [step 4] Using (E)-2-{8-[(2-cyclopropylimidazo[1,2-b]pyridazin-3-yl)(hydroxy)methyl]-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (65 mg, 0.144 mmol) obtained in step 3, and in the same manner as in Reference Example 8A, step 4, the title compound (40 mg, 64%) was obtained.
ESIMS m/z: 437 (M + H)+; 1H NMR (300 MHz, CDCl3, Ī“): 0.99-1.08 (m, 2H), 1.09-1.16 (m, 2H), 1.99-2.10 (m, 1H), 2.22 (s, 3H), 4.46 (s, 2H), 4.78 (d, J = 12.5 Hz, 1H), 5.42 (d, J = 12.5 Hz, 1H), 6.51-6.66 (m, 2H), 6.90-7.05 (m, 2H), 7.26-7.28 (m, 1H), 7.31-7.40 (m, 2H), 7.78-7.83 (m, 1H), 8.22 (dd, J = 4.6, 1.6 Hz, 1H). -
- [step 1] 4-Chloropyrimidin-2-amine (200 mg, 1.54 mmol) was dissolved in methanol (2 mL), and the mixture was stirred with heating at 110Ā°C for 1 hr in a microwave synthesizer.
Saturated aqueous sodium hydrogen carbonate solution was added to the mixture, and the mixture was extracted 3 times with chloroform. The combined organic layers were dried over anhydrous magnesium sulfate, and concentration under reduced pressure to give 4-methoxypyrimidin-2-amine (140 mg, 73%).
ESIMS m/z: 126 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 3.88 (s, 3H), 4.96 (br s, 2H), 6.04-6.17 (m, 1H), 7.93-8.10 (m, 1H). - [step 2] Using 4-methoxypyrimidin-2-amine (100 mg, 0.799 mmol) and 1-bromo-3-methylbutan-2-one (158 mg, 0.959 mmol), and in the same manner as in Reference Example 8A, step 1, 2-isopropyl-7-methoxyimidazo[1,2-a]pyrimidine (67 mg, 44%) was obtained.
ESIMS m/z: 192 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 1. 30-1.37 (m, 6H), 2.94-3.10 (m, 1H), 4.01-4.03 (m, 3H), 6.26-6.39 (m, 1H), 7.03 (s, 1H), 8.03-8.09 (m, 1H). - [step 3] Using 2-isopropyl-7-methoxyimidazo[1,2-a]pyrimidine (67 mg, 0.35 mmol) obtained in step 2, and in the same manner as in Reference Example 8A, step 2, 3-iodo-2-isopropyl-7-methoxyimidazo[1,2--a]pyrimidine (66 mg, 59%) was obtained.
ESIMS m/z: 318 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 1.35 (d, J = 7.2 Hz, 6H), 2.85-3.18 (m, 1H), 4.06 (s, 3H), 6.44 (d, J = 7.4 Hz, 1H), 7.99 (d, J = 7.4 Hz, 1H). - [step 4] Using 3-iodo-2-isopropyl-7-methoxyimidazo[1,2-a]pyrimidine (649 mg, 2.05 mmol) obtained in step 3 and (E)-2-(3-fluoro-8-formyldibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (300 mg, 1.02 mmol) obtained in Reference Example 5, and in the same manner as in Reference Example 8A, step 3, (E)-2-{3-fluoro-8-[(hydroxy)(2-isopropyl-7-methoxyimidazo[1,2-a]pyrimidin-3-yl)methyl]dibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (310 mg, 63%) was obtained.
ESIMS m/z: 485 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 1.31-1.47 (m, 6H), 2.24 (s, 3H), 3.05-3.25 (m, 1H), 3.91-4.09 (m, 3H), 4.75-4.88 (m, 1H), 5.35-5.51 (m, 1H), 6.13-6.22 (m, 1H), 6.32-6.41 (m, 1H), 6.49-6.72 (m, 2H), 6.94-7.09 (m, 1H), 7.22-7.55 (m, 3H), 7.83-8.02 (m, 1H). - [step 5] Using (E)-2-{3-fluoro-8-[(hydroxy)(2-isopropyl-7-methoxyimidazo[1,2-a]pyrimidin-3-yl)methyl]dibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (310 mg, 0.64 mmol) obtained in step 4, and in the same manner as in Reference Example 8A, step 4, the title compound (300 mg, 100%) was obtained.
ESIMS m/z: 469 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 1.34-1.53 (m, 6H), 2.23 (s, 3H), 3.00-3.29 (m, 1H), 4.03 (s, 3H), 4.17-4.35 (m, 2H), 4.77 (d, J = 12.8 Hz, 1H), 5.41 (d, J = 12.8 Hz, 1H), 6.26-6.42 (m, 1H), 6.48-6.72 (m, 2H), 6.90-7.12 (m, 2H), 7.14-7.23 (m, 1H), 7.39-7.50 (m, 1H), 7.67-7.80 (m, 1H). -
- [step 1] Using 2-(8-ethynyl-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (1.00 g, 3.46 mmol, E/Z = 1/1) obtained in Reference Example 9 and 2-amino-pyrazine (493 mg, 5.18 mmol), and in the same manner as in Reference Example 8B, the title compound (28 mg, 1.9%) was obtained.
ESIMS m/z: 437 (M + H)+; 1H NMR (300 MHz, CDCl3, Ī“): 1.01-1.20 (m, 4H), 2.00-2.09 (m, 1H), 2.23 (s, 3H), 4.34 (d, J = 17.6 Hz, 1H), 4.42 (d, J = 17.6 Hz, 1H), 4.76 (d, J = 12.8 Hz, 1H), 5.42 (d, J = 12.8 Hz, 1H), 6.52-6.68 (m, 2H), 6.99-7.10 (m, 2H), 7.22 (d, J = 8.1 Hz, 1H), 7.42 (d, J = 8.1 Hz, 1H), 7.57-7.60 (m, 1H), 7.74 (d, J = 4.8 Hz, 1H), 8.95 (d, J = 1.1, 1H). - Using cyclopropanecarboxyaldehyde (0.586 mL, 7.74 mmol), 4-trifluoromethylpyrimidin-2-amine (930 mg, 5.7 mmol) and 2-(8-ethynyl-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (1.5 g, 5.18 mmol) obtained in Reference Example 9, and in the same manner as in Reference Example 8B, the title compound (150 mg, 6%) was obtained.
ESIMS m/z: 505 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 1.02-1.39 (m, 4H), 1.97-2.12 (m, 1H), 2.17-2.29 (m, 3H), 4.30-4.56 (m, 2H), 4.69-5.00 (m, 1H), 5.31-5.55 (m, 1H), 6.46-6.81 (m, 3H), 6.98-7.18 (m, 1H), 7.26-7.62 (m, 3H), 7.97-8.11 (m, 1H). - Using cyclopropanecarboxyaldehyde (0.586 mL, 7.74 mmol), 3-chloropyrazin-2-amine (739 mg, 5.7 mmol) and 2-(8-ethynyl-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (1.5 g, 5.18 mmol) obtained in Reference Example 9, and in the same manner as in Reference Example 8B, 2-{8-[(8-chloro-2-cyclopropylimidazo[1,2-a]pyrazin-3-yl)methyl]-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile was obtained. Successively, the obtained 2-{8-[(8-chloro-2-cyclopropylimidazo[1,2-a]pyrazin-3-yl)methyl]-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile was dissolved in methanol (1 mL), 28% sodium methoxide (0.3 mL, 0.425 mmol) was added, and the mixture was stirred with heating at 60Ā°C. Water was added to the mixture, and the mixture was extracted 3 times with ethyl acetate. The combined organic layers were dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate-1/1 v/v) to give the title compound (25 mg, 1%).
ESIMS m/z: 467 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 0.89-1.05 (m, 2H), 1.11-1.30 (m, 2H), 1.89-2.09 (m, 1H), 2.23 (s, 3H), 4.11 (s, 3H), 4.25-4.40 (m, 2H), 4.76 (d, J = 12.8 Hz, 1H), 5.41 (d, J = 12.8 Hz, 1H), 6.51-6.61 (m, 1H), 6.60-6.71 (m, 1H), 6.96-7.11 (m, 2H), 7.16-7.29 (m, 3H), 7.37-7.47 (m, 1H). -
- [step 1] Using pyrimidin-2-amine (500 mg, 5.26 mmol), and in the same manner as in Reference Example 8A, step 1, 2-cyclopropylimidazo[1,2-a]pyrimidine (294 mg, 35%) was obtained.
ESIMS m/z: 160 (M + H)+; 1H NMR (300 MHz, CDCl3, Ī“): 0.96-1.11 (m, 4H), 1.99-2.08 (m, 1H), 6.78 (dd, J = 6.8, 4.2 Hz, 1H), 7.32 (s, 1H), 8.30 (dd, J= 6.8, 2.0 Hz, 1H), 8.44 (dd, J = 4.2, 2.0 Hz, 1H). - [step 2] Using 2-cyclopropylimidazo[1,2-a]pyrimidine (280 mg, 1.76 mmol) obtained in step 1, and in the same manner as in Reference Example 8A, step 2, 2-cyclopropyl-3-iodoimidazo[1,2-a]pyrimidine (366 mg, 73%) was obtained.
ESIMS m/z: 286 (M + H)+; 1H NMR (300 MHz, CDCl3, Ī“): 1.02-1.09 (m, 2H), 1.21-1.27 (m, 2H), 2.00-2.09 (m, 1H), 6.91 (dd, J = 6.8, 4.0 Hz, 1H), 8.32 (dd, J = 6.8, 2.0 Hz, 1H), 8.42 (dd, J = 4.0, 2.0 Hz, 1H). - [step 3] Using 2-cyclopropyl-3-iodoimidazo[1,2-a]pyrimidine (350 mg, 1.23 mmol) obtained in step 2, and in the same manner as in Reference Example 8A, step 3, (E)-2-{8-[(2-cyclopropylimidazo[1,2-a]pyrimidin-3-yl)(hydroxy)methyl]-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (168 mg, 61%) was obtained.
ESIMS m/z: 453 (M + H)+; 1H NMR (400 MHz, CDCl3, Ī“): 0.55-1.01 (m, 4H), 1.72-1.83 (m, 1H), 2.23 (s, 3H), 4.83 (dd, J = 12.7, 3.9 Hz, 1H), 5.44 (d, J = 12.7, 4.9, 1H), 5.78 (br s, 1H), 6.51-6.68 (m, 4H), 7.03 (d, J = 8.8, 6.8, 1H), 7.40-7.55 (m, 3H), 8.26-8.37 (m, 2H). - [step 4] Using (E)-2-{8-[(2-cyclopropylimidazo[1,2-a]pyrimidin-3-yl)(hydroxy)methyl]3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (147 mg, 0.325 mmol) obtained in step 3, and in the same manner as in Reference Example 8A, step 4, the title compound (118 mg, 83%) was obtained.
ESIMS m/z: 437 (M + H)+; 1H NMR (300 MHz, CDCl3, Ī“): 1.00-1.07 (m, 2Hz, 1.24-1.30 (m, 2H), 1.98-2.06 (m, 1H), 2.24 (s, 3H), 4.32 (d, J = 17.6 Hz, 1H), 4.42 (d, J = 17.6 Hz, 1H), 4.76 (d, J = 12.5 Hz, 1H), 5.41 (d, J = 12.5 Hz, 1H), 6.53-6.73 (m, 3H), 7.00-7.06 (m, 1H), 7.09-7.11 (m, 1H), 7.42 (d, J = 7.4 Hz, 1H), 7.88 (dd, J = 7.4, 2.0 Hz, 1H), 7.74 (d, J = 4.8 Hz, 1H), 8.41 (dd, J = 4.2, 2.0 Hz, 1H). - Using 2-cyclopropyl-2-(8-ethynyl-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)acetonitrile (300 mg, 0.95 mmol) obtained in Reference Example 10, and in the same manner as in Reference Example 8B, the title compound (66 mg, 17%) was obtained.
ESIMS m/z: 496 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 0.86-1.26 (m, 8H), 1.96-2.05 (m, 2H), 4.30-4.42 (m, 2H), 4.73-4.76 (m, 1H), 5.44-5.48 (m, 1H), 6.54-6.67 (m, 4H), 7.06-7.23 (m, 2H), 7.33-7.40 (m, 1H), 7.48-7.55 (m, 2H). - Using 2-cyclopropyl-2-(8-ethynyl-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)acetonitrile (250 mg, 0.793 mmol) obtained in Reference Example 10, and in the same manner as in Reference Example 8B, the title compound (75 mg, 25%) was obtained.
ESIMS m/z: 464 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 0.84-1.06 (m, 4H), 1.39-1.43 (m, 6H), 1.92-2.05 (m, 1H), 3.14-3.22 (m, 1H), 4.29-4.31 (m, 2H), 4.71-4.75 (m, 1H), 5.43-5.49 (m, 1H), 6.53-6.69 (m, 4H), 7.03-7.19 (m, 3H), 7.34-7.39 (m, 1H), 7.60-7.64 (m, 2H). - Using 2-cyclopropyl-2-(8-ethynyl-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)acetonitrile (300 mg, 0.951 mmol) obtained in Reference Example 10, and in the same manner as in Reference Example 8B, the title compound (51 mg, 14%) was obtained.
ESIMS m/z: 462 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 0.69-1.28 (m, 8H), 1.97-2.05 (m, 2H), 4.35-4.37 (m, 2H), 4.74-4.80 (m, 1H), 5.44-5.50 (m, 1H), 6.49-6.69 (m, 3H), 7.06-7.25 (m, 3H), 7.31-7.45 (m, 2H), 7.51-7.55 (m, 1H), 7.61-7.65 (m, 1H). -
- [step 1] Using 3-iodo-2-methoxymethylimidazo[1,2-a]pyridine (700 mg, 2.43 mmol) obtained in Reference Example 8F, step 3 and (E)-2-cyclopropyl-2-(3-fluoro-8-formyldibenzo[b,e]oxepin-11(6H)-ylidene)acetonitrile (388 mg, 1.22 mmol) obtained in Reference Example 7, and in the same manner as in Reference Example 8F, step 4, (E)-2-cyclopropyl-2-{3-fluoro-8-[hydroxy(2-(methoxymethyl)imidazo[1,2-a]pyridin-3-yl)methyl]dibenzo[b,e]oxepin-11(6H)-ylidene}acetonitrile (360 mg, 62%) was obtained.
ESIMS m/z: 482 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 0.89-1.14 (m, 4H), 1.97-2.01 (m, 1H), 3.42 (s, 3H), 4.53-4.72 (m, 2H), 4.79-4.82 (m, 1H), 5.48-5.51 (m, 1H), 6.39-6.71 (m, 4H), 7.15-7.25 (m, 1H), 7.34-7.44 (m, 4H), 7.57-7.59 (m, 1H), 7.92-7.98 (m, 1H). - [step 2] Using (E)-2-cyclopropyl-2-(3-fluoro-8-{hydroxy[2-(methoxymethyl)imidazo[1,2-a]pyridin-3-yl]methyl}dibenzo[b,e]oxepin-11(6H)-ylidene)acetonitrile (114 mg, 0.24 mmol) obtained in step 1, and in the same manner as in Reference Example 8F, step 5, the title compound (75 mg, 68%) was obtained.
ESIMS m/z: 466 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 0.86-1.30 (m, 4H), 1.91-2.00 (m, 1H), 3.47 (s, 3H), 4.31-4.37 (m, 2H), 4.66-4.74 (m, 3H), 5.38-5.46 (m, 1H), 6.529-6.77 (m, 3H), 7.10-7.36 (m, 5H), 7.55-7.69 (m, 2H). -
- [step 1] Using 8-chloro-3-iodo-2-methoxymethylimidazo[1,2-a]pyridine (700 mg, 2.17 mmol) obtained in Reference Example 8K, step 3 and (E)-2-cyclopropyl-2-(3-fluoro-8-formyldibenzo[b,e]oxepin-11(6H)-ylidene)acetonitrile (347 mg, 1.09 mmol) obtained in Reference Example 7, and in the same manner as in Reference Example 8F, step 4, (E)-2-{8-[(8-chloro-2-(methoxymethyl)imidazo[1,2-a]pyridin-3-yl)(hydroxy)methyl]-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene}-2-cyclopropylacetonitrile (470 mg, 84%) was obtained.
ESIMS m/z: 516 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 0.71-1.10 (m, 4H), 1.89-2.05 (m, 1H), 3.39 (s, 3H), 4.55-4.72 (m, 2H), 4.79-4.82 (m, 1H), 5.47-5.54 (m, 1H), 6.41-6.43 (m, 1H), 6.54-6.74 (m, 3H), 7.23-7.25 (m, 2H), 7.34-7.63 (m, 3H), 7.89-8.14 (m, 1H). - [step 2] Using (E)-2-{8-[(8-chloro-2-(methoxymethyl)imidazo[1,2-a]pyridin-3-yl)(hydroxy)methyl]-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene}-2-cyclopropylacetonitrile (269 mg, 0.52 mmol) obtained in step 1, and in the same manner as in Reference Example 8F, step 5, the title compound (39 mg, 15%) was obtained.
ESIMS m/z: 500 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 0.85-1.09 (m, 4H), 1.91-2.05 (m, 1H), 3.45 (s, 3H), 4.31-4.47 (m, 2H), 4.71-4.75 (m, 3H), 5.45 (d, J = 12.8 Hz, 1H), 6.53-6.68 (m, 3H), 7.09-7.10 (m, 1H), 7.20-7.27 (m, 2H), 7.32-7.39 (m, 2H), 7.61-7.64 (m, 1H). -
- [step 1] Using 7-chloro-3-iodo-2-methylimidazo[1,2-a]pyridine (700 mg, 2.39 mmol) obtained in Reference Example 10J, step 2 and (E)-2-cyclopropyl-2-(3-fluoro-8-formyldibenzo[b,e]oxepin-11(6H)-ylidene)acetonitrile (382 mg, 1.20 mmol) obtained in Reference Example 7, and in the same manner as in Reference Example 8F, step 4, (E)-2-{8-[(7-chloro-2-methylimidazo[1,2-a]pyridin-3-yl)(hydroxy)methyl]-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene}-2-cyclopropylacetonitrile (550 mg, 95%) was obtained.
ESIMS m/z: 486 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 0.85-1.04 (m, 4H), 1.92-2.02 (m, 1H), 2.52 (s, 1.5H), 2.57 (s, 1.5H), 4.78-4.84 (m, 1H), 5.45-5.53 (m, 1H),6.38 (br s, 1H), 6.53-6.66 (m, 2H), 6.84-6.85 (m, 1H), 7.27-7.35 (m, 2H), 7.38-7.42 (m, 2H), 7.50-7.53 (m, 1H), 8.10-8.14 (m, 1H). - [step 2] Using (E)-2-{8-[(7-chloro-2-methylimidazo[1,2-a]pyridin-3-yl)(hydroxy)methyl]-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene}-2-cyclopropylacetonitrile (550 mg, 1.13 mmol) obtained in step 1, and in the same manner as in Reference Example 8F, step 5, the title compound (424 mg, 80%) was obtained.
ESIMS m/z: 470 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 0.81-1.08 (m, 4H), 1.94-2.02 (m, 1H), 2.50 (s, 3H), 4.19-4.30 (m, 2H), 4.76 (d, J = 12.7 Hz, 1H), 5.46 (d, J = 12.7 Hz, 1H), 7.00-7.10 (m, 1H), 7.15-7.17 (m, 1H), 7.32-7.40 (m, 2H), 7.52-7.58 (m, 3H), 7.86-8.18 (m, 2H). -
- [step 1] Using 7-chloro-3-iodo-2-methoxymethylimidazo[1,2-a]pyridine (700 mg, 2.17 mmol) obtained in Reference Example 10E, step 3 and (E)-2-cyclopropyl-2-(3-fluoro-8-formyldibenzo[b,e]oxepin-11(6H)-ylidene)acetonitrile (347 mg, 1.09 mmol) obtained in Reference Example 7, and in the same manner as in Reference Example 8F, step 4, (E)-2-{8-[(7-chloro-2-(methoxymethyl)imidazo[1,2-a]pyridin-3-yl)(hydroxy)methyl]-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene}-2-cyclopropylacetonitrile (203 mg, 36%) was obtained.
ESIMS m/z: 516 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 0.84-1.09 (m, 4H), 1.93-2.03 (m, 1H), 3.44-3.51 (m, 3H), 4.69-5.01 (m, 3H), 5.43-5.52 (m, 1H), 6.52-6.66 (m, 3H), 6.99-7.02 (m, 1H), 7.30-7.64 (m, 4H), 7.83-7.93 (m, 1H), 8.27-8.30 (m, 1H). - [step 2] Using (E)-2-(8-{[7-chloro-2-(methoxymethyl)imidazo[1,2-a]pyridin-3-yl](hydroxy)methyl}-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)-2-cyclopropylacetonitrile (200 mg, 0.39 mmol) obtained in step 1, and in the same manner as in Reference Example 8F, step 5, the title compound (81 mg, 42%) was obtained.
ESIMS m/z: 500 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 0.86-1.08 (m, 4H), 1.93-2.02 (m, 1H), 3.52 (s, 3H), 4.07-4.13 (m, 2H), 4.28-4.50 (m, 2H), 4.70-4.77 (m, 1H), 5.41-5.47 (m, 1H), 6.52-6.67 (m, 2H), 6.98-7.16 (m, 2H), 7.28-7.44 (m, 3H), 7.80-7.88 (m, 1H), 8.31-8.32 (m, 1H). -
- [step 1] Using 3-iodo-2-(methoxy-d3-methyl)imidazo[1,2-a]pyridine (700 mg, 2.41 mmol) obtained in Reference Example 8G, step 2 and (E)-2-cyclopropyl-2-(3-fluoro-8-formyldibenzo[b,e]oxepin-11(6H)-ylidene)acetonitrile (384 mg, 1.20 mmol) obtained in Reference Example 7, and in the same manner as in Reference Example 8F, step 4, (E)- 2-cyclopropyl-2-(8-hydroxy{[2-(methoxy-d3methyl)imidazo[1,2-a]pyridin-3-yl]methyl}-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)acetonitrile (580 mg, 99%) was obtained.
ESIMS m/z: 485 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 0.86-1.08 (m, 4H), 1.95-2.04 (m, 1H), 4.45-4.67 (m, 2H), 4.72-4.82 (m, 1H), 5.47-5.51 (m, 1H), 6.38-6.41 (m, 1H), 6.53-6.70 (m, 2H), 6.75-6.79 (m, 1H), 7.13-7.17 (m, 1H), 7.34-7.47 (m, 2H), 7.53-7.59 (m, 2H), 7.95-8.00 (m, 2H). - [step 2] Using (E)-2-cyclopropyl-2-(8-hydroxy{[2-(methoxy-d3 methyl)imidazo[1,2-a]pyridin-3-yl]methyl}-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)acetonitrile (200 mg, 0.39 mmol) obtained in step 1, and in the same manner as in Reference Example 8F, step 5, the title compound (81 mg, 42%) was obtained.
ESIMS m/z:469 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 0.83-1.26 (m, 4H), 1.93-2.05 (m, 1H), 4.31-4.42 (m, 2H), 4.65-4.79 (m, 3H), 5.44-5.47 (m, 1H), 6.53-6.57 (m, 3H), 7.10-7.17 (m, 3H), 7.33-7.38 (m, 2H), 7.59-7.69 (m, 2H). - Commercially available 2-methyl-1H-indole (100 mg, 0.76 mmol) and (E)-2-(3-fluoro-8-formyldibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (246 mg, 0.84 mmol) obtained in Reference Example 5 were dissolved in methylene chloride (3.8 mL), TFA (88 mL, 1.1 mmol), and triethylsilane (365 mL, 2.29 mmol) were added at 0Ā°C, and the mixture was stirred at room temperature overnight. The reaction mixture was adjusted to pH = 8 with 2 mol/L sodium hydroxide solution, extracted with chloroform, and the extract was dried over sodium sulfate and filtered. The filtrate was concentrated under reduced pressure and the obtained residue was purified by silica gel column chromatography (hexane/ethyl acetate = 1/1 v/v) to give the target compound (107 mg, 34%).
ESIMS m/z: 409 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 2.22 (s, 3H), 2.38 (s, 3H), 4.08 (s, 2H), 4.75 (d, J = 12.7 Hz, 1H), 5.40 (d, J = 12.7 Hz, 1H), 6.52-6.55 (m, 1H), 6.59-6.64 (m, 1H), 6.99-7.05 (m, 2H), 7.09-7.16 (m, 2H), 7.21-7.39 (m, 4H), 7.83 (br s, 1H). -
- [step 1] Commercially available 2-nitrophenol (1.0 g, 7.2 mmol) was dissolved in methylene chloride (36 mL), and the solution was cooled to 0Ā°C. Triethylamine (1.2 mL, 8.6 mmol) and trifluoromethanesulfonic anhydride (1.2 mL, 8.6 mmol) were added, and the mixture was stirred at 0Ā°C for 30 min. The reaction was discontinued with aqueous saturated ammonium chloride, and the mixture was extracted with chloroform, and the extract was dried over sodium sulfate. Filtration and concentration under reduced pressure gave 2-nitrophenyl trifluoromethanesulfonate (1.71 g, 88%).
ESIMS m/z: 272 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 7.39-7.52 (m, 1H), 7.58-7.62 (m, 1H), 7.75-7.79 (m, 1H), 8.17-8.20 (m, 1H). - [step 2] Using 2-nitrophenyl trifluoromethanesulfonate (3.0 g, 11 mmol) obtained in step 1 and 1-pentyne (2.15 mL, 22 mmol), and in the same manner as in Reference Example 10, step 1, 1-nitro-2-(pent-1-ynyl)benzene (2.01 g, 96%) was obtained.
ESIMS m/z: 190 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 1.08 (t, J = 7.4 Hz, 3H), 1.60-1.74 (m, 2H), 2.46 (t, J = 7.2 Hz, 2H), 7.36-7.42 (m, 1H), 7.49-7.60 (m, 2H), 7.95-7.98 (m, 1H). - [step 3] 1-Nitro-2-(pent-1-ynyl)benzene (1.0 g, 5.3 mmol) obtained in step 2 was dissolved in pyrrolidine (8.68 mL, 106 mmol), and the mixture was stirred at room temperature for 2 hr. The mixture was cooled to 0Ā°C, and the reaction was discontinued with 1 mmol/L hydrochloric acid. The reaction mixture was extracted with chloroform, the extract was dried over sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give 1-(2-nitrophenyl)pentan-2-one (0.61 g, 56%).
ESIMS m/z: 208 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 0.96 (t, J = 7.3 Hz, 3H), 1.64-1.72 (m, 2H), 2.59 (t, J = 7.3 Hz, 2H), 4.10 (s, 2H), 7.26-7.30 (m, 1H), 7.44-7.47 (m, 1H), 7.57-7.61 (m, 1H), 8.11 (d, J = 9.8 Hz, 1H). - [step 4] 1-(2-Nitrophenyl)pentan-2-one (0.31 g, 1.5 mmol) obtained in step 3 was dissolved in ethanol (3.0 mL), 10% palladium carbon (0.032 mg, 0.30 mmol) was added, and the mixture was stirred at room temperature overnight under a hydrogen atmosphere. The reaction solution was filtered through celite, and the filtrate was concentrated under reduced pressure. The obtained reaction residue was purified by silica gel column chromatography (hexane/ethyl acetate = 10/1 v/v) to give 2-propyl-1H-indole (100 mg, 42%).
ESIMS m/z: 160 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 1.03 (t, J = 7.3 Hz, 3H), 1.71-1.80 (m, 2H), 2.74 (t, J = 7.3 Hz, 2H), 6.21 (br s, 1H), 7.04-7.12 (m, 2H), 7.30 (d, J = 7.8 Hz, 1H), 7.52 (d, J= 7.8 Hz, 1H), 7.86 (br s, 1H). - [step 5] Using 2-propyl-1H-indole (100 mg, 0.64 mmol) obtained in step 4 and (E)-2-(3-fluoro-8-formyldibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (153 mg, 0.52 mmol) obtained in Reference Example 5, and in the same manner as in Reference Example 13A, the target compound (125 mg, 55%) was obtained.
ESIMS m/z: 437 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 0.94 (t, J = 7.5 Hz, 3H), 1.61-1.70 (m, 2H), 2.22 (s, 3H), 2.69-2.72 (m, 2H), 4.09 (s, 2H), 4.74 (d, J = 12.7 Hz, 1H), 5.40 (d, J = 12.7 Hz, 1H), 6.52-6.55 (m, 1H), 6.59-6.64 (m, 1H), 6.99-7.04 (m, 2H), 7.06-7.10 (m, 2H), 7.23-7.37 (m, 4H), 7.85 (br s, 1H). -
- [step 1] 2-Isopropyl-1H-imidazole (600 mg, 5.45 mmol) was dissolved in 1,4-dioxane (6 mL)-2-methoxyethanol (6 mL), N-chlorosuccinimide (1.0 g, 7.51 mmol) was added, and the mixture was heated at room temperature for 30 min. N-chlorosuccinimide (450 mg, 3.38 mmol) was further added, and the mixture was stirred at room temperature for 1 hr. Water was added to the mixture, and the precipitated crystals were collected by suction filtration to give 4,5-dichloro-2-isopropyl-1H-imidazole (477 mg, 49%).
ESIMS m/z: 179 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 1.32 (d, J = 7.2 Hz, 6H), 2.89-3.11 (m, 1H). - [step 2] Using 4,5-dichloro-2-isopropyl-1H-imidazole (68 mg, 0.381 mmol) obtained in step 1 and (E)-2-[8-(bromomethyl)-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene]propanenitrile (130 mg, 0.363 mmol) obtained in Reference Example 1, and in the same manner as in Reference Example 1A, the title compound (150 mg, 91%) was obtained.
ESIMS m/z: 456 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 1.12-1.31 (m, 6H), 2.24 (s, 3H), 2.77-2.93 (m, 1H), 4.80 (d, J = 12.8 Hz, 1H), 5.06-5.17 (m, 2H), 5.43 (d, J = 12.8 Hz, 1H), 6.48-6.74 (m, 2H), 6.94-7.17 (m, 3H), 7.40-7.53 (m, 1H). -
- [step 1] 3,4-Diaminothiophene dihydrochloride (300 mg, 1.60 mmol) was suspended in ethanol (12 mL), triethylamine (0.45 mL, 3.21 mmol) and ethyl 2-methoxyacetimidate monohydrochloride (Journal of Medicinal Chemistry, 1991, vol. 34, p2468; 906 mg, 4.01 mmol) were added, and the mixture was stirred at room temperature for 70 hr. To the mixture was added saturated aqueous sodium hydrogen carbonate, and the mixture was extracted 3 times with chloroform. The combined organic layers were dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate = 100/0 v/v - 0/100 v/v) to give 2-(methoxymethyl)-1H-thieno[3,4-d]imidazole (156 mg, 58%).
ESIMS m/z: 169 (M + H)+; 1H NMR (300 MHz, CDCl3, Ī“): 3.49 (s, 3H), 4.64 (s, 2H), 6.33-7.16 (m, 2H), 8.89 (br s, 1H). - [step 2] Using 2-(methoxymethyl)-1H-thieno[3,4-d]imidazole (65 mg, 0.39 mmol) obtained in step 1 and (E)-2-[8-(bromomethyl)-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene]propanenitrile (141 mg, 0.39 mmol) obtained in Reference Example 1, and in the same manner as in Reference Example 1A, the title compound (167 mg, 97%) was obtained.
ESIMS m/z: 446 (M + H)+; 1H NMR (300 MHz, CDCl3, Ī“): 2.24 (s, 3H), 3.39 (s, 3H), 4.60 (s, 2H), 4.79 (d, J = 12.8 Hz, 1H), 5.19-5.35 (m, 2H), 5.43 (d, J = 12.8 Hz, 1H), 6.32 (d, J = 2.6 Hz, 1H), 6.57 (dd, J = 10.3, 2.6 Hz, 1H), 6.61-6.69 (m, 1H), 7.04 (dd, J = 8.8, 6.6 Hz, 1H), 7.10 (d, J = 2.6 Hz, 1H), 7.17-7.22 (m, 1H), 7.27-7.33 (m, 1H), 7.45 (d, J = 7.7 Hz, 1H). -
- [step 1] 3,4-Diaminothiophene dihydrochloride (300 mg, 1.60 mmol) was suspended in ethanol (12 mL), triethylamine (0.45 mL, 3.21 mmol) and ethyl cyclopropanecarboimidate monohydrochloride (
WO200970485
ESIMS m/z: 165 (M + H)+; 1H NMR (300 MHz, DMSO-d6, Ī“): 0.94-1.08 (m, 4H), 1.87-2.00 (m, 1H), 6.61-6.91 (m, 2H), 11.46 (br s, 1H). - [step 2] Using 2-cyclopropyl-1H-thieno[3,4-d]imidazole (65 mg, 0.40 mmol) obtained in step 1 and (E)-2-[8-(bromomethyl)-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene]propanenitrile (145 mg, 0.40 mmol) obtained in Reference Example 1, and in the same manner as in Reference Example 1A, the title compound (166 mg, 95%) was obtained.
ESIMS m/z: 442 (M + H)+; 1H NMR (300 MHz, CDCl3, Ī“): 1.00-1.09 (m, 2H), 1.18-1.26 (m, 2H), 1.73-1.84 (m, 1H), 2.25 (s, 3H), 4.80 (d, J = 12.8 Hz, 1H), 5.19-5.35 (m, 2H), 5.43 (d, J = 12.8 Hz, 1H), 6.29 (d, J = 2.6 Hz, 1H), 6.57 (dd, J= 9.9, 2. 6 Hz, 1H), 6.61-6.69 (m, 1H), 6.94 (d, J = 2.6 Hz, 1H), 7.04 (d, J = 8.8, 6.6 Hz, 1H), 7.16-7.19 (m, 1H), 7.27-7.32 (m, 1H), 7.47 (d, J = 8.1 Hz, 1H). - Using 2-ethyl-4-phenyl-1H-imidazole (Tetrahedron Letters, 1967, p265, 47 mg, 0.273 mmol) and (E)-2-[8-(bromomethyl)-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene]propanenitrile (90 mg, 0.273 mmol) obtained in Reference Example 1, and in the same manner as in Reference Example 1A, the title compound (114 mg, 92%) was obtained.
ESIMS m/z: 450 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 1.32 (t, J = 7.6 Hz, 3H), 2.24 (s, 3H), 2.70 (q, J = 7.6 Hz, 2H), 4.79 (d, J = 12.8 Hz, 1H), 5.14 (s, 2H), 5.43 (d, J = 12.8 Hz, 1H), 6.52-6.61 (m, 1H), 6.61-6.73 (m, 1H), 7.00-7.10 (m, 2H), 7.11 (s, 1H), 7.14-7.30 (m, 2H), 7.30-7.39 (m, 2H), 7.38-7.51 (m, 1H), 7.73-7.80 (m, 2H). -
- [step 1] Ethyl 3-oxohexanoate (883 mg, 5,58 mmol) was dissolved in THF (9 mL), sodium hydride (60% w/w, 190 mg, 4.75 mmol) was added, and the mixture was stirred at room temperature for 30 min. To the mixture was added dropwise a solution (9 mL) of (E)-2-[8-(bromomethyl)-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene]propanenitrile (1.0 g, 2.79 mmol) obtained in Reference Example 1 in tetrahydrofuran, and the mixture was stirred at room temperature overnight. Water was added to the mixture, and the mixture was extracted 3 times with ethyl acetate. The combined organic layers were dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate = 4/1 v/v) to give (E)-ethyl 2-{[11-(1-cyanoethylidene)-3-fluoro-6,11-dihydrodibenzo[b,e]oxepin-8-yl]methyl}-3-oxohexanoate (1.19 g, 98%).
ESIMS m/z: 436 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 0.75-0.89 (m, 3H), 1.18 (t, J = 7.2 Hz, 3H), 1.49-1.62 (m, 2H), 2.16-2.43 (m, 4H), 2.43-2.62 (m, 1H), 3.11-3.22 (m, 2H), 3.70-3.82 (m, 1H), 4.13 (q, J = 7.2 Hz, 2H), 4.80 (d, J = 12.8 Hz, 1H), 5.44 (d, J = 12.8 Hz, 1H), 6.54-6.69 (m, 2H), 6.96-7.08 (m, 1H), 7.17-7.27 (m, 2H), 7.33-7.45 (m, 1H). - [step 2] (E)-ethyl 2-{[11-(1-cyanoethylidene)-3-fluoro-6,11-dihydrodibenzo[b,e]oxepin-8-yl]methyl}-3-oxohexanoate (1.18 g, 2.71 mmol) obtained in step 1 was dissolved in methanol (14 mL), acetimidamide hydrochloride (640 mg, 6.77 mmol) and 28% sodium methoxide methanol solution (1.83 mL, 9.48 mmol) were added, and the mixture was stirred at room temperature for 2 hr. The mixture was concentrated under reduced pressure, methanol was added to the obtained residue, and the precipitated crystals were collected by suction filtration to give (E)-2-{3-fluoro-8-[(2-methyl-6-oxo-4-propyl-1,6-dihydropyrimidin-5-yl)methyl]dibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (960 mg, 82%).
ESIMS m/z: 430 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 0.83-0.98 (m, 3H), 1.43-1.76 (m, 2H), 2.21 (s, 3H), 2.28-2.42 (m, 3H), 2.50-2.59 (m, 2H), 3.90 (s, 2H), 4.81 (d, J = 12.8 Hz, 1H), 5.40 (d, J = 12.8 Hz, 1H), 6.44-6.70 (m, 2H), 6.95-7.12 (m, 1H), 7.23-7.44 (m, 3H), 12.92 (s, 1H). - [step 3] (E)-2-{3-fluoro-8-[(2-methyl-6-oxo-4-propyl-1,6-dihydropyrimidin-5-yl)methyl]dibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (960 mg, 2.23 mmol) obtained in step 2 was dissolved in phosphorus oxychloride (2.5 mL, 26.8 mmol), and the mixture was stirred at 100Ā°C for 2 hr. The mixture was concentrated under reduced pressure, and the obtained residue was purified by silica gel column chromatography (hexane/ethyl acetate = 1/1 v/v) to give (E)-2-{8-[(4-chloro-2-methyl-6-propylpyrimidin-5-yl)methyl]-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (970 mg, 97%).
ESIMS m/z: 448 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 0.74-0.98 (m, 3H), 1.48-1.77 (m, 2H), 2.24 (s, 3H), 2.59-2.72 (m, 5H), 4.03-4.25 (m, 2H), 4.77 (d, J = 12.8 Hz, 1H), 5.42 (d, J = 12.8 Hz, 1H), 6.51-6.70 (m, 2H), 6.94-7.10 (m, 2H), 7.13-7.20 (m, 1H), 7.38-7.47 (m, 1H). - [step 4] (E)-2-{8-[(4-chloro-2-methyl-6-propylpyrimidin-5-yl)methyl]-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (140 mg, 3.13 mmol) obtained in step 3 was dissolved in ethanol (3 mL), azetidine (0.148 mL, 2.19 mmol) was added, and the mixture was stirred with heating at 50Ā°C for 2 hr. The mixture was concentrated under reduced pressure, and the obtained residue was purified by silica gel column chromatography (hexane/ethyl acetate = 1/2 v/v) to give the title compound (145 mg, 99%).
ESIMS m/z: 469 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 0.77-0.97 (m, 3H), 1.49-1.76 (m, 2H), 2.11-2.30 (m, 5H), 2.38-2.58 (m, 5H), 3.79-4.00 (m, 2H), 4.02-4.18 (m, 4H), 4.78 (d, J= 12.8 Hz, 1H), 5.42 (d, J = 12.8 Hz, 1H), 6.51-6.61 (m, 1H), 6.61-6.72 (m, 1H), 6.97-7.10 (m, 2H), 7.10-7.20 (m, 1H), 7.34-7.46 (m, 1H). -
- [step 1] Using methyl 4-methoxy-3-oxobutanoate (816 mg, 5.58 mmol) and (E)-2-[8-(bromomethyl)-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene]propanenitrile (1.0 g, 2.79 mmol) obtained in Reference Example 1, and in the same manner as in Reference Example 13G, step 1, (E)-methyl 2-{[11-(1-cyanoethylidene)-3-fluoro-6,11-dihydrodibenzo[b,e]oxepin-8-yl]methyl}-4-methoxy-3-oxobutanoate (977 mg, 83%) was obtained.
ESIMS m/z: 424 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 2.27 (s, 3H), 3.04-3.43 (m, 5H), 3.71 (s, 3H), 3.83-4.15 (m, 3H), 4.83 (d, J = 12.8 Hz, 1H), 5.43 (d, J = 12.8 Hz, 1H), 6.40-6.72 (m, 2H), 6.97-7.12 (m, 1H), 7.17-7.48 (m, 3H). - [step 2] Using (E)-methyl 2-{[11-(1-cyanoethylidene)-3-fluoro-6,11-dihydrodibenzo[b,e]oxepin-8-yl]methyl}-4-methoxy-3-oxobutanoate (977 mg, 2.31 mmol) obtained in step 1, and in the same manner as in Reference Example 13G, step 2, (E)-2-(3-fluoro-8-{[4-(methoxymethyl)-2-methyl-6-oxo-1,6-dihydropyrimidin-5-yl]methyl}dibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (926 mg, 93%) was obtained.
ESIMS m/z: 432 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 2.22 (s, 3H), 2.42 (s, 3H), 3.42 (s, 3H), 3.93 (s, 2H), 4.35 (s, 2H), 4.78 (d, J = 12.8 Hz, 1H), 5.42 (d, J = 12.8 Hz, 1H), 6.46-6.71 (m, 2H), 6.93-7.07 (m, 1H), 7.18-7.45 (m, 3H), 12.66 (s, 1H). - [step 3] Using (E)-2-(3-fluoro-8-{[4-(methoxymethyl)-2-methyl-6-oxo-1,6-dihydropyrimidin-5-yl]methyl}dibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (924 mg, 2.14 mmol) obtained in step 2, and in the same manner as in Reference Example 13G, step 3, (E)-2-(8-{[4-chloro-6-(methoxymethyl)-2-methylpyrimidin-5-yl]methyl}-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (487 mg, 51%) was obtained.
ESIMS m/z: 450 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 2.19-2.27 (m, 3H), 2.73 (s, 3H), 3.38 (s, 3H), 4.25 (s, 2H), 4.45 (s, 2H), 4.78 (d, J = 12.8 Hz, 1H), 5.42 (d, J = 12.8 Hz, 1H), 6.53-6.59 (m, 1H), 6.60-6.67 (m, 1H), 6.99-7.05 (m, 1H), 7.06-7.09 (m, 1H), 7.15-7.20 (m, 1H), 7.32-7.42 (m, 1H). - [step 4] Using (E)-2-(8-{[4-chloro-6-(methoxymethyl)-2-methylpyrimidin-5-yl]methyl}-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (164 mg, 0.365 mmol) obtained in step 3 and 2 mol/L dimethylamine methanol solution (1.28 mL, 2.55 mmol), and in the same manner as in Reference Example 13G, step 4, the title compound (96 mg, 56%) was obtained.
ESIMS m/z: 459 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 2.24 (s, 3H), 2.57 (s, 3H), 2.92 (s, 6H), 3.30 (s, 3H), 4.13 (s, 2H), 4.23 (s, 2H), 4.77 (d, J = 12.8 Hz, 1H), 5.43 (d, J= 12.8 Hz, 1H), 6.54-6.60 (m, 1H), 6.61-6.69 (m, 1H), 6.98-7.08 (m, 2H), 7.12-7.19 (m, 1H), 7.36-7.41 (m, 1H). -
- [step 1] 3-Methylpyrazin-2-amine (16 g, 147 mmol) was dissolved in 1,2-dimethoxyethane (122 mL) and THF (61 mL), 2-promo-1-cyclopropylethanone (36 g, 220 mmol) was added, and the mixture was stirred at room temperature for 70 hr. Saturated aqueous sodium hydrogen carbonate solution was added to the mixture, and the mixture was extracted 3 times with chloroform. The combined organic layers were dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform/methanol = 100/0 v/v - 85/15 v/v) to give 2-cyclopropyl-8-methylimidazo[1,2-a]pyrazine (11 g, 43%).
ESIMS m/z: 174 (M + H)+; 1H NMR (300 MHz, CDCl3, Ī“): 0.87-0.95 (m, 2H), 0.96-1.08 (m, 2H), 2.04-2.17 (m, 1H), 2.84 (s, 3H), 7.34 (s, 1H), 7.67 (d, J = 4.4 Hz, 1H), 7.82 (d, J= 4.4 Hz, 1H). - [step 2] Using 2-cyclopropyl-8-methylimidazo[1,2-a]pyrazine (11 g, 66 mmol) obtained in step 1, and in the same manner as in Reference Example 8A, step 2, 2-cyclopropyl-3-iodo-8-methylimidazo[1,2-a]pyrazine (17 g, 85%) was obtained.
ESIMS m/z: 300 (M + H)+; 1H NMR (300 MHz, CDCl3, Ī“): 1.00-1.18 (m, 4H), 2.02-2.14 (m, 1H), 2.82 (s, 3H), 7.79 (d, J = 4.8 Hz, 1H), 7.84 (d, J = 4.8 Hz, 1H). - [step 3] 2-Cyclopropyl-3-iodo-8-methylimidazo[1,2-a]pyrazine (14 g, 45 mmol) obtained in step 2 was suspended in THF (100 mL), and the suspension was cooled to -20Ā±10Ā°C in a dry ice-acetone bath. A 1.3 mol/L isopropylmagnesium chloride lithium chloride complex THF solution (39 mL, 51 mmol) was added dropwise, and the mixture was stirred at -10Ā±10Ā°C for 1 hr. A solution (40 mL) of (E)-2-(3-fluoro-8-formyldibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (8.3 g, 28 mmol) obtained in Reference Example 5 in THF was added, and the mixture was stirred at -10Ā±10Ā°C for 1.5 hr. To the mixture was added aqueous ammonium chloride solution, and the mixture was extracted 3 times with ethyl acetate. The combined organic layers were dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform/methanol = 100/0 v/v - 85/15 v/v) to give (E)-2-{8-[(2-cyclopropyl-8-methylimidazo[1,2-a]pyrazin-3-yl)(hydroxy)methyl]-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (21 g, quantitative).
ESIMS m/z: 467 (M + H)+; 1H NMR (400 MHz, CDCl3, Ī“): 0.86-1.06 (m, 3H), 1.16-1.27 (m, 1H), 1.75-1.92 (m, 1H), 2.23 (s, 3H), 2.72-2.81 (m, 3H), 3.76-3.93 (m, 1H), 4.75-4.89 (m, 1H), 5.45 (d, J = 12.7 Hz, 1H), 6.42 (d, J = 9.8 Hz, 1H), 6.50-6.61 (m, 1H), 6.61-6.68 (m, 1H), 7.03 (dd, J = 8.8, 6.8 Hz, 1H), 7.30-7.37 (m, 1H), 7.39-7.53 (m, 3H), 7.72-7.29 (m, 1H). - [step 4] (E)-2-{8-[(2-cyclopropyl-8-methylimidazo[1,2-a]pyrazin-3-yl)(hydroxy)methyl]-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (18 g, 39 mmol) obtained in step 3 was dissolved in trifluoroacetic acid (181 mL, 2.3 mol), triethylsilane (31 mL, 0.19 mol) was added, and the mixture was stirred with heating at 60Ā°C for 1 hr. The mixture was concentrated under reduced pressure, saturated aqueous sodium hydrogen carbonate solution (100 mL) was added to the obtained residue, and the mixture was extracted 3 times with a mixed solvent of chloroform-methanol. The combined organic layers were dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. To the obtained residue was added isopropylalcohol (133 mL), and the mixture was stirred at room temperature for 4 hr and further for 1 hr under ice-cooling. The precipitated crystals were collected by suction filtration to give the title compound (13 g, 72%).
ESIMS m/z: 451 (M + H)+; 1H NMR (300 MHz, CDCl3, Ī“): 0.97-1.08 (m, 2H), 1.08-1.18 (m, 2H), 1.97-2.09 (m, 1H), 2.23 (s, 3H), 2.83 (s, 3H), 4.27-4.44 (m, 2H), 4.75 (d, J = 12.8 Hz, 1H), 5.41 (d, J = 12.8 Hz, 1H), 6.55 (dd, J = 9.9, 2.6 Hz, 1H), 6.60-6.68 (m, 1H), 7.03 (dd, J = 8.6, 6.4 Hz, 1H), 7.05-7.09 (m, 1H), 7.18-7.24 (m, 1H), 7.41 (d, J = 7.7 Hz, 1H), 7.46 (d, J = 4.8 Hz, 1H), 7.61 (d, J = 4.8 Hz, 1H). -
- [step 1] 4-Bromopyridin-2-amine (10 g, 58 mmol) was dissolved in ethanol (58 mL), 2-bromo-1-cyclopropylethanone (14 g, 87 mmol) was added, and the mixture was heated under reflux for 5.5 hr. To the mixture was added saturated aqueous sodium hydrogen carbonate, and the mixture was extracted twice with ethyl acetate. The combined organic layers were dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (heptane/ethyl acetate = 100/0 v/v - 10/90 v/v) to give 7-bromo-2-cyclopropylimidazo[1,2-a]pyridine (5.6 g, 41%).
ESIMS m/z: 237 (M + H)+; 1H NMR (300 MHz, CDCl3,Ī“): 0.87-1.02 (m, 4H), 1.94-2.06 (m, 1H), 6.81 (dd, J= 7.1, 2.0 Hz, 1H), 7.32 (s, 1H), 7.67 (d, J = 2.0 Hz, 1H), 7.86 (d, J= 7.1 Hz, 1H). - [step 2] Using 7-bromo-2-cyclopropylimidazo[1,2-a]pyridine (3.1 g, 13 mmol) obtained in step 1, and in the same manner as in Reference Example 8A, step 2, 7-bromo-2-cyclopropyl-3-iodoimidazo[1,2-a]pyridine (4.6 g, 95%) was obtained.
ESIMS m/z: 363 (M + H)+; 1H NMR (400 MHz, CDCl3,Ī“): 0.96-1.14 (m, 4H), 1.96-2.07 (m, 1H), 6.94 (dd, J= 6.8, 2.0 Hz, 1H), 7.64 (s, 1H), 7.91 (d, J = 6.8 Hz, 1H). - [step 3] Using 7-bromo-2-cyclopropyl-3-iodoimidazo[1,2-a]pyridine (4.6 g, 13 mmol) obtained in step 2 and (E)-2-(3-fluoro-8-formyldibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (2.3 g, 7.9 mmol) obtained in Reference Example 5, and in the same manner as in Reference Example 14A, step 3, (E)-2-{8-[(7-bromo-2-cyclopropylimidazo[1,2-a]pyridin-3-yl)(hydroxy)methyl]-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (4.1 g, 98%) was obtained.
ESIMS m/z: 530 (M + H)+; 1H NMR (400 MHz, DMSO-d6,Ī“): 0.78-1.00 (m, 4H), 2.05-2.19 (m, 1H), 2.16 (s, 3H), 4.97-5.07 (m, 1H), 5.48 (d, J = 12.7 Hz, 1H), 6.40-6.51 (m, 2H), 6.66-6.76 (m, 1H), 6.78-6.86 (m, 1H), 6.88-6.95 (m, 1H), 7.22-7.32 (m, 1H), 7.34-7.52 (m, 2H), 7.53-7.67 (m, 1H), 7.69-7.78 (m, 1H), 8.14 (d, J= 7.8 Hz, 1H). - [step 4] Using (E)-2-{8-[(7-bromo-2-cyclopropylimidazo[1,2-a]pyridin-3-yl)(hydroxy)methyl]-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (4.1 g, 7.7 mmol) obtained in step 3, and in the same manner as in Reference Example 14A, step 4, (E)-2-{8-[(7-bromo-2-cyclopropylimidazo[1,2-a]pyridin-3-yl)methyl]-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (3.3 g, 83%) was obtained.
ESIMS m/z: 514 (M + H)+; 1H NMR (400 MHz, DMSO-d6,Ī“): 0.89-0.98 (m, 4H), 2.13-2.21 (m, 1H), 2.16 (s, 3H), 4.39-4.52 (m, 2H), 4.94 (d, J = 12.7 Hz, 1H), 5.45 (d, J= 12.7 Hz, 1H), 6.67-6.73 (m, 1H), 6.77-6.85 (m, 1H), 6.92-6.98 (m, 1H), 7.21-7.30 (m, 2H), 7.34-7.40 (m, 2H), 7.74 (s, 1H), 8.10 (d, J = 6.8 Hz, 1H). - [step 5] (E)-2-{8-[(7-bromo-2-cyclopropylimidazo[1,2-a]pyridin-3-yl)methyl]-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (2.5 g, 4.8 mmol) obtained in step 4 was dissolved in DMF (26 mL), water (6.8 mL), 1,3-bis(diphenylphosphino)propane (0.60 g, 1.5 mmol), potassium carbonate (0.80 g, 5.8 mmol) and palladium acetate (0.33 g, 1.5 mmol) were added. After purging 3 times with carbon monoxide under reduced pressure, the mixture was stirred with heating at 80Ā°C for 7 hr. The reaction mixture was filtered through celite, activated carbon (0.75 g) was added to the obtained filtrate, and the mixture was stirred with heating at 60Ā°C for 1.5 hr. The mixture was filtered again through celite, 2 mol/L hydrochloric acid was added to the filtrate, and the mixture was extracted 3 times with a mixed solvent of chloroform-methanol. The combined organic layers were washed 3 times with water, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. To the obtained residue were added isopropylalcohol (25 mL) and ethanol (20 mL), and the mixture was stirred at 80Ā°C for 1 hr and further at room temperature for 1 hr. The precipitated crystals were collected by suction filtration to give (E)-3-{[11(6H)-(1-cyanoethylidene)-3-fluorodibenzo[b,e]oxepin-8-yl]methyl}-2-cyclopropylimidazo[1,2-a]pyridine-7-carboxylic acid (2.4 g, quantitative).
ESIMS m/z: 480 (M + H)+; 1H NMR (300 MHz, DMSO-d6,Ī“): 0.90-1.01 (m, 4H), 2.15 (s, 3H), 2.17-2.29 (m, 1H), 4.48-4.55 (m, 2H), 4.94 (d, J = 12.7 Hz, 1H), 5.45 (d, J = 12.7 Hz, 1H), 6.69 (dd, J = 10.6, 2.6 Hz, 1H), 6.76-6.85 (m, 1H), 7.18-7.30 (m, 3H), 7.33-7.41 (m, 2H), 7.97 (s, 1H), 8.24 (d, J= 7.1 Hz, 1H). - [step 6] (E)-3-{[11(6H)-(1-cyanoethylidene)-3-fluorodibenzo[b,e]oxepin-8-yl]methyl}-2-cyclopropylimidazo[1,2-a]pyridine-7-carboxylic acid (2.4 g, 5.1 mmol) obtained in step 5 was suspended in THF (25 mL), 1,1'-carbonyldiimidazole (4.1 g, 25 mmol) was added, and the mixture was stirred with heating at 60Ā°C for 1.5 hr. To the reaction mixture was added 25% aqueous ammonia solution (4.4 mL, 51 mmol), and the mixture was stirred at room temperature for 15 min. To the mixture was added 2 mol/L hydrochloric acid, and the mixture was stirred at room temperature for 1.5 hr. The precipitated crystals were collected by suction filtration, and dried at 50Ā°C under reduced pressure. The obtained residue was purified by silica gel column chromatography (chloroform/methanol = 100/0 v/v - 10/90 v/v) to give the title compound (2.1 g, 86%).
ESIMS m/z: 479 (M + H)+; 1H NMR (400 MHz, DMSO-d6,Ī“): 0.90-1.03 (m, 4H), 2.16 (s, 3H), 2.16-2.25 (m, 1H), 4.47-4.54 (m, 2H), 4.94 (d, J = 12.7 Hz, 1H), 5.45 (d, J = 12.7 Hz, 1H), 6.70 (dd, J = 10.7, 2.9 Hz, 1H), 6.77-6.85 (m, 1H), 7.21-7.31 (m, 3H), 7.35-7.41 (m, 2H), 7.49-7.56 (m, 1H), 7.98-8.08 (m, 2H), 8.23 (d, J = 7.8 Hz, 1H). -
- [step 1] Using 3-bromopyridin-2-amine (2.0 g, 12 mmol) and 2-bromo-1-cyclopropylethanone (2.6 g, 16 mmol), and in the same manner as in Reference Example 8A, step 1, 8-bromo-2-cyclopropylimidazo[1,2-a]pyridine (2.4 g, 89%) was obtained.
ESIMS m/z: 237 (M + H)+; 1H NMR (270 MHz, CDCl3,Ī“): 0.82-0.91 (m, 2H), 0.92-1.05 (m, 2H), 2.05-2.18 (m, 1H), 6.57 (t, J = 7.1 Hz, 1H), 7.31-7.38 (m, 2H), 7.98 (d, J= 6.6 Hz, 1H). - [step 2] Using 8-bromo-2-cyclopropylimidazo[1,2-a]pyridine (2.4 g, 10 mmol) obtained in step 1, and in the same manner as in Reference Example 8A, step 2, 8-bromo-2-cyclopropyl-3-iodoimidazo[1,2-a]pyridine (3.4 g, 90%) was obtained.
ESIMS m/z: 363 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 0.95-1.07 (m, 2H), 1.10-1.20 (m, 2H), 1.97-2.11 (m, 1H), 6.66-6.77 (m, 1H), 7.38-7.46 (m, 1H), 8.00-8.09 (m, 1H). - [step 3] Using 8-bromo-2-cyclopropyl-3-iodoimidazo[1,2-a]pyridine (2.2 g, 5.9 mmol) obtained in step 2 and (E)-2-(3-fluoro-8-formyldibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (1.1 g, 3.7 mmol) obtained in Reference Example 5, and in the same manner as in Reference Example 14A, step 3, (E)-2-{8-[(8-bromo-2-cyclopropylimidazo[1,2-a]pyridin-3-yl)(hydroxy)methyl]-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (1.6 g, 80%) was obtained.
ESIMS m/z: 530 (M + H)+; 1H NMR (400 MHz, DMSO-d6,Ī“): 0.84-1.05 (m, 4H), 2.13-2.22 (m, 1H), 2.16 (s, 3H), 4.97-5.06 (m, 1H), 5.45-5.53 (m, 1H), 6.40-6.52 (m, 2H), 6.63-6.77 (m, 2H), 6.77-6.88 (m, 1H), 7.24-7.31 (m, 1H), 7.38-7.65 (m, 4H), 8.23 (d, J= 5.9 Hz, 1H). - [step 4] Using (E)-2-{8-[(8-bromo-2-cyclopropylimidazo[1,2-a]pyridin-3-yl)(hydroxy)methyl]-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (1.6 g, 3.0 mmol) obtained in step 3, and in the same manner as in Reference Example 14A, step 4, (E)-2-{8-[(8-bromo-2-cyclopropylimidazo[1,2-a]pyridin-3-yl)methyl]-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (1.4 g, 92%) was obtained.
ESIMS m/z: 514 (M + H)+; 1H NMR (270 MHz, CDCl3,Ī“): 0.96-1.95 (m, 2H), 1.12-1.21 (m, 2H), 1.96-2.07 (m, 1H), 2.23 (s, 3H), 4.26-4.45 (m, 2H), 4.74 (d, J = 12.8 Hz, 1H), 5.40 (d, J= 12.8 Hz, 1H), 6.49-6.58 (m, 2H), 6.60-6.68 (m, 1H), 6.99-7.08 (m, 2H), 7.19-7.25 (m, 1H), 7.34 (dd, J = 7.2, 1.0 Hz, 1H), 7.40 (d, J = 7.6 Hz, 1H), 7.58 (dd, J = 6.9, 1.0 Hz, 1H). - [step 5] Using (E)-2-{8-[(8-bromo-2-cyclopropylimidazo[1,2-a]pyridin-3-yl)methyl]-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (1.3 g, 2.5 mmol) obtained in step 4, and in the same manner as in Reference Example 14B, step 5, (E)-3-{[11(6H)-(1-cyanoethylidene)-3-fluorodibenzo[b,e]oxepin-8-yl]methyl}-2-cyclopropylimidazo[1,2-a]pyridine-8-carboxylic acid (1.0 g, 83%) was obtained.
ESIMS m/z: 480 (M + H)+; 1H NMR (400 MHz, CDCl3,Ī“): 1.02-1.19 (m, 4H), 1.98-2.09 (m, 1H), 2.24 (s, 3H), 4.32-4.48 (m, 2H), 4.78 (d, J = 12.7 Hz, 1H), 5.42 (d, J = 12.7 Hz, 1H), 6.56 (dd, J = 10.2, 2.4 Hz, 1H), 6.61-6.69 (m, 1H), 6.89 (t, J= 7.3 Hz, 1H), 7.03 (d, J = 8.8, 6.8 Hz, 1H), 7.10-7.16 (m, 1H), 7.21-7.26 (m, 1H), 7.43 (d, J = 7.8 Hz, 1H), 7.82 (d, J = 6.8 Hz, 1H), 8.06 (d, J = 7.8 Hz, 1H). - [step 6] Using (E)-3-{[11(6H)-(1-cyanoethylidene)-3-fluorodibenzo[b,e]oxepin-8-yl]methyl}-2-cyclopropylimidazo[1,2-a]pyridine-8-carboxylic acid(0.80 g, 1.7 mmol) obtained in step 5, and in the same manner as in Reference Example 14B, step 6, the title compound (0.62 g, 77%) was obtained.
ESIMS m/z: 479 (M + H)+; 1H NMR (400 MHz, CDCl3,Ī“): 0.99-1.08 (m, 2H), 1.09-1.16 (m, 2H), 1.98-2.07 (m, 1H), 2.24 (s, 3H), 4.31-4.46 (m, 2H), 4.77 (d, J = 12.7 Hz, 1H), 5.42 (d, J= 12.7 Hz, 1H), 5.89-5.97 (m, 1H), 6.55 (dd, J = 10.2, 2.4 Hz, 1H), 6.61-6.68 (m, 1H), 6.82 (t, J = 6.8 Hz, 1H), 6.99-7.07 (m, 1H), 7.09-7.13 (m, 1H), 7.21-7.26 (m, 1H), 7.42 (d, J = 7.8 Hz, 1H), 7.76 (d, J = 6.8 Hz, 1H), 8.11 (d, J = 6.8 Hz, 1H), 10.05 (br s, 1H). -
- [step 1] Using 3-methylpyrazin-2-amine (1.0 g, 9.2 mmol) and 1-bromopentan-2-one (3.9 g, 18 mmol), and in the same manner as in Reference Example 14A, step 1, 8-methyl-2-propylimidazo[1,2-a]pyrazine (1.2 g, 73%) was obtained.
ESIMS m/z: 176 (M + H)+; 1H NMR (400 MHz, CDCl3,Ī“): 1.02 (t, J = 7.3 Hz, 3H), 1.72-1.85 (m, 2H), 2.82 (t, J = 7.3 Hz, 2H), 2.88 (s, 3H), 7.42 (s, 1H), 7.69 (d, J= 3.9 Hz, 1H), 7.87 (d, J = 3.9 Hz, 1H). - [step 2] Using 8-methyl-2-propylimidazo[1,2-a]pyrazine (1.2 g, 6.7 mmol) obtained in step 1, and in the same manner as in Reference Example 8A, step 2, 3-iodo-8-methyl-2-propylimidazo[1,2-a]pyrazine (1.7 g, 85%) was obtained.
ESIMS m/z: 302 (M + H)+; 1H NMR (400 MHz, CDCl3,Ī“) : 1.01 (t, J = 7.3 Hz, 3H), 1.74-1.86 (m, 2H), 2.82 (t, J = 7.3 Hz, 2H), 2.89 (s, 3H), 7.83 (d, J = 4.9 Hz, 1H), 7.87 (d, J = 4.9 Hz, 1H). - [step 3] Using 3-iodo-8-methyl-2-propylimidazo[1,2-a]pyrazine (0.5 g, 1.7 mmol) obtained in step 2 and (E)-2-(3-fluoro-8-formyldibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (0.3 g, 1.0 mmol) obtained in Reference Example 5, and in the same manner as in Reference Example 14A, step 3, (E)-2-{3-fluoro-8-[hydroxy(8-methyl-2-propylimidazo[1,2-a]pyrazin-3-yl)methyl]dibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (0.51 g, quantitative) was obtained.
ESIMS m/z: 469 (M + H)+; 1H NMR (300 MHz, CDCl3,Ī“): 0.89-1.03 (m, 3H), 1.68-1.84 (m, 2H), 2.24 (s, 3H), 2.64-2.75 (m, 2H), 2.80-2.87 (m, 3H), 3.15-3.34 (m, 1H), 4.74-4.87 (m, 1H), 5.45 (d, J= 12.8 Hz, 1H), 6.34 (br d, J = 4.8 Hz, 1H), 6.50-6.70 (m, 2H), 7.03 (dd, J = 8.8, 6.2 Hz, 1H), 7.28-7.36 (m, 1H), 7.39-7.49 (m, 2H), 7.52 (d, J= 4.4 Hz, 1H), 7.71-7.80 (m, 1H). - [step 4] Using (E)-2-{3-fluoro-8-[hydroxy(8-methyl-2-propylimidazo[1,2-a]pyrazin-3-yl)methyl]dibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (0.5 g, 1.1 mmol) obtained in step 3, and in the same manner as in Reference Example 14A, step 4, the title compound (0.35 g, 73%) was obtained.
ESIMS m/z: 453 (M + H)+; 1H NMR (400 MHz, CDCl3, Ī“): 1.00 (t, J = 7.3 Hz, 3H), 1.73-1.85 (m, 2H), 2.23 (s, 3H), 2.83 (t, J = 7.3 Hz, 2H), 2.90 (s, 3H), 4.21-4.35 (m, 2H), 4.74 (d, J = 12.7 Hz, 1H), 5.41 (d, J = 12.7 Hz, 1H), 6.55 (dd, J= 10.2, 2.4 Hz, 1H), 6.61-6.68 (m, 1H), 6.98-7.06 (m, 2H), 7.13-7.18 (m, 1H), 7.41 (d, J = 7.8 Hz, 1H), 7.46 (d, J = 3.9 Hz, 1H), 7.63 (d, J= 4.9 Hz, 1H). -
- [step 1] Using 3-methoxypyrazin-2-amine (9.7 g, 78 mmol) and 2-bromo-1-cyclopropylethanone (16 g, 101 mmol), and in the same manner as in Reference Example 14A, step 1, 2-cyclopropyl-8-methoxyimidazo[1,2-a]pyrazine (7.4 g, 50%) was obtained.
ESIMS m/z: 190 (M + H)+; 1H NMR (400 MHz, CDCl3,Ī“): 0.94-1.04 (m, 4H), 1.99-2.10 (m, 1H), 4.12 (s, 3H), 7.30 (d, J = 4.9 Hz, 1H), 7.37 (s, 1H), 7.60 (d, J = 4.9 Hz, 1H). - [step 2] Using 2-cyclopropyl-8-methoxyimidazo[1,2-a]pyrazine (7.1 g, 37 mmol) obtained in step 1, and in the same manner as in Reference Example 8A, step 2, 2-cyclopropyl-3-iodo-8-methoxyimidazo[1,2-a]pyrazine (9.2 g, 78%) was obtained.
ESIMS m/z: 316 (M + H)+; 1H NMR (400 MHz, CDCl3,Ī“): 0.96-1.08 (m, 2H), 1.13-1.21 (m, 2H), 2.00-2.11 (m, 1H), 4.14 (s, 3H), 7.44 (d, J = 4.8 Hz, 1H), 7.64 (d, J = 4.8 Hz, 1H). - [step 3] Using 2-cyclopropyl-3-iodo-8-methoxyimidazo[1,2-a]pyrazine (9.2 g, 29 mmol) obtained in step 2 and (E)-2-(3-fluoro-8-formyldibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (5.3 g, 18 mmol) obtained in Reference Example 5, and in the same manner as in Reference Example 14A, step 3, (E)-2-{8-[(2-cyclopropyl-8-methoxyimidazo[1,2-a]pyrazin-3-yl)(hydroxy)methyl]-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (9.1 g, quantitative) was obtained.
ESIMS m/z: 483 (M + H)+; 1H NMR (300 MHz, DMSO-d6,Ī“): 0.77-1.00 (m, 4H), 2.10-2.21 (m, 1H), 2.16 (s, 3H), 3.96 (s, 3H), 4.96-5.05 (m, 1H), 5.44-5.53 (m, 1H), 6.41-6.53 (m, 2H), 6.65-6.76 (m, 1H), 6.77-6.87 (m, 1H), 7.23-7.32 (m, 2H), 7.39-7.53 (m, 2H), 7.54-7.65 (m, 1H), 7.90 (d, J = 4.8 Hz, 1H). - [step 4] Using (E)-2-{8-[(2-cyclopropyl-8-methoxyimidazo[1,2-a]pyrazin-3-yl)(hydroxy)methyl]-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (9.1 g, 19 mmol) obtained in step 3, and in the same manner as in Reference Example 8A, step 4, (E)-2-{8-[(2-cyclopropyl-8-hydroxyimidazo[1,2-a]pyrazin-3-yl)methyl]-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (8.9 g, quantitative) was obtained.
ESIMS m/z: 453 (M + H)+; 1H NMR (300 MHz, DMSO-d6,Ī“): 0.93-1.07 (m, 4H), 2.13-2.24 (m, 1H), 2.17 (s, 3H), 4.41-4.54 (m, 2H), 4.94 (d, J = 12.8 Hz, 1H), 5.48 (d, J= 12.8 Hz, 1H), 6.71 (dd, J = 10.6, 2.6 Hz, 1H), 6.78-6.87 (m, 1H), 7.14-7.23 (m, 1H), 7.27 (dd, J = 8.8, 6.6 Hz, 1H), 7.31-7.43 (m, 3H), 7.46-7.53 (m, 1H), 11.90-12.13 (m, 1H). - [step 5] To (E)-2-{8-[(2-cyclopropyl-8-hydroxyimidazo[1,2-a]pyrazin-3-yl)methyl]-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (3.8 g, 8.3 mmol) obtained in step 4 was added phosphorus oxychloride (19 mL, 207 mmol), and the mixture was stirred with heating at 110Ā°C for 4 hr. The mixture was concentrated under reduced pressure, saturated aqueous sodium hydrogen carbonate solution was added to the residue, and the mixture was extracted 3 times with ethyl acetate. The combined organic layers were dried over anhydrous magnesium sulfate and concentrated under reduced pressure to give (E)-2-{8-[(8-chloro-2-cyclopropylimidazo[1,2-a]pyrazin-3-yl)methyl]-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (3.7 g, 96%).
ESIMS m/z: 471 (M + H)+; 1H NMR (400 MHz, CDCl3,Ī“): 1.04-1.11 (m, 2H), 1.17-1.25 (m, 2H), 2.00-2.09 (m, 1H), 2.24 (s, 3H), 4.31-4.46 (m, 2H), 4.77 (d, J = 12.7 Hz, 1H), 5.42 (d, J= 12.7 Hz, 1H), 6.56 (dd, J = 10.2, 2.4 Hz, 1H), 6.61-6.69 (m, 1H), 7.03 (dd, J = 8.8, 6.8 Hz, 1H), 7.06-7.09 (m, 1H), 7.19-7.24 (m, 1H), 7.43 (d, J = 7.8 Hz, 1H), 7.52-7.57 (m, 2H). - [step 6] (E)-2-{8-[(8-chloro-2-cyclopropylimidazo[1,2-a]pyrazin-3-yl)methyl]-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (0.2 g, 0.43 mmol) obtained in step 5 was dissolved in THF (1.4 mL), and 2 mol/L dimethylamine THF solution (1.7 mL, 3.4 mmol) was added. The mixture was stirred with heating at 100Ā°C for 1.5 hr in an Emrys Optimizer microwave synthesizer. Water was added to the mixture, and the mixture was extracted 3 times with ethyl acetate. The combined organic layers were dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (heptane/ethyl acetate = 100/0 v/v - 50/50 v/v) to give the title compound (0.18 g, 87%).
ESIMS m/z: 480 (M + H)+; 1H NMR (400 MHz, CDCl3,Ī“): 0.91-0.99 (m, 2H), 1.01-1.11 (m, 2H), 1.90-2.00 (m, 1H), 2.23 (s, 3H), 3.51 (s, 6H), 4.15-4.36 (m, 2H), 4.75 (d, J = 12.7 Hz, 1H), 5.41 (d, J = 12.7 Hz, 1H), 6.55 (dd, J = 10.2, 2.4 Hz, 1H), 6.60-6.67 (m, 1H), 6.97 (d, J = 3.9 Hz, 1H), 7.02 (dd, J = 8.8, 5.9 Hz, 1H), 7.04-7.07 (m, 1H), 7.18-7.24 (m, 2H), 7.39 (d, J = 7.8 Hz, 1H). - (E)-2-{8-[(8-bromo-2-cyclopropylimidazo[1,2-a]pyridin-3-yl)methyl]-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (0.36 g, 0.69 mmol) obtained in Reference Example 14C, step 4 was dissolved in toluene (14 mL), Pd2(dba)3 (0.13 g, 0.14 mmol), 2-(di-tert-butylphosphino)biphenyl (0.04 g, 0.14 mmol), sodium tert-butoxide (0.13 g, 1.4 mmol) and 2 mol/L dimethylamine THF solution (4.5 mL, 9.0 mmol) were added, and the mixture was stirred with heating at 120Ā°C for 2.5 hr in an Emrys Optimizer microwave synthesizer. The mixture was filtered through celite, the filtrate was concentrated under reduced pressure, and the obtained residue was purified by silica gel column chromatography (heptane/ethyl acetate = 100/0 v/v - 70/30 v/v) to give the title compound (0.10 g, 29%).
ESIMS m/z: 479 (M + H)+; 1H NMR (270 MHz, CDCl3,Ī“): 0.87-0.98 (m, 2H), 1.09-1.18 (m, 2H), 1.91-2.03 (m, 1H), 2.23 (s, 3H), 3.15 (s, 6H), 4.22-4.40 (m, 2H), 4.74 (d, J = 12.8 Hz, 1H), 5.40 (d, J = 12.8 Hz, 1H), 6.22 (d, J = 7.2 Hz, 1H), 6.48-6.58 (m, 2H), 6.58-6.67 (m, 1H), 7.01 (dd, J = 8.7, 6.4 Hz, 1H), 7.06-7.11 (m, 1H), 7.17-7.23 (m, 2H), 7.38 (d, J = 7.9 Hz, 1H). -
- [step 1] Using 2-amino-4-bromopyridine (1.5 g, 8.7 mmol) and bromoacetone (1.58 g, 10 mmol), and in the same manner as in Reference Example 8A, step 1, 7-bromo-2-methylimidazo[1,2-a]pyridine (1.5 g, 82%) was obtained.
ESIMS m/z: 211 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 2.45 (s, 3H), 6.84 (dd, J = 8.2, 2.0 Hz, 1H), 7.33 (s, 1H), 7.70 (d, J= 2.0 Hz, 1H), 7.91 (d, J = 8.2 Hz, 1H). - [step 2] Using 7-bromo-2-methylimidazo[1,2-a]pyridine (2.0 g, 9.5 mmol) obtained in step 1, and in the same manner as in Reference Example 8A, step 2, 7-bromo-3-iodo-2-methylimidazo[1,2-a]pyridine (3.2 g, 99%) was obtained.
ESIMS m/z: 337 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 2.51 (s, 3H), 6.80-7.11 (m, 1H), 7.58-7.82 (m, 1H), 7.83-8.02 (m, 1H). - [step 3] Using 7-bromo-3-iodo-2-methylimidazo[1,2-a]pyridine (3.2 g, 9.5 mmol) obtained in step 2 and (E)-2-(3-fluoro-8-formyldibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (1.7 g, 5.9 mmol) obtained in Reference Example 5, and in the same manner as in Reference Example 14A, step 3, (E)-2-{3-fluoro-8-[hydroxy(7-bromo-2-methylimidazo[1,2-a]pyridin-3-yl)methyl]dibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (3.0 g, 99%) was obtained.
ESIMS m/z: 504 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 2.22 (s, 3H), 2.35-2.44 (m, 3H), 4.76-4.87 (m, 1H), 5.39-5.51 (m, 1H), 6.27-6.39 (m, 1H), 6.48-6.79 (m, 3H), 6.95-7.07 (m, 1H), 7.29-7.53 (m, 3H), 7.62-1.72 (m, 1H), 7.76-7.92 (m, 1H). - [step 4] Using (E)-2-{3-fluoro-8-[hydroxy(7-bromo-2-methylimidazo[1,2-a]pyridin-3-yl)methyl]dibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (3.0 g, 5.9 mmol) obtained in step 3, and in the same manner as in Reference Example 14A, step 4, (E)-2-{3-fluoro-8-[(7-bromo-2-methylimidazo[1,2-a]pyridin-3-yl)methyl]dibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (2.2 g, 75%) was obtained.
ESIMS m/z: 488 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 2.24 (s, 3H), 2.49 (s, 3H), 4.13-4.36 (m, 2H), 4.74 (d, J = 12.0 Hz, 1H), 5.40 (d, J = 12.0 Hz, 1H), 6.52-6.60 (m, 1H), 6.60-6.70 (m, 1H), 6.72-6.82 (m, 1H), 6.97-7.07 (m, 2H), 7.11-7.21 (m, 1H), 7.35-7.44 (m, 1H), 7.44-7.52 (m, 1H), 7.68-7.77 (m, 1H). - [step 5] (E)-2-{3-fluoro-8-[(7-bromo-2-methylimidazo[1,2-a]pyridin-3-yl)methyl]dibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (350 mg, 0.72 mmol) obtained in step 4 was dissolved in toluene (4.0 mL), cyclopropylboronic acid (123 mg, 1.4 mmol), tricyclohexylphosphine (80mg, 0.29 mmol), palladium acetate (32 mg, 0.14 mmol), potassium phosphate (532 mg, 2.5 mmol) and water (13 mg, 0.72 mmol) were added, and the mixture was stirred with heating at 100Ā°C for 3 hr. The reaction mixture was filtered through celite, and the filtrate was concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (chloroform/methanol = 19/1 v/v) to give the title compound (280 mg, 87%).
ESIMS m/z: 450 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 0.66-0.75 (m, 2H), 0.87-1.07 (m, 2H), 1.80-2.00 (m, 1H), 2.24 (s, 3H), 2.46 (s, 3H), 4.15-4.32 (m, 2H), 4.75 (d, J = 12.0 Hz, 1H), 5.39 (d, J = 12.0 Hz, 1H), 6.35-6.43 (m, 1H), 6.49-6.72 (m, 2H), 6.97-7.10 (m, 2H), 7.15-7.24 (m, 2H), 7.34-7.43 (m, 1H), 7.44-7.55 (m, 1H). -
- [step 1] To a mixture of (E)-2-{3-fluoro-8-[(7-bromo-2-methylimidazo[1,2-a]pyridin-3-yl)methyl]dibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (400 mg, 0.82 mmol) obtained in Reference Example 14G, step 4, trimethylsilylacetylene (0.23 mL, 1.6 mmol), triethylamine (0.34 mL, 2.5 mmol), bis(triphenylphosphine)dichloropalladium (II) (29 mg, 0.04 mmol) and triphenylphosphine (54 mg, 0.21 mmol) were added THF (4.0 mL), copper (I) iodide (1.6 mg, 0.008 mmol), and the mixture was stirred with heating at 60Ā°C for 3 hr. The reaction mixture was filtered through celite, and the filtrate was concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (heptane/ethyl acetate = 1/2 v/v) to give (E)-2-{8-[(2-methyl-7-trimethylsilylethynylimidazo[1,2-a]pyridin-3-yl)methyl]-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (340 mg, 82%).
ESIMS m/z: 506 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 0.23 (s, 9H), 2.24 (s, 3H), 2.49 (s, 3H), 4.19-4.36 (m, 2H), 4.75 (d, J= 12.4 Hz, 1H), 5.41 (d, J = 12.4 Hz, 1H), 6.49-6.77 (m, 3H), 6.96-7.09 (m, 2H), 7.14-7.23 (m, 1H), 7.36-7.45 (m, 1H), 7.49-7.60 (m, 1H), 7.62-7.70 (m, 1H). - [step 2] (E)-2-{8-[(2-methyl-7-trimethylsilylethynylimidazo[1,2-a]pyridin-3-yl)methyl]-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (340 mg, 0.62 mmol) obtained in step 1 was dissolved in THF (3 ml), 1 mmol/L tetrabutylammonium fluoride THF solution (0.81 ml, 0.81 mmol) was added, and the mixture was stirred at room temperature for 4 hr. Water was added to the reaction mixture and the mixture was extracted 3 times with ethyl acetate. The combined organic layers were dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (heptane/ethyl acetate = 1/2 v/v) to give the title compound (152 mg, 53%).
ESIMS m/z: 434 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 2.25 (s, 3H), 2.52 (s, 3H), 3.16-3.24 (m, 1H), 4.17-4.40 (m, 2H), 4.75 (d, J= 12.4 Hz, 1H), 5.41 (d, J = 12.4 Hz, 1H), 6.50-6.80 (m, 3H), 6.96-7.08 (m, 2H), 7.13-7.23 (m, 1H), 7.36-7.47 (m, 1H), 7.51-7.63 (m, 1H), 7.63-7.78 (m, 1H). -
- [step 1] Using 2-amino-4-fluoropyridine (3.2 g, 28.5 mmol) and ethyl bromopyruvate (4.3 ml, 34.3 mmol), and in the same manner as in Reference Example 8A, step 1, ethyl 7-fluoroimidazo[1,2-a]pyridine-2-carboxylate (3.5 g, 59%) was obtained.
ESIMS m/z: 209 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 1.44 (t, J = 7.3 Hz, 3H), 4.46 (q, J = 7.3 Hz, 2H), 6.74-6.86 (m, 1H), 7.21-7.36 (m, 1H), 8.06-8.14 (m, 1H), 8.18 (s, 1H). - [step 2] Using ethyl 7-fluoroimidazo[1,2-a]pyridine-2-carboxylate (2.8 g, 13.5 mmol) obtained in step 1, and in the same manner as in Reference Example 8A, step 2, ethyl 7-fluoro-3-iodo-imidazo[1,2-a]pyridine-2-carboxylate (2.6 g, 57%) was obtained.
ESIMS m/z: 335 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 1.46 (t, J = 7.3 Hz, 3H), 4.51 (q, J = 7.3 Hz, 2H), 6.83-7.00 (m, 1H), 7.23-7.43 (m, 1H), 8.11-8.35 (m, 1H). - [step 3] Using ethyl 7-fluoro-3-iodo-imidazo[1,2-a]pyridine-2-carboxylate (4.5 g, 13.5 mmol) obtained in step 2 and (E)-2-(3-fluoro-8-formyldibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (2.5 g, 8.4 mmol) obtained in Reference Example 5, and in the same manner as in Reference Example 14A, step 3, (E)-ethyl 3-({11(6H)-[1-(cyanoethylidene)]-3-fluorodibenzo[b,e]oxepin}(hydroxy)methyl)-7-fluoroimidazo[1,2-a]pyridine-2-carboxylate (1.8 g, 76%) was obtained.
ESIMS m/z: 502 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 1.46 (t, J = 7.3 Hz, 3H), 2.24 (s, 3H), 4.48 (q, J = 7.3 Hz, 2H), 4.73-4.86 (m, 1H), 5.28-5.49 (m, 1H), 6.47-6.72 (m, 3H), 6.94-7.13 (m, 2H), 7.19-7.29 (m, 1H), 7.36-7.55 (m, 3H), 8.03-8.20 (m, 1H). - [step 4] Using (E)-ethyl 3-({11(6H)-[1-(cyanoethylidene)]-3-fluorodibenzo[b,e]oxepin}(hydroxy)methyl)-7-fluoroimidazo[1,2-a]pyridine-2-carboxylate (2.0 g, 8.9 mmol) obtained in step 3, and in the same manner as in Reference Example 14A, step 4, (E)-ethyl 3-({11(6H)-[1-(cyanoethylidene)]-3-fluorodibenzo[b,e]oxepin}methyl)-7-fluoroimidazo[1,2-a]pyridine-2-carboxylate (1.4 g, 74%) was obtained.
ESIMS m/z: 486 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 1.45 (t, J = 7.3 Hz, 3H), 2.22 (s, 3H), 4.49 (q, J = 7.3 Hz, 2H), 4.62-4.88 (m, 3H), 5.39 (d, J = 12.4 Hz, 1H), 6.39-6.78 (m, 3H), 6.98-7.06 (m, 2H), 7.22-7.34 (m, 2H), 7.37-7.44 (m, 1H), 7.72-7.79 (m, 1H). - [step 5] (E)-ethyl 3-({11(6H)-[1-(cyanoethylidene)]-3-fluorodibenzo[b,e]oxepin}methyl)-7-fluoroimidazo[1,2-a]pyridine-2-carboxylate (350 mg, 0,72 mmol) obtained in step 4 was dissolved in THF (5 mL)-ethanol (2.5 mL), lithium hydroxide (26 mg, 1.1 mmol) was added, and the mixture was stirred at room temperature for 7 hr. To the reaction mixture was added 1 mol/L hydrochloric acid (1.5 mL), and precipitated crystals were collected by suction filtration.
- The obtained crystals (330 mg) were dissolved in THF (5 mL), carbonyldiimidazole (585 mg, 3.6 mmol) was added, and the mixture was stirred at room temperature for 1 hr. To the reaction mixture was added 25% aqueous ammonia solution (0.63 mL, 7.2 mmol), and the mixture was further stirred for 1 hr. To the reaction mixture was added 5% aqueous citric acid solution, and the mixture was extracted 3 times with chloroform. The combined organic layers were dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (chloroform/methanol = 9/1 v/v) to give the title compound (253 mg, 77%).
ESIMS m/z: 457 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 2.22 (s, 3H), 4.67-4.85 (m, 3H), 5.39 (d, J = 12.4 Hz, 1H), 5.49-5.57 (m, 1H), 6.49-6.59 (m, 1H), 6.59-6.73 (m, 2H), 6.95-7.07 (m, 1H), 7.16-7.24 (m, 2H), 7.24-7.32 (m, 1H), 7.32-7.43 (m, 2H), 7.72-7.82 (m, 1H). -
- [step 1] Using 2-amino-4-fluoropyridine (294 mg, 2.6 mmol) and 3-bromoacetyltetrahydrofuran (
WO2002/046198 , 607 mg, 3.1 mmol), and in the same manner as in Reference Example 8A, step 1, 7-fluoro-2-(tetrahydrofuran-3-yl)imidazo[1,2-a]pyridine (150 mg, 27%) was obtained.
ESIMS m/z: 207 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 2.12-2.27 (m, 1H), 2.31-2.47 (m, 1H), 3.54-3.68 (m, 1H), 3.87-3.99 (m, 2H), 3.99-4.11 (m, 1H), 4.12-4.23 (m, 1H), 6.56-6.70 (m, 1H), 7.13-7.25 (m, 1H), 7.38 (s, 1H), 7.86-8.07 (m, 1H). - [step 2] Using 7-fluoro-2-(tetrahydrofuran-3-yl)imidazo[1,2-a]pyridine (150 mg, 0.73 mmol) obtained in step 1, and in the same manner as in Reference Example 8A, step 2, 7-fluoro-3-iodo-2-(tetrahydrofuran-3-yl)imidazo[1,2-a]pyridine (180 mg, 75%) was obtained.
ESIMS m/z: 333 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 2.25-2.47 (m, 2H), 3.54-3.68 (m, 1H), 3.83-4.07 (m, 2H), 4.11-4.23 (m, 2H), 6.71-6.84 (m, 1H), 7.17-7.34 (m, 1H), 8.00-8.17 (m, 1H). - [step 3] Using 7-fluoro-3-iodo-2-(tetrahydrofuran-3-yl)imidazo[1,2-a]pyridine (180 mg, 0.54 mmol) obtained in step 2 and (E)-2-(3-fluoro-8-formyldibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (99 mg, 0.34 mmol) obtained in Reference Example 5, and in the same manner as in Reference Example 14A, step 3, (E)-2-(3-fluoro-8-{[7-fluoro-2-(tetrahydrofuran-3-yl)(hydroxy)imidazo[1,2-a]pyridin-3-yl]methyl}dibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (137 mg, 81%) was obtained.
ESIMS m/z: 500 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 2.20-2.48 (m, 5H), 3.46-3.70 (m, 1H), 3.83-4.01 (m, 2H), 4.01-4.23 (m, 2H), 4.73-4.89 (m, 1H), 5.37-5.54 (m, 1H), 6.33-6.45 (m, 1H), 6.45-6.71 (m, 3H), 6.97-7.10 (m, 1H), 7.10-7.23 (m, 1H), 7.32-7.54 (m, 3H), 7.86-8.02 (m, 1H). - [step 4] Using (E)-2-(3-fluoro-8-{[7-fluoro-2-(tetrahydrofuran-3-yl)(hydroxy)imidazo[1,2-a]pyridin-3-yl]methyl}dibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (137 mg, 0.27 mmol) obtained in step 3, and in the same manner as in Reference Example 14A, step 4, (E)-2-(3-fluoro-8-{[7-fluoro-2-(tetrahydrofuran-3-yl)imidazo[1,2-a]pyridin-3-yl]methyl}dibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (104 mg, 78%) was obtained.
ESIMS m/z: 484 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 2.16-2.52 (m, 5H), 3.50-3.69 (m, 1H), 3.88-4.05 (m, 2H), 4.07-4.22 (m, 2H), 4.22-4.37 (m, 2H), 4.63-4.83 (m, 1H), 5.33-5.50 (m, 1H), 6.52-6.72 (m, 3H), 6.98-7.11 (m, 2H), 7.10-7.18 (m, 1H), 7.21-7.32 (m, 1H), 7.39-7.47 (m, 1H), 7.51-7.63 (m, 1H). -
- [step 1] 2-chloro-iodoimidazo[1,2-a]pyridine
By reference to Journal of Medicinal Chemistry (J. Med. Chem.) 2003, 46, 1449-1455, 2-chloro-3-iodoimidazo[1,2-a]pyridine (2.3 g, 33%) was obtained in 3 steps using pyridin-2-amine (2.5 g, 26 mmol).
ESIMS m/z: 279 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 6.95-7.00 (m, 1H), 7.26-7.32 (m, 1H), 7.51-7.55 (m, 1H), 8.04-8.08 (m, 1H). - [step 2] Using 2-chloro-3-iodoimidazo[1,2-a]pyridine (500 mg, 1.80 mmol) obtained in step 1 and (E)-2-(3-fluoro-8-formyldibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (263 mg, 0.90 mmol) obtained in Reference Example 5, and in the same manner as in Reference Example 8F, step 4, (E)-2-{8-[(2-chloroimidazo[1,2-a]pyridin-3-yl)(hydroxy)methyl]-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (179 mg, 45%) was obtained.
ESIMS m/z: 446 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 2.24 (s, 3H), 4.81-4.85 (m, 1H), 5.41-5.47 (m, 1H), 6.46-6.72 (m, 4H), 7.00-7.05 (m, 1H), 7.19-7.23 (m, 1H), 7.40-7.56 (m, 4H), 8.01-8.03 (m, 1H). - [step 3] Using (E)-2-{8-[(2-chloroimidazo[1,2-a]pyridin-3-yl)(hydroxy)methyl]-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (170 mg, 0.38 mmol) obtained in step 2, and in the same manner as in Reference Example 8F, step 5, the title compound (66 mg, 40%) was obtained.
ESIMS m/z: 430 (M + H)+; 1H NMR (270 MHz, CDCl3, 5): 2.23 (s, 3H), 4.29-4.34 (m, 2H), 4.73-4.97 (m, 1H), 5.38-5.54 (m, 1H), 6.52-6.79 (m, 4H), 6.99-7.05 (m, 1H), 7.39-7.42 (m, 1H), 7.52-7.62 (m, 2H), 7.65-7.73 (m, 1H), 7.77-7.82 (m, 1H). -
- [step 1] By reference to Journal of Medicinal Chemistry (J. Med. Chem.) 2003, 46, 1449-1455, 2-chloro-3-iodo-7-(trifluoromethyl)imidazo[1,2-a]pyridine (0.5 g, 16%) was obtained in 3 steps using 4-(trifluoromethyl)pyridin-2-amine (0.81 g, 8.6 mmol).
ESIMS m/z: 347 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 7.14-7.17 (m, 1H), 7.84-7.85 (m, 1H), 8.17-8.19 (m, 1H). - [step 2] Using 2-chloro-3-iodo-7-(trifluoromethyl)imidazo[1,2-a]pyridine (1.81 g, 5.22 mmol) obtained in step 1 and (E)-2-(3-fluoro-8-formyldibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (0.77 g, 2.6 mmol) obtained in Reference Example 5, and in the same manner as in Reference Example 8F, step 4, (E)-2-{8-[(2-chloro-7-(trifluoromethyl)imidazo[1,2-a]pyridin-3-yl)(hydroxy)methyl]-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (1.21 g, 90%) was obtained.
ESIMS m/z: 514 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 2.25 (s, 3H), 4.82-4.86 (m, 1H), 5.41-5.48 (m, 1H), 6.43-6.68 (m, 3H), 6.88-6.92 (m, 1H), 7.01-7.06 (m, 1H), 7.38-7.56 (m, 3H), 7.80-7.82 (m, 1H), 8.23-8.30 (m, 1H). - [step 3] (E)-2-{8-[(2-chloro-7-(trifluoromethyl)imidazo[1,2-a]pyridin-3-yl)(hydroxy)methyl]-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (0.985 g, 1.92 mmol) obtained in step 2 was dissolved in methylene chloride (9.6 mL), Dess-Martin periodinane (0.976 g, 2.30 mmol) was added at 0Ā°C, and the mixture was stirred for 30 min. To the mixture was added saturated aqueous sodium hydrogen carbonate solution and the reaction was discontinued with saturated aqueous sodium thiosulfate solution. The mixture was extracted 3 times with chloroform. The combined organic layers were dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained residue was re-slurried with isopropyl ether to give (E)-2-{8-[(2-chloro-7-(trifluoromethyl)imidazo[1,2-a]pyridine-3-carbonyl]-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (0.98 g, 100%).
ESIMS m/z: 512 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 2.29 (s, 3H), 4.94-4.99 (m, 1H), 5.51-5.56 (m, 1H), 6.60-6.74 (m, 2H), 7.06-7.12 (m, 1H), 7.31-7.34 (m, 1H), 7.61-7.64 (m, 1H), 7.81-8.00 (m, 2H), 7.99-8.01 (m, 1H), 9.48-9.51 (m, 1H). - [step 4] (E)-2-{8-[(2-chloro-7-(trifluoromethyl)imidazo[1,2-a]pyridine-3-carbonyl]-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (0.300 g, 0.59 mmol) obtained in step 3 was dissolved in 28% sodium methoxide methanol solution (0.93 mL, 4.7 mmol), and the mixture was stirred with heating under reflux for 3 hr. Water was added to the mixture, and the residue collected by filtration was purified by silica gel column chromatography (hexane/ethyl acetate = 70/30 v/v) to give (E)-2-{3-fluoro-8-[2-methoxy-7-(trifluoromethyl)imidazo[1,2-a]pyridine-3-carbonyl)dibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (0.21 g, 71%).
ESIMS m/z: 508 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 2.29 (s, 3H), 4.00 (s, 3H), 4.93-4.97 (m, 1H), 5.51-5.55 (m, 1H), 6.60-6.72 (m, 2H), 7.06-7.11 (m, 1H), 7.55-7.64 (m, 1H), 7.77-7.86 (m, 4H), 9.80-9.82 (m, 1H). - [step 5] (E)-2-{3-fluoro-8-[2-methoxy-7-(trifluoromethyl)imidazo[1,2-a]pyridine-3-carbonyl)dibenzo[b,e]oxepin-11(6H)-ylidene}propanenitrile (0.100 g, 0.197 mmol) obtained in step 4 was dissolved in ethanol (0.985 mL) and THF (0.985 mL), lithium borohydride (0.44 g, 1.2 mmol) was added, and the mixture was stirred at room temperature for 3 hr. The reaction was discontinued with water, and the mixture was extracted 3 times with chloroform. The combined organic layers were dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to give (E)-2-(3-fluoro-8-{hydroxy[2-methoxy-7-(trifluoromethyl)imidazo[1,2-a]pyridin-3-yl]methyl}dibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (100 mg, 100%).
ESIMS m/z: 510 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 2.24 (s, 3H), 4.14 (s, 3H), 4.81-4.86 (m, 1H), 5.42-5.48 (m, 1H), 6.38-6.42 (m, 1H), 6.52-6.68 (m, 2H), 6.83-6.86 (m, 1H), 7.00-7.06 (m, 1H), 7.40-7.53 (m, 3H), 7.74-7.76 (m, 1H), 7.98-8.04 (m, 1H). - [step 6] Using (E)-2-(3-fluoro-8-{hydroxy[2-methoxy-7-(trifluoromethyl)imidazo[1,2-a]pyridin-3-yl]methyl}dibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (100 mg, 0.20 mmol) obtained in step 5, and in the same manner as in Reference Example 8F, step 5, the title compound (89 mg, 92%) was obtained.
ESIMS m/z: 494 (M + H)+; 1H NMR (270 MHz, CDCl3, Ī“): 2.24 (s, 3H), 4.14 (s, 3H), 4.23-4.25 (m, 2H), 4.75-4.79 (m, 1H), 5.39-5.43 (m, 1H), 6.53-6.67 (m, 2H), 6.90-6.94 (m, 1H), 6.99-7.05 (m, 1H), 7.10-7.11 (m, 1H), 7.21-7.24 (m, 1H), 7.38-7.41 (m, 1H), 7.69-7.79 (m, 2H). -
- [step 1] 5-Bromoisobenzofuran-1(3H)-one (18.0 g, 84.5 mmol) was dissolved in DMF (18 mL), and 3-fluorophenol (11.5 mL, 126.8 mmol) and sodium methoxide (28% methanol solution, 24 g, 126.8 mmol) were added. A trap bulb of an evaporator was connected, a nitrogen balloon was set, and the mixture was refluxed under heating at 130Ā°C for 10 hr. The reaction mixture was allowed to cool to room temperature, water (100 mL) and 4 mol/L aqueous sodium hydroxide solution (30 mL) were added, and the mixture was washed once with each of diethyl ether (200 mL) and toluene (550 mL). The aqueous layer was adjusted to pH 1-2 by adding 4 mol/L hydrochloric acid (about 20 mL), ethanol (70 mL) was added to a dark-brown aqueous solution, and the mixture was stirred at room temperature overnight. The precipitated crystals were collected by suction filtration with a Hirsch funnel, and washed twice with a mixed solvent of ethanol/water =1/1 (20 ml) to give 4-bromo-2-[(3-fluorophenoxy)methyl]benzoic acid (20.5 g, 75%).
ESIMS m/z: 323, 325 (M - H)-; 1H NMR (270MHz, CDCl3, Ī“): 5.48 (s, 2H), 6.66-6.86 (m, 3H), 7.21-7.32 (m, 1H), 7.58 (dd, J = 8.5, 2.0 Hz, 1H), 7.99 (d, J = 2.0 Hz, 1H), 8.03 (d, J = 8.5 Hz, 1H). - [step 2] 4-Bromo-2-[(3-fluorophenoxy)methyl]benzoic acid (18.8 g, 57.8 mmol) obtained in step 1 was dissolved in dichloromethane (193 mL), trifluoroacetic anhydride (16.0 mL, 115.6 mmol) and trifluoroborane diethyl ether complex (7.3 mL, 57.8 mmol) were added, and the mixture was stirred at room temperature for 3 hr. To the mixture were added 2 mol/L aqueous sodium hydroxide solution (150 mL) and saturated aqueous sodium hydrogen carbonate solution (50 mL), and the mixture was extracted 3 times with dichloromethane (200 mL). The combined organic layers were dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained brown solid (18.7 g) was suspended in chloroform (100 mL), and the suspension was stirred at room temperature for 1 hr. The suspension was suction filtered to give a first crop of crystals (9.42 g). The filtrate was concentrated under reduced pressure, chloroform (50 mL) was added to the obtained residue, and the mixture was stirred for 1 hr and suction filtered again to give a second crop of crystals (2.47 g). The first crop of crystals and the second crop of crystals were combined, and dried under reduced pressure to give 8-bromo-3-fluorodibenzo[b,e]oxepin-11(6H)-one (11.9 g, 67%).
1H NMR (270MHz, CDCl3, Ī“): 5.16 (s, 2H), 6.76 (dd, J = 9.8, 2.5 Hz, 1H), 6.83-6.93 (m, 1H), 7.54 (d, J = 1.7 Hz, 1H), 7.63 (dd, J = 8.5, 1.7 Hz, 1H), 7.80 (d, J = 8.5 Hz, 1H), 8.28 (dd, J = 10.8, 8.1 Hz, 1H). - [step 3] Commercially available diethyl 1-cyanoethylphosphonate (38.0 g, 199 mmol) was dissolved in THF (170 mL), LDA (99.0 mL, 199 mmol, 2.0 mol/L heptane/THF/ethylbenzene solution) was added dropwise at 0Ā°C, and the mixture was stirred at 0Ā°C for 1 hr. 8-Bromo-3-fluorodibenzo[b,e]oxepin-11(6H)-one (30.5 g, 99.0 mmol) obtained in step 2 and dissolved in THF (120 ml) was added to the reaction system, and the mixture was stirred at room temperature for 1 hr. To the mixture was added saturated aqueous ammonium chloride solution (500 mL), and the mixture was extracted 3 times with ethyl acetate. The combined organic layers were washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate = 100/0 v/v - 80/20 v/v) to give 2-(8-bromo-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (31.4 g, 92%, E/Z = 1/1).
1H NMR (300 MHz, CDCl3, Ī“): 2.01 (s, 1.5H), 2.24 (s, 1.5H), 4.74-4.88 (m, 1H), 5.42 (d, J = 12.8 Hz, 1H), 6.51-6.62 (m, 1H), 6.62-6.74 (m, 1H), 6.99-7.08 (m, 1H), 7.35 (d, J = 8.1 Hz, 1H), 7.48 (dd, J = 8.8, 6.6 Hz, 1H), 7.51-7.60 (m, 1H). - [step 4] 2-(8-Bromo-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (5.0 g, 14.5 mmol, E/Z=1/1) obtained in step 3 was dissolved in DMF (37 mL) and n-propanol (19 mL), cesium carbonate (5.7 g, 17.4 mmol) was added, and the mixture was stirred at 50Ā°C for 45 min under a nitrogen stream. The reaction mixture was allowed to cool to room temperature, palladium (II) acetate (163 mg, 0.73 mmol) and 1,3-bis(diphenylphosphino)propane (300 mg, 0.73 mmol) were added, and the mixture was stirred at 70Ā°C for 3 hr in the presence of CO gas. The mixture was filtered through celite, water (50 mL) was added to the filtrate, and the mixture was extracted 3 times with ethyl acetate. The combined organic layers were washed with water, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate = 100/0 v/v - 70/30 v/v) to give propyl 11-(1-cyanoethylidene)-3-fluoro-6,11-dihydrodibenzo[b,e]oxepin-8-carboxylate (4.2 g, 83%, E/Z = 1/1).
1H NMR (300 MHz, CDCl3, Ī“) : 0.96-1.09 (m, 3H), 1.72-1.87 (m, 2H), 2.02 (s, 1.5H), 2.27 (s, 1.5H), 4.22-4.36 (m, 2H), 4.87-5.00 (m, 1H), 5.49 (d, J = 12.7 Hz, 1H), 6.50-6.63 (m, 1H), 6.63-6.75 (m, 1H), 7.06 (dd, J = 8.8, 5.9 Hz, 0.5H), 7.26 (d, J = 7.8 Hz, 0.5H), 7.50 (dd, J = 8.8, 5.9 Hz, 0.5H), 7.55 (d, J = 7.8 Hz, 0.5H), 8.00-8.16 (m, 2H). - [step 5] Propyl 11-(1-cyanoethylidene)-3-fluoro-6,11-dihydrodibenzo[b,e]oxepin-8-carboxylate (15.5 g, 44.1 mmol, E/Z = 1/1) obtained in step 4 was dissolved in THF (220 mL), lithium borohydride (4.8 g, 221 mmol) was added, and the mixture was stirred at 60Ā°C for 3 hr. Under ice-cooling, the mixture was added dropwise to 2 mol/L hydrochloric acid, and the mixture was extracted 3 times with chloroform (550 mL).
The combined organic layers were dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified 3 times by silica gel column chromatography (hexane/ethyl acetate = 100/0 v/v - 40/60 v/v) to give (E)-2-[3-fluoro-8-(hydroxymethyl)dibenzo[b,e]oxepin-11(6H)-ylidene]propanenitrile (6.06 g, 47%).
ESIMS m/z: 296 (M + H)+; 1H NMR (300 MHz, CDCl3,Ī“): 1.71 (t, J = 6.0 Hz, 1H), 2.25 (s, 3H), 4.73 (d, J = 6.0 Hz, 2H), 4.88 (d, J = 12.8 Hz, 1H), 5.48 (d, J = 12.8 Hz, 1H), 6.58 (dd, J = 10.8, 2.6 Hz, 1H), 6.61-6.69 (m, 1H), 7.04 (dd, J = 8.8, 6.6 Hz, 1H), 7.38-7.50 (m, 3H). - [step 6] (E)-2-[3-fluoro-8-(hydroxymethyl)dibenzo[b,e]oxepin-11(6H)-ylidene]propanenitrile (13.3 g, 45.0 mmol) obtained in step 5 was dissolved in THF (450 mL), methanesulfonic anhydride (19.6 g, 112.6 mmol), lithium bromide (23.5 g, 270.2 mmol) and 2,6-lutidine (31.5 mL, 270.2 mmol) were added, and the mixture was stirred at room temperature for 13 hr. To the mixture was added water (200 mL), and the mixture was extracted 3 times with ethyl acetate. The combined organic layers were washed with 1 mol/L hydrochloric acid (100 mL), saturated aqueous sodium hydrogen carbonate solution (100 mL) and saturated brine (100 mL), dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform/methanol = 100/0 v/v - 97/3 v/v) to give the title compound (13.4 g, 83%). 1H NMR (270 MHz, CDCl3, Ī“): 2.25 (s, 3H), 4.48 (s, 2H), 4.86 (d, J = 12.9 Hz, 1H), 5.45 (d, J = 12.9 Hz, 1H), 6.58 (dd, J = 10.2, 2.6 Hz, 1H), 6.61-6.70 (m, 1H), 7.04 (dd, J= 8.6, 6.6 Hz, 1H), 7.39-7.49 (m, 3H).
-
- [step 1] Using 5-bromoisobenzofuran-1(3H)-one (10.0 g, 46.9 mmol) and 3,5-difluorophenol (18.3 g, 140.7 mmol), and in the same manner as in Reference Example 1, step 1, 4-bromo-2-[(3,5-difluorophenoxy)methyl]benzoic acid (14.4 g, 90%) was obtained.
ESIMS m/z: 341, 343 (M - H)-; 1H NMR (270 MHz, DMSO-d6,Ī“): 5.45 (s, 2H), 6.75-6.88 (m, 3H), 7.69 (dd, J= 8.4, 2.1 Hz, 1H), 7.83 (br d, J = 2.1 Hz, 1H), 7.87 (d, J = 8.4 Hz, 1H). - [step 2] 4-Bromo-2-[(3,5-difluorophenoxy)methyl]benzoic acid (11.4 g, 33.2 mmol) obtained in step 1 was dissolved in dichloromethane (111 mL), trifluoroacetic anhydride (9.4 mL, 66.4 mmol) and trifluoroborane diethyl ether complex (4.2 mL, 33.2 mmol) were added, and the mixture was stirred at room temperature for 4 hr. To the mixture were added 2 mol/L aqueous sodium hydroxide solution (100 mL) and saturated aqueous sodium hydrogen carbonate solution (30 mL), and the mixture was extracted 3 times with dichloromethane (300 mL). The combined organic layers were dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained brown solid (12.6 g) was suspended in isopropylalcohol (100 mL), and the suspension was stirred at room temperature for 13 hr. The suspension was suction filtered, and the obtained solid was dried under reduced pressure to give 8-bromo-1,3-difluorodibenzo[b,e]oxepin-11(6H)-one (9.3 g, 86%).
1H NMR (270MHz, CDCl3, Ī“): 5.17 (s, 2H), 6.56-6.69 (m, 2H), 7.48 (br d, J= 1.6 Hz, 1H), 7.62 (dd, J = 8.6, 1.6 Hz, 1H), 7.75 (d, J = 8.6 Hz, 1H). - [step 3] Using 8-bromo-1,3-difluorodibenzo[b,e]oxepin-11(6H)-one (8.3 g, 25.4 mmol) obtained in step 2, and in the same manner as in Reference Example 1, step 3, 2-(8-bromo-1,3-difluorodibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (4.6 g, 50%, E/Z = 1/1) was obtained.
1H NMR (270 MHz, CDCl3,Ī“): 2.02 (s, 1.5H), 2.11 (d, J = 4.3 Hz, 1.5H), 4.76-4.88 (m, 1H), 5.49 (d, J = 12.8 Hz, 1H), 6.34-6.46 (m, 1H), 6.46-6.58 (m, 1H), 7.11 (d, J= 8.9 Hz, 0.5H), 7.35 (d, J = 8.2 Hz, 0.5H), 7.48-7.63 (m, 2H). - [step 4] Using 2-(8-bromo-1,3-difluorodibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (4.2 g, 11.5 mmol) obtained in step 3, and in the same manner as in Reference Example 1, step 4, (E)-propyl 11-(1-cyanoethylidene)-1,3-difluoro-6,11-dihydrodibenzo[b,e]oxepin-8-carboxylate (1.3 g, 31%) was obtained.
1H NMR (300 MHz, CDCl3,Ī“): 1.03 (t, J = 7.5 Hz, 3H), 1.72-1.87 (m, 2H), 2.13 (d, J = 4.0 Hz, 3H), 4.30 (td, J = 6.7, 1.0 Hz, 2H), 4.96 (d, J = 12.8 Hz, 1H), 5.56 (d, J = 12.8 Hz, 1H), 6.38-6.52 (m, 2H), 7.55 (d, J = 7.7 Hz, 1H), 8.07 (br d, J = 1.5 Hz, 1H), 8.13 (dd, J = 7.9, 1.6 Hz, 1H). - [step 5] Using (E)-propyl 11-(1-cyanoethylidene)-1,3-difluoro-6,11-dihydrodibenzo[b,e]oxepin-8-carboxylate (1.3 g, 3.5 mmol) obtained in step 4, and in the same manner as in Reference Example 1, step 5, (E)-2-[1,3-difluoro-8-(hydroxymethyl)dibenzo[b,e]oxepin-11(6H)-ylidene]propanenitrile (0.85 g, 77%) was obtained.
ESIMS m/z: 314 (M + H)+; 1H NMR (300 MHz, CDCl3,Ī“): 1.72 (t, J = 5.9 Hz, 1H), 2.11 (d, J = 4.0 Hz, 3H), 4.73 (d, J= 5.9 Hz, 2H), 4.89 (d, J = 12.8 Hz, 1H), 5.55 (d, J = 12.8 Hz, 1H), 6. 36-6.52 (m, 2H), 7.37-7.50 (m, 3H). - [step 6] Using (E)-2-[1,3-difluoro-8-(hydroxymethyl)dibenzo[b,e]oxepin-11(6H)-ylidene]propanenitrile (0.85 g, 2.7 mmol) obtained in step 5, and in the same manner as in Reference Example 1, step 6, the title compound (0.78 g, 76%) was obtained.
1H NMR (300 MHz, CDCl3,Ī“): 2.11 (d, J = 3,7 Hz, 3H), 4.43-4.53 (m, 2H), 4.88 (d, J = 12.8 Hz, 1H), 5.53 (d, J = 12.8 Hz, 1H), 6.37-6.52 (m, 2H), 7.38-7.50 (m, 3H). -
- [step 1] Using 5-bromoisobenzofuran-1(3H)-one (15.0 g, 70.4 mmol) and 3,4-difluorophenol (27.5 g, 211 mmol), and in the same manner as in Reference Example 1, step 1, 4-bromo-2-[(3,4-difluorophenoxy)methyl]benzoic acid (18.8 g, 78%) was obtained.
ESIMS m/z: 341, 343 (M - H)-; 1H NMR (300 MHz, DMSO-d6,Ī“): 5.42 (s, 2H), 6.79-6.89 (m, 1H), 7.11-7.22 (m, 1H), 7.31-7.45 (m, 1H), 7.68 (dd, J = 8.2, 2.0 Hz, 1H), 7.83 (br d, J= 2.2 Hz, 1H), 7.86 (d, J = 8.4 Hz, 1H), 13.31 (br s, 1H). - [step 2] Using 4-bromo-2-[(3,4-difluorophenoxy)methyl]benzoic acid (18.8 g, 54.9 mmol) obtained in step 1, and in the same manner as in Reference Example 2, step 2, 8-bromo-2,3-difluorodibenzo[b,e]oxepin-11(6H)-one (13.2 g, 74%) was obtained.
1H NMR (300MHz, CDCl3,Ī“): 5.15 (s, 2H), 6.89 (dd, J = 10.6, 6.2 Hz, 1H), 7.54 (br d, J = 1.8 Hz, 1H), 7.64 (dd, J = 8.4, 1.8 Hz, 1H), 7.82 (d, J = 8.4 Hz, 1H), 8.07 (dd, J = 11.5, 9.3 Hz, 1H). - [step 3] Using 8-bromo-2,3-difluorodibenzo[b,e]oxepin-11(6H)-one (9.3 g, 28.6 mmol) obtained in step 2, and in the same manner as in Reference Example 1, step 3, 2-(8-bromo-2,3-difluorodibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (9.8 g, 95%, E/Z = 1/1) was obtained.
1H NMR (300 MHz, CDCl3, Ī“): 2.01 (s, 1.5H), 2.26 (s, 1.5H), 4.72-4.87 (m, 1H), 5.38 (d, J = 12.8 Hz, 1H), 6.60-6.75 (m, 1H), 6.89 (dd, J = 10.6, 8.8 Hz, 0.5H), 7.05 (d, J= 8.1 Hz, 0.5H), 7.29-7.38 (m, 1H), 7.50-7.61 (m, 2H). - [step 4] Using 2-(8-bromo-2,3-difluorodibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (9.8 g, 27.0 mmol) obtained in step 3, and in the same manner as in Reference Example 1, step 4, propyl 11-(1-cyanoethylidene)-2,3-difluoro-6,11-dihydrodibenzo[b,e]oxepin-8-carboxylate (7.6 g, 76%) was obtained.
1H NMR (300 MHz, CDCl3, Ī“): 0.97-1.09 (m, 3H), 1.71-1.87 (m, 2H), 2.02 (s, 1.5H), 2.28 (s, 1.5H), 4.24-4.36 (m, 2H), 4.86-4.99 (m, 1H), 5.45 (d, J = 12.8 Hz, 1H), 6.60-6.75 (m, 1H), 6.92 (dd, J = 10.6, 8.6 Hz, 0.5H), 7.22-7.28 (m, 0.5H), 7.31-7.42 (m, 0.5H), 7.55 (d, J = 7.9 Hz, 0.5H), 8.01-8.18 (m, 2H). - [step 5] Using propyl 11-(1-cyanoethylidene)-2,3-difluoro-6,11-dihydrodibenzo[b,e]oxepin-8-carboxylate (7.6 g, 20.6 mmol) obtained in step 4, and in the same manner as in Reference Example 1, step 5, (E)-2-[2,3-difluoro-8-(hydroxymethyl)dibenzo[b,e]oxepin-11(6H)-ylidene]propanenitrile (2.7 g, 41%) was obtained.
ESIMS m/z: 314 (M + H)+; 1H NMR (300 MHz, CDCl3,Ī“): 1.83 (t, J = 5.9 Hz, 1H), 2.26 (s, 3H), 4.72 (d, J = 5.9 Hz, 2H), 4.86 (d, J = 12.8 Hz, 1H), 5.44 (d, J = 12.8 Hz, 1H), 6.68 (dd, J= 11.4, 7.0 Hz, 1H), 6.90 (dd, J = 10.8, 8.6 Hz, 1H), 7.36-7.48 (m, 3H). - [step 6] Using (E)-2-[2,3-difluoro-8-(hydroxymethyl)dibenzo[b,e]oxepin-11(6H)-ylidene]propanenitrile (2.1 g, 6.8 mmol) obtained in step 5, and in the same manner as in Reference Example 1, step 6, the title compound (2.2 g, 84%) was obtained.
1H NMR (300 MHz, CDCl3, Ī“): 2.26 (s, 3H), 4.48 (s, 2H), 4.86 (d, J = 12.8 Hz, 1H), 5.42 (d, J= 12.8 Hz, 1H), 6.69 (dd, J = 11.4, 7.0 Hz, 1H), 6.90 (dd, J = 10.6, 8.4 Hz, 1H), 7.38-7.48 (m, 3H). -
- [step 1] Using 5-bromoisobenzofuran-1(3H)-one (20.0 g, 93.9 mmol) and 2,3-difluorophenol (36.6 g, 282 mmol), and in the same manner as in Reference Example 1, step 1, 4-bromo-2-[(2,3-difluorophenoxy)methyl]benzoic acid (6.6 g, 20%) was obtained.
ESIMS m/z: 341, 343 (M - H)-; 1H NMR (300 MHz, DMSO-d6,Ī“): 5.54 (s, 2H), 7.00-7.09 (m, 2H), 7.10-7.19 (m, 1H), 7.70 (dd, J = 8.4, 2.2 Hz, 1H), 7.83-7.90 (m, 2H). - [step 2] Using 4-bromo-2-[(2,3-difluorophenoxy)methyl]benzoic acid (6.5 g, 18.9 mmol) obtained in step 1, and in the same manner as in Reference Example 2, step 2, 8-bromo-3,4-difluorodibenzo[b,e]oxepin-11(6H)-one (4.4 g, 72%) was obtained.
1H NMR (300MHz, CDCl3,Ī“): 5.26 (s, 2H), 6.91-7.02 (m, 1H), 7.57 (br d, J= 1.8 Hz, 1H), 7.65 (dd, J = 8.4, 1.8 Hz, 1H), 7.80 (d, J = 8.4 Hz, 1H), 7.98-8.07 (m, 1H). - [step 3] Using 8-bromo-3,4-difluorodibenzo[b,e]oxepin-11(6H)-one (4.0 g, 12.4 mmol) obtained in step 2, and in the same manner as in Reference Example 1, step 3, 2-(8-bromo-3,4-difluorodibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (4.3 g, 96%, E/Z = 1/1) was obtained.
1H NMR (300 MHz, CDCl3,Ī“): 2.03 (s, 1.5H), 2.24 (s, 1.5H), 4.93-5.03 (m, 1H), 5.48 (d, J = 12.5 Hz, 1H), 6.70-6.87 (m, 1.5H), 7.06 (d, J = 8.1 Hz, 0.5H), 7.19-7.26 (m, 0.5H), 7.35 (d, J = 8.1 Hz, 0.5H), 7.54-7.66 (m, 2H). - [step 4] Using 2-(8-bromo-3,4-difluorodibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (4.3 g, 11.8 mmol) obtained in step 3, and in the same manner as in Reference Example 1, step 4, propyl 11-(1-cyanoethylidene)-3,4-difluoro-6,11-dihydrodibenzo[b,e]oxepin-8-carboxylate (3.0 g, 69%) was obtained.
1H NMR (270 MHz, CDCl3,Ī“): 0.98-1.08 (m, 3H), 1.71-1.88 (m, 2H), 2.03 (s, 1.5H), 2.27 (s, 1.5H), 4.22-4.36 (m, 2H), 5.04-5.17 (m, 1H), 5.54 (d, J = 12.6 Hz, 1H), 6.70-6.87 (m, 1.5H), 7.22-7.26 (m, 0.5H), 7.26-7.30 (m, 0.5H), 7.56 (d, J = 7.9 Hz, 0.5H), 8.06-8.17 (m, 2H). - [step 5] Using propyl 11-(1-cyanoethylidene)-3,4-difluoro-6,11-dihydrodibenzo[b,e]oxepin-8-carboxylate (3.0 g, 8.1 mmol) obtained in step 4, and in the same manner as in Reference Example 1, step 5, (E)-2-[3,4-difluoro-8-(hydroxymethyl)dibenzo[b,e]oxepin-11(6H)-ylidene]propanenitrile (1.0 g, 40%) was obtained.
ESIMS m/z: 314 (M + H)+; 1H NMR (300 MHz, CDCl3,Ī“): 1.76 (t, J = 5.9 Hz, 1H), 2.25 (s, 3H), 4.74 (d, J = 5.9 Hz, 2H), 5.04 (d, J = 12.8 Hz, 1H), 5.54 (d, J = 12.8 Hz, 1H), 6.67-6.85 (m, 2H), 7.40-7.50 (m, 3H). - [step 6] Using (E)-2-[3,4-difluoro-8-(hydroxymethyl)dibenzo[b,e]oxepin-11(6H)-ylidene]propanenitrile (1.0 g, 3.2 mmol) obtained in step 5, and in the same manner as in Reference Example 1, step 6, the title compound (1.1 g, 88%) was obtained.
1H NMR (270 MHz, CDCl3, Ī“): 2.25 (s, 3H), 4.49 (s, 2H), 5.03 (d, J = 12.8 Hz, 1H), 5.51 (d, J= 12.8 Hz, 1H), 6.68-6.85 (m, 2H), 7.42-7.51 (m, 3H). - (E)-2-[3-fluoro-8-(hydroxymethyl)dibenzo[b,e]oxepin-11(6H)-ylidene]propanenitrile (6.2 g, 21.0 mmol) obtained in Reference Example 1, step 5 was dissolved in dichloromethane (93 mL), Dess-Martin periodinane (10.7 g, 25.2 mmol) was added under ice-cooling, and the mixture was stirred at room temperature for 1 hr. To the mixture were added saturated aqueous sodium hydrogen carbonate solution (300 mL) and saturated aqueous sodium thiosulfate solution (300 mL), and the mixture was extracted twice with dichloromethane. The combined organic layers were washed with water, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The obtained amorphous form (6.9 g) was suspended in diisopropyl ether, the precipitated crystals were suction filtered, and the solid was dried under reduced pressure to give the title compound (5.5 g, 90%).
1H NMR (400 MHz, CDCl3, Ī“): 2.28 (s, 3H), 4.99 (d, J = 12.7 Hz, 1H), 5.51 (d, J = 12.7 Hz, 1H), 6.61 (dd, J = 9.8, 2.9 Hz, 1H), 6.65-6.72 (m, 1H), 7.07 (dd, J = 8.8, 6.8 Hz, 1H), 7.66 (d, J = 7.8 Hz, 1H), 7.90-7.98 (m, 2H), 10.04 (s, 1H). -
- [step 1] LDA (65 mL, 130 mmol, 2.0 mol/L heptane/THF/ethylbenzene solution) was dissolved in THF (300 mL), and cooled to -78Ā°C. Commercially available 2-cyclopropylacetonitrile (6.0 mL, 65 mmol) dissolved in THF (50 mL) was added, and the mixture was stirred at -78Ā°C for 30 min. Diethyl chloroformate phosphate (9.3 mL, 78 mmol) dissolved in THF (50 mL) was added, and the mixture was stirred at -78Ā°C for 30 min. The reaction was discontinued with 1 mol/L hydrochloric acid at 0Ā°C, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure to give diethyl cyano(cyclopropyl)methylphosphonate (14 g, 99%).
ESIMS m/z: 218 (M + H)+; 1H NMR (300 MHz, CDCl3,Ī“): 0.53-1.29 (m, 4H), 1.35-1.44 (m, 6H), 2.61-2.82 (m, 1H), 4.05-4.17 (m, 1H), 4.21-4.33 (m, 4H). - [step 2] Diethyl cyano(cyclopropyl)methylphosphonate (2.8 g, 13 mmol) obtained in step 1 was dissolved in THF (20 mL), LDA (6.5 mL, 13 mmol, 2.0 mol/L heptane/THF/ethylbenzene solution) was added dropwise at 0Ā°C, and the mixture was stirred at room temperature for 1 hr. A solution of 8-bromo-3-fluorodibenzo[b,e]oxepin-11(6H)-one (2.0 g, 6.5 mmol) obtained in Reference Example 1, step 2 in DMF (6.5 mL) was added to the reaction system, and the mixture was stirred at 80Ā°C for 2 hr. To the mixture was added saturated aqueous ammonium chloride solution (500 mL), and the mixture was extracted 3 times with ethyl acetate. The combined organic layers were washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate = 4/1 v/v) to give 2-(8-bromo-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)-2-cyclopropylacetonitrile (1.96 g, 82%, E/Z = 1/1).
1H NMR (300 MHz, CDCl3,Ī“): 0.73-1.13 (m, 4H), 1.94-2.04 (m, 1H), 4.82 (d, J = 12.9 Hz, 1H), 5.48 (d, J = 12.9 Hz, 1H), 6.52-6.61 (m, 1H), 6.63-6.72 (m, 1H), 7.21-7.47 (m, 2H), 7.53-7.59 (m, 2H). - [step 3] Using 2-(8-bromo-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)-2-cyclopropylacetonitrile (3.0 g, 8.1 mmol, E/Z = 1/1) obtained in step 2, and in the same manner as in Reference Example 1, step 4, propyl 11-[1-cyano(cyclopropyl)methylene]-3-fluoro-6,11-dihydrodibenzo[b,e]oxepin-8-carboxylate (1.3 g, 43%, E/Z = 1/1) was obtained.
1H NMR (300 MHz, CDCl3,Ī“):0.90-1.27 (m, 7H), 1.75-1.83 (m, 2H), 1.95-2.05 (m, 1H), 4.27-4.33 (m, 2H), 4.95 (d, J = 12.5 Hz, 1H), 5.54 (d, J = 12.5 Hz, 1H), 6.52-6.70 (m, 2H), 7.34-7.55 (m, 2H), 8.07-8.11 (m, 2H). - [step 4] Using propyl 11-[1-cyano(cyclopropyl)methylene]-3-fluoro-6,11-dihydrodibenzo[b,e]oxepin-8-carboxylate (5.22 g, 13.8 mmol, E/Z = 1/1) obtained in step 3, and in the same manner as in Reference Example 1, step 5, (E)-2-cyclopropyl-2-[3-fluoro-8-(hydroxymethyl)dibenzo[b,e]oxepin-11(6H)-ylidene]acetonitrile (1.6 g, 36%) was obtained.
ESIMS m/z: 322 (M + H)+; 1H NMR (300 MHz, CDCl3, Ī“): 0.90-1.28 (m, 4H), 1.73 (t, J = 6.3 Hz, 1H) ,1.96-2.05 (m, 1H), 4.73 (s, 2H), 4.88 (d, J = 12.7 Hz, 1H), 5.54 (d, J = 12.7 Hz, 1H), 6.56-6.59 (m, 1H), 6.63-6.68 (m, 1H), 7.35-7.52 (m, 4H). - [step 5] Using (E)-2-cyclopropyl-2-[3-fluoro-8-(hydroxymethyl)dibenzo[b,e]oxepin-11(6H)-ylidene]acetonitrile (1.62 g, 5.07 mmol) obtained in step 4, and in the same manner as in Reference Example 1, step 6, the title compound (1.6 g, 84%) was obtained.
1H NMR (270 MHz, CDCl3,Ī“): 0.87-1.08 (m, 4H), 1.95-2.04 (m, 1H), 4.42 (s, 2H), 4.87 (d, J = 12.5 Hz, 1H), 5.51 (d, J = 12.5 Hz, 1H), 6.56-6.69 (m, 2H), 7.33-7.44 (m, 4H). - Using (E)-2-cyclopropyl-2-[3-fluoro-8-(hydroxymethyl)dibenzo[b,e]oxepin-11(6H)-ylidene]acetonitrile (1.0 g, 3.11 mmol) obtained in Reference Example 6, step 4, and in the same manner as in Reference Example 5, the title compound (680 mg, 69%) was obtained.
1H NMR (400 MHz, CDCl3,Ī“): 0.96-1.14 (m, 4H), 2.01-2.04 (m, 1H), 4.99 (d, J = 12.7 Hz, 1H), 5.56 (d, J = 12.5 Hz, 1H), 6.59-6.71 (m, 2H), 7.36-7.40 (m, 1H), 7.64-7.65 (m, 1H), 7.92-7.96 (m, 2H), 10.0 (s, 1H). -
- [step 1] Using 8-bromo-3-fluorodibenzo[b,e]oxepin-11(6H)-one (5.0 g, 16 mmol) obtained in Reference Example 1, step 2, and in the same manner as in Reference Example 1, step 3, 2-(8-bromo-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)butanenitrile (3.5 g, 60%) was obtained.
1H NMR (270 MHz, CDCl3, Ī“): 1.13-1.23 (m, 1.5H), 1.23-1.35 (m, 1.5H), 2.20-2.35 (m, 1H), 2.49-2.65 (m, 1H), 4.71-4.88 (m, 1H), 5.34-5.49 (m, 1H), 6.50-6.61 (m, 1H), 6.62-6.74 (m, 1H), 6.96-7.06 (m, 1H), 7.32-7.38 (m, 0.5H), 7.43-7.49 (m, 0.5H), 7.51-7.60 (m, 2H). - [step 2] Using (E)-2-(8-bromo-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)butanenitrile (20 g, 57 mmol) obtained in step 1, and in the same manner as in Reference Example 1, step 4, propyl 11-(1-cyanopropylidene)-3-fluoro-6,11-dihydrodibenzo[b,e]oxepin-8-carboxylate was obtained. Using the obtained propyl 11-(1-cyanopropylidene)-3-fluoro-6,11-dihydrodibenzo[b,e]oxepin-8-carboxylate (14 g, 38 mmol), and in the same manner as in Reference Example 1, step 5, (E)-2-[3-fluoro-8-(hydroxymethyl)dibenzo[b,e]oxepin-11(6H)-ylidene]butanenitrile (800 mg, 4.5%) was obtained.
1H NMR (270 MHz, CDCl3,Ī“): 1.20-1.37 (m, 3H), 1.66-1.85 (m, 1H), 2.43-2.68 (m, 2H), 4.68-4.76 (m, 2H), 4.87 (d, J = 12.8 Hz, 1H), 5.48 (d, J = 12.8 Hz, 1H), 6.54-6.60 (m, 1H), 6.60-6.68 (m, 1H), 6.91-7.06 (m, 1H), 7.36-7.53 (m, 3H). - [step 3] Using (E)-2-[3-fluoro-8-(hydroxymethyl)dibenzo[b,e]oxepin-11(6H)-ylidene]butanenitrile (940 mg, 3.04 mmol) obtained in step 2, and in the same manner as in Reference Example 1, step 6, the title compound (960 mg, 85%) was obtained.
1H NMR (270 MHz, CDCl3,Ī“): 1.21-1.40 (m, 3H), 2.49-2.71 (m, 2H), 4.49 (s, 2H), 4.86 (d, J = 12.8 Hz, 1H), 5.45 (d, J = 12.8 Hz, 1H), 6.50-6.75 (m, 2H), 6.94-7.11 (m, 1H), 7.39-7.52 (m, 3H). - 2-(8-Bromo-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)propanenitrile (5.0 g, 14.5 mmol) obtained in Reference Example 1, step 3 was dissolved in DMF (41 mL), bistriphenylphosphinedichloropalladium (1.02 g, 1.45 mmol), copper iodide (280 mg, 1.45 mmol), triethylamine (8.1 mL, 58.1 mmol) and trimethylsilylacetylene (4.1 mL, 29.1 mmol) were added, and the mixture was stirred at room temperature for 6 hr. Water was added to the mixture, and the mixture was extracted 3 times with ethyl acetate. The combined organic layers were dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane/ethyl acetate=1/1 v/v) to give a white amorphous (4.08 g). The obtained amorphous was dissolved in methanol (80 mL), potassium carbonate (1.56 g, 11.3 mmol) was added, and the mixture was stirred at room temperature for 5 hr. Water was added to the mixture, and the mixture was extracted 3 times with ethyl acetate. The combined organic layers were dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane/ethyl acetate=5/1 v/v) to give the title compound (2.5 g, 59%).
1H NMR (270 MHz, CDCl3,Ī“): 2.01 (s, 1.2H), 2.27 (s, 1.8H), 3.06-3.19 (m, 1H), 4.74-4.92 (m, 1H), 5.33-5.52 (m, 1H), 6.47-6.77 (m, 2H), 6.98-7.18 (m, 1H), 7.36-7.60 (m, 3H). -
- [step 1] 2-(8-Bromo-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)-2-cyclopropylacetonitrile (1.0 g, 2.7 mmol) obtained in Reference Example 6, step 2 was dissolved in DMF (7.7 mL), copper (I) iodide (0.051 g, 0.27 mmol), trimethylsilylacetylene (0.76 mL, 5.4 mmol), bis(triphenylphosphine)dichloropalladium (0.19 g, 0.27 mmol) and triethylamine (1.5 mL, 10 mmol) were added, and the mixture was stirred at room temperature for 6 hr. The reaction was discontinued with water, and the mixture was extracted 3 times with ethyl acetate. The combined organic layers were washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure.
The residue was purified by silica gel column chromatography (hexane/ethyl acetate = 10/1 v/v) to give 2-cyclopropyl-2-{3-fluoro-8-[(trimethylsilyl)ethynyl]dibenzo[b,e]oxepin-11(6H)-ylidene}acetonitrile (1.04 g, 99%, E/Z = 1/1).
1H NMR (300 MHz, CDCl3,Ī“): 0.24 (s, 9H), 0.70-1.08 (m, 4H), 1.92-2.05 (m, 1H), 4.82 (d, J = 12.5 Hz, 1H), 5.48 (d, J = 12.5 Hz, 1H), 6.50-6.68 (m, 2H), 7.30-7.53 (m, 4H). - [step 2] 2-Cyclopropyl-2-{3-fluoro-8-[(trimethylsilyl)ethynyl]dibenzo[b,e]oxepin-11(6H)-ylidene}acetonitrile (1.0 g, 2.6 mmol) obtained in step 1 was dissolved in methanol (10 mL), potassium carbonate (0.35 g, 2.6 mmol) was added, and the mixture was stirred at room temperature for 1 hr. The reaction was discontinued with water, and the mixture was extracted 3 times with ethyl acetate. The combined organic layers were washed with saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was crystallized from isopropyl ether and collected by filtration to give the title compound (600 mg, 74%, E/Z = 1/1).
1H NMR (300 MHz, CDCl3, Ī“): 0.74-1.16 (m, 4H), 1.97-2.02 (m, 1H), 3.13 (s, 1H), 4.84 (d, J = 13.7 Hz, 1H), 5.49 (d, J = 13.7 Hz, 1H), 6.52-6.70 (m, 2H), 7.30-7.57 (m, 4H). -
- [step 1] Using 8-bromo-3-fluorodibenzo[b,e]oxepin-11(6H)-one (5.00 g, 16.3 mmol) obtained in Reference Example 1, step 2 and diethyl cyanomethylphosphate (5.77 g, 32.6 mmol), and in the same manner as in Reference Example 1, step 3, 2-(8-bromo-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)acetonitrile (3.39 g, 63%, E/Z = 10/1) was obtained.
1H NMR (400 MHz, CDCl3,Ī“): 5.10 (s, 2H), 5.82 (s, 1H), 6.58-6.62 (m, 1H), 6.69-6.75 (m, 1H), 7.27-7.31 (m, 1H), 7.46 (d, J = 8.0 Hz, 1H), 7.57-7.58 (m, 1H), 7.62 (dd, J = 8.0, 2.0 Hz, 1H). - [step 2] Using 2-(8-bromo-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)acetonitrile (1.00 g, 3.03 mmol) obtained in step 1, and in the same manner as in Reference Example 10, step 1, (E)-2-{3-fluoro-8-[(trifluoromethylsilyl)ethynyl]dibenzo[b,e]oxepin-11(6H)-ylidene}acetonitrile (799 mg, 76%) was obtained.
1H NMR (400 MHz, CDCl3, Ī“): 0.26 (s, 9H), 5.10 (s, 2H), 5.80 (s, 1H), 6.59 (dd,J = 9.8, 2.9 Hz, 1H), 6.68-6.73 (m, 1H), 7.26-7.31 (m, 1H), 7.49-7.57 (m, 3H) - [step 3] Using (E)-2-{3-fluoro-8-[(trifluoromethylsilyl)ethynyl]dibenzo[b,e]oxepin-11(6H)-ylidene}acetonitrile (799 mg, 2.30 mmol) obtained in step 2, and in the same manner as in Reference Example 10, step 2, the title compound (540 mg, 85%) was obtained.
1H NMR (400 MHz, CDCl3,Ī“): 3.18 (s, 1H), 5. 12 (s, 2H), 5.82 (s, 1H), 6.60 (dd, J = 9.8, 2.9 Hz, 1H), 6.68-6.75 (m, 1H), 7.26-7.32 (m, 1H), 7.51-7.61 (m, 3H). -
- [step 1] Ethyl 2-(diethoxyphosphoryl)-2-fluoroacetate (315 mg, 1.3 mmol) was dissolved in THF (2 mL), lithium diisopropylamide (2 mol/L THF solution, 0.65 mL, 1.3 mmol) was added, and the mixture was stirred at 0Ā°C for 30 min. 8-Bromo-3-fluorodibenzo[b,e]oxepin-11(6H)-one (200 mg, 0.651 mmol) obtained in Reference Example 1, step 2 was dissolved in THF (2 mL), added dropwise in the reaction system, and the mixture was stirred at room temperature for 2 hr. To the mixture was added aqueous ammonium chloride solution, and the mixture was extracted 3 times with ethyl acetate. The combined organic layers were dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane/ethyl acetate = 4/1 v/v) to give ethyl 2-(8-bromo-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)-2-fluoroacetate (217 mg, 84%).
1H NMR (270 MHz, CDCl3,Ī“): 1.10-1.33 (m, 3H), 4.05-4.38 (m, 2H), 4.67-4.95 (m, 1H), 5.43-5.68 (m, 1H), 6.47-6.77 (m, 2H), 6.97-7.61 (m, 4H). - [step 2] Ethyl 2-(8-bromo-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)-2-fluoroacetate (1.6 g, 4.05 mmol) obtained in step 1 was dissolved in THF (14 mL), 2 mol/L ammonia methanol solution (20 mL, 40.5 mmol) was added, and the mixture was stirred at 55Ā°C overnight. The mixture was concentrated under reduced pressure and the obtained residue was purified by silica gel column chromatography (hexane/ethyl acetate = 2/1 v/v) to give 2-(8-bromo-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)-2-fluoroacetamide (910 mg, 61%).
1H NMR (270 MHz, CDCl3, Ī“): 4.59-4.89 (m, 1H), 5.30-5.64 (m, 1H), 6.10-6.72 (m, 4H), 6.98-7.64 (m, 4H). - [step 3] 2-(8-Bromo-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)-2-fluoroacetamide (910 mg, 2.49 mmol) obtained in step 2 was dissolved in dichloromethane (8 mL), triethylamine (1.04 mL, 7.46 mmol) and trifluoroacetic anhydride (0.70 mL, 4.97 mmol) were added, and the mixture was stirred at room temperature for 2 hr. Water was added to the mixture, and the mixture was extracted 3 times with ethyl acetate. The combined organic layers were dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane/ethyl acetate = 4/1 v/v) to give 2-(8-bromo-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)-2-fluoroacetonitrile (750 mg, 87%).
1H NMR (270 MHz, CDCl3, Ī“): 5.16 (br s, 2H), 6.54-6.80 (m, 2H), 7.17-7.52 (m, 2H), 7.52-7.71 (m, 2H). - [step 4] Using 2-(8-bromo-3-fluorodibenzo[b,e]oxepin-11(6H)-ylidene)-2-fluoroacetonitrile (400 mg, 1.15 mmol) obtained in step 3, and in the same manner as in Reference Example 9, the title compound (260 mg, 77%) was obtained.
1H NMR (270 MHz, CDCl3,Ī“): 3.06-3.24 (m, 1H), 4.94-5.40 (m, 2H), 6.53-6.67 (m, 1H), 6.67-6.81 (m, 1H), 7.17-7.61 (m, 4H). - According to the present invention, a dibenzoxepin derivative having a PPAR Ī³ activating action, which is useful as a therapeutic and/or prophylactic agent for type 2 diabetes, impaired glucose tolerance, insulin resistance syndrome, hypertension, hyperlipidemia, metabolic syndrome, visceral obesity, obesity, hypertriglyceridemia, inflammatory skin diseases (e.g., psoriasis, atopic dermatitis, seborrheic dermatitis, solar dermatitis etc.), inflammatory diseases (e.g., rheumatoid arthritis, ulcerative colitis, Crohn's disease, endometritis etc.), inflammatory neuropsychiatric diseases (e.g., multiple sclerosis etc.), neurodegenerative neuropsychiatric diseases (e.g., Alzheimer's disease, Parkinson's disease etc.), cardiovascular diseases such as arteriosclerosis, cardiac disease, cerebral apoplexy, renal diseases, or the like, a pharmaceutically acceptable salt thereof and the like are provided.
Claims (30)
- A tricyclic compound represented by the general formula (I)
RA is a hydrogen atom, halogen, hydroxy, lower alkoxy, or lower alkyl,
X is the formula (b1) - (b16)
A is the formula (a1) - (a29)
and RK is a hydrogen atom, halogen, hydroxy, lower alkoxy, lower alkyl or -NRFbRGb (wherein RFb and RGb are as defined for the aforementioned RF and RG, respectively)], or a pharmaceutically acceptable salt thereof. - The tricyclic compound according to claim 1, wherein Y is halogen, lower alkyl or cycloalkyl, or a pharmaceutically acceptable salt thereof.
- The tricyclic compound according to claim 1, wherein Y is lower alkyl, or a pharmaceutically acceptable salt thereof.
- The tricyclic compound according to claim 1, wherein Y is cycloalkyl, or a pharmaceutically acceptable salt thereof.
- The tricyclic compound according to any of claims 1, 2, 3, 4, 5 or 6, wherein A is the formula (a15), (a16), (a17), (a18), (a19), (a21), (a22), (a23), (a24), (a25), (a26), (a28) or (a29)
- The tricyclic compound according to any of claims 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10, wherein R1 is cyano; halogen; lower alkoxy; lower alkyl optionally substituted by 1 to 3 substituents of halogen, lower alkylamino, di-lower alkylamino, cycloalkyl or lower alkoxy; cycloalkyl optionally substituted by 1 to 3 substituents of halogen or lower alkyl; an aromatic heterocyclic group; an aliphatic heterocyclic group; or di-lower alkylamino, or a pharmaceutically acceptable salt thereof.
- The tricyclic compound according to any of claims 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10, wherein R1 is lower alkyl optionally substituted by 1 to 3 substituents of halogen or lower alkoxy, or a pharmaceutically acceptable salt thereof.
- The tricyclic compound according to any of claims 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10, wherein R1 is cycloalkyl, or a pharmaceutically acceptable salt thereof.
- The tricyclic compound according to any of claims 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or 13, wherein RC and RD are the same or different and each is a hydrogen atom; cyano; lower alkyl optionally substituted by 1 to 3 substituents of halogen, hydroxy or lower alkoxy; lower alkoxy optionally substituted by 1 to 3 halogens; lower alkylsulfanyl; lower alkylsulfonyl; cycloalkyl; lower alkynyl; -CONRH-1RI-1 (wherein RH-1 and RI-1 are the same or different and each is a hydrogen atom or lower alkyl, or RH-1 and RI-1 form, together with the adjacent nitrogen atom, a nitrogen-containing heterocyclic group); -NRFa-1RGa-1 (wherein RFa-1 and RGa-1 are the same or different and each is a hydrogen atom or lower alkyl); or halogen, or a pharmaceutically acceptable salt thereof.
- The tricyclic compound according to any of claims 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or 13, wherein RC and RD are the same or different and each is lower alkyl optionally substituted by 1 to 3 substituents of halogen, hydroxy or lower alkoxy; lower alkoxy optionally substituted by 1 to 3 halogens; or halogen, or a pharmaceutically acceptable salt thereof.
- The tricyclic compound according to claim 14 or 15, wherein RC is a hydrogen atom, or a pharmaceutically acceptable salt thereof.
- The tricyclic compound according to any of claims 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16, wherein RA is a hydrogen atom or halogen, or a pharmaceutically acceptable salt thereof.
- A pharmaceutical composition comprising the tricyclic compound or the pharmaceutically acceptable salt thereof according to any of claims 1 to 17, as an active ingredient.
- A PPAR Ī³ agonist comprising the tricyclic compound or the pharmaceutically acceptable salt thereof according to any of claims 1 to 17 as an active ingredient.
- A therapeutic and/or prophylactic agent for a disease associated with PPAR Ī³, which comprises the tricyclic compound or the pharmaceutically acceptable salt thereof according to any of claims 1 to 17, as an active ingredient.
- The agent according to claim 20, wherein the disease associated with PPAR Ī³ is a disease selected from the group consisting of type 2 diabetes, impaired glucose tolerance, insulin resistance syndrome, hypertension, hyperlipidemia, metabolic syndrome, visceral obesity, obesity and hypertriglyceridemia.
- A method of activating PPAR Ī³, comprising administering the tricyclic compound or the pharmaceutically acceptable salt thereof according to any of claims 1 to 17.
- A therapeutic and/or prophylactic method of a disease associated with PPAR Ī³, comprising administering the tricyclic compound or the pharmaceutically acceptable salt thereof according to any of claims 1 to 17.
- The method according to claim 23, wherein the disease associated with PPAR Ī³ is a disease selected from the group consisting of type 2 diabetes, impaired glucose tolerance, insulin resistance syndrome, hypertension, hyperlipidemia, metabolic syndrome, visceral obesity, obesity and hypertriglyceridemia.
- Use of the tricyclic compound or the pharmaceutically acceptable salt thereof according to any of claims 1 to 17, for the manufacture of a PPAR Ī³ agonist.
- Use of the tricyclic compound or the pharmaceutically acceptable salt thereof according to any of claims 1 to 17, for the manufacture of a therapeutic and/or prophylactic agent for a disease associated with PPAR Ī³.
- The use according to claim 26, wherein the disease associated with PPAR Ī³ is a disease selected from the group consisting of type 2 diabetes, impaired glucose tolerance, insulin resistance syndrome, hypertension, hyperlipidemia, metabolic syndrome, visceral obesity, obesity and hypertriglyceridemia.
- The tricyclic compound according to any of claims 1 to 17 or a pharmaceutically acceptable salt thereof, for use in activating PPARĪ³.
- The tricyclic compound according to any of claims 1 to 17 or a pharmaceutically acceptable salt thereof, for use in the treatment and/or prophylaxis of a disease associated with PPARĪ³.
- The tricyclic compound according to claim 29 or a pharmaceutically acceptable salt thereof, wherein the disease associated with PPARĪ³ is a disease selected from the group consisting of type 2 diabetes, impaired glucose tolerance, insulin resistance syndrome, hypertension, hyperlipidemia, metabolic syndrome, visceral obesity, obesity, and hypertriglyceridemia.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011169701 | 2011-08-03 | ||
PCT/JP2012/069876 WO2013018899A1 (en) | 2011-08-03 | 2012-08-03 | Dibenzooxepin derivative |
Publications (3)
Publication Number | Publication Date |
---|---|
EP2740730A1 true EP2740730A1 (en) | 2014-06-11 |
EP2740730A4 EP2740730A4 (en) | 2015-04-15 |
EP2740730B1 EP2740730B1 (en) | 2016-11-16 |
Family
ID=47629412
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP12820117.5A Not-in-force EP2740730B1 (en) | 2011-08-03 | 2012-08-03 | Dibenzooxepin derivative |
Country Status (7)
Country | Link |
---|---|
US (1) | US8969345B2 (en) |
EP (1) | EP2740730B1 (en) |
JP (1) | JP6086865B2 (en) |
KR (1) | KR20140051998A (en) |
CN (1) | CN103874697A (en) |
TW (1) | TW201311678A (en) |
WO (1) | WO2013018899A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019038195A1 (en) | 2017-08-22 | 2019-02-28 | Bayer Aktiengesellschaft | Heterocyclene derivatives as pest control agents |
WO2020250183A1 (en) | 2019-06-13 | 2020-12-17 | Pi Industries Ltd. | Fused heterocyclic compounds and their use as pest control agents |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3081213B1 (en) | 2008-08-06 | 2020-04-01 | Kyowa Kirin Co., Ltd. | Tricyclic compound |
EP2881394B1 (en) | 2012-07-31 | 2018-03-21 | Kyowa Hakko Kirin Co., Ltd. | Condensed ring heterocyclic compound |
GB201321736D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
WO2016029146A1 (en) * | 2014-08-22 | 2016-02-25 | University Of Washington | Specific inhibitors of methionyl-trna synthetase |
CN105061386A (en) * | 2015-08-17 | 2015-11-18 | čå·é»ę²³å¶čÆęéå ¬åø | Method for synthesizing doxepin hydrochloride by utilizing phthalic anhydride as raw material |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3849458A (en) | 1966-01-21 | 1974-11-19 | Incentive Res & Dev Ab | Method for deuterating organic compounds |
JPS61148141A (en) | 1984-12-21 | 1986-07-05 | Mitsubishi Rayon Co Ltd | Production of deuterated methyl acrylate or deuterated methyl methacrylate |
AR240698A1 (en) | 1985-01-19 | 1990-09-28 | Takeda Chemical Industries Ltd | Process for the preparation of 5-(4-(2-(5-ethyl-2-pyridil)-ethoxy)benzyl)-2,4-thiazolodinedione and their salts |
JPS61277648A (en) | 1985-06-03 | 1986-12-08 | Mitsubishi Rayon Co Ltd | Production of deuterated acrylic acid or deuterated methacrylic acid |
JPS61275241A (en) | 1985-05-29 | 1986-12-05 | Mitsubishi Rayon Co Ltd | Production of deuterated acrylic acid or methacrylic acid |
DE3701302A1 (en) | 1987-01-17 | 1988-07-28 | Hoechst Ag | METHOD FOR PRODUCING DEUTERED ORGANIC COMPOUNDS |
US5521201A (en) | 1987-09-04 | 1996-05-28 | Beecham Group P.L.C. | Method for treatment of atherosclerosis |
EP0842925A1 (en) | 1987-09-04 | 1998-05-20 | Beecham Group Plc | Substituted thiazolidinedione derivatives |
EP0400835A1 (en) | 1989-05-15 | 1990-12-05 | Merck & Co. Inc. | Substituted benzimidazoles as angiotensin II antagonists |
US5332744A (en) | 1989-05-30 | 1994-07-26 | Merck & Co., Inc. | Substituted imidazo-fused 6-membered heterocycles as angiotensin II antagonists |
ATE102610T1 (en) | 1989-08-10 | 1994-03-15 | Nippon Chemiphar Co | IMIDAZOL DERIVATIVES, PROCESS FOR THEIR PREPARATION AND ANTIULCIC AGENTS CONTAINING THEM. |
FI112942B3 (en) | 1991-02-21 | 2012-03-13 | Daiichi Sankyo Co Ltd | Process for the preparation of 4 '- (1H-imidazol-1-ylmethyl) -1,1'-biphenyl derivatives useful for the treatment and prevention of hypertension |
US5378701A (en) | 1991-12-27 | 1995-01-03 | Kyowa Hakko Kogyo | Tricyclic compounds |
JP2526005B2 (en) * | 1991-12-27 | 1996-08-21 | ååéé µå·„ę„ę Ŗå¼ä¼ē¤¾ | Tricyclic compound |
PL362144A1 (en) | 2000-12-04 | 2004-10-18 | Pfizer Products Inc. | Coupling process and intermediates useful for preparing cephalosphorins |
US20050032854A1 (en) * | 2001-12-03 | 2005-02-10 | Kiminori Kawahara | Insulin resistance improving agents |
US7232828B2 (en) * | 2002-08-10 | 2007-06-19 | Bethesda Pharmaceuticals, Inc. | PPAR Ligands that do not cause fluid retention, edema or congestive heart failure |
ES2308296T3 (en) * | 2003-12-19 | 2008-12-01 | Eli Lilly And Company | MODULAR NUCLEAR RECEPTOR OF TRICICLIC STEROID HORMONES. |
JP4981662B2 (en) | 2004-05-05 | 2012-07-25 | ćć¤ć»ćć¤ć³ćć»ćć”ć¼ćć¹ć¼ćć£ć«ć«ćŗććØć«ćØć«ć·ć¼ | New compounds, their preparation and use |
ATE402932T1 (en) * | 2004-06-14 | 2008-08-15 | Janssen Pharmaceutica Nv | NEW TETRACYCLIC TETRAHYDROFURAN DERIVATIVES |
CN101516865B (en) | 2006-10-02 | 2013-01-23 | ä½ååå¦ę Ŗå¼ä¼ē¤¾ | Tertiary alkyl ester of oxodibenzoxepin acetic acid |
CN101646666A (en) * | 2007-02-07 | 2010-02-10 | åååé µéŗéŗę Ŗå¼ä¼ē¤¾ | Tricyclic compounds |
KR101126383B1 (en) | 2007-02-07 | 2012-04-12 | źµģ ķ«ź¼¬ źø°ė¦° ź°ė¶ģķ¤ź°ģ“ģ¤ | Tricyclic compounds |
AR068032A1 (en) | 2007-08-27 | 2009-10-28 | Kalypays Inc | CHINOLONES REPLACED WITH USEFUL HETEROCICLICS AS INHIBITORS OF NITRICAL SYNTHEASE OXIDE |
JP5485164B2 (en) | 2007-11-29 | 2014-05-07 | ćć¼ćŖć³ć¬ć¼ ć¤ć³ć²ć«ćć¤ć ć¤ć³ćæć¼ćć·ć§ćć« ć²ć¼ć«ć·ć£ćć ććć ćć·ć„ć¬ć³ćÆćć« ćććć³ć° | Derivatives of 6,7-dihydro-5H-imidazo [1,2-a] imidazole-3-carboxylic acid amide |
WO2009086123A1 (en) | 2007-12-21 | 2009-07-09 | Wyeth | Imidazo [1,2-a] pyridine compounds |
EP3081213B1 (en) | 2008-08-06 | 2020-04-01 | Kyowa Kirin Co., Ltd. | Tricyclic compound |
CN102196809B (en) * | 2008-10-22 | 2013-06-26 | åååé µéŗéŗę Ŗå¼ä¼ē¤¾ | Agent for treatment of diabetic nephropathy |
-
2012
- 2012-08-03 WO PCT/JP2012/069876 patent/WO2013018899A1/en active Application Filing
- 2012-08-03 JP JP2013526970A patent/JP6086865B2/en not_active Expired - Fee Related
- 2012-08-03 US US14/236,545 patent/US8969345B2/en active Active
- 2012-08-03 EP EP12820117.5A patent/EP2740730B1/en not_active Not-in-force
- 2012-08-03 CN CN201280048053.XA patent/CN103874697A/en active Pending
- 2012-08-03 KR KR1020147005517A patent/KR20140051998A/en not_active Application Discontinuation
- 2012-08-03 TW TW101128175A patent/TW201311678A/en unknown
Non-Patent Citations (2)
Title |
---|
No further relevant documents disclosed * |
See also references of WO2013018899A1 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019038195A1 (en) | 2017-08-22 | 2019-02-28 | Bayer Aktiengesellschaft | Heterocyclene derivatives as pest control agents |
WO2020250183A1 (en) | 2019-06-13 | 2020-12-17 | Pi Industries Ltd. | Fused heterocyclic compounds and their use as pest control agents |
Also Published As
Publication number | Publication date |
---|---|
WO2013018899A1 (en) | 2013-02-07 |
JP6086865B2 (en) | 2017-03-01 |
US20140163008A1 (en) | 2014-06-12 |
CN103874697A (en) | 2014-06-18 |
KR20140051998A (en) | 2014-05-02 |
US8969345B2 (en) | 2015-03-03 |
JPWO2013018899A1 (en) | 2015-03-05 |
EP2740730A4 (en) | 2015-04-15 |
EP2740730B1 (en) | 2016-11-16 |
TW201311678A (en) | 2013-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10669277B2 (en) | Inhibitors of activin receptor-like kinase | |
AU2019416589B2 (en) | Heterocyclic compound intermediate, preparation method therefor and application thereof | |
US9598423B2 (en) | Substituted 4,5,6,7-tetrahydropyrazolo[1,5-A]pyrazine derivatives as casein kinase 1 D/E inhibitors | |
US8969345B2 (en) | Dibenzooxepin derivative | |
EP2885288B1 (en) | 1,4-disubstituted pyridazine analogs and methods for treating smn-deficiency-related conditions | |
EP2892891B1 (en) | Alkoxy pyrazoles as soluble guanylate cyclase activators | |
US11427601B1 (en) | Inhibitors of KEAP1-Nrf2 protein-protein interaction | |
US11332459B2 (en) | Benzimidazole derivatives and their uses | |
EP1789045A2 (en) | Chemical compounds | |
EP2714688B1 (en) | Heterocyclic compounds as protein kinase inhibitors | |
CA3109195A1 (en) | Transglutaminase 2 (tg2) inhibitors | |
WO2018066718A1 (en) | Therapeutic compounds | |
EP4103564A1 (en) | P2x3 modulators | |
EP3860998B1 (en) | Compounds and compositions for treating conditions associated with apj receptor activity | |
JP2021525247A (en) | Complex condensed pyridone compounds and their use as IDH inhibitors | |
CA3074059A1 (en) | Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists | |
WO2021194982A1 (en) | Potent and selective irreversible inhibitors of irak1 | |
JP6193233B2 (en) | Fused heterocyclic compounds | |
EP2327690A1 (en) | Tricyclic compound | |
CN118488953A (en) | Bicyclic heterocyclic compounds useful as monoacylglycerol lipase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20140212 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
RA4 | Supplementary search report drawn up and despatched (corrected) |
Effective date: 20150316 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 31/454 20060101ALI20150310BHEP Ipc: A61K 31/4245 20060101ALI20150310BHEP Ipc: A61K 31/519 20060101ALI20150310BHEP Ipc: C07D 413/14 20060101AFI20150310BHEP Ipc: A61P 9/12 20060101ALI20150310BHEP Ipc: A61K 31/4439 20060101ALI20150310BHEP Ipc: A61P 3/04 20060101ALI20150310BHEP Ipc: A61P 3/10 20060101ALI20150310BHEP Ipc: A61K 31/5025 20060101ALI20150310BHEP Ipc: A61K 31/4985 20060101ALI20150310BHEP Ipc: C07D 471/04 20060101ALI20150310BHEP Ipc: C07D 487/04 20060101ALI20150310BHEP Ipc: C07D 495/04 20060101ALI20150310BHEP Ipc: A61K 31/437 20060101ALI20150310BHEP Ipc: A61P 3/06 20060101ALI20150310BHEP Ipc: A61P 43/00 20060101ALI20150310BHEP |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Ref document number: 602012025546 Country of ref document: DE Free format text: PREVIOUS MAIN CLASS: C07D0413140000 Ipc: A61K0031335000 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 31/335 20060101AFI20160425BHEP |
|
INTG | Intention to grant announced |
Effective date: 20160525 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 845239 Country of ref document: AT Kind code of ref document: T Effective date: 20161215 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602012025546 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602012025546 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161116 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20161116 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 845239 Country of ref document: AT Kind code of ref document: T Effective date: 20161116 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161116 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161116 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170217 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170216 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161116 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170316 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161116 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161116 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161116 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161116 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161116 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161116 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161116 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161116 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161116 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161116 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161116 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 6 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602012025546 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161116 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170216 Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161116 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161116 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20170817 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161116 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161116 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170831 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170831 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170803 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170803 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 7 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170803 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20120803 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20161116 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161116 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R082 Ref document number: 602012025546 Country of ref document: DE Representative=s name: VOSSIUS & PARTNER PATENTANWAELTE RECHTSANWAELT, DE Ref country code: DE Ref legal event code: R081 Ref document number: 602012025546 Country of ref document: DE Owner name: KYOWA KIRIN CO., LTD., JP Free format text: FORMER OWNER: KYOWA HAKKO KIRIN CO., LTD., TOKYO, JP |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161116 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161116 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170316 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20220706 Year of fee payment: 11 Ref country code: DE Payment date: 20220630 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20220707 Year of fee payment: 11 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 602012025546 Country of ref document: DE |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20230803 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230803 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230803 Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230831 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240301 |